Drug ID	Drug name	Synonymous	CID	Formula	Highest_phase
M6ADRUG0001	Betaine	Cystadane	247	C5H11NO2	Approved
M6ADRUG0002	Berberine	"Berberin; Umbellatine; UNII-0I8Y3P32UF; 0I8Y3P32UF; CHEBI:16118; EINECS 218-229-1; Berberal; BRN 3570374; ST055798; 9,10-Dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetrahydroberbinium; Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy-; 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium; Berbamine sulphate acid; CHEMBL12089; 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)berbinium; BERBINIUM, 7,8,13,13a-TETRAHYDRO-9,10-DIMETHOXY-2,3-(METHYLE"	2353	C20H18NO4+	Phase 4
M6ADRUG0003	Chloroquine	Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244	2719	C18H26ClN3	Approved
M6ADRUG0005	Fluorouracil	"5-Fluorouracil; 51-21-8; fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-;  Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU"	3385	C4H3FN2O2	Approved
M6ADRUG0006	Meclofenamic acid	"Arquel; Meclofenamate; Acide meclofenamique; Acido meclofenamico; Acidum meclofenamicum; Meclophenamic acid; CL 583; INF 4668; Acide meclofenamique [INN-French]; Acido meclofenamico [INN-Spanish]; Acidum meclofenamicum [INN-Latin]; INF-4668; Meclomen (free acid); Meclofenamic acid (USAN/INN); Meclofenamic acid [USAN:INN:BAN]; N-(2,6-Dichloro-3-methylphenyl)anthranilic acid; N-(2,6-Dichloro-m-tolyl)anthranilic acid; N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid; 2-((2,6-Dichloro-3-methylphenyl)amino)benzoic acid; 2-(2,6-Dichloro-3-methylphenyl)aminobenzoic acid; 2-(2,6-dichloro-3-methylanilino)benzoic acid; 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid"	4037	C14H11Cl2NO2	Approved
M6ADRUG0007	Metformin	"657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metiguanide; Dimethylbiguanide; Glucophage; Haurymelin; Gliguanid; Fluamine; Glumetza; Flumamine; Melbin; Diabex; N,N-Dimethylbiguanide; Metformina; Metforminum; Metformine; Islotin; Glifage; Siofor; N1,N1-Dimethylbiguanide; DMGG; NNDG; Dimethyldiguanide; N,N-Dimethyldiguanide; Metformina [DCIT]; Imidodicarbonimidic diamide, N,N-dimethyl-; Metformina [Spanish]; Metforminum [INN-Latin]; Metformine [INN-French]; Metformin [USAN:INN:BAN]; 1,1-Dimethyl; Diabetosan; Dimethylbiguanidine; Dimethylguanylguanidine; Glycon; Diabex (TN); Diaformin (TN); Dianben (TN); Fortamet (TN); Gen-Metformin; Glucophage (TN); Glumetza (TN); LA-6023; Nu-Metformin; Obimet (TN); Riomet (TN); Metformin (USAN/INN); 1,1-Dimethyl biguanide; 3-(diaminomethylidene)-1,1-dimethylguanidine; [14C]metformin"	4091	C4H11N5	Approved
M6ADRUG0010	Temozolomide	"Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida; Temozolomidum; Essex brand of temozolomide; Scheringbrand of temozolomide; Temozolodida [Spanish]; Temozolomidum [Latin]; M B 39831; MB 39831; Sch 52365; M & B 39831; M&B 39831; M-39831; Sch-52365; Schering-Plough brand of temozolomide; TMZ-Bioshuttle; Temodal (TN); Temodar (TN); Temozolomide [INN:BAN]; M&B-39831; Temozolomide (JAN/USAN/INN); 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; TMZ"	5394	C6H6N6O2	Approved
M6ADRUG0011	Dexamethasone	"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone"	5743	C22H29FO5	Approved
M6ADRUG0019	Pt	"Precision tolerogens (autoimmune disease), NaniRx"	23939	Pt	Investigative
M6ADRUG0021	Daunorubicin	"daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142;  Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	C27H29NO10	Approved
M6ADRUG0022	Doxil	"doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin"	31703	C27H29NO11	Approved
M6ADRUG0024	Gemcitabine	Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)	60750	C9H11F2N3O4	Approved
M6ADRUG0025	Epigallocatechin gallate	"(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE"	65064	C22H18O11	Phase 3
M6ADRUG0026	AcSDKP	AcSDKP; Seraspenide; BIM-32001; Goralatide; Acetyl-seryl-aspartyl-lysyl-proline	65938	C20H33N5O9	Phase 2
M6ADRUG0027	Sarsasapogenin	"Parigenin; Sarsagenin; (25S)-5beta-Spirostan-3beta-ol; Sasarasapogenin; sarsapogenin; Sarsasapogenenin; UNII-CFS802C28F; Spirostan-3-ol, (3b,5b,25S)-; CFS802C28F; CHEBI:15578; (3beta,5beta,25S)-spirostan-3-ol; MFCD00270414; Spirostan-3-ol, (3beta,5beta,25S)- (9CI); Spirostan-3-ol; Sarsapogenine; 82597-74-8; (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S,16S,18R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-ol; (2aR,4S,5'S,6aS,6bS,8aS,8bR,9S,10R,11aS,12aS,12bR)-5',6a,8a,9-tetramethyldocosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-ol; Sarsagenin [INN]; SR-05000002243; cogan; sarsasopogenin; Sarsasapogenine; Sarsasapogenin;; PYM50028; Parigenin;; (25S)-5-beta-spirostan-3-beta-ol; NSC 1615; EINECS 204-776-3; Sarsasapogenin, 95%; Sarsasapogenin, >=98%; (25S)-Spirostan-3beta-ol; (25S)-5-spirostan-3-ol; SCHEMBL180164; CHEMBL1171146; DTXSID00903921; HY-N0073; ZINC8218968; 2770AC; BDBM50442865; LMST01080007; s3607; AKOS015960455; Spirostan-3-ol, (3ss,5ss,25S)-; ACN-035281; CCG-208441; CS-7949; Spirostan-3-ol, (3beta,5beta,25S)-; AC-11191; AC-33951; AS-77870; Spirostan-3-ol, (3-beta,5-beta,25S)-; 5beta-Spirostan-3beta-ol, (25S)- (8CI); N1451; Resorufin-; A-D-glucuronide sodium salt, 98%; C03963; Q7424590; SR-05000002243-2; SR-05000002243-3; SR-05000002243-4; (1'R,2R,2'S,4'S,5S,7'S,8'R,9'S,12'S,13'S,16'S,18'R)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0,.0,.0,]icosane]-16'-ol"	92095	C27H44O3	Investigative
M6ADRUG0028	Fulvestrant	"Faslodex; AstraZeneca brand of fulvestrant; Fulvestrant [USAN]; Ici 182780; ZD 182780; ZM 182780; Faslodex (TN); ZD-182780; ZD-9238; ZM-182780; Faslodex(ICI 182,780); Faslodex, ICI 182780, Fulvestrant; Fulvestrant (JAN/USAN/INN); (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; ICI"	104741	C32H47F5O3S	Approved
M6ADRUG0029	Saikosaponins	"Beta-D-Galactopyranoside, (3beta,4alpha,16alpha)-13,28-epoxy-16,23-dihydroxyolean-11-en-3-yl 6-deoxy-3-O-beta-D-glucopyranosyl-; UR635J3F00; (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-2-[[(1S,2R,4S,5R,8R,9R,10S,13S,14R,17S,18R)-2-hydroxy-9-(hydroxymethyl)-4,5,9,13,20,20-hexamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracos-15-en-10-yl]oxy]-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol; Saikosaponins; Saikosaponin D from Bupleurum falcatnum; SCHEMBL929710; CHEMBL3613719; (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-2-[hydroxy-(hydroxymethyl)-hexamethyl-[]yl]oxy-6-methyl-tetrahydropyran-4-yl]oxy-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; HY-N0250; MFCD09028095; s5454; AKOS016034270; ZINC247647500; CCG-270465; CS-0008281; N1887; Q-100262; Q27291219; beta-D-Galactopyranoside, (3beta,4alpha,16alpha)-13,28-epoxy-16,23-dihydroxyolean-11-en-3-yl 6-deoxy-3-O-beta-D-glucopyranosyl"	107793	C42H68O13	Investigative
M6ADRUG0030	Gefitinib	Iressa; ZD1839; Irressat; gefitinib (zd1839); N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; ZD 1839; ZD-1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; UNII-S65743JHBS; CCRIS 9011; CHEMBL939; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4	123631	C22H24ClFN4O3	Approved
M6ADRUG0032	Sorafenib	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	C21H16ClF3N4O3	Approved
M6ADRUG0034	Adriamycin	"25316-40-9; Doxorubicin HCl; Adriacin; ADRIAMYCIN HYDROCHLORIDE; Hydroxydaunorubicin hydrochloride; Doxorubicin (Adriamycin) HCl; UNII-82F2G7BL4E; ADRIAMYCIN, HYDROCHLORIDE; KW-125; Lipodox; MLS001401460; 82F2G7BL4E; SMR000058570; CPD000058570; DSSTox_RID_78854; DSSTox_RID_80678; DSSTox_CID_10636; DSSTox_GSID_30636; DSSTox_GSID_45111; CCRIS 740; CAS-NOCAS_45111"	443939	C27H30ClNO11	Phase 3
M6ADRUG0035	Tretinoin	"Retinoic acid; tretinoin; 302-79-4; Vitamin A acid; all-trans-Retinoic acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; Dermairol; Aknoten; Eudyna; Aberel; all-trans-Vitamin A acid; Aknefug; All-trans Retinoic Acid; Cordes vas; Epi-aberel; Atralin; Vitamin A1 acid, all-trans-; Tretin M; Retin-A Micro; all-trans-Vitamin A1 acid; Vitamin A acid, all-trans-; all-trans-Tretinoin; Effederm; Retionic acid; TRETINON; Retinoic acid, all-trans-; Alltrans-retinoic acid; beta-Ra; all-(E)-Retinoic acid; beta-Retinoic acid; Avitoin; Aberela; Acnavit; Atragen; Betarretin; Lsotretinoin; Nexret; Panretyn; REA; Retacnyl; Retinoate; Retinova; Solage; Tretinoina; Tretinoine; Tretinoino; Tretinoinum; Vesnaroid; Vitinoin; Aberela [Norway]; Accutane Roche; Acnavit [Denmark]; All Trans Retinoic Acid; Avita Gel; Avitoin [Norway]; Beta all trans Retinoic Acid; Cordes VAS [Germany]; Effederm [France]; Panretin Gel; Retin A; Trans Retinoic Acid; Tretinoin Potassium Salt; Tretinoin Sodium Salt; Tretinoin Zinc Salt; Tretinoin liposome; AGN100335; AGN 192013; ALRT 1057; BAL4079; LGD 100057; R 2625; [3H]Retinoic acid; A-Vitaminsyre; A-Vitaminsyre [Denmark]; AT-RA; Aberela (TN); Acid, Retinoic; Acid, Vitamin A; All trans-Retinoic acid; Atra-IV; Avita (TN); B-Retinoic acid; BML2-E05; Beta-Ra; Beta-Retinoic acid; Potassium Salt, Tretinoin; RETINOIC ACID, ALL TRANS; Renova (TN); Retin A (TN); Retisol-A; Ro 1-5488; Salt, Tretinoin Potassium; Salt, Tretinoin Sodium; Salt, Tretinoin Zinc; Sodium Salt, Tretinoin; Stieva-A; Stieva-a Forte; Trans-Retinoicacid; Tretinoin (TN); Tretinoina [INN-Spanish]; Tretinoine [INN-French]; Tretinoino [INN-Spanish]; Tretinoinum [INN-Latin]; Tri-Luma; Vesanoid (TN); Zinc Salt, Tretinoin; A-Acido (Argentina); Acid A Vit (Belgium, Netherlands); Acid, trans-Retinoic; Acide retinoique (French) (DSL); All-trans-Retinoic acid; All-trans-Tretinoin; All-trans-Vitamin A acid; All-trans-Vitamin A1 acid; PDT-002-002; Retin-A (TN); Stieva-A (TN); Tretinoin 01% cream or placebo; Tretinoin [USAN:INN:BAN]; Tretinoin/All-Trans Retinoic Acid; Tretinoine (French) (EINECS); Acid, all-trans-Retinoic; All-(E)-Retinoic acid; All-trans-b-Retinoic acid; All-trans-beta-Retinoic acid; Beta-all-trans-Retinoic acid; Tretinoin (JAN/USP/INN); Acid, beta-all-trans-Retinoic; Retinoic acid, all-trans-(8CI); Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin; 15-Apo-beta-caroten-15-oic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 9(Z)-Retinoic acid; 9-cis-RA; 9-trans-retinoic acid"	444795	C20H28O2	Approved
M6ADRUG0037	Teniposide	"PTG; Teniposido; Teniposidum; Vehem; Vumon; Demethyl Epipodophyllotoxin Thenylidine Glucoside; VM 26; Teniposido [INN-Spanish]; Teniposidum [INN-Latin]; VM-26; Vee M-26; Veham-Sandoz; Vumon (TN); Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; VM-26 (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside"	452548	C32H32O13S	Approved
M6ADRUG0039	Tamoxifen	"tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene;  Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen"	2733526	C26H29NO	Approved
M6ADRUG0040	P5091	"P005091; P5091; P-5091; 1-(5-(2,3-dichlorophenylthio)-4-nitrothiophen-2-yl)ethanone; 1-[5-(2,3-Dichloro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159495; P5091 (P005091); 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-(5-((2,3-Dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; Cyto5D7; C12H7Cl2NO3S2; SCHEMBL2681288; DTXSID90384841; 1-[5-[(2,3-Dichlorophenyl)thio]-4-nitro-2-thienyl]ethanone; HMS3653E09; HMS3743M19; ZINC125366; BCP07750; EX-A2120; BDBM50393437; MFCD00123202; s7132; AKOS024458314; CCG-240421; CS-1445; MCULE-6661883192; QC-8200; SB19505; NCGC00379189-01; AC-32692; BS-17872; DA-40897; HY-15667; FT-0714931; SW219710-1; Y1893; J3.502.625H; C76908; P 5091; P-05091; P005091(P5091); P 005091; 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-(2,3-dichlorophenylsulfanyl)-4-nitro-2-thienyl]ethanone; 1-[5-[(2,3-Dichlorophenyl)thio]-4-nitro-2-thienyl]ethanone; 1-(5-((2,3-Dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethan-1-one; 1-{5-[(2,3-Dichlorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one"	2819993	C12H7Cl2NO3S2	Investigative
M6ADRUG0041	Artenimol	"Dihydroartemisinin; Artenimol; Dihydroqinghaosu; UNII-6A9O50735X; 81496-82-4; (3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano[4,3-j][1,2]benzodioxepin-10-ol; GNF-PF-5634; 6A9O50735X; b-Dihydroartemisinin; GTPL9957; SCHEMBL17156483; CHEBI:135921; HY-N0176; ZINC15449187; AKOS032949625; CS-5595; FT-0649320; BRD-K62213621-001-01-6; Dihydroartemisinin (mixture of alfa and beta isomers); (3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-ol"	3000518	C15H24O5	Approved
M6ADRUG0042	Dasatinib	"Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel"	3062316	C22H26ClN7O2S	Approved
M6ADRUG0044	Rapamycin	"Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	C51H79NO13	Approved
M6ADRUG0045	Colistin	"Colistin sulphate; Polymyxin E; Colistin sulfate, nonsterile; Polymyxin E. Sulfate; Coly-Mycin M Parenteral (TN)"	5311054	C52H98N16O13	Approved
M6ADRUG0047	Cisplatin	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	Cl2H6N2Pt	Approved
M6ADRUG0048	Oxaliplatin	Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN)	9887053	C8H14N2O4Pt	Approved
M6ADRUG0054	PLX4032	PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)	42611257	C23H18ClF2N3O3S	Approved
M6ADRUG0055	AZD6482	"AZD6482; 1173900-33-8; AZD 6482; (R)-2-(1-(7-methyl-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino)benzoic acid; 2-[[(1R)-1-[7-Methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]benzoic acid; AZD-6482; CHEMBL2165191; UNII-78G6MP5PZ5; 78G6MP5PZ5; 2-({(1R)-1-[7-Methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl}amino)benzoic acid; 2-{[(1R)-1-[7-methyl-2-(morpholin-4-yl)-4-oxopyrido[1,2-a]pyrimidin-9-yl]ethyl]amino}benzoic acid"	44137675	C22H24N4O4	Terminated
M6ADRUG0056	JQ-1	"1268524-70-4; (+)-JQ-1; JQ1 compound; (+)-JQ1; JQ-1; UNII-1MRH0IMX0W; (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; (S)-JQ1; 1MRH0IMX0W; JQ1; CHEMBL1957266; AK109409; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate; (S)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3"	46907787	C23H25ClN4O2S	Phase 1
M6ADRUG0058	PMID31239444-anti-PD1 antibody	.	.	.	Investigative
M6ADRUG0059	3-Methyladenine	"3-Methyl-3H-purin-6-amine; 6-Amino-3-methylpurine; 3-MA; 3-Methyl-3H-adenine; 3H-Purin-6-amine, 3-methyl-; 3-methylpurin-6-amine; NSC 66389; n3-methyladenine; ADENINE, 3-METHYL-; MFCD00010531; CHEBI:38635; UNII-DR88TV7SNU; DR88TV7SNU; 3-METHYL-3H-PURIN-6-YLAMINE; UNII-3899G64TKW; 3899G64TKW; 3-Methyladenine autophagy inhibitor; 60192-57-6; 3-MA nucleobase; 3MA; N(3)-methyladenine; EINECS 225-908-6; BRN 0146087; 3-methyl-7H-purin-6-imine; 3mea; 3-methyl-Adenine; 3-Methyladenine; NSC66389; 1p7m; 4ai5; 3-Methyladenine (3-MA); Autophagy Inhibitor, 3-MA; NCIOpen2_000270; SCHEMBL48369; 5-26-17-00151 (Beilstein Handbook Reference); MLS006010995; SCHEMBL254058; CHEMBL292268; CHEMBL4303725; SCHEMBL15764619; 3-Methyl-3H-purin-6-amine #; AOB2548; DTXSID80199406; EX-A130; Bio1_000422; Bio1_000911; Bio1_001400; HMS3656P04; ZINC403086; 3-Methyl-7H-purine-6(3H)-imine; ACN-C001131; AMY11868; BCP02452; 3-Methyladenine, autophagy inhibitor; BDBM50488841; NSC-66389; QC-518; s2767; AKOS003382321; AKOS006228458; ZINC100003619; ACN-001131; CCG-206388; CS-5207; DB04104; MCULE-5086156902; NSC 66389 (3-MA); NCGC00345447-02; 3,9-dihydro-3-methyl-6H-Purin-6-imine; AC-28818; AS-19224; HY-19312; Purine, 3,6-dihydro-6-imino-3-methyl-; SMR002530641; SY026559; DB-051961; 6H-Purin-6-imine, 3,7-dihydro-3-methyl-; 6H-Purin-6-imine, 3,9-dihydro-3-methyl-; A7582; FT-0635560; FT-0671432; M2518; SW220216-1; X5709; 3-methyl-3H-purin-6-amine (ACD/Name 4.0); C00913; 3-methyl-3H-purin-6-ylamine (ACD/Name 4.0); J-640198; J-800199; W-202935; BRD-K81647657-001-01-9; Q27094948"	135398661	C6H7N5	Investigative
M6ADRUG0063	Meclofenamate sodium	.	4038	C14H10Cl2NNaO2	Approved
M6ADRUG0064	Asparagine inhibitor	Agedoite; Altheine; Crystal VI	6267	C4H8N2O3	Approved
M6ADRUG0066	R-2HG	"(R)-2-Hydroxypentanedioic acid; 13095-47-1; D-2-Hydroxyglutaric acid; (R)-2-hydroxyglutaric acid; (R)-Hydroxyglutarate; (R)-2-hydroxyglutarate; Pentanedioic acid, 2-hydroxy-, (2R)-; CHEMBL1614745; CHEBI:32796; D-2-Hydroxyglutarate; Glutaric acid, 2-hydroxy-; d-alpha-hydroxyglutaric acid; D-Hydroxyglutarate; 2HG; D-a-Hydroxyglutarate; 2-hydroxy-D-Glutarate; (R)-a-Hydroxyglutarate; delta-2-Hydroxyglutarate; D-a-Hydroxyglutaric acid; 2-hydroxy-delta-Glutarate; D-; A-Hydroxyglutaric acid; (2R)-hydroxyglutaric acid; 2-hydroxy-D-Glutaric acid; (R)-alpha-Hydroxyglutarate; delta-alpha-Hydroxyglutarate; SCHEMBL8032; (R)-a-Hydroxyglutaric acid; delta-2-Hydroxyglutaric acid; (R)-2-hydroxy-Pentanedioate; 2-hydroxy-delta-Glutaric acid; (R)-alpha-Hydroxyglutaric acid; delta-alpha-Hydroxyglutaric acid; (R)-2-hydroxy-Pentanedioic acid; DTXSID80897218; ZINC402968; BDBM50361471; AKOS027325193; FD21404; BS-50252; HY-113038; CS-0059411; C01087; 93397C3E-3CE9-4FEA-A2ED-8F6FA59A1FEA; Q27104222; Z2217110365; 636-67-9"	439391	C5H8O5	Investigative
M6ADRUG0067	Arsenite	"Sodium metaarsenite; Sodium dioxoarsenate; sodium;oxoarsinite; Arsenite, sodium; UNII-48OVY2OC72; NaAsO2; Sodium (meta)arsenite; 48OVY2OC72; CHEBI:29678; Arsenenous acid, sodium salt (1:1); Prodalumnol; Sodanit; Penite; Kill-All; Prodalumnol double; Rat Death Liquid; Chem Pels C; sodium meta-arsenite; Chem-Sen 56; Caswell No. 744; MFCD00003472; Atlas A; Arsenite de sodium; Arsenenous acid, sodium salt; Arsenite de sodium [French]; Arsenious acid, monosodium salt; CCRIS 5554; HSDB 693; EINECS 232-070-5; EPA Pesticide Chemical Code 013603; Sodium arsenenite; AsO2.Na; (NaAsO2)n; CHEMBL1909078; DTXSID5020104; Sodium (meta)arsenite, >=90%; 5497AF; AKOS025295751; Na(+)n-(-As(O(-))O-)-n; Sodium (meta)arsenite, p.a., 98.0%; catena-poly[(oxidoarsenate-mu-oxido)]sodium; Sodium arsenite, 0.1N Standardized Solution; Sodium arsenite, 0.5M standardized solution; Q419586"	443495	AsNaO2	Phase 2
M6ADRUG0068	RSL3	"RSL3; 1219810-16-8; RSL3 (1S,3R-); CHEMBL4747331; (1S,3R)-RSL3; RSL3 1S,3R-; methyl (1S,3R)-2-(2-chloroacetyl)-1-(4-(methoxycarbonyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate; methyl (1S,3R)-2-(2-chloroacetyl)-1-(4-methoxycarbonylphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxylate; RSL3 1S; SCHEMBL13402744; (1S,3R)-RSL-3; EX-A1392; ZINC2094071; BDBM50547192; NSC833292; s8155; AKOS030632788; CCG-269132; CS-5650; HY-100218A; NSC-833292; CID 1750826; AS-55795; C21479; C71823; Q55879537; (1S,3R)-Methyl 2-(2-chloroacetyl)-1-(4-(methoxycarbonyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate; (1S,3R)-Methyl 2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1-[4-(methoxycarbonyl)phenyl]-1H-pyrido[3,4-b]indole-3-carboxylate; methyl (1S,3R)-2-(2-chloroacetyl)-1-[4-(methoxycarbonyl)phenyl]-1H,2H,3H,4H,9H-pyrido[3,4-b]indole-3-carboxylate"	1750826	C23H21ClN2O5	Investigative
M6ADRUG0069	ML162	ML162; 2-[(chloroacetyl)(3-chloro-4-methoxyphenyl)amino]-N-(2-phenylethyl)-2-thien-2-ylacetamide; ML-162; SMR000206941; MLS000583955; 2-(3-chloro-N-(2-chloroacetyl)-4-methoxyanilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide; alpha-[(2-chloroacetyl)(3-chloro-4-methoxyphenyl)amino]-N-(2-phenylethyl)-2-thiopheneacetamide; BRD5421; BRD-5421; 2-(3-chloro-N-(2-chloro-1-oxoethyl)-4-methoxyanilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide; MLS002588779; MLS002703080; CHEMBL1499544; SCHEMBL15428380; BDBM66431; CHEBI:91657; cid_3689413; AOB1514; HMS2544O20; HMS3874J03; EX-A4946; s4452; AKOS024440074; AS-16657; HY-100002; CS-0017910; SR-01000705401; SR-01000705401-2; BRD-A36275421-001-04-6; BRD-A36275421-001-06-1; BRD-A36275421-001-09-5; BRD-A36275421-001-11-1; BRD-A36275421-001-13-7; BRD-A36275421-001-14-5; BRD-A36275421-001-15-2; Q27163480; 2-(3-chloro-N-(2-chloroacetyl)-4-methoxy-anilino)-N-phenethyl-2-(2-thienyl)acetamide; 2-[3-chloro(2-chloroacetyl)-4-methoxyanilino]-N-phenethyl-2-(2-thienyl)acetamide; 2-[Chloroacetyl(3-chloro-4-methoxyphenyl)amino]-N-phenethyl-2-(2-thienyl)acetamide; 2-[2-chloranylethanoyl-(3-chloranyl-4-methoxy-phenyl)amino]-N-(2-phenylethyl)-2-thiophen-2-yl-ethanamide	3689413	C23H22Cl2N2O3S	Investigative
M6ADRUG0072	ML-210	"ML-210; ML 210; [4-[bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone; ML210; (4-(bis(4-chlorophenyl)methyl)piperazin-1-yl)(5-methyl-4-nitroisoxazol-3-yl)methanone; CHEMBL1951048; CID 49766530; BRD7528; BRD-7528; TL_HRAS26; MLS003265661; SCHEMBL21965947; CHEBI:92034; HMS3874L03; BCP29439; EX-A3516; BDBM50547193; MFCD22666407; ZINC73278737; NCGC00386679-01; NCGC00386679-02; BM170835; BS-51618; SMR001941104; HY-100003; ML 210, >=98% (HPLC); CS-0017911; S0788; D83838; BRD-K01877528-001-01-6; BRD-K01877528-001-02-4; BRD-K01877528-001-03-2; BRD-K01877528-001-04-0; BRD-K01877528-001-07-3; BRD-K01877528-001-08-1; BRD-K01877528-001-09-9; BRD-K01877528-001-11-5; Q27163827; [4-[Bis(4-chlorophenyl)methyl]-1-piperazinyl](5-methyl-4-nitro-3-isoxazolyl)methanone; [4-[bis(4-chlorophenyl)methyl]-1-piperazinyl]-(5-methyl-4-nitro-3-isoxazolyl)methanone; CID 49766530; CID-49766530; CID49766530; ML-210; ML 210"	49766530	C22H20Cl2N4O4	Investigative
M6ADRUG0073	CB-839	"CB-839; 1439399-58-2; 2-(pyridin-2-yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide; CB839; CB 839; UNII-U6CL98GLP4; U6CL98GLP4; N-[6-[4-[5-[(2-pyridin-2-ylacetyl)amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide; 2-(Pyridin-2-Yl)-N-(5-{4-[6-({[3-(Trifluoromethoxy)phenyl]acetyl}amino)pyridazin-3-Yl]butyl}-1,3,4-Thiadiazol-2-Yl)acetamide; 2-(PYRIDIN-2-YL)-N-{5-[4-(6-{2-[3-(TRIFLUOROMETHOXY)PHENYL]ACETAMIDO}PYRIDAZIN-3-YL)BUTYL]-1,3,4-THIADIAZOL-2-YL}ACETAMIDE; 2-Pyridineacetamide, N-(5-(4-(6-((2-(3-(trifluoromethoxy)phenyl)acetyl)amino)-3-pyridazinyl)butyl)-1,3,4-thiadiazol-2-yl)-; 2-Pyridineacetamide, N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-; 63J; Telaglenastat [USAN]; CB-839(Telaglenastat); Telaglenastat (USAN/INN); GTPL9053; CB-839 [WHO-DD]; CHEMBL3639788; SCHEMBL14987180; BDBM109086; HMS3741E19; HMS3873G13; AMY16835; BCP28287; EX-A1310; MFCD28167826; NSC783415; NSC795998; NSC798057; s7655; WHO 10815; AKOS025396175; ZINC169698697; CCG-270102; CS-3393; DB15232; NSC-783415; NSC-795998; NSC-798057; SB17221; NCGC00356145-11; 2-Pyridineacetamide, N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridaz; AC-31603; AS-75090; CB839; CB 839 pound>>Telaglenastat,; DA-34988; HY-12248; FT-0767818; A14396; D11738; A857288; US8604016, 670; Q27075751; 2-Pyridineacetamide, N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-; N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-2-pyridineacetamide; N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-thiadiazol-2-yl]-2-pyridineacetamide;CB-839; N-[6-(4-{5-[2-(pyridin-2-yl)acetamido]-1,3,4-thiadiazol-2-yl}butyl)pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide"	71577426	C26H24F3N7O3S	Phase 2
M6ADRUG0074	Beta-Elemen	"Beta-Elemen; (-)-beta-Elemene; Levo-beta-elemene; b-elemene; Levo-b-elemene; UNII-2QG8CX6LXD; (1S,2S,4R)-1-methyl-2,4-di(prop-1-en-2-yl)-1-vinylcyclohexane; 2,4-Diisopropenyl-1-methyl-1-vinylcyclohexane; (-)-b-Elemene; CHEBI:62855; 2QG8CX6LXD; (1S,2S,4R)-2,4-diisopropenyl-1-methyl-1-vinylcyclohexane; (1S,2S,4R)-(-)-1-methyl-1-vinyl-2,4-diisopropenylcyclohexane; (1S,2S,4R)-1-ethenyl-1-methyl-2,4-bis(prop-1-en-2-yl)cyclohexane; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S,2S,4R)-; 33880-83-0; (1S,2S,4R)-1-ethenyl-1-methyl-2,4-di(prop-1-en-2-yl)cyclohexane; beta-Elemene, (-)-; b-Elemen; E- .beta.-Elemene; Epitope ID:153551; Levo-b-elemene(-)-b-Elemene; CHEMBL448502; DTXSID60881211; SDP-111; 8064AH; s6957; ZINC14096289; AKOS028108977; (-)-beta-Elemene, analytical standard; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S-(1-alpha,2-beta,4-beta))-; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, [1S-(1alpha,2beta,4beta)]-; AS-82909; HY-107324; CS-0028143; C17094; E79113; 880E830; Q27132237; 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-cyclohexane; Cyclohexane, 2,4-diisopropenyl-1-methyl-1-vinyl-, (1S,2S,4R)-"	6918391	C15H24	Phase 3
M6ADRUG0076	Ethyl ester form of meclofenamic acid	"Ethyl ester form of meclofenamic acid (MA), MA2"	.	.	Approved
M6ADRUG0077	P22077	.	.	.	Investigative
M6ADRUG0078	MK22606	.	.	.	Investigative
M6ADRUG0079	Pembrolizumab	.	.	.	Approved
M6ADRUG0080	Nivolumab	Ipilimumab	.	.	Phase 2
M6ADRUG0082	GLS-IN-968	"Compound 968; 5-[3-bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one; CHEBI:60279; GLS-IN-968; 5-(3-bromo-4-(dimethylamino)phenyl)-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one; 5-[3-bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-1,3,5,6-tetrahydrobenzo[a]phenanthridin-4-one; 5-[3-Bromo-4-(dimethylamino)phenyl]-2,3,5,6-tetrahydro-2,2-dimethylbenzo[a]phenanthridin-4(1H)-one; GAC Inhibitor 968; MLS006011732; SCHEMBL2635251; CHEMBL2133369; DTXSID90389215; GLS-968; HMS3865C03; BCP18024; EX-A2335; Glutaminase Inhibitor Compound 968; Glutaminase C-IN-1; Compound 968; QC-219; AKOS000518068; CS-4585; MCULE-7842076917; NCGC00263232-01; NCGC00263232-02; BS-16481; HY-12682; SMR003863855; EU-0084810; Y11333; AG-690/36107028; Q27127161; 5-[3-Bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridine-4(1H)-one"	3099980	C27H27BrN2O	Investigative
M6ADRUG0086	Glucocorticoid	.	.	.	Investigative
M6ADRUG0089	Paclitaxel	Paclitaxel	36314	C47H51NO14	Approved
M6ADRUG0090	Osimertinib	Osimertinib	71496458	C28H33N7O2	Approved
M6ADRUG0091	Tucatinib	"Irbinitinib; Tucatinib; 937263-43-9; ONT-380; 6-DIAMINE; Tukysa; UNII-234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 234248D0HH; Irbinitinib; ARRY-380; ONT-380; N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine; N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine; Irbitinib; ONT 380; Tukysa (TN); ONT-380;Tucatinib; Tucatinib (USAN/INN); Tucatinib [USAN:INN]; Irbinitinib(ARRY-380); Irbinitinib; ARRY-380; GTPL9922; SCHEMBL1193050; CHEMBL3989868; BDBM471617; BCP15983; EX-A1031; MFCD22380467; NSC764581; NSC799335; s8362; ZINC68250462; ARRY-380 (ONT-380); AKOS026750449; CCG-264747; CS-3906; DB11652; NSC-764581; NSC-799335; SB17126; US10822334, Compound ONT380; NCGC00482879-02; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; AC-33037; AS-56109; BT177688; HY-16069; Example 11 [WO2007059257A2]; DB-130430; A16413; D11141; A857335; Q25100690; 4,6-QuinazolinediaMine,N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine;; N6-(4,5-dihydro-4,4-dmethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-A)pyridin-7-Yloxy)phenyl)-4,6-quinazolinediamine"	51039094	C26H24N8O2	Approved
M6ADRUG0092	Trastuzumab	.	.	.	Approved
M6ADRUG0093	Sunitinib	"Sunitinib; 557795-19-4; Sutent; SU11248; Sunitinib Base; SU-11248; Su-011248; SU 11248; 342641-94-5; (Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide; UNII-V99T50803M; N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; CHEMBL535; CHEBI:38940; SU011248; NSC750690; NSC-750690; V99T50803M; sunitinibum; Sunitinib (INN); 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-; n-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide; Sunitinib (free base); NSC-736511; Sunitinib [INN:BAN]; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; C22H27FN4O2; MFCD09260778; HSDB 7932; (Z)-Sunitinib; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; 5-(5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide; Sutent (free base); KS-5022; SCHEMBL8081; BDBM4814; GTPL5713; QCR-67; Sutent, Sunitinib, SU11248; CHEBI:91430; EX-A553; BCPP000057; K00588a; AOB87111; ZINC3964325; HY-10255A; NSC800937; s7781; AKOS015908193; AKOS025312424; CCG-268638; CS-1670; DB01268; NSC 736511; NSC 750690; NSC-800937; NCGC00164631-02; NCGC00164631-04; BD164426; Q572; 1,2,4,5-tetramethylpyrrole-3-carboxamide; AM20090630; 95S194; D08552; J90060; AB01273976-01; AB01273976-02; AB01273976_04; A822143; A830806; Q417542; SR-00000000005; SR-00000000005-2; Q27163278; Z2568722545; 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylamino-ethyl)-amide; N-[2-(Diethylamino)ethyl]-5-(2-oxo-5-fluoroindoline-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carbo"	5329102	C22H27FN4O2	Approved
M6ADRUG0094	RG7112	"RG7112; 939981-39-2; RG-7112; RO5045337; RO-5045337; UNII-Q8MI0X869M; RG 7112; Q8MI0X869M; CHEMBL2386346; ((4S,5R)-2-(4-(tert-Butyl)-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethyl-4,5-dihydro-1H-imidazol-1-yl)(4-(3-(methylsulfonyl)propyl)piperazin-1-yl)methanone; [(4S,5R)-2-(4-tert-butyl-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethylimidazol-1-yl]-[4-(3-methylsulfonylpropyl)piperazin-1-yl]methanone; Ro 5045337; GTPL9599; Mdm2 antagonist ro5045337; SCHEMBL12704861; DTXSID60240182; BCP07937; EX-A1686; BDBM50434287; NSC809100; s7030; ZINC96270381; CCG-270414; CS-0330; DB14793; NSC-809100; SB19057; AC-32970; HY-10959; RO5045337; RG7112; RG7112 (RO5045337); R 7112; A857519; Q27287118; RG-7112;RG 7112; RO-5045337; RO 5045337; RO5045337; [(4R,5S)-4,5-Bis(4-chlorophenyl)-2-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl][4-[3-(methylsulfonyl)propyl]-1-piperazinyl]methanone;R7112 RG7112 RG 7112; RG7112; RO5045337; RO 5045337; RO5045337; [(4s,5r)-2-(4-t-butyl-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethylimidazol-1-yl]-[4-(3-methylsulfonylpropyl)piperazin-1-yl]methanone; Methanone, [(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl][4-[3-(methylsulfonyl)propyl]-1-piperazinyl]-"	57406853	C38H48Cl2N4O4S	"	Phase 1"
M6ADRUG0095	Pertuzumab	.	.	.	Approved
M6ADRUG0096	PARPi	"Parpi; UNII-OWV057OPZ3; OWV057OPZ3; CHEMBL4650351; SCHEMBL19372384; 4-(4-fluoro-3-(4-(4-fluorobenzoyl)piperazine-1-carbonyl)benzyl)phthalazin-1(2h)-one; 1(2H)-Phthalazinone, 4-((4-fluoro-3-((4-(4-(fluoro)benzoyl)-1-piperazinyl)carbonyl)phenyl)methyl)-; 1919043-65-4"	130443213	C27H22F2N4O3	Investigative
M6ADRUG0097	Olaparib	"Olaparib; 763113-22-0; AZD2281; Lynparza; KU-0059436; AZD 2281; AZD-2281; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine; 4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Olaparib (AZD2281, Ku-0059436); UNII-WOH1JD9AR8; KU-59436; Olaparib (AZD-2281); 4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one; MFCD13185161; WOH1JD9AR8; C24H23FN4O3; CHEBI:83766; AZ2281; 4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one; NSC-747856; KU59436; 4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one; OLAPARIB cpd; Olaparib (AZD2281; Ku-0059436); Olaparib [USAN:INN]; Olaparib (AZD2281); Acylpiperazine analogue, 47; Olaparibum; AZD221; 4-[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2H)-one; Olaparib- Bio-X; Lynparza (TN); 09L; 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one; 937799-91-2; KU 59436; KU0059436; Olaparib - AZD2281; AZD-2281 (Olaparib); Olaparib (JAN/USAN/INN); MLS006010185; SCHEMBL426568; CHEMBL521686; GTPL7519; BDBM27566; AOB1085; DTXSID60917988; EX-A002; BCPP000360; HMS3295I09; HMS3426C03; HMS3654G13; HMS3746K07; HMS3870H03; AMY10295; BCP01872; 763113-22-0, Lynparza,; NSC747856; NSC753686; s1060; ZINC40430143; AKOS005145764; AC-7939; AZ-2281; BCP9000363; CCG-264799; CS-0075; DB09074; EX-7210; KEYLYNK-010 COMPONENT OLAPARIB; NSC 747856; NSC-753686; QC-2660; SB14617; SS-4573; AZD2281,Olaparib, KU-0059436; NCGC00238451-01; NCGC00238451-02; NCGC00238451-08; NCGC00238451-09; NCGC00238451-11; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; BO164169; HY-10162; Olaparib (AZD2281, KU0059436); SMR004701291; SY040527; OLAPARIB COMPONENT OF KEYLYNK-010; Olaparib(AZD2281,KuDOSKU-0059436); A9666; BB 0260909; FT-0651458; KU 0059436; SW218142-2; EC-000.2324; D09730; J-503540; Q7083106; BRD-K02113016-001-08-9; BRD-K02113016-001-09-7; AZD 2281; ; ; KU 0059436; ; ; KU 59436; 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine; 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; (2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-; [4-(Cyclopropanecarbonyl)piperazin-1-yl]{2-fluoro-5-[(4-hydroxyphthalazin-1-yl)methyl]phenyl}methanone; 1021843-02-6; 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one"	23725625	C24H23FN4O3	Approved
M6ADRUG0098	Melittin	"Melittin; 20449-79-0; Forapine; Honeybee melittin; Bee venom melittin; Forapin; Melitten; UNII-24VT8NVE75; 24VT8NVE75; CHEBI:6736; Melittin I; MFCD00076868; Melittin (apis cerana); L-Glutamamide, glycyl-L-isoleucylglycyl-L-alanyl-L-valyl-L-leucyl-L-lysyl-L-valyl-L-leucyl-L-threonyl-L-threonylglycyl-L-leucyl-L-prolyl-L-alanyl-L-Leucyl-L-isoleucyl-L-seryl-L-tryptophyl-L-isoleucyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-L-glutaminyl-; GIGAVLKVLTTGLPALISWIKRKRQQ-NH2; CHEMBL412927; AKOS024456456; Melittin, >=97% (HPLC), synthetic; RS-2008; NCGC00167171-01; AC-32561; Honey Bee Venom Extract ~ 70% Melittin; XM176021; Melittin (GIGAVLKVLTTGLPALISWIKRKRQQ-amide); Melittin from honey bee venom, >=65% (HPLC); Melittin from honey bee venom, >=85% (HPLC); G-I-G-A-V-L-K-V-L-T-T-G-L-P-A-L-I-S-W-I-K-R-K-R-Q-Q-NH2; Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-NH2; Gly-L-Ile-Gly-L-Ala-L-Val-L-Leu-L-Lys-L-Val-L-Leu-L-Thr-L-Thr-Gly-L-Leu-L-Pro-L-Ala-L-Leu-L-Ile-L-Ser-L-Trp-L-Ile-L-Lys-L-Arg-L-Lys-L-Arg-L-Gln-L-Gln-NH2; glycyl-L-isoleucylglycyl-L-alanyl-L-valyl-L-leucyl-L-lysyl-L-valyl-L-leucyl-L-threonyl-L-threonylglycyl-L-leucyl-L-prolyl-L-alanyl-L-leucyl-L-isoleucyl-L-seryl-L-tryptophyl-L-isoleucyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-L-glutaminyl-L-glutamamide; H-Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-NH2"	16133648	C131H229N39O31	Investigative
M6ADRUG0099	Linsitinib	"Linsitinib; 867160-71-2; OSI-906; Linsitinib(OSI-906); OSI906; OSI 906; OSI-906 (Linsitinib); OSI-906AA; ASP-7487; UNII-15A52GPT8T; 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; 15A52GPT8T; CHEMBL1091644; MMV676605; cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol; C26H23N5O; cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol; (1r,3r)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol.; Kinome_3532; Linsitinib [USAN:INN]; Linsitinib; OSI-906; Linsitinib (USAN/INN); Linsitinib (OSI-906); MLS006010304; SCHEMBL400369; SCHEMBL400734; SCHEMBL400735; GTPL7423; CHEMBL1996234; SCHEMBL10255925; CHEBI:91402; EX-A719; QCR-128; BCPP000137; BDBM185150; DTXSID401007055; HMS3295G15; HMS3654C19; AOB87170; BCP01831; BDBM50315887; MFCD12912153; NSC756652; NSC800784; s1091; ZINC53239527; AKOS024464740; ZINC100071817; ZINC113742575; BCP9001035; CCG-264815; CS-0242; DB06075; NSC-756652; NSC-800784; PB22643; NCGC00250375-02; NCGC00250375-03; NCGC00250375-11; NCGC00250375-14; AC-26953; AS-16999; HY-10191; SMR004700744; FT-0670821; SW218150-2; X7473; D09925; SR-05000022538; J-520074; Q6554803; SR-05000022538-1; BRD-K07667918-001-01-3; Q27163260; 3-[8-amino-1-(2-phenyl-7-quinolinyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol; (1s,3r)-3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol; 1356958-77-4; 3-(8-amino-1-(2-phenylquinolin-7-yl)-2,3-dihydroimidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol; 3-[8-AMINO-1-(2-PHENYL-QUINOLIN-7-YL)-IMIDAZO[1,5-A]PYRAZIN-3-YL]-1-METHYL-CYCLOBUTANOL; 3-[8-Imino-1-(2-phenylquinolin-7-yl)-7,8-dihydroimidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; Cis-3-(8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol"	11640390	C26H23N5O	Phase 3
M6ADRUG0100	Erlotinib	"Erlotinib; 183321-74-6; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; Erlotinib free base; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; OSI-774; UNII-J4T82NDH7E; 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; 183321-74-6 (free base); NSC 718781; CHEMBL553; J4T82NDH7E; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; CP358774; CHEBI:114785; MFCD02089651; NCGC00164574-01; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; DSSTox_CID_26454; DSSTox_RID_81628; DSSTox_GSID_46454; CP-358,774; Erlotinib(Tarceva); OSI-744; CAS-183321-74-6; NSC718781; RG-1415; Erlotinib [INN:BAN]; SR-05000001460; erlotinibum; Erotinib; R-1415; HSDB 8082; OSI 744; nchembio866-comp3; Erlotinib, Free Base; Kinome_3317; n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine monohydrochloride; R 1415; SCHEMBL8413; BDBM5446; cid_176870; GTPL4920; DTXSID8046454; QCR-100; HMS2089F05; HMS3244M19; HMS3244M20; HMS3244N19; HMS3295A19; HMS3713C22; HMS3745M05; ZINC1546066; Tox21_112202; 3615AH; AC-399; NSC800097; s7786; STK623143; AKOS000282911; Tox21_112202_1; CCG-220420; CS-0620; DB00530; MCULE-7764565391; NSC-800097; Ro-508231; SB16916; NCGC00164574-03; NCGC00164574-05; NCGC00164574-06; NCGC00164574-14; NCGC00164574-25; AS-35132; BCB03_000783; BE164419; HY-50896; P443; SY028059; AM20090621; FT-0651539; R1415; CP-35877401; K00241; AB01273955-01; AB01273955-02; AB01273955-03; 321E746; Q418369; SR-05000001460-1; SR-05000001460-2; SR-05000001460-3; SR-05000001460-6; BRD-K70401845-003-04-7; n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy) quinazolin-4-amine; 1429636-49-6"	176870	C22H23N3O4	Approved
M6ADRUG0101	Cetuximab	.	.	.	Approved
M6ADRUG0102	Bortezomib	"Bortezomib; 179324-69-7; Velcade; PS-341; Bortezomib (PS-341); LDP-341; Ps 341; ((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid; DPBA; LDP 341; UNII-69G8BD63PP; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; Bortezomib (Velcade); N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; MG 341; MG-341; Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-; NSC 681239; NSC-681239; 69G8BD63PP; CHEMBL325041; Peptide boronate; CHEBI:52717; MFCD09056737; NSC681239; NCGC00242506-02; S1013; DSSTox_CID_20980; DSSTox_RID_79609; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; DSSTox_GSID_40980; radiciol; Pyz-Phe-boroLeu; (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid; [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid; Velcade (TN); CAS-179324-69-7; PS 341 (pharmaceutical); Brotezamide; PROSCRIPT BORONIC ACID; Bortezomib [USAN:INN:BAN]; Bortezomib accord; C19H25BN4O4; HSDB 7666; Bortezomib hydrate; Bortezomib,Velcade; LPD 341; LPD-341; Velcade, Radiciol; NCGC00168751-01; NCGC00181022-01; Bortezomib- Bio-X; Velcade (Millenium); 3mg0; MLS004774142; Bortezomib (JAN/USAN/INN); SCHEMBL192129; GTPL6391; DTXSID3040980; AOB6368; ((1R)-3-Methyl-1-(((2S)-3-phenyl-2-((pyrazinylcarbonyl)amino)propanoyl)amino)butyl)boronic acid; Tox21_112630; Tox21_112672; BDBM50069989; NSC756655; AKOS015909706; Tox21_112672_1; ZINC169746649; AM81235; CCG-268449; CS-1039; DB00188; NSC-756655; Bortezomib (Velcade,MG-341,PS-341); NCGC00242506-01; NCGC00242506-06; NCGC00242506-07; AS-15721; BB164258; HY-10227; NCI60_029010; Q425; SMR003500787; SW208077-3; A18332; D03150; AB01273951-01; AB01273951-02; AB01273951_03; 324B697; Q419319; SR-01000939863; SR-01000939863-2; BRD-K88510285-001-02-0; (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-6-carboxamido)propanamido)butylboronic acid; (1R)-3-Methyl-1-({(2S)-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propanoyl}amino)butylboronic acid, AldrichCPR; (R)-3-METHYL-1-((S)-3-PHENYL-2-(PYRAZINE-2-CARBOXAMIDO)PROPANAMIDO)BUTAN-2-YLBORONIC ACID; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]-butyl]boronic acid; Boronic acid, ((1R)-3-methyl-1-(((2S)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-; Boronic acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (S-(R*,S*))-; Boronic acid, [(1(R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-; N-((1S)-1-Benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide; N-((1S)-1-benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)2-oxoethylpyrazinecarboxamide; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide"	387447	C19H25BN4O4	Approved
M6ADRUG0103	Atorvastatin	"atorvastatin; 134523-00-5; Cardyl; Lipitor; Torvast; ATORVASTATIN CALCIUM; 110862-48-1; UNII-A0JWA85V8F; (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid; CI 981; Lipitor (TN); Tozalip; Xavator; A0JWA85V8F; CHEMBL1487; (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; CHEBI:39548; (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 134523-03-8; Atorvastatin [INN:BAN]; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (R-(R*,R*))-; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID; Atorvastatin calcium salt; atorvastatina; atorvastatine; atrovastin; Atofast; Atorcor; Atorlip; Lipilou; Lipinon; Atorin; Ator; Lipitor(TM); (3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; Atorvastatin (INN); Sortis (TN); CCRIS 7159; MFCD00899261; C33H35FN2O5; HSDB 7039; NCGC00159458-03; atorvastatinum; rel-Atorvastatin; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; Atorvastatin & Primycin; DSSTox_CID_9868; SCHEMBL3831; DSSTox_RID_78825; DSSTox_GSID_29868; BIDD:GT0336; Atorvastatin (Relative Stereo); GTPL2949; DTXSID8029868; BDBM22164; DTXSID60274003; HMS3715L05; HMS3886C20; Lipilou; Tozalip; Torvast; Cardyl; (3S,5S)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; ACT03225; HY-B0589; ZINC3920719; Tox21_302417; s5715; AKOS000281127; AC-9386; CCG-221172; DB01076; MCULE-2368532812; MRF-0000761; NCGC00159458-02; NCGC00159458-20; NCGC00255181-01; (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (betaR,deltaR)-; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; AS-35260; H942; CAS-134523-00-5; C06834; D07474; 523A005; A802259; A806791; A806793; Q668093; SR-01000872702; SR-01000872702-1; BRD-K69726342-001-02-6; UNII-36TN91XZ0V component XUKUURHRXDUEBC-KAYWLYCHSA-N; (3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-PROPAN-2-YL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (beta-R,delta-R)-;; sodium 7-[5-(4-fluorophenyl)-2-isopropyl-4-phenyl-3-(phenylcarbamoyl)-2,3-dihydropyrrol-1-yl]-3,5-dihydroxy-heptanoate"	60823	C33H35FN2O5	Approved
M6ADRUG0104	Apatinib	"Apatinib; 811803-05-1; rivoceranib; YN968D1; Apatinib free base; N-(4-(1-Cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide; UNII-5S371K6132; N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide; 5S371K6132; N-(4-(1-cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide; apatinib (in China); Rivoceranib (USAN/INN); GTPL7648; SCHEMBL1814966; CHEMBL3186534; Apatinib free base; YN-968D1; AMY21302; BCP02840; EX-A1794; HY-13342A; MFCD21648511; NSC772886; NSC799333; s5248; ZINC70466461; AKOS024464453; CCG-268625; DB14765; DS-7455; NSC-772886; NSC-799333; SB16590; 3-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-; N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide; NCGC00249393-01; NCGC00249393-08; AC-27461; BA175030; DA-35324; CS-0003200; C76598; D11288; AB01274807-01; AB01274807_02; Q27262801; N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]nicotinamide"	11315474	C24H23N5O	Approved
M6ADRUG0105	Everolimus	"001, RAD; 40-O-(2-hydroxyethyl)-rapamycin; 40-O-(2-Hydroxyethyl)rapamycin; Afinitor; Certican; Everolimus; RAD; RAD 001; RAD, SDZ; RAD001; SDZ RAD; SDZ-RAD; Zortress; 159351-69-6; 42-O-(2-Hydroxyethyl)rapamycin; Votubia; Afinitor Disperz; CHEBI:68478; RAD-001; Rapamycin, 42-O-(2-hydroxyethyl)-; UNII-9HW64Q8G6G; 9HW64Q8G6G; NCGC00167512-01; Everolimus (RAD001); (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1,18-dihydroxy-12-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; everolimusum; NSC733504; Everolimus solution; Everolimus (INN); SDZRAD; XIENCE V; Everolimus - RAD001; SCHEMBL4378; DSSTox_CID_20599; DSSTox_RID_79508; NVP-RAD001; DSSTox_GSID_40599; Everolimus [USAN:INN:BAN]; NVP-RAD-001; Everolimus, analytical standard; GTPL5889; RAD-001C; CHEMBL1908360; DTXSID0040599; HSDB 8255; RAD 666; RAD-666; Everolimus; RAD001; SDZ-RAD; C53H83NO14; 42-O-(2-Hydroxyethyl)-rapamycin; EX-A2057; Tox21_112510; BDBM50088378; AKOS015850977; ZINC169677008; CS-0064; DB01590; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; AS-16971; HY-10218; CAS-159351-69-6; V2036; Everolimus solution, 1.0 mg/ml in acetonitrile; 351E696; Q421052; Q-101413; BRD-K13514097-001-01-2; BRD-K13514097-001-05-3; dihydroxy-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxy-cyclohexyl]-1-methyl-ethyl]-dimethoxy-hexamethyl-[]pentone; Everolimus solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material"	6442177	C53H83NO14	Approved
M6ADRUG0106	Crizotinib	Xalkori (TN); novel ALK inhibitors; Crizotinibum; 	11626560	C21H22Cl2FN5O	Approved
M6ADRUG0107	Imatinib	Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI	5291	C29H31N7O	Approved
M6ADRUG0108	STM2457	"STM2457, STM-2457, CHEBI:172325, STM 2457, N-((6-(((cyclohexylmethyl)amino)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide, N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[6-[(cyclohexylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide, N-((6-(((cyclohexylmethyl)amino)methyl)imidazo(1,2-a)pyridin-2-yl)methyl)-4-oxo-4H-pyrido(1,2-a)pyrimidine-2-carboxamide, N-((6-((cyclohexylmethylamino)methyl)imidazo(1,2-a)pyridin-2-yl)methyl)-4-oxopyrido(1,2-a)pyrimidine-2-carboxamide, 2499663-01-1, CHEMBL5291234, SCHEMBL22499068, GTPL11529, EX-A5018, STM2457, BDBM50611061, s9870, AKOS040759643, AT32657, AC-36769, MS-28015, HY-134836, CS-0159584, N-((6-((Cyclohexylmethylamino)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide, N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide, STM2457, STM-2457, CHEBI:172325, STM 2457, N-((6-(((cyclohexylmethyl)amino)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide, N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[6-[(cyclohexylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide, N-((6-(((cyclohexylmethyl)amino)methyl)imidazo(1,2-a)pyridin-2-yl)methyl)-4-oxo-4H-pyrido(1,2-a)pyrimidine-2-carboxamide, N-((6-((cyclohexylmethylamino)methyl)imidazo(1,2-a)pyridin-2-yl)methyl)-4-oxopyrido(1,2-a)pyrimidine-2-carboxamide, 2499663-01-1, CHEMBL5291234, SCHEMBL22499068, GTPL11529, EX-A5018, STM2457, BDBM50611061, s9870, AKOS040759643, AT32657, AC-36769, MS-28015, HY-134836, CS-0159584, N-((6-((Cyclohexylmethylamino)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide, N-[(6-{[(cyclohexylmethyl)amino]methyl}imidazo[1,2-a]pyridin-2-yl)methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide"	155167581	C25H28N6O2	Investigative
M6ADRUG0109	Xuefu Zhuyu decoction	.	.	.	Investigative
M6ADRUG0110	Verbascoside	"Verbascoside, Acteoside, 61276-17-3, Kusaginin, TJC 160, NSC 603831, TJC-160, UNII-3TGX09BD5B, 3TGX09BD5B, RUSSETINOL, STEREOSPERMIN, CHEBI:132853, NSC-603831, VERBASCOSIDE (USP-RS), VERBASCOSIDE [USP-RS], 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-alpha-L-mannopyranosyl)-4-O-((2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl)-beta-D-glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-alpha-L-mannopyranosyl)-4-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-D-glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(alpha-L-rhamnopyranosyl)-4-O-((2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl)-beta-D-glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(alpha-L-rhamnopyranosyl)-4-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-D-glucopyranoside, acetoside, Verbacoside, C29H36O15, [(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate, beta-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-alpha-L-mannopyranosyl)-, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate], MFCD00221751, (2R,3R,4R,5R,6R)-6-(3,4-Dihydroxyphenethoxy)-5-hydroxy-2-(hydroxymethyl)-4-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-3-yl (E)-3-(3,4-dihydroxyphenyl)acrylate, [(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-tetrahydropyran-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate, Reh-acteoside, .BETA.-D-GLUCOPYRANOSIDE, 2-(3,4-DIHYDROXYPHENYL)ETHYL 3-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)-, 4-((2E)-3-(3,4-DIHYDROXYPHENYL)-2-PROPENOATE), .beta.-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-.alpha.-L-mannopyranosyl)-, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate], Acteoside; Verbascoside, Verbascoside (Standard), Acetoside (Verbascoside), Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-alpha-L-mannopyranosyl)-, 4-(3-(3,4-dihydroxyphenyl)-2-propenoate), (E)-beta-D-, MLS002473233, SCHEMBL657970, CHEBI:9953, CHEMBL231853, CHEMBL444478, cid_5281800, GTPL12550, HY-N0021R, Verbascoside, >=99% (HPLC), cid_24978601, DTXSID701021953, HMS2205K11, HY-N0021, BDBM50241867, MSK000876, s5458, AKOS015897165, CCG-270269, DB12996, OV08034, NCGC00378687-03, AS-75167, SMR001397320, 1ST000876, NS00070422, B864379, Q411426, BRD-K36201510-001-06-7, Verbascoside, primary pharmaceutical reference standard, Verbascoside, United States Pharmacopeia (USP) Reference Standard, ((2R,3R,4R,5R,6R)-6-(3,4-dihydroxyphenethoxy)-5-hydroxy-2-(hydroxymethyl)-4-((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)tetrahydro-2H-pyran-3-yl) 3-(3,4-dihydroxyphenyl)acrylate, ((2R,3R,4R,5R,6R)-6-(3,4-dihydroxyphenethoxy)-5-hydroxy-2-(hydroxymethyl)-4-((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)tetrahydro-2H-pyran-3-yl)3-(3,4-dihydroxyphenyl)acrylate, (2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate, (3,4-Dihydroxyphenyl)ethyl O-.alpha.-rhamnopyranosyl(1->3)-4-O-caffeoyl-.beta.-D glucopyranoside, .beta.-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl3-O-(6-deoxy-.alpha.-L-mannopyranosyl)-, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate], |A-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-|A-L-mannopyranosyl)-, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate]"	5281800	C29H36O15	Investigative
M6ADRUG0111	Tislelizumab	.	.	.	Approved
M6ADRUG0113	Tegaserod	Tegaserod (USAN/INN); 1-[[(Z)-(5-methoxyindol-3-ylidene)methyl]amino]-2-pentylguanidine	135409453	C16H23N5O	Approved
M6ADRUG0115	Spautin 1	"Spautin-1; 1262888-28-7; 6-Fluoro-N-(4-fluorobenzyl)quinazolin-4-amine; 6-fluoro-N-[(4-fluorophenyl)methyl]quinazolin-4-amine; CHEMBL2391504; 6-Fluoro-N-[(4-Fluorophenyl)methyl]-4-quinazolinamine; 4-Quinazolinamine, 6-fluoro-N-[(4-fluorophenyl)methyl]-; Spautin-1 analogue; MBCQ derivative C43; MLS006010730; SCHEMBL1068401; AOB5088; EX-A668; HMS3750O05; HMS3871D13; Spautin-1, >=98% (HPLC); BCP15695; BCP16463; BDBM50069761; MFCD16962292; s7888; ZINC41470892; AKOS016367939; CCG-267171; CS-4616; MCULE-4088585655; SB19056; NCGC00263555-02; NCGC00263555-05; NCGC00263555-07; AK161228; AS-69827; HY-12990; SMR004701692; DS-017062; B5873; FT-0700152; J-690113; Spautin 1 analogue;Spautin1 analogue;N-(4-chlorobenzyl)-6-fluoroquinazoline-4-amine; C43"	51037431	C15H11F2N3	Preclinical
M6ADRUG0116	Short-chain fatty acid-butyric acid	"butyric acid, butanoic acid, 107-92-6, n-Butanoic acid, propylformic acid, ethylacetic acid, 1-propanecarboxylic acid, Butanic acid, 1-Butyric acid, Buttersaeure, Butyric acid (natural), Kyselina maselna, FEMA No. 2221, Propanecarboxylic acid, 1-butanoic acid, acide butyrique, butoic acid, Butyricum acidum, CCRIS 6552, HSDB 940, NSC 8415, acide butanoique, NORMAL BUTYRIC ACID, AI3-15306, NSC-8415, EINECS 203-532-3, UNII-40UIR9Q29H, BRN 0906770, 40UIR9Q29H, C4:0, DTXSID8021515, CHEBI:30772, Acid, Butanoic, NSC8415, CH3-[CH2]2-COOH, DTXCID401515, EC 203-532-3, 4-02-00-00779 (Beilstein Handbook Reference), CH3-(CH2)2-COOH, Butyric Acid (Normal), Acid, Butyric, Tetranoic Acid, 203-532-3, 0.166666666666667, n-Butyric acid, butanoate, Buttersaeure [German], FEMA Number 2221, Kyselina maselna [Czech], fattyacids, MFCD00002814, 2-butanoate, UN2820, BUTYRIC ACID (D8), Butyric acid [UN2820]  [Corrosive], Sodium n-butyrate, BUA, CAS-107-92-6, sodium-butyrate, Honey robber, ethyl acetic acid, 1ugp, 3umq, butanoic acid, 4, TNFa + NaBut, 715 - Chocolate, Butyrate, sodium salt, Butyric acid [UN2820] [Corrosive], BUTYRIC_ACID, n-C3H7COOH, TNFa + Sodium Butyrate, Butyric acid, >=99%, bmse000402, BUTYRIC ACID [MI], NCIMech_000707, BUTYRIC ACID [FCC], WLN: QV3, BUTYRIC ACID [HSDB], BUTYRIC ACID [VANDF], CHEMBL14227, BUTYRIC ACID [WHO-DD], Butyric acid, >=99%, FG, N-BUTYRIC ACID [FHFI], GTPL1059, BUTYRICUM ACIDUM [HPUS], BDBM26109, Butyric acid, analytical standard, Bio1_000444, Bio1_000933, Bio1_001422, STR06290, Tox21_202382, Tox21_300164, CCG-35836, FA 4:0, LMFA01010004, STL169349, AKOS000118961, MSK1702-1000W, DB03568, UN 2820, NCGC00247914-01, NCGC00247914-02, NCGC00247914-05, NCGC00253919-01, NCGC00259931-01, BP-21420, FB159569, NCI60_001424, Butyric acid, natural, >=99%, FCC, FG, DB-318878, B0754, Butyric acid Solution in Water, 1000ug/mL, NS00001284, Butyric acid 1000 microg/mL in Acetonitrile, Butyric acid, SAJ special grade, >=99.5%, EN300-21334, C00246, Q193213, BRD-K05878375-236-02-4, BRD-K05878375-236-05-7, BRD-K05878375-236-06-5, 9B27B3D0-9643-40EC-9A5F-7CA1A6ED7F9F, F2191-0094, Z104495380, InChI=1/C4H8O2/c1-2-3-4(5)6/h2-3H2,1H3,(H,5,6"	264	C4H8O2	Phase 4
M6ADRUG0117	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH"	439155	C14H20N6O5S	Investigative
M6ADRUG0118	Rucaparib	"283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one"	9931954	C19H18FN3O	Approved
M6ADRUG0119	Rituximab	MAbThera (TN)	.	.	Approved
M6ADRUG0120	RHEIN	"478-43-3; Monorhein; Rheic acid; Rhubarb Yellow; Cassic acid; 4,5-Dihydroxyanthraquinone-2-carboxylic acid; Chrysazin-3-carboxylic acid; 4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; NSC 38629; Rheinic acid; 1,8-Dihydroxyanthraquinone-3-carboxylic acid; dipropionyl rhein; 1,8-Dihydroxy-3-carboxyanthraquinone; UNII-YM64C2P6UX; Rhein(Monorhein); 2-Anthracenecarboxylic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-; CCRIS 5129; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid; C15H8O6"	10168	C15H8O6	Investigative
M6ADRUG0121	Remimazolam	"CNS-7054; CNS-7056; CNS-7056B; CNS-7056X; GW-351564X; GW-418259X; GW-457837A; GW-502056X; ONO-2745; Short-acting sedatives, Therasci; GABA A agonist (anesthesia, sedation) CeNeS/Ono; Sedatives (short acting), CeNeS/Ono; Sedatives (short acting), PAION/Ono; Sedatives (short-acting), TheraSci; Short-acting sedatives, Therasci/GSK; Sedatives (short-acting), TheraSci/GSK"	9867812	C21H19BrN4O2	Approved
M6ADRUG0122	Regorafenib	755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]	11167602	C21H15ClF4N4O3	Approved
M6ADRUG0123	Raltitrexed	"Tomudex; 112887-68-0; ZD1694; ZD-1694; ICI-D1694; D-1694; ZD 1694; ICI D1694; UNII-FCB9EGG971; D1694; D 1694; CHEBI:5847; Raltitrexed (Tomudex); C21H22N4O6S; ZD-16; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; FCB9EGG971; CHEMBL225071; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; ICI-D-1694; NSC-639186; NCGC00229704-01; DSSTox_RID_81653; DSSTox_CID_26482; DSSTox_GSID_46482"	135400182	C21H22N4O6S	Approved
M6ADRUG0124	Propranolol	"Anaprilin; Anapriline; Avlocardyl; Bedranol; Berkolol; Betachron; Betadren; Betalong; Caridolol; Corpendol; Dociton; Efektolol; Etalong; Euprovasin; Herzbase; Ikopal; Inderal; Inderalici; Inderex; Inderol; Intermigran; Kemi; Migrastat; Naprilin; Obsidan; Obzidan; Pranolol; Pronovan; Propanalol; Propanix; Propanolol; Propranalol; Propranololo; Propranololum; Proprasylyt; Reducor; Sawatal; Servanolol; Sumial; Beta Neg; Inderal hydrochloride; Kemi S; Propranolol Hcl Intensol; Propranololo [DCIT]; Racemic propranolol; Reducorline; AY 64043; AY-20694; Anaprilinum (TN); Avlocardyl (TN); Beta-Propranolol; Beta-Tablinen; Beta-Timelets; DL-Propranolol hydrochloride; Deralin (TN); Dociton (TN); Inderal (TN); Inderal LA (TN); Inderalici (TN); InnoPran XL (TN); Propanolol [INN-Spanish]; Propranolol (INN); Propranolol (TN); Propranolol [INN:BAN]; Propranololum [INN-Latin]; Sumial (TN); D,L-Propranolol; INDERIDE-40/25; R,S-Propranolol Hydrochloride; (+-)-Propranolol; (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; (R)-(+)-propranolol; (S)-(-)-PROPRANOLOL; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-(9CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-(9CI); 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol"	4946	C16H21NO2	Approved
M6ADRUG0125	Phenethyl isothiocyanate	"2-Phenylethyl isothiocyanate, Phenethyl isothiocyanate, 130638, Phenylethyl isothiocyanate, (2-Isothiocyanatoethyl)benzene, Benzene, (2-isothiocyanatoethyl)-, PEITC, Phenylaethylsenfoel, PHENETHYLISOTHIOCYANATE, ISOTHIOCYANIC ACID, PHENETHYL ESTER, 2-phenethyl isothiocyanate, beta-Phenylethyl isothiocyanate, .beta.-Phenylethyl isothiocyanate, CHEBI:351346, 6U7TFK75KV, beta-Phenethyl isothiocyanate, Phenylaethylsenfoel [German], NSC 87868, CCRIS 3146, DTXSID5021120, EINECS 218-855-5, NSC-87868, BRN 2084162, DTXCID901120, FEMA NO. 4014, NSC87868, PHENETHYL ISOTHIOCYANATE [MI], PHENYLETHYL ISOTHIOCYANATE [FHFI], 4-12-00-02476 (Beilstein Handbook Reference), 2Phenylethyl isothiocyanate, betaPhenethyl isothiocyanate, betaPhenylethyl isothiocyanate, (2Isothiocyanatoethyl)benzene, Benzene, (2isothiocyanatoethyl), 218-855-5, 130638, 2-isothiocyanatoethylbenzene, phenethyl-isothiocyanate, MFCD00004821, CHEMBL151649, .beta.-Phenethyl isothiocyanate, 1-Isothiocyanato-2-phenylethane, Isothiocyanic Acid 2-Phenylethyl Ester, 2-phenylethylisothiocyanate, 1-ISOTHIOCYANATO-2-PHENYLETHANE (1,1,2,2-D4), 2-Phenylethyl Isothiocyanate; (2-Isothiocyanatoethyl)benzene; Phenethyl Mustard Oil;, WLN: SCN2R, ss-Phenethyl isothiocyanate, Epitope ID:138724, UNII-6U7TFK75KV, SCHEMBL156960, Phenethyl isothiocyanate, 99%, IZJDOKYDEWTZSO-UHFFFAOYSA-, (2-Isothiocyanato-ethyl)-benzene, (2-Isothiocyanatoethyl)benzene #, 1-(2-isothiocyanatoethyl)benzene, 2-Phenylethyl isothiocyanate, FG, HMS1783C17, HMS3870G13, Tox21_200100, (2-Isothiocyanatoethyl)benzene, 9CI, BBL009999, BDBM50240850, STK397325, AKOS000119469, DB12695, FP08224, JC-5411, NCGC00248526-01, NCGC00257654-01, AC-12769, AS-17373, BP-12941, DA-66670, HY-23155, NCI60_041942, CAS-2257-09-2, DB-045947, Isothiocyanic acid .beta.-phenylethyl ester, NS00013118, P0986, Phenethyl isothiocyanate, analytical standard, EN300-17386, D92051, Q7181339, BRD-K56700933-001-02-1, BRD-K56700933-001-03-9, Phenethyl isothiocyanate; 2-Phenylethyl isothiocyanate, Z56924472, F0001-0795, InChI=1/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2"	16741	C9H9NS	Investigative
M6ADRUG0126	Perhexiline	"Perhexilene; Perhexilina; Perhexilinum; Perhexilline; Perhexilina [INN-Spanish]; Perhexiline (INN); Perhexiline [INN:BAN]; Perhexilinum [INN-Latin]; (+)-2-(2,2-Dicyclohexylethyl)piperidine; (-)-2-(2,2-Dicyclohexylethyl)piperidine; 2-(2,2-Dicyclohexylethyl)piperidine"	4746	C19H35N	Approved
M6ADRUG0127	Oxymatrine	"Oxymatrine, Matrine, 1-oxide, 16837-52-8, 85U4C366QS, OXYMATRINE [WHO-DD], UNII-85U4C366QS, Matrine N-oxide, HSDB 8102, Matrine 1beta-oxide, Matridin-15-one, 1-oxide, (1-beta)-, (4R,7AS,13AR,13BR,13CS)-DODECAHYDRO-1H,5H,10H-DIPYRIDO(2,1-F:3',2',1'-IJ)(1,6)NAPHTHYRIDIN-10-ONE 4-OXIDE, (7AS,13AR,13BR,13CS)-DODECAHYDRO-1H,5H,10H-DIPYRIDO(2,1-F:3',2',1'-IJ)(1,6)NAPHTHYRIDIN-10-ONE 4-OXIDE, 1H,5H,10H-Dipyrido(2,1-f:3',2',1'-ij)(1,6)naphthyridin-10-one, dodecahydro-, 4-oxide, (4R,7aS,13aR,13bR,13cS)-, (7aS,13aR,13bR,13cS)-dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one 4-oxide, 1H,5H,10H-Dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one, dodecahydro-, 4-oxide, (4R,7aS,13aR,13bR,13cS)-, 605-514-4, (1r,2r,9s,17s)-13-oxido-7-aza-13-azoniatetracyclo(7.7.1.02,7.013,17)heptadecan-6-one, (1r,2r,9s,17s)-13-oxido-7-aza-13-azoniatetracyclo[7.7.1.02,7.013,17]heptadecan-6-one, 5-hydroxy-5,6-dihydrobenzo(b)(1)benzazepine-11-carboxamide, 5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide, xvpbinopnyfxid-lhduffhysa-n, Ammothamnine, Matrine oxide, Oxymatrine (Standard), HY-N0158R, HY-N0158, CS-6157, Q63396010"	24864132	C15H24N2O2	Investigative
M6ADRUG0129	OSMI-1	"OSMI-1, 1681056-61-0, (R)-N-(furan-2-ylmethyl)-2-(2-methoxyphenyl)-2-(2-oxo-1,2-dihydroquinoline-6-sulfonamido)-N-(thiophen-2-ylmethyl)acetamide, OSMI 1, (2R)-N-(furan-2-ylmethyl)-2-(2-methoxyphenyl)-2-[(2-oxo-1H-quinolin-6-yl)sulfonylamino]-N-(thiophen-2-ylmethyl)acetamide, ylmethyl)acetamide, (aR)-a-[[(1,2-Dihydro-2-oxo-6-quinolinyl)sulfonyl]amino]-N-(2-furanylmethyl)-2-methoxy-N-(2-thienylmethyl)benzeneacetamide; (R)-N-(Furan-2-ylmethyl)-2-(2-methoxyphenyl)-2-(2-oxo-1,2-dihydroquinoline-6-sulfonamido)-N-(thiophen-2-ylmethyl)acetamide, OSMI1, SCHEMBL17405138, CHEBI:139128, DTXSID401104617, GLXC-06077, (2R)-N-[(furan-2-yl)methyl]-2-(2-methoxyphenyl)-2-(2-oxo-1,2-dihydroquinoline-6-sulfonamido)-N-[(thiophen-2-yl)methyl]acetamide, (R)-N-(Furan-2-ylmethyl)-2-(2-methoxyphenyl)-2-(2-oxo- 1,2-dihydroquinoline-6-sulfonamido)-N-(thiophen-2- ylmethyl)acetamide, EX-A4758, s9835, AKOS040742350, OSMI-1, >=98% (HPLC), (2R)-N-(2-furylmethyl)-2-(2-methoxyphenyl)-2-{[(2-oxo-1,2-dihydroquinolin-6-yl)sulfonyl]amino}-N-(2-thienylmethyl)acetamide, AC-36678, BO168473, DA-66389, HY-119738, CS-0077906, E78764, 1,2-dihydroquinoline-6-sulfonamido)-N-(thiophen-2-, (R)-N-(Furan-2-ylmethyl)-2-(2-methoxyphenyl)-2-(2-oxo-, (2R)-N-(FURAN-2-YLMETHYL)-2-(2-METHOXYPHENYL)-2-(2-OXO-1H-QUINOLINE-6-SULFONAMIDO)-N-(THIOPHEN-2-YLMETHYL)ACETAMIDE, (aR)-a-[[(1,2-Dihydro-2-oxo-6-quinolinyl)sulfonyl]amino]-N-(2-furanylmethyl)-2-methoxy-N-(2-thienylmethyl)benzeneacetamide, (I+/-R)-I+/--[[(1,2-Dihydro-2-oxo-6-quinolinyl)sulfonyl]amino]-N-(2-furanylmethyl)-2-methoxy-N-(2-thienylmethyl)benzeneacetamide, (R)-N-(furan-2-ylmethyl)-2-(2-methoxyphenyl)-2-((2-oxo-1,2-dihydroquinoline)-6-sulfonamido)-N-(thiophen-2-ylmethyl)acetamide, [(alphar)-alpha-[[(1,2-dihydro-2-oxo-6-quinolinyl)sulfonyl]amino]-N-(2-furanyl methyl)-2-methoxy-N-(2-thienylmethyl)-benzeneacetamide"	118634407	C28H25N3O6S2	.
M6ADRUG0130	Nicotine	"Habitrol; Micotine; NCT; NICOTINE AND SALTS; Nicoderm Patch; Nicotina [Italian]; Nicotine Patch; Nicotine [USAN]; Nicotine replacement patch; Nicotine solution; Nictoine patch; Nikotin [German]; Nikotyna [Polish]; Transdermal Nicotine; Nicotine [UN1654] [Poison]; ENT 3,424; Habitrol (TN); Nicorette (TN); Nicotine (USP); Nicotine (compounds related to); Nicotine [BSI:ISO]; L(-)-nicotine; Beta-Pyridyl-alpha-N-methyl pyrrolidine; (-)-Nicotine solution; (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine; (S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE; (S)-(-)-Nicotine; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; (S)-3-(N-methylpyrrolidin-2-yl)pyridine; (S)-Nicotine; 3-(2-(N-methylpyrrolidinyl))pyridine; 3-(N-Methylpyrollidino)pyridine; 3-(N-Methylpyrrolidino)pyridine; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine"	89594	C10H14N2	Approved
M6ADRUG0132	Mitoxantrone	"DHAD; DHAQ; Dihydroxyanthraquinone; MIX; Misostol; Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantronum; Mitozantrone; DHAQ HCl; Mitoxantrone [INN]; Mitozantrone hydrochloride; Mitoxantrone 2HCl; Liposome Encapsulated Mitoxantrone (LEM); Misostol (TN); Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantronum [INN-Latin]; Novantrone (TN); AN-584/42007670; Novantrone(R) (mitoxantrone for injection concentrate); DHAQ (*Diacetate salt*); MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI)"	4212	C22H28N4O6	Approved
M6ADRUG0133	MICROCYSTIN-LR	"Akerstox; Microcystin-a; 5-L-Argininecyanoginosin LA; Toxin I (Microcystis aeruginosa); Cyanoginosin LA, 5-L-arginine-; Toxin T 17 (Microcystis aeruginosa); BRN 4779759; Toxin, blue green alga, Microcystis aeruginosa; AC1O5MXK; DTXSID00424146; 128657-50-1; LS-55782"	445434	C49H74N10O12	Investigative
M6ADRUG0134	Methyl piperidine-3-carboxylate	"methyl piperidine-3-carboxylate, 50585-89-2, Piperidine-3-carboxylic acid methyl ester, methyl nipecotate, Methylpiperidine-3-carboxylate, MFCD00797850, 3-Piperidinecarboxylic acid, methyl ester, MFCD09752680, METHYL 3-PIPERIDINECARBOXYLATE, NSC522506, nipecotic acid methylester, 3-methoxycarbonylpiperidine, SCHEMBL763374, DTXSID20325989, BCDBHIAXYFPJCT-UHFFFAOYSA-N, Methyl (S)-3-piperidinecarboxylate, BBL101450, STL555246, AKOS005259002, AC-5453, CS-W005063, FM56436, NSC-522506, PB17641, PB34398, SB10235, 3-piperidinecarboxylic acid methyl ester, DS-10878, SY003160, SY030269, DB-007697, EN300-25335, A828186, Piperidine-3-carboxylic acid methyl ester;Methyl nipecotate"	351626	C7H13NO2	.
M6ADRUG0135	LPS	"OD29173, Lipopolysaccharide;KDO-(a,2-4)-KDO-(a,2-6)-lipid A;KDO2-Lipid A;KLA, Di[3-deoxy-D-manno-octulosonyl]-lipid A sodium salt - 0.5mg/ml aqueous solution, OD29173, Lipopolysaccharide;KDO-(a,2-4)-KDO-(a,2-6)-lipid A;KDO2-Lipid A;KLA, Di[3-deoxy-D-manno-octulosonyl]-lipid A sodium salt - 0.5mg/ml aqueous solution"	172642637	C110H198N2Na4O39P2	.
M6ADRUG0136	Liproxstatin-1	"Liproxstatin-1, 950455-15-9, Liproxstatin 1, Lip-1, liproxstatin1, N-(3-Chlorobenzyl)-1'H-spiro[piperidine-4,2'-quinoxalin]-3'-amine, CHEBI:173097, N-[(3-CHLOROPHENYL)METHYL]-1'H-SPIRO[PIPERIDINE-4,2'-QUINOXALIN]-3'-AMINE, N-(3-chlorobenzyl)-1'H-spiro(piperidine-4,2'-quinoxalin)-3'-amine, N-((3-chlorophenyl)methyl)-1'H-spiro(piperidine-4,2'-quinoxalin)-3'-amine, N-[(3-chlorophenyl)methyl]spiro[1,4-dihydroquinoxaline-3,4'-piperidine]-2-imine, 1-(3-chlorophenyl)-N-{1',4'-dihydrospiro[piperidine-4,2'-quinoxalin]-3'-ylidene}methanamine, MFCD14948691, C19H21ClN4, CHEMBL2094750, SCHEMBL17757281, EX-A558, Liproxstatin-1, >98% (HPLC), BCP15985, DNDI1417503, s7699, AKOS001973583, N-[(3-chlorophenyl)methyl]spiro[4H-quinoxaline-3,4'-piperidine]-2-amine, CCG-175950, CS-3994, AC-33023, BS-18273, DA-65002, HY-12726, EN300-202271, F17363, N-[(3-chlorophenyl)methyl]-1'H-spiro[piperidine-4,2'-quinoxaline]-3'-amine"	135735917	C19H21ClN4	.
M6ADRUG0138	Lenvatinib	"E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide"	9823820	C21H19ClN4O4	Approved
M6ADRUG0139	Isoforsythiaside	"Isoforsythiaside, [(2R,3R,4S,5R,6R)-2-[2-(3,4-dihydroxyphenyl)ethoxy]-3,5-dihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-4-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate, ((2R,3R,4S,5R,6R)-2-(2-(3,4-dihydroxyphenyl)ethoxy)-3,5-dihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl)oxan-4-yl) (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate, Forsythoside I, 1177581-50-8, ForsythosideI, 1357910-26-9, ACon1_001686, HY-N5042, MFCD32645094, MSK156851, AKOS037514702, FF74345, NCGC00180246-01, DA-53382, DA-54419, MS-30811, 1ST156851, CS-0032163, D85071, (2R,3R,4S,5R,6R)-2-(3,4-Dihydroxyphenethoxy)-3,5-dihydroxy-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-4-yl (E)-3-(3,4-dihydroxyphenyl)acrylate"	23958169	C29H36O15	.
M6ADRUG0140	IOX1	"5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, > AKOS016371793"	459617	C10H7NO3	Investigative
M6ADRUG0141	iFSP1	"13-Amino-11-(4-methylphenyl)-1,8-diazatricyclo[7.4.0.0,2,7]trideca-2,4,6,8,10,12-hexaene-10,12-dicarbonitrile, 851-482-1, iFSP1, 150651-39-1, 1-Amino-3-p-tolyl-benzo[4,5]imidazo[1,2-a]pyridine-2,4-dicarbonitrile, 1-amino-3-(4-methylphenyl)pyrido[1,2-a]benzimidazole-2,4-dicarbonitrile, MLS000578038, SMR000187223, MFCD01572665, iFSP 1, iFSP-1, iFSP1, Oprea1_094186, cid_699043, CHEMBL1490169, SCHEMBL16941529, BDBM54217, CHEBI:176501, HMS2306H22, AGA65139, EX-A4300, s9663, STK759754, 1-amino-3-(p-tolyl)benzo[4,5]imidazo[1,2-a]pyridine-2,4-dicarbonitrile, AKOS000122129, AC-36527, BS-45796, DA-74421, HY-136057, CS-0119295, EU-0085305, EN300-02854, E73442, AB00097494-01, AG-205/37224011, SR-01000523391, SR-01000523391-1, Z55430237, 1-amino-3-(p-tolyl)pyrido[1,2-a]benzimidazole-2,4-dicarbonitrile, 1-azanyl-3-(4-methylphenyl)pyrido[1,2-a]benzimidazole-2,4-dicarbonitrile, 1-AMINO-2-CYANO-3-(4-METHYLPHENYL)PYRIDO[1,2-A][1,3]BENZIMIDAZOL-4-YL CYANIDE, 13-AMINO-11-(4-METHYLPHENYL)-1,8-DIAZATRICYCLO[7.4.0.0(2),]TRIDECA-2,4,6,8,10,12-HEXAENE-10,12-DICARBONITRILE, 13-amino-11-(4-methylphenyl)-1,8-diazatricyclo[7.4.0.0,2,7]trideca-2(7),3,5,8,10,12-hexaene-10,12-dicarbonitrile"	699043	C20H13N5	.
M6ADRUG0142	ICG-001	"ICG-001, 847591-62-2, 780757-88-2, ICG 001, (S,S)-ICG 001, (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide, ICG001, (6S,9aS)-6-(4-hydroxybenzyl)-N-benzyl-8-(naphthalen-1-ylmethyl)-4,7-dioxo-hexahydro-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide, (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-8-(naphthalen-1-ylmethyl)-4,7-dioxo-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide, CHEMBL2312139, (6S,9AS)-N-BENZYL-6-(4-HYDROXYBENZYL)-8-(NAPHTHALEN-1-YLMETHYL)-4,7-DIOXOHEXAHYDRO-2H-PYRAZINO[1,2-A]PYRIMIDINE-1(6H)-CARBOXAMIDE, 780757-88-2 (ICG001), (5R,6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-8-[(naphthalen-1-yl)methyl]-4,7-dioxohexahydro-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide, (6S,9aS)-6-(4-Hydroxybenzyl)-8-[(naphthalen-1-yl)methyl]-4,7-dioxohexahydropyrazino[1,2-a]pyrimidine-1-carboxylic acid N-benzylamide, PRI 724, (6S,9AS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-8-(NAPHTHALEN-1-YLMETHYL)-4,7-DIOXO-TETRAHYDRO-2H-PYRAZINO[1,2-A]PYRIMIDINE-1-CARBOXAMIDE, MFCD12196918, MLS006011197, SCHEMBL178745, CHEBI:95032, (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-8-[(naphthalen-1-yl)methyl]-4,7-dioxo-octahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide, EX-A1745, ICG-001, XIB59162, BDBM50468575, HB0331, NSC756641, s2662, s8262, AKOS015966600, BCP9000771, CCG-269997, CCG-269998, CS-0273, FI24532, NSC-756641, NCGC00263116-01, (6S,9AS)-HEXAHYDRO-6-[(4-HYDROXYPHENYL)METHYL]-8-(1-NAPHTHALENYLMETHYL)-4,7-DIOXO-N-(PHENYLMETHYL)-2H-PYRAZINO[1,2-A]PYRIMIDINE-1(6H)-CARBOXAMIDE, AC-32988, AS-16543, HY-14428, SMR004702966, BRD-K73261812-001-01-1, Q27166797, (6S,9aS)-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide, (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrimido[1,2-a]pyrazine-1-carboxamide, (6S,9aS)-rel-hexahydro-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-  1(6H)-carboxamide"	11238147	C33H32N4O4	Investigative
M6ADRUG0143	ICARIIN	"489-32-7; Ieariline; UNII-VNM47R2QSQ; CHEBI:78420; VNM47R2QSQ; Icariine; 3-((6-Deoxymannopyranosyl)oxy)-7-(glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one; Icarin; 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-7-(be"	5318997	C33H40O15	Investigative
M6ADRUG0144	Hydroxyurea	"Biosupressin; Droxia; Hidrix; Hidroxicarbamida; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxycarbamine; Hydroxyharnstoff; Hydroxylurea; Hydura; Hydurea; Idrossicarbamide; Litaler; Litalir; Mylocel; NHY; Oncocarbide; Oxyurea; Siklos; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; Hydroxyharnstoff [German]; Idrossicarbamide [DCIT]; H 8627; SK 22591; SQ 1089; DRG-0253; Droxia (TM); Droxia (TN); HYDREA (TN); HYDROXY-UREA; Hidroxicarbamida [INN-Spanish]; Hydrea (TM); Hydroxycarbamidum [INN-Latin]; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; Onco-carbide; SQ-1089; Tetratogen: inhibits ribonucleoside diphosphate reductase; Hydroxycarbamide (JAN/INN); N-(Aminocarbonyl) Hydroxyamine; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; S-phase/G-1 interface inhibitor; 1-HYDROXYUREA"	3657	CH4N2O2	Approved
M6ADRUG0147	LY2157299	"Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	C22H19N5O	Investigative
M6ADRUG0148	Fluorene-9-bisphenol	"3236-71-3, 9,9-Bis(4-hydroxyphenyl)fluorene, Fluorene-9-bisphenol, Phenol, 4,4'-(9H-fluoren-9-ylidene)bis-, Bisphenol fluorenone, 9,9'-Bis(4-hydroxyphenyl)fluorene, 4-[9-(4-hydroxyphenyl)-9H-fluoren-9-yl]phenol, 4,4'-(9h-fluoren-9-ylidene)bisphenol, CHEBI:136855, 9,9-Bis(p-hydroxyphenyl)fluorene, EC 406-950-6, 9,9-bis[4-hydroxyphenyl]fluorene, 4-(9-(4-hydroxyphenyl)-9H-fluoren-9-yl)phenol, 406-950-6, 624-416-2, 4,4'-(9H-fluorene-9,9-diyl)diphenol, 4,4'-(9-Fluorenylidene)diphenol, bisphenol FL, 4-[9-(4-hydroxyphenyl)fluoren-9-yl]phenol, 9,9-bis (4-hydroxyphenyl) fluorene, MFCD00191392, DTXSID5037731, Fluorene-9-biphenol, BHPF, 4,4-(9-Fluorenylidene)diphenol, Q3VX5H3K3X, SCHEMBL45826, CHEMBL434829, DTXCID3017731, Bisphenol FL, analytical standard, BP_13, 9,9-bis(4'-hydroxyphenyl)fluorene, 9,9-bis(4-hydroxyphenyl) fluorene, BCP26097, Tox21_301584, 9,9-bis (4-hydroxyphenyl)-fluorene, 9,9-bis-(4-hydroxyphenyl)-fluorene, AKOS005255127, AC-4552, AC-4883, CS-W009810, SB66591, 9,9-bis(4-hydroxyphenyl)-9h-fluorene, NCGC00164160-01, NCGC00255689-01, 4,4'-(9-Fluorenylidene)diphenol, 97%, 4,4'-(9-Fluorenylidene)diphenol, 98%, AS-13055, CAS-3236-71-3, 4,4'-(9H-Fluoren-9-ylidene)bis[phenol], DB-028624, B1715, B4834, NS00001837, A10981, Q29460410, 9,9-Bis(4-hydroxyphenyl)fluorene (purified by sublimation), 9,9-Bis(4-hydroxyphenyl)fluorene;9,9-Bis(4-hydroxyphenyl)fluorene"	76716	C25H18O2	.
M6ADRUG0149	Fludarabine	"FaraA; Fludarabina; Fludarabinum; Fluradosa; Fludarabina [Spanish]; Fludarabine [INN]; Fludarabinum [Latin]; SQ Fludarabine; Fludara, Fludarabine; Fludarabine (INN); Fluradosa (TN); F-Ara-A; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-F-ara-A; 2-Fluoro Ara-A; 2-Fluoro-9-beta-D-arabinofuranosyladenine; 9-beta-D-Arabinofuranosyl-2-fluoroadenine; 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-(9CI)"	657237	C10H12FN5O4	Approved
M6ADRUG0150	Ferrostatin-1	"Ferrostatin-1, 347174-05-4, Fer-1, ferrrostatin 1, 3-amino-4-cyclohexylaminobenzoic acid ethyl ester, CHEBI:173086, Ethyl 3-amino-4-(cyclohexylamino)benzoate, Ferrostatin-1 (Fer-1), Ferrostatin 1, Benzoic acid, 3-amino-4-(cyclohexylamino)-, ethyl ester, MFCD08072959, ethyl 3-amino-4-cyclohexylaminobenzoate, 3-amino-4-(cyclohexylamino)-benzoic acid, ethyl ester, Ferrostatin-1 (Fer-1), SCHEMBL2032512, CHEMBL3633556, SCHEMBL18137149, UJHBVMHOBZBWMX-UHFFFAOYSA-N, GLXC-04905, HMS3653M21, ALBB-024198, BCP17366, EX-A4243, s7243, AKOS003388952, CCG-267075, SB19587, Ethyl3-amino-4-(cyclohexylamino)benzoate, NCGC00370951-06, AC-36537, AS-57497, FE131927, SY270013, DB-297431, HY-100579, CS-0019733, F1302, SW219400-1, C74788, 3-Amino-4-cyclohexylaminobenzoic acid, ethyl ester, 3-Amino-4-cyclohexylamino-benzoic Acid Ethyl Ester, BRD-K97375133-001-01-3, BRD-K97375133-001-02-1, BRD-K97375133-001-03-9, 3-Amino-4-cyclohexylaminobenzoic Acid Ethyl Ester; Fer-1"	4068248	C15H22N2O2	.
M6ADRUG0151	Fentanyl	"Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT]; Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals"	3345	C22H28N2O	Approved
M6ADRUG0152	FB23-2	"2243736-45-8, FB23-2, 2-((2,6-Dichloro-4-(3,5-dimethylisoxazol-4-yl)phenyl)amino)-N-hydroxybenzamide, 2-[2,6-dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)anilino]-N-hydroxybenzamide, FB23-2(FTO Demethylase inhibitor FB23-2), CHEMBL4567838, SCHEMBL23261120, BDBM589237, GLXC-25980, BCP31164, EX-A3403, US11555009, Compound 25, MFCD32174281, s8837, AKOS040759087, AC-36448, DA-73314, MS-26546, HY-127103, CS-0093102, D81008, FB23-2(FTO Demethylase inhibitor FB23-2), FB-23-2; FB 23-2; FB232; FB-232; FB 232, 2-{[2,6-Dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]amino}-N-hydroxybenzamide"	138454779	C18H15CL2N3O3  	.
M6ADRUG0153	FB23	"FB23, 2243736-35-6, 2-((2,6-Dichloro-4-(3,5-dimethylisoxazol-4-yl)phenyl)amino)benzoic acid, 2-[[2,6-bis(chloranyl)-4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]amino]benzoic acid, Fb23 inhibitor, CHEMBL4572939, SCHEMBL23261118, BDBM589235, FB23, GLXC-25979, BCP33227, EX-A3402, FB-23;FB 23, TPD73635, US11555009, Compound 15, US11555009, Compound 29, s6291, AKOS040759557, AC-36734, MS-26128, HY-137187, CS-0136974, G17189, 2-[2,6-dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)anilino]benzoic acid, 2-{[2,6-dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]amino}benzoic acid, 8S3"	138393314	C18H14Cl2N2O3	.
M6ADRUG0154	Etoposide	"33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; Etoposido; Vepesid J; Eposin; Etoposidum [INN-Latin]; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP-16-213; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC 141540; CCRIS 2392; HSDB 6517; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EINECS 251-509-1; NSC-141540; Eposide; Etopol; Etosid; Vepeside; Demethyl EpipodophyllotoxinEthylidine Glucoside; E0675; Demethyl-epiodophyllotoxin ethylidene glucoside; Epipodophyllotoxin VP-16213; Eposin (TN); Etopophos (TN); VePESID (TN); DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; VP-16 (TN); Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Eposin, Vepesid, VP-16, Toposar, Etoposide; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside"	36462	C29H32O13	Approved
M6ADRUG0156	Erianin	"Erianin, 95041-90-0, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol, 2-methoxy-5-(3,4,5-trimethoxyphenethyl)phenol, CHEMBL10557, 2-Methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-phenol, Phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]-, Erianin, 2-Methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol; NSC 613744, Erianin (Standard), MFCD06795132, NSC613744, SCHEMBL1535646, GTPL13781, HY-N0517R, DTXSID40326751, CHEBI:233659, UXDFUVFNIAJEGM-UHFFFAOYSA-N, B817373-K388, same as, BCP07974, EX-A7098, HY-N0517, BDBM50005478, MSK175543, s9137, AKOS025401669, CCG-267683, NSC-613744, AC-24234, AS-78334, DB-347219, CS-0009056, B817373-K346, 7BA, Erianin2-methoxy-5-(3,4,5-trimethoxyphenethyl)phenol; 2-Methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-phenol, W4F"	356759	C18H22O5	.
M6ADRUG0157	Erastin	"ERASTIN, 571203-78-6, 2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4(3H)-Quinazolinone, CHEBI:94287, DTXSID80458949, 2-(1-(4-(2-(4-Chlorophenoxy)acetyl)-1-piperazinyl)ethyl)-3-(2-ethoxyphenyl)-4(3H)-quinazolinone, 2-(1-(4-((4-chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4(3H)-one, 2-(1-{4-[(4-chlorophenoxy)acetyl]piperazin-1-yl}ethyl)-3-(2-ethoxyphenyl)quinazolin-4(3H)-one, DTXCID70409768, 637-217-0, 2-(1-(4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4(3H)-one, MFCD09837984, 2-[1-[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4-one, Erastin, 2-(1-(4-(2-(4-Chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4-one, 2-[1-[4-[2-(4-Chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4(3H)-quinazolinone;, ZJA3NS42T9, CHEMBL401989, SCHEMBL4457820, Erastin, >=98% (HPLC), EX-A295, GLXC-05731, HMS3653K21, HMS3868M03, BCP27907, WXA20378, BDBM50376126, s7242, AKOS025147365, CCG-269987, CS-1675, Erastin - CAS 571203-78-6, SB19588, NCGC00351608-10, NCGC00351608-14, AC-35446, AS-55898, DA-42059, HY-15763, SY345515, E7781, SW208651-2, C21478, E-7781, BRD-A25004090-001-01-9, BRD-A25004090-001-02-7, BRD-A25004090-001-06-8, BRD-A25004090-001-08-4, BRD-A25004090-001-09-2, Q27166099, 2-[1-[4-[2-(4-chlorophenoxy)-1-oxoethyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4-quinazolinone, 2-[1-[4-[2-(4-Chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4(3H)-one, 4(3H)-Quinazolinone, 2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-, Piperazine, 1-((4-chlorophenoxy)acetyl)-4-(1-(3-(2-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl)ethyl)-"	11214940	C30H31ClN4O4	.
M6ADRUG0158	Enzalutamide	MDV3100; Enzalutamide (AR inhibitor)	15951529	C21H16F4N4O2S	Approved
M6ADRUG0160	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	C20H21F3N8O3S	Phase 2
M6ADRUG0161	Darolutamide	"1297538-32-9; BAY-1841788; N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Darolutamide [USAN]; Darolutamide (JAN/USAN/INN); SCHEMBL1814935; SCHEMBL13733117; KS-00000TSX; EX-A759; BLIJXOOIHRSQRB-PXYINDEMSA-N; MolPort-046-033-692; MolPort-044-560-277; AKOS030526387; CS-5174; BAY1841788; DB12941; BAY 1841788; HY-16985; S7559; FT-0700158; J3.501.129C; D11045; J-690121; 1H-Pyrazole-3-carboxamide, N-((1S)-2-(3-(3-chloro-4-cyanophen"	67171867	C19H19ClN6O2	Approved
M6ADRUG0162	Dactolisib	"dactolisib, 915019-65-7, NVP-BEZ235, BEZ235, NVP-BEZ 235, BEZ-235, 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile, NVPBEZ235, BEZ 235, NVP-BEZ-235, NVP BEZ235, Dactolisib [USAN], RTB101, RTB-101, Dactolisib [USAN:INN], RUJ6Z9Y0DT, NSC-751249, CHEBI:71952, DACTOLISIB [INN], DACTOLISIB [WHO-DD], 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile, DTXSID10238599, NSC 751249, 2-methyl-2-(4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-1h-imidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile, 2-methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile, 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile, Benzeneacetonitrile, 4-(2,3-dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-, dactolisibum, 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile, 2-methyl-2-(4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile, 2-Methyl-2-(4-{3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl}phenyl)propanenitrile, DTXCID10161090, BEZ235 (NVP-BEZ235, Dactolisib), 915019-65-7 (free base), 2-Methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, S1009, BEZ235 (NVP-BEZ235), 2-Methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile., UNII-RUJ6Z9Y0DT, MFCD10565944, Kinome_2911, CT-BEZ, Dactolisib (BEZ235), Dactolisib; BEZ-235, Dactolisib (USAN/INN), Nvp-bez235, free base, mTOR Inhibitor, BEZ235, NVP BEZ 235, NVP-BEZ235, SCHEMBL143623, GTPL7950, CHEMBL1879463, BDBM92862, EX-A404, BCPP000344, HMS3244G21, HMS3244G22, HMS3244H21, HMS3672E19, BCP00216, IVB20674, NSC751249, NSC755807, NSC800085, AKOS005217097, BCP9000397, CCG-207981, CS-0080, DB11651, ES-0038, FD26487, NSC-755807, NSC-800085, PB26555, SDCCGSBI-0646961.P003, Dactolisib (BEZ235, NVP-BEZ235), NCGC00187481-01, NCGC00187481-02, NCGC00187481-04, NCGC00187481-05, NCGC00187481-06, NCGC00187481-11, NCGC00187481-15, 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile, AC-25486, HY-50673, NS00071714, EN300-60135, D10552, Q4835503, BRD-K12184916-001-01-4, BRD-K12184916-001-15-4, BRD-K12184916-001-19-6, Z329731510, 1028385-31-0, 2-Methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)phenyl)propionitrile, 2-methyl-2-[4-[3-methyl-2-oxo-8-(3-quinolyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile, 2-METHYL-2-{4-[3-METHYL-2-OXO-8-(QUINOLIN-3-YL)-1H,2H,3H-IMIDAZO[4,5-C]QUINOLIN-1-YL]PHENYL}PROPANENITRILE, 4-[2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo[4, 5-c]quinolin-1-yl]-.alpha.,.alpha.-dimethylbenzeneacetonitrile, 4-[2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo[4,5-c]quinolin-1-yl]-,-dimethyl-benzeneacetonitrile;2-Methyl-2-[4-[3-met hyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile;BEZ 235"	11977753	C30H23N5O	Investigative
M6ADRUG0163	Dac51	"2243944-92-3, FTO-IN-1, UUN44923, Dac51, Benzamide, 2-[[2,6-dichloro-4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl]amino]-N-hydroxy-, 2-{[2,6-dichloro-4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl]amino}-N-hydroxybenzamide, 2-((2,6-dichloro-4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)amino)-N-hydroxybenzamide, SCHEMBL26228904, BDBM589244, EX-A5100, US11555009, Compound 32, UUN44923, TS-09945, HY-138843, CS-0169449, H39527, B6C"	152940130	C18H16Cl2N4O2	.
M6ADRUG0164	3-deazidenosine	"3-DEAZAADENOSINE, 6736-58-9, 3-deaza-adenosine, Deaza-Ado, Adenosine, 3-deaza-, UNII-037V4520IY, 3dAdo, 037V4520IY, NSC 167897, DTXSID2040941, NSC-167897, 1H-Imidazo(4,5-c)pyridine, 4-amino-1-beta-D-ribofuranosyl-, 1H-IMIDAZO(4,5-C)PYRIDIN-4-AMINE, 1-.BETA.-D-RIBOFURANOSYL, (2R,3R,4S,5R)-2-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-5-(hydroxymethyl)oxolane-3,4-diol, 1-beta-D-Ribofuranosyl-1H-Imidazo(4,5-c)pyridin-4-amine, 1-beta-D-ribofuranosyl-1H-imidazo[4,5-c]pyridin-4-amine, (2R,3R,4S,5R)-2-(4-amino-1H-imidazo(4,5-c)pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol, 1-.beta.-D-Ribofuranosyl-1H-Imidazo[4,5-c]pyridin-4-amine, DTXCID0020941, 1H-IMIDAZO(4,5-C)PYRIDIN-4-AMINE, 1-BETA-D-RIBOFURANOSYL, 1H-Imidazo(4,5-c)pyridine, 4-amino-1-beta-D-ribofuranosyl-(8CI), dbzqfunlcalwdy-abhrneansa-n, 3-Deaza Adenosine, (2R,3R,4S,5R)-2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol, 4-Amino-1-(beta-D-ribofuranosyl)-1H-imidazo(4,5)-pyridine, AD3, 3DZA, (2R,3R,4S,5R)-2-(4-Amino-1H-imidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, NSC167897, 9-Deazaado, MFCD00153951, DHCDA, C^3Ado, 1hp0, 3-Deazaadenosine, 3-DeazaA, BIDD:GT0703, CHEMBL202701, GTPL5115, SCHEMBL1738519, BDBM82055, DBZQFUNLCALWDY-PNHWDRBUSA-N, AKOS024260271, CS-W014048, DB04546, HY-W013332, ND04697, NCGC00093846-07, AC-32285, AS-78389, PD019530, CAS_6736-58-9, NS00071576, G12425, Q27073728, 1-(beta-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridin-4-amine, 1H-Imidazo(4,5-c)pyridin-4-amine, 1-beta-D-ribofuranosyl-, {1H-Imidazo[4,5-c]pyridine,} 4-amino-1-.beta.-D-ribofuranosyl-, 4-Amino-1--D-ribofuranosyl-1H-imidazo[4,5-c]pyridine;3-Deaza-D-adenosine, (2R,3R,4S,5R)-2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol"	23190	C11H14N4O4	Investigative
M6ADRUG0165	Cytarabine	"Alexan; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Citarabina; Cytarabin; Cytarabina; Cytarabinoside; Cytarabinum; Cytarbel; Cytonal; Cytosar; Cytosinearabinoside; DepoCyte; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; Arabinosyl Cytosine; Cytarabine liposome injection; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; AR3; BTB15125; CHX 3311; U 19920A; Ara-C; Ara-Cytidine; Beta-Ara C; Beta-Arabinosylcytosine; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabinum [INN-Latin]; Cytosar-U; Cytosine arabinoside (VAN); Depocyt (TN); Depocyt (liposomal); Intrathecal (injected into the spinal fluid) DepoCyt; U-19920; Beta-D-Arabinosylcytosine; Cytosar-U (TN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine-beta-arabinoside; Intrathecal cytarabine (also known as ara-C); U-19,920; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytosine 1-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine-1-beta-D-arabinofuranoside; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; (beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one"	6253	C9H13N3O5	Approved
M6ADRUG0166	Cycloleucine	"1-Aminocyclopentanecarboxylic acid; 52-52-8; 1-Aminocyclopentane-1-carboxylic acid; Cycloleucin; 1-Amino-1-cyclopentanecarboxylic acid; 1-Amino-1-carboxycyclopentane; 1-Amino-cyclopentanecarboxylic acid; CYCLO-LEUCINE; Cyclopentanecarboxylic acid, 1-amino-; NSC 1026; CB 1639; X 201; UNII-0TQU7668EI; 1-Aminocyclopentanecarboxylate; HSDB 5195; WR 14,997; NSC1026; 1-amino cyclopentane carboxylic acid; EINECS 200-144-6; BRN 0636626; aminocyclopentanecarboxylic acid; Cyclopentanecarboxylic acid, 1-amino-, L-; AI3-26442"	2901	C6H11NO2	Investigative
M6ADRUG0167	JNJ-74494550	Cusatuzumab	.	.	Phase 2
M6ADRUG0169	CP028	"cp028, 347397-83-5, 1-(2-Ethylphenyl)-5-((5-(4-fluorophenyl)furan-2-yl)methylene) pyrimidine-2,4,6 (1H,3H,5H)-trione, 1-(2-ethylphenyl)-5-{(E)-1-[5-(4-fluorophenyl)-2-furyl]methylidene}-2,4,6(1H,3H,5H)-pyrimidinetrione, MFCD02624148, STK855704, AKOS001644857, AKOS005632311, (5E)-1-(2-ethylphenyl)-5-[[5-(4-fluorophenyl)furan-2-yl]methylidene]-1,3-diazinane-2,4,6-trione, DA-62480, HY-136951, CS-0135545, (5E)-3-(2-ethylphenyl)-5-{[5-(4-fluorophenyl)furan-2-yl]methylidene}-6-hydroxypyrimidine-2,4(3H,5H)-dione"	1926482	C23H17FN2O4	.
M6ADRUG0170	Coptisine	"Coptisine, 3486-66-6, Coptisin, UNII-0GCL71VN14, 0GCL71VN14, bis[methylenedioxy]protoberberine, YHL II, 7,8,13,13a-Tetradehydro-2,3-9,10-bis(methylenedioxy)berbinium, HSDB 8323, DTXSID10188404, Bis(1,3)benzodioxolo(5,6-a:4',5'-g)quinolizinium, 6,7-dihydro-, Bis[1,3]benzodioxolo[5,6-a:4',5'-g]quinolizinium, 6,7-dihydro-, BIS(METHYLENEDIOXY)PROTOBERBERINE, 7,8,13,13a-tetradehydro-2,3:9,10-bismethylenedioxyberbinium, ALKALOID A, FROM COPTIS GROENLANDICA, Berbinium, 7,8,13,13a-tetradehydro-2,3:9,10-bis(methylenedioxy)-, 6,7-DIHYDROBIS(1,3)BENZODIOXOLO(5,6-A:4',5'-G)QUINOLIZINIUM, DTXCID00110895, Coptisine sulfate, 1198398-71-8, CHEBI:67862, 5,7,17,19-tetraoxa-13-azoniahexacyclo[11.11.0.02,10.04,8.015,23.016,20]tetracosa-1(13),2,4(8),9,14,16(20),21,23-octaene, 6,7-Dihydro[1,3]dioxolo[4,5-G][1,3]dioxolo[7,8]isoquino[3,2-A]isoquinolin-5-Ium, 6,7-Dihydro-[1,3]dioxolo[4',5':7,8]isoquinolino[3,2-a][1,3]dioxolo[4,5-g]isoquinolin-5-ium, 6,7-Dihydrobis[1,3]benzodioxolo[5,6-a:4',5'-g]quinolizinium chloride, COPTISINE [MI], SCHEMBL156866, CHEMBL362071, MEGxp0_001731, XYHOBCMEDLZUMP-UHFFFAOYSA-N, HY-N0430, BDBM50030257, AKOS015903291, FC73787, AC-34308, NCI60_000465, NS00094622, C16938, Q5169053, 5,7,17,19-tetraoxa-13-azahexacyclo[11.11.0.0(2),(1).0,.0(1),(2)(3).0(1),(2)]tetracosa-1(24),2,4(8),9,13,15,20,22-octaen-13-ylium"	72322	C19H14NO4+	Investigative
M6ADRUG0171	Colivelin	"COLIVELIN, 867021-83-8, Colivelin TFA, Colivelin, Colivelin trifluoroacetate salt, s9664, AKOS024457889, FC109801, TS-10482, H-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro-OH; H-SALLRSIPAPAGASRLLLLT GEIDLP-OH"	90477169	C119H206N32O35	.
M6ADRUG0172	Chromium	"CHROMIUM, 7440-47-3, Chrome, Chrom, cromo, chromium atom, Dinakrome, BioChrome, CCRIS 159, HSDB 910, 24Cr, EINECS 231-157-5, CHEBI:28073, 0R0008Q3JB, DTXSID3031022, EC 231-157-5, CHROMIUM, METALLIC (IARC), CHROMIUM, METALLIC [IARC], CHROMIUM ELEMENT, Chromium Metallicum, ALPASTE RRA 030, ALPASTE RRA 050, DTXCID1011022, CHROMIUM FULLERIDE (CRC20), 231-157-5, chromium, metal (acgih), Cr, nsc293779, Chromium, elemental, Chromium metal, Chromium, metal, Chromium chips, Chromium powder, chromide(1-), CHROMIUM ION, Chromium powder, APS <10 micron, Chrome [French], Chrom [German], Chromium AA Standard: Cr @ 1000 microg/mL in 5% HCl, MFCD00010944, Sulfur-Free Chromium Concentrate: Cr @ approx. 3.5 wt% in Hydrocarbons, 19498-56-7, Chromium Standard: Cr @ 1000 microg/mL in 5% HCl, Chromium Standard: Cr @ 10000 microg/mL in 5% HCl, Chromium Standard: Cr @ 1000 microg/mL in 5% HNO3, Chromium Standard: Cr @ 10000 microg/mL in 5% HNO3, chromium anion, Chromium flakes, UNII-0R0008Q3JB, Chromium pellets, Chromium MOF, Chromium Nanorods, Chromium Standard, chromide(-I), Chromium Nanopowder, Chromium Nanoprisms, Chromium crystallites, Chromium Metal Chips, Chromium Micro Powder, 10A - Metals, Chromium, ion(Cr3+), CHROMIUM [HSDB], CHROMIUM [MI], CHROMIUM [VANDF], Chromium, ion (Cr1-), Chromium, ion (Cr3 ), Chromium pieces, irregular, CHROMIUM [WHO-DD], Epitope ID:114071, Chromium, ion (Cr 3+), Chromium pellets 3mm x 6mm, Ultra Thin Chromium Nanofoil, Chromium powder, -100 mesh, Chromium powder, -325 mesh, Cr(-), Chromium Standard: Cr @ 10 microg/mL in 2% HNO3, Chromium, puriss., 98.0%, Chromium granules, -4+7 mesh, Chromium Metal Organic Framework, Chromium Metal-Organic Framework, Chromium Powder, 99.5% Nano, Titanium Metal Organic Framework, CHEBI:33010, Chromium powder, -10+20 mesh, Chromium Standard: Cr @ 1000 microg/g in Hydrocarbon Oil, Chromium Standard: Cr @ 5000 microg/g in Hydrocarbon Oil, DTXSID401315238, Chromium Hollow Cathode Lamp: 1.5"" Diameter, 2-pin, Non-Coded, Chromium Hollow Cathode Lamp: 2.0"" Diameter, 4-pin, Cableless, Chromium Hollow Cathode Lamp: 2.0"" Diameter, 9-pin, Non-Coded, Chromium nanopowder  (60-80 nm), Chromium powder, -100+325 mesh, Silica (SiO2) Photoelectric Crystal, Sulfur-Free Chromium Standard: Cr @ 1000 microg/g in Hydrocarbon Oil, Sulfur-Free Chromium Standard: Cr @ 5000 microg/g in Hydrocarbon Oil, Chromium flake, electrolytic <1 inch, AKOS015833211, DB11136, Chromium pieces, 1-25mm (0.04-1in), Chromium, powder, 99.5%, -100 mesh, Q725, Chromium pieces, 3-8mm (0.1-0.31in), Chromium, coating quality, 99.95%, grit, Chromium cubes, 12.5mm (0.492in) square, Chromium, chips, thickness ~2 mm, 99.5%, NS00099583, Chromium chunks, 2-15mm (0.08-0.59in), Chromium pieces, 3-12mm (0.12-0.47in), C06268, Chromium - Cr @ 1000 microg/mL in 5% HCl, Chromium, chips, 99.995% trace metals basis, Chromium - Cr @ 1000 microg/mL in 5% HNO3, Chromium pieces, 2-3mm (0.08-0.12in) thick, Chromium powder, -100 mesh, 99% (metals basis), Chromium powder, -325 mesh, 99% (metals basis), Chromium, bar, 100mm x 2mm x 2mm, 99.7+%, Chromium, rod, 10mm, diameter 2.0mm, 99.7+%, Chromium, rod, 10mm, diameter 5.0mm, 99.7+%, Chromium, rod, 25mm, diameter 2.0mm, 99.7+%, Chromium, rod, 25mm, diameter 5.0mm, 99.7+%, Chromium, rod, 50mm, diameter 2.0mm, 99.7+%, Chromium, rod, 50mm, diameter 5.0mm, 99.7+%, Chromium - Cr @ 1000 microg/g in Hydrocarbon Oil, Chromium - Cr @ 5000 microg/g in Hydrocarbon Oil, Chromium cubes, typically 6.35mm (0.25in) square, Chromium, rod, 100mm, diameter 2.0mm, 99.7+%, Chromium, rod, 100mm, diameter 5.0mm, 99.7+%, Chromium crystallite pieces, 2-15mm (0.08-0.59in), Q27115184, Chromium, powder, >=99% trace metals basis, -325 mesh, Chromium, foil, 100x100mm, thickness 3.0mm, hard, 99.95%, Chromium, foil, 25x25mm, thickness 2.0mm, hard, 99.7+%, Chromium, foil, 50x50mm, thickness 2.0mm, hard, 99.7+%, Chromium, foil, 50x50mm, thickness 3.0mm, hard, 99.95%, Chromium pieces, electrolytic, 6mm & down, 99.997% (metals basis), Chromium, rod, 0.5 mm diameter, length 50 mm, purity 99.7+%, Chromium, rod, 1.0 mm diameter, length 50 mm, purity 99.7+%, Chromium, rod, 8.0 mm diameter, length 100 mm, purity 99.7+%, Chromium, rod, 8.0 mm diameter, length 50 mm, purity 99.7+%, Chromium, rod, length 25 mm, 0.5 mm diameter, purity 99.7+%, Chromium single crystal, 8-10mm (0.3-0.4in) dia, random orientation, Chromium, foil, thickness 0.5 mm, size 100 x 100 mm, purity 99.99%, Chromium, foil, thickness 0.5 mm, size 12.5 x 12.5 mm, purity 99.99%, Chromium, foil, thickness 0.5 mm, size 25 x 25 mm, purity 99.99%, Chromium, foil, thickness 0.5 mm, size 50 x 50 mm, purity 99.99%, Chromium, foil, thickness 1.0 mm, size 100 x 100 mm, purity 99.99%, Chromium, foil, thickness 1.0 mm, size 12.5 x 12.5 mm, purity 99.99%, Chromium, foil, thickness 1.0 mm, size 25 x 25 mm, purity 99.99%, Chromium, foil, thickness 1.0 mm, size 50 x 50 mm, purity 99.99%, Chromium, foil, thickness 1.0 mm, size 75 x 75 mm, purity 99.99%, Chromium, foil, thickness 1.5 mm, size 100 x 100 mm, purity 99.99%, Chromium, foil, thickness 1.5 mm, size 25 x 25 mm, purity 99.99%, Chromium, foil, thickness 1.5 mm, size 50 x 50 mm, purity 99.99%, Chromium, foil, thickness 2.0 mm, size 100 x 100 mm, purity 99.99%, Chromium, foil, thickness 2.0 mm, size 25 x 25 mm, purity 99.99%, Chromium, foil, thickness 2.0 mm, size 50 x 50 mm, purity 99.99%, Chromium, lump, 10 mm max. lump size, weight 10 g, purity 99.99%, Chromium, lump, 10 mm max. lump size, weight 100 g, purity 99.95%, Chromium, lump, 10 mm max. lump size, weight 100 g, purity 99.99%, Chromium, lump, 10 mm max. lump size, weight 20 g, purity 99.95%, Chromium, lump, 10 mm max. lump size, weight 20 g, purity 99.99%, Chromium, lump, 10 mm max. lump size, weight 200 g, purity 99.95%, Chromium, lump, 10 mm max. lump size, weight 200 g, purity 99.99%, Chromium, lump, 10 mm max. lump size, weight 50 g, purity 99.95%, Chromium, lump, 10 mm max. lump size, weight 50 g, purity 99.99%, Chromium, lump, 25 mm max. lump size, weight 100 g, purity 99.95%, Chromium, lump, 25 mm max. lump size, weight 1000 g, purity 99.95%, Chromium, lump, 25 mm max. lump size, weight 200 g, purity 99.95%, Chromium, lump, 25 mm max. lump size, weight 50 g, purity 99.95%, Chromium, powder, mean particle size <10 micron, weight 20 g, purity 99%, Chromium, powder, mean particle size <10 micron, weight 50 g, purity 99%, Chromium single crystal, 8-10mm (0.3-0.4in) dia, (100) orientation, +/-2 degrees, Chromium single crystal, 8-10mm (0.3-0.4in) dia, (110) orientation, +/-2 degrees, Chromium single crystal, 8-10mm (0.3-0.4in) dia, (111) orientation, +/-2 degrees, Chromium sputtering target, 50.8mm (2.0in) dia x 3.18mm (0.125in) thick, Chromium sputtering target, 76.2mm (3.0in) dia x 6.35mm (0.250in) thick, Chromium, powder, <10 mean particle size (micron), weight 100 g, purity 99%, Chromium, powder, <10 mean particle size (micron), weight 200 g, purity 99%, Chromium, powder, 200 max. part. size (micron), weight 200 g, purity 99.0+%, Chromium, powder, 200 max. part. size (micron), weight 2000 g, purity 99.0+%, Chromium, powder, 200 max. part. size (micron), weight 50 g, purity 99.0+%, Chromium, powder, 38 max. part. size (micron), weight 100 g, purity 99.0+%, Chromium, powder, max. particle size 200 micron, weight 100 g, purity 99.+%, Chromium, powder, max. particle size 200 micron, weight 1000 g, purity 99.+%, Chromium, powder, max. particle size 200 micron, weight 500 g, purity 99.+%, Chromium, powder, max. particle size 38 micron, weight 1000 g, purity 99.+%, Chromium, powder, max. particle size 38 micron, weight 200 g, purity 99.+%, Chromium, powder, max. particle size 38 micron, weight 50 g, purity 99.+%, Chromium, powder, max. particle size 38 micron, weight 500 g, purity 99.+%, Chromium, powder, max. particle size 45 micron, weight 100 g, min. particle size 38 micron, Chromium, powder, max. particle size 45 micron, weight 200 g, min. particle size 38 micron, Chromium, powder, max. particle size 45 micron, weight 50 g, min. particle size 38 micron, Chromium, powder, max. particle size 45 micron, weight 500 g, min. particle size 38 micron, Chromium single crystal disc, 10mm (0.39in) dia, 1-3mm (0.04-0.1in) thick, (100) orientation, +/-0.5 degrees, Chromium single crystal disc, 10mm (0.39in) dia, 1-3mm (0.04-0.1in) thick, (110) orientation, +/-0.5 degrees, Chromium single crystal disc, 10mm (0.39in) dia, 1-3mm (0.04-0.1in) thick, (111) orientation, +/-0.5 degrees, Chromium, microfoil, disks, 10mm, thinness 0.025mum, specific density 18.21mug/cm2, permanent mylar 3.5mum support, 99.99+%, Chromium, microfoil, disks, 10mm, thinness 0.05mum, specific density 37.27mug/cm2, permanent mylar 3.5mum support, 99.99+%, Chromium, microfoil, disks, 10mm, thinness 0.25mum, specific density 178.7mug/cm2, permanent mylar 3.5mum support, 99.99+%, Chromium, microfoil, disks, 10mm, thinness 0.5mum, specific density 355mug/cm2, permanent mylar 3.5mum support, 99.99+%, Chromium, microfoil, disks, 10mm, thinness 1.0mum, specific density 719mug/cm2, permanent mylar 3.5mum support, 99.99+%, Chromium, microfoil, disks, 25mm, thinness 0.05mum, specific density 37.27mug/cm2, permanent mylar 3.5mum support, 99.99+%, Chromium, microfoil, disks, 25mm, thinness 0.25mum, specific density 178.7mug/cm2, permanent mylar 3.5mum support, 99.99+%, Chromium, microfoil, disks, 25mm, thinness 0.5mum, specific density 355mug/cm2, permanent mylar 3.5mum support, 99.99+%, Chromium, microfoil, disks, 25mm, thinness 1.0mum, specific density 719mug/cm2, permanent mylar 3.5mum support, 99.99+%, Chromium, powder, max. particle size 45 micron, weight 1000 g, min. particle size 38 micron, Chromium, sputtering target, diam. x thickness 3.00 in. x 0.125 in., 99.95% trace metals basis"	23976	Cr	Approved
M6ADRUG0173	Chlorogenic acid	"327-97-9; 3-Caffeoylquinic acid; 3-O-Caffeoylquinic acid; 3-(3,4-Dihydroxycinnamoyl)quinic acid; Chlorogenate; Heriguard; Hlorogenic acid; Caffeoyl quinic acid; NSC-407296; 3-Caffeoylquinate; UNII-318ADP12RI; 5-O-(3,4-Dihydroxycinnamoyl)-L-quinic acid; CCRIS 1400; Chlorogenic acid (8CI); EINECS 206-325-6; NSC 70861; NSC 407296; 3-trans-Caffeoylquinic acid; CHEMBL284616; 318ADP12RI; CHEBI:16112; 1,3,4,5-tetrahydroxycyclohexanecarboxylic acid 3-(3,4-dihydroxycinnamate); 3-(3,4-Dihydroxycinnamoyl)quinate"	1794427	C16H18O9	Investigative
M6ADRUG0174	Chidamide	"743420-02-2, 1883690-47-8, 462284YV3M, UNII-462284YV3M, Benzamide, N-(2-amino-5-fluorophenyl)-4-(((1-oxo-3-(3-pyridinyl)-2-propen-1-yl)amino)methyl)-, N-(2-Amino-5-fluorophenyl)-4-(((1-oxo-3-(3-pyridinyl)-2-propen-1-yl)amino)methyl)benzamide, N-(2-Amino-5-fluorophenyl)-4-[[[1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl]benzamide, Chidamide, HDAC-IN-7, N-(2-amino-5-fluorophenyl)-4-[[[(E)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide, CHEMBL4087968, (E)-N-(2-amino-5-fluorophenyl)-4-((3-(pyridin-3-yl)acrylamido)methyl)benzamide, N-(2-Amino-5-fluorophenyl)-4-((3-(pyridin-3-yl)acrylamido)methyl)benzamide, De-4-fluoro 5-Fluoro Chidamide, N-(2-Amino-4-fluorophenyl)-4-[[[1-oxo-3-(3-pyridinyl)-2-propenyl]amino]methyl]benzamide; Isochidamide; (E)-N-(2-Amino-4-fluorophenyl)-4-((3-(pyridin-3-yl)acrylamido)methyl)benzamide, MFCD18382123, Tucidinostat(Chidamide), SCHEMBL8057949, WXHHICFWKXDFOW-BJMVGYQFSA-N, DTXSID801348099, GLXC-05969, EX-A2209, Chidamide; CS055; HBI-8000, BDBM50242817, HBI-8000;CS-055, s8567, AKOS027339700, CCG-208658, CS-3554, NCGC00263598-10, AS-47017, BP-40079, HY-13592, F11457, BRD-K28537285-001-01-8, Q27075960, N-(2-Amino-5-fluorophenyl)-4-{[(2E)-3-(3-pyridinyl)-2-propenamido]methyl}benzamide"	9800555	C22H19FN4O2	Investigative
M6ADRUG0175	Celecoxib	"CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide"	2662	C17H14F3N3O2S	Approved
M6ADRUG0176	Celastrol	"Tripterin; Tripterine; Celastrol, Celastrus scandens; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid"	122724	C29H38O4	Preclinical
M6ADRUG0177	Carboplatin	"Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)"	426756	C6H12N2O4Pt	Approved
M6ADRUG0178	Canagliflozin	"842133-18-0; Invokana; Canagliflozin anhydrous; canagliflozin hemihydrate; UNII-6S49DGR869; JNJ-28431754; JNJ 24831754ZAE; Canagliflozin hydrate; TA-7284; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; CHEBI:73274; 6S49DGR869; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; TA 7284; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; 928672-86-0"	24812758	C24H25FO5S	Approved
M6ADRUG0179	BTYNB	"BTYNB, 304456-62-0, 2-(((5-Bromothiophen-2-yl)methylene)amino)benzamide, Benzamide, 2-[[(5-bromo-2-thienyl)methylene]amino]-, MDK6620, 2-[(5-bromothiophen-2-yl)methylideneamino]benzamide, 2-{[(E)-(5-bromothiophen-2-yl)methylidene]amino}benzamide, 2-{[(5-bromo-2-thienyl)methylene]amino} benzamide, 2-[(E)-[(5-BROMOTHIOPHEN-2-YL)METHYLIDENE]AMINO]BENZAMIDE, BTYNB IMP1 Inhibitor, TimTec1_002386, SCHEMBL10090730, HMS1540M10, MFCD00977636, s9871, STK014922, AKOS000484586, AKOS040759630, BS-48808, DA-71795, HY-124447, CS-0086494, E85137, 2-((5-Bromothiophen-2-yl)methyleneamino)benzamide, 2-{[(5-Bromothien-2-yl)methylene]amino}benZamide, SR-01000204166, 2-[[(5-bromo-2-thienyl)methylene]amino]-benzamide, SR-01000204166-1, (E)-2-(((5-Bromothiophen-2-yl)methylene)amino)benzamide"	721984	C12H9BrN2OS	.
M6ADRUG0180	Bleomycin	BLM; Blenoxane; Bleo; Bleocin; Bleogin; Bleomicin; Bleomicina; Bleomycine; Bleomycins; Bleomycinum; Bleomycin sulfate; Bleomycin a2; Pingyangmyvin A2; Zhengguangmycin A2; Zhengguangmycin A2 [Chinese]; Blenoxane (TN); Bleomicina [INN-Spanish]; Bleomycin A(2); Bleomycin A2 & Bleomycin B2; Bleomycin B(2); Bleomycine [INN-French]; Bleomycinum [INN-Latin]; NDC 0015-3010; N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide; N1-(3-(Dimethylsulfonio)propyl)bleomycinamide	5360373	C55H84N17O21S3+	Approved
M6ADRUG0181	Bisphenol A	BPA	6623	C15H16O2	Investigative
M6ADRUG0182	Benzo[a]pyrene	"benzo[a]pyrene, 50-32-8, 3,4-Benzopyrene, BENZO(A)PYRENE, benzo[pqr]tetraphene, 3,4-Benzpyrene, 6,7-Benzopyrene, 3,4-BP, Benz[a]pyrene, 3,4-Benz[a]pyrene, 3,4-Benzopirene, 3,4-Benzpyren, B(a)P, Benz(a)pyrene, Benzo(d,e,f)chrysene, 3,4-Benz(a)pyrene, 3,4 Benzpyrene, (B(a)P), RCRA waste number U022, Benzo[d,e,f]chrysene, 3,4-Benzo(a)pyrene, B[a]p, NSC 21914, 3,4 Benzopyrene, 3,4-benzylpyrene, CCRIS 76, CHEBI:29865, HSDB 2554, 3,4-Benzypyrene, EINECS 200-028-5, UNII-3417WMA06D, DTXSID2020139, AI3-50461, 3417WMA06D, NSC-21914, DTXCID40139, NSC21914, benzo(pqr)tetraphene, BENZO(A)PYRENE (IARC), BENZO(A)PYRENE [IARC], Benzopireno, 6,7-Benzpyren, 3,4-BENZPYRENE (CARCINOGEN), 200-028-5, bap, benzo[def]chrysene, Benzpyrene, Benzo(def)chrysene, BP, Benzo[A]-Pyrene, MFCD00003602, CHEMBL31184, BENZO(A)PYRENE-7 8-D2  98, 3,4-Benzopyrene (purified by sublimation), 3,4-Benzpyren [German], 3,4-Benzopirene [Italian], Benzo[a]pyrene (BaP), RCRA waste no. U022, Benzo(a)pyrene radical cation, Benzo(a)pyrene, radical ion(1+), Benzo(a)pyrene, radical ion(1-), Benzo (a) pyrene, Benzo[d,f]chrysene, W62, Benzo(a)pyrene, labeled with tritium, Benzo(3,4)pyrene, radical ion(1+), 42299-33-2, Spectrum_001871, Coal tar pitch volatiles: benzo(a)pyrene, SpecPlus_000953, Benzo[a]pyrene 1000 microg/mL in Acetone, Spectrum2_001081, Spectrum3_001695, Spectrum4_000609, Spectrum5_001824, 3 pound not4-Benzopyrene, Benzo[a]pyrene 10 microg/mL in Acetonitrile, Benzo[a]pyrene 100 microg/mL in Acetonitrile, Benzo[a]pyrene 100 microg/mL in Cyclohexane, Benzo[a]pyrene (Standard), Epitope ID:117721, BENZO(A)PYRENE [MI], BSPBio_003250, KBioGR_001138, KBioSS_002390, MLS002695983, BIDD:ER0497, DivK1c_007049, SPBio_001122, 3,4-Benzopyrene (carcinogen), BENZO(A)PYRENE [HSDB], KBio1_001993, KBio2_002385, KBio2_004953, KBio2_007521, KBio3_002470, MSK4305, HMS3089C04, HMS3746C17, 52 - Low Level CIP2 contaminants, Benzo[a]pyrene, >=96% (HPLC), Tox21_200710, BDBM50137506, CCG-39759, AKOS015907666, CS-7789, FB18224, HY-107377R, CAS-50-32-8, WLN: L D6 B6666 2AB TJ, NCGC00178185-01, NCGC00178185-02, NCGC00258264-01, 34505-58-3, 6699-27-0, NCI60_001824, SMR000393676, SY048151, DB-071166, HY-107377, B0085, NS00006321, C07535, A828067, Benzo[a]pyrene, vial of 1 g, analytical standard, Q306051, Benzo[a]pyrene;3,4-Benz[a]pyrene;3,4-Benzopyrene, BRD-K09668667-001-02-0, Benzo[a]pyrene, certified reference material, TraceCERT(R), Benzo[a]pyrene, analytical standard, for environmental analysis, Benzo[a]pyrene; 3,4-Benzopyrene; benzo[pqr]tetraphene; BENZO(A)PYRENE, benzo[a]pyrene, 50-32-8, 3,4-Benzopyrene, BENZO(A)PYRENE, benzo[pqr]tetraphene, 3,4-Benzpyrene, 6,7-Benzopyrene, 3,4-BP, Benz[a]pyrene, 3,4-Benz[a]pyrene, 3,4-Benzopirene, 3,4-Benzpyren, B(a)P, Benz(a)pyrene, Benzo(d,e,f)chrysene, 3,4-Benz(a)pyrene, 3,4 Benzpyrene, (B(a)P), RCRA waste number U022, Benzo[d,e,f]chrysene, 3,4-Benzo(a)pyrene, B[a]p, NSC 21914, 3,4 Benzopyrene, 3,4-benzylpyrene, CCRIS 76, CHEBI:29865, HSDB 2554, 3,4-Benzypyrene, EINECS 200-028-5, UNII-3417WMA06D, DTXSID2020139, AI3-50461, 3417WMA06D, NSC-21914, DTXCID40139, NSC21914, benzo(pqr)tetraphene, BENZO(A)PYRENE (IARC), BENZO(A)PYRENE [IARC], Benzopireno, 6,7-Benzpyren, 3,4-BENZPYRENE (CARCINOGEN), 200-028-5, bap, benzo[def]chrysene, Benzpyrene, Benzo(def)chrysene, BP, Benzo[A]-Pyrene, MFCD00003602, CHEMBL31184, BENZO(A)PYRENE-7 8-D2  98, 3,4-Benzopyrene (purified by sublimation), 3,4-Benzpyren [German], 3,4-Benzopirene [Italian], Benzo[a]pyrene (BaP), RCRA waste no. U022, Benzo(a)pyrene radical cation, Benzo(a)pyrene, radical ion(1+), Benzo(a)pyrene, radical ion(1-), Benzo (a) pyrene, Benzo[d,f]chrysene, W62, Benzo(a)pyrene, labeled with tritium, Benzo(3,4)pyrene, radical ion(1+), 42299-33-2, Spectrum_001871, Coal tar pitch volatiles: benzo(a)pyrene, SpecPlus_000953, Benzo[a]pyrene 1000 microg/mL in Acetone, Spectrum2_001081, Spectrum3_001695, Spectrum4_000609, Spectrum5_001824, 3 pound not4-Benzopyrene, Benzo[a]pyrene 10 microg/mL in Acetonitrile, Benzo[a]pyrene 100 microg/mL in Acetonitrile, Benzo[a]pyrene 100 microg/mL in Cyclohexane, Benzo[a]pyrene (Standard), Epitope ID:117721, BENZO(A)PYRENE [MI], BSPBio_003250, KBioGR_001138, KBioSS_002390, MLS002695983, BIDD:ER0497, DivK1c_007049, SPBio_001122, 3,4-Benzopyrene (carcinogen), BENZO(A)PYRENE [HSDB], KBio1_001993, KBio2_002385, KBio2_004953, KBio2_007521, KBio3_002470, MSK4305, HMS3089C04, HMS3746C17, 52 - Low Level CIP2 contaminants, Benzo[a]pyrene, >=96% (HPLC), Tox21_200710, BDBM50137506, CCG-39759, AKOS015907666, CS-7789, FB18224, HY-107377R, CAS-50-32-8, WLN: L D6 B6666 2AB TJ, NCGC00178185-01, NCGC00178185-02, NCGC00258264-01, 34505-58-3, 6699-27-0, NCI60_001824, SMR000393676, SY048151, DB-071166, HY-107377, B0085, NS00006321, C07535, A828067, Benzo[a]pyrene, vial of 1 g, analytical standard, Q306051, Benzo[a]pyrene;3,4-Benz[a]pyrene;3,4-Benzopyrene, BRD-K09668667-001-02-0, Benzo[a]pyrene, certified reference material, TraceCERT(R), Benzo[a]pyrene, analytical standard, for environmental analysis, Benzo[a]pyrene; 3,4-Benzopyrene; benzo[pqr]tetraphene; BENZO(A)PYRENE"	2336	C20H12	.
M6ADRUG0183	Bacillus Calmette	.	.	.	.
M6ADRUG0184	Azacitidine	"Azacitidina; Azacitidinum; Azacytidine; Ladakamycin; Mylosar; Vidaza; Mylo sar; Pharmion Brand of Azacitidine;A 2385; Antibiotic U 18496; U 18496; Wr 183027; Azacitidina [INN-Spanish]; Azacitidine [USAN:INN]; Azacitidinum [INN-Latin]; NS-17; Pyrimidine antimetabolite: inhibits nucleic acid replication; U-18496; Vidaz (TN); Vidaza (TN); WR-183027; Azacitidine (JAN/USAN/INN); S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5 AZC; 5 Azacytidine; 5-AC; 5-AZAC; 5-AZCR; 5-aza-CR; 5-azacitidine; 5-azacytidine; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; 5AzaC"	9444	C8H12N4O5	Approved
M6ADRUG0186	MLN8237	Alisertib	24771867	C27H20ClFN4O4	Phase 3
M6ADRUG0187	4-Vinylcyclohexene diepoxide	"4-Vinylcyclohexene dioxide, 106-87-6, 4-Vinyl-1-cyclohexene dioxide, 4-Vinylcyclohexene diepoxide, VINYLCYCLOHEXENE DIOXIDE, 3-(oxiran-2-yl)-7-oxabicyclo[4.1.0]heptane, 4-Vinyl-1-cyclohexene diepoxide, Vinyl cyclohexene dioxide, Vinyl cyclohexene diepoxide, 1-Vinyl-3-cyclohexene dioxide, 1-Ethyleneoxy-3,4-epoxycyclohexane, 1-Epoxyethyl-3,4-epoxycyclohexane, Chissonox 206, 7-Oxabicyclo[4.1.0]heptane, 3-oxiranyl-, 4-Vinyl-1,2-cyclohexene diepoxide, Unox epoxide 206, Chissonox 206 monomer, Vinylcyclohexene Diepoxide, 4-(Epoxyethyl)-7-oxabicyclo(4.1.0)heptane, 3-Oxiranyl-7-oxabicyclo(4.1.0)heptane, EP-206, 4-(1,2-Epoxyethyl)-7-oxabicyclo(4.1.0)heptane, 3-(Epoxyethyl)-7-oxabicyclo(4.1.0)heptane, Erla-2270, Erla-2271, 3-(1,2-Epoxyethyl)-7-oxabicyclo(4.1.0)heptane, CCRIS 278, NSC 54752, CHEBI:59001, HSDB 4332, NCI-C60135, NCI-C60139, EINECS 203-437-7, UCET textile finish 11-74 (Obs.), 7-Oxabicyclo(4.1.0)heptane, 3-(epoxyethyl)-, BRN 0106071, Cyclohexane, 1,2-epoxy-4-(epoxyethyl)-, DTXSID0020604, AI3-26353, 7-Oxabicyclo(4.1.0)heptane, 3-oxiranyl-, NSC-7583, NSC-54752, NSC-61281, 1-(Epoxyethyl)-3,4-epoxycyclohexane, 596C064IG4, 3-(1,2-Epoxyethyl)-7-oxabicyclo[4.1.0]heptane, 7-Oxa-3-oxiranylbicyclo(4.1.0)heptane, DTXCID80604, 3-(Epoxyethyl)-7-oxabicyclo[4.1.0]heptane, NSC7583, 7-Oxabicyclo[4.1.0]heptane, 3-(epoxyethyl)-, 7-Oxabicyclo(4.1.0)heptane, 3-(2-oxiranyl)-, 5-19-01-00295 (Beilstein Handbook Reference), NSC54752, NSC61281, VINYL CYCLOHEXENE DIOXIDE [HSDB], 3-oxiranyl-7-oxabicyclo[4.1.0]heptane, 7-oxa-3-oxiranylbicyclo[4.1.0]heptane, 3-Oxiranyl-7-oxabicyclo(4.1.0)heptene, 4-VINYLCYCLOHEXENE DIEPOXIDE [IARC], 4-(Epoxyethyl)-7-oxabicyclo[4.1.0]heptane, 4-(1,2-Epoxyethyl)-7-oxabicyclo[4.1.0]heptane, 3-Oxiranyl-7-oxabicyclo[4.1.0]heptene, 4-VINYLCYCLOHEXENE DIEPOXIDE (IARC), 3-(oxiran-2-yl)-7-oxabicyclo(4.1.0)heptane, 7-Oxabicyclo[4.1.0]heptane, 3-(2-oxiranyl)-, vinyl cyclohexane diepoxide, 1-Epoxyethyl-3,4-epoxy-cyclohexane, 4Vinlycyclohexene dioxide, 4Vinylcyclohexene dioxide, Vinylcyclohexane diepoxide, 1Vinyl3cyclohexene dioxide, 4Vinyl1cyclohexene dioxide, 4Vinylcyclohexene diepoxide, 4Vinyl1cyclohexene diepoxide, 1Epoxyethyl3,4epoxycyclohexane, VINYLCYCLOHEXANE DIOXIDE, 4Vinyl1,2cyclohexene diepoxide, 1Ethyleneoxy3,4epoxycyclohexane, 1,2Epoxy4(epoxyethyl)cyclohexane, VINYL CYLCOHEXENE DIEPOXIDE, Cyclohexane, 1,2epoxy4(epoxyethyl), 3Oxiranyl7oxabicyclo(4.1.0)heptane, UCET textile finish 1174 (Obs.), 3-EPOXYETHYL-7-OXABICYCLOHEPTANE, 7Oxabicyclo(4.1.0)heptane, 3oxiranyl, 3(Epoxyethyl)7oxabicyclo(4.1.0)heptane, 4(Epoxyethyl)7oxabicyclo(4.1.0)heptane, 3-Oxiranyl-7-oxabicyclo(4.1.0) heptane, 7Oxabicyclo(4.1.0)heptane, 3(epoxyethyl), 3(1,2Epoxyethyl)7oxabicyclo(4.1.0)heptane, 4(1,2Epoxyethyl)7oxabicyclo(4.1.0)heptane, CYCLOHEXANE,1,2-EPOXY-4(EPOXY ETHYL), 7-oxabicyclo(4.1.0) heptane, 3-(epoxyethyl)-, 203-437-7, 4-Vinlycyclohexene dioxide, 1,2-Epoxy-4-(epoxyethyl)cyclohexane, Unox 4206, 25086-25-3, RD4, 3-oxiran-2-yl-7-oxabicyclo[4.1.0]heptane, MFCD00022354, Erl 4206, Araldite RD 4, Tissonox 206, Araldite DY 032, Bakelite ERL 4206, Unox 206, WLN: T36 BOTJ A- BT3OTJ, Unox EP 206, CAS-106-87-6, RD 4, EHPE 3158, EHPE 3300, ERRA 4206, DY032, KRM 2206, 4-(oxiran-2-yl)-7-oxabicyclo[4.1.0]heptane, CX 206, EP 206, 3-Oxiranyl- 7-oxabicyclo(4.1.0)heptane, UNII-596C064IG4, 4-vinylcyclohexenedioxide, Epitope ID:119422, EP-206 (Salt/Mix), Vinylcyclohexene dioxide;VCD, MLS001065620, Vinylcyclohexene dioxide, VCD, SCHEMBL106572, 3-EPOXYETHYL-7-OXABICYCLO [4.1.0] HEPTANE, CHEMBL1734307, Unox epoxide 206 (Salt/Mix), HMS3039M16, 1-Epoxyethyl-3,4-epoxy-cyclohexan, AAA10687, ERL-4206, Tox21_201505, Tox21_300311, BBL011322, STL146309, AKOS005722221, NCGC00091429-01, NCGC00091429-02, NCGC00091429-03, NCGC00091429-04, NCGC00254198-01, NCGC00259056-01, AS-34998, SMR000568467, SY113814, CS-0166800, NS00020724, NS00115895, C19311, 3-(2-Oxiranyl)-7-oxabicyclo[4.1.0]heptane #, Q2618250, 3-oxiranyl-7-Oxabicyclo[4.1.0]heptane, mixture of isomers"	7833	C8H12O2	.
M6ADRUG0188	44/ZLD115	"ZLD115, CHEMBL5410889, ZLD-115, GLXC-27563, BDBM50624049, HY-149334, CS-0880285, 2-((1,4-Oxazepan-4-yl)methyl)-6-((2-chloro-6-cyclopropyl-4-(3,5-dimethylisoxazol-4-yl)phenyl)amino)benzoic acid, 2980653-93-6"	168475863	C27H30ClN3O4	.
M6ADRUG0190	Reserpine	"Abesta; Abicol; Adelfan; Adelphin; Alkarau; Alkaserp; Alserin; Apoplon; Apsical; Ascoserp; Ascoserpina; Austrapine; Banasil; Banisil; Benazyl; Bioserpine; Brinderdin; Briserine; Broserpine; Cardioserpin; Carditivo; Carpacil; Carrserp; Darebon; Deserpine; Dralserp; Eberpine; Eberspine; Ebserpine; Elfanex; Elserpine; Enipresser; Escaspere; Eserpine; Eskaserp; Eskaserpine; Gammaserpine; Gilucard; Helfoserpin; Hexaplin; Hiposerpil; Hiserpia; Hydropine; Hydroserp; Hypersil; Hypersine; Hypertensan; Idoserp; Idsoserp; Interpina; Kitine; Klimanosid; Lemiserp; Loweserp; Mallopress; Maviserpin; Mayserpine; Mephaserpin; Modenol; Naquival; Nembuserpin; Neoserfin; Neoserp; Neoslowten; Orthoserpina; Perskleran; Pressimedin; Purserpine; Quiescin; Raucap; Raudiford; Raudixin; Raudixoid; Raugal; Raulen; Rauloydin; Raumorine; Raunervil; Raunorine; Raunova; Raupasil; Raupoid; Raurine; Rausan; Rausedan; Rausedil; Rausedyl; Rauserpin; Rauserpine; Rauserpol; Rausingle; Rautrin; Rauvlid; Rauwasedin; Rauwilid; Rauwiloid; Rauwipur; Rauwita; Rauwoleaf; Rawilid; Recipin; Regroton; Resaltex; Resedrex; Resedril; Reserbal; Resercaps; Resercen; Reserfia; Reserjen; Reserlor; Reserp; Reserpal; Reserpamed; Reserpanca; Reserpene; Reserpex; Reserpidefe; Reserpil; Reserpin; Reserpina; Reserpinum; Reserpka; Reserpoid; Reserpur; Reserutin; Resiatric; Residin; Residine; Resine; Resocalm; Resperin; Resperine; Respital; Restran; Rezerpin; Riserpa; Rivased; Rivasin; Rolserp; Roxel; Roxinoid; Roxynoid; Ryser; Salupres; Sandril; Sandron; Sedaraupin; Sedaraupina; Sederaupin; Sedserp; Seominal; Serfin; Serfolia; Serolfia; Serpalan; Serpaloid; Serpaneurona; Serpanray; Serpasil; Serpasol; Serpate; Serpazil; Serpazol; Serpedin; Serpen; Serpena; Serpentil; Serpentin; Serpentina; Serpicon; Serpil; Serpiloid; Serpilum; Serpine; Serpipur; Serpivate; Serpivite; Serpogen; Serpoid; Serpone; Serpyrit; Sertabs; Sertens; Sertensin; Sertina; Supergan; Tefaserpina; Temposerpine; Tensanyl; Tenserpinie; Tensional; Tensionorme; Tepserpine; Terbolan; Transerpin; Triserpin; Tylandril; Unilord; Unipres; VIXO; Esc aspere; Hydromox R; Hypercal B; Loweser p; Neose rfin; Rau sedyl; Renese R; Rese rpamed; Se rpate; V Serp; VI XO; Diupres 250; Diupres 500; ENT 50146; H 520; Hydropres 25; Hydropres 50; Hydrosine 25; R 0875; Apoplon (TN); Diupres-250; Diupres-500; Diurese-R; Diutensen-R; HYDRO-RESERP; Hydrap-ES; Hydromox-R; Key-serpine; L-Carpserp; Neo-serp; Rau-Sed; Renese-R; Rese-lar; Reser-ar; SK-Reserpine; T-Serp; Usaf cb-27; V-Serp; Vio-Serpine; Cam-Ap-Es; L""-Carpserp; R-e-s; Ser-A-Gen; 3P Reserp"	5770	C33H40N2O9	Approved
M6ADRUG0192	Suxiao Jiuxin Pill	.	.	.	.
M6ADRUG0193	Levetiracetam	"102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; Levetiracetamum; ucb L059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L 059; UCB-L059; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; UCB-22059; Levetiracetamum [INN-Latin]; Levetiractam; CHEBI:6437; ucb L060; Levetiracetam In Sodium Chloride; 44YRR34555; Levroxa; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,; Leviteracetam; Torleva; Levetiracetam [INN]; Etiracetam levo-isomer; Keppra (TN); L-059; Etiracetam, S-isomer; Keppra, Keppra XR),Levetiracetam; Levetriacetam"	5284583	C8H14N2O2	Approved
M6ADRUG0194	Docetaxel	"EmDOC; TXL; Taxotere; Docetaxel anhydrous; ANX-514; Docetaxel (INN); Docetaxel, Trihydrate; RP-56976; SDP-014; Taxotere (TN); Taxotere(R); XRP-6976L; Docetaxel 114977-28-5; N-debenzoyl-N-Boc-10-deacetyl taxol; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate"	148124	C43H53NO14	Approved
M6ADRUG0195	Sodium iodide I 131	"UNII-29VCO8ACHH; Sodium Iodide (131I); 29VCO8ACHH; 7790-26-3; Sodium iodide (Na131I); sodium iodine-131(1-); Theriodide; Oriodide; Iodotope; Hicon; Natrii radioiodidum; Tracervial-131; Iodotope (TN); Radiocaps-131; Iodotope Therapeutic; Sodium iodide-131; Iodotope I-131; Sodium iodide I-131; AC1Q1UKC; sodium iodine(-1) anion; Ioduro sodico (131I); (131-I)Sodium iodide; Natrii iodidum (131I); Sodium Iodide, I-131; Sodium iodide, radioactive; Sodium iodide (I-131); Ioduro sodico (131 I); Natrii iodidum (131 I)"	71368	INa	Approved
M6ADRUG0197	BaP metabolite BPDE	"7,8,8a,9a-tetrahydrobenzo[1,12]tetrapheno[10,11-b]oxirene-7,8-diol, Anti BaPDE, Anti-BaPDE, BP 7,8-Diol-9,10-epoxide 2, benzo[a]pyrene diol epoxide I, 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide, Benzo(a)pyrene 7,8-dihydrodiol 9,10-epoxide, CHEBI:30614, 7,8-BaP-9,10-Diol Epoxide, 7,8-Dihydro-7,8-dihydroxybenzo[a]pyrene 9,10-oxide, 5Z16Y5VG9Y, Benzo[a]pyrene-7,8-dihydrodiol-9,10-oxide, 7,8,8a,9a-Tetrahydrobenzo[10,11]chryseno[3,4-b]oxirene-7,8-diol, Benzo(a)pyrene diol epoxide I, 7,8,9,10-Tetrahydrobenzo(a)pyrene-7,8-diol 9,10-epoxide, Benzo(a)pyrene-7,8-dihydrodiol-9,10-oxide, Benzo[a]pyrene-7,8-dihydrodiol 9,10-epoxide, BENZO(a)PYRENE-7,8-DIHYDRODIOL 9,10-EPOXIDE, 7,8,8a,9a-tetrahydrobenzo(10,11)chryseno(3,4-b)oxirene-7,8-diol, 7,8,8a,9a-tetrahydrobenzo(1,12)tetrapheno(10,11-b)oxirene-7,8-diol, 7,8,8a,9a-tetrahydrobenzo(1,12)tetrapheno(10,11-b)oxirene-7,8-diol;7,8,8a,9a-tetrahydrobenzo(10,11)chryseno(3,4-b)oxirene-7,8-diol, 7,8,8a,9a-tetrahydrobenzo[1,12]tetrapheno[10,11-b]oxirene-7,8-diol;7,8,8a,9a-tetrahydrobenzo[10,11]chryseno[3,4-b]oxirene-7,8-diol, (+-)-trans-Benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide, 55097-80-8, BPDE, Benzo(a)pyrene diol epoxide, Benzo(a)pyrene diolepoxide I, 7,8,8a,9a-Tetrahydrobenzo[1,12]tetrapheno-[10,11-b]oxirene-7,8-diol, 7,8-Dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene, Benzo[A]Pyrene Diol Epoxide (Bpde), BDPE, Benzo[a]pyrene Diol Epoxide, 4-oxahexacyclo[11.6.2.02,8.03,5.010,20.017,21]henicosa-1(20),2(8),9,11,13(21),14,16,18-octaene-6,7-diol, benzo(a)pyrene diol epoxide 1, UNII-5Z16Y5VG9Y, 7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene, Benzo(a)pyrene-7,8-diol 9,10-Epoxide, Benzo(a)pyrene diolepoxide, SCHEMBL6299813, CHEMBL1743211, (+/-)-trans-Benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide, DQEPMTIXHXSFOR-UHFFFAOYSA-N, 7,8,9,10-Tetrahydro-7,8-dihydroxybenzo(a)pyrene 9,10-epoxide, FCA09780, ICA91767, Benzo(10,11)chryseno(3,4-b)oxirene-7,8-diol, 7,8,8a,9a-tetrahydro-, NS00115934, (+- )-anti-benzo[a]pyrene-7,8-diol-9,10-epoxide, Q26840771, 1,2-Epoxy-3,4-dihydroxycyclohexano[a]pyrene, (3s,4s-), 7,8,8a,9a-Tetrahydrobenzo[10,11]chryseno[3,4-b]oxirene-7,8-diol #, BENZO(a)PYRENE, 7,8-DIHYDRO-7,8-DIHYDROXY-9,10-EPOXY-, trans-, 4-oxahexacyclo[11.6.2.0^{2,8.0^{3,5.0^{10,20.0^{17,21]henicosa-1(20),2(8),9,11,13(21),14,16,18-octaene-6,7-diol"	41322	C20H14O3	.
M6ADRUG0198	"Trans-3,5,4'-trimethoxystilbene"	"22255-22-7, trans-Trimethoxyresveratrol, (E)-1,3-Dimethoxy-5-(4-methoxystyryl)benzene, 3,4',5-trimethoxy-trans-stilbene, (E)-3,5,4'-Trimethoxystilbene, 3,4',5-trimethoxystilbene, 3,5,4'-trimethoxystilbene, TRIMETHOXYSTILBENE, TRISMETHOXYRESVERATROL, E-Resveratrol trimethyl ether, 1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene, CHEMBL296411, trans-3,4',5-trimethoxystilbene, 1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)vinyl]benzene, (Z)-3,5,4'-TRIMETHOXYSTILBENE, MFCD02093500, 1,3-Dimethoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]benzene, 3,4`,5-Trimethoxy-trans-stilbene, NSC631363, SCHEMBL918739, SCHEMBL918740, trans-Stilbene Derivative, 4a, 5-[2-(4-Methoxyphenyl)Ethenyl]-1,3-Dimethoxy Benzene, 8E-3,4',5-trimethoxystilbene, BDBM23928, trans-3,5,4'-trimethoxystilbene, (E)-3,5,40-Trimethoxystilbene, DTXSID701034889, HY-N1408, s3888, AKOS015915036, AC-7024, CCG-267163, CS-5797, FT43010, NSC-631363, 63844-75-7, AS-19232, LS-14572, 1,3-Dimethoxy-5-(4-methoxystyryl)benzene, DB-027166, T1829, Z2216901131, trans-1-(3,5-Dimethoxyphenyl)-2-(4-methoxyphenyl)ethylene, Benzene, 1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]-, Benzene,1,3-dimethoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]-, 1,3-dimethoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]-benzene; Tri-O-methylresveratrol; Trimethoxy-trans-stilbene"	5388063	C17H18O3	.
M6ADRUG0199	Bisphenol F	"4,4'-Methylenediphenol, 620-92-8, 4,4'-Dihydroxydiphenylmethane, Bisphenol F, Bis(4-hydroxyphenyl)methane, Phenol, 4,4'-methylenebis-, p-(p-Hydroxybenzyl)phenol, 4,4'-Methylenebisphenol, Phenol, 4,4'-methylenedi-, BIS(P-HYDROXYPHENYL)METHANE, 4,4'-Methylene diphenol, p,p'-Bis(hydroxyphenyl)methane, 4,4'-bisphenol F, 4-(4-hydroxybenzyl)phenol, 4,4'-Methylenebis(phenol), NSC 401136, p,p'-BPF, PP-BIP-F, 4,4'-methylenebis-phenol, EINECS 210-658-2, BRN 2049425, CCRIS 9461, DTXSID9022445, CHEBI:34575, HSDB 8091, QD2C19044Z, NSC-401136, phenol, 4,4'-methylenebis, 4,4'-Methylenebis[Phenol], 4,4'-methanediyl-di-phenol, bis(para-hydroxyphenyl)methane, DTXCID202445, para-(para-hydroxybenzyl)phenol, PHENOL, P,P'-METHYLENEDI-, 4-06-00-06664 (Beilstein Handbook Reference), 4,4'-BIS-(HYDROXYPHENYL)METHANE, 210-658-2, bisphenol-f, inchi=1/c13h12o2/c14-12-5-1-10(2-6-12)9-11-3-7-13(15)8-4-11/h1-8,14-15h,9h, p-hydroxydiphenylmethane, 4-[(4-hydroxyphenyl)methyl]phenol, Bis-(4-hydroxyphenyl)methane, 4,4-Dihydroxydiphenylmethane, MFCD00002385, HDM, KUC106448N, KSC-19-052, BPF, 4,4-bisphenol F, UNII-QD2C19044Z, 4,4-Methylenediphenol, p,p'-Methylenediphenol, Bisphenol F 100 microg/mL in Acetonitrile, Phenol,4'-methylenebis-, WLN: QR D1R DQ, bis-(p-hydroxyphenyl)methane, SCHEMBL36454, cid_12111, BIDD:ER0181, bis-(p-hydroxyphenyl)-methane, CHEMBL138061, phenol, 4-(4-hydroxybenzyl)-, 4,4'-Bis(hydroxyphenyl)methane, BDBM76093, BP_04 (BPF), MSK8708, BisphenolF, analytical standard, Bis(4-hydroxyphenyl)methane, 98%, HY-W014901R, Tox21_201163, NSC401136, AKOS015909171, CS-W015617, HY-W014901, Bisphenol F 100 microg/mL in Methanol, NCGC00248941-01, NCGC00258715-01, 4,4'-Dihydroxydiphenylmethane (Standard), AS-17296, CAS-620-92-8, DA-70037, PD196956, SY048317, B0819, NS00009451, F16585, 4,4 inverted exclamation mark -Methylenediphenol, AE-562/40896944, Q9658061, T0U"	12111	C13H12O2	.
M6ADRUG0200	4-(4-hydroxyphenyl)sulfonylphenol	"4,4'-Sulfonyldiphenol, 29465, Bisphenol S, Bis(4-hydroxyphenyl) sulfone, Phenol, 4,4'-sulfonylbis-, 4-(4-hydroxyphenyl)sulfonylphenol, 4,4'-Dihydroxydiphenyl sulfone, 4-Hydroxyphenyl sulfone, 4,4'-Sulfonylbisphenol, Bis(p-hydroxyphenyl) sulfone, Diphone C, Bis(4-hydroxyphenyl)sulfone, 4,4-Sulfonyldiphenol, Sulphonylbisphenol, 4,4'-Bisphenol S, 1,1'-Sulfonylbis(4-hydroxybenzene), Bis(p-hydroxyphenyl)sulfone, BPS 1, 4,4'-Sulphonyldiphenol, P,P'-Dihydroxydiphenyl sulfone, NSC 8712, PHENOL, 4,4'-SULFONYLDI-, BISPHENOL-S, CCRIS 2647, NSC 683541, EINECS 201-250-5, DHDPhS, BRN 2052954, 3OX4RR782R, DTXSID3022409, CHEBI:34372, AI3-08667, HSDB 8087, NSC-8712, NSC-683541, DTXCID602409, EC 201-250-5, 4-06-00-05809 (Beilstein Handbook Reference), EINECS 247-158-9, 1,1'-Sulfonylbis[4-hydroxybenzene], NSC 57909, BIS(4-HYDROXY(PHENYL))SULFONE, BIS(4-HYDROXY(PHENYL))SULPHONE, 1, 1'-SULFONYLBIS(4-HYDROXYBENZENE), 4,4'Bisphenol S, 4,4'Sulfonylbisphenol, 4,4'Sulphonyldiphenol, Phenol, 4,4'sulfonyldi, Bis(phydroxyphenyl)sulfone, bis(4hydroxyphenyl)sulfone, Phenol, 4,4'sulfonylbis, Bis(phydroxyphenyl) sulfone, bis(4hydroxyphenyl) sulfone, p,p'Dihydroxydiphenyl sulfone, 4,4'dihydroxydiphenyl sulfone, 1,1'Sulfonylbis(4hydroxybenzene), 247-158-9, 4-[(4-hydroxyphenyl)sulfonyl]phenol, MFCD00002350, 4,4'-dihydroxy diphenyl sulfone, NSC8712, 4-(4-hydroxyphenylsulfonyl)phenol, NSC683541, 25641-61-6, CAS-80-09-1, C12H10O4S, bisphenols, UNII-3OX4RR782R, 4,4'-dihydroxydiphenylsulfone, 4,4'-Dihydroxydiphenyl sulphone, 4-(4-hydroxybenzenesulfonyl)phenol, Phenol,4'-sulfonylbis-, 4,4\'-sulfonyldiphenol, WLN: QR DSWR DQ, Bisphenol S (4,4'), ChemDiv3_000253, 4,4'-Sulfonylbis[phenol], Cambridge id 5137133, di-(4-Hydroxyphenyl)sulfone, Oprea1_709121, SCHEMBL18838, MLS001195068, BIDD:ER0209, bis(4-hydroxylphenyl) sulfone, 4,4'-Dihydroxydiphenylsulphone, 4,4'-dihydroxy diphenylsulfone, CHEMBL384441, 4,4'-Sulfonyldiphenol, 98%, 4,4'-Sulfonyldiphenol (4,4'-Dihydroxydiphenylsulfone), BP_06 (BPS), BisphenolS, analytical standard, HMS2866C04, Tox21_201743, Tox21_302843, BBL004108, MSK000912, STK267009, AKOS000119535, CS-W012643, DS-5781, FB62571, HY-W011927, IDI1_019571, NCGC00164029-01, NCGC00164029-02, NCGC00256437-01, NCGC00259292-01, AC-11720, SMR000554491, B0495, EU-0066997, NS00010610, EN300-18083, E82999, AB00275288-05, Q418379, Z57158549, F0266-0794, Bisphenol S;4,4'-Dihydroxydiphenyl Sulfone;4,4'-Sulfonyldiphenol, 6JD, InChI=1/C12H10O4S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8,13-14"	6626	C12H10O4S	.
M6ADRUG0201	BPAF	"Bisphenol AF, 1478-61-1, 2,2-Bis(4-hydroxyphenyl)hexafluoropropane, Hexafluorobisphenol a, Biphenol AF, Hexafluorodiphenylolpropane, Hexafluoroacetone bisphenol A, Hexafluoroisopropylidenebis(4-hydroxybenzene), 4,4'-(1,1,1,3,3,3-Hexafluoropropane-2,2-diyl)diphenol, 2,2-Bis-(p-hydroxyphenyl)-hexafluoropropane, NSC 152522, CHEBI:72754, UNII-OH7IX8A37J, EINECS 216-036-7, 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenol, Phenol, 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis-, Phenol, 4,4'-(bis(trifluoromethyl)methylene)di-, DTXSID7037717, HSDB 8090, Phenol, 4,4'-(trifluoro-1-(trifluoromethyl)ethylidene)di-, CURATIVE 30, 4,4'-(2,2,2-Trifluoro-1-(trifluoromethyl)ethylidene)bisphenol, NSC-152522, Phenol, 4,4'-(2,2,2-trifluoro-1-(trifluoromethyl)ethylidene)bis-, 4,4'-(Trifluoro-1-(trifluoromethyl)ethylidene)diphenol, DTXCID5017717, 2,2-bis(4'-hydroxyphenyl)hexafluoropropane, 2,2-BIS(4-HYDROXYPHENYL)-1,1,1,3,3,3-HEXAFLUOROPROPANE, 1,1,1,3,3,3-hexafluoro-2,2-bis(4-hydroxyphenyl)propane, 4-(1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl)phenol, 4,4'-hexafluorisopropylidene diphenol, Phenol, 4,4'-, 2,2-bis(p-hydroxyphenyl)hexafluoropropane, Phenol, 4,4, (2,2,2, trifluoro-1-(trifluoromethyl)ethylidene) bis, 216-036-7, 4,4'-, zfvmwevvkglcij-uhfffaoysa-n, 4,4'-(Hexafluoroisopropylidene)diphenol, 4,4'-(perfluoropropane-2,2-diyl)diphenol, 2,2-Bis(4-hydroxyphenyl)perfluoropropane, 2,2-Bis-(4-hydroxyphenyl)hexafluoropropane, MFCD00000439, OH7IX8A37J, CHEMBL1900054, 4-[2,2,2-trifluoro-1-(4-hydroxyphenyl)-1-(trifluoromethyl)ethyl]phenol, 4,4 inverted exclamation marka-(Hexafluoroisopropylidene)diphenol, Bisphenol A Hexafluoride, CAS-1478-61-1, BPAF, C15H10F6O2, TimTec1_001644, Hexafluorobisphenol A, 98%, SCHEMBL21027, BIDD:ER0048, BP_02 (BPAF), 4,4'-(Hexafluoroisopropylidene)diphenol (Bisphenol AF), MSK8728, HMS1538K16, BisphenolAF, analytical standard, 4,4'-(2,2,2-Trifluoro-1-(trifluoromethyl)ethylidene)diphenol, Tox21_201467, Tox21_303641, BDBM50544707, NSC152522, STK396229, AKOS005433772, 4,4'-(perfluoroisopropylidene)diphenol, CS-W014498, FB54805, Bisphenol AF 100 microg/mL in Methanol, NCGC00164114-01, NCGC00164114-02, NCGC00164114-03, NCGC00164114-04, NCGC00257463-01, NCGC00259018-01, AC-15007, AS-14550, SY014750, DB-005805, B0945, NS00011437, hexafluoro-2,2-bis-(4-hydroxyphenyl)-propane, Phenol,4'-(bis(trifluoromethyl)methylene)di-, 4,4'-(Hexafluoroisopropylidene)diphenol, 97%, Q9658045, 4,2,2-Trifluoro-1-(trifluoromethyl)ethylidene]bisphenol, Phenol,4'-[trifluoro-1-(trifluoromethyl)ethylidene]di-, 2,2-Bis-(4-hydroxyphenyl)-1,1,1,3,3,3-hexafluoropropane, Phenol,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis-, phenol,4,4-(2,2,2-triflouro-1-(trifluromethyl)ethylidene], 4,4 inverted exclamation mark -(Hexafluoroisopropylidene)diphenol, Hexafluoroisopropylidenebis(4-hydroxybenzene); Hexafluorobisphenol A; Bisphenol AF, 0CZ"	73864	C15H10F6O2	.
M6ADRUG0202	RS-102895	"RS102895; GTPL779; SCHEMBL9972649; CHEMBL1593104; CHEBI:93458; ZINC2563946; BCP05302; HY-18611A; AKOS030526775; CS-3487; NCGC00092306-02; AJ-40982; KB-62464; BRD-K83063356-003-01-7; 1'-[2-[4-(trifluoromethyl)phenyl]ethyl]spiro[1H-3,1-benzoxazine-4,4'-piperidine]-2-one; 1-(4-(Trifluoromethyl)phenethyl)spiro[benzo[d][1,3]oxazine-4,4-piperidin]-2(1H)-one hydrochloride"	10000456	C21H21F3N2O2	Investigative
M6ADRUG0203	Marasviroc	.	.	C41H52N4O4S	Investigative
M6ADRUG0204	Cenicriviroc	"497223-25-3; TBR-652; TAK-652; Cenicriviroc mesylate; UNII-15C116UA4Y; TAK652; 15C116UA4Y; TBR652; Cenicriviroc (USAN/INN); SCHEMBL3157768; SCHEMBL3157748; CHEMBL2110727; MolPort-044-723-655; MolPort-044-649-359; EX-A1608; BDBM50422828; AKOS027250788; CS-6148; DB11758; SB16976; HY-14882; AS-35184; D09878; UNII-15C116UA4Y component PNDKCRDVVKJPKG-WHERJAGFSA-N; 1-Benzazocine-5-carboxamide, 8-[4-(2-butoxyethoxy)phenyl]-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-[4-[[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (5E)-"	11285792	C41H52N4O4S	Phase 2
M6ADRUG0206	Dexmedetomidine	"Dexmedetomidina; Dexmedetomidinum; MPV 1440; MPV-1440; Precedex (TN); Dexmedetomidine (USAN/INN); (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole; 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole"	5311068	C13H16N2	Approved
M6ADRUG0208	ANGIOTENSIN II	"Human angiotensin II; Angiotensin II human; 4474-91-3; Angiotensin II (mouse); Angiotensin II (human); Giapreza; Ang II; 5-Isoleucine-angiotensin II; 5-L-Isoleucineangiotensin II; Ile(5)-angiotensin II; 1-8-Angiotensin I; isoleucine(5)-angiotensin II;Angiotensin II, human; Isoleucine5-angiotensin II; Angiotensin II, ile(5)-; Angiotensin ii [INN:JAN]"	172198	C50H71N13O12	Approved
M6ADRUG0209	A939572	"1032229-33-6, A939572, 4-(2-chlorophenoxy)-N-[3-(methylcarbamoyl)phenyl]piperidine-1-carboxamide, 4-(2-chlorophenoxy)-N-(3-(methylcarbamoyl)phenyl)piperidine-1-carboxamide, 4-(2-CHLOROPHENOXY)-N-[3-[(METHYLAMINO)CARBONYL]PHENYL]-1-PIPERIDINECARBOXAMIDE, 1-Piperidinecarboxamide,4-(2-chlorophenoxy)-N-[3-[(methylamino)carbonyl]phenyl]-, CHEMBL469169, A 939572, A-939572, 4-(2-chlorophenoxy)-N-(3-(methylcarbamoyl)-phenyl)piperidine-1-carboxamide, 4-(2-Chlorophenoxy)-N-[3-(methylcarbamoyl)-phenyl]piperidine-1-carboxamide, SCHEMBL14554165, DTXSID40648006, GLXC-03463, BCP27670, EX-A3456, A 939572 - Bio-X trade mark, BDBM50261716, s9607, AKOS022179820, CS-0305, AC-36384, AS-73726, BA162794, BA300005, HY-50709, DB-002537, DB-014948, C71136, EN300-6745729, Z1511753827, stearoyl-CoA desaturase (SCD) inhibitor;SCD-inhibitor; A-939572; A 939572, (Z)-4-(2-chlorophenoxy)-N-(3-((Z)-hydroxy(methylimino)methyl)phenyl)piperidine-1-carbimidic acid"	24905400	C20H22ClN3O3	Investigative
M6ADRUG0210	Simvastatin	"Cholestat; Coledis; Colemin; Corolin; Denan; Labistatin; Lipex; Lipovas; Lodales; Medipo; Nivelipol; Pantok; Rendapid; Simovil; Simvastatina; Simvastatine; Simvastatinum; Sinvacor; Sivastin; Synvinolin; Vasotenal; Zocor; Zocord; Simvast CR; Simvastatina [Spanish]; Simvastatine [French]; Simvastatinum [Latin]; MK 0733; MK 733; MK733; TNP00259; DRG-0320; KS-1113; L 644128-000U; MK-0733; MK-733; Simcard (TN); Simlup (TN); Simvacor (TN); Simvastatin & Primycin; Simvastatin, Compactin; Zocor (TN); Simvastatin [USAN:INN:BAN]; Simvastatin (JAN/USP/INN); Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one"	54454	C25H38O5	Approved
M6ADRUG0211	Oxycodone	"oxycodone, Dihydrone, Dihydrohydroxycodeinone, Oxycodeinone, Dihydroxycodeinone, Oxicon, Diphydrone, Eucodalum, Oxycodon, Percobarb, Oxicodona, Endone, Oxanest, Dihydro-14-hydroxycodeinone, (-)-14-Hydroxydihydrocodeinone, Oxycodonum, Oxyfast, Supendol, Xtampza, OxyIR, Ossicodone, Endine (Australia), Oxycodonum [INN-Latin], Oxicodona [INN-Spanish], 14-Hydroxydihydrocodeinone, Eubine [France], Supendol [Canada], Codeinone, dihydrohydroxy-, Avridi, Oxyneo, PTI-821, Oxycodone cii, Pancodone Retard, Apo-oxycodone CR, Codeinone, dihydro-14-hydroxy-, 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, Pancodone retard (United Kingdom), HSDB 3142, 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, EINECS 200-960-2, Pti 821, UNII-CD35PMG570, NSC 19043, NSC-19043, PF-00345439, Codeinone, 7,8-dihydro-14-hydroxy-, BRN 0043446, CD35PMG570, CHEBI:7852, IDS-NO-002, N02AA05, Oxycodeinon, DTXSID5023407, Oxycone, Eubine (France), NSC19043, Supendol (Canada), Oxycodonum (INN-Latin), Oxicodona (INN-Spanish), OXYCODONE (MART.), OXYCODONE [MART.], OXYCODONE CII (USP-RS), OXYCODONE CII [USP-RS], oxicodone, Oxycodone SR, HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE IMPURITY D (EP IMPURITY), HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE IMPURITY D [EP IMPURITY], Oxycodonum (Latin), XTAMPZAER, DTXCID903407, (5-alpha)-4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, (5alpha)-4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYLMORPHINAN-6-ONE, 200-960-2, 76-42-6, Oxycontin, Remoxy, Xtampza ER, Pavinal, oxymorphone 3-methyl ether, Oxicone, Tekodin (free base), Ossicodone [DCIT], Oxycodone [USAN:INN:BAN], Dihydrohydroxycondeinone, 14-hydroxy-3-methoxy-17-methyl-5beta-4,5-epoxymorphinan-6-one, (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one, (-)-Oxycodone, CHEMBL656, Oxycodone (USAN/INN), 4,5.alpha.-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5.alpha.)-, Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)-, OOX, OXYCODONE [INN], OXYCODONE [MI], OXYCODONE [HSDB], OXYCODONE [USAN], Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-, OXYCODONE [VANDF], OXYCODONE [WHO-DD], SCHEMBL2737, 14-cis-Hydroxydihydrocodeinone, GTPL7093, PF06, OXYCODONE [ORANGE BOOK], Codeinone,8-dihydro-14-hydroxy-, Oxycodone 0.1 mg/ml in Methanol, Oxycodone 1.0 mg/ml in Methanol, 14-hydroxy-3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one, BDBM50370595, Morphinan-6-one, 4,5-alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)-14-hydroxy-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one, DB00497, AC-16043, DB-243425, C08018, D05312, Q407535, Morphinan-6-one,5.alpha.-epoxy-14-hydroxy-3-methoxy-17-methyl-, Morphinan-6-one,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5.alpha.)-, WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ CQ JO1 P1, (5.ALPHA.)-4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYLMORPHINAN-6-ONE, 4aH-8,5-bcd]furan-5(6H)-one, 7,7a,8,9-tetrahydro-7a-hydroxy-3-methoxy-12-methyl-, (1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one, (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one"	5284603	C18H21NO4	Approved
M6ADRUG0212	MM-102	"MM-102, 1417329-24-8, HMTase Inhibitor IX, N-[bis(4-fluorophenyl)methyl]-1-[[(2S)-5-(diaminomethylideneamino)-2-[[2-ethyl-2-(2-methylpropanoylamino)butanoyl]amino]pentanoyl]amino]cyclopentane-1-carboxamide, MM102, (S)-N-(Bis(4-fluorophenyl)methyl)-1-(2-(2-ethyl-2-isobutyramidobutanamido)-5-guanidinopentanamido)cyclopentanecarboxamide, CHEMBL3883592, SCHEMBL12035529, CHEBI:233480, BDBM200723, GLXC-05980, BCP11764, EX-A1503, s7265, AKOS030526507, CCG-270356, MM-102, NCGC00351775-01, AC-36316, DA-65547, HY-12220, TS-09297, US9233086, 10L, SW220028-1, G14355, BRD-K68474068-001-01-8, cyclopentanecarboxamide, 1-[[(2S)-5-[(aminoiminomethyl)amino]-2-[[2-ethyl-2-[(2-methyl-1-oxopropyl)amino]-1-oxobutyl]amino]-1-oxopentyl]amino]-N-[bis(4-fluorophenyl)methyl]-, N-[bis(4-fluorophenyl)methyl]-1-[(2S)-5-carbamimidamido-2-[2-ethyl-2-(2-methylpropanamido)butanamido]pentanamido]cyclopentane-1-carboxamide"	54766613	C35H49F2N7O4	.
M6ADRUG0213	C646	"328968-36-1; CHEMBL1797936; 4-[(4Z)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid; C24H19N3O6; 4-[4-[[5-(4,5-Dimethyl-2-nitrophenyl)-2-furanyl]methylene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]benzoic acid; C 646; AC1LPE4V; GTPL7004; SCHEMBL12092858; QCR-235; DTXSID30361651; MolPort-002-171-380; CHEBI:132974; ZINC8780879; s7152; 2295AH; AKOS000113052; SB19338; ST020490; C646, &gt; J-018925; BRD-K73383190-001-03-1"	1285940	C24H19N3O6	Investigative
M6ADRUG0214	SETDB1-TTD-IN-1	"SETDB1-TTD-IN-1, 2755823-12-0, (R,R)-59, 2-[[(3~{R},5~{R})-1-methyl-5-(4-phenylmethoxyphenyl)piperidin-3-yl]amino]-3-prop-2-enyl-5~{H}-pyrrolo[3,2-d]pyrimidin-4-one, 3-Allyl-2-(((3R,5R)-5-(4-(benzyloxy)phenyl)-1-methylpiperidin-3-yl)amino)-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one, GLXC-26047, SETDB1-TTD-IN-(R,R)-59, AKOS040759958, MS-28686, HY-141539, CS-0179804, G18254, 2-[[(3R,5R)-1-methyl-5-(4-phenylmethoxyphenyl)piperidin-3-yl]amino]-3-prop-2-enyl-5H-pyrrolo[3,2-d]pyrimidin-4-one, CYH-260, 3-allyl-2-(((3R,5R)-5-(4-(benzyloxy)phenyl)-1-methylpiperidin-3-yl)amino)-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one, G09"	155884456	C28H31N5O2	.
M6ADRUG0215	Acetaminophen	4-Acetamidophenol; Paracetamol; 103-90-2; Tylenol; N-(4-Hydroxyphenyl)acetamide; APAP; Acetaminofen; Panadol; Datril; p-Hydroxyacetanilide; N-Acetyl-p-aminophenol; p-Acetamidophenol; Algotropyl; Naprinol; Lonarid; 4'-Hydroxyacetanilide; Multin; Acenol; Acamol; Anelix; p-Acetaminophenol; Liquagesic; Acetagesic; Gelocatil; Servigesic; Acetalgin; Abensanil; Pyrinazine; Injectapap; Clixodyne; Valgesic; Tussapap; Finimal; Paracet; Homoolan; Febrolin; Febrilix; Febridol; Dymadon; Anaflon; Apamide; Valadol; Tralgon; Tabalgin; Lestemp; Alvedon; Abenol; Abrol; Abrolet; Acephen; Acertol; Acetaco; Acetamol; Acetavance; Acetofen; Actamin; Actimol; Afebrin; Afebryl; Aferadol; Algesidal; Algina; Algomol; Alpiny; Alpinyl; Amadil; Aminofen; Analter; Anapap; Andox; Anhiba; Antidol; Anuphen; Apacet; Apadon; Apitrelal; Arfen; Arthralgen; Asetam; Asomal; Aspac; Asplin; Atasol; Atralidon; Babikan; Bacetamol; Banesin; Benmyo; Biocetamol; Cadafen; Calapol; Calmanticold; Calonal; Calpol; Capital; Captin; Causalon; Cefalex; Cetadol; Codabrol; Codalgin; Codapane; Codicet; Codisal; Codoliprane; Cofamol; Conacetol; Cosutone; Cuponol; Curadon; Curpol; Custodial; Dafalgan; Darocet; Darvocet; Daygrip; Deminofen; Democyl; Demogripal; Desfebre; Dhamol; Dimindol; Dirox; Disprol; Dolcor; Dolefin; Dolegrippin; Dolgesic; Doliprane; Dolko; Dolofugin; Doloreduct; Dolorfug; Dolorstop; Dolotec; Dolprone; Dorocoff; Dresan; Dristancito; Duaneo; Dularin; Duorol; Duracetamol; Durapan; Dypap; Ecosetol; Elixodyne; Empracet; Enelfa; Eneril; Excipain; Exdol; Fanalgic; Farmadol; Febranine; Febrectal; Febrectol; Febrex; Febricet; Febrin; Febrinol; Fendon; Fensum; Fepanil; Fevor; Finiweh; Fluparmol; Geluprane; Genapap; Genebs; Grippostad; Gynospasmine; Hedex; Ildamol; Inalgex; Infadrops; Janupap; Kataprin; Korum; Labamol; Lekadol; Lemgrip; Lemsip; Liqiprine; Lupocet; Lyteca; Magnidol; Malgis; Malidens; Maxadol; Medocodene; Mexalen; Minafen; Minoset; Miralgin; Momentum; NEBS; Napafen; Nealgyl; NeoCitran; Neodol; Neodolito; Neopap; Neotrend; Neuridon; NilnOcen; Nina; Nobedon; Nodolex; Noral; Ofirmev; Oltyl; Oralgan; Ortensan; Oxycocet; Paceco; Pacemo; Pacemol; Pacet; Pacimol; Paedialgon; Paedol; Painex; Paldesic; Pamol; Panacete; Panadeine; Panadiene; Panaleve; Panamax; Panasorb; Panasorbe; Panets; Panex; Panodil; Panofen; Pantalgin; Paracemol; Paracenol; Paracetamole; Paracetamolo; Paracetanol; Paracetol; Paracin; Paracod; Paracodol; Parador; Paradrops; Parakapton; Parake; Paralen; Paralief; Paralink; Paralyoc; Paramol; Paramolan; Paranox; Parapan; Parasedol; Parasin; Paraspen; Parcetol; Parelan; Parmol; Parogal; Paroma; Pasolind; Pediapirin; Pediatrix; Pedric; Perfalgan; Phendon; Phenipirin; Phogoglandin; Pinex; Piramin; Pirinasol; Plicet; Polmofen; Predimol; Predualito; Prodol; Prompt; Prontina; Puernol; Pulmofen; Pyrigesic; Pyromed; Redutemp; Reliv; Remedol; Rivalgyl; Robigesic; Rounox; RubieMol; Rubophen; Rupemol; Salzone; Sanicet; Sanicopyrine; Scanol; Scentalgyl; Schmerzex; Sedalito; Semolacin; Seskamol; Setakop; Setamol; Setol; Sifenol; Sinaspril; Sinedol; Sinmol; Stanback; Stopain; Sunetheton; Supofen; Suppap; TYL; Tachiprina; Tapanol; Tapar; Tazamol; Temlo; Tempanal; Tempra; Termacet; Termalgin; Termalgine; Termofren; Tiffy; Titralgan; Treuphadol; Tricoton; Tylex; Tylol; Tymol; Upsanol; Utragin; Valorin; Veralgina; Vermidon; Verpol; Vips; Viruflu; Vivimed; Volpan; Zatinol; Zolben; Aceta Elixir; Actifed Plus; Aspirin free anacin; Bayer Select; D oliprane; Dymadon Co; Fortalidon P; Gattaphen T; Gripin Bebe; Helon N; Influbene N; Jin Gang; Lonarid Mono; Lyteca Syrup; Malex N; Panadeine Co; Panale ve; Pasolind N; Spalt N; Supadol mono; Toximer P; Treupel N; Treupel mon; Ty lenol; Tylex CD; Anacin 3; A-Per; Accu-Tap; Ultracet	1983	C8H9NO2	Approved
M6ADRUG0216	BHBA	"3-hydroxybutyric acid, 3-hydroxybutanoic acid, 300-85-6, Butanoic acid, 3-hydroxy-, DL-3-Hydroxybutyric Acid, 625-71-8, beta-Hydroxybutyric acid, 3 HBA, 3-Hydroxybuttersaeure, Butyric acid, 3-hydroxy-, DL-beta-Hydroxybutyric acid, beta-Hydroxybuttersaeure, 26063-00-3, beta-Hydroxy-n-butyric acid, poly(3-hydroxybutyric acid), 3-hydroxy-butanoic acid, .beta.-Hydroxybutyric acid, (1)-3-Hydroxybutyric acid, (+-)-3-Hydroxybutyric acid, beta-hydroxy-butyrate, D,l-3 hydroxybutyrate, beta-hydroxybutanoic acid, NSC 3806, NSC-3806, Hydroxybutyric acid, dl-, MFCD00004546, .beta.-Hydroxy-n-butyric acid, AI3-21675, (+/-)-3-Hydroxybutyric Acid, D(-)-beta-hydroxy butyric acid, CHEBI:20067, 3-hydroxybutyric acid, (+/-)-, TZP1275679, Butyric acid, 3-hydroxy- (8CI), 3-Hydroxybutanoic Acid + 3-(3-Hydroxybutyryloxy)butyric Acid (CAS:7565-79-9) (50:50 Mixture), SMR000112209, (+/-)-3-Hydroxybutyric Acid (Technical Grade), MFCD00137685, UNII-TZP1275679, EINECS 206-099-9, EINECS 210-908-0, 3-OH-butyric acid, BHBA, 3- hydroxybutyric acid, 3-hydroxy-butyric acid, DL-3-HydroxybutyricAcid, d,l-3-hydroxybutyric acid, bmse000161, bmse000905, SCHEMBL2731, (RS)-3-hydroxybutyric acid, (+/-)-beta-Hydroxybutyrate, MLS001332397, MLS001332398, 3-Hydroxybutyric acid, 95%, DL-.beta.-Hydroxybutyric acid, (+/-)-3-Hydroxybutanoic acid, CHEMBL1162496, .BETA.HYDROXYBUTYRIC ACID, DTXSID60859511, NSC3806, (.+/-.)-3-Hydroxybutyric acid, 3-Hydroxybutyric acid, tech grade, HMS2270C20, HMS3369F13, BBL027467, HB4640, LMFA01050005, s1031, STL377875, AKOS009156821, AB88579, AC-5701, FH30882, SB44475, Butanoic acid, 3-hydroxy-, (+/-)-, .BETA.-HYDROXYBUTYRIC ACID [MI], Butanoic acid, 3-hydroxy-, (A+/-)-, BETA-HYDROXYBUTYRIC ACID [WHO-DD], FP179872, SY074781, SY076545, SY114480, VS-08544, HY-113378, CS-0062335, H0228, NS00014717, Poly(3-hydroxybutyric acid), MW~500,000, D84191, EN300-147463, Poly[(R)-3-hydroxybutyrate], Mn ~500,000, Q223092, BRD-A41387824-001-06-0, (+/-)-3-Hydroxybutanoic acid;DL--Hydroxybutyric acid, 869DD3C9-3114-4BE2-B4A6-6F1787476E95"	441	C4H8O3	.
M6ADRUG0217	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	C17H12F3NO4S	Investigative
M6ADRUG0218	"US9650366, 12"	Cystadane	247	C25H19F4N7O2	Patented
M6ADRUG0219	Octanol	"2086-83-1; Berberin; Umbellatine; UNII-0I8Y3P32UF; 0I8Y3P32UF; CHEBI:16118; EINECS 218-229-1; Berberal; BRN 3570374; ST055798; 9,10-Dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetrahydroberbinium; Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy-; 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium; Berbamine sulphate acid; CHEMBL12089; 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)berbinium; BERBINIUM, 7,8,13,13a-TETRAHYDRO-9,10-DIMETHOXY-2,3-(METHYLE"	2353	C8H18O	Investigative
M6ADRUG0220	AVI-5126	Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244	2719	.	Phase 2
M6ADRUG0221	Ocriplasmin	"5-Fluorouracil; 51-21-8; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU"	3385	.	Approved
M6ADRUG0222	Contusugene ladenovec	"Arquel; Meclofenamate; Acide meclofenamique; Acido meclofenamico; Acidum meclofenamicum; Meclophenamic acid; CL 583; INF 4668; Acide meclofenamique [INN-French]; Acido meclofenamico [INN-Spanish]; Acidum meclofenamicum [INN-Latin]; INF-4668; Meclomen (free acid); Meclofenamic acid (USAN/INN); Meclofenamic acid [USAN:INN:BAN]; N-(2,6-Dichloro-3-methylphenyl)anthranilic acid; N-(2,6-Dichloro-m-tolyl)anthranilic acid; N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid; 2-((2,6-Dichloro-3-methylphenyl)amino)benzoic acid; 2-(2,6-Dichloro-3-methylphenyl)aminobenzoic acid; 2-(2,6-dichloro-3-methylanilino)benzoic acid; 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid"	4037	.	Phase 3
M6ADRUG0224	Palbociclib	"657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metiguanide; Dimethylbiguanide; Glucophage; Haurymelin; Gliguanid; Fluamine; Glumetza; Flumamine; Melbin; Diabex; N,N-Dimethylbiguanide; Metformina; Metforminum; Metformine; Islotin; Glifage; Siofor; N1,N1-Dimethylbiguanide; DMGG; NNDG; Dimethyldiguanide; N,N-Dimethyldiguanide; Metformina [DCIT]; Imidodicarbonimidic diamide, N,N-dimethyl-; Metformina [Spanish]; Metforminum [INN-Latin]; Metformine [INN-French]; Metformin [USAN:INN:BAN]; 1,1-Dimethyl; Diabetosan; Dimethylbiguanidine; Dimethylguanylguanidine; Glycon; Diabex (TN); Diaformin (TN); Dianben (TN); Fortamet (TN); Gen-Metformin; Glucophage (TN); Glumetza (TN); LA-6023; Nu-Metformin; Obimet (TN); Riomet (TN); Metformin (USAN/INN); 1,1-Dimethyl biguanide; 3-(diaminomethylidene)-1,1-dimethylguanidine; [14C]metformin"	4091	C24H29N7O2	Approved
M6ADRUG0225	PMID27841036-Compound-37	"Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida; Temozolomidum; Essex brand of temozolomide; Scheringbrand of temozolomide; Temozolodida [Spanish]; Temozolomidum [Latin]; M B 39831; MB 39831; Sch 52365; M & B 39831; M&B 39831; M-39831; Sch-52365; Schering-Plough brand of temozolomide; TMZ-Bioshuttle; Temodal (TN); Temodar (TN); Temozolomide [INN:BAN]; M&B-39831; Temozolomide (JAN/USAN/INN); 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; TMZ"	5394	C18H15N5O	Phase 2
M6ADRUG0226	PHA848125	"Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone"	5743	C25H32N8O	Phase 2
M6ADRUG0227	PTI-125	"Precision tolerogens (autoimmune disease), NaniRx"	23939	C15H21N3O	Phase 2
M6ADRUG0228	E-2007	"Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline"	30323	C23H15N3O	Approved
M6ADRUG0229	PMID26666870-Compound-16	"23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin"	31703	.	Patented
M6ADRUG0230	Arsenic trioxide	Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)	60750	As2O3	Approved
M6ADRUG0231	RG7625	"(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE"	65064	C25H23F6N5O4S	Phase 2
M6ADRUG0232	Trimethoprim	AcSDKP; Seraspenide; BIM-32001; Acetyl-seryl-aspartyl-lysyl-proline	65938	C14H18N4O3	Approved
M6ADRUG0233	Acitretin	.	.	C21H26O3	Approved
M6ADRUG0234	ISIS 1570	"Faslodex; AstraZeneca brand of fulvestrant; Fulvestrant [USAN]; Ici 182780; ZD 182780; ZM 182780; Faslodex (TN); ZD-182780; ZD-9238; ZM-182780; Faslodex(ICI 182,780); Faslodex, ICI 182780, Fulvestrant; Fulvestrant (JAN/USAN/INN); (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; ICI"	104741	.	Approved
M6ADRUG0235	ISIS 3792	.	.	.	Investigative
M6ADRUG0236	RG7388	.	.	C31H29Cl2F2N3O4	Phase 3
M6ADRUG0237	ASTX660	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	216239	C30H42FN5O3	Phase 2
M6ADRUG0238	ABT-263	.	.	C47H55ClF3N5O6S3	Phase 3
M6ADRUG0160	VS-6063	"Retinoic acid; 302-79-4; Vitamin A acid; all-trans-Retinoic acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; Dermairol; Aknoten; Eudyna; Aberel; all-trans-Vitamin A acid; Aknefug; All-trans Retinoic Acid; Cordes vas; Epi-aberel; Atralin; Vitamin A1 acid, all-trans-; Tretin M; Retin-A Micro; all-trans-Vitamin A1 acid; Vitamin A acid, all-trans-; all-trans-Tretinoin; Effederm; Retionic acid; TRETINON; Retinoic acid, all-trans-; Alltrans-retinoic acid; beta-Ra; all-(E)-Retinoic acid; beta-Retinoic acid; Avitoin; Aberela; Acnavit; Atragen; Betarretin; Lsotretinoin; Nexret; Panretyn; REA; Retacnyl; Retinoate; Retinova; Solage; Tretinoina; Tretinoine; Tretinoino; Tretinoinum; Vesnaroid; Vitinoin; Aberela [Norway]; Accutane Roche; Acnavit [Denmark]; All Trans Retinoic Acid; Avita Gel; Avitoin [Norway]; Beta all trans Retinoic Acid; Cordes VAS [Germany]; Effederm [France]; Panretin Gel; Retin A; Trans Retinoic Acid; Tretinoin Potassium Salt; Tretinoin Sodium Salt; Tretinoin Zinc Salt; Tretinoin liposome; AGN100335; AGN 192013; ALRT 1057; BAL4079; LGD 100057; R 2625; [3H]Retinoic acid; A-Vitaminsyre; A-Vitaminsyre [Denmark]; AT-RA; Aberela (TN); Acid, Retinoic; Acid, Vitamin A; All trans-Retinoic acid; Atra-IV; Avita (TN); B-Retinoic acid; BML2-E05; Potassium Salt, Tretinoin; RETINOIC ACID, ALL TRANS; Renova (TN); Retin A (TN); Retisol-A; Ro 1-5488; Salt, Tretinoin Potassium; Salt, Tretinoin Sodium; Salt, Tretinoin Zinc; Sodium Salt, Tretinoin; Stieva-A; Stieva-a Forte; Trans-Retinoicacid; Tretinoin (TN); Tretinoina [INN-Spanish]; Tretinoine [INN-French]; Tretinoino [INN-Spanish]; Tretinoinum [INN-Latin]; Tri-Luma; Vesanoid (TN); Zinc Salt, Tretinoin; A-Acido (Argentina); Acid A Vit (Belgium, Netherlands); Acid, trans-Retinoic; Acide retinoique (French) (DSL); PDT-002-002; Retin-A (TN); Stieva-A (TN); Tretinoin 01% cream or placebo; Tretinoin [USAN:INN:BAN]; Tretinoin/All-Trans Retinoic Acid; Tretinoine (French) (EINECS); Acid, all-trans-Retinoic; All-trans-b-Retinoic acid; All-trans-beta-Retinoic acid; Beta-all-trans-Retinoic acid; Tretinoin (JAN/USP/INN); Acid, beta-all-trans-Retinoic; Retinoic acid, all-trans-(8CI); Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin; 15-Apo-beta-caroten-15-oic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 9(Z)-Retinoic acid; 9-cis-RA; 9-trans-retinoic acid"	444795	C20H21F3N8O3S	Phase 2
M6ADRUG0240	THZ531	"PTG; Teniposido; Teniposidum; Vehem; Vumon; Demethyl Epipodophyllotoxin Thenylidine Glucoside; VM 26; Teniposido [INN-Spanish]; Teniposidum [INN-Latin]; VM-26; Vee M-26; Veham-Sandoz; Vumon (TN); Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; VM-26 (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside"	452548	C30H32ClN7O2	Investigative
M6ADRUG0241	"2,4-epi-neodysiherbaine"	"10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen"	2733526	C11H16NO8-	Investigative
M6ADRUG0242	E7820	.	.	C17H12N4O2S	Phase 2
M6ADRUG0243	Curcumin	.	.	C21H20O6	Phase 4
M6ADRUG0244	BI6015	"Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel"	3062316	C15H13N3O4S	Investigative
M6ADRUG0245	Recombinant human endostatin	"53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)"	5284616	.	Approved
M6ADRUG0246	Peptide analog 8	"Colistin sulphate; Polymyxin E; Colistin sulfate, nonsterile; Polymyxin E. Sulfate; Coly-Mycin M Parenteral (TN)"	5311054	.	Patented
M6ADRUG0247	BVD-523	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	5702198	C21H22Cl2N4O2	Phase 2
M6ADRUG0248	Pregnenolone-16alpha-carbonitrile	Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN)	9887053	C22H31NO2	Investigative
M6ADRUG0249	PD-0183812	PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)	42611257	C28H35N5O2	Terminated
M6ADRUG0250	Dactinomycin	"Cosmegen; Dactinomicina; Dactinomycine; Dactinomycinum; Meractinomycin; ACT D; ACTINOMYCIN D AMP; Actactinomycin A IV; Actinomycin A IV; Actinomycin Aiv; Actinomycin I; Actinomycin IV; Actinomycin cl; Actinomycin x i; Antibiotic from Streptomyces parvullus; Chounghwamycin B; D Actinomycin; Dactinomycin D; Dactinomyein d; Dilactone actin omycindioic D acid; Dilactone actinomycin D acid; Dilactone actinomycindioic D acid; Lyovac cosmegen; Oncostatin K; Actinomycin 11 cosmegen; Actinomycin 7; Actinomycin C1; Actinomycin I1; Actinomycin X 1; Actinomycin X1; HBF 386; HBF 386 meractinomycin; X 97; AD (VAN); Actinomycin C (sub1); Actinomycin C(sub1); Actinomycin D (JP15); Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin I (sub1); Actinomycin I(sub 1); Actinomycin I(sub1); Actinomycin-IV; Actinomycindioic D acid, dilactone; Acto-D; COSMEGEN (TN); Dactinomicina [INN-Spanish]; Dactinomycin (USP); Dactinomycin [USAN:BAN]; Dactinomycine [INN-French]; Dactinomycinum [INN-Latin]; NP-005932; Actinomycin D deriv. of 3H-phenoxaocardazine; GNF-PF-1977; Actinomycin-[threo-val-pro-sar-meval]; Actinomyein-theo-val-pro-sar-meval; Actinomycin-(threo-val-pro-sar-meval); O)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide"	457193	C62H86N12O16	Approved
M6ADRUG0252	Decitabine	"AzadC; Dacogen; Dezocitidine; NCGC_5ADOC; Dacogen (TN); E-7373; Decitabine (USAN/INN); Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine; 2'-Deoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 5-AZAdC; 5-Aza-2&prime;-Deoxycytidine; 5-Aza-2'-deoxycytidine; 5-Azadeoxycytidine; 5-Deoxy-2&prime;-azacytidine; 5-aza-2-deoxycytidine; 5-aza-CdR; 5-aza-dC; 5A2dc"	451668	C8H12N4O4	Approved
M6ADRUG0253	GLYCYRRHIZIN	"Glycyrrhizic acid; Glycyrrhizinic acid; 1405-86-3; Glycyron; Glycyrrhetinic acid glycoside; glyzyrrhizin; 18-beta-Glycyrrhizic acid; Glycyrrizin; Liquorice; UNII-6FO62043WK; Rizinsan K2 A2 (free acid); HSDB 496; EINECS 215-785-7; C42H62O16; Glycyrrhizin [JAN]; NSC 167409; NSC 234419; BRN 0077922; CHEMBL441687; NSC 2800; beta-Glycyrrhizin; CHEBI:15939; 6FO62043WK; DSSTox_RID_82047; DSSTox_CID_27006; DSSTox_GSID_47006; Glycyram; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-"	14982	C42H62O16	Phase 3
M6ADRUG0254	GSK-J4	"GSK J4; GSKJ4; Ethyl 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate"	71729975	C24H27N5O2	.
M6ADRUG0255	Propofol	"Ampofol; Aquafol; Diisopropylphenol; Dipravan; Diprivan; Disoprivan; Disoprofol; Fresofol; Ivofol; PFL; Propofolum; Rapinovet; Recofol; Abbott Brand of Propofol; Alpha Brand of Propofol; Astra Brand of Propofol; AstraZeneca Brand of Propofol; Braun Brand of Propofol; Curamed Brand of Propofol; Diprivan Injectable emulsion; Fresenius Brand of Propofol; Fresenius Kabi Brand of Propofol; Juste Brand of Propofol; Parnell Brand of Propofol; Pisa Brand of Propofol; Propofol Abbott; Propofol Fresenius; Propofol MCT; Propofol Rovi; Propofolum [Latin]; Rovi Brand of Propofol; Schering Brand of Propofol; Zeneca Brand of Propofol; AM-149; DDS-04F; Diprivan (TN); Propofol IDD-D; Propofol-Lipuro; ZD-0859; Ghl.PD_Mitscher_leg0.558; Propofol [USAN:INN:BAN]; Propofol (JAN/USAN/INN); Propofol(2,6-Diisopropylphenol); 2, 6-Diisopropylphenol; 2,6 Diisopropylphenol; 2,6-Bis(1-methylethyl)phenol; 2,6-Bis(Isopropyl)-phenol; 2,6-DIISOPROPYLPHENOL; 2,6-Diisopropyl phenol; 2,6-bis(1-methylethyl)-phenol; 2,6-di(propan-2-yl)phenol"	4943	C12H18O	Approved
M6ADRUG0256	Salicylic acid derivative 2	PMID26394986-Compound-14	53388144	C29H27F5N2O6S	.
M6ADRUG0257	Tadalafil	"ADCIRCA; Acdirca; Cialis; Tadanafil; Lilly brand of tadalafil; Tadalafil [USAN]; GF 196960; IC 351; ICOS 351; Ic351; Cialis (TN); GF-196960; IC-351; KS-1117; Tadalafil (JAN/USAN/INN); Cialis, GF 196960, IC 351, ICOS 351, Tadalafil; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione"	110635	C22H19N3O4	Approved
M6ADRUG0258	Trichostatin A	"58880-19-6; Trichostatin A (TSA); TSA; Trichostatin; Tricostatin A; UNII-3X2S926L3Z; CHEBI:46024; (2E,4E,6R)-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide; GNF-PF-1011; RTKIYFITIVXBLE-QEQCGCAPSA-N; 3X2S926L3Z; 7-(4-(Dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide; 2,4-Heptadienamide, 7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-; 7-[4-(DIMETHYLAMINO)PHENYL]-N-HYDROXY-4,6-DIMETHYL-7-OXO-2,4-HEPTADIENAMIDE"	444732	C17H22N2O3	Investigative
M6ADRUG0259	Triptonide	"(-)-triptonide; NSC 165677; Triptolide, 14-deoxy-14-oxo-; CHEBI:132267; (1S,2S,4S,5S,7S,9S,11S,13S)-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-ene-8,17-dione; (3bS,4aS,5aS,6aS,7aS,7bS,8aS,8bS)-6a-isopropyl-8b-methyl-3b,4,4a,7a,7b,8b,9,10-octahydrotrisoxireno[6,7:8a,9:4b,5]phenanthro[1,2-c]furan-1,6(3H,6aH)-dione; (1S,2S,4S,5S,7S,9S,11S,13S)-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo(11.7.0.02,4.02,9.05,7.09,11.014,18)icos-14(18)-ene-8,17-dione"	65411	C20H22O6	.
M6ADRUG0260	Verteporfin	Visudyne (TN)	11980904	C82H84N8O16	Approved
M6ADRUG0261	Vorinostat	"NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)"	5311	C14H20N2O3	Approved
M6APDG04235	GSK4069889	TSR-022	.	.	Phase 2
M6APDG02690	ASC-J9	"Dimethylcurcumin; 52328-98-0; 917813-54-8; ASCJ-9; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; 1,7-Bis-(3,4-dimethoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; 1,7-Bis-(3,4-dimethoxy-phenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; GO-Y-025; (1E,4E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; Dimethylcurcumin (ASC-J9); 1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; SCHEMBL3487103; CHC-004; DTXSID10200352; EX-A927; AMY15692; 3454AH; MFCD12912341; MFCD22123809; NSC734923; RSC004738; s6630; AKOS015891371; AKOS025311328; ZINC100007120; CS-0533; DB06133; LS40141; NSC-734923; SB18767; 1,4,6-Heptatrien-3-one, 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-, (1E,4Z,6E)--; 1,4,6-Heptatrien-3-one, 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-, (Z,E,E)-; AC-31058; DS-14720; HY-15194; ASC-J9,CAS:52328-98-0; W9512; J3.606.945G; A11300; W-5544; GO-Y025; Dimethylcurcumin; ASC J9; GO Y025; 1, 4-dimethoxyphenyl)-1, 6-heptadiene-3,5-dione; (1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatriene-3-one; 1,7-Bis-(3,4-dimethoxy-phenyl)- 5-hydroxy-hepta-1,4,6-trien-3-one; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatrien-3-one; (1E,4Z,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatriene-3-one; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; 115851-85-9"	6477182	C23H24O6	Phase 2
M6APDG03869	PF-07220060	.	.	.	Phase 1
M6APDG04221	HCB1019	.	.	.	Phase 2
M6APDG03792	Iomab-ACT	.	.	.	Phase 1
M6APDG02948	HHCYH33	"CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate"	72550012	C24H29F3N8O5S	Phase 1
M6APDG03851	EPI-7386	.	.	.	Phase 1
M6APDG04000	ZL-1201	.	.	.	Phase 1
M6APDG00097	Thymoquinone	"490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; Thymoquinone; 2-isopropyl-5-methylbenzo-1,4-quinone; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI"	10281	C10H12O2	Phase 2/3
M6APDG04065	TAS-0728	.	.	.	Phase 1/2
M6APDG04233	SEphB4-HSA	.	.	.	Phase 2
M6APDG04070	CPI-0209	.	.	.	Phase 1/2
M6APDG04016	IBI318	.	.	.	Phase 1
M6APDG04083	EMB-01	.	.	.	Phase 1/2
M6APDG04291	ASP1929	Cetuximab sarotalocan	.	.	Phase 3
M6APDG03892	BI 907828	.	.	.	Phase 1
M6APDG02819	IU1	"314245-33-5; 1-[1-(4-Fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(1-pyrrolidinyl)ethanone; 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one; IU-1; 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidin-1-ylethanone; 1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-2-(pyrrolidin-1-yl)ethanone; CHEMBL1410015; MFCD01917473; 1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-2-(pyrrolidin-1-yl)ethan-1-one; 1-[1-(4-Fluoro-phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone; Usp14 inhibitor; MLS001032847; GTPL8880; SCHEMBL6923146; ZINC38235; DTXSID80350196; HMS1726C11; HMS2742M13; HMS3653I09; HMS3743A07; AMY24153; BCP12722; EX-A2079; 2486AH; BDBM50437694; s7134; AKOS000811299; IU1, >=98% (HPLC); CCG-190730; CS-7546; MCULE-9620933012; NE48827; QC-8208; SB19054; NCGC00249377-01; NCGC00249377-04; NCGC00249377-08; AC-32694; DA-33458; HY-13817; SMR000363441; ST054127; AB0097167; FT-0716455; MLS001032847-02; SW219677-1; EN300-72884; SR-01000010584; J-018415; SR-01000010584-1; Z55133506; F1142-1244; 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidinylethan-1-one; 1-[1-(4-FLUOROPHENYL)-2,5-DIMETHYLPYRROL-3-YL]-2-(PYRROLIDIN-1-YL)ETHANONE"	675434	C18H21FN2O	Preclinical
M6APDG03936	CV8102	.	.	.	Phase 1
M6APDG03889	INCAGN2390	.	.	.	Phase 1
M6APDG03972	MCLA-158	.	.	.	Phase 1
M6APDG02937	APL-101	"Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine"	72202701	C20H15F3N8	Phase 2
M6APDG04192	KN026	.	.	.	Phase 2
M6APDG02201	Tarloxotinib	"Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0"	51038316	C24H24BrClN9O3+	Phase 2
M6APDG04055	NM21-1480	.	.	.	Phase 1/2
M6APDG03886	SYNB1891	.	.	.	Phase 1
M6APDG00711	NT219	"UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-"	135914977	C16H14BrNO5S	Phase 1/2
M6APDG03915	SBT6050	.	.	.	Phase 1
M6APDG04006	SNX281	.	.	.	Phase 1
M6APDG04329	GL21.T	.	.	.	Preclinical
M6APDG03881	TR1801-ADC	.	.	.	Phase 1
M6APDG04026	MB-103	.	.	.	Phase 1
M6APDG02952	CTP-543	"Deuruxolitinib; D8-ruxolitinib; UNII-0CA0VSF91Y; Deuruxolitinib (USAN); Deuruxolitinib [USAN]; C-21543; (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; 1513883-39-0; CTP543; CHEMBL4594381; SCHEMBL19555526; GTPL11410; WHO 11622; D11866; (3R)-3-(2,2,3,3,4,4,5,5-D8)cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1Hpyrazol-1-yl)propanenitrile; H-Pyrazole-1-propanenitrile, beta-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (betaR)-"	72704611	C17H18N6	Phase 2
M6APDG03884	TAK-676	.	.	.	Phase 1
M6APDG03818	CA102N	.	.	.	Phase 1
M6APDG03998	IMC-002	.	.	.	Phase 1
M6APDG03833	FT-7051	.	.	.	Phase 1
M6APDG03910	GQ1001	.	.	.	Phase 1
M6APDG04327	SD1003	.	.	.	Preclinical
M6APDG00562	GS-4224	"Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632"	12439252	C6H6N2O2	Phase 1/2
M6APDG03911	MT-5111	.	.	.	Phase 1
M6APDG04079	BT5528	.	.	.	Phase 1/2
M6APDG04031	ARV-471	.	.	.	Phase 1/2
M6APDG04232	ZN-c3	.	.	.	Phase 2
M6APDG04331	ADC-01	.	.	.	Preclinical
M6APDG04036	CYT-0851	.	.	.	Phase 1/2
M6APDG03824	INB03	.	.	.	Phase 1
M6APDG03971	D2C7	.	.	.	Phase 1
M6APDG03813	BI 1701963	.	.	.	Phase 1
M6APDG03830	INCB81776	INCB081776	.	.	Phase 1
M6APDG04234	RO7121661	RG7769	.	.	Phase 2
M6APDG04007	GSK3745417	.	.	.	Phase 1
M6APDG04277	Amivantamab	.	.	.	Phase 3
M6APDG04188	MK-1454	.	.	.	Phase 2
M6APDG04059	AZD0466	.	.	.	Phase 1/2
M6APDG03909	MBS301	.	.	.	Phase 1
M6APDG04325	TFM735	.	.	.	Preclinical
M6APDG01550	NSC-207895	"58131-57-0; NSC 207895; NSC207895; NSC 179940; MLS000756495; Benzofurazan, 4-(4-methyl-1-piperazinyl)-7-nitro-, 3-oxide; 4-(4-Methyl-1-piperazinyl)-7-nitro-benzofurazan 3-oxide; BENZOFURAZAN, 7-(4-METHYL-1-PIPERAZINYL)-4-NITRO-, 1-OXIDE; 4-(4-methylpiperazin-1-yl)-7-nitro-3-oxido-2,1,3-benzoxadiazol-3-ium; SMR000528763; NSC 207895 (XI-006); NSC-207895 (XI-006); 4-(4-methyl-1-piperazinyl)-7-nitro-2,1,3-benzoxadiazole, 3-oxide; XI-006; WLN: T56 BNONJ BO FNW I- AT6N DNTJ D1; 7-(4-Methyl-1-piperazinyl)-4-nitrobenzofurazan 1-oxide; B2368; NCIStruc1_000831; NCIStruc2_001869; cc-262; cid_42640; MLS006011023; SCHEMBL8738959; CHEMBL1608727; BDBM51256; DTXSID50206858; HMS2861M23; XI006; ZINC5180959; NSC179940; s2678; BCP9000997; NCGC00246958-01; NCGC00246958-02; NCGC00246958-03; HY-14714; NCI60_001741; BCP0726000315; NSC-207895?XI-006?; A4209; CS-0003525; NSC-207895 - XI-006; NSC?207895?(XI-006); X7598; Z-3234; 7-(4-methylpiperazino)-4-nitro-1-oxido-benzofurazan-1-ium; 2,1,3-Benzoxadiazole, 4-(4-methyl-1-piperazinyl)-7-nitro-, 3-oxide; 2,1,3-benzoxadiazole, 7-(4-methyl-1-piperazinyl)-4-nitro-, 1-oxide; 4-(4-methyl-1-piperazinyl)-7-nitro-3-oxido-2,1,3-benzoxadiazol-3-ium; 7-(4-methylpiperazin-1-yl)-4-nitrobenzo[c][1,2,5]oxadiazole 1-oxide; 4-(4-methylpiperazin-1-yl)-7-nitro-3-oxidanidyl-2,1,3-benzoxadiazol-3-ium; 4-(hydroxy(oxido)amino)-7-(4-methyl-1-piperazinyl)-2,15,3-benzoxadiazol-1-ol"	42640	C11H13N5O4	Preclinical
M6APDG03941	VOB560	S 65487	.	.	Phase 1
M6APDG03888	PF-07265807	PF-5807; ARRY-067	.	.	Phase 1
M6APDG04124	Stenoparib	.	.	.	Phase 2
M6APDG00232	C-176	314054-00-7; N-(4-iodophenyl)-5-nitrofuran-2-carboxamide; C-176 STING inhibitor; STING inhibitor C-176; STING Inhibitor 1; Cambridge id 5344639; Oprea1_000586; Oprea1_014551; 5-Nitro-furan-2-carboxylic acid (4-iodo-phenyl)-amide; CHEMBL3593839; SCHEMBL13219564; ZINC830011; BCP30174; EX-A2974; s6575; STK016322; AKOS000670518; MCULE-4963641555; BS-16912; HY-112906; AK00792625; CS-0067918; ST50232559; STING inhibitor C-176; C176; C 176; AB00081654-01; N-(4-iodophenyl)(5-nitro(2-furyl))carboxamide; SR-01000406953; SR-01000406953-1	1103958	C11H7IN2O4	Investigative
M6APDG00528	Palomid-529	"Palomid 529; 914913-88-5; P529; Palomid 529 (P529); 8-(1-Hydroxyethyl)-2-methoxy-3-((4-methoxybenzyl)oxy)-6H-benzo[c]chromen-6-one; SG 00529; SG-00529; P-529; 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one; UNII-XV9409EWG4; 6H-Dibenzo(b,d)pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-; 8-(1-hydroxyethyl)-2-methoxy-3-(4-methoxybenzyloxy)-6H-benzo[c]chromen-6-one; Palomid529; 6H-Dibenzo[b,d]pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]-; 8-(1-Hydroxyethyl)-2-methoxy-3-[(4-methoxybenzyl)oxy]-6H-benzo[c]chromen-6-one; RES-529; XV9409EWG4; Palomid 529,P529; cc-513; MLS006011187; Palomid 529 - P529; SCHEMBL290034; C22H26Cl2N2O8; CHEMBL2141712; EX-A254; QCR-215; SYN5215; BCPP000131; HMS3655L14; HMS3673G05; AMY22735; BCP02474; ABP000907; MFCD18633224; NSC775306; NSC801008; s2238; 8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo(c)chromen-6-one; AKOS024463339; ACN-030389; BCP9001049; CCG-268719; CS-0258; DB12812; NSC-775306; NSC-801008; Palomid 529 (P529) /P529; SB16564; SG00529; 8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-6h-dibenzo(b,d)pyran-6-one; NCGC00263125-01; NCGC00263125-10; AC-31523; AK160239; AS-16573; HY-14581; SMR004702956; AB0008147; SW219676-1; Y0291; W-5766; J-519339; Q27294013"	11998575	C24H22O6	Phase 1
M6APDG03933	AIC100	.	.	.	Phase 1
M6APDG02120	ETP-46321	"1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine"	46927938	C20H27N9O3S	Investigative
M6APDG04308	COR-D	.	.	.	Preclinical
M6APDG04009	E7766	.	.	.	Phase 1
M6APDG04316	227Th-labelled HER2-TTC	.	.	.	Preclinical
M6APDG04253	OT-101	.	.	.	Phase 2/3
M6APDG03885	NMS-03305293	NMS-P293	.	.	Phase 1
M6APDG03899	CC-94676	.	.	.	Phase 1
M6APDG01187	MI-219	"CHEMBL572933; (2'R,3S,4'R,5'R)-6-chloro-4'-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2'-neopentyl-2-oxospiro[indoline-3,3'-pyrrolidine]-5'-carboxamide; 908027-55-4; SCHEMBL2624351; BDBM50300121; US8680132, MI- 219; (2''R,3S,4''R,5''R)-6-chloro-4''-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2''-neopentyl-2-oxospiro[indoline-3,3''-pyrrolidine]-5''-carboxamide; (3S)-N-[(3S)-3,4-Dihydroxybutyl]-5-fluoro-6-chloro-2-oxo-2'alpha-(2,2-dimethylpropyl)-4'beta-(3-chlorophenyl)spiro[1H-indole-3(2H),3'-pyrrolidine]-5'alpha-carboxamide"	24877503	C27H32Cl2FN3O4	Investigative
M6APDG00571	DS-3201b	"Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551"	126481870	C26H34ClN3O4	Phase 2
M6APDG04066	ISB 1302	.	.	.	Phase 1/2
M6APDG03878	OPB-111077	.	.	.	Phase 1
M6APDG03811	AG-270	.	.	.	Phase 1
M6APDG01461	I3C	"Indole-3-carbinol; 700-06-1; 3-Indolemethanol; INDOLE-3-METHANOL; (1H-Indol-3-yl)methanol; 1H-indol-3-ylmethanol; 3-Hydroxymethylindole; 1H-Indole-3-methanol; 3-Indolylcarbinol; Indinol; 3-(Hydroxymethyl)indole; 3-Indole methanol; Indole 3 carbinol; (1H-Indol-3-yl)-methanol; MFCD00005632; UNII-C11E72455F; CHEBI:24814; C11E72455F; NSC-525801; NCGC00090701-06; indol-3-ylmethan-1-ol; I0496; Indole-3-carbinol, 97%; SMR000385784; CCRIS 3261; EINECS 211-836-2; 1H-Indol-3-Yl-Methanol; NSC 525801; BRN 0121323; AI3-60090; 3-Indolecarbinol; 3-Indolylmethanol; Prevention 4 (indole-3-carbinol); indole-3-carbinole; zlchem 356; PubChem7265; 3-hydroxymethyl indole; Spectrum2_001710; Spectrum3_001973; ACMC-209oc7; DSSTox_CID_11458; DSSTox_RID_78876; DSSTox_GSID_31458; BSPBio_003573; MLS001333161; MLS001333162; SCHEMBL195520; SPECTRUM1505320; SPBio_001700; CHEMBL155625; 1H-Indole-3-methanol (9CI); 3-Phenoxybenzylaminehydrochloride; DTXSID7031458; GTPL10047; KBio3_002949; ZLC0198; HMS1789O22; HMS2235E10; HMS3369B02; HMS3651I18; HMS3749E07; ZINC158743; ACN-S002804; ACT03591; BCP00087; HY-N0170; INDOLE-3-CARBINOL  (I3C); Tox21_400055; 9344AF; ANW-35813; CCG-38786; HSCI1_000097; NSC525801; s2313; SBB004095; AKOS001075120; AC-7583; CS-7780; DB12881; GS-0916; LS20980; MCULE-6344603304; SB14958; SDCCGMLS-0065970.P001; SDCCGMLS-0065970.P002; VI30396; Indole-3-methanol (Indole-3-carbinol); SMP2_000172; NCGC00090701-01; NCGC00090701-02; NCGC00090701-03; NCGC00090701-04; NCGC00090701-05; NCGC00090701-07; AK-53373; CAS-700-06-1; SY015976; AB0008317; DB-011567; A9256; FT-0615875; ST50308202; SW219849-1; I-2100; M-3233; A836732; SR-01000838318; Q1770257; SR-01000838318-3; BRD-K01815685-001-02-3; BRD-K01815685-001-07-2; Z85923165"	3712	C9H9NO	Phase 3
M6APDG04138	DKN-01	.	.	.	Phase 2
M6APDG03820	IO-202	.	.	.	Phase 1
M6APDG04201	MRG002	.	.	.	Phase 2
M6APDG00806	Z-Phe-Ala-diazomethylketone	"Z-Phe-Ala-Diazomethylketone; 71732-53-1; CHEMBL2179950; carbobenzoxycarbonyl-phenylalanyl-alaninyldiazomethane; ZPAD; Z-FA-DMK; SCHEMBL9364460; SCHEMBL17747846; SCHEMBL17747847; ZINC4899534; BDBM50400264; MFCD00077029; (Z,3S)-1-diazonio-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]but-1-en-2-olate; Q27278127; benzyl (S)-1-((S)-4-diazo-3-oxobutan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate; benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate"	155664	C21H22N4O4	Preclinical
M6APDG04056	SHR2554	.	.	.	Phase 1/2
M6APDG03875	PF-06939999	.	.	.	Phase 1
M6APDG04069	ASTX029	.	.	.	Phase 1/2
M6APDG04087	HPN328	.	.	.	Phase 1/2
M6APDG02972	"1,2,3,4,5,6-hexabromocyclohexane"	"1,2,3,4,5,6-Hexabromocyclohexane; 1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694"	74603	C6H6Br6	Investigative
M6APDG04288	KN046	.	.	.	Phase 3
M6APDG03808	TP-1454	.	.	.	Phase 1
M6APDG03823	DSP-0337	.	.	.	Phase 1
M6APDG04004	SL-172154	.	.	.	Phase 1
M6APDG04191	INCB86550	.	.	.	Phase 2
M6APDG02934	FN-1501	"1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide"	72195175	C22H25N9O	Phase 1
M6APDG03995	ABBV-151	.	.	.	Phase 1
M6APDG04085	AFM24	.	.	.	Phase 1/2
M6APDG03953	ION 224	IONIS-DGAT2-Rx	.	.	Phase 1
M6APDG02521	CYC140	"Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-"	57336523	C36H53N7O6	Phase 1
M6APDG03990	RG6084	.	.	.	Phase 1
M6APDG04023	KD033	.	.	.	Phase 1
M6APDG00732	MS012	"CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine"	137348638	C22H35N5O2	Preclinical
M6APDG00616	CCS1477	"CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one"	134457551	C30H32F2N4O3	Phase 1/2
M6APDG04002	CC-90002	.	.	.	Phase 1
M6APDG02382	UNC569	"unc569; 1350547-65-7; 1-[(Trans-4-Aminocyclohexyl)methyl]-N-Butyl-3-(4-Fluorophenyl)-1h-Pyrazolo[3,4-D]pyrimidin-6-Amine; CHEMBL2036808; 1-(((1r,4r)-4-aminocyclohexyl)methyl)-N-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine; SCHEMBL12185720; SCHEMBL14755115; SCHEMBL17173901; SCHEMBL17178092; UNC 569; UNC-569; BDBM336260; UNC-569;UNC 569; BCP27883; EX-A2464; BDBM50384576; ZINC101508966; ZINC254077925; NCGC00386692-01; AS-35154; US9744172, Compound UNC00000569A; Q27458844; 1-[(4-aminocyclohexyl)methyl]-N-butyl-3-(4-fluorophenyl)pyrazolo[3,4-d]pyrimidin-6-amine; 1-((4-aminocyclohexyl)methyl)-N-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine; CKJ; rel-1-(((1r,4r)-4-Aminocyclohexyl)methyl)-N-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine"	53355503	C22H29FN6	Investigative
M6APDG00502	PF-06821497	"UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD"	118572065	C22H24Cl2N2O5	Phase 1
M6APDG04089	Enapotamab vedotin	.	.	.	Phase 1/2
M6APDG03036	GSK3368715	"1629013-22-4; N~1~-({5-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl}methyl)-N~1~,N~2~-dimethylethane-1,2-diamine; EPZ019997; SCHEMBL16121956; EX-A4367; NSC823806; EPZ-019997; NSC-823806; GSK-3368715; HY-128717; CS-0099584; KZS; N1-((3-(4,4-Bis(ethoxymethyl)cyclohexyl)-1H-pyrazol-4-yl)methyl)-N1,N2-dimethylethane-1,2-diamine"	90462880	C20H38N4O2	Phase 1
M6APDG04185	OT551	.	.	.	Phase 2
M6APDG04012	PD-L1 t-haNK	.	.	.	Phase 1
M6APDG03912	ZW49	.	.	.	Phase 1
M6APDG04321	BAP-15	.	.	.	Preclinical
M6APDG04323	VCB102	.	.	.	Preclinical
M6APDG03994	SRK-181	.	.	.	Phase 1
M6APDG00572	JNJ-64619178	"2086772-26-9; UNII-N8VKI8FPW0; N8VKI8FPW0; JNJ64619178; CHEMBL4249337; (1S,2R,3S,5R)-3-(2-(2-Amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol; Onametostat; (1S,2R,3S,5R)-3-(2-(2-Amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo(2,3-d)pyrimidin-7-yl)cyclopentane-1,2-diol; entane-1,2-diol; Onametostat [INN]; SCHEMBL18572106; EX-A2791; BDBM50462572; NSC808507; NSC-808507; JNJ45031882; HY-101564; CS-0021720; S8624; A16861; (1~{S},2~{R},3~{S},5~{R})-3-[2-(2-azanyl-3-bromanyl-quinolin-7-yl)ethyl]-5-(4-azanylpyrrolo[2,3-d]pyrimidin-7-yl)cyclop; (1~{S},2~{R},3~{S},5~{R})-3-[2-(2-azanyl-3-bromanyl-quinolin-7-yl)ethyl]-5-(4-azanylpyrrolo[2,3-d]pyrimidin-7-yl)cyclop entane-1,2-diol; 1,2-Cyclopentanediol, 3-(2-(2-amino-3-bromo-7-quinolinyl)ethyl)-5-(4-amino-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-, (1S,2R,3S,5R)-; K8N"	126637809	C22H23BrN6O2	Phase 1
M6APDG03935	MK-4621	.	.	.	Phase 1
M6APDG00054	SIS-3	"SIS3 free base; Smad3 Inhibitor, SIS3; 1009104-85-1; Specific Inhibitor of Smad3; SIS3 (free base); (E)-1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 521985-36-4; Smad3 inhibitor SIS3; (E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; SCHEMBL6479525; SCHEMBL6479530; CHEMBL4303604; CHEBI:87589; 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; ZINC34299760; NCGC00387473-03; 6,7-Dimethyl-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-prop-2-enoyl))-1,2,3,4-tetrahydroisoquinoline; HY-100444; CS-0019029; J3.550.832E; J-000258; Q27159754; (2E)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 2-Propen-1-one, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-"	10138988	C28H27N3O3	Preclinical
M6APDG03822	TPST-1120	.	.	.	Phase 1
M6APDG04184	CXA10	.	.	.	Phase 2
M6APDG04084	ZN-e4	.	.	.	Phase 1/2
M6APDG02246	Fucoxanthin	"3351-86-8; UNII-06O0TC0VSM; all-trans-Fucoxanthin; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-beta,beta-carotene; (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-3'-yl acetate; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; CCRIS 4055; BRN 0073179; Fucoxanthol; cis-Fucoxanthin; yl acetate; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'-yl acetate; C42H58O6; Beta-sitosterol 45%; SCHEMBL37284; 5-18-04-00673 (Beilstein Handbook Reference); beta,beta-Carotene, 3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-, (3S,3'S,5R,5'R,6S,6'R)-; MLS000728353; Fucoxanthin, analytical standard; CHEMBL1575074; SJWWTRQNNRNTPU-ABBNZJFMSA-; Fucoxanthin carotenoid antioxidant; Fucoxanthin, carotenoid antioxidant; HMS2219K22; Fucoxanthin (from Wakame) (Brown Seaweed) (Undaria Pinnatifida); HY-N2302; ZINC8221218; 1772AH; LMPR01070300; MFCD01745140; AKOS037514648; CS-8167; NCGC00247434-01; AS-56344; SMR000453597; C08596; Q96385; 351F868; Fucoxanthin solution, 1 mg/L in ethanol, analytical standard; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaenylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S)-3'-Acetoxy-5alpha,6alpha-epoxy-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6,7,8-tetrahydro-beta,beta-carotene; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'-"	5281239	C42H58O6	Phase 2
M6APDG03907	NJH395	.	.	.	Phase 1
M6APDG03997	TJC4	TJ011133	.	.	Phase 1
M6APDG03981	Sym023	.	.	.	Phase 1
M6APDG03908	AIP-303	.	.	.	Phase 1
M6APDG04049	ASTX295	.	.	.	Phase 1/2
M6APDG04169	ZYH7	.	.	.	Phase 2
M6APDG02916	HC-1119	"Enzalutamide D3; UNII-3OKI556HC2; 3OKI556HC2; HC 1119; 1443331-82-5; CHEMBL4594421; SCHEMBL18789402; HY-70002S; CS-0019855; 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide; Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)-"	71580408	C21H16F4N4O2S	Phase 3
M6APDG02791	TVB-2640	"FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile"	66548316	C27H29N5O	Phase 2
M6APDG00533	Almonertinib	"HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide"	121280087	C30H35N7O2	Phase 3
M6APDG04057	A166	.	.	.	Phase 1/2
M6APDG04326	SD1002	.	.	.	Preclinical
M6APDG02055	WZB-117	"WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester"	46830365	C20H13FO6	Preclinical
M6APDG02964	UNC2025	"1429881-91-3; UNC-2025; mrx-6313; (1r,4r)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; CHEMBL3326006; 4-[2-(butylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol; UNC2025A; SCHEMBL14854194; SCHEMBL15978986; SCHEMBL21797957; BDBM350845; BCP16544; EX-A1030; BDBM50055496; MFCD28142874; s9662; AKOS025289796; ZINC210464182; ZINC249857461; CS-3354; SB16838; NCGC00390618-01; NCGC00482875-01; AK171371; AS-52179; DA-44845; HY-12344; US9795606, B4; B8016; FT-0743029; (1r,4r)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexan-1-ol; 2109176-09-0; 4-(2-(Butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexan-1-ol; 4beta-[2-(Butylamino)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-7-yl]cyclohexane-1alpha-ol; R6N"	73425588	C28H40N6O	Investigative
M6APDG04187	ADU- S100	.	.	.	Phase 2
M6APDG03982	LY3415244	.	.	.	Phase 1
M6APDG04298	131I-labelled aCD45	.	.	.	Phase 3
M6APDG03987	PRT543	.	.	.	Phase 1
M6APDG04098	BGB-A333	.	.	.	Phase 1/2
M6APDG04097	IMSA101	.	.	.	Phase 1/2
M6APDG03883	LP-108	.	.	.	Phase 1
M6APDG03931	JSI-1187	.	.	.	Phase 1
M6APDG03860	BP1002	.	.	.	Phase 1
M6APDG03826	GMI-1359	.	.	.	Phase 1
M6APDG03853	OS2966	.	.	.	Phase 1
M6APDG00586	NV-5138	"UNII-06CA9QMG6Z; 4-(difluoromethyl)-L-leucine; 2095886-80-7; SCHEMBL18762589; ZINC585143195; HY-114384; N[C@H](C(=O)O)CC(C(F)F)(C)C; CS-0084893; ((S)-2-Amino-5,5-difluoro-4,4-dimethylpentanoic acid; Pentanoic acid, 2-amino-5,5-difluoro-4,4-dimethyl-, (2S)-; K94"	129050791	C7H13F2NO2	Phase 1
M6APDG02953	2-aminophenoxazine-3-one	"Questiomycin A; 2-Amino-3H-phenoxazin-3-one; 2-Aminophenoxazin-3-one; 1916-59-2; 2-Aminophenoxazon; 2-Aminophenoxazone; 3-Aminophenoxazone; 2-Amino-3-phenoxazone; 3H-Phenoxazin-3-one, 2-amino-; Isophenoxazine; 2-amino-phenoxazin-3-one; NSC 94945; MLS000736964; CHEBI:17293; SMR000528446; BRN 0014215; Questinomycine A; 3H-Phenoxazin-3-one,2-amino-; AV toxin C; 2-Aminophenoxazinone; Phx-3 cpd; Phx-3; 2-amino-3-phenoxazinone; 2-azanylphenoxazin-3-one; Acrospermum viticola toxin C; NCIOpen2_006212; 4-27-00-05519 (Beilstein Handbook Reference); cid_72725; CHEMBL146710; SCHEMBL2609261; BDBM76155; DTXSID60172691; HMS2270F19; NSC94945; ZINC4095812; MFCD00207317; NSC-94945; 2-acetylamino-(3h)-phenoxazin-3-one; AKOS027339724; NCGC00246903-01; AS-47041; C02161; J-012388; BRD-K66640612-001-05-8; Q15424786"	72725	C12H8N2O2	Investigative
M6APDG04344	M102	.	.	.	Preclinical
M6APDG04005	SB 11285	.	.	.	Phase 1
M6APDG04096	AO-176	.	.	.	Phase 1/2
M6APDG04017	INBRX-105	.	.	.	Phase 1
M6APDG03039	ONO-7475	"1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO-7475; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide"	90645873	C32H26N4O6	Phase 1/2
M6APDG02962	HBX19818	"HBX 19818; 1426944-49-1; CHEMBL2398213; 9-Chloro-5,6,7,8-tetrahydro-N-[3-[methyl(phenylmethyl)amino]propyl]-2-acridinecarboxamide; N-(3-(benzyl(methyl)amino)propyl)-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; N-[3-[benzyl(methyl)amino]propyl]-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; SCHEMBL20007093; BDBM50436150; HBX-19818; NCGC00378705-01; HY-17540; J3.502.626F"	73349008	C25H28ClN3O	Preclinical
M6APDG04043	MTL-CEPBA	.	.	.	Phase 1/2
M6APDG03989	HPP971	ANT 401	.	.	Phase 1
M6APDG03890	TAK-252	SL-279252	.	.	Phase 1
M6APDG04265	Faricimab	RO6867461; RG7716	.	.	Phase 3
M6APDG02785	CA-074Me	"147859-80-1; Cathepsin B Inhibitor IV; CA-074 methyl ester; CA-074 Me; Methyl N-({(2s,3s)-3-[(Propylamino)carbonyl]oxiran-2-Yl}carbonyl)-L-Isoleucyl-L-Prolinate; CA-074-Me; MFCD03452890; methyl N-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]carbonyl}-L-isoleucyl-L-prolinate; CA 074 methyl ester; CA 074Me; CA074Me; CA inhibitor 6; (S)-methyl 1-((2S,3S)-3-methyl-2-((2S,3S)-3-(propylcarbamoyl)oxirane-2-carboxamido)pentanoyl)pyrrolidine-2-carboxylate; PrNH-tES-Ile-Pro-OMe; epoxysuccinyl derivative 6; KBioGR_000234; KBioSS_000234; CHEMBL262103; SCHEMBL1974424; BDBM16503; KBio2_000234; KBio2_002802; KBio2_005370; KBio3_000467; KBio3_000468; DTXSID50881386; Bio2_000234; Bio2_000714; HMS1361L16; HMS3886D15; EX-A1196; ZINC4899858; s7420; CCG-268623; CS-6086; DB07223; CA-074 methyl ester (CA-074 Me); IDI1_033984; NCGC00163431-01; AC-32670; methyl (2S)-1-[(2S,3S)-3-methyl-2-[[(2S,3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylate; methyl (2S)-1-[(2S,3S)-3-methyl-2-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]formamido}pentanoyl]pyrrolidine-2-carboxylate; QC-10413; HY-100350; 859C801; Q27096448; (L-3-trans-(Propylcarbamyl)oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester; CA074ME; N-(L-3-TRANS-PROPYLCARBAMOYLOXIRANE-2-CARBONYL)-L-ISOLEUCYL-L-PROLINE METHYL ESTER"	6610318	C19H31N3O6	Preclinical
M6APDG00797	BDTX-189	2414572-47-5; EX-A4379	154824631	C29H29ClN6O4	Phase 1/2
M6APDG03978	AMG 119	.	.	.	Phase 1
M6APDG03951	BPI-9016 M	.	.	.	Phase 1
M6APDG04092	FCN-437	.	.	.	Phase 1/2
M6APDG00796	RGLS4326	UNII-UCH3QQH1C0; UCH3QQH1C0; RGLS-4326; 2229964-07-0	154824286	C95H115F3N32O51P8S8	Phase 1
M6APDG04003	TG-1801	NI-1701	.	.	Phase 1
M6APDG04054	AMXI 5001	.	.	.	Phase 1/2
M6APDG04091	OT-58	.	.	.	Phase 1/2
M6APDG03077	SPHINX31	"1818389-84-2; N-(2-(4-(pyridin-2-ylmethyl)piperazin-1-yl)-5-(trifluoromethyl)phenyl)-5-(pyridin-4-yl)furan-2-carboxamide; 5-(4-pyridinyl)-N-[2-[4-(2-pyridinylmethyl)-1-piperazinyl]-5-(trifluoromethyl)phenyl]-2-furancarboxamide; SPHINX 31;SPHINX-31; SCHEMBL17196904; BDBM221074; AMY11306; BCP30381; EX-A2804; s8810; BS-16147; HY-117661; CS-0066777; US9695160, 12; RXZ"	91972002	C27H24F3N5O2	Preclinical
M6APDG04015	ALPN-202	.	.	.	Phase 1
M6APDG04088	BGB-A425	.	.	.	Phase 1/2
M6APDG00734	TPX-0022	CSF1R-IN-2; SCHEMBL20694441; TPX0022; NSC820832; NSC-820832; HY-111787; CS-0091874; 2271119-26-5	137455315	C20H20FN7O2	Phase 1
M6APDG00781	Disufenton	"168021-77-0; UNII-797K01YF1M; 797K01YF1M; N-tert-butyl-1-(2,4-disulfophenyl)methanimine oxide; SCHEMBL727315; CHEMBL2111090; 2,4-disulfophenyl-N-t-butylnitrone; alpha-(2,4-disulfophenyl)-N-tert-butylnitrone; Q27266726"	151179	C11H15NO7S2	Phase 2
M6APDG03979	AMG 757	.	.	.	Phase 1
M6APDG01282	Dichloroacetate	"2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050"	25975	C2HCl2O2-	Phase 4
M6APDG02915	RXDX-106	"CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide"	71576419	C31H26F2N4O6	Phase 1
M6APDG01338	C-178	"329198-87-0; STING inhibitor C-178; N-(dibenzo[b,d]furan-3-yl)-5-nitrofuran-2-carboxamide; N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide; Oprea1_355995; Oprea1_671722; 5-Nitro-furan-2-carboxylic acid dibenzofuran-3-ylamide; SCHEMBL21065360; BCP31292; ZINC4838645; s6667; AKOS000544527; MCULE-6315822200; BS-17017; C 178;C178;STING inhibitor C-178; HY-123963; CS-0087693; ST51004028; N-benzo[3,4-b]benzo[d]furan-3-yl(5-nitro(2-furyl))carboxamide"	2866412	C17H10N2O5	Investigative
M6APDG03896	BMS-986299	.	.	.	Phase 1
M6APDG03882	BGB-11417	.	.	.	Phase 1
M6APDG04050	Zenocutuzomab	MCLA-128; PB4188	.	.	Phase 1/2
M6APDG02057	ATI-502	"ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one"	46851625	C20H18FN5O3	Phase 2
M6APDG04029	SI-B001	.	.	.	Phase 1
M6APDG04030	BAY 2701439	HER2-TTC	.	.	Phase 1
M6APDG04209	ATI-501	.	.	.	Phase 2
M6APDG03932	HH2853	.	.	.	Phase 1
M6APDG03876	LY3410738	.	.	.	Phase 1
M6APDG03970	CLN-081	.	.	.	Phase 1
M6APDG00743	MS1943	"2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide"	139211327	C42H54N8O3	Investigative
M6APDG04161	BHQ880	"BHQ-880A; Anti-DKK1 monoclonal antibody (multiple myeloma), Novartis"	.	.	Phase 2
M6APDG02971	M012	"Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; alpha,alpha-Dichlorotoluene; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886]  [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard"	7411	C7H6Cl2	Phase 1
M6APDG04001	IBI188	.	.	.	Phase 1
M6APDG03868	PF-07104091	.	.	.	Phase 1
M6APDG01358	Lithium	"7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415]  [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414]  [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805]  [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis"	3028194	Li	Phase 2
M6APDG04243	Bintrafusp alfa	.	.	.	Phase 2
M6APDG03999	TTI-622	.	.	.	Phase 1
M6APDG03377	Brolucizumab	.	.	.	Approved
M6APDG03815	ABBV-CX-2029	.	.	.	Phase 1
M6APDG04324	YW327.6S2	.	.	.	Preclinical
M6APDG04040	APG-1252	.	.	.	Phase 1/2
M6APDG01895	9-ING-41	"1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione"	44582816	C22H13FN2O5	Phase 2
M6APDG04328	DP-3975	.	.	.	Preclinical
M6APDG03960	FPI-1434	.	.	.	Phase 1
M6APDG04008	MK-2118	.	.	.	Phase 1
M6APDG04341	Cu-anti-hAXL	.	.	.	Preclinical
M6APDG04039	GLR2007	.	.	.	Phase 1/2
M6APDG04330	VCB101	.	.	.	Preclinical
M6APDG04218	Telisotuzumab vedotin	ABBV-399	.	.	Phase 2
M6APDG04061	ARV-110	.	.	.	Phase 1/2
M6APDG01864	WP1220	"mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide"	44554865	C19H16BrN3O	Phase 1
M6APDG04304	CS1001	.	.	.	Phase 3
M6APDG03993	LY2624587	.	.	.	Phase 1
M6APDG04014	GEN1046	.	.	.	Phase 1
M6APDG03914	M802	.	.	.	Phase 1
M6APDG04013	CA-170	.	.	.	Phase 1
M6APDG00733	APG-2575	"Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-"	137355972	C45H48ClN7O8S	Phase 1/2
M6APDG03841	MCLA-145	.	.	.	Phase 1
M6APDG04345	MAb173	.	.	.	Preclinical
M6APDG03891	BMS-986301	.	.	.	Phase 1
M6APDG02121	P22077	"1247819-59-5; P 22077; 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159498; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]-ethanone; 1-(5-(2,4-difluorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-22077; 1-(5-((2,4-Difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; 1-{5-[(2,4-Difluorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one; C12H7F2NO3S2; SCHEMBL2680945; DTXSID40677376; HMS3653G09; BCP07858; EX-A1445; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethan-1-one; 2624AH; BDBM50393440; MFCD22580421; s7133; ZINC91696068; AKOS024458186; CCG-267643; CS-1860; QC-8199; AC-32695; AK313221; AS-55923; DA-46729; HY-13865; AB0003913; FT-0707469; SW219709-1; EC-000.2542; J3.502.624J; Z1646327284; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]ethanon; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl) ethanone"	46931953	C12H7F2NO3S2	Preclinical
M6APDG04108	SPL-108	.	.	.	Phase 2
M6APDG02208	Torin2	"Torin 2; 1223001-51-1; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE"	51358113	C24H15F3N4O	Investigative
M6APDG04343	CAT4001	.	.	.	Preclinical
M6APDG03807	OTSA-101-DTPA-90Y	.	.	.	Phase 1
M6APDG04058	DSP-107	.	.	.	Phase 1/2
M6APDG00744	XL092	SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2	139350422	C29H25FN4O5	Phase 1
M6APDG03988	PRT811	.	.	.	Phase 1
M6APDG04198	SXC-2023	.	.	.	Phase 2
M6APDG04068	HH2710	.	.	.	Phase 1/2
M6APDG03742	ABTAA	.	.	.	Investigative
M6APDG03849	IN10018	.	.	.	Phase 1
M6APDG03913	DZD1516	.	.	.	Phase 1
M6APDG02014	NPS-1034	"1221713-92-3; CHEMBL3810063; 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide.; SCHEMBL1963111; BCP15998; NPS1034;NPS 1034; BDBM50172077; s7669; ZINC68204845; CCG-270007; NCGC00481564-01; AC-31427; AK685795; BS-14709; HY-100509; CS-0019643; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide; S4K"	46194178	C31H23F2N5O3	Preclinical
M6APDG03793	NG-641	.	.	.	Phase 1
M6APDG03879	Cosibelimab	CK-301/TG-1501	.	.	Phase 1
M6APDG00210	Deguelin	"522-17-8; (-)-Deguelin; (-)-cis-deguelin; DEGUELIN(-); UNII-K5Z93K66IE; CHEBI:4357; K5Z93K66IE; MFCD01740600; C23H22O6; (7as,13as)-13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-3h-bis[1]benzopyrano[3,4-b:6',5'-e]pyran-7(7ah)-one; (7aS,13aS)-9,10-Dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-pyrano[2,3-c:6,5-f']dichromen-7(7aH)-one; (7aS,13aS)-9,10-dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-pyrano[2,3-c:6,5-f']dichromen-7(7aH)-one.; SR-01000597503; CCRIS 8104; Deguelin/; (-)-Deguelin, Mundulea sericea; Spectrum_001044; Tocris-1770; Spectrum2_000298; Spectrum3_001122; Spectrum4_001965; Spectrum5_001852; SCHEMBL73183; BSPBio_002583; KBioGR_002434; KBioSS_001524; SPECTRUM201138; MLS006010295; SPBio_000236; CHEMBL393417; KBio2_001524; KBio2_004092; KBio2_006660; KBio3_002083; DTXSID10200231; HMS1923A05; HMS3268E12; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS-cis)-; EX-A4158; ZINC3978987; 1702AH; ABP000411; BDBM50505204; CCG-39856; LMPK12060019; s8132; AKOS024456769; ACN-053693; BCP9000596; CS-1802; SDCCGMLS-0066380.P001; NCGC00025288-01; NCGC00025288-02; NCGC00025288-03; (-)-Deguelin, >98% (HPLC), powder; AS-56004; HY-13425; SMR004701363; C10417; Q5251862; SR-01000597503-1; SR-01000597503-3; SR-01000597503-4; BRD-K61401890-001-02-0; BRD-K61401890-001-03-8; BRD-K61401890-001-04-6; (1S,14S)-17,18-dimethoxy-7,7-dimethyl-2,8,21-trioxapentacyclo[12.8.0.03,12.04,9.015,20]docosa-3(12),4(9),5,10,15,17,19-heptaen-13-one; (7aS,13aS)-9,10-Dimethoxy-3,3-dimethyl-13,13a-dihydro-3H,7aH-pyrano[2,3-c;6,5-f']dichromen-7-one; 13,13aS-Dihydro-9,10-dimethoxy-3,3-dimethyl-3H-[1]benzopyrano[3,4-b]pyrano[2,3-h][1]benzopyran-7(7aS)-one; 3H-[1]Benzopyrano[3,4-b]pyrano[2,3-h][1]benzopyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS,13aS)-; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS,13aS)-"	107935	C23H22O6	Investigative
M6APDG03026	MRX-2843	"1429882-07-4; UNC-2371A; UNII-2MT30EHI63; 2MT30EHI63; CHEMBL3326007; (1r,4r)-4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; UNC2371A; SCHEMBL14854108; SCHEMBL17175579; BDBM350861; BCP30180; BDBM50055490; MFCD28502224; ZINC299829706; CS-8117; SB17283; AS-35252; HY-101549; US9795606, B20; A16958; UNC2371;UNC-2371;UNC 2371;MRX 2843 ;MRX2843; Cyclohexanol, 4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methyl-1-piperazinyl)methyl)phenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-, trans-; trans-(1R,4R)-4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; trans-4-(2-((2-Cyclopropylethyl)amino)-5-(4-((4-methyl-1-piperazinyl)methyl)phenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)cyclohexanol"	89495685	C29H40N6O	Phase 1
M6APDG02565	FADROZOLE	"102676-47-1; CGS-16949A; Fadrozole [INN]; Fadrozolum [INN-Latin]; Fadrozol [INN-Spanish]; CHEMBL9298; Fadrozole (INN); 5-p-cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine; Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo(1,5-a)pyridin-5-yl)-; Fadrozolum; Fadrozol; 4-{5H,6H,7H,8H-imidazo[1,5-a]pyridin-5-yl}benzonitrile; Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)-"	59693	C14H13N3	Approved
M6APDG01150	SGX523	"SGX-523; SGX523, SGX-523"	24779724	C18H13N7S	Phase 1
M6APDG02679	Cochliobolic acid	"Cochliobolic acid; CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid"	6450172	C25H30O6	Investigative
M6APDG04038	T3D-959	.	.	.	Phase 1/2
M6APDG03887	JSM 6427	.	.	.	Phase 1
M6APDG01038	"6,7-Dimethoxy-4-(3-nitro-phenoxy)-quinoline"	"CHEMBL99272; 6,7-Dimethoxy-4-(3-nitro-phenoxy)-quinoline; SCHEMBL7482913; OMYGYNKHKZLDSH-UHFFFAOYSA-N; BDBM50290844"	22132767	C17H14N2O5	Investigative
M6APDG00293	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219339; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)	11331592	C36H47N11O6	Investigative
M6APDG00896	1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine	1-[4-(2-Oxo-2-Phenylethyl)phenyl]guanidine; SCHEMBL20553177; DB07122	16758228	C15H15N3O	Investigative
M6APDG01745	Gly-b7Pro-Glu	Gly-b7Pro-Glu	44408837	C14H21N3O6	Investigative
M6APDG00933	R-ketoprofen	"(R)-Ketoprofen; 56105-81-8; (R)-Ketoprophen; UNII-S03709D0TH; (R)-(-)-Ketoprofen; (R)-2-(3-benzoylphenyl)propanoic acid; CHEMBL372052; S03709D0TH; (R)-2-(3-Benzoylphenyl)propionic acid; Benzeneacetic acid,3-benzoyl-a-methyl-, (aR)-; Ketoprofen, (R)-; NCGC00016757-01; CAS-22071-15-4; (2R)-2-(3-benzoylphenyl)propanoic acid; Lopac-K-1751; SCHEMBL195303; ZINC2272; AC1L47D6; CTK5A4646; DTXSID50204652; DKYWVDODHFEZIM-LLVKDONJSA-N; BDBM50169048; AKOS022182275"	180540	C16H14O3	Discontinued in Phase 2
M6APDG02045	BZ5	.	46241905	C16H16O6S	Investigative
M6APDG01896	3 beta-O-acetyloleanolic acid	3 beta-O-acetyloleanolic acid; CHEMBL503071	44583799	C32H50O4	Investigative
M6APDG00341	Tivantinib	"Tivantinib; 905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; Tivantinib; ARQ197; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102"	11494412	C23H19N3O2	Phase 3
M6APDG02321	Pellitorin	"Pellitorine; Pellitorin; 18836-52-7; trans-Pellitorin; (E,E)-N-(2-Methylpropyl)-2,4-decadienamide; (E,E)-N-Isobutyl-2,4-decadienamide; N-Isobutyldeca-trans-2,trans-4-dienamide; UNII-8IS5231171; 2,4-DECADIENAMIDE, N-ISOBUTYL-, (E,E)-; 2,4-Decadienamide, N-(2-methylpropyl)-, (E,E)-; BRN 1725967; AI3-19560; CHEBI:69686; MAGQQZHFHJDIRE-BNFZFUHLSA-N; Pellitorine (6CI); 2,4-Decadienamide, N-(2-methylpropyl)-, (2E,4E)-; 8IS5231171; (2E,4E)-N-(2-methylpropyl)deca-2,4-dienamide; N-(2-Methylpropyl)-2,4-Decadienamide; Optaflow A"	5318516	C14H25NO	Investigative
M6APDG03327	AG1478	"AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; Tyrphostin AG-1478; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255"	2051	C16H14ClN3O2	Preclinical
M6APDG03106	Thymidine-5'-Phosphate	Thymidine 5'-monophosphate; dTMP(-); thymidine 5'-phosphate(1-); CHEBI:46960; thymidine 5'-(hydrogen phosphate)	9700	C10H15N2O8P	Investigative
M6APDG00340	FR-180204	"865362-74-9; FR 180204; FR180204; FR-180204; ERK Inhibitor II, FR180204; 5-(2-Phenyl-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-ylamine; CHEMBL259551; 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE; C18H13N7; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-1H-pyrazolo[3,4-c]pyridazin-3-amine; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-2H-pyrazolo[3,4-c]pyridazin-3-amine; 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2H-pyrazolo[3,4-c]pyridazin-3-amine; ERK inhibitor II; MLS002607685"	11493598	C18H13N7	Investigative
M6APDG03138	"N,N'-Bis-(4-hexyl-phenyl)-guanidine"	"CHEMBL326741; SCHEMBL4985473; N,N'-Bis(4-hexylphenyl)guanidine; BDBM50066419"	9821194	C25H37N3	Investigative
M6APDG01711	Ac-YCit[CEHdFRWC]-NH2	CHEMBL412494; Ac-YCit[CEHdFRWC]-NH2	44400399	C60H78N18O14S2	Investigative
M6APDG01798	Folate gamma-L-proline-hydroxamic acid	CHEMBL388878	44428663	C24H27N9O7	Investigative
M6APDG02632	Radicicol	AC1L1JGN; CHEMBL3972342; CTK6B6269	6323491	C18H17ClO6	Investigative
M6APDG00871	FK-3311	"116686-15-8; FK 3311; FK-3311; FK3311; COX-2 Inhibitor V, FK3311; N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide; N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide; 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide; Methanesulfonamide, N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]-; C15H13F2NO4S; Methanesulfonamide, N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)-; DIIYLGZNZGPXRR-UHFFFAOYSA-N; AC1L4U0O; AC1Q6W4K; SCHEMBL441676; ZINC3880; DIIYLGZNZGPXRR-UHFFFAOYSA-; CTK8E9207; EX-A545; DTXSID90151474"	164009	C15H13F2NO4S	Phase 2
M6APDG03411	TG-1042	"TG-1041; Adv-IFN-gamma; Adenovirus-interferon gamma based therapy (basal cell carcinoma), Virax; Adenovirus-interferon gamma based therapy (cancer), Transgene; Ad-IFN-gamma (basal cell carcinoma), Virax; Ad-IFN-gamma (lymphoma), Transgene"	.	.	Discontinued in Phase 2
M6APDG01922	RP101	"SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,"	446727	C11H13BrN2O5	Phase 2/3
M6APDG01600	2-phenylquinoline-8-carboxamide	2-phenylquinoline-8-carboxamide; CHEMBL480429; SCHEMBL6442515; ZINC3939668	44156952	C16H12N2O	Investigative
M6APDG01233	2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole	"2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole; SCHEMBL1407219; CHEMBL464189; BDBM26064; LGRUCHCYEMOENE-UHFFFAOYSA-N; 2-benzyl-3-aryl-7-trifluoromethylindazole, 5"	25137977	C21H15F3N2	Investigative
M6APDG01177	17-dehydroxyriccardin C	"17-dehydroxyriccardin C; Riccardin C derivative, 20b; CHEMBL409652; BDBM23849; 2',4-[Ethylene-1,4-phenylene-oxy-(6-hydroxy-1,3-phenylene)-ethylene]-1,1'-biphenyl-2-ol"	24860511	C28H24O3	Investigative
M6APDG03992	BMS-936564	.	.	.	Phase 1
M6APDG00931	6-Allyloxy-9H-purin-2-ylamine	"CHEMBL325053; 50663-54-2; O6-Allylguanine; O6-Substituted Guanine Deriv. 15; 6-prop-2-enoxy-7H-purin-2-amine; NU 2028; AC1L45IB; SCHEMBL1263549; BDBM5475; 6-(prop-2-en-1-yloxy)-9H-purin-2-amine; 9H-Purin-2-amine, 6-(2-propen-1-yloxy)-"	179571	C8H9N5O	Investigative
M6APDG01683	N-Hydroxy-4-(pentanoylamino-methyl)-benzamide	CHEMBL143102	44361923	C13H18N2O3	Investigative
M6APDG03235	LY-465608	LY465608; LY 465608	9890319	C28H27NO5	Investigative
M6APDG02365	PD-0173958	"PD173958; AC1NS9BT; PD-0173958; SCHEMBL1335649; CHEMBL578006; BDBM6570; 6-(2,6-dichlorophenyl)-2-(4-ethoxyanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 2-[(4-Ethoxyphenyl)amino]-8-methyl-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidine-7(8H)-one"	5330525	C22H18Cl2N4O2	Investigative
M6APDG02233	GOSSYPETIN	"Gossypetin; Articulatidin; Equisporol; 489-35-0; 3,5,7,8,3',4'-Hexahydroxyflavone; UNII-SET4M23ZTM; 3,3',4',5,7,8-Hexahydroxyflavone; SET4M23ZTM; 2-(3,4-Dihydroxyphenyl)-3,5,7,8-tetrahydroxy-4H-chromen-4-one; CHEMBL253570; 2-(3,4-Dihydroxyphenyl)-3,5,7,8-tetrahydroxychromen-4-one; CHEBI:16400; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7,8-tetrahydroxy-; 2-(3,4-dihydroxyphenyl)-3,5,7,8-tetrahydroxy-chromen-4-one; PubChem9855; AC1NQXCW; BSPBio_002552; SPECTRUM1505143; SCHEMBL157033; BDBM26655; DTXSID50197631"	5280647	C15H10O8	Investigative
M6APDG01317	CL82198	CL-82198; CL 82198	2777	C17H22N2O3	Investigative
M6APDG00527	CLEMATOMANDSHURICA SAPONIN B	CHEMBL525269; BDBM50241848; 6)-[(2-O-isoferuloyl)-beta-D-glucopyranosyl]-(1-&gt; 3)-alpha-L-rhamnopyranosyl-(1-&gt; 2)-alpha-L-arabinopyranosyloleanolic acid-28-O-alpha-L-rhamnopyranosyl-(1-&gt	11994182	C92H142O46	Investigative
M6APDG03749	ISIS 101960	.	.	.	Investigative
M6APDG01165	Cyclo-[-Arg-Gly-Asp-Amp23-]	CHEMBL410050	24822282	C20H32N8O7	Investigative
M6APDG04271	Andecaliximab	.	.	.	Phase 3
M6APDG03396	DS-6930	.	.	.	Discontinued in Phase 1
M6APDG00882	Famitinib	"Receptor tyrosine kinase inhibitors (cancer); SHR-1020; Receptor tyrosine kinase inhibitors (cancer), Shanghai Hengrui; Tyrosine-kinase inhibitor (oral, cancer), Jiangsu Hengrui; C-Kit/VEGFR2/PDGFR/VEGFR3/Flt1/Flt3 inhibitor (oral, cancer), Jiangsu Hengrui"	16662431	C23H27FN4O2	Phase 2
M6APDG02669	"(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid"	"13(S)-Hydroxyoctadeca-9Z,11E-dienoic acid; 29623-28-7; 13(S)-HODE; (13S)-Hydroxyoctadecadienoic acid; 13S-HODE; 13-Hydroxyoctadecadienoic acid; CHEMBL451721; CHEBI:34154; 13S-Hydroxy-9Z,11E-octadecadienoic acid; 13(S)-Hydroxy-9(Z),11(E)-octadecadienoic acid; (9Z, 11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; (9Z,11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; 9,11-Octadecadienoic acid, 13-hydroxy-, (R-(E,Z))-; 5204-88-6; 10219-69-9; (S)-Coriolic acid; AC1O5YAH"	6443013	C18H32O3	Investigative
M6APDG03561	ISIS 116505	.	.	.	Investigative
M6APDG04357	NMI-150	"NO-COX-2 inhibitor, NitroMed/Merck & Co; Nitric oxide-enhancing COX-2 inhibitor, NitroMed/Merck & Co"	.	.	Terminated
M6APDG00816	Tilmacoxib	"Tilmacoxib; JTE-522; 180200-68-4; RWJ-57504; JTP-19605; UNII-G6VI5P84SX; 4-(4-Cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide; Benzenesulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro-; G6VI5P84SX; CHEMBL34913; JTE522; 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo(4,5)imidazo(1,2a)pyridine-4-N-(2-fluorophenyl)carboxamide; CHEBI:73041; 4-(4-cyclohexyl-2-methyl-1,3-oxazol-5-yl)-2-fluorobenzenesulfonamide; 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide"	159271	C16H19FN2O3S	Discontinued in Phase 2
M6APDG00298	7-Mercapto-heptanoic acid benzothiazol-2-ylamide	CHEMBL178779	11346934	C14H18N2OS2	Investigative
M6APDG02190	IMD-0354	"IMD-2560; IMD-2560); I-kappaB kinase beta inhibitor (dermatological, atopic dermatitis/acne), Institute of Medicinal MolecularDesign; I-kappaB kinase beta inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD; IKK-beta inhibitor (dermatological, atopic dermatitis/acne), IMMD; IL-6 release inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD"	5081913	C15H8ClF6NO2	Phase 1
M6APDG03624	HuMax-cMet	"CMet-targeting human IgG1 antibody (cancer), Genmab"	.	.	Investigative
M6APDG01137	CUDC-101	CUDC-101; 1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149	24756910	C24H26N4O4	Phase 1
M6APDG01616	(E)-6-Nitrooctadec-5-enoic Acid	CHEMBL569372; (E)-6-Nitrooctadec-5-enoic Acid	44220889	C18H33NO4	Investigative
M6APDG03645	ZY H2	ZYH2	.	.	Investigative
M6APDG03763	ISIS 31996	.	.	.	Investigative
M6APDG03162	Ro 28-2653	"Ro 28-2653; Ro-28-2653; 261956-22-3; CHEMBL456911; SCHEMBL726759; SCHEMBL8471189; EX-A2614; BDBM50363130; ZINC33975062; Ro28-2653; KB-275261; 5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione"	9832179	C26H23N5O5	Investigative
M6APDG00117	7-Chloro-3-pyridin-4-yl-quinoline	CHEMBL86664; 7-chloro-3-pyridin-4-yl-quinoline; 7-Chloro-3-(4-pyridyl)quinoline	10354294	C14H9ClN2	Investigative
M6APDG02006	"4-(2,2-Diphenyl-vinyl)-pyridine"	"4-(2,2-diphenylethenyl)pyridine; 4-Pyridylmethylene 35; AC1NEND1; CHEMBL381194; BDBM8645; SCHEMBL16946606"	4594970	C19H15N	Investigative
M6APDG03574	ISIS 122990	.	.	.	Investigative
M6APDG03397	MP-136	.	.	.	Discontinued in Phase 1
M6APDG01107	Delta1-dihydrotestosterone	"1-testosterone; Delta1-dihydrotestosterone; 1-Testo; 65-06-5; 17beta-Hydroxy-5alpha-androst-1-en-3-one; UNII-Y984BV1Q0G; Y984BV1Q0G; 5alpha-androst-1-en-17beta-ol-3-one; 1-T [Steroid]; 5.alpha.-Androst-1-en-3-one, 17.beta.-hydroxy-; AC1L5X4C; Delta(1)-dihydrotestosterone; SCHEMBL867595; CHEBI:59714; DTXSID80215312; OKJCFMUGMSVJBG-ABEVXSGRSA-N; NSC39366; ZINC4791927; NSC121140; NSC-39366; LMST02020110; NSC-121140; DB01481; LS-193302; (5alpha,17beta)-hydroxyandrost-1-en-3-one; C15377; 171T609; 1-T"	236666	C19H28O2	Investigative
M6APDG03608	ISIS 6435	.	.	.	Investigative
M6APDG02015	GSK2033	GSK 2033; GSK-2033	46203250	C29H28F3NO5S2	Investigative
M6APDG01258	2-ethylquinoline-8-carboxamide	"CHEMBL526128; 2-ethylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 2-ethyl-; BDBM50255330"	25208752	C12H12N2O	Investigative
M6APDG00463	"N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane"	N-butyl-S-methyl-isothiourea; NTU; 100319-25-3; AC1L9JBU; SCHEMBL11844558; methyl N'-butylcarbamimidothioate	11740154	C18H38N4S2	Investigative
M6APDG03049	Bis(benzo[b]furan-2-yl)methanone	CHEMBL226417; bis(benzo[b]furan-2-yl)methanone; bis-benzofuranyl ketone; AC1PLNEG; SCHEMBL244107; bis(1-benzofuran-2-yl)methanone; MolPort-000-640-603; ZINC8048290; BDBM50202218; AKOS002385499; MCULE-1633046929; 2-(1-benzofuran-2-carbonyl)-1-benzofuran; Z232333564	9179241	C17H10O3	Investigative
M6APDG01440	5-(2-methylpiperazin-1-ylsulfonyl)isoquinoline	"1-(5-Isoquinolinylsulfonyl)-2-methylpiperazine; 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; 84477-87-2; H-7; 5-(2-methylpiperazine-1-sulfonyl)isoquinoline; H 7; H7; Piperazine, 1-(5-isoquinolinylsulfonyl)-2-methyl-; BRN 5482740; MLS000069615; CHEMBL323556; CHEBI:43385; Isoquinoline,5-[(2-methyl-1-piperazinyl)sulfonyl]-,hydrochloride (1:2); 5-[(2-methylpiperazin-1-yl)sulfonyl]isoquinoline; SMR000058749; Isoquinoline-5-sulfonic 2-methyl-1-piperazide; 5-(2-methylpiperazin-1-yl)sulfonylisoquinoline; Piperazine, 1-(5-isoquino"	3542	C14H17N3O2S	Investigative
M6APDG01659	"7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one"	CHEMBL326529; SCHEMBL7365237; BDBM50217957	44342825	C19H19F3O2	Investigative
M6APDG02896	Nicaraven	AVS; Antevan; Antevas	71234	C15H16N4O2	Phase 3
M6APDG03332	AZD-2014	"AZD2014; 1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)"	25262792	C25H30N6O3	Phase 2
M6APDG03758	ISIS 101997	.	.	.	Investigative
M6APDG00587	Ploglitazone	PLOGLITAZONE	12944192	C20H21NO3S	Investigative
M6APDG04242	CX-072	.	.	.	Phase 2
M6APDG01515	4-((4-methoxyphenyl)diazenyl)benzenesulfonamide	"CHEMBL213267; 4-((4-methoxyphenyl)diazenyl)benzenesulfonamide; 4-[(4-methoxyphenyl)diazenyl]benzenesulfonamide; NSC722840; AC1L8P6K; CTK7A1570; MolPort-002-934-354; ZINC6484196; STK037234; BDBM50190339; AKOS005382697; NSC-722840; MCULE-3486440340; 4-(4-Methoxy-phenylazo)-benzenesulfonamide; 4-[(E)-(4-methoxyphenyl)diazenyl]benzenesulfonamide; benzenesulfonamide, 4-[(e)-2-(4-methoxyphenyl)diazenyl]-"	405489	C13H13N3O3S	Investigative
M6APDG00045	MCL-129	MCL-129; CHEMBL362985; SCHEMBL5318500; SLGLZEJKMBCODK-UHFFFAOYSA-N; BDBM50166529; PDSP2_001273; PDSP1_001289; 1-(2-(4-fluorophenyl)-2-(4-isopropylpiperazin-1-yl)ethyl)-4-(4-(2-methoxynaphthalen-1-yl)butyl)piperazine; 1-[2-(4-fluorophenyl)-2-(4-isopropylhexahydro-1-pyrazinyl)ethyl]-4-[4-(2-methoxy-1-naphthyl)butyl]hexahydropyrazine; (+/-)-1-[2-(4-fluorophenyl)-2-(4-isopropylpiperazin-1-yl)ethyl]-4-[4-(2-methoxy-1-naphthyl)butyl]piperazine	10098971	C34H47FN4O	Investigative
M6APDG04045	IPP-204106	"NucAnt 6L; N-6-L; Nucleolin antagonist (cancer), ImmuPharma; Nucleolin antagonist (cancer), ImmuPharma/CNRS; Nucleolin antagonist (cancer), ImmuPharma/Centre National de la Recherche Scientifique"	.	.	Phase 1/2
M6APDG00564	"3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione"	"CHEMBL151212; 91567-07-6; 3-(4-aminophenyl)-3-ethylpyrrolidine-2,5-dione; 3-Apepd; AC1Q6LV5; AC1L3YU4; 3-(4-aminophenyl)-3-ethyl-2,5-Pyrrolidinedione; 3-(4'-Aminophenyl)-3-ethylpyrollidine-2,5-dione; 3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione; SCHEMBL9634038; BDBM50025152; DA-01219; FT-0716174; 3-Ethyl-3-(4-aminophenyl)pyrrolidine-2,5-dione; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-3-ethyl-"	124662	C12H14N2O2	Investigative
M6APDG00683	PNU156804	"Hexylglutathione; 24425-56-7; UNII-M73SNN908F; S-Hexyl-L-glutathione; L-gamma-glutamyl-S-hexyl-L-cysteinylglycine; NSC 131114; CHEMBL345292; M73SNN908F; CHEBI:27704; Glycine, N-(N-L-gamma-glutamyl-S-hexyl-L-cysteinyl)-; C16H29N3O6S; 1ydk; AC1L3YPR; GTX; S-Hexyl-L-glutathione reduced; SCHEMBL1158164; CTK4F3647; HXJDWCWJDCOHDG-RYUDHWBXSA-N; 2c80; ZINC3874923; BDBM50095998; AKOS015893910; DB04132; LS-174055; Glycine, L-g-glutamyl-S-hexyl-L-cysteinyl-; FT-0770776; C02886; Glycine, L-.gamma.-glutamyl"	135484060	C31H40ClN3O	Terminated
M6APDG00011	LY2090314	"603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt"	10029385	C28H25FN6O3	Phase 2
M6APDG03166	"2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene"	"CHEMBL42428; 2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene; SCHEMBL7042974; SCHEMBL7042968; ZINC13471769; BDBM50108048; AKOS015967551; (E)-2-(3,5-dimethoxystyryl)thiophene; 2-[(E)-3,5-Dimethoxystyryl]thiophene"	9834747	C14H14O2S	Investigative
M6APDG01665	Ro-43-5054	Ro-43-5054; CHEMBL117775; SCHEMBL7306316; BDBM50092124; 2-{2-[3-(4-Carbamimidoyl-benzoylamino)-propionylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid (Ro 43-5054)	44343754	C20H27N5O7	Terminated
M6APDG03263	L-006235-1	"294623-49-7; L 006235; CHEMBL426819; N-(1-((cyanomethyl)carbamoyl)cyclohexyl)-4-(2-(4-methylpiperazin-1-yl)thiazol-4-yl)benzamide; L006235; N-[1-[[(Cyanomethyl)amino]carbonyl]cyclohexyl]-4-[2-(4-methyl-1-piperazinyl)-4-thiazolyl]benzamide; L-006235-1; SCHEMBL6183485; CTK8E9371; BDBM19854; DTXSID90432735; MolPort-023-276-653; BCP28510; ZINC3993799; AKOS024457410; basic piperazine-containing compound, 1; NCGC00371088-01; RT-013466; CRA-013783/L-006235; J-017526; L-006235; L-006,235"	9912381	C24H30N6O2S	Preclinical
M6APDG02362	PD-0183812	"PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813"	5330258	C28H35N5O2	Terminated
M6APDG01436	Gossypol	"gossypol; 303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate"	3503	C30H30O8	Phase 2
M6APDG03115	JNJ-10198409	"JNJ-10198409; 627518-40-5; PDGFR Tyrosine Kinase Inhibitor IV; PDGF Receptor Tyrosine Kinase Inhibitor IV; CHEMBL120077; N-(3-fluorophenyl)-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine; 3-Fluoro-N-(6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine; ZDNURMVOKAERHZ-UHFFFAOYSA-N; SCHEMBL3088170; GTPL6020; CTK8E8807; jnj10198409; DTXSID70430890; MolPort-009-019-131; HMS3650O03; HMS3229I11; ZINC13677843; BDBM50179207; AKOS030525202; RWJ 540973; CCG-206773; NCGC00343986-02; RT-014973; KB-274227; SR-01000946814"	9797370	C18H16FN3O2	Investigative
M6APDG03924	SFLT-01	"AAV2-sFLT-01; VEGF/PIGF suppression gene therapy (cancer), Genzyme; SFLT-01 gene therapy (wet AMD), AGTC/Genzyme; VEGF suppression gene therapy (wet age-related macular degeneration), Applied Genetic Technologies/ Genzyme"	.	.	Phase 1
M6APDG03307	N-(6-Hydroxycarbamoyl-hexyl)-benzamide	"CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-"	9965141	C14H20N2O3	Investigative
M6APDG02862	Ortataxel	"UNII-8H61Y4E29N; 186348-23-2; 8H61Y4E29N; IDN-5109; IDN 5109; Ortataxel [INN]; Bay-59-8862; SB-T-101131; SB-T 101131; idn5109; SCHEMBL9932772; CHEMBL382300; BAY-59; IND-5109; DB11669; Z-3102; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-,;  Hexanoic acid; IND5109; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxy-baccatin-1,14-carbonate; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxybaccatin-1,14-carbonate; Genz29155"	6918412	C44H57NO17	Phase 2
M6APDG01472	ZM-39923	"ZM39923; 273727-89-2; ZM-39923; UNII-M0ZX82000S; M0ZX82000S; 3-[benzyl(propan-2-yl)amino]-1-(naphthalen-2-yl)propan-1-one; 3-(Benzyl(propan-2-yl)amino)-1-(naphthalen-2-yl)propan-1-one; JSASWRWALCMOQP-UHFFFAOYSA-N; Tocris-1367; NCGC00025126-01; AC1L1GQH; Lopac-Z-4626; Lopac0_000844; SCHEMBL2891331; GTPL5994; CHEMBL596674; CHEBI:92715; BDBM81346; CTK6A9359; M9440 (Me-3,4-dephostatin); ZINC1487934; HY-12589A; HSCI1_000104; AKOS030526763; CS-4952; CCG-204927; NCGC00025126-02; NCGC00016107-05; NCGC00016107-02; NCGC00016107-09"	3797	C23H25NO	Investigative
M6APDG02114	JNJ-38877605	"C-met inhibitor, Ortho Biotech Oncology Research & Development; C-met inhibitor (solid tumors), ORD/J&J PRD"	46911863	C19H13F2N7	Phase 1
M6APDG02727	3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 26a; SCHEMBL4221327; SCHEMBL4221321; CHEMBL175791; BDBM8600; AC1O7053; 3-[(E)-(7-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539776	C16H15NO	Investigative
M6APDG00526	Setmelanotide	"RM-493; UNII-N7T15V1FUY; BIM-22493; N7T15V1FUY; 920014-72-8; Setmelanotide [USAN:INN]; GTPL9272; CHEMBL3301624; CS-6399; DB11700; HY-19870; L-Cysteinamide, N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-&gt; 8)-disulfide; (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-d"	11993702	C49H68N18O9S2	Approved
M6APDG02998	N-(2-aminophenyl)-4-methoxybenzamide	"N-(2-aminophenyl)-4-methoxybenzamide; AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394"	785232	C14H14N2O2	Investigative
M6APDG04046	UshStat	"Myosin 7A gene therapy (Usher syndrome 1B, LentiVector), Oxford BioMedica; Myosin VIIA gene therapy (Usher syndrome 1B, LentiVector), Oxford BioMedica"	.	.	Phase 1/2
M6APDG01491	LG100268	"AmbkkkkK580; LG 100268; LG2; LG-100268; 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)nicotinic acid; 6-[1-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)CYCLOPROPYL]PYRIDINE-3-CARBOXYLIC ACID; 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-nicotinic acid; 6-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid"	3922	C24H29NO2	Discontinued in Phase 1
M6APDG01051	N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide	22319604	C17H16ClN3O	Investigative
M6APDG03387	Atezolizumab	.	.	.	Approved
M6APDG03671	PAC-10649	"PAC-10549; COX-2 inhibitors (pain/inflammation), Pacific Corp"	.	.	Investigative
M6APDG00660	N2-(3-trifluoromethylphenyl)guanine	.	135435057	C12H8F3N5O	Investigative
M6APDG03429	Bevasiranib	.	.	.	Discontinued in Phase 3
M6APDG04018	HER2-specific CAR T cell	.	.	.	Phase 1
M6APDG03277	"4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline"	"CHEMBL327300; Ki-6783; 6,7-Dimethoxy-4-(3,4-dimethoxyphenoxy)quinoline; SCHEMBL925876; 4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline; ZQSHUGGLESWJFP-UHFFFAOYSA-N"	9927943	C19H19NO5	Investigative
M6APDG02740	4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine	"(4-Pyridylmethylene)indane 8a; SCHEMBL4231646; CHEMBL175554; BDBM8618; SCHEMBL4231651; AC1O705Z; ZINC13610827; 4-[(E)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539792	C15H12ClN	Investigative
M6APDG03080	MT-II	"Melanotan II; 121062-08-6; Melanotan-II; Melanotan (MT)-II; Melatonan; Melanotan II acetate salt; CHEMBL430239; L-Lysinamide, N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-7)-peptide; (3S,6S,9R,12S,15S,23S)-12-((1H-imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide; Melanotan -Ii; C50H69N15O9; Asp5; Melanotan II acetate; D-Phe7;  melanotan II; MTII; MTII Melanotan-II; Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2"	92432	C50H69N15O9	Investigative
M6APDG00808	CI-1033	"Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride"	156414	C24H25ClFN5O3	Phase 2
M6APDG01023	4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide	CHEMBL272622; SCHEMBL5312313; JAKLWQFGJXPTHN-UHFFFAOYSA-N; BDBM50371742	21862753	C13H11FN2O2S	Investigative
M6APDG04134	Efungumab	"Mycograb; Hsp90 mAb; Myc-123C28Y; Hsp90 mAb (cancer), NeuTec; Hsp90 mAb (Candida albicans infection/Cryptococcus neoformans meningitis), NeuTec"	.	.	Phase 2
M6APDG01446	NSC-625409	NSC-625409; CHEMBL496777; 1-benzyl-3-(1H-imidazol-1-ylmethyl)-5-nitro-1H-indole-2-carbaldehyde; 3-((1H-imidazol-1-yl)methyl)-1-benzyl-5-nitro-1H-indole-2-carbaldehyde; NSC625409; AC1Q1ZRX; AC1L7JNH; CTK7H8129; ZINC13220122; BDBM50265439; NCI60_007821	361928	C20H16N4O3	Investigative
M6APDG01507	DCB-3503	"DCB-3503; UNII-TXF835U41K; NSC-716802; CHEMBL399454; TXF835U41K; NSC716802; AC1L8JU6; (13aS,14S)-Tylophorinine; 87302-58-7; SCHEMBL12389871; CTK7A0055; BDBM50213933; Dibenzo(f,H)pyrrolo(1,2-b)isoquinolin-14-ol, 9,11,12,13,13a,14-hexahydro-2,3,6,7-tetramethoxy-, (13aS,14S)-; NCI60_040362; Dibenzo(f,H)pyrrolo(1,2-b)isoquinolin-14-ol, 9,11,12,13,13a,14-hexahydro-2,3,6,7-tetramethoxy-, (13as-trans)-; (13aS,14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14-hexahydrophenanthro[9,10-f]indolizin-14-ol; Dibenzo[f,2-b]isoquinolin-14-ol, 9"	402628	C24H27NO5	Investigative
M6APDG02471	Docosapentaenoic acid	"Docosa-4,7,10,13,16-pentaenoic acid; 2313-14-6; 25182-74-5; 4-7-10-13-16 Docsapentaenoic acid; CTK1A5509; CTK1A4905; AVKOENOBFIYBSA-UHFFFAOYSA-N; 4,7,10,13,16-Docosapentaenoicacid; 4,7,10,13,16-Docosapentaenoicacid, (4Z,7Z,10Z,13Z,16Z)-; CH3(CH2)4-CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CH(CH2)2COOH"	5497182	C22H34O2	Investigative
M6APDG01231	EMD-1204831	.	25134692	C25H27N7O3	Phase 1
M6APDG03070	Cypate-[(RGD)4-NH2]1	.	91936299	C88H120N27O23+	Investigative
M6APDG04262	PF-06410293	.	.	.	Phase 3
M6APDG00051	"4-Ethyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine"	"CHEMBL260277; 4-Ethyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine; BDBM50237936; AKOS006359116; 4-Ethyl-1,2,5,6-tetrahydropyridine-2-imine"	10130105	C7H12N2	Investigative
M6APDG01305	L-NIL	"L-NIL; N(6)-acetimidoyllysine; H-Lys(acetimidoyl)-OH; N~6~-[(1z)-Ethanimidoyl]-L-Lysine; N(6)-acetimidoyl-L-lysine; N(6)-ethanimidoyl-L-lysine; CHEMBL7889; L-N(6)-(1-iminoethyl)lysine; CHEBI:63971; L-N(omega)-(1-iminoethyl)lysine; 53774-63-3; N-(iminoethyl)-L-lysine; L-NIL;H-Lys(1-iminoethyl)-OH;N-(5-Amino-5-carboxypentyl)-acetamidine; L-N6-(1-Iminoethyl)lysine; Tocris-1139; NCGC00015566-01; N6-ethanimidoyl-L-lysine; Lopac-I-8021; AC1MBZ26; (L-N6-1-iminoethyl)lysine; SCHEMBL322091; L-Lysine,n6-(1-iminoethyl)-; DTXSID9041071"	2733506	C8H17N3O2	Terminated
M6APDG03752	ISIS 101984	.	.	.	Investigative
M6APDG02730	3-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 21b; CHEMBL366570; BDBM8605; AC1O705D; 3-[(Z)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539781	C16H15N	Investigative
M6APDG01942	4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine	CHEMBL1080666	44820377	C20H16N4	Investigative
M6APDG01041	"5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione"	"CHEMBL367524; 94209-48-0; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[1,1'-biphenyl]-4-yl-5-ethyl-; ACMC-20lyhc; AC1M3WRE; Oprea1_691960; MLS001000776; 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione; NIOSH/CQ0532020; CTK3G9325; DTXSID20367041; MolPort-002-095-507; HMS2827O03; BDBM50099119; ZINC96299878; STK760260; AKOS005616072; MCULE-2406616532; Acido 5-etil 5-(p-difenilil)barbiturici; NCGC00245692-01; 5-(4-Biphenylyl)-5-ethylbarbituric acid; SMR000498104; LS-23825; M.G. 3419; CQ05320200; Barbituric acid, 5-(4-biphenylyl)-5-ethyl-"	2220392	C18H16N2O3	Investigative
M6APDG01610	Baricitinib	"Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant"	44205240	C16H17N7O2S	Approved
M6APDG02252	Galangin	"Galangin; 548-83-4; Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; UNII-142FWE6ECS; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; EINECS 208-960-4; NSC407229; FLAVONE, 3,5,7-TRIHYDROXY-; NSC 407229; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; BRN 0272179; 142FWE6ECS; 3,5,7-trihydroxy-2-phenylchromen-4-one; CHEBI:5262; CHEMBL309490; VCCRNZQBSJXYJD-UHFFFAOYSA-N; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one"	5281616	C15H10O5	Investigative
M6APDG03196	Coumate	.	9859866	C10H9NO5S	Phase 2
M6APDG00845	NRC-2694	.	16129168	C24H26N4O3	Investigative
M6APDG04353	CYC-103	"Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel"	.	.	Terminated
M6APDG01932	6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine	6-Cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine; CHEMBL340813; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}phenol; N20; NU-6086; 1oi9; AC1L9L2Q; BDBM5541; SCHEMBL6792176; O6-Cyclohexylmethylguanine deriv 25; DB08233; 6-Cyclohexylmethoxy-2-(4 -hydroxyanilino)purine	447649	C18H21N5O2	Investigative
M6APDG03704	ISIS 173840	.	.	.	Investigative
M6APDG02001	NU-6102	"nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467"	4566	C18H22N6O3S	Investigative
M6APDG00335	ENMD-1198	"EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed"	11483754	C20H25NO2	Phase 1
M6APDG03986	AVB-S6-500	.	.	.	Phase 1
M6APDG04292	MPDL-3280A	.	.	.	Phase 3
M6APDG02506	Phylomers	"PYC-35; PYC-35T; PYC-36D; PYC-36S; PYCAG-5; S-20; S-22; S-30; S-35; SP-34; SP-36; SP-71; Jun N terminal kinase inhibitors (stroke), Phylogica; Phylomers (traumatic brain injury/stroke); Phylomers (traumatic brain injury/stroke), Phylogica"	56947089	C23H28N2O3	Investigative
M6APDG03669	Silicon-modified indomethacin	"Silexsyn; RND-100; SiM-100; Silicon-modified indomethacin (cancer); Silicon-modified indometacin (cancer), Silamed; Silicon-modified indomethacin (cancer), Silamed"	.	.	Investigative
M6APDG01424	NSC-369087	"NSC-369087; CHEMBL522733; NSC369087; AC1Q6ZTK; AC1L7R8L; BDBM50265438; 6-[1H-imidazol-1-yl(4-methoxyphenyl)methyl]-1,3-benzodioxol-5-ol; 6-[imidazol-1-yl-(4-methoxyphenyl)methyl]-1,3-benzodioxol-5-ol; 6-((1H-imidazol-1-yl)(4-methoxyphenyl)methyl)benzo[d][1,3]dioxol-5-ol"	340000	C18H16N2O4	Investigative
M6APDG02091	N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	CHEMBL1097278; N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide	46887333	C16H13N3OS	Investigative
M6APDG02788	Edoxudine	"5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-dihydropyrimidine-2,4-d ione; ORF-15817; RWJ-15817; Edurid (Salt/Mix); 1-(2-deoxypentofuranosyl)-5-ethylpyrimidine-2,4(1h,3h)-dione; AC1L1CAR; .beta.-5-Ethyldeoxyuridine; TimTec1_004024; SCHEMBL65580; MLS001360450; AC1Q69H9; 5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; .beta.-5-Ethyl-2'-deoxyuridine; XACKNLSZYYIACO-UHFFFAOYSA-N; HMS3056J10; HMS3369L22; HMS1545G20; EDU; AKOS024282522; 5-Ethyl-2'-deoxyuridine ; Edoxudine; MCULE-3445830855; ST056929"	66377	C11H16N2O5	Investigative
M6APDG02209	PF-4708671	PF4708671; PF 4708671	51371303	C19H21F3N6	Clinical trial
M6APDG01948	CP-271485	"CP-271485; 2-(1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL) ETHYL-4-(4'-ETHOXY [1,1'-BIPHENYL]-4-YL)-4-OXOBUTANOIC ACID; CP8; (6R)-4-BENZYL-6-(1-METHYL-2,2-DIOXIDO-1,3-DIHYDRO-2,1-BENZISOTHIAZOL-5-YL)MORPHOLIN-3-ONE; 1utt; AC1L9MIT; DB02118; CP 271485; (6S)-4-benzyl-6-(1-methyl-2,2-dioxo-3H-2,1-benzothiazol-5-yl)morpholin-3-one; 3-Morpholinone, 6-(1,3-dihydro-1-methyl-2,1-benzisothiazol-5-yl)-4-(phenylmethyl)-, S,S-dioxid; 35580-46-2; (6S)-4-benzyl-6-(1-methyl-2,2-dioxido-1,3-dihydro-2,1-benzisothiazol-5-yl)morpholin-3-one"	448940	C19H20N2O4S	Investigative
M6APDG00487	"9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione"	"CHEMBL209907; 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione; SCHEMBL5829446; IJHAYZZOYYQESB-UHFFFAOYSA-N; BDBM50192426"	11844342	C14H8N2O3	Investigative
M6APDG00847	TN-14003	"UNII-1TW3FT746I; 1TW3FT746I; TN14003; BDBM194584; US9205085, MSX-207; H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2; L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4-&gt;13)-disulfide"	16130647	C90H141N33O18S2	Investigative
M6APDG03564	ISIS 16507	.	.	.	Investigative
M6APDG01268	Glionitrin A	Glionitrin A; CHEMBL550491	25243252	C13H11N3O5S2	Investigative
M6APDG00924	YM-511	"YM 511; YM511 (pharmaceutical); 148869-05-0; YM-511; Benzonitrile,4-[[(4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]-; 4-[[(4-BROMOPHENYL)METHYL]-4H-1,2,4-TRIAZOL-4-YLAMINO]BENZONITRILE; YM511; ACMC-20n5jr; SCHEMBL544997; CHEMBL108425; AC1L430I; CTK4C5946; BDBM10016; DTXSID50164121; GGPPBTSXFROGAE-UHFFFAOYSA-N; MolPort-023-276-728; ZINC598425; AKOS024457519; B5405; 4-[N-(4-bromobenzyl)-N-(4-cyanophenyl)amino]-4H-1,2,4-triazole; 4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile; Benzonitrile, 4-(((4-bromophenyl"	177865	C16H12BrN5	Discontinued in Phase 2
M6APDG02888	MLN1117	.	70798655	C19H17N5O3	Phase 1/2
M6APDG02333	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41	5328038	C14H9BrN4O2	Investigative
M6APDG04347	AZD-9935	.	.	.	Terminated
M6APDG00585	SC-44463	"SC-44463; CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth"	128564	C19H29N3O5	Terminated
M6APDG01226	VS-6063	"Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu"	25117126	C20H21F3N8O3S	Phase 2
M6APDG01837	Ocophyllals b	Ocophyllals B; CHEMBL571617; BDBM50303153	44470606	C20H20O6	Investigative
M6APDG00679	2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one	.	135471354	C15H12N2O2	Investigative
M6APDG03653	RX-1792	"EGF antagonist, Rexahn; RX-0183"	.	.	Investigative
M6APDG00975	Org-33201	148714-92-5	196932	C21H29ClN2S	Investigative
M6APDG02039	4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	CHEMBL611630; 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine	46225260	C17H16N6O	Investigative
M6APDG01651	"4-(3-Ethoxy-phenoxy)-6,7-dimethoxy-quinoline"	"CHEMBL98169; 4-(3-Ethoxy-phenoxy)-6,7-dimethoxy-quinoline"	44331209	C19H19NO4	Investigative
M6APDG01421	Flutamide	"Apimid; ApoFlutamide; Cebatrol; Chimax; Cytamid; Drogenil; Eulexin; Eulexine; Fluken; Flulem; Flumid; FlutaGRY; Flutacell; Flutamida; Flutamidum; Flutamin; Flutandrona; Flutaplex; Flutexin; Fugerel; METHOXYCHLOR; NFBA; Niftholide; Niftolid; Niftolide; NovoFlutamide; Odyne; Oncosal; Prostacur; Prostandril; Prostica; Prostogenat; Testotard; Alphapharm Brand of Flutamide; Apo Flutamide; Apogepha Brand of Flutamide; Apotex Brand of Flutamide; Azupharma Brand of Flutamide; Cell pharm Brand of Flutamide; Chephasaar Brand of Flutamide; Chiron Brand of Flutamide; Ciclum Brand of Flutamide; Esparma Brand of Flutamide; Essex Brand of Flutamide; Fluta GRY; Fluta cell; Gry Brand of Flutamide; Hexal Brand of Flutamide; InibsaBrand of Flutamide; Ipsen Brand of Flutamide; Juta Brand of Flutamide; Kendrick Brand of Flutamide; Lemery Brand of Flutamide; Novo Flutamide; Novopharm Brand of Flutamide; PMS Flutamide; Pharmascience Brand of Flutamide; Prasfarma Brand of Flutamide; Q Pharm Brand of Flutamide; Schering Brand of Flutamide; Schering Plough Brand of Flutamide; TAD Brand of Flutamide; Tedec Meiji Brand of Flutamide; F 9397; F0663; Fluta 1A Pharma; Flutamide USP25; SCH13521; Sch 13521; Apo-Flutamide; Cebatrol, veterinary; Eulexin (TN); Fluta-GRY; Fluta-cell; Flutamida [INN-Spanish]; Flutamide(pubertal study); Flutamidum [INN-Latin]; NK-601; Novo-Flutamide; PMS-Flutamide; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; Q-Pharm Brand of Flutamide; Sch-13521; Schering-Plough Brand of Flutamide; Flutamide [USAN:BAN:INN]; Ham's F-12 medium; Eulexin, Flutamin, Drogenil,Flutamide; Flutamide (JAN/USP/INN); Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; M-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; M-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-(8CI); 1A Brand of Flutamide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; 4'-Nitro-3'-trifluoromethylisobutyramilide; 4'-Nitro-3'-trifluoromethylisobutyranilide; 4-Nitro-3-(trifluoromethyl)isobutyranilide; Flutamide (AR inhibitor)"	3397	C11H11F3N2O3	Approved
M6APDG00206	"5-((1H-imidazol-1-yl)methyl)-7,8-dihydroquinoline"	"CHEMBL53068; dihydroquinoline 44; BDBM10025; ZINC13808186; 5-(1H-imidazol-1-ylmethyl)-7,8-dihydroquinoline; 5-[(Imidazol-1-yl)methyl]-7,8-dihydroquinoline"	10774864	C13H13N3	Investigative
M6APDG03920	PF-05230905	ATN-192	.	.	Phase 1
M6APDG01120	6-Nitroindazole	"6-Nitro-1H-indazole; 6-Nitroindazole; 7597-18-4; 6-Nitro-2H-indazole; 6-Nitroisoindazole; 1H-INDAZOLE, 6-NITRO-; 65750-02-9; 2H-Indazole, 6-nitro-; CCRIS 3263; EINECS 231-500-9; NSC 35066; NSC 56816; BRN 0007812; CHEMBL54277; MLS000069593; ORZRMRUXSPNQQL-UHFFFAOYSA-N; SMR000059016; 6NI; 6-nitro-indazol; indazole,6-nitro; Tocris-0710; PubChem20594; Opera_ID_909; 2H-Indazole,6-nitro-; AC1Q1XVW; 6-Nitroindazole, 97%; ACMC-209p0z; AC1L2NB1; AC1Q1Y5L; MLS001148387; KSC379M3P; 5-23-06-00183 (Beilstein Handbook Reference); SCHEMBL271522"	24239	C7H5N3O2	Investigative
M6APDG02116	PWT-33597	"PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics"	46917355	C26H30F2N8O4S	Phase 1
M6APDG01459	Indirubin-3'-monoxime	"INDIRUBIN-3'-MONOXIME; indirubin-3'-oxime; 160807-49-8; indirubin-3-oxime; Indirubin-3monoxime; Indirubin-3-monoxime; 3-[3-(Hydroxyamino)-1H-indol-2-yl]indol-2-one; CHEBI:43645; Indirubin 3'-monoxime; indirubin-3'-monooxime; Indirubin-3&amp; CHEMBL216543; CHEMBL126077; (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME; UNM-0000305771; 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one; 667463-82-3; IXM; SR-01000075929; Indirubin-3; Indirubin 3-oxime; Tocris-1813; BiomolKI_000070; Indirubin-3-oxime"	3707	C16H11N3O2	Investigative
M6APDG02618	7-hydroxy-2-(3-hydroxyphenyl)chroman-4-one	"CHEMBL255110; 62252-06-6; 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-2-(3-hydroxyphenyl)-; AC1LDLCQ; CTK2C3909; DTXSID60347362; MXNJBOFUFMJXOB-UHFFFAOYSA-N; BDBM50374256; AKOS030552838; 7-hydroxy-2-(3-hydroxyphenyl)-2,3-dihydrochromen-4-one; 2,3-Dihydro-7-hydroxy-2-(3-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-Hydroxy-2-(3-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one #"	620596	C15H12O4	Investigative
M6APDG02756	3-[3-Phenyl-indan-(1E)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 37a; BDBM8648; AC1O707H; CHEMBL193555; 3-[(E)-(3-phenyl-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539819	C21H17N	Investigative
M6APDG03540	PUP-1	MMP-12 inhibitor (chronic obstryctive pulmonary disorder) Abiogen	.	.	Investigative
M6APDG00241	8-Mercapto-octanoic acid phenylamide	8-Mercapto-octanoic acid phenylamide; 8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343	11149404	C14H21NOS	Investigative
M6APDG01861	2-(3-Chlorophenyl)-2H-indazole-7-carboxamide	CHEMBL1094953; 2-(3-Chlorophenyl)-2H-indazole-7-carboxamide; SCHEMBL2265628	44549374	C14H10ClN3O	Investigative
M6APDG03061	BLU-554	"MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide"	91885617	C24H24Cl2N4O4	Phase 1
M6APDG02369	(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone	"CHEMBL7735; PDGF Receptor Tyrosine Kinase Inhibitor I; D-64406; (5-Hydroxy-1H-2-indolyl)(1H-2-indolyl)-methanone; 249762-62-7; AC1NS9CN; BDBM6581; SCHEMBL4456469; CHEBI:92486; ZINC24261; CTK0J4476; DTXSID20416205; Bis(1H-2-indolyl)methanone 39; IN1158; HSCI1_000198; NCGC00185731-01; 5-Hydroxy-[2,2'-carbonylbis(1H-indole)]; 2-(1H-indol-2-ylcarbonyl)-1H-indol-5-ol; BRD-K27665173-001-01-3; (5-hydroxy-1H-indol-2-yl)-(1H-indol-2-yl)methanone; Methanone, (5-hydroxy-1H-indol-2-yl)-1H-indol-2-yl-"	5330535	C17H12N2O2	Investigative
M6APDG02395	1-(4-Aminophenyl)-2-(1H-imidazol-1-yl)ethanone	"1-(4-aminophenyl)-2-(1h-imidazol-1-yl)ethanone; CHEMBL162431; AC1Q5E94; AC1L1F89; SCHEMBL9663730; BDBM50322067; AKOS022646799; 73932-42-0; 1-(4-aminophenyl)-2-imidazol-1-ylethanone; 1-(4-Amino-phenyl)-2-imidazol-1-yl-ethanone; alpha-(1H-Imidazole-1-yl)-4'-aminoacetophenone; Ethanone, 1-(4-aminophenyl)-2-(1H-imidazol-1-yl)-"	53602	C11H11N3O	Investigative
M6APDG01803	Epierenone	epierenone; CHEMBL237122; SCHEMBL13806060	44433505	C24H30O6	Investigative
M6APDG04027	FS118	.	.	.	Phase 1
M6APDG01642	Ro-37-9790	Ro-37-9790; CHEMBL306412; BDBM50290086	44313734	C15H29N3O4	Investigative
M6APDG00134	5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine	"CHEMBL185024; CHEMBL552935; 190909-71-8; SCHEMBL7624096; BDBM50066778; AKOS027401526; AKOS006376472; DA-08771; FT-0744003; 2-ethyl-3,4-dihydro-3-methyl-2H-Pyrrol-5-amine; 5-Ethyl-4-methyl-pyrrolidin-(2E)-ylideneamine"	10396852	C7H14N2	Investigative
M6APDG03044	OICR-9429	"OICR-9429; 1801787-56-3; OICR9429; CHEMBL3798846; N-(4-(4-Methylpiperazin-1-Yl)-3'-(Morpholinomethyl)-[1,1'-Biphenyl]-3-Yl)-6-Oxo-4-(Trifluoromethyl)-1,6-Dihydropyridine-3-Carboxamide; N-[2-(4-methylpiperazin-1-yl)-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide; GTPL8231; OICR 9429; MolPort-039-101-294; EX-A2417; BCP18185; BDBM50164794; s7833; AKOS025147341; ZINC231558892; SB19642; CS-5776; NCGC00371263-02; AK468854; HY-16993; J3.618.049H"	91623360	C29H32F3N5O3	Investigative
M6APDG04167	APC-8015F	"CD54-postive autologous cell immunotherapy (hormone refractory prostate cancer), Dendreon"	.	.	Phase 2
M6APDG00803	4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol	CHEMBL172912; 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol; SCHEMBL7212305	15516780	C11H16O3S2	Investigative
M6APDG00501	AZD0156	"AOTRIQLYUAFVSC-UHFFFAOYSA-N; 1821428-35-6; AZD-0156; UNII-P5T0XWC07Z; P5T0XWC07Z; GTPL9942; CHEMBL3960662; SCHEMBL17246146; AZD 0156 [WHO-DD]; MolPort-044-560-374; BDBM245474; BCP18990; EX-A1321; s8375; ZINC498035578; AKOS030629510; CS-5889; SB19769; AZD0156 (AZD-0156); AS-35329; compound 64  [PMID: 29683659]; HY-100016; US9428503, 1; 8-[6-[3-(dimethylamino)propoxy]pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]quinolin-2-one; 8-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo["	118502708	C26H31N5O3	Phase 1
M6APDG00676	2-(1H-indazol-3-yl)-1H-benzo[d]imidazole	"3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE; CHEMBL383990; 3-(1H-1,3-benzodiazol-2-yl)-2H-indazole; 2-(2H-indazol-3-yl)-1H-1,3-benzodiazole; IDZ; 1097816-83-5; Indazole Compound 2; 2c3l; AC1Q4XAS; AC1NS1P1; SCHEMBL311148; BDBM16590; 3-benzimidazol-2-yl-1h-indazole; JTKFRFMSUBOCIQ-UHFFFAOYSA-N; MolPort-016-542-829; ZINC14961821; AKOS009356321; NE25942; MCULE-6782886882; DB07959; 2-(1H-indazol-3-yl)-1H-benzimidazole; 3-(1H-benzoimidazol-2-yl)-1H-indazole; 2-(1H-Indazole-3-yl)-1H-benzoimidazole; EN300-70692"	135464491	C14H10N4	Investigative
M6APDG03670	CX-9051	"J-13016; COX-2 inhibitors (cancer); COX-2 inhibitors (cancer), National Taiwan University"	.	.	Investigative
M6APDG04174	BGB-324	"BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio"	.	.	Phase 2
M6APDG01893	PD-068235	CHEMBL455856; PD-068235; BDBM50266362; PD-068253	44581800	C11H15N3O3S	Investigative
M6APDG03288	Bremelanotide	Bremelanotide (USAN/INN); PT-141; Rekynda	9941379	C50H68N14O10	Approved
M6APDG01311	3-Methylphenylalanine	5472-70-8; 2-Amino-3-(m-tolyl)propanoic acid; 2-amino-3-m-tolyl-propionic acid; 3-Methy-DL-Phenylalanine; DL-3-ME-PHE-OH; 2-amino-3-(3-methylphenyl)propanoic acid; 3-METHYLPHENYLALANINE; 3-Methylphe; NSC14793; AC1L5E1A; SCHEMBL42906; AC1Q5S51; ss-m-Tolyl-a-amino-propionsaure; CTK8E3667; KS-00000JHC; 3-METHYL-DL-PHENYLALANINE; MolPort-003-990-079; 2-amino-3-(m-tolyl)propionic acid; 2283-42-3; NSC29447; NSC-29447; NSC-14793; AKOS016843161; AKOS000174493; MCULE-1997175050; AM83420; AB21660; 2-AMINO-3-M-TOLYLPROPANOIC ACID	2761494	C10H13NO2	Investigative
M6APDG00205	5-(2-(1H-imidazol-1-yl)ethyl)quinoline	CHEMBL54803; quinoline 33; BDBM10028; ZINC13808193; 5-[2-(Imidazol-1-yl)ethyl]quinoline; 5-[2-(1H-imidazol-1-yl)ethyl]quinoline	10751574	C14H13N3	Investigative
M6APDG03634	ISIS 298701	.	.	.	Investigative
M6APDG00531	MBX-102	"Arhalofenate; Mbx-102; MBX 102; 24136-23-0; UNII-1P01UJR9X1; JNJ-39659100; 1P01UJR9X1; CB-102; M-102; Arhalofenate [USAN:INN]; Arhalofenate (USAN/INN); SCHEMBL3302781; CHEMBL2103824; BJBCSGQLZQGGIQ-QGZVFWFLSA-N; ZINC2012859; BDBM50093473; AKOS032945719; DB11811; CS-6812; SB16866; (-)-2-(Acetylamino)ethyl (2R)-(4-chlorophenyl)(3-(trifluoromethyl)phenoxy)acetate; CJ-31172; Benzeneacetic acid, 4-chloro-alpha-(3-(trifluoromethyl)phenoxy)-, 2-(acetylamino)ethyl ester, (-)-; HY-14831; D09579; UNII-K9TZK4MNO6 component BJBCSGQLZQGGIQ-QGZV"	12082259	C19H17ClF3NO4	Phase 2/3
M6APDG00005	2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one	CHEMBL435507; 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one; SCHEMBL3545107	10017389	C18H17NO3	Investigative
M6APDG00525	BGT226	"BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939"	11978790	C28H25F3N6O2	Phase 1/2
M6APDG04231	PTX-200	"Plant-derived antiparkinsonian, Phytrix"	.	.	Phase 2
M6APDG01638	3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid	CHEMBL42415; 3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid; BDBM50280277; 6-Chloro-3-carbamoyl-1H-indole-2-carboxylic acid	44289108	C10H7ClN2O3	Investigative
M6APDG03871	AP32788	.	.	.	Phase 1
M6APDG00771	"2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one"	"CHEMBL3144577; CHEMBL8355; 2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one; SCHEMBL9645961; BDBM50009006"	14898720	C18H14N2O	Investigative
M6APDG01512	4-(4-fluoro-benzylideneamino)-benzenesulfonamide	CHEMBL427835; 4-[(4-fluorobenzylidene)amino]benzenesulfonamide; 4-{[(e)-(4-fluorophenyl)methylidene]amino}benzenesulfonamide; NSC720519; AC1L8N2R; SCHEMBL5311683; CTK7B9640; BKZPDMSMFWCHPI-UHFFFAOYSA-N; MolPort-003-705-944; ZINC18102137; BDBM50371768; ZINC95919526; AKOS001613042; ZINC253618202; AKOS016038195; NSC-720519; MCULE-4378033729; ST009698; KB-117288; N-(4-Fluorobenzylidene)-4-sulfamoylaniline; EU-0002043; SR-01000079257; SR-01000079257-1; 4-[(4-Fluoro-benzylidene)-amino]-benzenesulfonamide	404324	C13H11FN2O2S	Investigative
M6APDG00966	4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL363477; 4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine; BDBM50150933	19049121	C7H14N2	Investigative
M6APDG03289	3-Methyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL359703; CHEMBL545291; 3-Methylpyrrolidine-2-imine; BDBM50066781; AKOS006353988; 3-Methyl-pyrrolidin-(2E)-ylideneamine	9942127	C5H10N2	Investigative
M6APDG03579	FAS-031	"FASi; FAS inhibitors (cancer); FAS-093; FAS-31; FAS-93; FAS inhibitors (cancer), FASgen/Johns Hopkins; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins; FAS inhibitors (cancer), FASgen/Johns Hopkins/Johnson & Johnson; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins/ Johnson & Johnson"	.	.	Investigative
M6APDG04317	KOS-2484	"KOS-2539; KOS-2540; HSP90 inhibitors (cancer), Kosan"	.	.	Preclinical
M6APDG01754	"3-isopropyl-4-(phenylamino)naphthalene-1,2-dione"	"CHEMBL204939; 3-isopropyl-4-(phenylamino)naphthalene-1,2-dione"	44409841	C19H17NO2	Investigative
M6APDG00722	"(11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid"	CHEMBL32961; ZINC29223888	13640143	C15H12O4	Investigative
M6APDG00874	3-bromo-7-nitro-1H-indazole	"3-Bromo-7-nitroindazole; 3-Bromo-7-nitro-1H-indazole; 3-bromo-7-nitroindazole; 74209-34-0; 1H-Indazole,3-bromo-7-nitro-; 3-bromo-7-nitro-2H-indazole; CHEMBL479014; NFSTZPMYAZRZPC-UHFFFAOYSA-N; MFCD00159910; AK-27879; SR-01000075708; 3-bromo-7NI; Tocris-0735; 3-Br-7-Nitroindazole; AC1L1BXC; Lopac-B-2050; 3-Br-7NI; Lopac0_000161; BSPBio_002434; BSPBio_001502; KBioGR_000222; KBioSS_000222; SPECTRUM1505105; SCHEMBL499422; SCHEMBL499421; GTPL5113; KBio3_000444; KBio3_000443; KBio2_002790; CTK5D9545; BCBcMAP01_000129; KBio2_005358; KBio2_000222; DTXSID90274319; OR6862T; 3-Bromo-7-Nitroindazole"	1649	C7H4BrN3O2	Investigative
M6APDG02780	MDL-105519	"Mdl 105519; MDL 105,519; 161230-88-2; Lopac-M-216; AC1O7G4O; Lopac0_000805; C18H11Cl2NO4; SCHEMBL499902; CHEMBL180427; AOB5684; HMS3262B11; ZINC1540415; Tox21_500805; AKOS027324667; LP00805; CCG-204889; CS-3882; NCGC00015639-04; NCGC00015639-01; NCGC00094138-02; NCGC00015639-03; NCGC00261490-01; NCGC00015639-02; HY-15085; X6860; M-216; EU-0100805; SR-01000075460; SR-01000075460-1"	6603913	C18H11Cl2NO4	Terminated
M6APDG00184	"2-(2-phenethylphenyl)isoindoline-1,3-dione"	CHEMBL246144; PP2P; SCHEMBL2464969; BDBM23840; N-(2-Phenethylphenyl)phthalimide	10616182	C22H17NO2	Investigative
M6APDG02298	Triazolopyridine	"CP-808844; 6-[4-(4-FLUOROPHENYL)-1,3-OXAZOL-5-YL]-3-ISOPROPYL[1,2,4]TRIAZOLO[4,3-A]PYRIDINE; 1zzl; AC1NRDFA; Triazolopyridine deriv. 25; SCHEMBL40860; CHEMBL194322; BDBM15414; DB04797; 6-[4-(4-fluorophenyl)-1,3-oxazol-5-yl]-3-(1-methylethyl)[1,2,4]triazolo[4,3-a]pyridine; 6-[4-(4-Fluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine; 4-(4-fluorophenyl)-5-[3-(propan-2-yl)-[1,2,4]triazolo[3,4-a]pyridin-6-yl]-1,3-oxazole"	5289514	C18H15FN4O	Investigative
M6APDG00076	"N4-(3-methylphenyl)-4,6-quinazolinediamine"	"CHEMBL336113; Anilinoquinazoline, 4a; N4-(3-methylphenyl)-4,6-quinazolinediamine; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline"	10220590	C15H14N4	Investigative
M6APDG03976	DS-7423	.	.	.	Phase 1
M6APDG03177	4557W	"EGFR/ErbB-2 Inhibitor; 179248-61-4; 4557W; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine"	9843206	C23H21N3O3	Investigative
M6APDG04256	Radiosensitizer gene therapy	Radiosensitizer gene therapy (prostate cancer)	.	.	Phase 3
M6APDG00591	"4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one"	"CHEMBL490292; 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one"	13015959	C17H14O3S2	Investigative
M6APDG00057	8-O-(4-toluenesulfonyl)manzamine A	CHEMBL403561	101437199	C43H50N4O4S	Investigative
M6APDG03973	BI-836845	.	.	.	Phase 1
M6APDG00142	AcDRGDS	CHEMBL241297; AcDRGDS; Acetyl-Asp-Arg-Gly-Asp-Ser-OH	10415998	C21H34N8O12	Investigative
M6APDG03183	CHIR-98023	CT-98014	9847557	C20H16Cl2N8O2	Investigative
M6APDG03895	OMP-52M51	.	.	.	Phase 1
M6APDG02046	SRT3025	.	46245047	C31H31N5O2S2	Phase 1
M6APDG02882	L-Tryptophan-L-leucine	"H-Trp-Leu-OH; 13123-35-8; L-tryptophyl-L-leucine; CHEMBL477627; CHEBI:74871; Tryptophyl-Leucine; L-Tryptophan-L-leucine; L-Trp-L-Leu; L-Trp-L-Leu-OH; L-Leucine,L-tryptophyl-; AC1OE28P; SCHEMBL7622341; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)propanamido)-4-methylpentanoic acid; CTK4B7168; ZINC1865984; WL; BDBM50266681; AKOS022180848; AJ-32151; FT-0772989; C-48470; (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoic acid"	6997510	C17H23N3O3	Investigative
M6APDG03756	ISIS 101995	.	.	.	Investigative
M6APDG00159	1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea	CHEMBL233022; 1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea; SCHEMBL6067873	10467406	C10H12N4S2	Investigative
M6APDG02511	XL418	.	56963011	C26H32BrF3N8O	Phase 1
M6APDG01987	N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide	CHEMBL575857; N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide	45481821	C22H17NO3	Investigative
M6APDG01219	Ac-YRC(Me)*EHdFRWC(Me)NH2	CHEMBL427666; Ac-YRC(Me)*EHdFRWC(Me)NH2	25078242	C62H85N19O13S2	Investigative
M6APDG00997	MTR105	"UNII-CTD25O6OBI; CTD25O6OBI; MTR 105; S-Ethylisothiuronium diethyl phosphate; 21704-46-1; Carbamimidothioic acid, ethyl ester, mono(diethyl phospate); Phosphoric acid, diethyl ester, compd. with 2-ethyl-2-thiopseudourea (1:1); Difetur; AC1Q6SNE; AC1L4PKY; CTK4E7529; nitric oxide synthase inhibi-tors; ethyl carbamimidothioate- diethyl hydrogen phosphate(1:1); MTR-105; DTXSID60176093; AKOS030611139; LS-107705; diethyl hydrogen phosphate; Carbamimidothioic acid, ethyl ester, diethyl phosphate (1"	210823	C7H19N2O4PS	Phase 2
M6APDG00832	GSK579289A	compound 25 [PMID 19237286]; GSK-579289A	16051023	C26H27ClN4O3S	Investigative
M6APDG02766	"3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine"	"3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 9; AC1O70HH; SCHEMBL4507080; CHEMBL206070"	6540053	C16H15N	Investigative
M6APDG02814	"(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone"	"AC1LDSBN; BAS 02052919; (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone; N-Benzoylpyrazole deriv., 8; CHEMBL244917; ZINC37156; BDBM23706; MolPort-001-906-669; 3,4-dichlorophenyl pyrazolyl ketone; STK044137; AKOS000577014; MCULE-6190861509; ST033189; (3,4-dichlorophenyl)-pyrazol-1-ylmethanone; (3,4-Dichloro-phenyl)-pyrazol-1-yl-methanone; 1-[(3,4-dichlorophenyl)carbonyl]-1H-pyrazole; SR-01000521426; SR-01000521426-1"	674628	C10H6Cl2N2O	Investigative
M6APDG02372	1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 15; AC1NS9HQ; BDBM6655; CHEMBL140589; SCHEMBL12856374; ZINC13471114; 1-(9-oxofluoren-4-yl)-3-pyridin-2-ylurea; 3-(9-oxo-9H-fluoren-4-yl)-1-pyridin-2-ylurea; 1-(9-Oxo-9H-fluorene-4-yl)-3-(2-pyridyl)urea; N-(9-Oxo-9H-fluoren-4-yl)-N -pyridin-2-ylurea	5330596	C19H13N3O2	Investigative
M6APDG03530	ISIS 101998	.	.	.	Investigative
M6APDG01854	"9-Hydroxypropyladenine, R-Isomer"	"14047-28-0; (R)-9-(2-Hydroxypropyl)adenine; (R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; (R)-(+)-9-(2-HYDROXYPROPYL)ADENINE; (2R)-1-(6-aminopurin-9-yl)propan-2-ol; UNII-43H6SBP55W; 9-HYDROXYPROPYLADENINE, R-ISOMER; (R)-9-(2-hydroxypropyl) adenine; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaR)-; 43H6SBP55W; AK-59150; (2R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; ARP; W-201193; 9-(2-Hydroxypropyl)adenine, (R)-; PubChem9984; R-9-(2-hydroxypropyl)adenine [WHO-DD]; AC1L9HLR; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, D-"	445211	C8H11N5O	Investigative
M6APDG03874	BMS-986189	.	.	.	Phase 1
M6APDG03013	Diphenylacetic Acid	"DIPHENYLACETIC ACID; 2,2-diphenylacetic acid; 117-34-0; Diphenylethanoic acid; Acetic acid, diphenyl-; Benzeneacetic acid, .alpha.-phenyl-; 1,1-Diphenylacetic acid; UNII-658NCZ0NKO; Diphenyl-acetic acid; alpha-Toluic acid, alpha-phenyl-; Benzeneacetic acid, alpha-phenyl-; EINECS 204-185-0; NSC 120417; BRN 1910978; 658NCZ0NKO; AI3-23777; CHEBI:41967; PYHXGXCGESYPCW-UHFFFAOYSA-N; .alpha.,.alpha.-Diphenylacetic acid; MFCD00004251; .alpha.-Toluic acid, .alpha.-phenyl-; A-Toluic Acid, A-Phenyl-; Diphenylacetic acid, 99+%"	8333	C14H12O2	Investigative
M6APDG00835	"2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide"	"CHEMBL214839; 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide; BDBM50196033"	16090303	C16H17NO4	Investigative
M6APDG01139	CYC-800	.	24759764	C21H25FO8	Preclinical
M6APDG00153	"6,7-Dimethoxy-3-phenylethynyl-quinoline"	"CHEMBL67059; 6,7-Dimethoxy-3-phenylethynyl-quinoline; ZINC3834029"	10446889	C19H15NO2	Investigative
M6APDG02301	I-BET151	GSK1210151A	52912189	C23H21N5O3	Investigative
M6APDG03017	G1T38	"YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4"	86269224	C26H34N8O	Phase 2
M6APDG01628	(O10eq)-Benzyloxycarbonyl-beta-alanylryanodine	CHEMBL435162; (O10eq)-Benzyloxycarbonyl-beta-alanylryanodine	44275861	C36H46N2O12	Investigative
M6APDG01953	L-751250	Purvalanol B; 212844-54-7; PURVALANOL; Purvalanol B(NG-95); (R)-2-chloro-4-((2-((1-hydroxy-3-methylbutan-2-yl)amino)-9-isopropyl-9H-purin-6-yl)amino)benzoic acid; (2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL; CHEMBL23254; CHEBI:49840; NG 95; NG-95; C20H25ClN6O3; 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid; J-502183; PVB	448991	C20H25ClN6O3	Preclinical
M6APDG04146	AC-201	.	.	.	Phase 2
M6APDG00697	2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one	.	135547083	C15H11N5O2	Investigative
M6APDG02109	4'-(Pyridin-4-ylmethyl)biphenyl-3-amine	CHEMBL1171987; SCHEMBL18770411; BDBM50322783	46901444	C18H16N2	Investigative
M6APDG03692	DM-204	"Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune"	.	.	Investigative
M6APDG03598	ISIS 113021	.	.	.	Investigative
M6APDG02495	GS-5745	.	56776542	C7H5BrFNO3	Phase 3
M6APDG00752	"4-(3,5-Dimethoxyphenethyl)benzenamine"	"4-(3,5-Dimethoxyphenethyl)benzenamine; CHEMBL1171818; SCHEMBL10384348"	14256034	C16H19NO2	Investigative
M6APDG00407	"C[RGDf-(S,R)-alpha-Dfm-F]"	"c[RGDf-(S,R)-alpha-Dfm-F]; CHEMBL379911"	11614485	C31H38F2N8O7	Investigative
M6APDG01819	C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2	CHEMBL267265; c[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2	44445085	C46H61N11O7	Investigative
M6APDG01705	Ac-YR[CEH(pF-dF)RWC]-NH2	CHEMBL407809; Ac-YR[CEH(pF-dF)RWC]-NH2	44400321	C60H78FN19O13S2	Investigative
M6APDG03662	MDP-01	"Peptabody-EGF (anticancer), Med Discovery"	.	.	Investigative
M6APDG04340	VPM-4-001	"Allogenic LNCaP cell vaccine (prostate tumor), Vakzine Projekt Management; Cell vaccine (prostate cancer), Vakzine Projekt Management; Allogenic LNCaP cells (IL-2, IFN-gamma), Vakzine Projekt Management"	.	.	Preclinical
M6APDG02066	4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one	CHEMBL1083665; 4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one	46867540	C17H11N3O3S	Investigative
M6APDG01614	(E)-10-Nitrohexadec-9-enoic Acid	CHEMBL564368; (E)-10-Nitrohexadec-9-enoic Acid; 10-nitropalmitoleic acid; E-10-nitropalmitoleic acid; SCHEMBL15633718; WZWPBDQYCAJWSX-FYWRMAATSA-N	44220887	C16H29NO4	Investigative
M6APDG01474	Ketoprofen	"Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid"	3825	C16H14O3	Approved
M6APDG02126	N-oxo-2-(phenylsulfonylamino)ethanamide	N-oxo-2-(phenylsulfonylamino)ethanamide; SCHEMBL20553203; 2-benzenesulfonamido-N-oxoacetamide; DB07922; N-oxo-N~2~-(phenylsulfonyl)glycinamide	46937108	C8H8N2O4S	Investigative
M6APDG00620	ANDROSTENEDONE	"androsta-1,4-diene-3,17-dione; Boldione; 1,4-Androstadiene-3,17-dione; 897-06-3; Androstadienedione; 1-Dehydroandrostenedione; NSC 49080; UNII-2166Q8568W; EINECS 212-977-2; ANDROSTA-1,4-DIEN-3,17-DIONE; CHEBI:40799; LUJVUUWNAPIQQI-QAGGRKNESA-N; Androstra-1,4-diene-3,17-dione; 2166Q8568W; (8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-dione; (8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione; ANB"	13472	C19H24O2	Investigative
M6APDG01571	"4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol"	"CHEMBL1240676; 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol; BDBM50326004"	43743432	C14H13N3O2	Investigative
M6APDG03523	AS-1708727	.	.	.	Investigative
M6APDG00826	N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide	CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355	15986510	C16H12N2O2	Investigative
M6APDG03249	RPR-101511	"RPR-101511; CHEMBL66643; 6,7-Dimethoxy-3-(3-thienyl)quinoline; 3-(3-Thienyl)-6,7-dimethoxyquinoline; 6,7-dimethoxy-3-thiophen-3-yl-quinoline; 146535-06-0; SCHEMBL8172666; ZINC8075; BDBM50039082"	9903563	C15H13NO2S	Investigative
M6APDG03425	Sitimagene ceradenovec	"Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark"	.	.	Discontinued in Phase 3
M6APDG01093	P-276	"CDK4 inhibitor (cancer), Nicholas Piramal; P-664-02; CDK4 inhibitor (iv, cancer), Piramal Life Sciences; CDK4 inhibitor(iv, cancer), NPIL Research & Development"	23643976	C21H20ClNO5	Phase 2
M6APDG04337	MEDI-543	"MEDI-EphA2; L/A Lm-MCMV vaccine, Cerus/MedImmune; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus/MedImmune; Live-attenuated Listeria monocytogenes (Lm)-based vaccine (CMV), Cerus/MedImmune"	.	.	Preclinical
M6APDG03386	Bavencio	.	.	.	Approved
M6APDG03616	DP-3590	"DP-4157; DP-4693; DP-4756; C-Met kinase inhibitors (solid tumor/metastatic cancer); C-Met kinase inhibitors (solid tumor/metastatic cancer), Deciphera"	.	.	Investigative
M6APDG03529	Andromustine	"GTx-200; SARM (hormone refractory prostate cancer), GTx; Selective androgen receptor modulator (hormone refractory prostate cancer), GTx; Selective androgen receptor modulator (hormone refractory prostate cancer), Merck & Co"	.	.	Investigative
M6APDG00839	1-[7-(triphenylmethoxy)heptyl]thymine	"1-[7-(triphenylmethoxy)heptyl]thymine; CHEMBL219367; 921587-94-2; CTK3G1843; DTXSID20582671; BDBM50200997; 5-Methyl-1-[7-(triphenylmethoxy)heptyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[7-(triphenylmethoxy)heptyl]-"	16098874	C31H34N2O3	Investigative
M6APDG00693	DR2313	.	135522417	C8H10N2OS	Investigative
M6APDG04010	Anti-PD-L1 CSR T cells	.	.	.	Phase 1
M6APDG01468	"2-Propanol, Isopropanol"	"Isopropyl alcohol; isopropanol; 2-Propanol; Propan-2-ol; 67-63-0; 2-Hydroxypropane; Hartosol; Avantine; Alkolave; Dimethylcarbinol; sec-Propyl alcohol; Takineocol; Petrohol; Alcojel; Avantin; i-Propanol; 1-Methylethanol; 2-Propyl alcohol; Propol; Lutosol; Isohol; Alcolo; Lavacol; Alcosolve 2; Imsol A; 1-Methylethyl alcohol; Arquad DMCB; Alcosolve; Spectrar; n-Propan-2-ol; i-Propylalkohol; Combi-schutz; i-Propyl alcohol; Isopropyl alcohol, rubbing; Iso-propylalkohol; Alcool isopropilico; Visco 1152; Alcool isopropylique; Sterisol hand; Isopropyl Alcohol"	3776	C3H8O	Investigative
M6APDG00031	6-Methoxy-3-thiophen-3-yl-quinoline	CHEMBL303184; 6-methoxy-3-thiophen-3-yl-quinoline; ZINC3832230	10083051	C14H11NOS	Investigative
M6APDG02494	Alpelisib	"alpelisib; 1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide"	56649450	C19H22F3N5O2S	Approved
M6APDG02407	"2,5-Dimethoxy-4'-amino-trans-stilbene"	"BRN 2855929; 4-(2,5-Dimethoxy)stilbenamine; 4'-Stilbenamine, 2,5-dimethoxy-; 4-(2,5-Dimethoxyphenethyl)aniline; 2,5-Dimethoxy-4'-aminostilbene(trans); 4'-AMINO-2,5-DIMETHOXY STILBENE; CHEMBL1173699; 4-(2-(2,5-Dimethoxyphenyl)ethyl)benzenamine; Stilbenamine, 2',5'-dimethoxy-; 2',5'-Dimethoxy-4-stilbenamine; 23435-31-6; 4-[(E)-2-(2,5-Dimethoxyphenyl)ethenyl]aniline; 32180-65-7; 4-[2-(2,5-dimethoxyphenyl)vinyl]aniline; 4-[2-(2,5-dimethoxyphenyl)ethenyl]aniline; 2,5-Dimethoxy-4'-aminostilbene; 5803-51-0; DMBAS; AC1NTB1S"	5377410	C16H17NO2	Investigative
M6APDG00432	C[-Arg-Gly-Asp-Acpca20-]	CHEMBL540618	11656381	C18H29N7O8	Investigative
M6APDG00189	10-hydroxy-18-methoxybetaenone	CHEMBL498247; 10-hydroxy-18-methoxybetaenone; BDBM50269144	10644450	C22H36O6	Investigative
M6APDG00919	L-767679	"L-767679; CHEMBL57886; L 767679; AC1L42P7; BDBM50054538; 182198-53-4; 3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid(L-767679); (S)-3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid; (3S)-3-[[2-(1-oxo-7-piperazin-1-yl-3,4-dihydroisoquinolin-2-yl)acetyl]amino]pent-4-ynoic acid; 4-Pentynoic acid, 3-(((3,4-dihydro-1-oxo-7-(1-piperazinyl)-2(1H)-isoquinolinyl)acetyl)amino)-, (3S)-"	177364	C20H24N4O4	Investigative
M6APDG01118	NSC-158324	"Acediasulfone; UNII-30YP2YHH8W; 80-03-5; 30YP2YHH8W; CHEMBL48396; N-[4-[(4-AMINOPHENYL)SULPHONYL]PHENYL]GLYCINE; 2-[4-(4-aminophenyl)sulfonylanilino]acetic acid; Acediasulfonum; N-(4-((4-Aminophenyl)sulphonyl)phenyl)glycine; NSC-158324; EINECS 201-243-7; AC1L25EF; ZINC862; SCHEMBL143660; CTK5E7379; DTXSID00229991; CHEBI:135300; BDBM50099670; AKOS027327086; DB08926; Glycine,N-[4-[(4-aminophenyl)sulfonyl]phenyl]-; {4-[(4-aminophenyl)sulfonyl]anilino}acetic acid; 2-(4-(4-aminophenylsulfonyl)phenylamino)acetic acid"	24193827	C14H15ClN2O4S	Investigative
M6APDG00418	CH-4933468	"CH-5137291; Androgen receptor antagonists (oral, prostate tumor); Androgen receptor antagonists (oral, prostate tumor), Chugai"	11632731	C15H17ClN4O3S2	Investigative
M6APDG03713	ISIS 133243	.	.	.	Investigative
M6APDG03728	ISIS 29154	.	.	.	Investigative
M6APDG01094	2-Imidazol-1-yl-7-methoxy-3-phenyl-chromen-4-one	CHEMBL192306; azole isoflavone analog 2a; BDBM9891; 2-(1H-imidazol-1-yl)-7-methoxy-3-phenyl-4H-chromen-4-one; 2-(1H-Imidazol-1-yl)-7-methoxy-3-phenyl-4H-1-benzopyran4-one; 2-(1h-imidazol-1-yl)-7-methoxy-3-phenyl-4h-1-benzo pyran-4-one	23644623	C19H14N2O3	Investigative
M6APDG02645	ML-3403	p38 MAP Kinase Inhibitor III; ML3403; 549505-65-9; ML 3403; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-N-(1-phenylethyl)pyridin-2-amine; CHEMBL111364; (RS)-{4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]pyridin-2-yl}-(1-phenylethyl)amine]; K00568a; AC1O4WCF; SCHEMBL2896072; GTPL6014; ml-3043; SCHEMBL15013352; MolPort-023-278-904; HMS3229M04; {4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine	6419739	C23H21FN4S	Investigative
M6APDG03393	DRF 10945	.	.	.	Discontinued in Phase 1
M6APDG04164	ABI-009	.	.	.	Phase 2
M6APDG03436	FSHR NAM	ADX-68692; ADX-68693	.	.	Investigative
M6APDG01198	MK-2206	"MK-2206; 1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;"	24964624	C25H21N5O	Phase 2
M6APDG03772	ISIS 32010	.	.	.	Investigative
M6APDG01566	PNU-142372	"PNU-142372; 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE; CHEMBL290140; 1usn; IN9; AC1N9ZM3; BDBM50076341; DB07988; 2,3,4,5,6-pentafluoro-N-methyl-Nalpha-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]-L-phenylalaninamide; (2S)-N-methyl-3-(pentafluorophenyl)-2-{[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]amino}propanamide; (2S)-N-methyl-3-(2,3,4,5,6-pentafluorophenyl)-2-[(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)carbamoylamino]propanamide"	4369080	C13H10F5N5O2S2	Investigative
M6APDG00088	2-(4-hydroxyphenyl)-7-methoxychroman-4-one	"Methyl-liquiritigenin; CHEMBL402970; 4'-hydroxy-7-methoxyflavanone; 32274-71-8; 7-Methylliquiritigenin; CTK1B9324; DTXSID80437613; LMPK12140062; BDBM50374257; AKOS030552775; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-(4-hydroxyphenyl)-7-methoxy-"	10265122	C16H14O4	Investigative
M6APDG03205	Broussoflavonol F	Broussoflavonol F; CHEMBL464007; 162558-94-3; Biooussoflavonol F; SCHEMBL6822778; MolPort-039-338-587; ZINC14727564; LMPK12111986	9866908	C25H26O6	Investigative
M6APDG02842	IK-862	YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic;  IK862; IK 862; compound 32; IK-682	6914621	C25H27N3O4	Investigative
M6APDG02094	N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide	CHEMBL1095412; BDBM50317998	46887379	C20H18N2O2	Investigative
M6APDG01729	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL200958	44406548	C16H13BrN2O3	Investigative
M6APDG03416	AVE-0847	"PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis"	.	.	Discontinued in Phase 2
M6APDG03716	ISIS 17152	.	.	.	Investigative
M6APDG03174	CG-100649	"Polmacoxib; 301692-76-2; UNII-IJ34D6YPAO; CG100649; IJ34D6YPAO; 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide; 4-[3-(3-Fluorophenyl)-5,5-Dimethyl-4-Oxidanylidene-Furan-2-Yl]benzenesulfonamide; 4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide; Polmacoxib [USAN:INN]; CG-100649; Acelex (S. Korea); CG 100649; Polmacoxib (USAN/INN); SCHEMBL3233093; CHEMBL166863; GTPL8316; EX-A601; IJWPAFMIFNSIGD-UHFFFAOYSA-N; ZINC589683; BCP15550; AKOS025149767; SB17177; DB12399"	9841854	C18H16FNO4S	Phase 3
M6APDG03198	Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	"2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893"	9860529	C17H15NO3	Investigative
M6APDG02637	4-(2-nitrovinyl)phenol	"4-(2-nitrovinyl)phenol; 3179-08-6; 4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-"	638437	C8H7NO3	Investigative
M6APDG02433	3-phenyl-4-hydroxyquinolin-2(1H)-one	"14933-29-0; 3-Phenyl-2,4-quinolinediol; 3-phenyl-4-hydroxyquinolin-2(1H)-one; 2,4-Dihydroxy-3-phenylquinoline; NSC16582; UNII-98SFL4LU2U; 98SFL4LU2U; 3-phenylquinoline-2,4-diol; CHEMBL324519; 4-hydroxy-3-phenylquinolin-2(1H)-one; 4-Hydroxy-3-phenyl-1H-quinolin-2-one; 2,4-quinolinediol, 3-phenyl-; NSC 16582; Maybridge1_005460; AC1L5EN7; Oprea1_589873; MLS000850648; DivK1c_001748; SCHEMBL625364; AC1Q6B83; HMS557A04; CTK4C6143; DTXSID90164221; MolPort-002-043-580; MolPort-000-808-473; HMS2269O16; NSC-16582; BDBM50001260; STK587488"	54677756	C15H11NO2	Investigative
M6APDG03757	ISIS 101996	.	.	.	Investigative
M6APDG00489	2-Amino-6-Chloropyrazine	"2-AMINO-6-CHLOROPYRAZINE; 33332-28-4; 6-chloropyrazin-2-amine; 2-chloro-6-aminopyrazine; Pyrazinamine, 6-chloro-; 2-Pyrazinamine, 6-chloro-; 6-Chloro-pyrazin-2-ylamine; 6-chloropyrazin-2-ylamine; 2-amino-6-chloro-pyrazine; CHEMBL191632; 6-CHLORO-2-PYRAZINAMINE; CIG; 6-chlorpyrazin-2-amin; 1wcc; PubChem8543; zlchem 1337; AI3-61778; AC1Q3PRB; AC1L3MZH; ACMC-209i0e; 6-chloropyrazine-2-ylamine; SCHEMBL67803; 6-chloro-pyrazin-2-yl-amine; 6-chloropyrazin-2-amine, 5; KSC222G6J; AC1Q52Q1; Jsp006119; DTXSID0067761; CTK1C2364; BDBM24626; ZLE0115"	118458	C4H4ClN3	Investigative
M6APDG04120	OMS405	.	.	.	Phase 2
M6APDG00198	4-[2-(4-Phenyl-butylamino)-ethyl]-phenol	CHEMBL118969; 4-[2-(4-Phenyl-butylamino)-ethyl]-phenol; SCHEMBL7379499; ZINC13781000; BDBM50066539	10707108	C18H23NO	Investigative
M6APDG01025	Anastrozole	"Anastrazole; Anastrole; Anastrozol; Arimidex; Asiolex; Astra brand of anastrozole; AstraZeneca brand of anastrozole; Zeneca brand of anastrozole; ZD 1033; ZD1033; Zeneca ZD 1033; Arimidex (TN); Arimidex (Zeneca); Arimidex, Anastrozole; ZD-1033; Anastrozole [USAN:INN:BAN]; Anastrozole (JAN/USAN/INN); Alpha,alpha,alpha',alpha'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; Alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 1,3-benzenediacetonitrile, a, a,a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl); 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile); 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile"	2187	C17H19N5	Approved
M6APDG03114	SB 235699	"4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; VK-19911; CHEMBL279416; UNII-NP7J08ZRYY; NP7J08ZRYY; 180869-32-3; SCHEMBL140202; HEP 689; sb235699; BDBM50099331; SB-235699; 4-(5-(4-Fluorophenyl)-3-(4-piperidyl)imidazol-4-yl)pyridine; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; Pyridine, 4-(4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl)-"	9797240	C19H19FN4	Discontinued in Phase 1
M6APDG03272	A-620223	"A-866111; A-966492; ABT-472; ABT-999; PARP inhibitor, Abbott; PARP inhibitors, Abbott; Poly (ADP)ribose polymer inhibitor, Abbott; Poly (ADP)ribose inhibitors (cancer), Abbott"	9925908	C16H22N4O	Investigative
M6APDG02997	benzylserine	O-benzyl-L-serine	78457	C10H13NO3	Investigative
M6APDG03238	Imiglitazar	TAK-559	9890879	C28H26N2O5	Phase 3
M6APDG04118	YSIL6	.	.	.	Phase 2
M6APDG01654	"6,7-Dimethoxy-4-m-tolyloxy-quinoline"	"CHEMBL98839; 6,7-Dimethoxy-4-m-tolyloxy-quinoline; SCHEMBL19373176"	44331325	C18H17NO3	Investigative
M6APDG02522	JNK-IN-8	JNK-IN-8; 1410880-22-6; JNK Inhibitor XVI; 3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[3-methyl-4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; JNK-IN8; GTPL8058; CHEMBL2216824; SCHEMBL14979761; BDBM86633; DTXSID40720937; CHEBI:124918; MolPort-035-395-752; EX-A2206; BCP09744; ZINC89464842; s4901; AKOS030526496; SB19427; CS-0601; NCGC00386243-05; HY-13319; BC600656; Y1469; SW219193-1; W-5897; J-007458; 3-{[(2E)-4-(Dimethylamino)but-2-enoyl]amino}-N-(3-methyl-4-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide	57340686	C29H29N7O2	Investigative
M6APDG03963	ONO-7475	.	.	.	Phase 1
M6APDG00524	BEZ235	"BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile"	11977753	C30H23N5O	Phase 2
M6APDG01878	4-(isopentylthio)-2-(trifluoromethyl)benzonitrile	CHEMBL503687; 4-(isopentylthio)-2-(trifluoromethyl)benzonitrile	44564659	C13H14F3NS	Investigative
M6APDG04152	JT02	.	.	.	Phase 2
M6APDG00024	(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate	CHEMBL117658; 1-(PHENYLMETHYL)CYCLOPENTYL[(1S)-1-FORMYLPENTYL]CARBAMATE; 2auz; (S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate; BDBM50148292; DB07593; 1-benzylcyclopentyl [(1S)-1-formylpentyl]carbamate; 1-benzylcyclopentyl N-[(2S)-1-oxohexan-2-yl]carbamate; ((S)-1-Formyl-pentyl)-carbamic acid 1-benzyl-cyclopentyl ester	10062714	C19H27NO3	Investigative
M6APDG01352	NSC-625987	NSC 625987	3004085	C15H13NO2S	Investigative
M6APDG01738	C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2	CHEMBL381739; c[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2	44408408	C42H57N11O7	Investigative
M6APDG02214	Oxindole 94	"SB 202190; 152121-30-7; SB202190; SB-202190; FHPI; SB202190 (FHPI); UNII-PVX798P8GI; 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole; CHEBI:79090; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole; PVX798P8GI; SB 202190, Immobilized; C20H14FN3O; Phenol, 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-; 4-[4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]phenol; 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-yl]phenol"	5169	C20H14FN3O	Investigative
M6APDG01008	5-Nitroindazole	"5-Nitro-1H-indazole; 5401-94-5; 1H-INDAZOLE, 5-NITRO-; UNII-235Y7P37ZD; CCRIS 4134; NSC 5032; EINECS 226-451-5; BRN 0007936; CHEMBL165372; WSGURAYTCUVDQL-UHFFFAOYSA-N; 235Y7P37ZD; MFCD00005693; 5NI; 2H-Indazole, 5-nitro-; 5-Nitroindazol; 5-nitro indazole; 5-nitro-indazole; 5-nitro-1H-indazol; 5-nitro-IH-indazole; 5-nitro-2H-indazole; PubChem15672; 4lm0; AC1L2IGS; ACMC-209lc9; DSSTox_RID_83391; DSSTox_CID_29272; 5-Nitroindazole, &gt; DSSTox_GSID_49316; KSC490O7N; 5-Nitro-1H-indazole 99%; MLS000728712; 5-23-06-00180 (B"	21501	C7H5N3O2	Investigative
M6APDG03413	CRx-191	.	.	.	Discontinued in Phase 2
M6APDG03799	PU-AD	.	.	.	Phase 1
M6APDG03774	ISIS 32015	.	.	.	Investigative
M6APDG02707	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid	CHEMBL448246; 3-(4-Hexyloxy-phenyl)-succinamic acid; AC1LCKXS; SMR000008837; MLS000073581; 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid; cid_651854; HMS2162F22; HMS3313H20; BDBM50247490; AKOS000505159; AKOS030483668; BAS 00404306; 4-amino-3-(4-hexoxyphenyl)-4-oxobutanoic acid; SR-01000514729	651854	C16H23NO4	Investigative
M6APDG01577	L-2-Amino-4-(Guanidinooxy)Butyric Acid	"L-canavanine; canavanine; Canavanin; 543-38-4; 2-Amino-4-(guanidinooxy)butyric acid; L-2-AMINO-4-(GUANIDINOOXY)BUTYRIC ACID; UNII-3HZV514J4B; O-((Aminoiminomethyl)amino)-L-homoserine; O-carbamimidamido-L-homoserine; 3HZV514J4B; CHEMBL443732; CHEBI:609827; (L)-CANAVANINE; O-((Aminoiminomethyl)amino)homoserine; GGB; HSDB 3471; AI3-52153; L-Homoserine, O-((aminoiminomethyl)amino)-; Butyric acid, 2-amino-4-(guanidinooxy)-, L-; C5H12N4O3; L(+)-Canavanine; Tocris-0673; Spectrum_001137; Spectrum3_001206; Spectrum2_000800"	439202	C5H12N4O3	Investigative
M6APDG01113	Bicalutamide	"Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide"	2375	C18H14F4N2O4S	Approved
M6APDG01826	1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene	CHEMBL265444	44452471	C13H10N2O2S	Investigative
M6APDG01194	"8alpha,19-dihydroxylabd-13 E-en-15-oic acid"	"CHEBI:65789; (2E)-5-[(1R,2R,4aR,5R,8aS)-2-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyldecahydronaphthalen-1-yl]-3-methylpent-2-enoic acid; CHEMBL507405; 8alpha-19-dihydroxylabd-13E-ene-15-oic acid; 8alpha,19-dihydroxylabd-13E-ene-15-oic acid; (13E)-8,18-Dihydroxylabda-13-ene-15-oic acid"	24899923	C20H34O4	Investigative
M6APDG00191	8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one	CHEMBL351167; 8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one; BDBM50097362; 8-((1H-imidazol-1-yl)methyl)-5-nitro-4H-chromen-4-one	10659706	C13H9N3O4	Investigative
M6APDG00109	7-Methoxy-3-thiophen-3-yl-quinoline	CHEMBL68185; 7-methoxy-3-thiophen-3-yl-quinoline; SCHEMBL8500071; ZINC8076	10331922	C14H11NOS	Investigative
M6APDG03504	ISIS 11158	.	.	.	Investigative
M6APDG02716	3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 5a; SCHEMBL4220971; AC1O704D; CHEMBL193997; BDBM8586; SCHEMBL4220959; ZINC13610768; 3-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539763	C15H12FN	Investigative
M6APDG03218	Zotarolimus	Abt-578; Zotarolimus (TN)	9876378	C52H79N5O12	Approved
M6APDG01996	Apogossypol	BI-79D10; BI-97C1; CNDO-103; CNDO-133	454878	C28H30O6	Investigative
M6APDG01364	PRINOMIDE TROMETHAMINE	3-(1-Methylpyrrol-2-yl)-3-oxo-2-(N-phenylcarbamoyl)propionitrile tromethamine salt	3033812	C19H24N4O5	Discontinued in Phase 3
M6APDG02380	PF-956980	"Janus kinase 3 inhibitors (inflammation); JAK3 inhibitors (inflammation), Pfizer; Janus kinase 3 inhibitors (inflammation), Pfizer"	53344620	C18H26N6O	Investigative
M6APDG00875	Cysteine Sulfenic Acid	"S-Hydroxycysteine; s-hydroxy-l-cysteine; Cysteinesulfenic acid; Cys-sulfenic acid; L-cysteinesulfenic acid; UNII-FB8KIA847T; L-Cysteinsulfensaeure; Alanine, 3-sulfeno-; Cys(OH); FB8KIA847T; L-2-amino-3-sulfeno-propionic acid; 5722-80-5; 2-amino-3-hydroxysulfanylpropionic acid; Cysteine-sulfenic acid; L-Alanine, 3-sulfeno-; S-(Propylcarbamoyl)cysteine; AC1Q5QNT; AC1L4WIO; SCHEMBL333356; CHEBI:41710; CTK1H0247; AKOS006339917; DB01915; L-Cysteine, S-[(propylamino)carbonyl]-; 73243-12-6"	165339	C3H7NO3S	Investigative
M6APDG02841	CN-105	"5-Nitroisoquinoline; 607-32-9; Isoquinoline, 5-nitro-; 5-Nitro-isoquinoline; MLS002637661; PYGMPFQCCWBTJQ-UHFFFAOYSA-N; 5-nitroisochinolin; EINECS 210-133-8; 5-nitro isoquinoline; PubChem6272; AI3-61887; Maybridge1_001820; ACMC-1AV1Q; AC1Q1X2S; 5-Nitroisoquinoline, 98%; Oprea1_032003; SCHEMBL1010663; AC1Q201M; AC1L2B31; CHEMBL353253; PYGMPFQCCWBTJQ-UHFFFAOYSA-; KS-00000DJC; CTK2F2846; ZINC93213; HMS546K16; DTXSID00209511; NSC3017; MolPort-001-761-771; HMS3078A13; ACT09900; ALBB-021274; NSC-3017; ANW-33564; SBB066313; MFCD00006905"	69085	C9H6N2O2	Phase 2
M6APDG00716	Indirubin-3-methoxime	.	136043836	C17H13N3O2	Investigative
M6APDG02108	3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile	CHEMBL1210236; 3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile; BDBM50322829	46894038	C18H12N6	Investigative
M6APDG00188	"Isoquinoline-1,3,4(2H)-trione"	"Phthalonimide; 1,3,4(2H)-Isoquinolinetrione; isoquinoline-1,3,4(2H)-trione; 521-73-3; isoquinoline-1,3,4-trione; 1,3,4-(2H)ISOQUINOLINETRIONE; UNII-BM68CV5X6Q; NSC 407248; BRN 0383773; BM68CV5X6Q; 1,2,3,4-tetrahydroisoquinoline-1,3,4-trione; isoquinoline-1,3,4-(2H)-trione; 3deh; NSC407248; AC1L1VMV; 5-21-11-00575 (Beilstein Handbook Reference); 1,4(2H)-Isoquinolinetrione; SCHEMBL1122624; Isoquinoline-1,3,4-trione 1; CHEMBL206435; CTK1H0848; BDBM10247; DTXSID40200103; ZINC1599708; FCH844329; ACM521733; AKOS006276226; NSC-407248"	10640	C9H5NO3	Investigative
M6APDG01768	C(his-L-phe-arg-trp-Aoc)	CHEMBL211131	44413592	C40H53N11O5	Investigative
M6APDG04194	Interferon beta 1a	Aerosolised interferon beta 1a; AZD-9412; Inhaled interferon beta 1a; SNG-001	.	.	Phase 2
M6APDG04144	ALT-801	"ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor"	.	.	Phase 2
M6APDG00195	4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol	CHEMBL327075; 4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol; SCHEMBL7374092; BDBM50066540; ZINC13781001	10685438	C20H27NO	Investigative
M6APDG01694	N-(5-Amino-6-oxo-heptyl)-acetamidine	.	44393463	C9H19N3O	Investigative
M6APDG03090	5-Methoxyflavone	"5-Methoxyflavone; 42079-78-7; 5-methoxy-2-phenyl-4h-chromen-4-one; 5-methoxy-2-phenylchromen-4-one; 5-Methoxy-2-phenyl-4-benzopyrone; CHEMBL16685; 4H-1-Benzopyran-4-one, 5-methoxy-2-phenyl-; 5-Methoxy-2-phenyl-chromen-4-one; MFCD00016942; ST069360; EINECS 255-652-0; 5 - Methoxyflavone; ACMC-20am2h; AC1Q6AKD; AC1L3SE9; Oprea1_859852; Oprea1_842256; BIDD:ER0473; ghl.PD_Mitscher_leg0.1155; ZINC5954; MEGxp0_001704; SCHEMBL1629391; ACon1_000175; DTXSID40194917; XRQSPUXANRGDAV-UHFFFAOYSA-N; MolPort-001-742-472; KS-000014KU; BDBM50296862"	94525	C16H12O3	Investigative
M6APDG04107	S-222611	.	.	.	Phase 1b
M6APDG00169	paxilline	"4b-Hydroxy-2-(1-hydroxy-1-methylethyl)-12b,12c-dimethyl-5,6,6a,7,12,12b,12c,13,14,14a-decahydro-2H-chromeno[5',6':6,7]indeno[1,2-b]indol-3(4bH)-one; paxillin; AC1L1IR1; GTPL2309; BDBM86263; CTK7H1286; ACNHBCIZLNNLRS-UHFFFAOYSA-N; NCGC00168476-01; CAS_57186-25-1; hydroxy-(1-hydroxy-1-methyl-ethyl)-dimethyl-[ ]one; 4b-Hydroxy-2-(1-hydroxy-1-methylethyl)-12b,12c-dimethyl-5,6,6a,7,12,12b,12c,13,14,14a-decahydro-2H-chromeno[5',6':6,7]indeno[1,2-b]indol-3(4bh)-one #"	105008	C27H33NO4	Investigative
M6APDG01225	WAY-214950	WAY-214950; SCHEMBL1407572; JMC517161 Compound 13; CHEMBL457977; BDBM26067	25113722	C21H13F5N2	Investigative
M6APDG03356	Interferon beta-1a	Avonex; Avonex (TN); Cinnovex (TN); Interferon beta-1a (USAN); Interferon beta-1a (genetical recombination); Interferon beta-1a (genetical recombination) (JAN); Rebif (TN)	.	.	Approved
M6APDG04372	OX-30	"Opioid (oral controlled-release, pain), Orexo"	.	.	Terminated
M6APDG02733	3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine	"AC1O705J; SCHEMBL4231098; SCHEMBL4231088; CHEMBL176287; BDBM8608; (3-Pyridylmethylene)indane 25a; 3-[(E)-(4-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539784	C15H12ClN	Investigative
M6APDG00252	YM-175735	"YM-175735; CHEMBL202990; BDBM18634; (2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-N-(2,4-difluorophenyl)-2,5-dimethylpiperazine-1-carboxamide"	11178122	C21H19F5N4O	Investigative
M6APDG02081	AdoC(beta-Ala)Arg6	CHEMBL611122	46877397	C49H88N30O12	Investigative
M6APDG02071	1-(4-nitro-2-phenoxybenzyl)-1H-imidazole	CHEMBL1083653; 1-(4-nitro-2-phenoxybenzyl)-1H-imidazole	46867546	C16H13N3O3	Investigative
M6APDG04215	P54	.	.	.	Phase 2
M6APDG00158	MP-0112	"DARPin (age related macular degeneration), Molecular Partners/Allergan; VEGF-A specific DARPin, Molecular Partners/Allergan"	10464700	C7H8N2O3	Phase 1
M6APDG04113	IMD-1041	"IMD-1041 (oral, COPD/interstitial cystis/type 2 diabetics/chronic inflammatory disease/metabolic syndrome/AD), IMMD"	.	.	Phase 2
M6APDG00363	5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide	CHEMBL84288	11528707	C11H14ClNO2	Investigative
M6APDG04204	INGN-225	"Cancer vaccine (p53), Introgen"	.	.	Phase 2
M6APDG02041	2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline	CHEMBL598330; 2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline	46232132	C22H17NO2S	Investigative
M6APDG04339	111In-hEGF	"Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto"	.	.	Preclinical
M6APDG00615	CGS-18320B	"Cgs-18320B; CHEMBL29482; AC1L33QO; SCHEMBL1507825; ZINC3775824; CGS-18320; BDBM50047260; 4,4''-((1H-imidazol-1-yl)methylene)dibenzonitrile; 4-[4-cyanophenyl(1H-1-imidazolyl)methyl]benzonitrile; 4-[(4-cyanophenyl)-imidazol-1-ylmethyl]benzonitrile"	133966	C18H12N4	Investigative
M6APDG03125	"8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione"	"CHEMBL93798; 8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione; 1H-1-Benzazepine-2,5-dione, 8-chloro-3-hydroxy-; SCHEMBL7350621; PUWRZSGQAPPNEC-UHFFFAOYSA-N; BDBM50054631; 144066-23-9; 3-Hydroxy-8-chloro-1H-1-benzazepine-2,5-dione; 8-chloro-3-hydroxy-2,5-dihydro-1h-benzazepine-2,5-dione"	9815930	C10H6ClNO3	Investigative
M6APDG03684	VER-54505	"Cdk2 inhibitors, Vernalis; RBT-0049985"	.	.	Investigative
M6APDG03511	ALM-301	"Akt inhibitors (cancer), Almac"	.	.	Investigative
M6APDG04354	CS-204	"CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience"	.	.	Terminated
M6APDG03661	mabionHER2	"Humanized monoclonal antibody (breast cancer), Mabion"	.	.	Investigative
M6APDG03313	C[RGD-(S)-alpha-TfmfV]	CHEMBL379056; c[RGD-(S)-alpha-TfmfV]	9986643	C27H37F3N8O7	Investigative
M6APDG02097	"9-Hydroxy-7,8-benzoflavone"	"CHEMBL1097042; 9-Hydroxy-7,8-benzoflavone"	46887421	C19H12O3	Investigative
M6APDG01296	Heme	"heme; protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin"	26945	C34H32FeN4O4	Investigative
M6APDG00287	Tideglusib	NP-031112; NP-12; NP031112; Tideglusib(NP-031112)	11313622	C19H14N2O2S	Phase 2
M6APDG00398	4-amino-biphenyl-3-carboxylic acid amide	"CHEMBL207940; 5-phenylanthranilamide; 2-amino-5-phenylbenzamide; SCHEMBL3781950; Amino-substituted benzamide, 8c; BDBM27462; ZINC13686738"	11600944	C13H12N2O	Investigative
M6APDG02199	GDC-0032	"Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N"	51001932	C24H28N8O2	Phase 3
M6APDG00480	Avapritinib	"1703793-34-3; UNII-513P80B4YJ; 513P80B4YJ; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; Avapritinib [INN]; BLU-285 (Avapritinib); SCHEMBL16652297; EX-A1366; BCP20175; CS-7577; ACN-051245; HY-101561; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine"	118023034	C26H27FN10	Approved
M6APDG00685	Para-sirtinol	.	135491748	C26H22N2O2	Investigative
M6APDG03067	Cypate-[(RGD)3-NH2]2	.	91936296	C112H161N40O32+	Investigative
M6APDG01416	GTP-14564	"GTP-14564; GTP 14564; 34823-86-4; 3-Phenyl-1H-benzofuro[3,2-c]pyrazole; 1-Phenyl-3-H-8-oxa-2,3-diaza-cyclopenta[a]inden; CHEMBL406375; 3-phenyl-1H-[1]benzofuro[3,2-c]pyrazole; 3-Phenyl-1H-benzofuro(3,2-c)pyrazole; AC1MPHAI; SCHEMBL2550165; GTPL5982; CHEBI:92300; DTXSID10188363; MolPort-002-816-012; HMS3268J15; HMS3229E17; ZINC5387628; HSCI1_000176; BDBM50375646; AKOS024456938; MCULE-3563628731; CCG-206757; NCGC00159539-01; AI-204/33265070; J-019773; BRD-K16664969-001-02-5; BRD-K16664969-001-01-7"	3385203	C15H10N2O	Investigative
M6APDG03902	Recombinant human Erbb3 fragment therapeutic tumor vaccine	"Fragment therapeutic tumor vaccine; Recombinant human Erbb3 fragment therapeutic tumor vaccine (injectable, Erbb2-overexpressing cancer)"	.	.	Phase 1
M6APDG03991	PF-06427878	.	.	.	Phase 1
M6APDG00179	5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one	CHEMBL161530; 5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one; BDBM50097371; 8-((1H-imidazol-1-yl)methyl)-5-bromo-4H-chromen-4-one	10566470	C13H9BrN2O2	Investigative
M6APDG02119	ML315	"ML315; CHEMBL1885748; 1440251-53-5; MLS004256649; GTPL8162; KUC107550N; BDBM50435474; ML 315; AKOS032952995; KSC-14-101; NCGC00241342-01; NCGC00241342-02; SMR003081704; BRD-K98168317-001-01-9; 5-(benzo[d][1,3]dioxol-5-yl)-N-(3,5-dichlorobenzyl)pyrimidin-4-amine"	46926514	C18H13Cl2N3O2	Investigative
M6APDG03366	Emapalumab	emapalumab; Emapalumab [INN]; Emapalumab [USAN:INN]; UNII-3S252O2Z4X; 3S252O2Z4X	.	.	Approved
M6APDG03605	ISIS 6443	.	.	.	Investigative
M6APDG01836	OCOPHYLLALS A	Ocophyllals A; CHEMBL571616; BDBM50303152	44470605	C18H14O5	Investigative
M6APDG02177	Fluoro loxoprofen	fluoro loxoprofen	49837499	C15H16FNaO3	Investigative
M6APDG01259	3-Ethylquinoline-8-carboxamide	"CHEMBL453989; 3-Ethylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-ethyl-; BDBM50255269"	25208904	C12H12N2O	Investigative
M6APDG00435	C-[-Arg-Gly-Asp-Acpca33-]	CHEMBL534712	11670104	C18H29N7O6	Investigative
M6APDG02306	(E)-2-(4-(methylsulfonyl)styryl)furan	CHEMBL1288742; (E)-2-(4-(methylsulfonyl)styryl)furan	52946891	C13H12O3S	Investigative
M6APDG00103	L-687414	"(3R,4R)-3-Amino-1-hydroxy-4-methylpyrrolidin-2-one; 130931-65-6; L-687414; CHEMBL283819; 132619-43-3; cis-3-amino-1-hydroxy-4-methylpyrrolidin-2-one; SCHEMBL561932; DTXSID00437953; SKYSFPFYQBZGDC-QWWZWVQMSA-N; ZINC3805040; BDBM50038169; AKOS006239328; KB-78073; AJ-45657; 3-Amino-1-hydroxy-4-methyl-pyrrolidin-2-one; r(+)-cis-beta-methyl-3-amino-1-hydroxypyrrolid-2-one"	10313147	C5H10N2O2	Terminated
M6APDG02597	[3H]cAMP	"Cyclic AMP; cAMP; 60-92-4; Adenosine 3',5'-cyclic monophosphate; 3',5'-cyclic AMP; Adenosine 3',5'-phosphate; Adenosine 3',5'-cyclophosphate; cyclic 3',5'-AMP; Adenosine cyclic monophosphate; cyclic 3',5'-Adenylic acid; Adenosine 3',5'-monophosphate; Adenosine-3',5'-cyclophosphate; Adenosine cyclophosphate; Cyclic Adenosine Monophosphate; cyclic Adenosine 3',5'-phosphate; Cyclic adenylic acid; Adenosine cyclic 3',5'-monophosphate; 3',5'-AMP; cyclic Adenosine 3',5'-monophosphate; Adenosine cyclic 3',5'-phosphate;  [3H]-cAMP"	6076	C10H12N5O6P	Investigative
M6APDG02965	DEHYDROLEUCODIN	"Dehydroleucodin; Dehydroleucodine; 36150-07-9; NSC 180034; CHEMBL441260; Azuleno(4,5-b)furan-2,7-dione, 3,3a,4,5,9a,9b-hexahydro-6,9-dimethyl-3-methylene-, (3aS-(3aalpha,9aalpha,9bbeta))-; Lidbeckialactone; Mesatlantin E; 11,13-Dehydroleucodin; AC1L2JV1; AC1Q69JZ; (3as,9as,9bs)-6,9-dimethyl-3-methylidene-3,3a,4,5,9a,9b-hexahydroazuleno[4,5-b]furan-2,7-dione; SCHEMBL4998391; CTK4H5993; ZINC5202250; Dehydroleucodine, &gt; BDBM50318392; NCGC00485131-01; LS-182153"	73440	C15H16O3	Investigative
M6APDG02848	NKS-01	"14alpha-Hydroxy-4-androstene-3,6,17-trione"	6918079	C19H24O4	Discontinued in Phase 2
M6APDG01884	4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile	CHEMBL462025; 4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile; BDBM50248593	44565202	C15H10F3NS	Investigative
M6APDG01484	Benzyl 4-aminobutyl(3-aminopropyl)carbamate	Benzyl 4-aminobutyl(3-aminopropyl)carbamate; CHEMBL418644; NSC685957; benzyl N-(4-aminobutyl)-N-(3-aminopropyl)carbamate; AC1L8YAY; SCHEMBL7535687; CTK8D1272; ZINC1650370; BDBM50184788; NSC-685957; NCI60_030939; benzyl(4-aminobutyl)(3-aminopropyl)carbamate; 3-Aminopropyl(4-aminobutyl)carbamic acid benzyl ester; (4-Amino-butyl)-(3-amino-propyl)-carbamic acid benzyl ester	389610	C15H25N3O2	Investigative
M6APDG01501	NU-6027	.	398148	C11H17N5O2	Investigative
M6APDG02020	Bemcentinib	"R428; 1037624-75-1; BGB324; R-428; BGB-324; UNII-0ICW2LX8AS; (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine; CHEMBL3809489; SYN1131; CS-1046; HY-15150; QC-11751; R 428; W-5845; Bemcentinib [USAN]; R428 (BGB324); Bemcentinib (USAN/INN); BemcentinibR428BGB324); SCHEMBL1639904; GTPL10478; BGB 324; DTXSID70673109; 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine; AMY16774; BCP21180; C30H34N8; EX-A1720; SYN-1131; BDBM50172079; NSC824183; s2841; WHO 10631; ZINC51951669; AKOS032947237; ACN-037541; DB12411; NSC-824183; SB16614; NCGC00386665-07; 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; AC-28444; AS-16270; KB-80319; D11438; Q27236818; BGB324; BGB-324; BGB 324; R 428; R-428; Bemcentinib; 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine"	46215462	C30H34N8	Phase 2
M6APDG02784	quinazoline deriv. 1	"Aurora Kinase Inhibitor II; quinazoline deriv 1; 331770-21-9; CHEMBL382590; -Benzamidoanilino)-6,7-dimethoxyquinazoline; N-{4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl}benzamide; N-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]benzamide; Anilinoquinazoline1; K00590a; CBiol_002061; 4-(4'-Benzamidoanilino)-6,7-dimethoxyquinazoline; GTPL5930; SCHEMBL1066538; AC1O7M16; CTK8E8821; BDBM12403; DTXSID00425012; MolPort-044-561-446; Bio1_000347; ZINC590935; HMS3229A17; Bio1_001325; Bio1_000836; IN1528; CCG-206735"	6610278	C23H20N4O3	Investigative
M6APDG02559	GDC-0349	MTORC1/2 inhibitors	59239165	C24H32N6O3	Phase 1
M6APDG01005	CIMICOXIB	Cimicoxib; 265114-23-6; UNII-W7FHJ107MC; UR-8880; W7FHJ107MC; CHEMBL435381; CHEBI:76127; 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide; 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzenesulfonamide; 4-(4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl)benzenesulfonamide; Cimicoxib [INN]; 4-(4-Chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl)benzenesulfonamide; AC1Q6UZ8; AC1L4U5V; SCHEMBL3123310; CTK4F8038; DTXSID30181093; KYXDNECMRLFQMZ-UHFFFAOYSA-N; BCP24933; ZINC1494105	213053	C16H13ClFN3O3S	Phase 2
M6APDG03200	MORACHALCONE A	"MORACHALCONE A; 76472-88-3; CHEMBL465880; SCHEMBL6818973; MolPort-035-705-759; BDBM50251013; LMPK12120119; ZINC14762498; W1241; 2,4,2'',4''-tetrahydroxy-3''-prenylchalcone; 2,2',4,4'-Tetrahydroxy-3'-(3-methyl-2-butenyl)chalcone"	9862769	C20H20O5	Investigative
M6APDG01889	AP-21967	CHEMBL525042; AP-21967; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin	44576241	C59H88N2O12	Investigative
M6APDG02979	N-(2-aminophenyl)benzamide	"N-(2-aminophenyl)benzamide; 2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046"	759408	C13H12N2O	Investigative
M6APDG03766	ISIS 32002	.	.	.	Investigative
M6APDG02555	"2-Methyl-1,2-dihydro-indazol-3-one"	"1848-40-4; 1,2-Dihydro-2-methyl-3H-indazol-3-one; 2-methyl-1H-indazol-3(2H)-one; 3H-Indazol-3-one, 1,2-dihydro-2-methyl-; CHEMBL3144583; FPNXGZRMUROVNY-UHFFFAOYSA-N; 2-methyl-1,2-dihydroindazol-3-one; 3-Indazolinone, 2-methyl-; 2-methyl-1H-indazol-3-one; 2-Methyl-1,2-dihydro-indazol-3-one; AC1LBX43; CHEMBL8364; SCHEMBL2673327; CTK0E2434; DTXSID30343553; MolPort-028-748-594; BDBM50009002; ZINC13820683; AKOS023543896; MB14910; CM10169; 2-Methyl-1,2-dihydro-3H-indazol-3-one #; 2-METHYL-2,3-DIHYDRO-1H-INDAZOL-3-ONE; INDAZOL-3-ONE, 1,"	590513	C8H8N2O	Investigative
M6APDG00171	"N,N'-Bis-(4-sec-butyl-phenyl)-guanidine"	"CHEMBL110909; CHEMBL320199; SCHEMBL4979578; BDBM50066057; 1,3-Bis(4-sec-butylphenyl)guanidine; AKOS030602595; N,N''-Bis-(4-sec-butyl-phenyl)-guanidine"	10526122	C21H29N3	Investigative
M6APDG03877	BCA101	.	.	.	Phase 1
M6APDG02721	3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 9b; BDBM8591; AC1O704N; CHEMBL176118; SCHEMBL4231365; 3-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539768	C15H12BrN	Investigative
M6APDG02415	Thalidomide	"Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide"	5426	C13H10N2O4	Approved
M6APDG02493	Roche 28-2653	.	56603788	C27H24N4O5	Investigative
M6APDG00885	Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2	CHEMBL194552; BDBM50268798	16724004	C53H66N12O9	Investigative
M6APDG01123	BPIQ-I	"bpiq-i; 174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1"	2427	C16H12BrN5	Investigative
M6APDG00285	4-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one	"CHEMBL225178; 2H-1-Benzopyran-2-one, 4-[2-(1H-imidazol-1-yl)ethoxy]-; 828265-57-2; Coumarin deriv. 22; BDBM9473; CTK3D6006; DTXSID60462004"	11311402	C14H12N2O3	Investigative
M6APDG03394	Figitumumab	"AC1OCENC; (2R)-3-[(4S,6R,7R,10S)-4-[(E,2R)-4-[(2S,2'S,4R,4aS,6R,8aR)-4-hydroxy-2-[(1S,3S)-1-hydroxy-3-[(6S,9R,10S)-9-methyl-5,11-dioxaspiro[5.5]undecan-10-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-7-hydroxy-2-methyl-5,11-dioxaspiro[5.5]undec-1-en-10-yl]-2-hydroxy-2-methylpropanoic acid"	.	.	Discontinued in Phase 1
M6APDG02751	5-[5-Methoxy-indan-(1Z)-ylidenemethyl]-thiazole	"CHEMBL195354; BDBM8633; AC1O706T; (5-Thiazolemethylene)indane 27b; 5-{[(1Z)-5-methoxy-2,3-dihydro-1H-inden-1-ylidene]methyl}-1,3-thiazole"	6539807	C14H13NOS	Investigative
M6APDG00688	2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one	.	135508369	C16H21N3O	Investigative
M6APDG03754	ISIS 101986	.	.	.	Investigative
M6APDG00238	Ac-His-DPhe-Arg-Trp-NH2	"Ac-His-Phe-Arg-Trp-NH2; CHEMBL50056; Ac-His-Phe-Arg-Trp-NH(2); L-Tryptophanamide, N-acetyl-L-histidyl-L-phenylalanyl-L-arginyl-; Ac-His-D-Phe-Arg-D-Trp-NH2; CTK0D4815; 2-{2-[2-Acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid [1-carbamoyl-2-(1H-indol-3-yl)-ethyl]-amide; 110392-38-6; BDBM50034910; (S)-2-{(S)-2-[(S)-2-Acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid [(S)-1-carbamoyl-2-(1H-indol-3-yl)-ethyl]-amide"	11093672	C34H43N11O5	Investigative
M6APDG01140	CHLOROCYCLINONE D	CHLOROCYCLINONE D; CHEMBL400132; BDBM50228361	24762578	C23H15ClO7	Investigative
M6APDG00012	DMP-757	"CHEMBL65617; DMP-757; BDBM50285199; [(5S,11S,14S)-11-(3-Guanidino-propyl)-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1(20),17(21),18-trien-5-yl]-acetic acid"	10031011	C26H38N8O7	Terminated
M6APDG00187	"2-(2-hexylphenyl)isoindoline-1,3-dione"	CHEMBL245943; PP60; BDBM23841	10638446	C20H21NO2	Investigative
M6APDG01976	"1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine"	"1-(Phenylsulfonyl)-4-azaindole; 677302-44-2; CHEMBL556118; 1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine; SCHEMBL3705420; HGOGRVVSSAWHTO-UHFFFAOYSA-N; BDBM50295729; ZINC42923799; AKOS032961360; KB-3354225"	45270766	C13H10N2O2S	Investigative
M6APDG00150	BMS-599626	"BMS-599626; 714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703"	10437018	C27H27FN8O3	Phase 2
M6APDG02904	Masoprocol	"NDGA; N 5023; TNP00263; Actinex (TN); Nordihydroguaiaretic acid (meso-form); (R*,S*)-4,4'-(2,3-Dimethylbutane-1,4-diyl)bispyrocatechol; 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol"	71398	C18H22O4	Approved
M6APDG03816	JNJ-26483327	"MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson"	.	.	Phase 1
M6APDG03127	AGL 2043	AGL-2043; HMS3229A05; AGL2043	9817165	C15H12N4S	Investigative
M6APDG02554	Oxandrolone	"Anavar; Lonavar; Ossandrolone; Oxandrin; Oxandrolona; Oxandrolonum; Protivar; Provitar; Vasorome; Ossandrolone [DCIT]; SC 11585; Anavar (TN); Oxandrin (TN); Oxandrolona [INN-Spanish]; Oxandrolonum [INN-Latin]; SC-11585; Oxandrin, Anavar, Oxandrolone; Oxandrolone (JAN/USP/INN); Oxandrolone [USAN:INN:BAN:JAN]; Dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimethyl-1H-benz(e)indene-7-acetic acid delta-lactone; (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one; (4aS,4bS,6aS,7S,9aS,9bR,11aS)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1H)-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one (9CI); 17beta-Hydroxy-17-methyl-2-oxa-5alpha-androstan-3-one; 17beta-Hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one; 2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-(8CI); 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-(9CI)"	5878	C19H30O3	Approved
M6APDG02958	Mannose phosphate	MANNOSE PHOSPHATE; SCHEMBL285569; SB17274	73014169	C6H15O10P	Discontinued in Phase 2
M6APDG01625	ANHYDRORYANIDINE	"anhydroryanidine; CHEMBL283783; BDBM50044991; 2,6,9,11,13,14-hexahydroxy-11-isopropyl-7,10-dimethyl-3-methylene-(2R,7S,12R)-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadec-12-yl 1H-2-pyrrolecarboxylate(Dehydroryanodine); 2,6,9,11,13,14-hexahydroxy-11-isopropyl-7,10-dimethyl-3-methylene-(1R,7S,9S,12R)-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadec-12-yl 1H-2-pyrrolecarboxylate"	44275813	C25H33NO9	Investigative
M6APDG02115	VS-5584	5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877	46912230	C17H22N8O	Phase 1
M6APDG02663	CGP-60474	"CGP60474; 164658-13-3; CGP-60474; UNII-16IP6G5MLC; CGP 60474; GNF-Pf-88; 16IP6G5MLC; 3-[[4-[2-[(3-Chlorophenyl)amino]-4-pyrimidinyl]-2-pyridinyl]amino]-1-propanol; MLS000911536; SMR000463552; 3-[[4-[2-(3-chloroanilino)pyrimidin-4-yl]-2-pyridyl]amino]propan-1-ol; 3-[[4-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propan-1-ol; 1-Propanol, 3-((4-(2-((3-chlorophenyl)amino)-4-pyrimidinyl)-2-pyridinyl)amino)-; 1-propanol, 3-[[4-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-pyridinyl]amino]-; AC1LD8S6; MLS003105942"	644215	C18H18ClN5O	Terminated
M6APDG00758	Src kinase inhibitor I	"Src Kinase Inhibitor I; 179248-59-0; Src I1; Src Inhibitor 1; Src I 1; Src Inhibitor-1; Src-l1; 6,7-dimethoxy-N-(4-phenoxyphenyl)quinazolin-4-amine; SKI-1; CHEMBL97771; CHEBI:78332; 6,7-dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine; 4-Quinazolinamine, 6,7-dimethoxy-N-(4-phenoxyphenyl)-; 4-(4'-PHENOXYANILINO)-6,7-DIMETHOXYQUINAZOLINE; -Phenoxyanilino)-6,7-dimethoxyquinazoline; Src-I1; AC1LT1HN; Bionet1_003516; Oprea1_231056; GTPL6042; SCHEMBL1387206; KS-00002WRA; HMS578L18; CTK0E3319; AOB5689; DTXSID50363056"	1474853	C22H19N3O3	Investigative
M6APDG03863	HER2p63-71 peptide vaccine	"Cancer vaccine, Mie University; HER2p63-71 peptide vaccine, Mie University; HER2p780-788 peptide vaccine, Mie University"	.	.	Phase 1
M6APDG01736	C[RGD-(R)-alpha-TfmfV]	CHEMBL377066; c[RGD-(R)-alpha-TfmfV]	44408397	C31H37F3N8O7	Investigative
M6APDG02903	Romazarit	"ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals"	71321	C15H16ClNO4	Preclinical
M6APDG02808	NERATINIB MALEATE	Neratinib maleate; UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892	67307512	C34H33ClN6O7	Approved
M6APDG01161	MERIOLIN 2	"MERIOLIN 2; SCHEMBL2999865; CHEMBL270897; 1H-Pyrrolo[2,3-b]pyridin-4-ol, 3-(2-amino-4-pyrimidinyl)-; BDBM50371403; 954143-47-6"	24801699	C11H9N5O	Investigative
M6APDG01767	C(his-D-phe-arg-trp-Abu)	CHEMBL379531	44413577	C36H45N11O5	Investigative
M6APDG01269	"3,4-dibenzyloxy-2'-hydroxychalcone"	"CHEMBL492554; SCHEMBL17509393; SCHEMBL17509394; LHMDXKJKKAITQJ-BMRADRMJSA-N; BDBM50257724; 3,4-dibenzyloxy-2''-hydroxychalcone"	25256831	C29H24O4	Investigative
M6APDG03730	ISIS 29156	.	.	.	Investigative
M6APDG01887	"6,7'-oxybis(2-phenyl-4H-chromen-4-one)"	CHEMBL466800; BDBM50254285	44569786	C30H18O5	Investigative
M6APDG00759	"2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid"	"CHEMBL76154; SCHEMBL6239733; CTK8H7205; ICJTVRXTYOYEOT-UHFFFAOYSA-N; BDBM50375601; ZINC26399260; 2-(2,6-Dimethylanilino)benzeneacetic acid; 2-[(2,6-dimethylphenyl]amino]phenylacetic acid; 2-[(2,6-dimethylphenyl] amino] phenylacetic acid"	14762941	C16H17NO2	Investigative
M6APDG01832	Cyclo-[-Arg-Gly-Asp-Amp27-]	CHEMBL272436	44456982	C17H28N8O6	Investigative
M6APDG03553	ISIS 188755	.	.	.	Investigative
M6APDG01936	"4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine"	"364334-94-1; 4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-amine; 4-(2,4-DIMETHYL-1,3-THIAZOL-5-YL)PYRIMIDIN-2-AMINE; 4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE; CTFDMGIBHFQWKB-UHFFFAOYSA-N; 4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamine; CK2; 4-(dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine; 1pxj; 2c5o; AC1L9LFI; Maybridge3_001247; CHEMBL47302; CS12; SCHEMBL4314069; BDBM8037; CTK4H6460; DTXSID70332264; MolPort-002-896-655; HMS1434I15; ZINC141286; HMS3604E21; ANW-58550; 4623AB; AKOS013063215; MCULE-3137548628; DB02091; CCG-243780"	447956	C9H10N4S	Investigative
M6APDG00254	TOK-001	"Galeterone; 851983-85-2; Galaterone; VN/124-1; UNII-WA33E149SW; TOK 001; VN/124; WA33E149SW; (3beta)-17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3-ol; (3S,8R,9S,10R,13S,14S)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol; Galeterone [USAN:INN]; Galeterone (USAN); TOK-001(Galeterone); SCHEMBL939234; GTPL8638; 17-(1H-Benzimidazol-1-yl)androsta-5,16-dien-3beta-ol; CHEMBL2105738; Galeterone, &gt"	11188409	C26H32N2O	Phase 2
M6APDG04179	MB-12066	"B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence"	.	.	Phase 2
M6APDG02550	PQR309	"Bimiralisib; PQR309; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; PQR309; Bimiralisib; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; PQR309; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)"	58507717	C17H20F3N7O2	Phase 2
M6APDG01772	3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid	"CHEMBL220128; 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid; BDBM50323318; 3-phenyl-3-(3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzamido)propanoic acid"	44418281	C26H25N3O4	Investigative
M6APDG01115	Bisindolylmaleimide-I	"Bisindolylmaleimide i; bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; 6850; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850"	2396	C25H24N4O2	Investigative
M6APDG03905	HER2-CAR T Cells	.	.	.	Phase 1
M6APDG00534	LY3214996	"JNPRPMBJODOFEC-UHFFFAOYSA-N; 1951483-29-6; GTPL9975; SCHEMBL17837273; MolPort-046-033-624; EX-A2560; BCP19982; CS-6974; HY-101494; LY 3214996; 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one; 6,6-dimethyl-2-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-5-(2-morpholinoethyl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one"	121408882	C22H27N7O2S	Phase 1
M6APDG02754	3-[3-Methyl-indan-(1E)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 36a; CHEMBL195688; AC1O707D; BDBM8646; SCHEMBL13877113; 3-[(E)-(3-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539817	C16H15N	Investigative
M6APDG00857	T22	"[Tyr5,12,Lys7]-polyphemusin II"	16197316	C109H164N38O22S4	Investigative
M6APDG01990	5-(biphenyl-4-yl)-3-methoxypentanoic acid	CHEMBL583771; 5-(biphenyl-4-yl)-3-methoxypentanoic acid	45482998	C18H20O3	Investigative
M6APDG01860	2-(2-Chlorophenyl)-2H-indazole-7-carboxamide	CHEMBL1094952; 2-(2-Chlorophenyl)-2H-indazole-7-carboxamide; SCHEMBL2265265	44549373	C14H10ClN3O	Investigative
M6APDG00578	Dapansutrile	"54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073"	12714644	C4H7NO2S	Phase 2
M6APDG02708	Thieno analogue of kenpaullone	"Thieno analogue of kenpaullone; Paullone Analogue 71; CHEMBL323657; SCHEMBL5688610; BDBM7336; NSC 703058; 8-Bromo-6,11-dihydro-thieno[3 ,2 :2,3]azepino[4,5-b]indol-5(4H)-one; 9-Bromo-5,4-(epithioetheno)-1,2,3,6-tetrahydroazepino[4,5-b]indole-2-one"	6538761	C14H9BrN2OS	Investigative
M6APDG03360	Canakinumab	Ilaris (TN)	.	.	Approved
M6APDG03562	ISIS 116507	.	.	.	Investigative
M6APDG03563	ISIS 116508	.	.	.	Investigative
M6APDG00830	3-(6-morpholino-9H-purin-2-yl)phenol	3-(6-morpholino-9H-purin-2-yl)phenol; CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N	16049458	C15H15N5O2	Investigative
M6APDG01411	Oxametacin	Oxametacin; Oxamethacin; Flogar; Indoxamic acid; Oxametacine; Oxametacin [INN]; 27035-30-9; Oxametacine [INN-French]; Oxametacinum [INN-Latin]; UNII-8G02RSW5CM; Oxametacina [INN-Spanish]; Acido indoxamico [Italian]; ABC 8/3; EINECS 248-179-6; BRN 0497721; 8G02RSW5CM; CHEMBL295829; Oxametacin (INN); 1-(4-Chlorobenzoyl)-N-hydroxy-5-methoxy-2-methyl-1H-indole-3-acetamide; 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetohydroxamic acid; 1-(p-Chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetohydroxamic acid; Acido 1-(p-clorobenzoi	33675	C19H17ClN2O4	Investigative
M6APDG00518	"4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine"	"CHEMBL43013; 4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine; SCHEMBL7047647; SCHEMBL7047642; BDBM50108054; ZINC13471766; AKOS015967530; 4-[(E)-3,5-Dimethoxystyryl]pyridine"	11957947	C15H15NO2	Investigative
M6APDG00605	GM6001	"Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup; ILOMASTAT"	132519	C20H28N4O4	Discontinued in Phase 2
M6APDG00022	"6,7-Dimethoxy-3-pyridin-4-yl-quinoline"	"CHEMBL280069; 6,7-dimethoxy-3-pyridin-4-yl-quinoline; BDBM50039650"	10061448	C16H14N2O2	Investigative
M6APDG03094	TWS-119	"TWS119; 601514-19-6; TWS-119; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB"	9549289	C18H14N4O2	Investigative
M6APDG00185	[3H]GW2331	"[3H]GW2331; GTPL2706; 2-[4-[2-[(2,4-difluoro-6-tritiophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid"	10624977	C27H36F2N2O4	Investigative
M6APDG03707	AHL	"AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark"	.	.	Investigative
M6APDG03505	CP-70949	"PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer"	.	.	Investigative
M6APDG01744	Gly-Amp-Glu	Gly-Amp-Glu	44408739	C12H20N4O6	Investigative
M6APDG03649	AL-6802	"EGFR modulators (cancer), Advenchen/Simcere"	.	.	Investigative
M6APDG04258	ZYH-1	"Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila"	.	.	Phase 3
M6APDG01881	2-methoxy-4-(p-tolyloxy)benzonitrile	CHEMBL501649; 2-methoxy-4-(p-tolyloxy)benzonitrile; SCHEMBL17354615	44565150	C15H13NO2	Investigative
M6APDG01824	1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea	CHEMBL253402; 1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea; SCHEMBL12793734	44447102	C15H16N2O3S	Investigative
M6APDG01327	SC-514	"354812-17-2; Sc 514; SC514; 4-Amino-[2,3'-bithiophene]-5-carboxamide; 3-amino-5-(thiophen-3-yl)thiophene-2-carboxamide; CHEMBL193093; IKK-2 Inhibitor, SC-514; 5-(Thien-3-yl)-3-aminothiophene-2-carboxamide; C9H8N2OS2; GK 01140; Curator_000007; 4-Amino-[2,3-bithiophene]-5-carboxamide; BiomolKI_000076; BiomolKI2_000080; AC1MD9M6; 3-amino-5-thiophen-3-ylthiophene-2-carboxamide; Oprea1_591652; SCHEMBL4082097; KS-00000XLB; CHEBI:92464; ZINC81904; CTK8E9458; BDBM26098; SYN5231"	2807869	C9H8N2OS2	Investigative
M6APDG03060	BL-8040	.	91865076	C97H144FN33O19S2	Phase 3
M6APDG01260	3-Prop-1-ynylquinoline-8-carboxamide	CHEMBL504903; 3-Prop-1-ynylquinoline-8-carboxamide; ZINC40829471	25208905	C13H10N2O	Investigative
M6APDG03358	Becaplermin	Regranex; Regranex (TN); Becaplermin (USAN/INN)	.	.	Approved
M6APDG03503	ISIS 148715	.	.	.	Investigative
M6APDG04148	TT-100	"TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct"	.	.	Phase 2
M6APDG01056	PETCM	1-(trichloromethyl)-2-(4-pyridine)ethanol	224859	C8H8Cl3NO	Investigative
M6APDG03246	PHA-690509	"PHA-404611; PHA-533533; PNU-252808; PNU-292137; CDK inhibitors (cancer), Nerviano; Cyclin dependent kinase inhibitors (cancer), Nerviano; CDK-2 inhibitors (anticancer), Pfizer; CDK-2 inhibitors (anticancer), Pharmacia"	9902100	C17H21N3O2S	Investigative
M6APDG03258	Primary alcohol metabolite of celecoxib	Hydroxy Celecoxib; hydroxycelecoxib; 170571-00-3; CHEMBL745; UNII-1DIW8DT7Q3; 1DIW8DT7Q3; PRIMARY ALCOHOL METABOLITE OF CELECOXIB; Hydroxymethylcelecoxib; 4-[5-[4-(Hydroxymethyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-[4-(hydroxymethyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; 4-(5-(4-Hydroxymethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4'-Hydroxycelecoxib; Celecoxib metabolite M3	9908776	C17H14F3N3O3S	Investigative
M6APDG00121	SCH-546909	"CDK2 inhibitors (cancer), Merck & Co; CDK2 inhibitors (cancer), Schering-Plough; Cyclindependent kinase 2 inhibitors (cancer), Schering-Plough"	10356352	C16H11NO4	Investigative
M6APDG01569	VER-49009	.	4369536	C19H18ClN3O4	Investigative
M6APDG00130	7-Mercapto-heptanoic acid quinolin-3-ylamide	CHEMBL112234	10379373	C16H20N2OS	Investigative
M6APDG03800	Neovastat	.	.	.	Phase 1
M6APDG01725	4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide	CHEMBL197632; 4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide	44404521	C14H19NO4	Investigative
M6APDG02558	MS417	"MS417; Methyl [(6s)-4-(4-Chlorophenyl)-2,3,9-Trimethyl-6h-Thieno[3,2-F][1,2,4]triazolo[4,3-A][1,4]diazepin-6-Yl]acetate; 916489-36-6; GGRCIHACOIMRKY-HNNXBMFYSA-N; 0S6; 4f3i; US9125915, compound 6; GTPL7512; CHEMBL3769755; SCHEMBL12228301; CHEBI:83406; BDBM179283; MS-417; ZINC95921068; HY-111139; CS-0034388; Methyl 2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; methyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6"	59190723	C20H19ClN4O2S	Investigative
M6APDG00648	8-Methoxy-2-methyl-3H-quinazolin-4-one	.	135411146	C10H10N2O2	Investigative
M6APDG00319	(S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid	iminoethyl-lysin	11446787	C8H17N3O2	Investigative
M6APDG02772	TENOSAL	MR-Y134; Tenosal; 2-(2-Thienoyloxy)benzoic acid; 2-Thiophenecarboxylic acid salicyl ester	65838	C12H8O4S	Investigative
M6APDG01891	NSC-666292	CHEMBL495565; BDBM50265440	44580826	C18H16ClN5	Investigative
M6APDG03207	IRX-5183	"AGN-195183; NRX-195183; NRX-5183; VTP-195183; VTP-5183; IRX-5183 (oral, autoimmune disease), Io Therapeutics; RARa (oral, cancer/autoimmune disease), Io Therapeutics; RARa agonist (topical, skin/eye diseases), Io Therapeutics; Retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease), Io Therapeutics; Retinoic acid receptor alpha agonist (topical, skin/eye diseases), Io Therapeutics; IRX-5183 (oral, cancer/autoimmune disease), Io Therapeutics; IRX-5183 (topical, skin/eye diseases), Io Therapeutics"	9867758	C22H22ClF2NO4	Phase 1
M6APDG02374	1-Pyridin-2-yl-3-quinolin-5-yl-urea	Diarylurea deriv. 14b; AC1NS9HW; BDBM6657; CHEMBL143704; ZINC13471117; 1-pyridin-2-yl-3-quinolin-5-ylurea; 3-pyridin-2-yl-1-quinolin-5-ylurea; 1-(5-Quinolyl)-3-(2-pyridyl)urea; N-Pyridin-2-yl-N -quinolin-5-ylurea	5330598	C15H12N4O	Investigative
M6APDG01024	4-(4-methyl-phenyliminomethyl)-benzenesulfonamide	CHEMBL271962; SCHEMBL5309671; GFCNORPCMFOXDQ-UHFFFAOYSA-N; BDBM50371756	21862824	C14H14N2O2S	Investigative
M6APDG03293	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	4-(4-Butylpiperidin-1-yl)-1-o-tolylbutan-1-one; AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one	9948320	C20H31NO	Investigative
M6APDG00247	ARM036	"ALADORIAN; UNII-PJ5KSA836G; PJ5KSA836G; 865433-00-7; ARM036; Aladorian [USAN:INN]; Aladorian (USAN/INN); S44121-1; SCHEMBL3423110; CHEMBL2104951; DTXSID40235657; FPWBHFYYVSNIFZ-UHFFFAOYSA-N; s44121; D10304; (7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)oxoacetic acid; 1,4-Benzothiazepine-4(5H)-acetic acid, 2,3-dihydro-7-methoxy-alpha-oxo-; 2-(7-Methoxy-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)-2-oxoacetic acid"	11161474	C12H13NO4S	Discontinued in Phase 2
M6APDG03495	6-((1H-imidazol-1-yl)methyl)-2H-chromene-2-thione	.	.	.	Investigative
M6APDG01144	TAK-593	"TAK-593; 1005780-62-0; UNII-H3I42X8XX7; H3I42X8XX7; CHEMBL2180604; 1H-Pyrazole-5-carboxamide, N-[5-[[2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl]oxy]-2-methylphenyl]-1,3-dimethyl-;1H-Pyrazole-5-carboxamide, N-[5-[[2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl]oxy]-2-methylphenyl]-1,3-dimethyl-; TAK 593; SCHEMBL2515478; DZFZXPPHBWCXPQ-UHFFFAOYSA-N; ZINC95579919; BDBM50399537; AKOS030526192; CS-2403; DB13093; NCGC00485933-01; 1H-Pyrazole-5-carboxamide, N-(5-((2-((cyclopropylcarbonyl)amino)imidazo"	24767976	C23H23N7O3	Phase 1
M6APDG03518	ALD-806	"Anti-HGF mAb (cancer), Alder Biopharmaceuticals"	.	.	Investigative
M6APDG01289	Pergularinine	"Tylophorinine; TYLOPHORININE; CHEMBL398325; 571-70-0; NSC100055; AC1L6CHR; (13as,14r)-3,6,7-trimethoxy-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol; AC1Q57Z0; CTK5A6391; Dibenzo(f,h)pyrrolo(1,2-b)isoquinolin-14-ol, 9,11,12,13,13a,14-hexahydro-3,6,7-trimethoxy-, (13aS-cis)-; BDBM50213934; NSC-100055; NCI60_000003; (13aS,14R)-3,6,7-trimethoxy-9,11,12,13,13a,14-hexahydrophenanthro[9,10-f]indolizin-14-ol; Dibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol,9,11,12,13,13a,14-hexahydro-3,6,7-trimethoxy-,"	264751	C23H25NO4	Investigative
M6APDG01751	Cyclo[RGDfK(cypate)]	CHEMBL407126; cyclo[RGDfK(cypate)]	44409643	C67H78N11O9+	Investigative
M6APDG01526	Phenethyl-(3-phenyl-propyl)-amine	CHEMBL283775; Phenethyl-(3-phenyl-propyl)-amine; AC1L8VET; SCHEMBL625373; N-Phenethylbenzenepropane-1-amine; ZINC1707035; N-phenethyl-3-phenylpropan-1-amine; BDBM50041250	408731	C17H21N	Investigative
M6APDG00277	MP470	"Amuvatinib; 850879-09-3; MP-470; MP470; MP 470; Amuvatinib (MP-470); HPK56; UNII-SO9S6QZB4R; Amuvatinib(MP470); N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; SO9S6QZB4R; HPK-56; HPK 56; N-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro-[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; N-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; Amuvatinib [USAN:INN]; Amuvatinib (MP-470, HPK 56); PubChem22479; Amuvatinib (USAN/INN)"	11282283	C23H21N5O3S	Phase 2
M6APDG01833	Cis-2-aminocyclohexylcarbamoylphosphonic acid	cis-ACCP; cis-2-aminocyclohexylcarbamoylphosphonic acid; 777075-44-2; CHEMBL270083; SCHEMBL569075; C7H15N2O4P; CTK8E9417; MolPort-039-139-066; BDBM50234465; 1683AH; ZINC29134634	44457233	C7H15N2O4P	Investigative
M6APDG01534	EPI-001	"227947-06-0; BADGE-HCl-H2O; Bisphenol A (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) ether; 3-[4-[2-[4-(3-chloro-2-hydroxypropoxy)phenyl]propan-2-yl]phenoxy]propane-1,2-diol; 3-(4-{2-[4-(3-chloro-2-hydroxypropoxy)phenyl]propan-2-yl}phenoxy)propane-1,2-diol; EPI 001; AC1N56RN; SCHEMBL12267194; CTK8F8201; CHEBI:59642; DTXSID30400170; MolPort-003-939-733; BCP18361; EX-A2389; s7955; AKOS030573303; ACM227947060; AC-29035; RT-011557; EPI-001, &gt; J-014857"	4166922	C21H27ClO5	Investigative
M6APDG01050	N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1083208; N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653	22319580	C15H15N3OS	Investigative
M6APDG01597	ST-2987	ST-2987; CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220	44138032	C17H15N3O5	Investigative
M6APDG04024	Anti-EGFR CAR T	.	.	.	Phase 1
M6APDG00269	Briciclib	"Briciclib; 865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); Briciclib; ON 014185; SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro"	11248490	C19H23O10PS	Phase 1
M6APDG03112	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol	CHEMBL63924	9796984	C20H16N2O2	Investigative
M6APDG02167	"3,4-Dimethoxy-4'-amino-trans-stilbene"	CHEMBL1172937; BDBM50322051	49799648	C16H17NO2	Investigative
M6APDG00016	"2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one"	"Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456"	10039361	C16H15N3O2	Investigative
M6APDG02320	9-hydroxyoctadecadienoic acid	"(9S,10E,12Z)-9-Hydroxyoctadeca-10,12-dienoic acid; 9(S)-HODE; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid; alpha-dimorphecolic acid; 9S-HODE; (9S)-Hydroxyoctadecadienoic acid; UNII-42KE04U9BM; 9S-hydroxy-10E,12Z-octadecadienoic acid; 42KE04U9BM; CHEBI:34496; (9S)-Hydroxyoctadecadinoiec acid; 73543-67-6; (10E,12Z)-(9S)-9-Hydroxyoctadeca-10,12-dienoic acid; (9s,10e,12z)-9-hydroxy-10,12-octadecadienoic acid; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoate; 9(S)-hydroxyoctadecadienoic acid; Alpha-dimorphecolic; AC1NSNNN; (9S)-Hydroxyoctadecadienoate; (+)-alpha-Dimorphecolic;  9(S)-HODE"	5312830	C18H32O3	Investigative
M6APDG02268	"7,4'-Dihydroxyflavone"	"7,4'-Dihydroxyflavone; 4',7-Dihydroxyflavone; 2196-14-7; 7-Hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-2-(4-hydroxyphenyl)-; FLAVONE, 4',7-DIHYDROXY-; UNII-53ZZF57X0U; CHEMBL294878; 53ZZF57X0U; 7-hydroxy-2-(4-hydroxyphenyl)chromen-4-one; CHEBI:29503; LCAWNFIFMLXZPQ-UHFFFAOYSA-N; BRN 0224356; PubChem9844; AC1NQZG5; 7, 4'-Dihydroxyflavone; Spectrum4_001280; 7,4''-Dihydroxyflavone; 7,4' - Dihydroxyflavone; C12123; 7,4&amp;#39-dihydroxyflavone; KBioGR_001900; SPECTRUM1500721; SCHEMBL157723"	5282073	C15H10O4	Investigative
M6APDG01097	2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid	4-anilinopyrimidine 6c; CHEMBL242701; BDBM15981; 2-{[2-(pentyloxy)pyrimidin-4-yl]amino}benzoic acid	23647241	C16H19N3O3	Investigative
M6APDG01921	5-Bromothienyldeoxyuridine	"5-BROMOTHIENYLDEOXYURIDINE; CHEMBL1231486; 5-(5-Bromo-2-thienyl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-2'-deoxyuridine; BTD; 134333-70-3; BTDU; Uridine,5-(5-bromo-2-thienyl)-2'-deoxy-; AC1L9K0Y; SCHEMBL1636648; CHEMBL358374; CTK4B9107; BDBM50054768; DB03804; 5-(5-Bromothien-2-yl)-2'-deoxyuridine-; 5-(5-bromothiophen-2-yl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-1- (.beta.-D-2-deoxyribofuranos-1-yl)uracil; 5-(5-Bromo-thiophen-2-yl)-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione"	446725	C13H13BrN2O5S	Investigative
M6APDG01783	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)	CHEMBL373637; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)	44418883	C40H53N11O6	Investigative
M6APDG02681	ONT-093	"MDR inhibitors, Ontogen; OC-144-093"	6450807	C32H38N4O	Discontinued in Phase 1
M6APDG02832	2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine	"(S)-3-(3-(4-(2-GUANIDINOETHYL)PIPERIDIN-1-YL)-2-(NAPHTHALENE-2-SULFONAMIDO)-3-OXOPROPYL)BENZIMIDAMIDE; 2gv6; AC1OA9XW; CHEMBL210771; SCHEMBL12960819; BDBM23902; 3-amidinophenylalanine deriv., 8; 3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-(naphthalene-2-sulfonamido)-3-oxopropyl]benzene-1-carboximidamide; 3-{(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-[(naphthalen-2-ylsulfonyl)amino]-3-oxopropyl}benzenecarboximidamide"	6852210	C28H35N7O3S	Investigative
M6APDG01961	GW0072	GW 0072	449532	C37H46N2O4S	Investigative
M6APDG01956	Nilutamide	"Anandron; Nilandron; Nilandrone; Nilutamida; Nilutamidum; Aventis Behring Brand of Nilutamide; Aventis Brand of Nilutamide; Hoechst Brand of Nilutamide; Nilutamida [Spanish]; Nilutamidum [Latin]; N 8534; RU 23908; Anandron (TN); RU 23908-10; RU-23908; Nilutamide (USAN/INN); Nilutamide [USAN:BAN:INN]; Nilutamide [USAN:INN:BAN]; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione"	4493	C12H10F3N3O4	Approved
M6APDG03630	ISIS 298711	.	.	.	Investigative
M6APDG04121	ISIS-FGFR4	.	.	.	Phase 2
M6APDG00769	"2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one"	"CHEMBL3144716; 1,2-dihydro-2-(2-furylmethyl)-3H-indazol-3-one; 120273-74-7; 2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one; CHEMBL268738; BDBM50009008; AKOS023543910"	14898715	C12H10N2O2	Investigative
M6APDG01894	"5,6,7,8-tetrahydroanthracene-1,4-dione"	"CHEMBL508233; 5,6,7,8-tetrahydroanthracene-1,4-dione; SCHEMBL11038167"	44582382	C14H12O2	Investigative
M6APDG03317	"5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline"	"CHEMBL86717; 5,6,7-trimethoxy-3-pyridin-4-yl-quinoline; BDBM50039649"	9994707	C17H16N2O3	Investigative
M6APDG00592	TRC-253	"OUEHJEYKNYQVRC-UHFFFAOYSA-N; TRC253; SCHEMBL19128768; EX-A1808; 2110426-27-0; 5-(8-oxo-5-(6-(piperidin-4-yloxy)pyridin-3-yl)-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)-3-(trifluoromethyl)picolinonitrile"	130229812	C23H21F3N6O2S	Phase 1/2
M6APDG00735	Ethylestrenol	Maxibolin	13765	C20H32O	Approved
M6APDG02702	Tanespimycin	"CNF-101; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374"	6505803	C31H43N3O8	Phase 2
M6APDG00953	"2-Methyl-[1,4]thiazepan-(5E)-ylideneamine"	"CHEMBL187008; 2-Methyl-[1,4]thiazepan-(5E)-ylideneamine; BDBM50155783"	18721719	C6H12N2S	Investigative
M6APDG02228	biochanin A	"Biochanin A; 491-80-5; Biochanin; 4'-Methylgenistein; 5,7-Dihydroxy-4'-methoxyisoflavone; 5,7-Dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; Genistein 4-methyl ether; 5,7-Dihydrox -4'-methoxyisoflavone; Biochanine A; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)-; olmelin; Pratensol; NSC 123538; Biochanin-A; 5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one; 4-Methylgenistein; C16H12O5; UNII-U13J6U390T; CCRIS 5449; 5,7-Dihydroxy-3-p-methoxyphenyl-4H-chromen-4-one; EINECS 207-744-7; NSC123538; Genistein 4'-methyl ether;  4'-methylgenistein; BIOCHANIN"	5280373	C16H12O5	Investigative
M6APDG02636	2'-Hydroxychalcone	"6'-hydroxychalcone; ACMC-1BLFY; 2-HYDROXY CHALCONE; 2-Propen-1-one, 1-(hydroxyphenyl)-3-phenyl-; SCHEMBL126857; CHEMBL1867065; CTK1E5803; CTK4B2371; MolPort-006-109-326; AETKQQBRKSELEL-UHFFFAOYSA-N; AC1L2476; ACT07806; CMLD2_000189; ANW-17633; MCULE-2929659613; TRA0032483; AN-6742; NCGC00017803-05; NCGC00017803-04; DB-021203; FT-0669974; FT-0612588; 2-Propen-1-one,1-(2-hydroxyphenyl)-3-phenyl-; 1-(2-hydroxyphenyl)-3-phenyl-prop-2-en-1-one"	638276	C15H12O2	Investigative
M6APDG00275	4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine	CHEMBL198334; 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine; BDBM50173628	11277481	C17H16N2S	Investigative
M6APDG01813	"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline"	"CHEMBL250924; 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline; BDBM50222419"	44442180	C24H18N2O2	Investigative
M6APDG00061	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	CHEMBL575896; N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	10155934	C19H15NO5S	Investigative
M6APDG00421	6-phenylsulfanylhexanoic acid hydroxamide	"Hexanamide, N-hydroxy-6-(phenylthio)-; 6-phenylsulfanylhexanoic acid hydroxamide; CHEMBL203028; SCHEMBL7317658"	11637291	C12H17NO2S	Investigative
M6APDG02889	BAY1125976	.	70817911	C23H21N5O	Phase 1
M6APDG03057	KML110	KML110	91827387	C22H23N3O3	Investigative
M6APDG01111	MERIOLIN 3	"MERIOLIN 3; 954143-48-7; 4-(4-Methoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2996575; CHEMBL270686; BDBM50371402; ZINC16052675; DB08178; KB-274295"	23727981	C12H11N5O	Investigative
M6APDG01415	NSC-356781	NSC-356781; CHEMBL523232; 80477-85-6; NSC356781; AC1L7MCE; DTXSID10320246; 5-nitro-2-pyridin-2-yl-1-(2-pyridin-4-ylethyl)benzimidazole; ZINC13211782; BDBM50265463; 5-nitro-2-(pyridin-2-yl)-1-(2-(pyridin-4-yl)ethyl)-1H-benzo[d]imidazole; 5-nitro-2-(pyridin-2-yl)-1-(2-(pyridin-4-yl) ethyl)-1H-benzo[d]imidazole	337743	C19H15N5O2	Investigative
M6APDG01001	2-Methylquinoline-8-carboxamide	"CHEMBL471966; 2-Methylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 2-methyl-; SCHEMBL422282; BDBM50255329; AKOS022882220"	21195867	C11H10N2O	Investigative
M6APDG00106	L-746233	"CHEMBL79294; L-746233; BDBM50078442; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-746233); (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[2-[2-(4-piperidinyl)ethyl]-3-oxoisoindolin-5-yl]carbonylamino]propanoic acid; (S)-3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid"	10324223	C24H29N5O6S	Investigative
M6APDG02593	ELIPRODIL	"Eliprodil; 119431-25-3; Eliprodil [INN]; C20H23ClFNO; SL 820715; SL 82-0715; CHEMBL28564; alpha-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol; NCGC00092329-02; 1-Piperidineethanol, alpha-(4-chlorophenyl)-4-(4-fluorophenyl)-, (+-)-; DSSTox_RID_81089; DSSTox_CID_25744; DSSTox_GSID_45744; 1-(4-Chlorophenyl)-2-(4-(4-fluorobenzyl)piperidin-1-yl)ethanol; (+-)-alpha-(p-Chlorophenyl)-4-(p-fluorobenzyl)-1-piperidineethanol; 1-(4-chlorophenyl)-2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethanol"	60703	C20H23ClFNO	Phase 2
M6APDG00818	XR-9577	XR-9577; CHEMBL428402	15950351	C34H30N4O2	Investigative
M6APDG04101	EMD 55900	"27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468"	.	.	Phase 1/2
M6APDG03318	N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide	"CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	9994848	C17H18N2O3	Investigative
M6APDG02163	"3,5-Diacetoxy-4'-amino-trans-stilbene"	CHEMBL1172400; BDBM50322065	49798801	C18H17NO4	Investigative
M6APDG02437	Tiaprofenic acid	Surgam; Tiaprofensaeure; Acide tiaprofenique; Acido tiaprofenico; Acidum tiaprofenicum; Surgam SR; FC 3001; RU 15060; Acide tiaprofenique [INN-French]; Acido tiaprofenico [INN-Spanish]; Acidum tiaprofenicum [INN-Latin]; Apo-Tiaprofenic Tablets; Dom-tiaprofenic; Surgam (TN); Surgamyl (TN); Tiaprofen (TN); Tiaprofenic acid (JAN/INN); Tiaprofenic-200-Tab; Tiaprofenic-300-Tab; Tiaprofenic acid [INN:BAN:DCF:JAN]; Alpha-methyl-5-benzoyl-2-thienylacetic acid; 2-(5-Benzyl-2-thienyl)propionsaeure; 2-(5-benzoylthiophen-2-yl)propanoic acid; 2-[5-(phenylcarbonyl)-2-thienyl]propanoic acid; 5-Benzoyl-alpha-methyl-2-thiopheneacetic acid; 5-benzoyl-alpha-methylthiophene-2-acetic acid	5468	C14H12O3S	Approved
M6APDG02981	PF-06260414	PF-14	76071881	C14H14N4O2S	Discontinued in Phase 1
M6APDG03927	MMI-0100	"Peptide MAPKAPK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix; Peptide MK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix"	.	.	Phase 1
M6APDG03329	Apalutamide	Arn-509 (AR inhibitor)	24872560	C21H15F4N5O2S	Approved
M6APDG02328	"2,6-dihydroxy-1,7-dimethoxyxanthone"	"calophymembranol A; 2,6-dihydroxy-1,7-dimethoxyxanthone; CHEMBL463769; AC1NRZXJ; BDBM50269644; 2,6-dihydroxy-1,7-dimethoxyxanthen-9-one"	5326145	C15H12O6	Investigative
M6APDG03135	Apricoxib	TG01	9820073	C19H20N2O3S	Discontinued in Phase 2
M6APDG00433	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide; Kinome_3019; CHEMBL210032; SCHEMBL1145340; BDBM15968; Aminopyridine-Based Inhibitor 24	11658882	C14H12N4O	Investigative
M6APDG00946	"6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione"	"25983-13-5; 6,7-Dichloroquinoxaline-2,3(1H,4H)-dione; DCQX; 6,7-dichloroquinoxaline-2,3-diol; 6,7-DICHLORO-1,4-DIHYDRO-2,3-QUINOXALINEDIONE; 6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione; 2,3-Dihydroxy-6,7-dichloroquinoxaline; 6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione; CHEMBL284028; Spectrum_001661; ACMC-209gnv; SpecPlus_000650; Lopac-D-133; AC1L1CDC; Spectrum5_001426; Spectrum4_000630; Spectrum3_001668; Spectrum2_000537; Biomol-NT_000181; AC1Q3Q7M; Lopac0_000418; KBioSS_002141; KBioGR_001220; BSPBio_003455; Benzil-related co"	1845	C8H4Cl2N2O2	Investigative
M6APDG00555	KRN-2391	Ki-3315	123957	C10H13N5O6S	Discontinued in Phase 2
M6APDG02490	GSK-677954	SCHEMBL2065429	56603715	C34H36F3N3O4S2	Discontinued in Phase 2
M6APDG01629	(O10eq)-beta-alanylryanodine	CHEMBL282089; (O10eq)-beta-alanylryanodine	44275867	C28H40N2O10	Investigative
M6APDG02988	QEDIIRNIARHLAQVGDSMDR	.	77280325	C100H169N35O34S	Investigative
M6APDG02331	Ro-3201195	"[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE; CHEMBL203567; CHEBI:45116; Ro 320-1195; Ro-3201195; 2gfs; PQB; [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl](3-{[(2S)-2,3-dihydroxypropyl]oxy}phenyl)methanone; aminopyrazole 63; RO3201195; AC1NS1L4; SCHEMBL4108597; BDBM15754; IJDQETGUEUJVTB-HNNXBMFYSA-N; DB08424; Ro-320-1195; J3.504.577E; UNII-TE3ESF890C component IJDQETGUEUJVTB-HNNXBMFYSA-N; 5-amino-1-(4-fluorophenyl)-4-[3-{2(S),3-dihydroxypropoxy}benzoyl]pyrazole"	5327067	C19H18FN3O4	Investigative
M6APDG01022	"3-Hydroxy-1H-benzo[b]azepine-2,5-dione"	"3-hydroxy-1H-1-benzazepine-2,5-dione; CHEMBL91742; 1H-1-Benzazepine-2,5-dione, 3-hydroxy-; 52280-64-5; 3-Hydroxy-1H-benzo[b]azepine-2,5-dione; SCHEMBL2639080; CTK1E4553; DTXSID10618296; BDBM50054638; 5-hydroxy-1H-1-benzazepine-2,3-dione"	21812299	C10H7NO3	Investigative
M6APDG03334	SNS-032	"BMS-387032; BMS-387072; BMS-387032, SNS-032; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide"	3025986	C17H24N4O2S2	Phase 1
M6APDG00304	(D)-Ala-Pro-Glu	CHEMBL205662	11370470	C13H21N3O6	Investigative
M6APDG03331	Glasdegib	Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2	25166913	C21H22N6O	Approved
M6APDG00700	BAY 80-6946	Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS	135565596	C23H28N8O4	Approved
M6APDG04303	VB-111	.	.	.	Phase 3
M6APDG01917	Deoxy-Bigchap	"Big CHAP, Deoxy; N,N-bis-(3-D-Gluconamidopropyl)deoxycholamide; AC1MTX5H; DTXSID70394140; AN-35629; FT-0629429; N,N -Bis(3-D -gluconamidopropyl)- deoxy-cholamide; N-[3-[4-(3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl-[3-(2,3,4,5,6-pentahydroxyhexanoylamino)propyl]amino]propyl]-2,3,4,5,6-pentahydroxyhexanamide"	446320	C42H75N3O15	Investigative
M6APDG03665	DP-802	"P38-alpha inhibitors (inflammation); P38-alpha inhibitors (inflammation), Deciphera"	.	.	Investigative
M6APDG00167	"N,N'-Bis-(4-butyl-phenyl)-guanidine"	"CHEMBL109210; SCHEMBL4980235; N,N'-Bis(4-butylphenyl)guanidine; BDBM50066427"	10496171	C21H29N3	Investigative
M6APDG00672	N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide	.	135458003	C17H17N3O2	Investigative
M6APDG02676	Pelitinib	EKB-569; EKI-569; WAY-EKB-569	6445562	C24H23ClFN5O2	Phase 2
M6APDG03789	ISIS 12882	.	.	.	Investigative
M6APDG03311	PIPERNONALINE	"CHEMBL450332; PKLGRWSJBLGIBF-JMQWPVDRSA-N; MolPort-006-668-470; ZINC14658236; Pipernonaline, &gt; 9-(3,4-Methylenedioxyphenyl)-2,8-nonadienoic acid piperidide; 1-[9-(1,3-Benzodioxol-5-yl)-1-oxo-2,8-nonadienyl]piperidine, 9CI; (2E,8E)-9-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)nona-2,8-dien-1-one; (2E,8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)nona-2,8-dien-1-one"	9974595	C21H27NO3	Investigative
M6APDG01377	4-(benzylideneamino)benzenesulfonamide	4-benzylideneamino-benzenesulfonamide	308405	C13H12N2O2S	Investigative
M6APDG03431	CDP571	.	.	.	Discontinued in Phase 3
M6APDG00069	Glitazone	"74772-78-4; 5-(4-Hydroxybenzyl)thiazolidine-2,4-dione; 5-(4-Hydroxybenzyl)-2,4-thiazolidinedione; 5-(4-HYDROXYBENZYL)-1,3-THIAZOLIDINE-2,4-DIONE; U-90441; 2,4-dioxo-5-[(p-hydroxyphenyl)-methyl]thiazolidine; 5-[(4-Hydroxyphenyl)methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[(4-hydroxyphenyl)methyl]-; Glitazone; 5-(4-Hydroxybenzyl)thiazolidin-2,4-dione; ACMC-1BF0J; Pioglitazone Metabolite M1; SCHEMBL623021; SCHEMBL18174924; CTK5E0483; MolPort-006-394-329; NKOHRVBBQISBSB-UHFFFAOYSA-N; ZX-AT015682; KM1640; CH-087"	10198397	C10H9NO3S	Phase 4
M6APDG02343	PD-0173952	"PD173952; PD-173952; TCMDC-137156; 305820-75-1; CHEMBL106772; SCHEMBL3458816; BDBM4213; AC1NS580; DTXSID00416167; HMS3263E07; Tox21_500983; ZINC13812765; NSC735422; CCG-222287; NSC-735422; NCGC00261668-01; PD 173952; FT-0673541; PD173952, &gt; 2-(4-morpholinophenylamino)-6-(2,3-d]pyrimidin-7(8H)-one; 6-(2,6-dichlorophenyl)-8-methyl-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidin-7-one; 6-(2,6-Dichlorophenyl)-8-methyl-2-(4-morpholin-4-ylphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one"	5328733	C24H21Cl2N5O2	Investigative
M6APDG01977	"1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine"	"CHEMBL540744; 1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine"	45272467	C15H13N3O2	Investigative
M6APDG03478	modified HA14-1 compounds (cancer)	"Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals"	.	.	Investigative
M6APDG00236	8-Oxo-8-phenyl-octanoic acid hydroxyamide	CHEMBL95959; 8-Oxo-8-phenyl-octanoic acid hydroxyamide; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide	11075845	C14H19NO3	Investigative
M6APDG00193	flavone	"Flavone; FLAVONE; 525-82-6; 2-Phenylchromone; 2-Phenyl-4H-chromen-4-one; 2-Phenyl-4-chromone; Asmacoril; 2-Phenyl-4H-1-benzopyran-4-one; 2-Phenyl-4-benzopyron; 4H-1-Benzopyran-4-one, 2-phenyl-; Chromocor; Cromaril; 2-phenylchromen-4-one; Phenylchromone; 2-Phenyl-chromen-4-one; 2-Phenyl-gamma-benzopyrone; 2-Phenylbenzopyran-4-one; Cromarile; 2-Phenyl-4H-benzopyran-4-one; Flavon; 2-Phenylchrome; UNII-S2V45N7G3B; NSC 19028; 2-Phenyl-4H-chromen-4-on; CCRIS 4288; NSC19028; EINECS 208-383-8; NSC-19028; BRN 0157598"	10680	C15H10O2	Investigative
M6APDG01779	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL375990; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)	44418873	C37H49N11O6	Investigative
M6APDG01529	"2-Phenyl-1,2-dihydro-indazol-3-one"	"3-Indazolinone, 2-phenyl-; 2-phenyl-1H-indazol-3-one; 17049-65-9; MLS-0315919.0001; CHEMBL412902; 2-phenylindazolone; NSC34813; 2-Phenyl-1,2-dihydro-indazol-3-one; 2-phenylindazolin-3-one; 3H-Indazol-3-one, 1,2-dihydro-2-phenyl-; AC1L91HU; cid_411519; SCHEMBL2438599; CHEMBL1719803; BDBM46671; DTXSID20328536; CFNJFZDGHGYAMU-UHFFFAOYSA-N; NSC-34813; ZINC84460115; AKOS023543908; 3H-Indazol-3-one,2-dihydro-2-phenyl-; 1,2-Dihydro-2-phenyl-3H-indazol-3-one; 2-Phenyl-1,2-dihydro-3H-indazol-3-one #"	411519	C13H10N2O	Investigative
M6APDG00092	1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole	CHEMBL95109; 1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole	10267149	C19H18N2O2	Investigative
M6APDG03854	Peginterferon beta	"AZ-01; AZ-60; Jak2 inhibitors (myeloproliferative disorders); Jak2 inhibitors (myeloproliferative disorders), AstraZeneca"	.	.	Phase 1
M6APDG04126	CVX-045	"CVX-22; CovX-045; PF-4856882; TSP-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), Pfizer"	.	.	Phase 2
M6APDG00970	Benzylcysteine	"S-Benzyl-L-cysteine; 3054/1/1; H-Cys(Bzl)-OH; Poly-S-benzylcysteine; (R)-S-Benzylcysteine; (R)-2-amino-3-(benzylthio)propanoic acid; (S)-Benzyl-L-Cys; cysteine, s-(phenylmethyl)-; CHEMBL63130; UNII-9VRE13M548; GHBAYRBVXCRIHT-VIFPVBQESA-N; 9VRE13M548; MFCD00002613; NSC 523123; 25988-62-9; (2R)-2-amino-3-benzylsulfanyl-propanoic acid; B-1025; J-300089; D-S-butylcysteine; BCS; (2R)-2-amino-3-(phenylmethylthio)propanoic acid"	193613	C10H13NO2S	Investigative
M6APDG04302	O6-Benzylguanine alkylade	KRX-0402; O6-Benzylguanine (BG)	.	.	Phase 3
M6APDG01785	Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219096; cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)	44418886	C37H49N11O6	Investigative
M6APDG01032	"3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine"	"3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine; CHEMBL538932; 633303-90-9; SCHEMBL3889418; CTK2A9458; DTXSID00621754; XIVJYIWQYBHEBJ-UHFFFAOYSA-N; BDBM50295740; 3-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine; 1H-Pyrrolo[2,3-b]pyridine, 3-(phenylsulfonyl)-"	22028181	C13H10N2O2S	Investigative
M6APDG03035	IDH305	"DCGDPJCUIKLTDU-SUNYJGFJSA-N; IDH-305; 1628805-46-8; UNII-A791KH7YZW; A791KH7YZW; CHEMBL3947537; SCHEMBL16045032; BDBM247859; CS-8084; HY-104036; US9434719, 466; (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one; (4R)-4-[(1S)-1-fluoroethyl]-3-[2-({(1S)-1-[4-methyl-2'-(trifluoromethyl)[3,4'-bipyridin]-6-yl]ethyl}amino)pyrimidin-4-yl]-1,3-oxazolidin-2-one; C81"	90415637	C23H22F4N6O2	Phase 1
M6APDG00315	"4,5,6-trihydroxy-3-methylphthalide"	"CHEMBL486813; 4,5,6-trihydroxy-3-methylphthalide; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one"	11424128	C9H8O5	Investigative
M6APDG00729	DEOXYCYTIDINE	"Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993"	13711	C9H13N3O4	Approved
M6APDG00515	MK-0773	C-8500; MK-773	11950726	C27H34FN5O2	Phase 2
M6APDG01345	8-Oxo-8-phenyl-octanoic acid	"8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837"	298878	C14H18O3	Investigative
M6APDG04371	GI-270384X	270384	.	.	Terminated
M6APDG02970	BRD9539	BRD-9539; BRD 9539	73755260	C24H21N3O3	Investigative
M6APDG01142	CHLOROCYCLINONE B	"CHLOROCYCLINONE B; CHEMBL254814; BDBM50228360; methyl 9-[1-(acetyloxyethyl)]-2-chloro-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate"	24762580	C26H21ClO9	Investigative
M6APDG04123	GFT14	.	.	.	Phase 2
M6APDG04153	FPI-01	"WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals"	.	.	Phase 2
M6APDG00028	BX-795	BX795; BX 795	10077147	C23H26IN7O2S	Investigative
M6APDG00120	"5,7-Dimethoxy-3-thiophen-3-yl-quinoline"	"CHEMBL66071; 5,7-dimethoxy-3-thiophen-3-yl-quinoline; ZINC3834026"	10355832	C15H13NO2S	Investigative
M6APDG04189	RetinoStat	"AngiStat; XiaGen; Cardiovascular disease therapy, Oxford Biomedica; Gene therapy (HRE), Oxford Biomedica; Angiostatin/endostatin gene therapy (LentiVector, AMD), Oxford Biomedica"	.	.	Phase 2
M6APDG01003	Ro 40-6055	AM580; CD-336; Ro406055	2126	C22H25NO3	Investigative
M6APDG02077	AdoC(beta-Ala)2AlaArg6	CHEMBL610875	46877391	C55H98N32O14	Investigative
M6APDG02648	(-)-CATECHINGALLATE	"(-)-Catechin gallate; 130405-40-2; (2S,3R)-2-(3,4-Dihydroxyphenyl)-5,7-dihydroxychroman-3-yl 3,4,5-trihydroxybenzoate; catechin gallate; UNII-0KT1FO6VO6; ent-Catechin 3-O-gallate; 0KT1FO6VO6; CHEMBL129451; CHEBI:76131; (2S,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; (2S,3R)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); (-)-CATECHINGALLATE; Catechin gallate, (-)-; CCRIS 9303; Catechin gallateCG; (-)-Catechin gallate"	6419835	C22H18O10	Investigative
M6APDG03856	DS-3078	.	.	.	Phase 1
M6APDG01117	CHLOROCYCLINONE C	"CHLOROCYCLINONE C; CHEMBL254815; BDBM50228359; methyl 2-chloro-6,8-dihydroxy-9-{1-[(hydroxyacetyl)oxy]ethyl}-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate"	24180661	C26H21ClO10	Investigative
M6APDG01809	ST-1646	CHEMBL392303	44439175	C21H33N7O6	Investigative
M6APDG01702	"(5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine"	"CHEMBL364230; (5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine"	44399941	C9H16N2	Investigative
M6APDG00372	C[-Arg-Gly-Asp-Acpca22-]	CHEMBL539850	11540715	C18H29N7O8	Investigative
M6APDG02481	"N-(3,5-dichlorophenyl)imidodicarbonimidic diamide"	"N-(3,5-dichlorophenyl)imidodicarbonimidic diamide; CHEMBL40929; 1672-93-1; Imidodicarbonimidic diamide, N-(3,5-dichlorophenyl)-; 1-(diaminomethylidene)-2-(3,5-dichlorophenyl)guanidine; AC1LBJDA; Maybridge1_007061; SCHEMBL891475; CTK7D2196; CTK0E5441; DTXSID50339817; 1-(3,5-dichlorophenyl)biguanide; BUXACHZAYWAZJL-UHFFFAOYSA-N; MolPort-003-943-662; ZINC4370978; ZX-AN037609; ALBB-022022; CCG-43794; STL482580; RJF 00091; BDBM50100971; AKOS003623024; MCULE-3366928787; CCG-245923; Biguanidine, 1-(3,5-dichlorophenyl)-; NCGC00331378-01"	558969	C8H9Cl2N5	Investigative
M6APDG01241	Tepotinib	"1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo"	25171648	C29H28N6O2	Approved
M6APDG01988	N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide	CHEMBL572484; N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide	45481844	C23H19NO3	Investigative
M6APDG01039	"6,7-Dimethoxy-4-(4-methoxy-phenoxy)-quinoline"	"CHEMBL98584; 6,7-Dimethoxy-4-(4-methoxyphenoxy)quinoline; 6,7-Dimethoxy-4-(4-methoxy-phenoxy)-quinoline; SCHEMBL7486400; GBYWCVLXEHHOFE-UHFFFAOYSA-N"	22132780	C18H17NO4	Investigative
M6APDG01086	9-N-ETHYL-8-ETHOXY-MANZAMINE A	9-N-ethyl-8-ethoxy-manzamine A; CHEMBL403562	23643537	C40H52N4O2	Investigative
M6APDG01382	Fludrocortisone	"fludrocortisone; Fluorocortisone; Fluorocortisol; Fluohydrisone; Florinef; Fluohydrocortisone; Astonin-H; Fludrocortone; Alflorone; Fludronef; Fludrone; Fluodrocortisone; 127-31-1; F-Cortef; 9alpha-Fluorocortisol; Fludrocortisona; Fludrocortisonum; F-COL; 9-Fluorocortisol; 9 alpha FF; 9-Fluorohydrocortisone; Cortisol, 9-fluoro-; StC 1400; 9alpha-Fludrocortisone; 9-AFH; 9-alpha-Fluorocortisol; 9-alpha-Fludrocortisone; Fludrocortisonum [INN-Latin]; Fludrocortisona [INN-Spanish]; 9-AF;  Alflorone; Astonin; FCOL; Astonin H; Astonin Merck; Merck Brand of Fludrocortisone; U 5963; ZK5; F-Cortef;Florinef (TN); Fludrocortisone (INN); Fludrocortisone [INN:BAN]; Merck, Astonin; Astonin-H (TN); Hydrocortisone-9alpha-fluoro; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-(8CI); (11beta)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione; (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 9 Fluoro 17 Hydroxycortisone; 9 Fluorocortisol; 9 Fluorohydrocortisone; 9 alpha Fludrohydrocortisone; 9 alpha Fluoro 17 Hydroxycorticosterone; 9 alpha Fluorohydrocortisone; 9 alpha-Fludrocortisone; 9 alpha-Fluoro-17-Hydroxycorticosterone; 9 alpha-Fluorocortisol; 9 alpha-Fluorohydrocortisone; 9-Fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-17-Hydroxycortisone; 9-alpha-Fluoro-17-hydroxycorticosterone; 9-alpha-Fluorohydrocortisone; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione; 9alpha-Fluoro-17-hydroxycorticosterone; 9alpha-Fluorohydrocortisone; 9alpha-Fluoro-hydrocortisone"	31378	C21H29FO5	Approved
M6APDG02381	TMP269	TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269	53344908	C25H21F3N4O3S	Investigative
M6APDG03233	HMN-214	N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide	9888590	C22H20N2O5S	Discontinued in Phase 1
M6APDG00943	"Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione"	"CHEMBL370869; pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione; SCHEMBL5381581"	18382004	C14H8N2O2	Investigative
M6APDG03549	BPI-704001	"BPI-705001; BPI-715001; PARP-1 inhibitors (cancer); PARP-1 inhibitors (cancer), Beta Pharma"	.	.	Investigative
M6APDG03244	"5,3'-Dipropyl-biphenyl-2,4'-diol"	"CHEMBL330227; 35406-31-6; Magreth-2; SCHEMBL12319404; CTK1B6970; DTXSID90432573; 3',5-Dipropylbiphenyl-2,4'-diol; BDBM50157312; AKOS030533140; 5,3''-Dipropyl-biphenyl-2,4''-diol; 5,3''''-Dipropyl-biphenyl-2,4''''-diol; [1,1'-Biphenyl]-2,4'-diol, 3',5-dipropyl-"	9900113	C18H22O2	Investigative
M6APDG00301	BMS-690514	BMS 690514; BMS690514	11349170	C19H24N6O2	Phase 2
M6APDG00145	N-(6-chloro-1H-indazol-3-yl)butyramide	CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; N-(6-chloro-1H-indazol-3-yl)butyramide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N	10421683	C11H12ClN3O	Investigative
M6APDG01102	ACTB-1003	"Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer"	23653175	C27H26F5N7O3	Investigative
M6APDG04356	Bivatuzumab mertansine	BIWI-1; Bivatuzumab-DM1	.	.	Terminated
M6APDG00579	RO-320432	"ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in"	127757	C28H28N4O2	Terminated
M6APDG00327	N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide	SCHEMBL7311087	11472431	C18H20N2O3	Investigative
M6APDG00019	FR-123826	"COX-2 inhibitor, Fujisawa"	10042938	C17H12FN3O2S	Terminated
M6APDG00412	AVE-8134	"PPAR alpha agonist, Genfit"	11625114	C22H23NO5	Discontinued in Phase 2
M6APDG03677	ISIS 5874	.	.	.	Investigative
M6APDG00775	"N4,N6-dibenzylpyrimidine-4,6-dicarboxamide"	"N4,N6-dibenzylpyrimidine-4,6-dicarboxamide; CHEMBL468901; 135002-40-3; ZINC14574; BDBM16594; Pyrimidine Dicarboxamide Inhibitor, 2; N,N -dibenzylpyrimidine-4,6-dicarboxamide; AX8335280"	15052873	C20H18N4O2	Investigative
M6APDG01766	C(his-D-phe-arg-trp-Ahx)	CHEMBL379627; c(his-D-phe-arg-trp-Ahx)	44413537	C38H49N11O5	Investigative
M6APDG01575	Quinoxaline1	quinoxaline1	438981	C9H7N5	Investigative
M6APDG00002	N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1085918; N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686	10016510	C16H16N4O	Investigative
M6APDG02613	Gallium nitrate	Ganite (TN)	61635	GaN3O9	Approved
M6APDG01624	MR-20496	CHEMBL9179; MR-20496; BDBM50070095	44265823	C21H15NO	Investigative
M6APDG00822	NB-325	PEHMB; Polyethylene hexamethylene biguanide	15954275	C16H36Cl2N14	Investigative
M6APDG04274	Zalutumumab	.	.	.	Phase 3
M6APDG03469	N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide	N-hydroxy-4-(3-phenylpropanamido)benzamide	.	.	Investigative
M6APDG03497	D-Phe-Arg-2-Nal-NHCH3	.	.	.	Investigative
M6APDG02670	GSK184072	"Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione"	6443207	C12H18N2O3	Discontinued in Phase 2
M6APDG03298	SB-265123	"SB-265123; CHEMBL288493; SCHEMBL244383; HODBWQCCKYDYPY-NRFANRHFSA-N; {3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; BDBM50078714; {(S)-3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; (S)-10,11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid"	9952958	C25H26N2O3	Investigative
M6APDG02571	NSC-122427	NSC-122427; CHEMBL583989; 4-(4-(5-oxothiophen-2(5H)-ylidene)hexan-3-yl)phenyl acetate; NSC122427; AC1O0LAU; BDBM50298487; [4-[(4Z)-4-(5-oxothiophen-2-ylidene)hexan-3-yl]phenyl] acetate	5994480	C18H20O3S	Investigative
M6APDG02285	BALANOL	"balanol; 63590-19-2; Azepinostatin; CHEMBL60254; Balanol, 1; 2-[2,6-dihydroxy-4-[(3R,4R)-3-[(4-hydroxybenzoyl)amino]azepan-4-yl]oxycarbonylbenzoyl]-3-hydroxybenzoic acid; BA1; (-)-Balanol; (3R-trans)-Balanol; AC1NRA6W; SCHEMBL62128; MEGxm0_000504; GTPL8142; BDBM3149; Acyclic Balanol Analog (-)-1; BDBM36607; ACon0_001438; ZINC3871640; MCULE-9310625171; 167937-47-5; FT-0662471; 33879-EP2275420A1; 33879-EP2295416A2; 33879-EP2295055A2; 33879-EP2311453A1; 33879-EP2305642A2; 33879-EP2298764A1; 33879-EP2298765A1; 33879-EP2298748A2"	5287736	C28H26N2O10	Terminated
M6APDG04334	FSA2	.	.	.	Preclinical
M6APDG03658	Anti-EGFR humanized mabs	"Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor"	.	.	Investigative
M6APDG00974	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID; CHEMBL11306; PLH; (n-(2-hydroxamatemethylene-4-methyl-pentoyl)phenylalanyl)methyl amine; 1mnc; 3-BMMHMH; AC1Q5QCC; AC1L4YVK; (2r)-n4-hydroxy-n1-[(2s)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-2-(2-methylpropyl)butanediamide; SCHEMBL5502507; PNU-99533; BDBM50031795; DB08403; 108383-58-0; (R)-N*4*-Hydroxy-2-isobutyl-N*1*-((S)-1-methylcarbamoyl-2-phenyl-ethyl)-succinamide; 3-((Benzyl)(methylaminocarbonyl)methylaminocarbonyl)N-hydroxy-5-methylhexanamide	194777	C18H27N3O4	Investigative
M6APDG01462	Indomethacin	"Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin"	3715	C19H16ClNO4	Approved
M6APDG01454	Ibuprofen	"ibuprofen; 15687-27-1; 2-(4-Isobutylphenyl)propanoic acid; Motrin; Brufen; Advil; Nurofen; Dolgit; Nuprin; Liptan; Ibuprocin; Buburone; Medipren; Butylenin; Ibumetin; Anflagen; Lamidon; Ebufac; Mynosedin; Trendar; Roidenin; Apsifen; Haltran; Epobron; Nobgen; Adran; Nobfen; Rufen; PediaProfen; Andran; Bluton; Nobfelon; Pantrop; Brufort; Suspren; Rebugen; Tabalon; Inabrin; (RS)-Ibuprofen; Urem; Anco; 2-[4-(2-methylpropyl)phenyl]propanoic acid; Ibu-slo; Napacetin; Brufanic; Ibuprohm; Ibufen; Ibren; 4-Isobutylhydratropic acid; p-Isobutylhydratropic acid;  Actiprofen; Alaxan; Algofen; Amelior; Amersol; Amibufen; Anafen; Antagil; Antalfene; Antarene; Antiflam; Artofen; Artril; Balkaprofen; Betaprofen; Bloom; Brofen; Bruflam; Bufeno; Bufigen; Bukrefen; Bupron; Buracaps; Burana; Carol;Cesra; Citalgan; Cobo; Codral; Combiflam; Cunil; Daiprophen; Dalsy; Dansida; Dentigoa; Dibufen; Dignoflex; Dolgirid; Dolibu; Dolmaral; Dolocyl; Dolofen; Dolofin; Dolofort; Dologel; Dolomax; Doloren; Dolormin; Doltibil; Dolven; Dorival; Drin; Duafen; Duobrus; Dysdolen; Easifon; Emflam; Eputex; Ergix; Esprenit; Exneural; Faspic; Femadon; Femafen; Femapirin; Femidol; Fenbid;Fendol; Fenspan; Fibraflex; Gelufene; Gofen; Grefen; Gynofug; Ibol; Ibu; Ibubest; Ibubeta; Ibucasen; Ibudol; Ibudolor; Ibuflamar; Ibufug; Ibugel; Ibugen; Ibugesic; Ibuhexal; Ibulagic; Ibular; Ibulav; Ibuleve; Ibulgan; Ibumed; Ibumerck; Ibupirac; Ibuprin; Ibuprofene; Ibuprofeno; Ibuprofenum; Ibuprophen; Ibusal; Ibutid; Ifen; Inflam; Inoven; Ipren; Irfen; Isodol; Jenaprofen; Junifen; Kesan; Kratalgin; Lebrufen; Librofem; Lidifen; Lopane; Malafene; Manypren; Melfen; Mensoton; Midol; Moment; Narfen; Neobrufen; Nerofen; Noalgil; Nobafon; Noritis; Norton; Novadol; Novogent; Novoprofen; Nuprilan; Optifen; Opturem; Oralfene; Ostarin; Ostofen; Ozonol; Paduden; Panafen; Paxofen; Perofen; Proartinal; Profen; Proflex; Provon; Quadrax; Rafen; Ranofen; Relcofen; Rhinadvil; Rofen; Rufin; Rupan; Sadefen; Salivia; Salprofen; Seclodin; Sednafen; Seklodin; Seskafen; Siyafen; Solpaflex; Solufen; Stelar; Sugafen; Suprafen; Syntofene; Tatanal; Tempil; Tofen; Tonal; Unipron; Upfen; Uprofen; Zafen; Zofen; DOLO PUREN; Deep Relief; Donjust B; Motrin IB; Novogent N; Togal N; Adex 200; Artril 300; Brufen 400; I 4883; IP 82; IP82; Midol 200; RD 13621; Tabalon 400; U 18573; UCB 79171; VUFB 9649; Act-3; Advil (TN); Ak+C2278tren; Aktre (TN); Alaxan (TN); Algoflex (TN); Alivium (TN); Am-Fam 400; Apsifen-F; Arthrofen (TN); Bonifen (TN); Brufen (TN); Bugesic (TN); Burana (TN); Caldolor (TN); Calprofen (TN); Cap-Profen; Dalsy (TN); Dismenol (TN); Diverin (TN); Dolgit (TN); Dolo-Dolgit; Dolofen-F; Dolofort (TN); Doloraz (TN); Dolormin (TN); Dorival (TN); Dura-Ibu; Ebufac (TN); Emflam-200; EmuProfen (TN); Espidifen (TN); Eve (TN); Fenbid (TN); Fenpaed (TN); Finalflex (TN); Galprofen (TN); Hedex (TN); Herron Blue (TN); IB-100; IBUFEN (TN); IP-82; Ibalgin (TN); Ibu-Attritin; Ibu-Tab; Ibu-Tab 200; Ibu-slow; IbuHEXAL (TN); Ibugel (TN); Ibuleve (TN); Ibum (TN); Ibumax (TN); Ibumetin (TN); Ibuprom (TN); Ibuprosyn (TN); Ibux (TN); Ibuxin (TN); Ipren (TN); Kratalgin (TN); Medicol (TN); Moment (TN); Motrin (TN); Nagifen-D; Narfen (TN); Neo-Helvagit; Neo-Mindol; Neobrufen (TN); Neofen (TN); Norvectan (TN); Novo-Profen; Nuprin (TN); Nureflex (TN); Nurofen (TN); Orbifen (TN); Panafen (TN); Pedia-Profen; Perifar (TN); Profin (TN); Ratiodolor (TN); Retard (TN); Rimafen (TN); Salvarina (TN); Solpaflex (TN); Spedifen (TN); Speedpain NANO (TN); Spidifen (TN); Tab-Profen; U-18573; Upfen (TN); ACHES-N-PAIN; Act-3 (TN); Dolo-Spedifen (TN); I-profen (TN); IBU-Ratiopharm (TN); Ibu-Vivimed (TN); U-18,573; IBUPROPHEN"	3672	C13H18O2	Approved
M6APDG01999	6-O-Cyclohexylmethyl Guanine	"6-(Cyclohexylmethoxy)-9H-purin-2-amine; nu2058; 161058-83-9; 6-(cyclohexylmethoxy)-9H-purin-2-amine; 6-O-CYCLOHEXYLMETHYL GUANINE; 2-amino-6-[(cyclohexylmethyl)oxy]purine; NU 2058; 2-amino-6-cyclohexylmethoxypurine; NU-2058; O6-Cyclohexylmethylguanine; CHEMBL269881; 1e1v; 1h1p; O-Cyclohexylmethylguanine; AC1Q4XUD; 9H-Purin-2-amine, 6-(cyclohexylmethoxy)-; O6-Cyclohexylmethyl guanine; AC1L1IG4; MLS001074898; SCHEMBL3462331; BDBM5485; CTK8D6642; CTK0E6580; EX-A790; AOB6207; MolPort-033-437-778; MolPort-003-958-993; MolPort-044-561-861; HMS3372K06; HMS3262L18; HMS2233F06"	4564	C12H17N5O	Investigative
M6APDG04180	HM-5016504	"C-Met inhibitor (cancer), Hutchison"	.	.	Phase 2
M6APDG00522	KU-0060648	KU 0060648	11964036	C33H34N4O4S	Investigative
M6APDG00382	3-(6-Ethoxy-naphthalen-2-yl)-pyridine	3-(6-ethoxynaphthalen-2-yl)pyridine; SCHEMBL4511117; BDBM8908; CHEMBL193343; 3-(6-ethoxy-2-naphthyl)pyridine; Pyridine-substituted naphthalene 5	11557864	C17H15NO	Investigative
M6APDG01853	"9-Hydroxypropyladenine, S-Isomer"	"(S)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; 14047-27-9; 9-hydroxypropyladenine, s-isomer; (S)-9-(2-Hydroxypropyl)adenine; (2S)-1-(6-amino-9H-purin-9-yl)propan-2-ol; AC1L9HLO; Tenofovir Related Compound 9; S-9-(2-hydroxypropyl)adenine; SCHEMBL5810639; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaS)-; CTK8C2128; DTXSID60332177; MolPort-003-848-032; ZINC2046907; ANW-67863; 6827AA; DB03000; SC-43410; AK-82057; AJ-33425; KB-106920; TX-015702; (2S)-1-(6-aminopurin-9-yl)propan-2-ol; AX8236781; FT-0696938; ST24035731"	445210	C8H11N5O	Investigative
M6APDG01704	Ac-YR[CEH(pCl-dF)RWC]-NH2	CHEMBL415661; Ac-YR[CEH(pCl-dF)RWC]-NH2	44400320	C60H78ClN19O13S2	Investigative
M6APDG00352	Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe	CHEMBL207196; Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe	11513217	C35H56N4O9S	Investigative
M6APDG01148	C[CO-o-C6H4-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2	CHEMBL253574; c[CO-o-C6H4-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2	24774356	C45H55N11O7	Investigative
M6APDG01555	LM-4108	"N-(2-Phenylethyl)indomethacin Amide; 261766-32-9; CHEMBL95311; N-(2-Phenylethyl)indomethacinamide; C27H25ClN2O3; 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-phenethylacetamide; 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}-N-(2-phenylethyl)acetamide; LM-4108; 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indol-3-yl]-n-phenethylacetamide; LM 4108; AC1L1HU5; Indomethacin derivative, 19; SCHEMBL678111; BDBM22966; CTK8E8937; DTXSID80274424; MolPort-001-581-215; HMS3649K21; ZINC602343; STK226516"	4292	C27H25ClN2O3	Investigative
M6APDG03440	4-Benzyl-1-phenethyl-piperidine hydrochloride	.	.	.	Investigative
M6APDG00047	"6,7-Difluoro-3-thiophen-3-yl-quinoline"	"CHEMBL68184; 6,7-difluoro-3-thiophen-3-yl-quinoline; SCHEMBL8501272; ZINC13737708"	10106010	C13H7F2NS	Investigative
M6APDG01079	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE; CHEMBL199237; CHEBI:41135; 4-phenoxy-N-[(pyridin-2-yl)methyl]benzamide; BI5; 1zyj; AC1M5EGY; Oprea1_773674; MolPort-004-000-036; HMS3604L15; BDBM50174097; ZINC13284470; AKOS027682522; MCULE-5005773275; DB07459; Z30166389	2352168	C19H16N2O2	Investigative
M6APDG02076	AdoC(Ahx)Arg6	CHEMBL610874	46877390	C52H94N30O12	Investigative
M6APDG02453	4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one	CHEMBL413773; 4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one; SCHEMBL4469573; ZINC36185238; BDBM50189455	54737894	C15H10N2O4	Investigative
M6APDG00286	N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide	SCHEMBL676080	11312563	C17H18N2O3	Investigative
M6APDG03977	LAM-001	.	.	.	Phase 1
M6APDG02192	Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine	"CHEMBL490794; N-benzyl-N-[(4-phenylphenyl)methyl]imidazol-1-amine; Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine; AC1LA79Y; BDBM50263717; 1H-Imidazol-1-amine, N-([1,1'-biphenyl]-4-ylmethyl)-N-(phenylmethyl)-"	508445	C23H21N3	Investigative
M6APDG00820	Enzalutamide	MDV3100; Enzalutamide (AR inhibitor)	15951529	C21H16F4N4O2S	Approved
M6APDG00790	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	"2-Anilino-6-cyclohexylmethoxypurine; 2-anilino-6-cyclohexylmethoxypurine; 6-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amine; CHEMBL122264; 444722-80-9; 2A6; NU-6094; 1h1q; AC1L1BOU; SCHEMBL6791643; BDBM5530; CTK1D2421; DTXSID30274313; XWWRLKIBRPJQJX-UHFFFAOYSA-N; O6-Cyclohexylmethylguanine deriv 2; AKOS030619892; DB06948; N-Phenyl-6-(cyclohexylmethoxy)-9H-purine-2-amine; 6-(cyclohexylmethoxy)-N-phenyl-9H-purin-2-amine; 1H-Purin-2-amine,"	1540	C18H21N5O	Investigative
M6APDG03768	ISIS 32004	.	.	.	Investigative
M6APDG03693	P-6915	"PI3K/mTOR inhibitors (cancer), Piramal"	.	.	Investigative
M6APDG03539	APG-103	"CD95 receptor inhibitor (inflammatory disease), Apogenix"	.	.	Investigative
M6APDG03217	Camobucol	"AGIX-4207; AGIX-4207 IV; V-protectant (rheumatoid arthritis), AtheroGenics"	9875498	C33H50O4S2	Discontinued in Phase 2
M6APDG00883	PHA848125	"Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; PHA848125; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide"	16718576	C25H32N8O	Phase 2
M6APDG01688	"5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione"	"CHEMBL175282; 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione; BDBM50099116"	44385624	C22H24N2O3	Investigative
M6APDG02666	LG100754	LG 100754; LG754	6442223	C26H36O3	Investigative
M6APDG00523	lifitegrast	"Lifitegrast; Xiidra; 1025967-78-5; SAR-1118; SAR 1118; UNII-038E5L962W; CHEMBL2048028; 038E5L962W; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;  SAR-1118; SAR-1119; SHP606; SPD606"	11965427	C29H24Cl2N2O7S	Approved
M6APDG03267	HKI-272	Neratinib (ERBB2 inhibitor)	9915743	C30H29ClN6O3	Phase 3
M6APDG00959	"3,5-Dimethoxy-4'-amino-trans-stilbene"	"CHEMBL324290; SCHEMBL3359253; BDBM50131692; ZINC27107058; AKOS030581623; trans-3,5-dimethoxyl-4''-aminostilbene; 3,5-Dimethoxy-4''-amino-trans-stilbene; (e)-1-(4'-aminostyryl)-3,5-dimethoxybenzene; 4-[2-(3,5-Dimethoxyphenyl)ethenyl]benzeneamine"	18785180	C16H17NO2	Investigative
M6APDG03279	BM-17.0744	"K-111; 12-(4-Chlorophenyl)-2,2-dichlorododecanoic acid"	9929731	C18H25Cl3O2	Discontinued in Phase 2
M6APDG00215	4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol	"CHEMBL100870; 763907-80-8; 4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol; CTK2G7823; DTXSID50445220; BDBM50079384; 4-[2-(4-Phenylpiperidino)ethoxy]phenol; Phenol, 4-[2-(4-phenyl-1-piperidinyl)ethoxy]-"	10806596	C19H23NO2	Investigative
M6APDG02443	"4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one"	"CHEMBL414672; 4-hydroxy-5-phenyl-Thieno[2,3-b]pyridin-6(7H)-one; 179337-87-2; SCHEMBL1077245; SCHEMBL16776799; CTK7H0273; ZINC13679983; AKOS015965514; DA-09113; 4-Hydroxy-5-phenyl-7H-thieno[2,3-b]; FT-0762488"	54688796	C13H9NO2S	Investigative
M6APDG00272	6-(4-Fluoro-phenylsulfanyl)-9H-purine	6-(4-fluorophenylsulfanyl)-9H-purine; 736142-69-1; CHEMBL175603	11265091	C11H7FN4S	Investigative
M6APDG03660	SYM-011	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h	.	.	Investigative
M6APDG03785	LP-0067	"CXCR4 antagonists (autoimmune disease); CXCR4 antagonists (autoimmune disease), Leo Pharma"	.	.	Investigative
M6APDG02647	K00244	GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; K00244; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine	6419766	C18H15N5	Investigative
M6APDG03325	AZD-1152-HQPA	Barasertib	16007391	C26H30FN7O3	Phase 1
M6APDG04176	BI-505	.	.	.	Phase 2
M6APDG02132	PD-153035	"183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo"	4705	C16H14BrN3O2	Discontinued in Phase 1
M6APDG02326	CGM097	.	53240420	C38H47ClN4O4	Phase 1
M6APDG02549	3-Amino-4'-amino-trans-stilbene	"3,4'-Diaminostilbene; CCRIS 6786; CHEMBL1171628; BRN 3129972; 3-(2-(4-Aminophenyl)ethenyl)benzenamine; Benzenamine, 3-(2-(4-aminophenyl)ethenyl)-; 79305-82-1; 3-[2-(4-aminophenyl)ethenyl]aniline; AC1NYYMC; Stilbene-3,4'-diamine; AC1Q51YO; (E)-Stilbene-3,4'-diamine; SCHEMBL2774636; SCHEMBL2774639; 3-Amino-4''-amino-trans-stilbene; ZINC5161777; BDBM50322063; AKOS030582755; LS-28069; 3-[(E)-2-(4-aminophenyl)ethenyl]aniline; 3-13-00-00512 (Beilstein Handbook Reference)"	5844100	C14H14N2	Investigative
M6APDG03900	APO-010	"MegaFasL; Anticancer therapeutics (FasL), APoxis; Cancer therapeutics (FasL), Apoxis; Soluble FasL (Mega-Ligand), Apoxis; Soluble FasL (Mega-Ligand), TopoTarget"	.	.	Phase 1
M6APDG01463	INDOPROFEN	Dexindoprofen; UNII-004T8726AU; 53086-13-8; 004T8726AU; (+)-indoprofen; Dexindoprofenum; Dexindoprofene; Dexindoprofeno; Dexindoprofen [INN]; Dexindoprofenum [INN-Latin]; Dexindoprofene [INN-French]; Dexindoprofeno [INN-Spanish]; Indoprofen (+)-; EINECS 258-351-2; AC1Q5QZO; AC1L2A9M; ZINC391; SCHEMBL286896; (+)-(S)-4-(1-Oxo-2-isoindolinyl)hydratropasaeure; CHEMBL2106252; AJ-07888; (+)-(S)-p-(1-Oxo-2-isoindolinyl)hydratropic acid; UNII-CPE46ZU14N component RJMIEHBSYVWVIN-NSHDSACASA-N	3718	C17H15NO3	Withdrawn from market
M6APDG02685	PHENCYCLIDINE	"1-(1-Phenylcyclohexyl)piperidine; Angel dust; Dust; PCP (Anesthetic); Fenciclidina; Phencyclidinum; Supergrass; Cadillac; Surfer; Crystal; Tranks; Whack; Zombie dust; Magic mist; Busy bee; Piperidine, 1-(1-phenylcyclohexyl)-; Elephant tranquilizer; 1977/10/1; Superweed; Superjoint; Cycline; Sherman; Cyclones; Scuffle; Snorts; Cl-395; Sheets; Selma; Peace; Aurora borealis; Embalming fluid; Pits; Goon; Mist; Crystal joints; Wobble weed; Rocket fuel; Horse tracks; Whacky weed; Monkey dust; Killer weed; Peace weed; Peace pill"	6468	C17H25N	Investigative
M6APDG03627	BP-100-1.02	"Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path"	.	.	Investigative
M6APDG01018	Lenalidomide	"Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)"	216326	C13H13N3O3	Approved
M6APDG00809	2-Sulfhydryl-Ethanol	"beta-Mercaptoethanol; 2-mercaptoethanol; 60-24-2; Thioglycol; Mercaptoethanol; Beta-Mercaptoethanol; Ethanol, 2-mercapto-; 2-Sulfanylethanol; 2-Thioethanol; Thioethylene glycol; 2-Hydroxyethanethiol; 2-Hydroxyethyl mercaptan; 2-Hydroxy-1-ethanethiol; Thiomonoglycol; Monothioglycol; 2-Mercapto-1-ethanol; 1-Ethanol-2-thiol; Hydroxyethyl mercaptan; Monothioethylene glycol; 2-Mercaptoethyl alcohol; 2-ME; Mercaptoetanol; Ethylene glycol, monothio-; 1-Hydroxy-2-mercaptoethane; 1-Mercapto-2-hydroxyethane; 2-Hydroxyethylmercaptan; Emery 5791; USAF EK-4196"	1567	C2H6OS	Investigative
M6APDG04133	AP-301-IH	"AP-301; AP-301-IRI; AP-301-PN; AP-301-PN); Peptide TNF alpha analog (pneumonia), Apeptico; Peptide TNF alpha modulator (edema in acute lung injury), Apeptico/Medical College of Georgia; Peptide TNF alpha modulator (ischemia/reperfusion injury), Apeptico"	.	.	Phase 2
M6APDG01672	Z-Arg-Leu-Val-Agly-Ileu-Val-OMe	.	44355092	C38H64N10O9	Investigative
M6APDG01615	(E)-5-Nitrooctadec-5-enoic Acid	CHEMBL561776; (E)-5-Nitrooctadec-5-enoic Acid; (E)-5-Nitro-5-octadecenoic acid; BDBM50295050	44220888	C18H33NO4	Investigative
M6APDG00013	Z-Arg-Leu-Val-Agly-Ile-Val-OMe	"Z-Arg-Leu-Val-Azagly-Ile-Val-OMe; CHEMBL2028907; 464883-21-4; Z-Arg-Leu-Val-Agly-Ile-Val-OMe; GTPL6534; BDBM50409586; ZINC95550984; 883Z214; methyl (2S)-2-[[(2S,3S)-2-[[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]carbamoylamino]-3-methylpentanoyl]amino]-3-methylbutanoate"	10033311	C38H64N10O9	Investigative
M6APDG00020	ARP100	ARP 100; ARP-100	10044321	C17H20N2O5S	Investigative
M6APDG02704	MANZAMINE A	Manzamine A; 104196-68-1; CHEMBL611781; SCHEMBL11915472	6509753	C36H44N4O	Investigative
M6APDG02102	N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	CHEMBL1097063; N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide	46887475	C21H16N2O2	Investigative
M6APDG02129	Furan-3-yl(4-(methylsulfonyl)phenyl)methanone	CHEMBL1240537; 3-(p-methylsulfonylbenzoyl)furan; 1244038-62-7; furan-3-yl(4-(methylsulfonyl)phenyl)methanone	46939837	C12H10O4S	Investigative
M6APDG03819	IT-139	.	.	.	Phase 1
M6APDG02928	GDC-0994	.	71727581	C21H18ClFN6O2	Phase 1
M6APDG00582	L-748780	"L-748780; CHEMBL159315; 168086-64-4; L 748780; L 748,780; AC1L2SX2; SCHEMBL3240332; L-748,780; CTK0H7371; DTXSID40168476; WUJUBERMAKRECF-UHFFFAOYSA-N; BDBM50289085; 5-Methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)-1H-indole-3-acetic acid; 1 -(2,4,6-Trichlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetic acid; 1H-Indole-3-aceticacid, 5-methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)-; 1-(2,4,6-Trichlorobenzoyl)-2-methyl-5-methoxy-1H-indole-3-acetic acid; 2-[5-methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)indol-3-yl]acetic acid"	127942	C19H14Cl3NO4	Investigative
M6APDG01064	BADGE	"SCHEMBL7915436; GTPL2708; 2,2-Bis[4-(oxiranyloxy)phenyl]propane"	2286	C21H24O4	Investigative
M6APDG02513	"2'-hydroxy-3,4,5-trimethoxychalcone"	"Crotaoprostrin; 2'-hydroxy-3,4,5-trimethoxychalcone; CHEMBL521653; 2'-Hydroxy-3,4,5-methoxychalcone; (E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (2E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; 59817-22-0; 142955-68-8; NSC331924; AC1NWOUH; MLS001049027; SCHEMBL5423339; MolPort-000-450-785; SRSBUHVXNLHWHU-CMDGGOBGSA-N; HMS2268N22; ZINC4042476; ZX-AT026929; LMPK12120198; STK888527; BDBM50257726; AKOS002181958; NSC-331924; NSC 331924; 2''-hydroxy-3,4,5-trimethoxychalcone; SMR000387055"	5709436	C18H18O5	Investigative
M6APDG00455	N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide	"894803-94-2; Acetamide,N-(4-amino-5-cyano-6-ethoxy-2-pyridinyl)-; Kinome_3025; aminopyridine deriv. 1; N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide; CHEMBL208637; SCHEMBL1145395; Acetamide, N-(4-amino-5-cyano-6-ethoxy-2-pyridinyl)-; BDBM15907; Aminopyridine-Based Inhibitor 6a; DXAJWOOLPAIVJG-UHFFFAOYSA-N; ZINC14959957; KB-74421"	11715520	C10H12N4O2	Investigative
M6APDG00245	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)	CHEMBL219474; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)	11158428	C36H47N11O6	Investigative
M6APDG03302	CT-98024	"556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284"	9957049	C20H17Cl2N9O2	Investigative
M6APDG02725	3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine	"CHEMBL176886; SCHEMBL4226316; BDBM8598; AC1O704Z; (3-Pyridylmethylene)indane 19b; 3-[(Z)-(5-ethoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539774	C17H17NO	Investigative
M6APDG02798	AG-213	.	667601	C10H8N2O2S	Investigative
M6APDG00030	3-Pyridin-4-yl-quinoline	3-(4-Pyridinyl)quinoline; CHEMBL89550; 3-Pyridin-4-yl-quinoline; 3-(pyridin-4-yl)quinoline; SCHEMBL2346887; QYCONSXONLLGHQ-UHFFFAOYSA-N; BDBM50039658	10081720	C14H10N2	Investigative
M6APDG03893	"Gene therapy, IFN-b"	Gene therapy (IFN-b)	.	.	Phase 1
M6APDG03473	ISIS 196103	.	.	.	Investigative
M6APDG01390	"24(S), 25-epoxycholesterol"	"24,25-epoxy-cholesterol"	3247059	C27H44O2	Investigative
M6APDG04151	MM-111	.	.	.	Phase 2
M6APDG01829	N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide	CHEMBL256440; N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide; SCHEMBL1066609	44454416	C16H13N3OS	Investigative
M6APDG02858	Tanomastat	Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid	6918336	C23H19ClO3S	Discontinued in Phase 3
M6APDG00255	(4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine	SCHEMBL6659391	11195892	C12H10FN5	Investigative
M6APDG02910	PRI-724	.	71509318	C33H35N6O7P	Phase 1/2
M6APDG03809	LY2780301	P70 S6 Kinase and AKT Dual Inhibitor	.	.	Phase 1
M6APDG00918	AGN193109	AGN 193109; AGN-93109	177238	C28H24O2	Investigative
M6APDG03744	ISIS 104253	.	.	.	Investigative
M6APDG03928	SNA-125	.	.	.	Phase 1
M6APDG03727	ISIS 29139	.	.	.	Investigative
M6APDG02112	3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol	CHEMBL1173260; SCHEMBL18770351; BDBM50322791	46901611	C18H14FNO	Investigative
M6APDG03674	NU-1001-41	"Anti-phospho-AKT monoclonal antibodies (cancer), Nuclea Biotechnologies"	.	.	Investigative
M6APDG00204	7-((1H-imidazol-1-yl)methyl)isoquinoline	CHEMBL298720; isoquinoline 56; BDBM10041; ZINC13808228; 7-[(Imidazol-1-yl)methyl]isoquinoline; 7-(1H-imidazol-1-ylmethyl)isoquinoline	10750911	C13H11N3	Investigative
M6APDG01862	2-(4-Chlorophenyl)-2H-indazole-7-carboxamide	CHEMBL1099295; 2-(4-Chlorophenyl)-2H-indazole-7-carboxamide; SCHEMBL2264064	44549375	C14H10ClN3O	Investigative
M6APDG03054	GE-137	GE-137	91827375	C156H212N34O52S8	Investigative
M6APDG03575	Lerdelimumab	.	.	.	Investigative
M6APDG04225	ONO-5129	"Dual PPAR alpha/gamma agonist (metabolic disorder), Ono"	.	.	Phase 2
M6APDG02021	Pacritinib	JAK inhibitor (alone or in combination)s	46216796	C28H32N4O3	Phase 3
M6APDG01200	CYC065	"DLPIYBKBHMZCJI-WBVHZDCISA-N; 1070790-89-4; CYC-065; UNII-YET2XNU791; YET2XNU791; SCHEMBL13300946; CHEMBL3655762; BDBM106950; CS-7615; HY-101212; US8592581, 1; 2-Pentanol, 3-((6-(((4,6-dimethyl-3-pyridinyl)methyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-, (2R,3S)-"	24983461	C21H31N7O	Phase 1
M6APDG01935	GW-3965	"GW3965; 405911-09-3; GW 3965; UNII-6JI5YOG7RC; GW-3965; 6JI5YOG7RC; CHEMBL59030; CHEBI:79995; (3-{3-[[2-CHLORO-3-(TRIFLUOROMETHYL)BENZYL](2,2-DIPHENYLETHYL)AMINO]PROPOXY}PHENYL)ACETIC ACID; 2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-[2,2-di(phenyl)ethyl]amino]propoxy]phenyl]acetic acid; [3-(3-{[2-Chloro-3-(Trifluoromethyl)benzyl](2,2-Diphenylethyl)amino}propoxy)phenyl]acetic Acid; GW-3965A; 3-(3-[[2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)-amino]-propoxy}-phenyl acetic acid; GW 3965A"	447905	C33H31ClF3NO3	Investigative
M6APDG00848	Amylin	Amlintide; Pancreatic amylin; IAPP; Islet amyloid polypeptide; Insulinoma amyloid peptide; Diabetes-associated peptide; Insulinoma amyloid polypeptide; Amylin (human); Amlintide [USAN:INN]; 122384-88-7; Human islet amyloid peptide; AC001; AC 001; SCHEMBL374892; C8H16N2O4.C4H10; LS-172011; FT-0688968	16132430	C165H261N51O55S2	Phase 4
M6APDG03706	ISIS 173831	.	.	.	Investigative
M6APDG00504	AZD5153	"RSMYFSPOTCDHHJ-GOSISDBHSA-N; AZD-5153; 1869912-39-9; UNII-C7C7U6YEAO; C7C7U6YEAO; SCHEMBL17477306; MolPort-044-561-768; AZD 5153 [WHO-DD]; AZD 5153; EX-A1317; BCP20057; ZINC575441177; AKOS030627661; SB18713; AS-35242; J3.544.368A; (3r)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one; XNH; 2-Piperazinone, 4-(2-(4-(1-(3-methoxy-1,2,4-triazolo(4,3-b)pyridazin-6-yl)-4-piperidinyl)phenoxy)ethyl)-1,3-dimethyl-, (3R)-; (R)-4-(2-(4-(1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)pipe"	118693659	C25H33N7O3	Phase 1
M6APDG03359	Infliximab	Remicade (TN)	.	.	Approved
M6APDG03804	PEDF gene therapy	"AdPEDF; AdGVPEDF.11D; PEDF gene therapy (ophthalmic); PEDF gene therapy (ophthalmic), GenVec; Pigment epithelium-derived factor gene therapy, GenVec"	.	.	Phase 1
M6APDG03746	ISIS 104255	.	.	.	Investigative
M6APDG02124	BVDU-MP	SCHEMBL4287705	46936977	C11H14BrN2O8P	Investigative
M6APDG04183	Cobomarsen	MRG-106	.	.	Phase 2
M6APDG04186	ABX-EGF	.	.	.	Phase 2
M6APDG00234	"(2R)-2-Methyl-4,5-dideoxy"	.	11064567	C7H15O7P	Investigative
M6APDG00859	Alicaforsen	"Alicaforsen [INN]; ISIS 2302; ISIS-2302; Intercellular adhesion molecule-1 antisense oligodeoxynucleotide; DNA, d((R)-P-thio)(G-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A); Deoxyribonucleic acid, d((R)-P-thio)(G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A)"	16197725	.	Phase 3
M6APDG00575	3-benzyloxy-4-methoxy-2'-hydroxychalcone	CHEMBL437006	12681944	C23H20O4	Investigative
M6APDG02402	Batimastat	"batimastat; 130370-60-4; BB-94; Batimastat (BB-94); BB 94; UNII-BK349F52C9; BB94; Batimastat(BB-94); C23H31N3O4S2; CHEMBL279786; BK349F52C9; Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-; 4-(N-HYDROXYAMINO)-2R-ISOBUTYL-2S-(2-THIENYLTHIOMETHYL)SUCCINYL-L-PHENYLALANINE-N-METHYLAMIDE; (2S,3R)-5-Methyl-3-(((alphaS)-alpha-(methylcarbamoyl)phenethyl)carbamoyl)-2-((2-thienylthio)methyl)hexanohydroxamic acid"	5362422	C23H31N3O4S2	Preclinical
M6APDG00400	GNF-PF-3037	GNF-Pf-3037; SMR000116549; MLS000526075; Oprea1_099756; Oprea1_432483; Oprea1_261700; CHEMBL600336; cid_1160447; BDBM40315; MolPort-001-513-008; MolPort-001-991-899; C23H16N4O2S2; HMS2507A20; ZINC8671257; STK223484; AKOS003264843; AKOS000636670; MCULE-7239362503; BAS 03422558; MLS-0072644.0001; N-[4-[6-(2-thenoylamino)-1H-benzimidazol-2-yl]phenyl]thiophene-2-carboxamide; N-(4-{5-[(thiophen-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)thiophene-2-carboxamide	1160447	C23H16N4O2S2	Investigative
M6APDG00719	Folate gamma-hydroxamic acid	.	136177317	C19H20N8O6	Investigative
M6APDG01780	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL375991; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)	44418878	C37H49N11O6	Investigative
M6APDG02696	TRIAZOLOPYRIMIDINE	"8-Azapurine; 273-40-5; 2H-triazolo[4,5-d]pyrimidine; 179268-22-5; 6H-1,2,3-Triazolo[4,5-d]pyrimidine; 2H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-1,2,3-Triazolo[4,5-d]pyrimidine; 3H-[1,2,3]triazolo[4,5-d]pyrimidine; triazolo[4,5-d]pyrimidine; triazolo(4,5-d)pyrimidine; 273-39-2; 99331-25-6; 3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDINE; ACMC-1CNOM; AC1L22AZ; SCHEMBL26606; 179268-21-4; SCHEMBL11026556; CTK1A0899; CTK0H1173; CTK0H1170; CTK3G7531; CTK0H1174; DTXSID80181745; GIIGHSIIKVOWKZ-UHFFFAOYSA-N; ZINC2020258; ACM273405; FCH907879; AKOS006372727"	64962	C4H3N5	Investigative
M6APDG03962	TGF-BR2 mab	.	.	.	Phase 1
M6APDG04074	GLG-801	.	.	.	Phase 1/2
M6APDG04048	INCB57643	.	.	.	Phase 1/2
M6APDG03019	THIOCTIC ACID	"dl-Thioctic acid; thioctic acid; 1077-28-7; 5-(1,2-Dithiolan-3-yl)pentanoic acid; DL-alpha-Lipoic acid; 1,2-dithiolane-3-pentanoic acid; Thioctacid; 6,8-Thioctic acid; 6-Thioctic acid; Lipothion; Biletan; dl-Lipoic acid; Tioctacid; Thioctsan; Liposan; Rac-lipoate; 1,2-Dithiolane-3-valeric acid; DL-6,8-Thioctic acid; alpha-Liponsaeure; DL-6-Thioctic acid; alpha-liponic acid; Thioktsaeure; Tioctidasi; (RS)-Lipoic acid; 6,8-Dithiooctanoic acid; espa-lipon; Thioctic acid dl-form; 62-46-4"	864	C8H14O2S2	Investigative
M6APDG00689	"5,6-Cyclic-Tetrahydropteridine"	.	135509077	C8H9N5O3	Investigative
M6APDG00783	VATALANIB	"Vatalanib; 212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919"	151194	C20H15ClN4	Phase 2
M6APDG03753	ISIS 101985	.	.	.	Investigative
M6APDG01285	NSC-94891	NSC-94891; CHEMBL574960; AC1L668K; CTK7H3473; BDBM50298485	261861	C19H26O3	Investigative
M6APDG04136	CHS-131	.	.	.	Phase 2
M6APDG01618	(E)-13-Nitrooctadec-12-enoic Acid	CHEMBL540732; (E)-13-Nitrooctadec-12-enoic Acid	44221101	C18H33NO4	Investigative
M6APDG03858	BI-811283	.	.	.	Phase 1
M6APDG04278	Trastuzumab-DM1	.	.	.	Phase 3
M6APDG00897	"5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione"	"5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione; CHEMBL323335; 136529-54-9; Biomol-NT_000208; SCHEMBL8123057; SCHEMBL8114607; SCHEMBL4706926; BPBio1_001268; BDBM50038162; NCGC00163270-01; 5,7-Dinitroquinoxaline-2,3(1H,4H)-dione"	16760018	C8H4N4O6	Investigative
M6APDG01750	Cypate-[(RGD)2-NH2]1	CHEMBL438186; cypate-[(RGD)2-NH2]1	44409497	C64H80N15O13+	Investigative
M6APDG01994	5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole	CHEMBL565567; 5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole	45484514	C16H15NO3S	Investigative
M6APDG03926	ABI-011	.	.	.	Phase 1
M6APDG00416	C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL203760; BDBM50184366	11629326	C46H59N11O7	Investigative
M6APDG03550	S-070	"S-158; Targeted synergy program (solid tumor), Sentinel Oncology; Chk1/PARP-1 inhibitors (cancer); Chk1/PARP-1 inhibitors (cancer), Sentinel Oncology"	.	.	Investigative
M6APDG02103	1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole	CHEMBL1098424; 1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole	46887506	C14H11FN2	Investigative
M6APDG00507	Gly-Hyp-Glu	Gly-Hyp-Glu; CHEMBL380624; SCHEMBL2084290; MPZCPLJCORMPJI-CSMHCCOUSA-N; glycyl-l-hydroxyprolyl-l-glutamic acid; Glycyl-trans-4-hydroxy-L-prolyl-L-glutamic acid	11902976	C12H19N3O7	Investigative
M6APDG02586	TEBUFELONE	"Tebufelone; 112018-00-5; Tebufelone [USAN:INN]; Tebufelonum [INN-Latin]; Tebufelona [INN-Spanish]; UNII-O048K9ZFHO; O048K9ZFHO; NE 11740; CHEMBL13878; 3',5'-Di-tert-butyl-4'-hydroxy-5-hexynophenone; NE-11740; 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one; 1-(3,5-di-tert-butyl-4-hydroxyphenyl)hex-5-yn-1-one; Tebufelonum; Tebufelona; 5-Hexyn-1-one, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-; 5-Hexyn-1-one, 1-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-; Tebufelone (USAN/INN); AC1Q5DB7; AC1L1TG2; SCHEMBL43674"	60542	C20H28O2	Discontinued in Phase 2
M6APDG01933	PD-0166326	PD-166326	447700	C21H16Cl2N4O2	Investigative
M6APDG03680	ISIS 3805	.	.	.	Investigative
M6APDG03938	INNO-305	.	.	.	Phase 1
M6APDG02859	CVT-313	AC1OCFD4; NG 26	6918386	C20H28N6O3	Investigative
M6APDG02143	N-Hydroxycarbamoylmethyl-4-methoxy-benzamide	"BRN 2736542; 2-(p-Methoxybenzamido)acetohydroxamic acid; ACETOHYDROXAMIC ACID, 2-(p-METHOXYBENZAMIDO)-; CHEMBL198048; 65654-08-2; N-Hydroxycarbamoylmethyl-4-methoxy-benzamide; AC1L2IK9; SCHEMBL11668774; CTK5C2963; DTXSID60215890; BDBM50175547; LS-13134; N-[2-(hydroxyamino)-2-oxoethyl]-4-methoxybenzamide; N-(HYDROXYCARBAMOYLMETHYL)-4-METHOXY-BENZAMIDE"	47697	C10H12N2O4	Investigative
M6APDG03229	BTS-67582	"1,1-Dimethyl-2-(2-morpholinophenyl)guanidine fumarate"	9885406	C17H24N4O5	Discontinued in Phase 2
M6APDG00957	"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline"	"CHEMBL250315; 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline; SCHEMBL6180450; BDBM50222433"	18770812	C18H14N2O2	Investigative
M6APDG03751	ISIS 101983	.	.	.	Investigative
M6APDG03295	6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole	CHEMBL63146	9950054	C20H15N3O3	Investigative
M6APDG02969	[125I]SB-236636	"[125I]SB-236636; GTPL2710; (2S)-3-(4-{2-[(1,3-benzoxazol-2-yl)(methyl)amino]ethoxy}-3-(125I)iodophenyl)-2-ethoxypropanoic acid"	73755028	C21H23IN2O5	Investigative
M6APDG02890	PHENIDONE	"Phenidone; 92-43-3; 1-phenylpyrazolidin-3-one; 1-Phenyl-3-pyrazolidone; 1-PHENYL-3-PYRAZOLIDINONE; Fenidon; 3-Pyrazolidinone, 1-phenyl-; 1-Phenyl-3-oxopyrazolidine; 2-Pyrazolin-3-ol, 1-phenyl-; 1-P-3-P; Pyrazolidinone, 1-phenyl-; 1-Phenyl-pyrazolidin-3-one; UNII-H0U5612P6K; CCRIS 3624; 1-Phenylpyrazolid-3-one; EINECS 202-155-1; NSC 30306; 3-Pyrazolidinone,1-phenyl-; CHEMBL7660; 1-phenyl-4,5-dihydro-1H-pyrazol-3-ol; MLS002639322; CMCWWLVWPDLCRM-UHFFFAOYSA-N; H0U5612P6K; MFCD00003094; Phenidone A (1-Phenyl-3-pyrazolidinone)"	7090	C9H10N2O	Investigative
M6APDG00053	OT-551	"Tempol-H prodrug, Othera"	10131000	C13H23NO3	Phase 2
M6APDG04247	MCLA-128	.	.	.	Phase 2
M6APDG02013	PHA-793887	"Cyclin-dependent kinase inhibitor (cancer), Nerviano"	46191454	C19H31N5O2	Phase 1
M6APDG01464	NC1153	.	373395	C18H36N2O	Investigative
M6APDG01603	4-(isopropylthio)-2-(trifluoromethyl)benzonitrile	CHEMBL453740; 4-(isopropylthio)-2-(trifluoromethyl)benzonitrile; BDBM50247976	44157043	C11H10F3NS	Investigative
M6APDG01560	Ac-Asp-Glu-Val-Asp-CHO	"ICE INHIBITOR; AC1L1HX4; SCHEMBL13194679; AL010; AKOS015916330; AN-30897; N-Acetyl-Asp-Glu-Val-Asp-al, &gt; =95%, powder; I14-51535; 4-[(2-acetamido-4-hydroxy-4-oxobutanoyl)amino]-5-[[1-[(4-hydroxy-1,4-dioxobutan-2-yl)amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid; 4-(3-carboxy-2-acetamidopropanamido)-4-({1-[(1-carboxy-3-oxopropan-2-yl)carbamoyl]-2-methylpropyl}carbamoyl)butanoic acid"	4330	C20H30N4O11	Investigative
M6APDG01383	"5,7-Dimethoxy-3-pyridin-4-yl-quinoline"	"5,7-Dimethoxy-3-(4-pyridinyl)quinoline; 137206-97-4; 5,7-dimethoxy-3-(pyridin-4-yl)quinoline; CHEMBL68423; Quinoline,5,7-dimethoxy-3-(4-pyridinyl)-; 5,7-Dmpq; Bio1_000429; Tocris-1222; 5,7-Dimethoxy-3-pyridin-4-yl-quinoline; ACMC-20c86u; AC1L1F9B; AC1Q4YD3; SCHEMBL3652915; CTK4C0691; DTXSID90160107; Bio1_001407; Bio1_000918; ZINC2581408; BDBM50039655; AKOS030239521; 5,7-Dimethoxy-3-(4-pyridyl)quinoline; 5,7-dimethoxy-3-pyridin-4-ylquinoline; NCGC00025053-01; AJ-43025; KB-291722; DB-063190"	3139	C16H14N2O2	Investigative
M6APDG01234	2-chloro-N-(6-cyanopyridin-3-yl)propanamide	2-chloro-N-(6-cyanopyridin-3-yl)propanamide; 1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N	25141337	C9H8ClN3O	Investigative
M6APDG00025	"3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline"	"CHEMBL67702; 3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline; SCHEMBL8502992; BDBM50039074"	10065445	C17H13Cl2NO2	Investigative
M6APDG00890	TG02	SB1317; 937270-47-8; TG02; TG-02; TG02 (Double bond Z/E); UNII-40D08182TT; CHEMBL1944698; 40D08182TT; SB-1317; 1204918-72-8; C23H24N4O; Tube011; SB-1317 free base; TG02 (Double bond E); TG02 [WHO-DD]; SCHEMBL823947; SCHEMBL2298965; GTPL9095; SCHEMBL17595943; EX-A239; MolPort-039-139-793; AOB87361; BCP07033; ZINC68251500; BDBM50363196; 4029AH; AKOS030527020; AKOS032950000; SB1317(TG-02); SB14606; CS-0884; compound 26h [PMID: 22148278]; KB-80503; HY-15166; W-5884	16739650	C23H24N4O	Phase 1/2
M6APDG00851	MG-111	"134865-04-6; EGF, Hitachi"	16143379	C270H401N73O83S7	Investigative
M6APDG03842	GSK1070916A	.	.	.	Phase 1
M6APDG01340	Cycloleucine	"cycloleucine; 1-Aminocyclopentanecarboxylic acid; 52-52-8; 1-Aminocyclopentane-1-carboxylic acid; Cycloleucin; 1-Amino-1-cyclopentanecarboxylic acid; 1-Amino-1-carboxycyclopentane; 1-Amino-cyclopentanecarboxylic acid; CYCLO-LEUCINE; Cyclopentanecarboxylic acid, 1-amino-; NSC 1026; CB 1639; X 201; UNII-0TQU7668EI; 1-Aminocyclopentanecarboxylate; HSDB 5195; WR 14,997; NSC1026; 1-amino cyclopentane carboxylic acid; EINECS 200-144-6; BRN 0636626; aminocyclopentanecarboxylic acid; Cyclopentanecarboxylic acid, 1-amino-, L-; AI3-26442"	2901	C6H11NO2	Investigative
M6APDG02009	GNF-PF-2272	"3-Methyltoxoflavin; GNF-Pf-2272; MLS000528498; SMR000121073; 1,3,6-Trimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione; BAS 00444306; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; SR-01000322764; methyltoxoflavin; CPXHNWKHOFNPDO-UHFFFAOYSA-N; 3-methyl toxoflavin; AC1LA2XZ; 32502-62-8; cid_460747; SCHEMBL2180986; CHEMBL601757; BDBM34671; CHEBI:95315; KUC104460N; HMS2304H14; STK397047; KSC-1-228; MCULE-2510138695; NCGC00093522-02; NCGC00093522-01; HY-111117"	460747	C8H9N5O2	Investigative
M6APDG03368	RG-7446	.	.	.	Approved
M6APDG01380	AP-7	"2-Amino-7-phosphonoheptanoic acid; DL-AP7; 78966-69-5; DL-2-Amino-7-phosphonoheptanoic acid; NSC672105; 85797-13-3; BRN 3544152; CHEMBL274440; Heptanoic acid, 2-amino-7-phosphono-, (+-)-; 2-Amino-7-phosphono-heptanoic acid; Heptanoic acid, 2-amino-7-phosphono-; (+/-)-2-Amino-7-phosphonoheptanoic acid; C7H16NO5P; AP-7 compound; L(+)-2-Amino-7-phosphonoheptanoic acid; AP-7 (drug); AC1L1F7W; Lopac0_000008; SCHEMBL154303; CTK7D4156; ( inverted question mark)-AP-7; MYDMWESTDPJANS-UHFFFAOYSA-N; MolPort-002-514-441"	3122	C7H16NO5P	Investigative
M6APDG00310	7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one	CHEMBL224649; Coumarin deriv. 27; BDBM9478; ZINC13586720	11401873	C13H10N2O2	Investigative
M6APDG04125	ABT-122	.	.	.	Phase 2
M6APDG00064	A-443654	A-4436554	10172943	C24H23N5O	Investigative
M6APDG01796	"1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene"	"CHEMBL229245; 1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene"	44424402	C19H20O3	Investigative
M6APDG03151	Sipoglitazar	TAK-654	9825652	C25H25N3O4S	Terminated
M6APDG03586	ISIS 138613	.	.	.	Investigative
M6APDG02563	L-aspartic acid	L-Asp; L-aspartate; Aspatofort	5960	C4H7NO4	Investigative
M6APDG03045	CM-352	compound 2 [PMID 25686022]	91623362	C24H29N3O6S	Investigative
M6APDG01222	AZ960	AZ 960; AZ-960	25099184	C18H16F2N6	Investigative
M6APDG03355	Follitropin beta	.	.	.	Approved
M6APDG03943	OP-R003	"VX-30; OP-R003-1; Elsilimomab derivative (hematological disease), OPi/Vaccinex; IL-6 antibodies (hematological disease), EUSA; IL6 antibodies (hematological disease), OPi/Vaccinex; OP-R003 (hematological cancer), GSK; OP-R003 (inflammation), GSK; Anti-IL-6 human MAb (hematological cancer), GSK; Anti-IL-6 human MAb(inflammation), GSK"	.	.	Phase 1
M6APDG01183	AMG 208	"AMG-208; 1002304-34-8; AMG 208; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8"	24864821	C22H17N5O2	Phase 2
M6APDG02366	PD-0179483	"PD179483; AC1NS9BW; PD-0179483; CHEMBL573820; BDBM6571; N-[2-[4-[[6-(2,6-dichlorophenyl)-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]phenoxy]ethyl]-N-ethylacetamide; N-[2-(4-{[6-(2,6-dichlorophenyl)-8-methyl-7-oxo-7H,8H-pyrido[2,3-d]pyrimidin-2-yl]amino}phenoxy)ethyl]-N-ethylacetamide"	5330526	C26H25Cl2N5O3	Investigative
M6APDG00655	8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one	.	135417274	C15H11N3O4	Investigative
M6APDG03009	1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane	"Triglyme; 2,5,8,11-TETRAOXADODECANE; 112-49-2; Triethylene glycol dimethyl ether; 1,2-Bis(2-methoxyethoxy)ethane; Glyme 4; Ansul ether 161; Glyme-3; TEGDME; TEGDIME; 1-METHOXY-2-[2-(2-METHOXY-ETHOXY]-ETHANE; UNII-32YXG88KK0; Ethane, 1,2-bis(2-methoxyethoxy)-; NSC 66400; 1-methoxy-2-[2-(2-methoxyethoxy)ethoxy]ethane; Dimethyl ether of triethylene glycol; EINECS 203-977-3; Glycol, triethylene-, dimethyl ether; BRN 1700630; AI3-28582; triethyleneglycol dimethyl ether; 32YXG88KK0; CHEBI:44842; YFNKIDBQEZZDLK-UHFFFAOYSA-N; Triethylene "	8189	C8H18O4	Investigative
M6APDG02384	RG7388	"Idasanutlin; RG7388; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856"	53358942	C31H29Cl2F2N3O4	Phase 3
M6APDG01201	SNS-314	SN-314	24995524	C18H15ClN6OS2	Phase 1
M6APDG02638	2-methoxy-4-(2-nitrovinyl)phenol	2-methoxy-4-(2-nitrovinyl)phenol; 6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924	638439	C9H9NO4	Investigative
M6APDG02412	TRISMETHOXYRESVERATROL	"22255-22-7; trans-Trimethoxyresveratrol; (E)-1,3-Dimethoxy-5-(4-methoxystyryl)benzene; (E)-3,5,4'-Trimethoxystilbene; 3,4',5-trimethoxy-trans-stilbene; 3,4',5-trimethoxystilbene; 3,5,4'-trimethoxystilbene; TRIMETHOXYSTILBENE; TRISMETHOXYRESVERATROL; E-Resveratrol trimethyl ether; CHEMBL296411; 1,3-dimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene; trans-3,4',5-trimethoxystilbene; GDHNBPHYVRHYCC-SNAWJCMRSA-N; (E)-3,4',5-Trimethoxystilbene; 5-[2-(4-Methoxyphenyl)Ethenyl]-1,3-Dimethoxy Benzene"	5388063	C17H18O3	Investigative
M6APDG03189	SC-58451	SC-58451; SC58451; CHEMBL92154; SCHEMBL215231; ZINC6366; VZCIAZMKVAJRCL-UHFFFAOYSA-N; HY-U00239; BDBM50049041; CS-7410; 168433-84-9; 5-(4-Fluoro-phenyl)-6-(4-methanesulfonyl-phenyl)-spiro[2.4]hept-5-ene	9851770	C20H19FO2S	Terminated
M6APDG00961	"[1,3]Thiazinan-(2E)-ylideneamine"	"2-Amino-5,6-dihydro-4H-1,3-thiazine; 5,6-Dihydro-4H-1,3-thiazin-2-amine; 30480-64-9; CHEMBL306541; 2-Iminotetrahydro-1,3-thiazine; [1,3]Thiazinan-(2E)-ylideneamine; AC1Q4UKS; AC1L4O0Q; SCHEMBL30950; 2799-75-9 (hydrobromide); CTK4G5273; DTXSID60184552; [1,3]Thiazinan-(2Z)-ylideneamine; BDBM50049250; ZINC17744492; FCH991782; AKOS006347653; AKOS003362396; 4H-1,3-Thiazin-2-amine,5,6-dihydro-; EN300-203949; 3,4,5,6-Tetrahydro-2H-1,3-thiazin-2-imine"	189081	C4H8N2S	Investigative
M6APDG03795	TrasGEX	.	.	.	Phase 1
M6APDG01170	Cyclo-[-Arg-Gly-Asp-Amp24-]	CHEMBL437072	24823110	C24H42N8O6	Investigative
M6APDG00306	CMPD1	MAPKAPK2a inhibitor	11382492	C22H20FNO2	Investigative
M6APDG03797	BIIB 022	.	.	.	Phase 1
M6APDG03726	ISIS 29138	.	.	.	Investigative
M6APDG02489	AZD3463	AZD-3463; CS-1382; HY-15609; KB-154896	56599293	C24H25ClN6O	Investigative
M6APDG01971	"3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine"	"3'-(1,2,3-Triazol)dT; 3'-Deoxy-3'-(1,2,3-triazol-1-yl)thymidine; 122370-58-5; CHEMBL1092729; Thymidine,3'-deoxy-3'-(1H-1,2,3-triazol-1-yl)- (9CI); AC1L9Q42; SCHEMBL9965127; CTK4B3087; DTXSID60153586; BDBM50314847; 3'-(1H-1,2,3-Triazol-1-yl)-3'-deoxythymidine; 3''-(1,2,3-Triazol-1-yl)-3''-deoxy-beta-D-thymidine; 1-[(2R,4S,5S)-5-(hydroxymethyl)-4-(triazol-1-yl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione"	452142	C12H15N5O4	Investigative
M6APDG03280	CT-1746	.	9930721	C19H28ClN3O4	Terminated
M6APDG00532	SC-102	"4-[3-(4-Fluorophenyl)-1h-Pyrazol-4-Yl]pyridine; 3hvc; GG5; SCHEMBL1554633; CHEMBL1233024; BDBM19429; BILJSHVAAVZERY-UHFFFAOYSA-N; ZINC16052350; DB07829; 5-(4-Fluorophenyl)-4-(pyridin-4-yl)pyrazole; 4-[3-(4-Fluorophenyl)-1H-pyrazole-4-yl]pyridine; 4-(3-(4-fluorophenyl)-1h-pyrazol-4-yl);  SC-102; SPC-0038B; SPC-0172; Temoporfin derivatives (cancer); Temoporfin derivatives (cancer), Scotia Holdings; 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE"	12106168	C14H10FN3	Terminated
M6APDG00751	"4-(3,4-Dimethoxyphenethyl)aniline"	"4-(3,4-Dimethoxyphenethyl)aniline; CHEMBL1171680; SCHEMBL6481605; MEJNYOQOZUXCOG-UHFFFAOYSA-N; ZINC34258590; BDBM50322060; 4-[2-[3,4-dimethoxyphenyl)ethyl]aniline; 4[2-(3,4-dimethoxyphenyl)ethyl]benzenamine; 4-[2-(3,4-dimethoxyphenyl)ethyl]benzenamine; 4-[2-(3,4-dimethoxyphenyl)ethyl]phenylamine; 4-[2-(3,4-Dimethoxy-phenyl)ethyl]-phenylamine; 4-[2-(3,4-dimethoxy-phenyl)-ethyl]phenylamine"	14256024	C16H19NO2	Investigative
M6APDG03513	Endo-CD	Endostatin-cytosine deaminase fusion protein	.	.	Investigative
M6APDG00694	8-Hydroxy-2-phenyl-3H-quinazolin-4-one	.	135528341	C14H10N2O2	Investigative
M6APDG01156	BMS-777607	"BMS-777607; 1025720-94-8; BMS 777607; 1196681-44-3; BMS777607; ASLAN-002; UNII-A3MMS6HDO1; N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; A3MMS6HDO1; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide"	24794418	C25H19ClF2N4O4	Phase 1/2
M6APDG00395	C[-Arg-Gly-Asp-Acpca34-]	CHEMBL534933	11584047	C18H29N7O7	Investigative
M6APDG02483	TA1-RTA	"CHEMBL8197; 8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate; 89565-68-4; 124583-47-7; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 1H-indole-3-carboxylate; 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester; 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-; NCGC00015984-03; ACMC-20mr3z; ACMC-20bn7f; Enamine_001310; Biomol-NT_000158; AC1L1KP5; REGID_for_CID_5595; Oprea1_655173; Lopac0_001253; Oprea1_462281; MLS000055682; SCHEMBL463128; AC1Q625H; SCHEMBL8946882"	5595	C17H20N2O2	Investigative
M6APDG03589	ISIS 138648	.	.	.	Investigative
M6APDG00786	2-amino-4-methylpyridine	"2-Amino-4-methylpyridine; 4-METHYLPYRIDIN-2-AMINE; 695-34-1; 2-Amino-4-picoline; Ascensil; 2-Pyridinamine, 4-methyl-; 4-Methyl-2-pyridinamine; 4-Methyl-2-aminopyridine; 4-Methyl-2-pyridylamine; W 45 Raschig; 4-PICOLINE, 2-AMINO-; Methyl-4 amino-2-pyridine; 4M2AP; Pyridine, 2-amino-4-methyl-; 4-methylpyridin-2-ylamine; 2-amino-4-methyl pyridine; RA 1226; alpha-Amino-gamma-picoline; NSC 6972; NSC 1490; VMI 20-4; UNII-394N1Z644H; EINECS 211-780-9; 4-Methyl-pyridin-2-ylamine; BRN 0107066; W 45; CHEMBL40833; AI3-23984; C6H8N2; 4-methylpyridin-2-amine"	1533	C6H8N2	Investigative
M6APDG03554	ISIS 188757	.	.	.	Investigative
M6APDG00630	NU1025	.	135398517	C9H8N2O2	Terminated
M6APDG03865	SRT2379	.	.	.	Phase 1
M6APDG03717	ISIS 17148	.	.	.	Investigative
M6APDG00357	Ridaforolimus	"Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus"	11520894	C53H84NO14P	Phase 3
M6APDG03585	ISIS 138612	.	.	.	Investigative
M6APDG00271	AMD-070	"AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate"	11256587	C21H27N5	Phase 3
M6APDG03211	GW7845	GW7845; GW-7845; GW 7845; CHEMBL106666; 196809-22-0; SCHEMBL614392; GTPL2704; BDBM50085046; ZINC49748569; GW 845; GW 347845; UNII-23Y783RURX component KEGOAFNIGUBYHZ-SANMLTNESA-N; N-(2-(Methoxycarbonyl)phenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; 2-((S)-1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester; 720711-63-7; 2-(1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester(GW 7845)	9870584	C29H28N2O6	Investigative
M6APDG02140	Nicorandil	"Adancor; Dancor; Ikorel; Nicorandilum; Sigmart; Aventis Brand of Nicorandil; Aventis Pharma Brand of Nicorandil; Merck Brand of Nicorandil; Merck Lipha Sante Brand of Nicorandil; Nicorandil Aventis Brand; Nicorandil Merck Brand; Rhone Poulenc Rorer Brand of Nicorandil; SG 75; SG75; Ikorel (TN); Nicorandilum [INN-Latin]; RP-46417; Rhone-Poulenc Rorer Brand of Nicorandil; SG-75; Sigmart (TN); Nitrate, 2-Nicotinamidethyl; Nitrate, 2-Nicotinamidoethyl; N-(2-Hydroxyethyl)nicotinamide nitrate; Nicorandil (JP15/USAN/INN); Nicorandil [USAN:BAN:INN:JAN]; N-(2-Hydroxyethyl)nicotinamide nitrate (ester); N-[2-(Nitrooxy)ethyl]pyridine-3-carboxamide; 2 Nicotinamidethyl Nitrate; 2 Nicotinamidoethyl Nitrate; 2-(Nicotinamido)ethyl nitrat; 2-(Pyridine-3-carboxamido)ethyl Nitrate; 2-(pyridine-3-carbonylamino)ethyl nitrate; 2-Nicotinamidethyl Nitrate; 2-Nicotinamidoethyl nitrate; 2-[(pyridin-3-ylcarbonyl)amino]ethylnitrat"	47528	C8H9N3O4	Approved
M6APDG03602	ISIS 6957	.	.	.	Investigative
M6APDG04127	Ertumaxomab	"Rexomab; Rexomun; Trifunctional antibody (breast cancer), TRION/Fresenius; Trifunctional bispecific (CD3/Her2/neu) antibody (breast cancer), TRION/Fresenius"	.	.	Phase 2
M6APDG00727	"3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione"	"CHEMBL29339; 3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione"	13660225	C17H24N2O2	Investigative
M6APDG00901	"4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole"	"4,5,6,7-tetrabromobenzotriazole"	1694	C6HBr4N3	Investigative
M6APDG02652	Squalestatin 1	"Zaragozic acid A; squalestatin 1; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo"	6438355	C35H46O14	Terminated
M6APDG01307	6-Hydroxyflavanone	"6-Hydroxyflavanone; 4250-77-5; 6-hydroxy-2-phenylchroman-4-one; 6-hydroxy-2-phenyl-2,3-dihydro-4H-chromen-4-one; 6-Hydroxy-Flavanone; CHEMBL195033; 4H-1-Benzopyran-4-one, 2,3-dihydro-6-hydroxy-2-phenyl-; CHEBI:34471; XYHWPQUEOOBIOW-UHFFFAOYSA-N; 6-hydroxy-2-phenyl-chroman-4-one; MFCD00017485; 6-hydroxy-2-phenyl-2,3-dihydrochromen-4-one; Flavanone, 6-hydroxy-; (+/-)-6-Hydroxyflavanone; 6 - Hydroxyflavanone; ACMC-209jpu; AC1MC1GQ; Maybridge3_000570; 6-Hydroxyflavanone, 99%; bmse000985; C14221; Oprea1_761592; SCHEMBL126598"	2734580	C15H12O3	Investigative
M6APDG02799	Piceatannol	"piceatannol; 10083-24-6; 3-Hydroxyresveratol; piceatanol; astringinin; 3,5,3',4'-Tetrahydroxystilbene; (E)-4-(3,5-dihydroxystyryl)benzene-1,2-diol; 3,3',4'5-Tetrahydroxystilbene; 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol; 3,3',4,5'-Tetrahydroxystilbene; UNII-6KS3LS0D4F; NSC 365798; NSC-365798; NSC 622471; 6KS3LS0D4F; CHEMBL69863; 3,3',4,5'-Stilbenetetrol; 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol; 4339-71-3; CHEBI:28814; C14H12O4; NSC365798; NSC622471; 1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-"	667639	C14H12O4	Investigative
M6APDG02711	PYRAZOLOPYRIDAZINE 2	"PYRAZOLOPYRIDAZINE 2; pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539367	C18H16N6O2	Investigative
M6APDG01237	JB-1	JB1	25150849	C28H50O3	Investigative
M6APDG00303	BI 2536	"BI2536, BI 2536"	11364421	C28H39N7O3	Phase 2
M6APDG03201	F-12509A	.	9862964	C21H28O4	Terminated
M6APDG03527	ASC-JMZ1	.	.	.	Investigative
M6APDG01250	"8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"CHEMBL370045; BDBM27512; indeno[1,2-c]isoquinolinone, 1d; ZINC13652896; 8-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one"	25190931	C16H10FNO	Investigative
M6APDG01697	"2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol"	"CHEMBL187185; 2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol"	44394887	C17H15N3O2	Investigative
M6APDG03617	BAY-85-3474	"Met inhibitor (cancer), Bayer Schering"	.	.	Investigative
M6APDG01636	(1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine	CHEMBL284485; (1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine; SCHEMBL8561085; BDBM50099965	44279444	C22H17N5	Investigative
M6APDG02762	"3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine"	"3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine; CHEMBL206351; Dihydronaphthalene 4; AC1O70H9; SCHEMBL4504105; BDBM8891"	6540049	C16H15NO	Investigative
M6APDG03466	ISIS 105989	.	.	.	Investigative
M6APDG00027	M3541	"Aminomalonic acid; 1068-84-4; Aminomalonate; 2-Aminomalonic acid; 2-Aminopropanedioic Acid; alpha-Aminomalonic acid; Propanedioic acid, amino-; aminopropanedioic acid; Propanedioic acid,2-amino-; CHEBI:17475; C00872; Q-102736; Malonic acid, amino-; Aminomalonicacid; Aminopropanedioate; amino-Propanedioate; amino-Malonic acid; a-aminomalonic acid; NSC 352096; amino-Propanedioic acid; AC1L2PBO; .alpha.-Aminomalonic acid; AC1Q5S2H; Propanedioic acid, 2-amino-; SCHEMBL209221; Malonic acid, amino- (8CI); Jsp000609; CHEMBL1232731; KS-00000K"	100714	C3H5NO4	Phase 1
M6APDG01982	BAY 10-00394	roniciclib; BAY 1000394; BAY 10-00394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874	45380979	C18H21F3N4O3S	Discontinued in Phase 2
M6APDG00347	"1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione"	"CHEMBL201907; 1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione; SCHEMBL2086780; ZINC28569089"	11506860	C13H10N2O2	Investigative
M6APDG02229	ACACETIN	"acacetin; 480-44-4; Linarigenin; 5,7-Dihydroxy-4'-methoxyflavone; Acacetine; 4'-Methoxyapigenin; Buddleoflavonol; Linarisenin; Akatsetin; 5,7-Dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; Apigenin 4'-methyl ether; 5,7-Dioxy-4'-methoxyflavone; Apisenin 4'-methyl ether; Apigenin 4'-dimethyl ether; UNII-KWI7J0A2CC; NSC 76061; Flavone, 5,7-dihydroxy-4'-methoxy-; 5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one; ACAETIN; 4'-Methoxy-5,7-dihydroxyflavone; NSC76061; EINECS 207-552-3; KWI7J0A2CC"	5280442	C16H12O5	Investigative
M6APDG00126	UK-356618	"UK 356618; 230961-08-7; CHEMBL117225; UK-356,618; SCHEMBL6437730; GTPL6528; CHEBI:94305; DTXSID50438778; MolPort-023-277-089; ZINC3924338; BDBM50097263; AKOS024458021; FT-0675728; PF 03890101; PF-03890101; UK-356618, &gt; J-014983; BRD-K57011718-001-01-5; (R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-N*4*-hydroxy-2-[3-(2-methyl-biphenyl-4-yl)-propyl]-succinamide"	10370504	C34H43N3O4	Investigative
M6APDG04320	Mteron-F1	.	.	.	Preclinical
M6APDG04282	RBT-101	"RBT-102; RBT-103; RBT-104; Seasonal/pandemic influenza vaccines (VLPs); Seasonal/pandemic influenza vaccines (VLPs), Redbiotec; Seasonal/pandemic influenza vaccines (virus-like-particles), Redbiotec"	.	.	Phase 3
M6APDG04103	CART-HER-2	.	.	.	Phase 1/2
M6APDG04244	PF-4523655	.	.	.	Phase 2
M6APDG01663	"8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL116023; SCHEMBL7368359; BDBM50218558	44343094	C20H21F3O2	Investigative
M6APDG01090	"12,13-DEHYDROMANZAMINE A"	"12,13-dehydromanzamine A; CHEMBL268202"	23643835	C36H42N4	Investigative
M6APDG02255	MORIN	"morin; 480-16-0; Aurantica; Calico Yellow; Al-Morin; Toxylon Pomiferum; Morin hydrate; 2',3,4',5,7-Pentahydroxyflavone; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; Bois d,Arc; Osage Orange; Osage Orange Extract; Bois d'arc; C.I. Natural Yellow 11; C.I. Natural Yellow 8; Osage Orange Crystals; 3,5,7,2',4'-Pentahydroxyflavone; 3,5,7,2',4'-Pentahydroxyflavonol; 2'-Hydroxypelargidenolon 1522; 2',4',3,5,7-Pentahydroxyflavone; C.I. 75660; Zlut prirodni 11; 2',4',5,7-Tetrahydroxyflavan-3-ol; Bois d'arc [French]"	5281670	C15H10O7	Investigative
M6APDG01906	WZ-3146	"WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals"	44607360	C24H25ClN6O2	Investigative
M6APDG01302	2-Pyridinethiol	"2-Mercaptopyridine; Pyridine-2-thiol; 2-Pyridinethiol; 2637-34-5; 2-Thiopyridine; Pyrid-2-thione; 2(1H)-PYRIDINETHIONE; Pyridinethione; 1H-pyridine-2-thione; 73018-10-7; 2-pyridylthiol; 2-Thiopyridone; 2-Pyridinethione; 2-Mercapto pyridine; 2-Pyridyl mercaptan; 1,2-dihydropyridine-2-thione; Thiopyridone-2 [French]; 2-pyridinylthiol; Alrithiol-2; NSC 41337; UNII-EE982KT952; CHEBI:45223; EINECS 220-131-9; WHMDPDGBKYUEMW-UHFFFAOYSA-N; EE982KT952; 29468-20-0; 2-Mercaptopyridine, 98%; Thiopyridone-2; PYS; Pyridinethiol; mercaptopyridine"	2723698	C5H5NS	Investigative
M6APDG02346	AG-538	"Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3&amp; -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02"	5328760	C16H11NO5	Investigative
M6APDG00749	(2S)-abyssinone II	"Licoflavanone; (2S)-abyssinone II; CHEMBL457680; SCHEMBL3364539; MolPort-006-668-332; BDBM50251004; LMPK12140288; AKOS027393733; MCULE-9485581712; 4',5,7-trihydroxy-3'-prenylflavanone; (S)-4',5,7-Trihydroxy-3'-prenylflavanone"	14218027	C20H20O5	Investigative
M6APDG03491	HYG-440	"HYG-410; HYG-420; HYG-430; Androgen receptor antagonists (topical, dermatological disorder), hygeia"	.	.	Investigative
M6APDG03803	EZN-2968	.	.	.	Phase 1
M6APDG03711	ISIS 133211	.	.	.	Investigative
M6APDG02168	"3,4,5-Trimethoxy-3'-amino-trans-stilbene"	CHEMBL1173065; SCHEMBL17236642; BDBM50322052	49799650	C17H19NO3	Investigative
M6APDG01974	"2,4'-Dimethoxy-5,3'-dipropyl-biphenyl"	CHEMBL560262; BDBM50295928	45267390	C20H26O2	Investigative
M6APDG03573	ISIS 122986	.	.	.	Investigative
M6APDG03699	AR-mTOR-26	"AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma"	.	.	Investigative
M6APDG02724	3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 19a; SCHEMBL4226312; CHEMBL425323; SCHEMBL4226322; BDBM8597; AC1O704X; 3-[(E)-(5-ethoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539773	C17H17NO	Investigative
M6APDG03068	Cypate-[(RGD)4-NH2]2	.	91936297	C136H201N52O42+	Investigative
M6APDG01728	N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide	CHEMBL198832; N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide	44405454	C21H16F3NO3	Investigative
M6APDG03737	ISIS 29178	.	.	.	Investigative
M6APDG01596	ST-2986	ST-2986; CHEMBL471041; SCHEMBL3444455; BDBM50278219	44138031	C17H11F5N2O3	Investigative
M6APDG00138	N-(4-(phenylamino)quinazolin-6-yl)acrylamide	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide	10401956	C17H14N4O	Investigative
M6APDG03672	XGP-110	"Synoviocyte/tumor cell inhibitor + COX-2 inhibitor (arthritis/cancer/cancer pain), Xaragen"	.	.	Investigative
M6APDG00909	(S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid	"delta-N-Methylarginine; N(5)-methyl-L-arginine; CHEMBL99636; N(5)-carbamimidoyl-N(5)-methyl-L-ornithine; CHEBI:21848; 77044-73-6; L-NMA; 6-monomethyl-l-arginine; AC1Q3XG3; AC1L5A8F; SCHEMBL2307076; DTXSID70227848; BDBM50049254; L-Ornithine, N(5)-(aminoiminomethyl)-N(5)-methyl-; (2S)-2-amino-5-[carbamimidoyl(methyl)amino]pentanoic acid; (2S)-2-amino-5-(carbamimidoyl-methylamino)pentanoic acid"	173566	C7H16N4O2	Investigative
M6APDG03037	BVB-808	"JAK2 tyrosine kinase inhibitors (cancer), Novartis; NVP-BSK-805"	90480481	C29H33F2N7O	Investigative
M6APDG01755	"4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione"	"CHEMBL204456; 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione"	44409922	C20H19NO2	Investigative
M6APDG02309	Asp-BrPmp-Leu	Asp-BrPmp-Leu; CHEMBL1289231; BDBM50331945	52949968	C20H29BrN3O9P	Investigative
M6APDG00486	4-(1-Imidazol-1-yl-vinyl)-benzonitrile	"CHEMBL31760; Benzonitrile, 4-[1-(1H-imidazol-1-yl)ethenyl]-; 112809-36-6; 4-(1-Imidazol-1-yl-vinyl)-benzonitrile; SCHEMBL1507802; BDBM50047259; 4-(1-(1H-imidazol-1-yl)vinyl)benzonitrile"	11819989	C12H9N3	Investigative
M6APDG03292	APC-100	.	99479	C14H20O2	Phase 1/2
M6APDG03673	VLI-27	"AKT inhibitor (pancreatic cancer), NovaLead Pharma"	.	.	Investigative
M6APDG01674	Z-Arg-Leu-Val-Agly-Val-Ala-NH2	.	44355111	C34H57N11O8	Investigative
M6APDG03729	ISIS 29155	.	.	.	Investigative
M6APDG00624	ADU-S100	MIW815; IZJJFUQKKZFVLH-LTKSHMRXSA-N; 1638241-89-0; AKOS027321070; HY-12885	135390762	C20H22N10Na2O10P2S2	Phase 2
M6APDG03947	Hepapoietin	"APS-1010; Hepapoietin, SnowBrand; Hepapoietin (liver/kidney disease); Hepapoietin (liver/kidney disease), Atlas Pharmaceuticals"	.	.	Phase 1
M6APDG03615	RP-1040	"RP-1086; RP-1087; RP-1088; RP-1101; RP-1103; RP-1105; RP-1109; RP-1110; RP-1111; RP-1112; C-Met kinase inhibitors (oral,cancer); C-Met kinase inhibitors (oral, cancer), Incozen Therapeutics/Rhizen Pharmaceuticals"	.	.	Investigative
M6APDG02927	CEP-37440	"Dual ALK/FAK inhibitor (cancer), Cephalon; Dual anaplastic lymphoma kinase/focal adhesion kinase inhibitor (cancer),Cephalon"	71721648	C30H38ClN7O3	Phase 1
M6APDG03285	THIQ	"MB-243; MC4 receptor agonists (obesity); MK-0489; MZ-767; PG-917; PG-946; RY-764; Anti-obesity therapy, Merck &Co; MC4 receptor agonists (obesity), Merck & Co; Melanocortin agonists (obesity/erectile dysfunction), Merck & Co"	9938402	C33H41ClN6O2	Investigative
M6APDG02318	KN-62	KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863	5312126	C38H35N5O6S2	Investigative
M6APDG00177	3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide	CHEMBL77258; 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide	10565532	C13H25NO4S	Investigative
M6APDG01604	AC-Nle-c[Asp-His-DPhe-Pro-Trp-Lys]-NH2	CHEMBL501642; AC-Nle-c[Asp-His-DPhe-Pro-Trp-Lys]-NH2	44158031	C49H64N12O9	Investigative
M6APDG02776	Repaglinide	"Actulin; GlucoNorm; NovoNorm; Prandin; Repaglinida; Repaglinidum; Glaxo Wellcome brand of replaginide; Novo Nordisk brand of repaglinide; Repaglinide [USAN]; Novo Nordisk brand 2 of repaglinide; AG-EE 388; AG-EE 388 ZW; AG-EE 623 ZW; AGEE-623ZW; GlucoNorm (TN); NN-623; NovoNorm (TN); Prandin (TN); Repa-glinide; Repaglinida [INN-Spanish]; Repaglinidum [INN-Latin]; SMP-508; AG-EE-388; AG-EE-623 ZW; Prandin, GlucoNorm, NovoNorm, Repaglinide; Repaglinide (JAN/USP/INN); Repaglinide, (+-)-isomer; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid"	65981	C27H36N2O4	Approved
M6APDG01973	"1-benzyl-1H-pyrrolo[3,2-b]pyridine"	"1-benzyl-1H-pyrrolo[3,2-b]pyridine; CHEMBL561256; 1-benzyl-4-azaindole; 1h-pyrrolo[3,2-b]pyridine,1-(phenylmethyl)-; SCHEMBL4716978; LOGFFHFLSCMKJF-UHFFFAOYSA-N; BDBM50295764; ZINC43079815; 50426-35-2"	45267314	C14H12N2	Investigative
M6APDG03384	Cetuximab	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	.	.	Approved
M6APDG04028	TAS3681	.	.	.	Phase 1
M6APDG01531	"5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione"	"5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione; 220510-17-8; 5-(Pyrrolidine-1-sulfonyl)-1H-indole-2,3-dione; Isatin Sulfonamide 20; 5-pyrrolidinylsulfonylisatin; AC1N3S5K; 5-pyrrolidin-1-ylsulfonyl-1H-indole-2,3-dione; SCHEMBL2486952; CHEMBL305545; BDBM10309; DTXSID80399500; QKCWUYHXHMXOLG-UHFFFAOYSA-N; ZINC2944777; 5-[1-(pyrrolidinyl)sulfonyl]isatin; 2991AJ; AKOS024262065; AJ-44312; 5-(Pyrrolizinosulfonyl)indoline-2,3-dione; AX8291337; FT-0734877; 5-(Pyrrolidin-1-ylsulfonyl)-1H-indole-2,3-dione"	4117381	C12H12N2O4S	Investigative
M6APDG00963	7-Nitroindazole-2-Carboxamidine	7-nitroindazole-2-carboxamidine; 7-nitro-2h-indazole-2-carboximidamide; 7I2; AC1L1CGX; SCHEMBL4315825; CTK5I3867; 7-nitroindazole-2-carboximidamide; 7-Nitro-2H-indazole-2-carboxamidine	1894	C8H7N5O2	Investigative
M6APDG01204	PF-04691502	"PF-04691502; 1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one"	25033539	C22H27N5O4	Phase 2
M6APDG03686	ISIS 114530	.	.	.	Investigative
M6APDG03432	Ranagengliotucel-T	"Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx"	.	.	Discontinued in Phase 3
M6APDG01541	SB-415286	"SB 415286; 264218-23-7; SB-415286; SB415286; 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione; CHEMBL322970; 3-(3-chloro-4-hydroxyanilino)-4-(2-nitrophenyl)pyrrole-2,5-dione; 3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione; 1H-Pyrrol-2,5-dione, 3-((3-chloro-4-hydroxyphenyl)amino)-4-(2-nitrophenyl)-; SMR000568415; SR-01000075855"	4210951	C16H10ClN3O5	Investigative
M6APDG00144	5-Fluoro-3-thiophen-3-yl-quinoline	CHEMBL305056; 5-fluoro-3-thiophen-3-yl-quinoline; SCHEMBL8501434; ZINC3834023	10421346	C13H8FNS	Investigative
M6APDG03414	Fontolizumab	Fontolizumab (USAN/INN)	.	.	Discontinued in Phase 2
M6APDG04166	APG-101	"CD95 receptor extracellular domain-IgG fused protein (GvHD), Apogenix; CD95 receptor extracellular domain-IgG fused protein (myocardial infarction), Apogenix; CD95 receptor extracellular domain-IgG fused protein (stroke), Apogenix; CD95 receptor extracellular domain-immunoglobulin G fused protein (graft versus hostdisease), Apogenix"	.	.	Phase 2
M6APDG02995	G749	G-749	78357765	C25H25BrN6O2	Investigative
M6APDG03864	MR1-1	"MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX"	.	.	Phase 1
M6APDG03382	Somatomedin-1	Igef (TN)	.	.	Approved
M6APDG00794	"[1,4]Thiazepan-(5E)-ylideneamine"	"CHEMBL88308; [1,4]Thiazepan-(5E)-ylideneamine; SCHEMBL10239183; 5-Iminohexahydro-1,4-thiazepine; [1,4]Thiazepan-(5Z)-ylideneamine; BDBM50104653"	15463447	C5H10N2S	Investigative
M6APDG04195	VAS-203	"NOS inhibitor, Vasopharm; Nitric oxide synthase inhibitor, Vasopharm"	.	.	Phase 2
M6APDG04297	Beperminogene perplasmid	.	.	.	Phase 3
M6APDG01396	Etodolac	"etodolac; 41340-25-4; Etodolic acid; Lodine; Ultradol; Lodine XL; Etodolacum; Etodolaco; Ramodar; AY 24236; Etodolacum [INN-Latin]; Etodolaco [INN-Spanish]; AY-24236; AY-24,236; Edolan; CCRIS 3923; 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; CHEMBL622; NSC 282126; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1"	3308	C17H21NO3	Approved
M6APDG02218	2-amino-quinoline-3-carboxylic acid amide	"2-aminoquinoline-3-carboxamide; 31407-28-0; 3-Quinolinecarboxamide, 2-amino-; 2-amino-quinoline-3-carboxylic acid amide; 2-amino-3-quinolinecarboxamide; CHEMBL206956; GXZOXGRLLFZVGF-UHFFFAOYSA-N; ZERO/004541; AC1NP94V; SCHEMBL30837; CTK7D2638; MolPort-002-742-881; ZX-AN021879; ALBB-023365; STK735522; BDBM50186621; SBB012747; ZINC19890815; FCH854771; AKOS003368785; MCULE-6676169786; NCGC00340196-01; 2-Aminoquinoline-3-carboxylic acid amide; OR346178; KB-118564; 2-amino-3-quinolinecarboxamide, AldrichCPR; ST4128359; R9463"	5200228	C10H9N3O	Investigative
M6APDG03555	ISIS 188759	.	.	.	Investigative
M6APDG00348	3-(6-methoxynaphthalen-2-yl)pyridine	CHEMBL362968; 3-(6-methoxynaphthalen-2-yl)pyridine; BDBM8905; SCHEMBL4500403; Pyridine-substituted naphthalene 2; 3-(6-methoxy-2-naphthyl)pyridine	11506923	C16H13NO	Investigative
M6APDG01287	Diacerein	"Diacerein; 13739-02-1; Diacetylrhein; Diacerhein; Fisiodar; Artrodar; 1,8-DIACETOXY-3-CARBOXYANTHRAQUINONE; DIACERIN; 4,5-Diacetylrhein; Diacereinum [Latin]; Diacereine [French]; Diacereina [Spanish]; UNII-4HU6J11EL5; Diacerein [INN]; SF-277; C19H12O8; EINECS 237-310-2; BRN 2184909; 4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid; MLS000028577; 4HU6J11EL5; 1,8-Diacetoxyanthraquinone-3-carboxylic acid; Diacerein (INN); 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid; NCGC00018274-04; SMR000058958; AK468692"	26248	C19H12O8	Phase 4
M6APDG02605	DARGLITAZONE	"CP-86325; Darglitazone < Rec INN; Rac-5-[4-[3-(5-Methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione"	60870	C23H20N2O4S	Terminated
M6APDG03576	F61F12	"Anti-Fas mAb (cancer), IMED"	.	.	Investigative
M6APDG00721	"(11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid"	CHEMBL33378; ZINC29221898	13640140	C15H12O4	Investigative
M6APDG02640	PSAMMAPLIN A	"Psammaplin A; 110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-"	6400741	C22H24Br2N4O6S2	Investigative
M6APDG02491	Ro-27-3225	.	56603736	C41H54N10O6	Preclinical
M6APDG02196	(E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide	CHEMBL1288802; (E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide	50908699	C12H11NO2S2	Investigative
M6APDG00971	3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol	CHEMBL295066; 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol; SCHEMBL7208466	19366816	C13H18O3S2	Investigative
M6APDG03086	Vitamin B3	Niacin (TN); Niacinamide (TN); Nicotinamide (TN)	938	C6H5NO2	Approved
M6APDG04212	ALD-518	.	.	.	Phase 2
M6APDG03147	CIPEMASTAT	"Cipemastat; Trocade; Ro 32-3555; 190648-49-8; UNII-02HQ4TYQ60; 02HQ4TYQ60; GFUITADOEPNRML-SJORKVTESA-N; Cipemastat [USAN:INN]; Ro 32-3555/000; Trocade (TN); Cipemastat (USAN/INN); GTPL6466; CHEMBL115653; SCHEMBL7088217; CTK8F1312; BDBM30344; MolPort-023-276-601; ZINC600699; (alphaR,betaR)-beta-(Cyclopentylmethyl)-gamma-oxo-alpha-((3,4,4-piperidinebutyrohydroxamic acid; AKOS024457333; HY-19677; Ro-32-03555; Ro-323555000; RT-015421; RO32-3555; CS-0016192; D03517; J-012306"	9824350	C22H36N4O5	Phase 3
M6APDG01533	CCX915	"Meglitinide; 54870-28-9; Meglitinide [INN]; Meglitinidum [INN-Latin]; Meglitinido [INN-Spanish]; HB 699; UNII-8V6OK1I088; BRN 2817215; 8V6OK1I088; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)benzoic acid; 4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)benzoasaeure [German]; p-(2-(5-Chloro-o-anisamido)ethyl)benzoic acid; C17H16ClNO4; 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid; Meglitinido; Meglitinidum; Benzoic acid, 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]-"	41214	C17H16ClNO4	Discontinued in Phase 1
M6APDG03461	Oxindole 95	.	.	.	Investigative
M6APDG00888	GSK690693	"937174-76-0; GSK690693; GSK-690693; GSK 690693; UNII-GWH480321B; (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol; CHEBI:90677; GWH480321B; 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol; 4-{2-(4-Amino-1,2,5-Oxadiazol-3-Yl)-1-Ethyl-7-[(3s)-Piperidin-3-Ylmethoxy]-1h-Imidazo[4,5-C]pyridin-4-Yl}-2-Methylbut-3-Yn-2-Ol; J-502225; C21H27N7O3"	16725726	C21H27N7O3	Phase 1
M6APDG01407	NSC-345763	"NSC-345763; 7-(8-hydroxyquinolin-5-yl)-4,7-dioxoheptanoic acid; NSC345763; AC1L7HSU; CHEMBL597114"	335596	C16H15NO5	Investigative
M6APDG00881	AZD1480	RET inhibitors	16659841	C14H14ClFN8	Phase 2
M6APDG01696	OXENDLONE	"oxendolone; 33765-68-3; Prostetin; 16b-Ethyl-19-nortestosterone; UNII-MN4I850D4P; TSAA-291; MN4I850D4P; NCGC00183854-01; Tsaa 291; Oxendolonum [INN-Latin]; Oxendolona [INN-Spanish]; Oxendolone [USAN:INN:JAN]; Oxendolona; Oxendolonum; 16-beta-Ethyl-19-nortestosterone; 16-Ethyl-17-hydroxyester-4-en-3-one; (8R,9S,10R,13S,14S,16S,17S)-16-ethyl-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; 16beta-Ethyl-17beta-hydroxyestr-4-en-3-one; 16-beta-Ethyl-17-beta-hydroxyestr-4-en-3-one"	443947	C20H30O2	Investigative
M6APDG01143	ARRY-614	"Pexmetinib; 945614-12-0; ARRY-614; Pexmetinib (ARRY-614); UNII-3750D0U8B5; 3750D0U8B5; Pexmetinib [INN]; Pexmetinib;ARRY-614; Pexmetinib(ARRY-614); ARRY614; SCHEMBL379035; GTPL9917; MolPort-039-193-822; LNMRSSIMGCDUTP-UHFFFAOYSA-N; BCP28410; EX-A1421; s7799; ZINC41747181; AKOS032945154; SB16914; Urea, N-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-((5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)phenyl)methyl)-"	24765037	C31H33FN6O3	Discontinued in Phase 1
M6APDG01955	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide	N-(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)BENZAMIDE; CHEMBL324942; N-(3-cyclopropyl-1H-pyrazol-5-yl)benzamide; N5B; 1vyz; AC1L9MPJ; SCHEMBL4314346; BDBM7127; LUCORKWTQSQFFU-UHFFFAOYSA-N; 3-Benzamidoaminopyrazole deriv. 4; DB02647	449088	C13H13N3O	Investigative
M6APDG00207	"Inositol 1,3,4,5-Tetrakisphosphate"	"inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate"	107758	C6H16O18P4	Investigative
M6APDG02251	"3,7,3',4'-TETRAHYDROXYFLAVONE"	"Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; 3,7,3',4'-Tetrahydroxyflavone; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1; FISETIN"	5281614	C15H10O6	Investigative
M6APDG04052	MP0250	.	.	.	Phase 1/2
M6APDG03821	RTA-901	.	.	.	Phase 1
M6APDG01827	N-(4-aminobiphenyl-3-yl)benzamide	N-(4-aminobiphenyl-3-yl)benzamide; CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide	44454143	C19H16N2O	Investigative
M6APDG00698	AZD-1080	.	135564570	C19H18N4O2	Discontinued in Phase 1
M6APDG02764	"3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine"	"3-(1-ethyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 7; AC1O70HD; 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine; CHEMBL205503; BDBM8893; SCHEMBL4505824; CTK6D0393; ZINC13684518; AKOS015965702"	6540051	C17H17N	Investigative
M6APDG01264	3-(4-cyanophenyl)quinoxaline-5-carboxamide	"CHEMBL481603; quinoxaline analogue, 3c; 3-(4-cyanophenyl)quinoxaline-5-carboxamide; SCHEMBL7108289"	25218518	C16H10N4O	Investigative
M6APDG01617	(E)-12-Nitrooctadec-12-enoic Acid	CHEMBL549351; (E)-12-Nitrooctadec-12-enoic Acid; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid	44221100	C18H33NO4	Investigative
M6APDG01828	N-(4-aminobiphenyl-3-yl)nicotinamide	CHEMBL255805; N-(4-aminobiphenyl-3-yl)nicotinamide; BDBM50232035	44454415	C18H15N3O	Investigative
M6APDG02202	Pyrotinib	"UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho"	51039030	C32H31ClN6O3	Phase 1
M6APDG03259	DRF 2519	"DRF 2519; 5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2"	9908833	C20H18N2O5S	Investigative
M6APDG02611	4-ANDROSTENE-3-17-DIONE	"Androstenedione; androstenedione; 4-Androstene-3,17-dione; Androst-4-ene-3,17-dione; 1963/5/8; 4-Androstenedione; Androtex; 3,17-Dioxoandrost-4-ene; delta-4-Androstenedione; SKF 2170; Fecundin; delta-4-Androsten-3,17-dione; delta-4-Androstene-3,17-dione; Androstendione; 4-Androsten-3,17-dione; NSC 9563; delta-(sup4)-Androsten-3,17-dione; delta(sup 4)-Androstene-3,17-dione; UNII-409J2J96VR; 17-Ketotestosterone; d4-androstenedione; CHEBI:16422; Androstenedione [JAN]; HSDB 7335; EINECS 200-554-5; MLS000028510; NSC9563; ANDROSTENEDIONE"	6128	C19H26O2	Investigative
M6APDG04370	MOR-102	"MOR-101; MOR-101); ICAM-1 antibody (inflammation), MorphoSys"	.	.	Terminated
M6APDG02371	1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 14; AC1NS9HN; CHEMBL140624; BDBM6654; ZINC13471112; 1-(7-Hydroxy-1-naphthyl)-3-(2-pyridyl)urea; N-(7-Hydroxy-1-naphthyl)-N -pyridin-2-ylurea; 1-(7-hydroxynaphthalen-1-yl)-3-pyridin-2-ylurea	5330595	C16H13N3O2	Investigative
M6APDG01544	ARRY-380	"937265-83-3; ARRY-380 Analog; ARRY-380 (analog ); UNII-H32S1659ED; HER2-Inhibitor-1; H32S1659ED; 6-[5-[[[2-(Methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4-quinazolinamine; HER2 Inhibitor 1; SCHEMBL10169911; C29H27N7O4S; DTXSID00239555; MolPort-023-293-540; HMS3656B04; BDBM185146; EX-A1261; AOB87708; BCP02833; ZINC73096245; 2227AH; s2752; AKOS026750520; CS-0484; SB16599; BCP9000319; NCGC00346672-01; NCGC00346672-06"	42598643	C29H27N7O4S	Phase 1
M6APDG02305	SB-207043	SB-207043; CHEMBL606910	52942958	C47H69N11O10S2	Investigative
M6APDG02717	3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 5b; BDBM8587; CHEMBL383806; AC1O704F; SCHEMBL4220962; ZINC13610771; 3-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539764	C15H12FN	Investigative
M6APDG01246	L-Tryptophan-L-arginine	"CHEMBL477417; CHEBI:74866; 88831-09-8; Tryptophyl-Arginine; L-tryptophyl-L-arginine; L-Arginine, L-tryptophyl-; L-Tryptophan-L-arginine; tryptophanyl-arginine; L-Trp-L-Arg; SCHEMBL4947728; CTK3A5775; WR; ZINC2561117; BDBM50266680; AKOS030606594; H-Trp-Arg-OH  inverted exclamation mark currency 2 HCl"	25186251	C17H24N6O3	Investigative
M6APDG00172	"Benzo[c][1,5]naphthyridin-6(5H)-one"	"benzo[c][1,5]naphthyridin-6(5H)-one; CHEMBL320031; Benzo[c]-1,5-naphthyridin-6(5H)-one; SCHEMBL12750384; BDBM50130585; 5H-Benzo[c][1,5]naphthyridin-6-one; Benzo[c][1,5]naphthyridine-6(5H)-one"	10535869	C12H8N2O	Investigative
M6APDG00267	"NEOLIGNAN 9-NOR-7,8-DEHYDRO-ISOLICARIN B"	"Neolignan 9-nor-7,8-dehydro-isolicarin B; CHEMBL571199; BDBM50303146"	11243755	C19H16O4	Investigative
M6APDG01775	Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)	CHEMBL374108; cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)	44418865	C33H40N8O6	Investigative
M6APDG00127	C[RGDf-(S)-N-Me-alpha-TfmF]	CHEMBL413574; c[RGDf-(S)-N-Me-alpha-TfmF]	10372586	C32H39F3N8O7	Investigative
M6APDG01006	Aminoglutethimide	"Aminoglutethimidum; Aminoglutetimida; Cytadren; Elipten; Orimeten; Ciba Vision Brand of Aminoglutethimide; Novartis Brand of Aminoglutethimide; A 9657; Ba 16038; AG-1; Aminoglutethimide (AG); Aminoglutethimide [INN:BAN]; Aminoglutethimidum [INN-Latin]; Aminoglutetimida [INN-Spanish]; Ba-16038; C 16038-BA; Cytadren (TN); Dl-Aminoglutethimide; P-Aminoglutethimide; Aminoglutethimide (USP/INN); Glutethimide, para-amino; Alpha-(p-Aminophenyl)-alpha-ethylglutarimide; (+-)-3-(p-Aminophenyl)-3-ethyl-2,6-piperidinedione; (+/-)-p-AMINOGLUTETHIMIDE; (inverted question mark)-p-Aminoglutethimide; 2-(p-Aminophenyl)-2-ethylglutarimide; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine"	2145	C13H16N2O2	Approved
M6APDG00202	Benzyl-(9-isopropyl-9H-purin-6-yl)-amine	"CHEMBL85015; 111853-20-4; 9H-Purin-6-amine, 9-(1-methylethyl)-N-(phenylmethyl)-; purine deriv. 9; ACMC-20mewm; SCHEMBL754120; BDBM10641; CTK0D3360; DTXSID10444118; 6-(benzylamino)-9-isopropylpurine; ZINC13538226; AKOS030562149; 6-(Benzylamino)-9-isopropyl-9H-purine; N-benzyl-9-isopropyl-9H-purin-6-amine"	10730551	C15H17N5	Investigative
M6APDG03571	ISIS 122984	.	.	.	Investigative
M6APDG02577	ML323	ML 323; ML-323	60167849	C23H24N6	Preclinical
M6APDG02191	Ro31-8220	"Bisindolylmaleimide IX; ro 31-8220; bisindolylmaleimide IX; 125314-64-9; Ro 31 8220; Ro 318220; UNII-W9A0B5E78O; Ro-318220; Ro-31-8220; CHEMBL6291; W9A0B5E78O; CHEBI:38912; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl carbamimidothioate; Ro 31-8220 ; 3-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}propyl imidothiocarbamate; CHEMBL1591531; Carbamimidothioic acid, 3-(3-(2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl;  Ro 318220; bisindolymaleimide IX; BISINDOLYLMALEIMIDE IX"	5083	C25H23N5O2S	Investigative
M6APDG00274	4-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one	"CHEMBL427247; 2H-1-Benzopyran-2-one, 4-(1H-imidazol-1-ylmethyl)-; 828265-54-9; Coumarin deriv. 19; BDBM9470; CTK3D6009; DTXSID40460922; ZINC13586713"	11276192	C13H10N2O2	Investigative
M6APDG00984	BzT-7	"CHEMBL1958337; 8-Chloro-1,4-Dimethyl-6-Phenyl-4h-[1,2,4]triazolo[4,3-A][1,3,4]benzotriazepine; BzT-7; 3u5l; GTPL7515; SCHEMBL11468349; UYIVCPRWMLOCSB-UHFFFAOYSA-N; BDBM50365263; 8-chloro-1,4-dimethyl-6-phenyl-[1,2,4]triazolo[4,3-a][1,3,4]benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a)(1,3,4)benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a)(1,3,4 )benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a) (1,3,4)benzotriazepine"	20350618	C17H14ClN5	Investigative
M6APDG03323	BMS 536924	.	135440466	C25H26ClN5O3	Preclinical
M6APDG04147	Resten-NG	Resten-NG (TN)	.	.	Phase 2
M6APDG02946	Parthenolide	"parthenolide; 20554-84-1; (-)-Parthenolide; CHEBI:7939; Parthenolide, Tanacetum parthenium; 4,5-alpha-Epoxy-6-beta-hydroxygermacra-1(10),11(13)-dien-12-oic acid gamma-lactone; partenolide; C15H20O3; 29552-41-8; Prestwick2_000550; Prestwick3_000550; Epitope ID:115014; SCHEMBL8220; BSPBio_001308; BSPBio_000599; MLS002153872; CHEMBL465158; BPBio1_000659; SCHEMBL13367522; BCBcMAP01_000041; Parthenolide, &gt; MolPort-008-268-168; MolPort-003-959-089; HMS1361B10; HMS3402B10; HMS1989B10; HMS1791B10; HMS1569N21; HMS2096N21"	7251185	C15H20O3	Phase 2
M6APDG00397	C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2	CHEMBL427205; c[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2	11593084	C42H59N11O7	Investigative
M6APDG01443	NSC-613604	"NSC-613604; CHEMBL572637; 5-(4-chlorophenylamino)-2-methyl-9-nitro-5H-chromeno[4,3-b]pyridine-3-carbonitrile; NSC613604; AC1Q21JI; AC1L78ZM; BDBM50298486; 5-(4-chloroanilino)-2-methyl-9-nitro-5H-chromeno[4,3-b]pyridine-3-carbonitrile"	356713	C20H13ClN4O3	Investigative
M6APDG01069	"[1,3]Oxazinan-(2E)-ylideneamine"	"5,6-dihydro-4h-1,3-oxazin-2-amine; CHEMBL161118; 1848-68-6; [1,3]Oxazinan-(2E)-ylideneamine; SCHEMBL31223; 2-iminotetrahydro-1,3-oxazine; MolPort-044-586-586; BDBM50049258; ZINC13746441; AKOS025312622; AKOS006338233; 2-amino-5,6-dihydro-4h-1,3-oxazine"	23042899	C4H8N2O	Investigative
M6APDG02520	CO-1686	"1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284"	57335384	C27H28F3N7O3	Phase 3
M6APDG03328	BMS-298585	Muraglitazar; 331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N	206044	C29H28N2O7	Phase 3
M6APDG01048	N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide	CHEMBL1097694; N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666	22319511	C18H18ClN3O	Investigative
M6APDG02503	KW-2450	.	56847547	C35H37N5O6S2	Discontinued in Phase 1/2
M6APDG00332	"4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine"	"4-(Phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine; 736142-84-0; 7h-pyrrolo[2,3-d]pyrimidine,4-(phenylthio)-; SCHEMBL191691; CHEMBL360302; TUBUPSQEQADRHY-UHFFFAOYSA-N; ZINC13608572; KB-270401; 7H-Pyrrolo[2,3-d]pyrimidine, 4-(phenylthio)-"	11481564	C12H9N3S	Investigative
M6APDG00063	RHEIN	"Rhein; 478-43-3; Monorhein; Rheic acid; Rhubarb Yellow; Cassic acid; 4,5-Dihydroxyanthraquinone-2-carboxylic acid; Chrysazin-3-carboxylic acid; 4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; NSC 38629; Rheinic acid; 1,8-Dihydroxyanthraquinone-3-carboxylic acid; dipropionyl rhein; 1,8-Dihydroxy-3-carboxyanthraquinone; UNII-YM64C2P6UX; Rhein(Monorhein); 2-Anthracenecarboxylic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-; CCRIS 5129; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid; C15H8O6"	10168	C15H8O6	Investigative
M6APDG02886	N-[(4-methoxyphenyl)sulfonyl]-D-alanine	"n-4'-methoxybenzenesulfonyl-d-alanine; N-[(4-methoxyphenyl)sulfonyl]-D-alanine; 918330-60-6; AC1LE3DF; SCHEMBL4618694; CTK3H8025; ZINC91137; DTXSID60351641; MolPort-013-146-011; AKOS017427177; DB08599; D-Alanine, N-[(4-methoxyphenyl)sulfonyl]-; (R)-2-(4-Methoxyphenylsulfonamido)propanoic acid; (2R)-2-(4-methoxybenzenesulfonamido)propanoic acid; (2R)-2-[(4-methoxyphenyl)sulfonylamino]propanoic acid"	705712	C10H13NO5S	Investigative
M6APDG01765	C(his-D-phe-arg-trp-Ahp)	CHEMBL379959	44413536	C39H51N11O5	Investigative
M6APDG01721	SB-227931	SB-227931; CHEMBL371720; BDBM50173166	44404442	C24H20IN7O	Investigative
M6APDG03725	ISIS 29137	.	.	.	Investigative
M6APDG03251	MDL-18962	"Plomestane; UNII-FL3VS913TW; MDL-18962; 77016-85-4; FL3VS913TW; 10-(2-Propynyl)estr-4-ene-3,17-dione; Plomestane [USAN:INN]; MDL 18,962; 10-propargylestr-4-ene-3,17-dione; Estr-4-ene-3,17-dione, 10-(2-propynyl)-; Plomestane (USAN/INN); SCHEMBL3434; CHEMBL2105261; JKPDEYAOCSQBSZ-OEUJLIAZSA-N; ZINC4217337; BDBM50421840; 10beta-propargyl-estra-4-ene-3,17-dione; 10-(2-propynyl)-estr-4-ene-3,17-dione"	9904788	C21H26O2	Investigative
M6APDG03583	AD-412	"JAK3 inhibitor (autoimmune disease/transplant rejection), INSERM"	.	.	Investigative
M6APDG02440	L-701324	"L-701324; 142326-59-8; L-701,324; L 701324; UNII-I9WY146163; C21H14ClNO3; L 701,324; CHEMBL31741; 7-Chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(1H)-quinolone; I9WY146163; 7-Chloro-4-hydroxy-3-(3-pheoxyphenyl)-2(1H)-quinolinone; 2(1H)-Quinolinone, 7-chloro-4-hydroxy-3-(3-pheoxyphenyl)-; SMR000326934; compund 13 [PMID: 8182696]; Tocris-0907; AC1L3GJN; Biomol-NT_000206; MLS002153302; MLS000860076; GTPL4240; SCHEMBL1998890; BPBio1_001264; CHEBI:92140; DTXSID00162016; EX-A587; MolPort-003-941-887; 2(1H)-Quinolinone, 7-chloro-4-hydroxy-3-(3-ph"	54682505	C21H14ClNO3	Terminated
M6APDG04373	INXC-ICAM1	"Antisense ICAM-1-TCS, Inex; ICAM-1 antisense (inflammation), INEX; Transmembrane carrier system (antisense ICAM-1), Inex; Antisense (ICAM-1, inflammation), INEX"	.	.	Terminated
M6APDG03619	PRS-110	"C-Met inhibitor (cancer), Pieris; C-mesenchymal-epithelial transition factor (lipoprotein/protein recombinant, cancer), Pieris AG"	.	.	Investigative
M6APDG00903	FARGLITAZAR	"Farglitazar; GI-262570; GI262570; 196808-45-4; GI 262570; UNII-3433GY7132; CHEMBL107367; GI-262570X; 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID; 3433GY7132; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl); N-(o-Benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; Farglitazar [USAN]; Farglitazar [USAN:INN]; L-tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-"	170364	C34H30N2O5	Phase 3
M6APDG00383	LGD-2226	"LGD-2226; UNII-RI376RM5MT; LGD2226; RI376RM5MT; CHEMBL436784; 328947-93-9; 6-[bis(2,2,2-Trifluoroethyl)amino]-4-(Trifluoromethyl)quinolin-2(1h)-One; 2hvc; SCHEMBL1771552; BDBM18524; DTXSID10186546; ZINC14968232; 6-(Bis-(2,2,2-trifluoroethyl)amino)-4-trifluoromethyl-1H-quinolin-2-one; DB08089; 4-(Trifluoromethyl)-6-[bis(2,2,2-trifluoroethyl)amino]quinoline-2(1H)-one; 6-[bis(2,2,2-trifluoroethyl)amino]-4-(trifluoromethyl)-1H-quinolin-2-one; 6-[bis(2,2,2-trifluoroethyl)amino]-4-(trifluoromethyl)-1,2-dihydroquinolin-2-one"	11560224	C14H9F9N2O	Investigative
M6APDG01398	N-[2-(4'-Nitrophenyl)ethyl]-imidazole	"1-(4-nitrophenethyl)-1H-imidazole; 56643-91-5; 1-[2-(4-nitrophenyl)ethyl]-1H-imidazole; CHEMBL1098425; 1H-Imidazole, 1-[2-(4-nitrophenyl)ethyl]-; 1-[2-(4-nitrophenyl)ethyl]imidazole; AC1MOACC; MLS001195428; SCHEMBL9663626; CTK1F4146; DTXSID30391397; MolPort-002-886-896; HCPMKJOVCNZGSD-UHFFFAOYSA-N; HMS2885O15; ZINC4025449; BDBM50318407; AKOS010189447; MCULE-3977633271; MS-1973; KS-0000281S; SMR000550723; N-[2-(4''-Nitrophenyl)ethyl]-imidazole; SR-01000308458"	3317166	C11H11N3O2	Investigative
M6APDG00419	C[RGDf-(R)-alpha-TfmF]	CHEMBL381589; c[RGDf-(R)-alpha-TfmF]	11636164	C31H37F3N8O7	Investigative
M6APDG03688	ISIS 114532	.	.	.	Investigative
M6APDG03372	PLEGRIDY	Peginterferon beta-1a	.	.	Approved
M6APDG03203	GFT-505	"GFT-1007; PPAR activator (dyslipidemia/type 2 diabetes), Genfit"	9864881	C22H24O4S	Phase 3
M6APDG02830	Savolitinib	"1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri"	68289010	C17H15N9	Phase 3
M6APDG00593	Gly-Arg-Gly-Asp-Ser-Pro-Lys	"Grgdspk; Gly-arg-gly-asp-ser-pro-lys; 111119-28-9; Glycyl-arginyl-glycyl-aspartyl-seryl-prolyl-lysine; CHEMBL58763; AC1L2XSM; SCHEMBL891576; DTXSID20149506; HY-P0322; BDBM50079446; ZINC38989354; MFCD00076462; AKOS027382824; N2-(1-(N-(N-(N-(N2-Glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-L-seryl)-L-prolyl)-L-lysine; NCGC00167196-01; FT-0773649; Gly-Arg-Gly-Asp-Ser-Pro-Lys, &gt; glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine; L-Lysine,glycyl-L-arginylglycyl-L-a-aspartyl-L-seryl-L-prolyl-"	130667	C28H49N11O11	Investigative
M6APDG03872	FAZ053	.	.	.	Phase 1
M6APDG03144	SB-223245	"SB-223245; CHEMBL50106; SCHEMBL245523; BDBM50059133; {7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid; {(S)-7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid"	9823503	C22H23N5O4	Terminated
M6APDG03370	Durvalumab	.	.	.	Approved
M6APDG00910	NSC-623548	"2581-36-4; NSC-623548; NSC 408488; o-Cresotic acid, 5,5'-methylenedi-; 2,3-CRESOTIC ACID, 5,5'-METHYLENEDI-; UNII-S3D8KC88KC; 5,5'-Methylenedi-2,3-cresotic acid; NSC 623548; BRN 3433298; S3D8KC88KC; CHEMBL113835; 5,5'-Methylenedi-o-cresotic acid; NSC623548; NSC408488; 5,5'-Methylenebis(2-hydroxy-3-methylbenzoic acid); 2, 5,5'-methylenedi-; AC1L29YK; Oprea1_231968; 2-10-00-00398 (Beilstein Handbook Reference); SCHEMBL9755153; CTK4F6504; DTXSID90180466; o-Cresotic acid,5'-methylenedi-; MolPort-000-698-522; ZINC4028795; STL511095"	17413	C17H16O6	Investigative
M6APDG01992	2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid	CHEMBL566511; 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid	45483015	C16H16O4S	Investigative
M6APDG01823	1-(4-(methylsulfonyl)phenyl)-3-phenylurea	CHEMBL252433; 1-(4-(methylsulfonyl)phenyl)-3-phenylurea; 1-[4-(methylsulfonyl)phenyl]-3-phenylurea; SCHEMBL9913187; MolPort-019-692-584; STL012316; ZINC29038894; BDBM50233182; AKOS005673001	44447099	C14H14N2O3S	Investigative
M6APDG03157	WAY170523	WAY-170523; WAY 170523	9830392	C33H31N3O7S	Investigative
M6APDG03433	ISIS 6603	.	.	.	Investigative
M6APDG01058	DS-3201	"QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione"	22627096	C14H13N3O2	Phase 1
M6APDG04366	TAR-1	"P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions"	.	.	Terminated
M6APDG00387	C[-Arg-Gly-Asp-Acpca19-]	CHEMBL539338	11569720	C18H29N7O8	Investigative
M6APDG03591	ISIS 138678	.	.	.	Investigative
M6APDG00662	BMS-695735	.	135441202	C26H31ClFN7O	Preclinical
M6APDG00967	Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine	CHEMBL365849; Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine; BDBM50150935	19049158	C7H12N2	Investigative
M6APDG00773	"8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione"	"1H-1-Benzazepine-2,5-dione, 8-fluoro-3-hydroxy-; SCHEMBL9007832; CHEMBL142890; 144066-26-2"	15029643	C10H6FNO3	Investigative
M6APDG00231	SPERMINE	"spermine; 71-44-3; neuridine; musculamine; gerontine; Spermin; 4,9-Diaza-1,12-dodecanediamine; Diaminopropyltetramethylenediamine; N,N'-Bis(3-aminopropyl)-1,4-butanediamine; Spermine, puriss; N,N'-Bis(3-aminopropyl)butane-1,4-diamine; 1,4-Butanediamine, N,N'-bis(3-aminopropyl)-; 1,4-Bis(aminopropyl)butanediamine; 4,9-Diazadodecamethylenediamine; 4,9-Diazadodecane-1,12-diamine; N1,N1'-(Butane-1,4-diyl)bis(propane-1,3-diamine); UNII-2FZ7Y3VOQX; 1,4-Bis(aminopropyl) butanediamine; Spermine Derivative; 1,4-Diaminobutane, N,N'-bis"	1103	C10H26N4	Terminated
M6APDG03866	PF-06747143	.	.	.	Phase 1
M6APDG02628	"2,3-dimethoxy-2'-hydroxychalcone"	"2'-HYDROXY-2,3-DIMETHOXYCHALCONE; AC1NQ7LG; CTK4I5873; CTK1B1409; 3-(2,3-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one; MCULE-6103350400; FT-0772376; 2-Propen-1-one, 3-(2,3-dimethoxyphenyl)-1-(2-hydroxyphenyl)-, (2E)-"	6296545	C17H16O4	Investigative
M6APDG00584	AD-5075	"2,4-Thiazolidinedione, 5-((4-(2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; AD 5075; 103788-05-2; 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 2,4-Thiazolidinedione,5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-; YVQKIDLSVHRBGZ-UHFFFAOYSA-N; [3H]AD5075; [3H]-AD5075; ACMC-20m6lh; AC1L2TSO; CHEMBL88496; SCHEMBL131888; GTPL2702; GTPL2701; CTK4A2384; AD5075; 5-(4-(2-(5-Methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy)benzyl)-2,4-thiazolidinedione; [3H]AD-5075"	128440	C22H20N2O5S	Terminated
M6APDG01991	5-(biphenyl-4-yl)-3-oxopentanoic acid	CHEMBL572979; 5-(biphenyl-4-yl)-3-oxopentanoic acid	45483008	C17H16O3	Investigative
M6APDG02286	GNF-PF-5434	"GNF-PF-5434; CHEMBL486232; N~2~-(MORPHOLIN-4-YLCARBONYL)-N~1~-[(1S,2E)-1-(2-PHENYLETHYL)-3-(PHENYLSULFONYL)PROP-2-ENYL]-D-LEUCINAMIDE; MORPHOLINE-4-CARBOXYLIC ACID (1-(3-BENZENESULFONYL-1-PHENETHYLALLYLCARBAMOYL)-3-METHYLBUTYL)-AMIDE; N-[(1S)-1-[[(E,1S)-3-(benzenesulfonyl)-1-phenethyl-allyl]carbamoyl]-3-methyl-butyl]morpholine-4-carboxamide; AC1NRAGB; SCHEMBL7352997; BDBM50243232; K-11017; 4-Morpholinecarboxamide, N-[(1S)-3-methyl-1-[[[(1S,2E)-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propenyl]amino]carbonyl]butyl]-"	5287864	C28H37N3O5S	Investigative
M6APDG03631	ISIS 298712	.	.	.	Investigative
M6APDG00218	"7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one"	"CHEMBL157925; 7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one; 4H-1-Benzopyran-4-one, 7-(4H-1,2,4-triazol-4-ylmethyl)-; BDBM50097361; 331684-17-4"	10823163	C12H9N3O2	Investigative
M6APDG02671	Ac-DEVD-CHO	"169332-60-9; Caspase-3 Inhibitor I; N-acetyl-asp-glu-val-asp-al; acetyl-aspartyl-glutamyl-valyl-aspartal; Ac-Asp-Glu-Val-Asp-Aldehyde; AC-ASP-GLU-VAL-ASP-H; CHEMBL417149; CHEBI:59385; 184179-08-6; (4S,7S,10S,13S)-7-(2-carboxyethyl)-4-(carboxymethyl)-13-formyl-10-isopropyl-2,5,8,11-tetraoxo-3,6,9,12-tetraazapentadecan-15-oic acid; acetyl-Asp-Glu-Val-Asp-aldehyde; acetyl-Asp-Glu-Val-Asp aldehyde; N-acetyl-Asp-Glu-Val-Asp aldehyde; N-acetyl-Asp-Glu-Val-Asp-aldehyde"	644345	C20H30N4O11	Investigative
M6APDG00260	ABT-737	"ABT-737; 852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide"	11228183	C42H45ClN6O5S2	Terminated
M6APDG03974	ARQ 751	.	.	.	Phase 1
M6APDG04275	Biferonex	"Beneferon; Beneserin; Interferon beta 1a, BioPartners; Interferon beta 1a, Rentschler/Berlex/Schering; Beta-interferon (1a), Schering/Dr Rentschler"	.	.	Phase 3
M6APDG01116	RO-316233	"119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3"	2399	C20H13N3O2	Investigative
M6APDG02449	"5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one"	CHEMBL104298	54710618	C15H9Cl2NO2	Investigative
M6APDG01563	4-(butylthio)-2-(trifluoromethyl)benzonitrile	CHEMBL462665; 4-(butylthio)-2-(trifluoromethyl)benzonitrile; BDBM50247959	43615786	C12H12F3NS	Investigative
M6APDG01565	"4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol"	"CHEMBL1240677; 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol; BDBM50326006"	43680262	C17H15NO2	Investigative
M6APDG04211	Anti-IP10	.	.	.	Phase 2
M6APDG01646	N-(Ethylphosphoryl)-L-isoleucyl-L-Trp-NHCH3	CHEMBL1160624	44324667	C20H30N4O5P-	Investigative
M6APDG00573	AZD1390	VQSZIPCGAGVRRP-UHFFFAOYSA-N; SCHEMBL18631972; AZD-1390; EX-A2670; CS-8217; 2089288-03-7; HY-109566	126689157	C27H32FN5O2	Phase 1
M6APDG00040	AGELADINE A	"AGELADINE A; CHEMBL230806; CHEBI:65373; 4-(4,5-dibromo-1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-2-amine; Ageladine A, TFA; SCHEMBL12563004; BDBM50215926"	10089677	C10H7Br2N5	Investigative
M6APDG03050	TI4	.	91808049	C14H18N2	Investigative
M6APDG00521	Valdecoxib	"Bextra; COX; Kudeq; Valdyn; Pfizer brand of valdecoxib; Valdecoxib [USAN]; SC 65872; ND-0214; SC-65872; YM-974; Valdecoxib (USAN/INN); P-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-(9CI); 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide"	119607	C16H14N2O3S	Approved
M6APDG02698	Plerixafor	"Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane"	65015	C28H54N8	Approved
M6APDG03632	ISIS 298699	.	.	.	Investigative
M6APDG02821	ANTHRAQUINONE	"84-65-1; 9,10-Anthraquinone; anthracene-9,10-dione; 9,10-Anthracenedione; Anthradione; Hoelite; 9,10-Dioxoanthracene; Corbit; Morkit; 9,10-Anthrachinon; Anthra-9,10-quinone; Anthrapel; 9,10-quinone; Anthrachinon; Caswell No. 052A; Anthraquinone [BSI:ISO]; UNII-030MS0JBDO; NSC 7957; Bis-alkylamino anthraquinone; 9,10-Anthrachinon [Czech]; CCRIS 649; 9,10-Anthracendion; Anthracene, 9,10-dihydro-9,10-dioxo-; CHEBI:40448; HSDB 2074; EINECS 201-549-0; Anthracene-9,10-quinone; EPA Pesticide Chemical Code 122701"	6780	C14H8O2	Investigative
M6APDG03064	N5-(1-iminobut-3-enyl)-L-ornithine	"Vinyl-L-NIO; LMDRHVQXMBGSGU-ZETCQYMHSA-N; (2S)-2-amino-5-(1-aminobut-3-enylideneamino)pentanoic Acid; v-NIO; hDDAH inhibitor, 1a; L-VNIO; AC1L9KK2; SCHEMBL2184864; GTPL8830; CTK7D1091; BDBM235685; ZINC2047715; AKOS006278503; compound 2e [PMID: 19013076]; (2S)-2-amino-5-[(Z)-(1-aminobut-3-en-1-ylidene)amino]pentanoic acid"	91935539	C9H17N3O2	Investigative
M6APDG00608	RU-58841	"154992-24-2; RU 58841; RU58841; 4-(3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile; ARBYGDBJECGMGA-UHFFFAOYSA-N; UNII-0D8FJQ0ADW; 0D8FJQ0ADW; CHEMBL9337; 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; AK-64424; 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile; Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)-"	132981	C17H18F3N3O3	Discontinued in Phase 1
M6APDG03137	CP-394531	"CP-394531; UNII-227D9ED2SI; CHEMBL77779; 227D9ED2SI; 305822-63-3; SCHEMBL3111189; BDBM50113783; 2,7-Phenanthrenediol, 2-(chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 2,7-Phenanthrenediol, 2-(2-chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 4a-Benzyl-2-chloroethynyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-2,7-diol(CP-394531)"	9820558	C23H23ClO2	Investigative
M6APDG01941	4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine	CHEMBL1080023	44820374	C20H16N4	Investigative
M6APDG00248	BX-517	"BX517; BX-517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-"	11161844	C15H14N4O2	Investigative
M6APDG00770	"2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one"	"CHEMBL3144578; CHEMBL8053; 2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one; BDBM50009009; ZINC138045856"	14898717	C16H16N2O	Investigative
M6APDG00692	N-omega-propargyl-L-arginine	.	135512453	C9H16N4O2	Investigative
M6APDG00190	"3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione"	"3-Hydroxy-6-methyl-1H-1-benzazepine-2,5-dione; 1H-1-Benzazepine-2,5-dione, 3-hydroxy-6-methyl-; SCHEMBL8580170; CHEMBL143225; LPRUKTXSSXGABW-UHFFFAOYSA-N"	10655753	C11H9NO3	Investigative
M6APDG03130	L-764406	L 764406; L764406	9818466	C15H11ClN2O2S	Investigative
M6APDG00403	3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	CHEMBL202875; 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	11609208	C20H18O3	Investigative
M6APDG02655	"4-(2-nitrovinyl)benzene-1,2-diol"	"SL-1; CHEMBL78224; 108074-44-8; 4-(2-nitrovinyl)benzene-1,2-diol; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-"	6439158	C8H7NO4	Investigative
M6APDG00441	"2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione"	"2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione; CHEMBL203552; SCHEMBL13442861; Isoquinoline-1,3,4-trione 2f; CTK7C0409; BDBM10253; AKOS015966191; 2-(4-FLUORO-BENZYL)-ISOQUINOLINE-1,3,4-TRIONE"	11680763	C16H10FNO3	Investigative
M6APDG03690	ISIS 14548	.	.	.	Investigative
M6APDG02869	BAY 86-5044	"Lonaprisan; ZK-230211; 211254-73-8; UNII-F5Z5EL4D26; F5Z5EL4D26; AC1OCFKM; ZK-PRA; Lonaprisan [USAN:INN]; Lonaprisan (USAN/INN); SCHEMBL977182; CHEMBL146032; zk230211; BDBM50409115; BAY86-5044; ZK 230211; ZK 232011; D10016; Z-3103; (8S,11R,13S,14S,17S)-11-(4-ACETYLPHENYL)-17-HYDROXY-13-METHYL-17-(PERFLUOROETHYL)-6,7,8,11,12,13,14,15,16,17-DECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-3(2H)-ONE;  Lonaprisan"	6918548	C28H29F5O3	Phase 2
M6APDG03494	CTCE-0324	"Vascular disease therapeutic, Chemokine Therapeutics"	.	.	Investigative
M6APDG02296	SU9516	"SU9516; 377090-84-1; SU 9516; SU-9516; AC1NRD9P; 666837-93-0; (3Z)-3-(1H-IMIDAZOL-5-YLMETHYLENE)-5-METHOXY-1H-INDOL-2(3H)-ONE; (Z)-3-((1H-imidazol-5-yl)methylene)-5-methoxyindolin-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-5-methoxy-2,3-dihydro-1H-indol-2-one; 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one; SU9; (Z)-1,3-DIHYDRO-3-(1H-IMIDAZOL-4-YLMETHYLENE)-5-METHOXY-2H-INDOL-2-ONE; 3py1; 3py0; imidazole indolinone driv.; MLS001074893; SCHEMBL1170686; BDBM7238; SCHEMBL1170687; CHEMBL258805"	5289419	C13H11N3O2	Investigative
M6APDG00250	9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine	CHEMBL176245	11175093	C18H13FN4S	Investigative
M6APDG03805	Pc4	"Pc4; Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC"	.	.	Phase 1
M6APDG03069	Cypate-[(RGD)3-NH2]1	.	91936298	C76H100N21O18+	Investigative
M6APDG02677	Fluoxymesterone	"Androfluorene; Androfluorone; Androsterolo; Fluossimesterone; Fluosterone; Fluotestin; Fluoximesteron; Fluoximesterona; Fluoximesterone; Fluoximesteronum; Fluoxymesteronum; Fluoxymestrone; Flusteron; Flutestos; Halotestin; Oralsterone; Oratestin; Testoral; Ultandren; Ultandrene; Component of Halodrin; Fluossimesterone [DCIT]; Ora Testryl; U 6040; Anadroid-F; Android-f; Fluoximesterona [INN-Spanish]; Fluoxymesteronum [INN-Latin]; Halotestin (TN); Neo-Ormonal; Ora-Testryl; Fluoxymesterone [INN:BAN:JAN]; Fluoxymesterone (JP15/USP/INN); Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3; Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3 [French]; Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN); Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN) (8CI); (11beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one; (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 11-beta,17-beta-Dihydroxy-9-alpha-fluoro-17-alpha-methyl-4-androster-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one; 17-alpha-Methyl-9-alpha-fluoro-11-beta-hydroxytesterone; 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone; 9-Fluoro-11-beta,17-beta-dihydroxy-17-methylandrost-4-en-3-one; 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one; 9-alpha-Fluoro-11-beta,17-beta-dihydroxy-17-alpha-methyl-4-androstene-3-one; 9-alpha-Fluoro-11-beta-hydroxy-17-methyltestosterone; 9-alpha-Fluoro-17-alpha-methyl-11-beta,17-dihydroxy-4-androsten-3-one;9-fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9.alpha.-Fluoro-11.beta.,17.beta.-dihydroxy-17.alpha.-methyl-4-androstene-3-one; 9.alpha.-Fluoro-11.beta.-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methyl-4-androstene-3-one; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta-hydroxy-17alpha-methyltestosterone; 9alpha-Fluoro-17alpha-methyl-11beta,17-dihydroxy-4-androsten-3-one"	6446	C20H29FO3	Approved
M6APDG03959	HF-0299	.	.	.	Phase 1
M6APDG03308	3-(4-methoxyphenyl)quinoxaline-5-carboxamide	"CHEMBL519443; 3-(4-methoxyphenyl)quinoxaline-5-carboxamide; quinoxaline analogue, 3e; SCHEMBL7045177"	9965481	C16H13N3O2	Investigative
M6APDG03667	PHA-666859	"SC-409; SD-0006; P38-alpha kinase inhibitor (inflammation/diabetic retinopathy); P38-alpha kinase inhibitor (inflammation/diabetic retinopathy), Pfizer"	.	.	Investigative
M6APDG01254	3-Phenylquinoline-8-carboxamide	CHEMBL450259; 3-Phenylquinoline-8-carboxamide; BDBM50255264	25208596	C16H12N2O	Investigative
M6APDG00448	C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL204864; BDBM50184360	11700739	C47H63N11O7	Investigative
M6APDG02739	3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	"CHEMBL176076; AC1O705X; BDBM8617; SCHEMBL4221244; (3-Pyridylmethylene)indane 24b; 3-[(Z)-(4-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539791	C15H12FN	Investigative
M6APDG03065	7-bromoindirubin-3-oxime	.	91936028	C16H10BrN3O2	Investigative
M6APDG02546	MK-8353	"KPQQGHGDBBJGFA-QNGWXLTQSA-N; GTPL9974; SCHEMBL10236331; MK8353; (3S)-3-methylsulfanyl-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxypyridin-3-yl)-1H-indazol-5-yl]pyrrolidine-3-carboxamide"	58282870	C37H41N9O3S	Phase 1
M6APDG01989	N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide	CHEMBL574107; N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide	45481863	C22H17NO3	Investigative
M6APDG03560	ISIS 188781	.	.	.	Investigative
M6APDG00619	Bis(5-acetoxybenzo[b]furan-2-yl)methanone	CHEMBL226182; bis(5-acetoxybenzo[b]furan-2-yl)methanone	13471348	C21H14O7	Investigative
M6APDG03470	ISIS 188782	.	.	.	Investigative
M6APDG03741	677T	.	.	.	Investigative
M6APDG02084	AdoC(betaAsp)2AlaArg6	CHEMBL611127	46877402	C57H98N32O18	Investigative
M6APDG03445	CR-4174	"NO-COX-2 inhibitors (osteoarthritis/inflammatory disease), Rottapharm Madaus"	.	.	Investigative
M6APDG03389	CEP-2563	"KT-8391; L-Lysyl-beta-alanine 9(S),12(R)-Epoxy-10(S)-methoxy-9-methyl-1-oxo-2,3,9,10,11,12-hexahydro-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-ylmethyl ester dihydrochloride"	.	.	Discontinued in Phase 1
M6APDG04021	Anti-PD-L1	BMS-936559	.	.	Phase 1
M6APDG01559	[3H]CGS19755	"ACMC-20mhnp; ACMC-20bxqj; 4-(phosphonomethyl)-2-piperidinecarboxylic acid; AC1N8SPX; SCHEMBL120235; 2-Piperidinecarboxylicacid, 4-(phosphonomethyl)-, (2R,4S)-rel-; GTPL4080; 113229-89-3; AKOS005066562; 4-phosphonomethyl-2-piperidinecarboxylic acid; A802182"	4324257	C7H14NO5P	Investigative
M6APDG02465	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	"Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-"	5491980	C12H14ClNO3	Investigative
M6APDG03237	YM-440	"2,2'-[2(Z)-Butene-1,4-diyl]dioxybis(1,4-phenylene)bis(methylene)bis[1,2,4-oxadiazole-3,5(2H,4H)-dione]"	9890786	C22H20N4O8	Discontinued in Phase 2
M6APDG03269	Exherin	"Exherin; 229971-81-7; UNII-B058ME29VU; ADH-1; ADH1; B058ME29VU; ADH 1; ADH-1 pepide; Exherin (ADH-1); ADH-1;ADH1;ADH 1; SCHEMBL13857500; CHEMBL3818130; ZINC3939935; ADH-10001; AKOS030526741; CS-3450; L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-l-alanyl-L-valyl-, cyclic (1-5)-disulfide; HY-13541"	9916058	C22H34N8O6S2	Phase 2
M6APDG04035	ISA-P53-01	"P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals"	.	.	Phase 1/2
M6APDG00720	BAY 1082439	.	136336430	C25H30N6O5	Phase 1
M6APDG02504	"4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline"	"4-[3-Hydroxyanilino]-6,7-dimethoxyquinazoline; whi-p180; 211555-08-7; 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; WHI-P180, Hydrochloride; JANEX 3; 4-[3-HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE; CHEMBL127907; 3-((6,7-Dimethoxyquinazolin-4-yl)amino)phenol; AK341047; DTQ; 4-(3&amp; -Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, HCl; JANEX-3; 4btk; 1di8; AC1L1KWT; AC1Q4XVE; 3-(6,7-dimethoxyquinazolin-4-ylamino)phenol; Anilinoquinazoline deriv 5; WHI-P180(Janex 3); BDBM4622; SCHEMBL1180103; CTK4E5981; AOB5495; MolPort-000-672-017; BNDYIYYKEIXHNK-UHFFFAOYSA-N; HMS3229P15; WHI-P180"	5687	C16H15N3O3	Investigative
M6APDG04141	Mapatumumab	.	.	.	Phase 2
M6APDG02875	Rigosertib	"Rigosertib; 592542-59-1; UNII-67DOW7F9GL; 67DOW7F9GL; N-[2-Methoxy-5-({[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine; ON-01910.Na; Rigosertib [USAN:INN]; 6FS; Rigosertib (USAN); AC1OCFT5; SCHEMBL498624; Estybon (proposed trade name); SCHEMBL498623; GTPL7833; CHEMBL1241855; ON01910.Na; DTXSID30207984; CHEBI:124939; OWBFCJROIKNMGD-BQYQJAHWSA-N; 1910 Na; ZINC3942646; BCP08296; BDBM50060917; 4006AH; AKOS015966442; DB12146; SB16468; (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic a"	6918736	C21H25NO8S	Phase 3
M6APDG00033	"3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline"	"CHEMBL66618; 3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline; ZINC8079; SCHEMBL4364039; BDBM50039090"	10083699	C16H17NO2	Investigative
M6APDG01668	(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one	CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201	44350655	C23H23NO2	Investigative
M6APDG04367	EC-154	"Heat shock protein 90 inhibitors (cancer), Biogen Idec; Hsp 90inhibitors (cancer), Biogen Idec"	.	.	Terminated
M6APDG01797	2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid	CHEMBL242702	44427133	C15H17N3O3	Investigative
M6APDG00682	"3-Pyridin-4-yl-quinoline-5,7-diol"	.	135474209	C14H10N2O2	Investigative
M6APDG00018	"3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline"	"CHEMBL66786; 3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline; SCHEMBL8166505; HLKSYKUFDFBKPC-UHFFFAOYSA-N; ZINC3834045; BDBM50039049"	10040402	C19H25NO2	Investigative
M6APDG00939	"4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline"	"CHEMBL50166; 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline; SCHEMBL6159581; ZINC26870; BDBM50127827"	18326767	C18H16N2	Investigative
M6APDG04229	CetuGEX	.	.	.	Phase 2
M6APDG01776	Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL373440; cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)	44418868	C30H43N11O5	Investigative
M6APDG04190	TVB-2640	.	.	.	Phase 2
M6APDG03484	DVD-Ig	"DVD-Ig (arthritis); DVD-Ig (arthritis), Abbott; Dual anti-CD20/CD3 immunoglobulin, Abbott; Dual anti-TNF/PGE2 innunoglobulin, Abbott; Dual anti-IL-1 alpha/beta immunoglobulin (arthritis), Abbott; Dual anti-IL-12/IL-18 immunoglobulin, Abbott; 1D4.1-2.5; 1D4.1-ABT325"	.	.	Investigative
M6APDG02396	AMG 386	"7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930"	5360545	.	Phase 3
M6APDG02417	Thiazolidinedione	"2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487"	5437	C3H3NO2S	Approved
M6APDG03452	LL-6531	"PPAR modulators (diabetes), Lupin"	.	.	Investigative
M6APDG01929	CRA_8696	AC1O4QGN	447476	C21H17N3O	Investigative
M6APDG03388	Avelumab	.	.	.	Approved
M6APDG04170	ABT-RTA-408	.	.	.	Phase 2
M6APDG01257	3-Ethenylquinoline-8-carboxamide	"CHEMBL481793; 3-Ethenylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-ethenyl-; BDBM50255270"	25208747	C12H10N2O	Investigative
M6APDG03643	ISIS 11665	.	.	.	Investigative
M6APDG02335	"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine"	"CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline"	5328045	C14H11BrN4	Investigative
M6APDG02951	EGF816	.	72703790	C26H31ClN6O2	Phase 3
M6APDG03243	N-(2-methoxybenzyl)cinnamamidine	N-(2-methoxybenzyl)cinnamamidine; CHEMBL158737; SCHEMBL4624632; BDBM50124885; N-(2-Methoxybenzyl)-trans-cinnamamidine; n-(2-methoxybenzyl)-3-phenylacrylamidine	9900027	C17H18N2O	Investigative
M6APDG01572	Kevetrin	.	437740	C5H9N3S	Phase 2
M6APDG00439	IN-1130	"IN-1130; UNII-KW4O83PQ97; 868612-83-3; CHEMBL492634; KW4O83PQ97; IN 1130; SCHEMBL139815; MolPort-042-665-839; ZINC13985930; BDBM50252542; AKOS032962854; Benzamide, 3-((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; Benzamide, 3-((4-(6-methyl-2-pyridinyl)-5-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; NCGC00386726-01; KB-274188; 3-[[5-(6-Methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide"	11676119	C25H20N6O	Investigative
M6APDG02275	8S-HETE	8-hydroxyeicosatetraenoic acid	5283154	C20H32O3	Investigative
M6APDG03509	AP-101	.	.	.	Investigative
M6APDG03354	Adalimumab	Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)	.	.	Approved
M6APDG02763	"3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine"	"3614-50-4; 3-(1-methyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 6; 2-yl)-pyridine; 3-(1-Methyl-3,4-dihydro-naphthalen-; AC1O70HB; 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine; SCHEMBL4514804; CHEMBL206283; BDBM8892; CTK4H5985; DTXSID90424897; ZINC13684515; AKOS015965701; ACM3614504; AC-20696; KB-232450"	6540050	C16H15N	Investigative
M6APDG02065	4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one	CHEMBL1083664; 4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one	46867417	C17H11N3O4	Investigative
M6APDG02169	"2,3,4-Trimethoxy-4'-amino-trans-stilbene"	CHEMBL1173067; BDBM50322053	49799652	C17H19NO3	Investigative
M6APDG02242	Rosiglitazone XR	"Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate"	5281055	C22H23N3O7S	Approved
M6APDG03063	E[c(RGDyK)]2-PTX conjugate	.	91933274	C109H140N20O33	Investigative
M6APDG01155	"N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine"	"N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine; DB07683; N-(dibenzo[b,d]thiophene-3-sulfonyl) valine; (2S)-3-methyl-2-{8-thiatricyclo[7.4.0.0^{2,7}]trideca-1(13),2,4,6,9,11-hexaene-5-sulfonamido}butanoic acid"	24794392	C17H17NO4S2	Investigative
M6APDG01701	"(5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine"	"CHEMBL193007; (5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine"	44399940	C9H16N2	Investigative
M6APDG02498	Cenersen	.	56841947	.	Phase 2
M6APDG02153	"5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione"	"5-Hexyl-5-phenylbarbituric acid; BRN 0297956; BARBITURIC ACID, 5-HEXYL-5-PHENYL-; 67051-21-2; CHEMBL173075; AC1L2LKK; 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione; 4-24-00-02103 (Beilstein Handbook Reference); CTK8J9653; DTXSID20217355; 5-hexyl-5-phenyl barbituric acid; BDBM50099125; LS-24512"	49292	C16H20N2O3	Investigative
M6APDG00246	"2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol"	"2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol; 1-(2,4,6-trihydroxybenzoyl)pyrrole; 288839-58-7; 3eko; CHEMBL513225; DB08443; 2-(1-Pyrrolylcarbonyl)benzene-1,3,5-triol; 2-(pyrrole-1-carbonyl)benzene-1,3,5-triol"	11160307	C11H9NO4	Investigative
M6APDG01612	"1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate"	"CHEMBL467905; 1,3-dinitrooxy-2-propyl 2-acetoxybenzoate; 1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate; SCHEMBL8318285; BDBM50258493"	44219619	C12H12N2O10	Investigative
M6APDG00334	LIQUIRTIGENIN	"578-86-9; 4',7-Dihydroxyflavanone; (S)-7-Hydroxy-2-(4-hydroxyphenyl)chroman-4-one; (2S)-liquiritigenin; 5-DEOXYFLAVANONE; UNII-T194LKP9W6; 7-hydroxy-2-(4-hydroxy-phenyl)-chroman-4-one; T194LKP9W6; CHEMBL252642; CHEBI:28777; AK121923; (2S)-7-Hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-1-benzopyran-4-one; (2S)-7-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; (2S)-2-(4-hydroxyphenyl)-7-oxidanyl-2,3-dihydrochromen-4-one"	114829	C15H12O4	Investigative
M6APDG00878	1-guanidino-7-isoquinolinesulphonamide	"SCHEMBL6436143; CHEMBL227583; 7-Isoquinolinesulfonamide, 1-[(aminoiminomethyl)amino]-; BDBM16130; NRVVFOKWKSWIIV-UHFFFAOYSA-N; 1-Guanidino-7-sulphamoylisoquinoline; 1-guanidino-7-sulfonamidoisoquinoline 4; 2-(7-sulfamoylisoquinolin-1-yl)guanidine"	16658352	C10H11N5O2S	Investigative
M6APDG00899	22R-hydroxycholesterol	22beta-hydroxycholesterol; 22R-OHC	167685	C27H46O2	Investigative
M6APDG02956	Custirsen	 OGX-001/TV-1011; OGX-011	72941942	C231H312N78O119P20S20	Phase 3
M6APDG01640	3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol	CHEMBL48474; 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol	44294677	C18H20O3S2	Investigative
M6APDG01067	5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide	CHEMBL541239; 5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide; SCHEMBL7045815	22915475	C17H19NO2	Investigative
M6APDG03654	EDP-13	"Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma"	.	.	Investigative
M6APDG01060	"3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenol"	"CHEMBL101389; 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenol; SCHEMBL6431286; CGIFTRWAYIWEGG-UHFFFAOYSA-N; BDBM50290850"	22646527	C17H15NO4	Investigative
M6APDG02745	4-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	"AC1O706F; CHEMBL365314; BDBM8626; (4-Pyridylmethylene)indane 16a; 4-[(E)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539800	C16H15NO	Investigative
M6APDG01392	"4-(2-nitroprop-1-enyl)benzene-1,2-diol"	"4-(2-nitroprop-1-enyl)benzene-1,2-diol; 13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192"	3260632	C9H9NO4	Investigative
M6APDG02342	4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine	"5-Substituted 1-Phenylbenzimidazole 22; AC1NS4PO; SCHEMBL7989819; CHEMBL309035; BDBM3933; AKOS023129997; 4-(5-methoxybenzimidazol-1-yl)aniline; 5-Methoxy-1-(4-aminophenyl)-1H-benzimidazole; 4-(5-methoxy-1H-1,3-benzodiazol-1-yl)aniline; 1-(4-aminophenyl)-5-methoxybenzimidazole dihydrochloride"	5328512	C14H13N3O	Investigative
M6APDG01811	"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline"	"CHEMBL250318; 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline; BDBM50222435"	44442165	C20H18N2O2	Investigative
M6APDG00873	3-aminobenzamide	"3-Aminobenzamide; 3544-24-9; m-Aminobenzamide; Benzamide, 3-amino-; 3-Amino-benzamide; Benzamide, m-amino-; meta-aminobenzamide; 3-ABA; 3-Aminobenzimide; 3-amino benzamide; aniline-3-carboxamide; 3-aminobenzoic acid amide; UNII-8J365YF1YH; CCRIS 3925; EINECS 222-586-9; NSC 36962; BRN 2802373; PARP Inhibitor I, 3-ABA; 3-H2NC6H4CONH2; CHEMBL81977; 3-AB; 8J365YF1YH; CHEBI:64042; GSCPDZHWVNUUFI-UHFFFAOYSA-N; MFCD00007989; 3-Aminobenzamide, 98%; SR-01000075657; HSDB 7581; 3-azanylbenzamide; m-amino benzamide; 4pml; 3-Aminobenzaminde"	1645	C7H8N2O	Investigative
M6APDG00529	"5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one"	"CHEMBL459071; 5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one; 5-(pyrid-3-yl)-2h-indolin-2-one; SCHEMBL748904; SCHEMBL6840746; LRXSVYIRRDZVNQ-UHFFFAOYSA-N; BDBM50273706; 220904-98-3"	12050204	C13H10N2O	Investigative
M6APDG01271	AZD8055	"AZD8055; 1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol"	25262965	C25H31N5O4	Discontinued in Phase 1/2
M6APDG00912	B-428	.	1747	C9H7IN2S	Terminated
M6APDG03485	ISIS 173813	.	.	.	Investigative
M6APDG00015	LEUCETTAMINE B	leucettamine B; CHEMBL485053; SCHEMBL13219029	10037501	C12H11N3O3	Investigative
M6APDG01912	5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	CHEMBL583588; SCHEMBL5613483; BDBM50300472; 5-(4''-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	44626352	C18H17NO3	Investigative
M6APDG01146	SNX-2112	"SNX-2112; 908112-43-6; SNX 2112; 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide; UNII-10C9P3FFOW; PF-04928473; 10C9P3FFOW; CHEMBL560895; SNX-2112 (PF-04928473); 945626-71-1; 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-hydroxycyclohexyl)amino]benzamide; 4-[6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(cis-4-hydroxycyclohexyl)amino]benzamide"	24772860	C23H27F3N4O3	Investigative
M6APDG01782	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)	CHEMBL373636; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)	44418880	C37H49N11O6	Investigative
M6APDG03124	DMP-802	"CHEMBL117989; CHEMBL275611; SCHEMBL7748060; BDBM50075566; (S)-3-{2-[(R)-3-(4-Carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-propionic acid"	9812185	C20H24N6O7S	Discontinued in Phase 1
M6APDG00102	Dilmapimod	"Dilmapimod; SB-681323; 444606-18-2; UNII-Q3238VQW0N; GW 681323; SB 681323; Q3238VQW0N; GW681323; SB681323; Dilmapimod [USAN:INN]; GSK 681323; Dilmapimod (USAN/INN); GTPL7815; SCHEMBL1065268; CHEMBL2103838; ORVNHOYNEHYKJG-UHFFFAOYSA-N; BCP23819; ZINC34997404; CS-6731; DB12140; SB16737; 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; HY-10404; GW-681323; DB-070558; FT-0718750; J3.498.915J; D09602; SB-681323; GW-681323"	10297982	C23H19F3N4O3	Phase 2
M6APDG03346	Dehydroepiandrosterone	"Dehydroepiandrosterone; DHEA; 53-43-0; PRASTERONE; Dehydroisoandrosterone; Androstenolone; trans-Dehydroandrosterone; Psicosterone; Diandrone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Prestara; 17-Chetovis; Andrestenol; 5-Dehydroepiandrosterone; Intrarosa; Siscelar plus; 5,6-Didehydroisoandrosterone; Dehydro-epi-androsterone; Prasteronum; 5,6-Dehydroisoandrosterone; Prasterona; Epiandrosterone, 5-dehydro-; Caswell No 051F; 5,6-Dehydroisoandrostorone"	5881	C19H28O2	Approved
M6APDG03566	ISIS 122970	.	.	.	Investigative
M6APDG01504	Bardoxolone methyl	BARD; WPTTVJLTNAWYAO-OYWPANLISA-N; 218600-53-4	400769	C32H43NO4	Phase 3
M6APDG00999	4-(3-nitro-benzylideneamino)-benzenesulfonamide	CHEMBL404921; BDBM50371766; AKOS003620777	21177358	C13H11N3O4S	Investigative
M6APDG03967	PF-05230907	.	.	.	Phase 1
M6APDG02128	4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline	CHEMBL1240925; 4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline	46937407	C13H12FNO2S	Investigative
M6APDG02316	Ro 41-5253	Ro-415253; Ro415253; LG629	5312120	C28H36O5S	Investigative
M6APDG03005	3-Methylpyridine	"3-METHYLPYRIDINE; 3-Picoline; 108-99-6; beta-Picoline; Pyridine, 3-methyl-; m-Picoline; m-Methylpyridine; B-Picoline; beta-Methylpyridine; 3-Methyl pyridine; .beta.-Methylpyridine; NSC 18251; .beta.-Picoline; meta-Methylpyridine; UNII-B083J4KF7F; 3-Mepy; CCRIS 1722; HSDB 4254; EINECS 203-636-9; AI3-24110; B083J4KF7F; 3-Methylpyridin; CHEBI:39922; ITQTTZVARXURQS-UHFFFAOYSA-N; 3-Picoline, 99%; DSSTox_CID_1897; DSSTox_RID_76391; DSSTox_GSID_21897; CAS-108-99-6; bpicolin; 3-methypyridine; 5-methylpyridine; 3-methyl-pyridin; 3-methyl pyridin"	7970	C6H7N	Investigative
M6APDG04025	CAR-T cells targeting HER2	.	.	.	Phase 1
M6APDG00085	Palodesangren E	Palodesangren E	10255841	C31H28O7	Investigative
M6APDG03701	CU-906	.	.	.	Investigative
M6APDG00870	Carba-Nicotinamide-Adenine-Dinucleotide	"Carba-NAD; Carbanicotinamide adenine dinucleotide; 112345-60-5; AC1L4TS7; AC1Q5J0L; SCHEMBL16445201; 5'-o-{[({[(1r,2r,3s,4r)-4-(3-carbamoylpyridinium-1-yl)-2,3-dihydroxycyclopentyl]methoxy}phosphinato)oxy](hydroxy)phosphoryl}adenosine; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(1R,2R,3S,4R)-4-(3-carbamoylpyridin-1-ium-1-yl)-2,3-dihydroxycyclopentyl]methyl phosphate; Adenosine 5'-(trihydrogen diphosphate), 5'-((4-(3-(aminocarbonyl)pyridinio)-2,3-dihydroxycyclopentyl)m"	163884	C22H30N7O13P2+	Investigative
M6APDG03524	SARMs	"SARMs (cancer); SARMs (cancer), CEAMED; Selective androgen receptor modulators (cancer), CEAMED"	.	.	Investigative
M6APDG02931	Omaveloxolone	"RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563"	71811910	C33H44F2N2O3	Phase 2
M6APDG01245	L-Tryptophan-L-2-aminoadipic acid	CHEMBL515773; L-Tryptophan-L-2-aminoadipic acid	25185696	C17H21N3O5	Investigative
M6APDG01979	OXA-01	MTORC1/mTORC2 inhibitor (cancer) OSI Pharmaceuticals	45276387	C21H20ClN5O2	Investigative
M6APDG01071	"N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide"	"N-(2,4-dimethoxyphenyl)-3,5-dimethoxybenzamide; CHEMBL42427; Oprea1_091011; N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide; MolPort-002-962-230; ZINC3192499; AC1M5424; BDBM50108051; STK167661; AKOS001091335; MCULE-2861059800; ST50986910"	2321450	C17H19NO5	Investigative
M6APDG04312	IDDBCP-150101	.	.	.	Preclinical
M6APDG00607	4-Benzyl-1-(2-phenoxy-ethyl)-piperidine	4-benzyl-1-(2-phenoxyethyl)piperidine; CHEMBL102659; 4-Benzyl-1-(2-phenoxy-ethyl)-piperidine; AC1LPA49; SCHEMBL5888854; HRBKFQYSVXXYDE-UHFFFAOYSA-N; ZINC1159765	1328600	C20H25NO	Investigative
M6APDG02408	3-Nitro-4'-nitro-trans-stilbene	"(E)-3,4'-Dinitrostilbene; 3,4'-Dinitrostilbene; CHEMBL1173131; (E)-1-Nitro-3-(2-(4-nitrophenyl)ethenyl)benzene; 51042-51-4; Benzene, 1-nitro-3-(2-(4-nitrophenyl)ethenyl)-, (E)-; Stilbene, 3,4'-dinitro-; CCRIS 8545; AC1NTBW4; Benzene, 1-nitro-3-(2-(4-nitrophenyl)ethenyl)-; WMOGPQFWQAXCTI-SNAWJCMRSA-N; 3-Nitro-4''-nitro-trans-stilbene; ZINC6092536; BDBM50322057; 27892-99-5; LS-30911; 1-Nitro-3-[2-[4-nitrophenyl]ethenyl]benzene; 1-Nitro-3-[(E)-2-(4-nitrophenyl)ethenyl]benzene; 1-Nitro-3-[(E)-2-(4-nitrophenyl)ethenyl]benzene #"	5377857	C14H10N2O4	Investigative
M6APDG01530	"2-Benzyl-1,2-dihydro-indazol-3-one"	"2-Benzyl-1,2-dihydro-indazol-3-one; 1848-46-0; CHEMBL1984519; NSC34822; 2-benzyl-1H-indazol-3-one; SCHEMBL9645952; CHEMBL267523; AC1L91I6; CTK4D8835; DTXSID40328538; 2-Benzyl-1H-indazol-3(2H)-one; ZINC1667231; NSC-34822; BDBM50009000; AKOS015963502; FCH2821694; ACM1848460; NCI60_003094"	411523	C14H12N2O	Investigative
M6APDG00907	N-(1H-indazol-5-yl)acetamide	"N-(1H-indazol-5-yl)acetamide; 95574-27-9; CHEMBL503641; Acetamide, N-1H-indazol-5-yl-; 5-acetylaminoindazole; SCHEMBL2565558; XGVHKKOLBJMLLQ-UHFFFAOYSA-N; MolPort-020-329-884; ZINC20495645; BDBM50246684; AKOS008998989"	17164245	C9H9N3O	Investigative
M6APDG03134	CP-409069	"CHEMBL78625; CP-409069; SCHEMBL3114566; BDBM50113780; (2R,4aS,10aR)-4a-benzyl-2-(prop-1-ynyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,7-diol"	9819614	C24H26O2	Investigative
M6APDG04095	ALX148	.	.	.	Phase 1/2
M6APDG00815	4-Methyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL183012; CHEMBL541090; 4-Methylpyrrolidine-2-imine; BDBM50066780; AKOS006351281; 4-Methyl-pyrrolidin-(2E)-ylideneamine	15887953	C5H10N2	Investigative
M6APDG03675	ISIS 5884	.	.	.	Investigative
M6APDG02145	ACCLAIM	"Depon; Excel; Furore; PUMA; Whip; Fenoxaprop ethyl; Fenoxaprop ethyl ester; Fenoxaprop ethyl ester [ANSI]; Tiller Herbicide; HOE 33171; FENOXAPROP-ETHYL; HOE-A 25-01; Ethyl 2-(4-((6-chlorobenzoxazol-2-yl)oxy)phenoxy)propionate; Ethyl 2-[4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy]propanoate; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate [French]; Ethyl 2-(4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy)propanoate; Ethyl 2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate; Ethyl-2-((4-(6-chloro-2-benzoxazolyloxy))-phenoxy)propionate; Ethyl (+-)-2-(4-(6-chloro-2-benzoxazolyloxy)phenoxy)propanoate; Propanoic acid, 2-(4-((6-chloro-2-benzoxazolyl)oxy)phenoxy)-, ethyl ester; (+/-)-2-(4-((6-Chloro-2-benzoxazolyl)oxy)phenoxy)propanoic acid ethyl ester; 2-(4-((6-Chloro-2-benzoxazolylen)oxy)phenoxy)propanoic acid, ethyl ester"	47938	C18H16ClNO5	Phase 2
M6APDG01630	(O10eq)-guanidino acetylryanodine	CHEMBL435362; (O10eq)-guanidino acetylryanodine	44275894	C28H40N4O10	Investigative
M6APDG01171	Cyclo-[-Arg-Gly-Asp-Amp28-]	CHEMBL270683	24824620	C17H28N8O6	Investigative
M6APDG02902	(R)-PFI-2	"PFI-2; 1627676-59-8; (R)-PFI-2; CHEMBL3414622; PFI-2 HCl; 8-Fluoro-N-{(2r)-1-Oxo-1-(Pyrrolidin-1-Yl)-3-[3-(Trifluoromethyl)phenyl]propan-2-Yl}-1,2,3,4-Tetrahydroisoquinoline-6-Sulfonamide; 1L8; GTPL8235; C23H25F4N3O3S; MolPort-035-789-712; EX-A1603; s7294; ZINC95920703; BDBM50075073; 2648AH; AKOS030526617; CS-4177; NCGC00351479-01; HY-18627; BC600610; (R)-8-Fluoro-N-(1-oxo-1-(pyrrolidin-1-yl)-3-(3-(trifluoromethyl)phenyl)propan-2-yl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide"	71300326	C23H25F4N3O3S	Preclinical
M6APDG01135	MK-5108	"1010085-13-8; VX-689; MK 5108; MK5108; MK-5108 (VX-689); UNII-H8J407531S; VX689; VX 689; CHEMBL3600873; H8J407531S; 4-(3-chloro-2-fluorophenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid; 4-(3-Chloranyl-2-Fluoranyl-Phenoxy)-1-[[6-(1,3-Thiazol-2-Ylamino)pyridin-2-Yl]methyl]cyclohexane-1-Carboxylic Acid; (1r,4r)-4-(3-chloro-2-fluorophenoxy)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid,; MK-5108/VX-689"	24748204	C22H21ClFN3O3S	Phase 1
M6APDG02805	NSC-622445	"5,5'-Methylenedisalicylic acid; 122-25-8; 5,5'-Methylenebis(2-hydroxybenzoic acid); Methylenebis(salicylic acid); 5,5-Methylenebis(salicylic acid); UNII-2KF4FVV76N; 5,5-Methylenedisalicylic acid; 5-(3-Carboxy-4-hydroxybenzyl)salicylic acid; 4,4'-Dihydroxy-3,3'-dicarboxydiphenylmethane; 3,3'-Dicarboxy-4,4'-dihydroxydiphenylmethane; NSC 14778; NSC-622445; 2KF4FVV76N; 4,4'-Dihydroxydiphenylmethane-3,3'-dicarboxylic acid; 3,3'-Methylenebis(6-hydroxybenzoic acid); CHEMBL115145; Benzoic acid, 3,3'-methylenebis[6-hydroxy-"	67145	C15H12O6	Investigative
M6APDG02351	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine; 4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397	5328819	C14H9Cl2N3	Investigative
M6APDG02452	AM-2S	AM-2S; CHEMBL470194; SCHEMBL13208678; BDBM50278743	54726664	C20H17NO3S	Investigative
M6APDG02012	"3,5-Dihydroxyl-4'-amino-trans-stilbene"	"CHEMBL1172402; Stilbene derivative, 3; SCHEMBL2516281; CHEBI:125141; (E)-4'-Aminostilbene-3,5-diol; BDBM50322066; 3,5-Dihydroxyl-4''-amino-trans-stilbene"	46191176	C14H13NO2	Investigative
M6APDG00681	RGB-286147	"pyrazolopyrimidone analog, RGB-286147"	135473382	C23H22Cl2N4O3	Investigative
M6APDG00325	(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid	(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; CHEMBL364748; SCHEMBL20553473; ZINC13671687; BDBM50171897; DB08760; (S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; (S)-2-(4-Chloro-phenoxy)-3-phenyl-propionic acid	11460087	C15H13ClO3	Investigative
M6APDG00476	4-Imidazol-1-yl-2-phenyl-chroman-7-ol	CHEMBL95919; 4-imidazol-1-yl-2-phenyl-chroman-7-ol	11779089	C18H16N2O2	Investigative
M6APDG03038	I-CBP112	"1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, &gt"	90488984	C27H36N2O5	Investigative
M6APDG01510	"6-Nitro-1,4-dihydro-quinoxaline-2,3-dione"	"6-nitroquinoxaline-2,3-diol; 1,4-Dihydro-6-nitroquinoxaline-2,3-dione; 6-Nitro-1,4-dihydroquinoxaline-2,3-dione; 6-Nitro-2,3-dihydroxyquinoxaline; 6-Nitro-2,3-quinoxalinediol; 2,3-Dihydroxy-6-nitroquinoxaline; 6-nitro-1,2,3,4-tetrahydroquinoxaline-2,3-dione; RYMLSFWVYNAKAR-UHFFFAOYSA-N; 6-Nitroquinoxaline-2,3(1H,4H)-dione; AC1N1YFP; 6-Nitro-1,4-dihydro-quinoxaline-2,3-dione; AC1Q1Y5W; Oprea1_565337; CHEMBL23044; ACMC-209g63; 6-nitro quinoxaline-2,3-dion; SCHEMBL1259529; SCHEMBL14385403; 6-Nitro-2,3-quinoxalinediol #"	4038142	C8H5N3O4	Investigative
M6APDG02456	Theliatinib	"HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	54759275	C25H26N6O2	Investigative
M6APDG02746	4-[6-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine	"(4-Pyridylmethylene)indane 16b; CHEMBL370281; AC1O706H; BDBM8627; 4-[(Z)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539801	C16H15NO	Investigative
M6APDG03435	PF 5208766	WAY-178357	.	.	Investigative
M6APDG03508	ISIS 17020	.	.	.	Investigative
M6APDG01855	S-Isopropyl-Isothiourea	S-Isopropylisothiourea hydrobromide; 4269-97-0; S-Isopropylthiourea hydrobromide; 57200-31-4; SR-01000597878; IPITU hydrobromide; C4H10N2S.HBr; S-Isopropylthiuronium bromide; S-Isopropyl-ITU hydrobromide; SCHEMBL7532633; S-ISOPROPYLISOTHIOUREA HBR; DTXSID10431048; MolPort-003-937-638; 2036AH; AKOS024458684; ACM4269970; B6494; SR-01000597878-2	445319	C4H10N2S	Investigative
M6APDG01286	NSC-95397	"NSC 95397; 93718-83-3; 2,3-Bis(2-hydroxyethylthio)-1,4-naphthalenedione; NSC95397; NSC-95397; 2,3-bis(2-hydroxyethylsulfanyl)naphthalene-1,4-dione; MLS002153403; CHEMBL429095; SMR001230781; SR-01000075930; 1,4-Naphthalenedione, 2,3-bis[(2-hydroxyethyl)thio]-; Tocris-1547; AC1Q6JAF; Lopac-N-1786; Lopac0_000629; KBioGR_000495; BSPBio_001155; KBioSS_000495; SCHEMBL2530685; AC1L66Q4; cid_262093; KBio3_000910; KBio2_005631; KBio2_003063; CHEBI:93193; KBio3_000909; KBio2_000495; CTK3I8111; DTXSID10294236; MolPort-003-958-936; HMS3268C19"	262093	C14H14O4S2	Investigative
M6APDG00125	CP-868596	"Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine"	10366136	C26H29N5O2	Phase 3
M6APDG03641	ISIS 3067	.	.	.	Investigative
M6APDG03747	ISIS 104256	.	.	.	Investigative
M6APDG01517	4-(3-hydroxy-benzylideneamino)-benzenesulfonamide	"CHEMBL270243; 66667-57-0; NSC722923; AC1L8PAB; CBDivE_016053; 4-[(3-hydroxyphenyl)methylideneamino]benzenesulfonamide; CTK1H9643; CTK7J9950; DTXSID20328076; BDBM50371761; AKOS030585458; MCULE-4187647437; NSC-722923; SR-01000199564; SR-01000199564-1; 4-[(3-Hydroxy-benzylidene)-amino]-benzenesulfonamide; Benzenesulfonamide, 4-[[(3-hydroxyphenyl)methylene]amino]-"	405560	C13H12N2O3S	Investigative
M6APDG00200	Phenethyl-(4-phenyl-butyl)-amine	CHEMBL280111; Phenethyl-(4-phenyl-butyl)-amine; SCHEMBL8084143; 4-Phenyl-N-phenethyl-1-butanamine; ZINC13736042	10708590	C18H23N	Investigative
M6APDG03486	HS014	.	.	.	Investigative
M6APDG01179	4-dehydroxyriccardin C	"4-dehydroxyriccardin C; Riccardin C derivative, 20d; CHEMBL411246; BDBM23851; 2',4-(Ethylene-1,4-phenylene-oxy-1,3-phenylene-ethylene)-1,1'-biphenyl-2,4'-diol"	24860513	C28H24O3	Investigative
M6APDG00470	BX-912	BX 912; BX912	11754511	C20H23BrN8O	Investigative
M6APDG00652	AG-024322	"AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine"	135413565	C23H20F2N6	Phase 1
M6APDG01858	2-phenyl-2H-indazole-7-carboxamide	2-phenyl-2H-indazole-7-carboxamide; CHEMBL594298; SCHEMBL1422404; BDBM50306166	44549251	C14H11N3O	Investigative
M6APDG02884	L-Tryptophan-L-asparagine	CHEMBL513911; 175027-11-9; WN dipeptide; H-Trp-Asn-OH; W-N Dipeptide; L-Tryptophyl-L-Asparagine; Tryptophan Asparagine dipeptide; L-Tryptophan-L-asparagine; CHEBI:141447; WN; ZINC2561118; BDBM50266679; (2S)-4-amino-2-{[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino}-4-oxobutanoic acid	7020170	C15H18N4O4	Investigative
M6APDG00258	WP-1066	"WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; WP-1066; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312"	11210478	C17H14BrN3O	Phase 1/2
M6APDG02925	1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	"AC1LERN1; 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide; TimTec1_001906; Oprea1_174326; N-Benzoylpyrazole deriv., 6; CHEMBL388239; BDBM23704; MolPort-001-664-680; ZINC115253; HMS1539G14; STK398485; AKOS003748858; MCULE-1390939767; 1-benzoyl-N-phenylpyrazole-3-carboxamide; ST025783; N-phenyl[1-(phenylcarbonyl)pyrazol-3-yl]carboxamide"	716930	C17H13N3O2	Investigative
M6APDG01280	Carprofen	"Carprofene; Carprofeno; Carprofenum; Imadyl; Ridamyl; Rimadyl; Carprofeno [Spanish]; C 5720; Ro 205720; C-5720; Carprofene [INN-French]; Carprofeno [INN-Spanish]; Carprofenum [INN-Latin]; Rimadyl (TN); Ro 20-5720; Carprofen (USAN/INN); Carprofen [USAN:INN:BAN]; Ro 20-5720/000; Ro-20-5720; Ro-20-5720/000; (+-)-6-Chloro-alpha-methylcarbazole-2-acetic acid; (+-)-isomer of carprofen; (+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid; (+/-)-6-Chloro-.alpha.-methylcarbazole-2-acetic acid; (-)-6-Chlor-alpha-methyl-2-carbazolessigsaeure; 2-(6-Chloro-9H-carbazol-2-yl)-propionic acid; 2-(6-Chloro-9H-carbazol-2-yl)propanoic acid; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure [German]; 6-Chloro-alpha-methyl-9H-carbazole-2-acetic acid; 6-Chloro-alpha-methylcarbazole-2-acetic acid; 9H-Carbazole-2-acetic acid, 6-chloro-.al"	2581	C15H12ClNO2	Approved
M6APDG02467	CMP-6	"Pyridone 6; 457081-03-7; JAK Inhibitor I; Merck-5; Merck 5; CMP 6; 2-tert-butyl-9-fluoro-3H-benzo[h]imidazo[4,5-f]isoquinolin-7(6H)-one; CHEMBL21156; 2-(1,1-Dimethylethyl)-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinolin-7-one; CHEBI:87103; Compound # 2; 2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE; 2-TERT-BUTYL-9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLINE-7-ONE; IZA; C18H16FN3O; MERk-5"	5494425	C18H16FN3O	Investigative
M6APDG00670	"3-Pyridin-3-yl-quinoline-6,7-diol"	.	135453851	C14H10N2O2	Investigative
M6APDG03083	PBIT	"2514-30-9; PBIT; 2-(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one; 2-(4-methylphenyl)-1,2-benzothiazol-3-one; MLS000583746; 2-(p-Tolyl)benzo[d]isothiazol-3(2H)-one; 2-(p-tolyl)-1,2-benzothiazol-3-one; SMR000200989; 2-(4-methylphenyl)-1,2-benzothiazol-3(2H)-one; 1,2-Benzisothiazol-3(2H)-one, 2-(4-methylphenyl)-; 2-(4-methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one; ChemDiv3_007090; AC1LIP69; cid_935415; SCHEMBL2443755; GTPL7026; CHEMBL1336959; CTK0J4356; BDBM34737; AOB6896; DTXSID10359056; MolPort-002-285-696; HMS2576N21"	935415	C14H11NOS	Investigative
M6APDG01223	Cabozantinib	Cabometyx; Cometriq	25102847	C28H24FN3O5	Approved
M6APDG02087	GSK1070916	GSK-1070916	46885626	C30H33N7O	Phase 1
M6APDG04157	LY2928057	.	.	.	Phase 2
M6APDG03315	N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086781; N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709	9993220	C15H15N3O2	Investigative
M6APDG02436	Metastat	.	54678924	C19H17NO7	Phase 1
M6APDG03187	CYCLORGDFV	"CYCLORGDFV; cyclo(Arg-Gly-Asp-D-Phe-Val); CHEMBL411941; cyclo[Arg-Gly-Asp-D-Phe-Val]; Cyclo(-Arg-Gly-Asp-D-Phe-Val); 137813-35-5; c-[-Arg-Gly-Asp-fV-]; c[Arg-Gly-Asp-(R)-Phe-Val]; cyclo-(Arg-Gly-Asp-D-Phe-Val); Cyclo(Arg-Gly-Asp-D-Phe-Val-); cyclo(-Arg-Gly-Asp-D-Phe-Val-); BDBM50237601; ZINC17655303; NCGC00167283-01; [(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-acetic acid"	9851104	C26H38N8O7	Investigative
M6APDG03074	GPYRMEHFRWGSPPKD-NH2	.	91936746	C89H127N27O22S	Investigative
M6APDG03444	Anti-miR-191 modified oligonucleotide	.	.	.	Investigative
M6APDG00950	(-)-hydroxycitrate	"Garcinia acid; 3-c-carboxy-2-deoxy-d-erythro-pentaric acid; CHEMBL118715; UNII-8W94T9026R; (1S,2S)-1,2-dihydroxypropane-1,2,3-tricarboxylic acid; 8W94T9026R; Super CitriMax HCA 600SXS; 4373-35-7; (-)-Hydroxycitrate; 27750-10-3; 7A3; Citric acid, 2-hydroxy-, (-)-; AC1Q5QYE; AC1L4H7S; (2S,3S)-3-Carboxy-2,3-dihydroxy-pentanedioic acid; SCHEMBL6773065; DTXSID20276669; ZINC1656422; BDBM50036210; LMFA01050511; AJ-28889; D-erythro-Pentaric acid,"	185620	C6H8O8	Investigative
M6APDG00540	Celastrol	"Tripterin; Tripterine; Celastrol, Celastrus scandens; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid"	122724	C29H38O4	Preclinical
M6APDG01902	1-Amino-6-Cyclohex-3-Enylmethyloxypurine	"1-AMINO-6-CYCLOHEX-3-ENYLMETHYLOXYPURINE; 872556-74-6; 4-(cyclohexylmethoxy)-1H-imidazo[4,5-c]pyridin-6-amine; AC1L9IVC; CTK2I2667; DTXSID90332206; 3h-imidazo[4,5-c]pyridin-6-amine,4-(cyclohexylmethoxy)-; ZINC20149007; AKOS030619175; DB02603; KB-268453; 1H-Imidazo[4,5-c]pyridin-6-amine, 4-(cyclohexylmethoxy)-"	445967	C13H18N4O	Investigative
M6APDG03426	PMI-001	.	.	.	Discontinued in Phase 3
M6APDG04206	RO5520985	.	.	.	Phase 2
M6APDG03073	NDP-SYSMEHFRWGKPVG	.	91936745	C90H127N25O26S	Investigative
M6APDG00535	BLZ-100	Tozuleristide; UNII-835UH424TU; 835UH424TU; Tozuleristide [INN]; Tozuleristide [USAN]; 1673565-40-6	121488172	C203H296N58O52S12	Phase 1/2
M6APDG03966	EGFR806-specific CAR T cell	.	.	.	Phase 1
M6APDG02210	Ethylisothiourea	"etiron; 2-Ethyl-2-thiopseudourea; ethyron; ETHYLISOTHIOUREA; 2-Ethyl-isothiourea; 2986-20-1; Carbamimidothioic acid, ethyl ester; UNII-236P47H4VR; Pseudourea, 2-ethyl-2-thio-; CHEMBL321691; VFIZBHJTOHUOEK-UHFFFAOYSA-N; 236P47H4VR; S-ethyl-thioureum; Ethiron (Salt/Mix); Ethyl imidothiocarbamate; Tocris-0873; ethylsulfanyl-formamidine; AC1L1JOU; Lopac-E-3149; Ethyl imidothiocarbamate #; AC1Q1UA8; WR 539 (Salt/Mix); Lopac0_000491; SCHEMBL160501"	5139	C3H8N2S	Investigative
M6APDG00446	"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline"	"CHEMBL473320; 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline; SCHEMBL5616932"	11696664	C18H14BrN3O2	Investigative
M6APDG01795	(benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone	CHEMBL226183; (benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone; BDBM50202215; (Benzofuran-2-yl)(1H-indole-2-yl) ketone	44423635	C17H11NO2	Investigative
M6APDG00478	ALPHA-NAPHTHOFLAVONE	"7,8-Benzoflavone; alpha-Naphthoflavone; 604-59-1; 2-Phenyl-4H-benzo[h]chromen-4-one; alpha-Naphthylflavone; 2-phenylbenzo[h]chromen-4-one; Benzo(h)flavone; 7,8-BF; 4H-Naphtho[1,2-b]pyran-4-one, 2-phenyl-; .alpha.-Naphthoflavone; 2-Phenyl-benzo[h]chromen-4-one; 2-Phenyl-4H-naphtho(1,2-b)pyran-4-one; CCRIS 3607; 2-Phenylbenzo(h)chromen-4-one; EINECS 210-071-1; UNII-FML65D8PY5; NSC 407011; BRN 0210862; FML65D8PY5; benzo[h]flavone; MLS003171601; CHEMBL283196; CHEBI:76995; VFMMPHCGEFXGIP-UHFFFAOYSA-N; 4H-NAPHTHO(1,2-b)PYRAN-4-ONE, 2-PH"	11790	C19H12O2	Investigative
M6APDG00915	Enzastaurin	"LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione"	176167	C32H29N5O2	Phase 3
M6APDG02691	1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine	"CHEMBL101135; 5-methyl-1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione; AC1O54TL; 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine; 5-Methyl-1-(4-trityloxy-but-2-enyl)-1H-pyrimidine-2,4-dione; SCHEMBL19196301; BDBM50118490; 5-Methyl-1-[(2Z)-4-(trityloxy)but-2-enyl]pyrimidine-2,4(1H,3H)-dione"	6477686	C28H26N2O3	Investigative
M6APDG03458	K-454	"JAK2 kinase inhibitor (cancer), Kyowa"	.	.	Investigative
M6APDG04267	RG7601	.	.	.	Phase 3
M6APDG02434	Tenoxicam	"Artriunic; Liman; Mobiflex; Reutenox; Tenoxicamum; Tilcotil; Apotex brand of tenoxicam; Novag brand of tenoxicam; Novopharm brand of tenoxicam; Roche brand of tenoxicam; Solvay brand of tenoxicam; Apo-Tenoxicam; Mobiflex (TN); Novo-Tenoxicam; Ro 12-0068; Ro-120068; Tenoxicamum [INN-Latin]; Tilcotil (TN); Ro 12-0068/000; Ro-12-0068; Tenoxicam (JAN/USAN/INN); Tenoxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide"	54677971	C13H11N3O4S2	Approved
M6APDG00846	T140	[L-3-(2-naphthyl)-alanine3]-T134	16130395	C90H141N33O18S2	Investigative
M6APDG01558	4-(propylthio)-2-(trifluoromethyl)benzonitrile	CHEMBL462664; 4-(propylthio)-2-(trifluoromethyl)benzonitrile; BDBM50247958	43138589	C11H10F3NS	Investigative
M6APDG03376	Etanercept	"Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon"	.	.	Approved
M6APDG04037	VIR-201	.	.	.	Phase 1/2
M6APDG01082	"1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole"	"CHEMBL598847; 1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole; SCHEMBL10172554"	23585406	C15H13N3	Investigative
M6APDG02761	"3-(3,4-dihydronaphthalen-2-yl)pyridine"	"3-(3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 2; AC1O70H5; BDBM8889; SCHEMBL4508891; CHEMBL205881"	6540047	C15H13N	Investigative
M6APDG01334	NSC-137546	"NSC-137546; NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid"	283188	C12H11Cl2NO5	Investigative
M6APDG00668	LY-518674	"LY-674; 2-Methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid"	135449333	C23H27N3O4	Phase 2
M6APDG03160	C[RGDf-(S)-alpha-TfmF]	CHEMBL204309; c[RGDf-(S)-alpha-TfmF]	9831456	C31H37F3N8O7	Investigative
M6APDG01153	GDC-0068	RG7440	24788740	C24H32ClN5O2	Phase 3
M6APDG03392	SURADISTA	"PNU-145156E; FCE-26644 (formerly); PNU-151484 (Na salt); 7,7'-[Carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrapotassium salt; 7,7-Ureylene-bis(1-methyl-4,2-pyrrolecarboxamido)bis(1-methyl-4,2-pyrrolecarboxamido)bis(1,3-naphthalenedisulfonic acid) tetrapotassium salt"	.	.	Discontinued in Phase 1
M6APDG00151	AdcAhxArg6	CHEMBL438544	10441484	C52H94N30O12	Investigative
M6APDG01699	"[1,4]Oxazepan-(3E)-ylideneamine"	"CHEMBL362772; [1,4]Oxazepan-(3E)-ylideneamine; SCHEMBL2593607; BDBM50155790"	44396203	C5H10N2O	Investigative
M6APDG00399	Bis-(5-hydroxy-1H-indol-2-yl)-methanone	Flt-3 Inhibitor II; 896138-40-2; CHEMBL377193; Bis-(5-hydroxy-1H-indol-2-yl)methanone; Bis(5-hydroxy-1H-indol-2-yl)methanone; SCHEMBL2230377; GTPL5971; CTK8F1061; DTXSID40469293; HMS3229E09; IN1480; BDBM50187351; AKOS028113701; CCG-206752; RT-012728; Flt-3 inhibitor II	11601743	C17H12N2O3	Investigative
M6APDG01087	9-N-METHYL-8-METHOXY-MANZAMINE A	9-N-methyl-8-methoxy-manzamine A	23643639	C38H48N4O2	Investigative
M6APDG00001	Palodesangren D	Palodesangren D	10005461	C30H26O6	Investigative
M6APDG00338	5-phenyl-1H-indazol-3-amine	5-phenyl-1H-indazol-3-amine; CHEMBL500779; SCHEMBL3359889; 3e63; BDBM50254831; DB07161	11492186	C13H11N3	Investigative
M6APDG02068	4-Imidazol-1-ylmethylthioxanthen-9-one	CHEMBL1083353; 4-Imidazol-1-ylmethylthioxanthen-9-one	46867543	C17H12N2OS	Investigative
M6APDG03622	CMET Avimer polypeptides	"CMET Avimer polypeptides (cancer); MEDI-555; CMET Avimer polypeptides (cancer), MedImmmue; CMET-targeting anticancer avimers, MedImmune; CMET-targeting avimers (cancer), Avidia/MedImmune"	.	.	Investigative
M6APDG02053	N-(2-amino-5-(furan-2-yl)phenyl)benzamide	CHEMBL1097651; N-(2-amino-5-(furan-2-yl)phenyl)benzamide	46830328	C17H14N2O2	Investigative
M6APDG03840	ABT-700	.	.	.	Phase 1
M6APDG01331	GNF-PF-2893	GNF-PF-2893; MLS001098045; SMR000657694; ({[4-(dimethylamino)anilino]carbonyl}amino)(4-methylphenyl)dioxo-lambda~6~-sulfane; AC1MDRKI; CHEMBL312032; cid_2815701; BDBM71503; MolPort-002-902-750; ZINC158170; HMS2998H18; CCG-43375; AKOS024379092; MCULE-5924445847; 1-[4-(dimethylamino)phenyl]-3-tosyl-urea; ST51023936; SR-01000633302-1; 1-[4-Dimethylaminophenyl]-3-(4-methylphenylsulfonyl)urea; 1-[4-(dimethylamino)phenyl]-3-(4-methylphenyl)sulfonylurea; 1-(4-dimethylaminophenyl)-3-(4-methylphenyl)sulfonylurea	2815701	C16H19N3O3S	Investigative
M6APDG01863	"2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide"	"CHEMBL1096560; 2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide; SCHEMBL2265205"	44549505	C13H10N4O	Investigative
M6APDG02110	4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine	CHEMBL1172882; SCHEMBL18770302; BDBM50322789; 4''-(pyridin-4-ylmethyl)biphenyl-3-ol	46901446	C18H15NO	Investigative
M6APDG03079	N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE	"2365-40-4; Isopentenyladenine; N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE; N6-Isopentenyladenine; N6-(2-Isopentenyl)adenine; Isopentenyl adenine; 6-(gamma,gamma-Dimethylallylamino)purine; IPADE; Dimethylallyladenine; N6-(2-Isopentenyl)-adenine; N6-Dimethylallyladenine; N6-(delta2-Isopentenyl)adenine; N-(3-Methyl-2-butenyl)adenine; N6-(3-Methyl-2-butenyl)adenine; N6-(delta 2-Isopentenyl)-adenine; N(6)-(delta(2)-Isopentenyl)adenine; 1H-Purin-6-amine, N-(3-methyl-2-butenyl)-; N-(3-methylbut-2-enyl)-7H-purin-6-amine; Adenine, N-"	92180	C10H13N5	Investigative
M6APDG02170	"2,4-Dimethoxy-4'-amino-trans-stilbene"	CHEMBL1170662; BDBM50322047	49799655	C16H17NO2	Investigative
M6APDG00718	7-fluoroindirubin-3-acetoxime	.	136104466	C18H12FN3O3	Investigative
M6APDG00307	SB-747651A	"SB-747651A; CHEMBL188434; compound 26; SCHEMBL4719834; GTPL8130; BDBM24996; oxadiazole-containing compound, 9; MBCJUIJWPYUEBX-UHFFFAOYSA-N; ZINC13998530; NCGC00273984-05; NCGC00273984-03; SB-747651; 4-{1-ethyl-7-[(piperidin-4-ylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine; [2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-piperidin-4-yl-amine"	11393719	C16H22N8O	Investigative
M6APDG03955	Anti-CD45 mabs	"AHCD45 therapy, Baylor College; YTH-24; YTH-24/54; YTH-25.4; YTH-54.12; Anti-CD45 mAbs (stem cell transplantation/cancer); Anti-CD45 mAbs (stem cell transplantation/cancer), Baylor College"	.	.	Phase 1
M6APDG02695	4-(methyl(4-phenylthiazol-2-yl)amino)phenol	CHEMBL460515; 4-[Methyl-(4-phenyl-thiazol-2-yl)-amino]-phenol; 4-(methyl(4-phenylthiazol-2-yl)amino)phenol; AC1LDK73; MLS000075845; cid_649391; ZINC813364; HMS2534H13; BDBM50247460; AKOS000563578; SMR000014954; BAS 08769335; SR-01000322128; SR-01000322128-1	649391	C16H14N2OS	Investigative
M6APDG04375	BVT-142	"BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum"	.	.	Terminated
M6APDG00366	Cbz-Ile-Leu-Ala-LeuVSMe	CHEMBL207403; Cbz-Ile-Leu-Ala-LeuVSMe	11534625	C31H50N4O7S	Investigative
M6APDG00017	"3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline"	"CHEMBL68401; 3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline; ZINC3834028"	10039460	C17H14FNO2	Investigative
M6APDG01430	STO609	STO-609; STO 609	3467590	C19H10N2O3	Investigative
M6APDG03844	SY-1425	.	.	.	Phase 1
M6APDG03364	Panitumumab	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)	.	.	Approved
M6APDG03606	ISIS 6431	.	.	.	Investigative
M6APDG01482	NSC-683634	.	388623	C20H14ClN3O	Investigative
M6APDG04264	PF-05280014	.	.	.	Phase 3
M6APDG02803	CGP-53353	"145915-60-2; CGP 53353; CGP-53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492"	6711154	C20H13F2N3O2	Terminated
M6APDG02206	L-5-iodo-2'-deoxyuridine	"CHEMBL408518; URIDINE, 2'-DEOXY-5-IODO-; AC1LAEAG; SCHEMBL51859; XQFRJNBWHJMXHO-XVMARJQXSA-N; ZINC5223557; BDBM50375780; FT-0620507; 5-Iodo-1-(2-deoxy-alpha-D-ribofuranosyl)uracil"	512326	C9H11IN2O5	Investigative
M6APDG02334	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine"	"N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221"	5328042	C14H11BrN4	Investigative
M6APDG00965	PAT5A	PAT5A; GTPL2709	18980163	C20H19N3O3S	Investigative
M6APDG00211	GSK618334	"Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride"	107969	C19H34ClNO2	Phase 1
M6APDG00323	Apratastat	"TMI-005; TMI-05; UNII-C6BZ5263BJ; 287405-51-0; C6BZ5263BJ; CHEMBL206815; TMI 005; Apratastat [USAN:INN]; Apratastat (USAN/INN); MLS006010301; SCHEMBL2834310; GTPL6482; TMI005; Apratastat, &gt; MolPort-021-805-014; BCPP000041; ZINC28571311; BDBM50181008; DB13020; API0013699; compound 5h [PMID: 16426848]; SMR004701369; 4CA-0170; D08859; 3-Thiomorpholinecarboxamide,N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-,(3S)-; TMI-1; Dual TACE/MMP-13 inhibitors (inflammation), Wyeth; Dual TACE/MMP-13 inhibitors (rheumatoid arthritis), Wyeth; Dual TACE/MMP-13 inhibitors, Wyeth-Ayerst"	11452716	C17H22N2O6S2	Phase 2
M6APDG02064	4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one	CHEMBL1083663; 4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one	46867416	C17H11N3O4	Investigative
M6APDG01178	12-dehydroxyriccardin C	"12-dehydroxyriccardin C; Riccardin C derivative, 20c; CHEMBL260632; BDBM23850; 2',4-[Ethylene-1,4-phenylene-oxy-(6-hydroxy-1,3-phenylene)-ethylene]-1,1'-biphenyl-4'-ol"	24860512	C28H24O3	Investigative
M6APDG00665	3-Pyridin-4-yl-quinolin-7-ol	.	135449022	C14H10N2O	Investigative
M6APDG04280	RG3638	Onartuzumab	.	.	Phase 3
M6APDG00748	8-Phenyl-octanoic acid hydroxyamide	8-Phenyl-octanoic acid hydroxyamide; CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174	14098189	C14H21NO2	Investigative
M6APDG01621	Clinopodic acid C	"Clinopodic acid C; CHEMBL1080779; BDBM50310832; (R)-3-(3,4-Dihydroxyphenyl)-2-[3-[2beta-(3,4-dihydroxyphenyl)-3beta-carboxy-2,3-dihydro-1,4-benzodioxin-6-yl]propenoyloxy]propionic acid"	44254596	C27H22O12	Investigative
M6APDG01673	Z-Arg-Leu-Val-Agly-Ala-Gly-NH2	.	44355110	C31H51N11O8	Investigative
M6APDG01727	N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide	CHEMBL199074; N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide	44405448	C21H16F3NO2	Investigative
M6APDG03569	ISIS 122975	.	.	.	Investigative
M6APDG03903	VM-206	.	.	.	Phase 1
M6APDG00629	OSI-027	.	135398516	C21H22N6O3	Phase 2
M6APDG01685	"4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one"	CHEMBL147690	44364737	C9H4Cl3NO2	Investigative
M6APDG00345	(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone	CHEMBL209042; (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone	11500099	C17H11FN2O	Investigative
M6APDG04073	IMX-110	.	.	.	Phase 1/2
M6APDG03775	ISIS 32020	.	.	.	Investigative
M6APDG02207	PF-03814735	"PF-03814735; 942490-07-5; PF 03814735; PF-3814735; PF03814735; Kinome_1769; MLS006010949; CHEMBL1983111; SB19308; NCGC00389594-01; KB-74441; SMR004703046; BCP0726000114; J3.628.238J; N-(2-(6-((4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl)-2-oxoethyl)acetamide; N-[2-(4-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-11-azatricyclo[6.2.1.0^{2,7}]undeca-2(7),3,5-trien-11-yl)-2-oxoethyl]acetamide"	51346455	C23H25F3N6O2	Discontinued in Phase 1
M6APDG00877	IN-1166	"UNII-86NAB50A9A; IN-1166; CHEMBL387748; 86NAB50A9A; SCHEMBL373674; BDBM50214857; Benzonitrile, 3-(((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)amino)-; 945244-71-3"	16654987	C25H19N7	Investigative
M6APDG00787	TAK-603	.	153980	C25H26N4O6	Discontinued in Phase 2
M6APDG03443	Geldanamycin-estradiol hybrid	.	.	.	Investigative
M6APDG01112	MERIOLIN 5	"MERIOLIN 5; 1011711-76-4; 4-(4-Propoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2997013; CHEMBL270687; ZINC16052674; BDBM50371400; DB08182"	23727982	C14H15N5O	Investigative
M6APDG02424	TAFA-93	"MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika"	54601137	C56H90N2O17S	Discontinued in Phase 1
M6APDG03391	Garnocestim	SB-251353	.	.	Discontinued in Phase 1
M6APDG03475	4-Chloro-3-hydroxy-1H-quinolin-2-one	.	.	.	Investigative
M6APDG00242	(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid	(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid; CHEMBL191060; ZINC13671697; BDBM50171895; DB07842; (S)-2-(4-Ethyl-phenoxy)-3-phenyl-propionic acid	11149906	C17H18O3	Investigative
M6APDG02101	N-(4-amino-4'-bromobiphenyl-3-yl)benzamide	CHEMBL1097748; BDBM50317990	46887439	C19H15BrN2O	Investigative
M6APDG01467	ISONIPECOTAMIDE	"Piperidine-4-carboxamide; Isonipecotamide; 39546-32-2; 4-Piperidinecarboxamide; Hexahydroisonicotinamide; 4-carbamoylpiperidine; UNII-CZE2810T4X; CZE2810T4X; DPBWFNDFMCCGGJ-UHFFFAOYSA-N; Piperidine-4-carboxylic acid amide; MFCD00038012; 4-Piperdinecarboxamide; Isonipecotamide, 98%; piperidin-4-carboxamid; iso nipecotamide; iso-nipecotamide; Isonipecotinamide; Piperidine-4-carboxylicacidamide; NSC82318; EINECS 254-501-6; NSC 82318; ISONIPECTOAMIDE; ACMC-20aipw; PubChem9754; Isonipecotic acid amide; 4-piperidine-carboxamide"	3772	C6H12N2O	Investigative
M6APDG03696	EC-0565	"Folate-everolimus conjugate (inflammation), Endocyte"	.	.	Investigative
M6APDG00474	"4-(6,7-Dimethoxy-quinolin-3-yl)-phenol"	"CHEMBL303704; 4-(6,7-dimethoxyquinolin-3-yl)phenol; 4-(6,7-Dimethoxy-quinolin-3-yl)-phenol; ZINC3834025"	11778467	C17H15NO3	Investigative
M6APDG04034	131I-radretumab	"L-19; L-19-IgG1; L-19-SIP; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Bayer Schering/Philogen; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; 125I-L-19; 125I-L-19-IgG1; 125I-L-19-SIP"	.	.	Phase 1/2
M6APDG00423	C[RGDf-(R)-N-Me-alpha-TfmF]	CHEMBL381590; c[RGDf-(R)-N-Me-alpha-TfmF]	11643340	C32H39F3N8O7	Investigative
M6APDG02127	2-(4-(methylsulfonyl)phenyl)pyridine	2-(4-(methylsulfonyl)phenyl)pyridine; CHEMBL1240924; 2-[4-(Methylsulfonyl)phenyl]pyridine; SCHEMBL8229590	46937403	C12H11NO2S	Investigative
M6APDG03917	BIIB 028	.	.	.	Phase 1
M6APDG00990	AG 9	tyrphostin 1; tyrphostin A1; AG9; AG-9	2063	C11H8N2O	Investigative
M6APDG01868	SNEWIQPRLPQH	CHEMBL448652; SNEWIQPRLPQH	44560069	C67H101N21O19	Investigative
M6APDG04053	AP-1030	"AP-1102; AP-1130; MS-05; Combined MC1/MC4 receptor agonists, Action Pharma; Melanocortin-1/-4 receptor agonists, ActionPharma; Melanocortin-1/melanocortin-4 receptor agonists, Action Pharma"	.	.	Phase 1/2
M6APDG03855	Autologous cell based gene therapy	Autologous cell based gene therapy (pulmonary hypertension)	.	.	Phase 1
M6APDG03651	TGF alpha	TGF alpha (neurological damage)	.	.	Investigative
M6APDG02184	9-Nitropaullone	"Alsterpaullone; alsterpaullone; 237430-03-4; NSC 705701; NSC-705701; CHEMBL50894; MLS002702475; 9-Nitro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; 9-nitro-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Nitro-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5)-one; 9-NITRO-5,12-DIHYDRO-7H-BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONE; Paullone Analog 1; AC1NMCUD; Kinome_3754; 1q3w; Alsterpaullone derivative, 2; Lopac0_000057; CBiol_001723; GTPL5925; BDBM7262; SCHEMBL2170104; CTK8F0374; ZINC23894; BDBM84528; DTXSID50407444"	5005498	C16H11N3O3	Investigative
M6APDG00556	27-hydroxycholesterol	27-OHC; 26-hydroxycholesterol	123976	C27H46O2	Investigative
M6APDG02398	Suramin	Antrypol; Belganyl; Farma; Fourneau; Germanin; Moranyl; Naganil; Naganin; Naganine; Naganol; Naphuride; SVR; Suramine; SURAMIN SODIUM; Sodium suramin; Suramine sodium; Farma 939; Naganol 6 Na; Germanin (TN); SGCTO-001	5361	C51H40N6O23S6	Phase 1
M6APDG00079	Phenyl-(3-phenyl-1H-indazol-6-yl)-amine	"CHEMBL383177; N,3-diphenyl-1H-indazol-6-amine; Phenyl-(3-phenyl-1H-indazol-6-yl)-amine; SCHEMBL6582340"	10236389	C19H15N3	Investigative
M6APDG03230	PKF-242-484	TNF-484	9886977	C19H29N3O6	Investigative
M6APDG02641	"4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole"	"4-(4-BROMOPHENYL)-1H-1,2,3-TRIAZOLE-5-CARBONITRILE; CHEMBL238828; 1119392-12-9; AC1O4QZZ; 5-(4-bromophenyl)-2H-triazole-4-carbonitrile; 4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL4105736; CTK7C5822; MolPort-006-755-219; ZINC6448351; BDBM50200765; AKOS022169659; MS-8537; KS-000029L0; 4-(4-Bromophenyl)-1H-1,2,3-triazole-5-carbonitrile, AldrichCPR"	6411478	C9H5BrN4	Investigative
M6APDG00701	PP-242	PP242; TORKinib	135565635	C16H16N6O	Investigative
M6APDG01128	NSC-56071	"NSC-56071; 32230-52-7; NSC56071; AC1L6EJV; AC1Q7ES0; NCIOpen2_007380; CHEMBL596910; CTK4G8394; DTXSID80288485; ZINC1686711; 2,2'-[piperazine-1,4-diylbis(carbonothioylsulfanediyl)]diacetic acid; AKOS030574801; Acetic acid,2,2'-[1,4-piperazinediylbis(carbonothioylthio)]bis- (9CI); 2-[4-(carboxymethylsulfanylcarbothioyl)piperazine-1-carbothioyl]sulfanylacetic acid"	244824	C10H14N2O4S4	Investigative
M6APDG02533	LY3023414	.	57519748	C23H26N4O3	Phase 2
M6APDG00385	TG-100435	"TG-100435; CHEMBL230686; SCHEMBL4266197; ZINC28702706; BDBM50198782; US8481536, 367; US8481536, 575; ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine); 7-(2,6-dichlorophenyl)-5-methyl-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)benzo[e][1,2,4]triazin-3-amine"	11562302	C26H25Cl2N5O	Investigative
M6APDG00993	TESAGLITAZAR	Tesaglitazar; 251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid	208901	C20H24O7S	Phase 3
M6APDG00855	"3-(4-Amino-phenyl)-pyrrolidine-2,5-dione"	"32856-49-8; 3-(4-Amino-phenyl)-pyrrolidine-2,5-dione; 3-(4-aminophenyl)pyrrolidine-2,5-dione; 3-(4-Aminophenyl)-2,5-pyrrolidinedione; CHEMBL148903; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-; WSP-3; 3-(4'-aminophenyl)pyrrolidine-2,5-dione; AC1Q6LVA; 2-(p-aminophenyl) succinimide; SCHEMBL3274268; AC1L4Q15; CTK4G9448; BDBM50025154; FCH920777; AKOS006343465; AB07636; CC-12440; KB-26942; AS-35730; 2,5-Pyrrolidinedione,3-(4-aminophenyl)-; AX8033232; AB0073720; FT-0691904; X-3375; C-33345; 3-(4-amino-phenyl)-pyrrolidine-2,5-dione, AldrichCP"	161760	C10H10N2O2	Investigative
M6APDG02639	Double Oxidized Cysteine	.	6398956	C3H6NO4S-	Investigative
M6APDG01138	2-(methylsulfonylthio)ethyl 2-propylpentanoate	CHEMBL271677; 2-(methylsulfonylthio)ethyl 2-propylpentanoate; SCHEMBL4156413	24759251	C11H22O4S2	Investigative
M6APDG02122	"Sp-Adenosine-3',5'-Cyclic-Monophosphorothioate"	AC1NRD1K	46936216	C10H12N5O5PS	Investigative
M6APDG01562	Macbecin	.	433447	C30H42N2O8	Investigative
M6APDG02175	torin 1	Torin-1	49836027	C35H28F3N5O2	Investigative
M6APDG02658	Dehydropipernonaline	"Dehydropipernonaline; 107584-38-3; Dehydropipernoline; Piperidine, 1-[9-(1,3-benzodioxol-5-yl)-1-oxo-2,4,8-nonatrienyl]-, (E,E,E)-; Piperidine, 1-(9-(1,3-benzodioxol-5-yl)-1-oxo-2,4,8-nonatrienyl)-, (E,E,E)-; AC1O5SQM; CHEMBL483708; MolPort-039-101-180; KAYVDASZRFLFRZ-PQECNABGSA-N; N-(9-(3,4-Methylenedioxyphenyl)-2,4,8-nonatrienoyl)piperidine; ZINC14658239; 9-(3,4-Methylenedioxy)-2,4,8-nonatrienoic acid piperidide; (2E,4E,8E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnona-2,4,8-trien-1-one; Piperidine, 1-[(2E,4E,8E)-9-(1"	6439947	C21H25NO3	Investigative
M6APDG02349	AG490	"(E)-N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 133550-30-8; AG-490; Tyrphostin B42; Tyrphostin AG 490; AG 490; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; Tyrphostin AG490; tyrphostin AG-490; AG-490 (Tyrphostin B42); alpha-Cyano-(3,4-dihydroxy)-N-benzylcinnamide; N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 134036-52-5; (2E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; CHEMBL56543; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; (2E)-2-CYANO-3-(3,4-DIHYDROXYPHENYL)-N-(PHENYLMETHYL)-2-PROPENAMIDE; SMR001230665"	5328779	C17H14N2O3	Terminated
M6APDG02299	N5-(1-iminobutyl)-L-ornithine	CHEMBL442896; N5-(1-iminobutyl)-L-ornithine; Ethyl-L-NIO; AC1NRDHJ; (2S)-2-amino-5-(1-aminobutylideneamino)pentanoic acid; BDBM152700; BDBM50255074; ZINC12503853; (S)-2-Amino-5-butyrimidoylamino-pentanoic acid; (S)-2-Amino-5-butyrimidamidopentanoic acid (9)	5289555	C9H19N3O2	Investigative
M6APDG02364	PD-0173956	"UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; PD-0173956; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one"	5330524	C20H13Cl2FN4O	Investigative
M6APDG02211	NM-PP1	"1-NM-PP1; 221244-14-0; PP1 Analog II, 1NM-PP1; 1-tert-butyl-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; NM-PP1; Mutant Kinases Inhibitor II; 1NM-PP1(PP1 Analog II); AC1NP9I6; CHEMBL573578; 1 NM-PP1; CHEBI:52309; 4-Amino-1-tert-butyl-3-(1'-naphthylmethyl)pyrazolo[3,4-d]pyrimidine; 1-(tert-butyl)-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; MMV676599; 1-(1,1-dimethylethyl)-3-(1-naphthalenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; W-201917; C20H21N5"	5154691	C20H21N5	Investigative
M6APDG03161	W-198	5-Bromotetrandrine	9831563	C38H41BrN2O6	Phase 1
M6APDG03253	AL-43	"AL-438; CHEMBL266282; A-240610.0; SCHEMBL4172433; BDBM50107347; A-224817.0; 5-Allyl-2,2,4-trimethyl-10-methoxy-2,5-dihydro-1H-1-aza-6-oxachrysene; 5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; 5-allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline; (+/-)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; (+)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene"	9906282	C23H25NO2	Investigative
M6APDG00083	3-(1H-Indol-3-yl)-quinoline	3-(1H-indol-3-yl)quinoline; CHEMBL309116; 3-(1H-Indol-3-yl)-quinoline; 3-(3-Quinolyl)-1H-indole; SCHEMBL8171583; ZINC13737696; BDBM50039096	10243546	C17H12N2	Investigative
M6APDG01632	(O10eq)-beta-guanidinopropionylryanodine	CHEMBL27669; (O10eq)-beta-guanidinopropionylryanodine	44275926	C29H42N4O10	Investigative
M6APDG00553	N-Omega-Hydroxy-L-Arginine	N-omega-Hydroxy-L-arginine; NG-Hydroxy-L-arginine acetate; CHEBI:43088; FQWRAVYMZULPNK-BYPYZUCNSA-N; N(omega)-hydroxy-L-arginine; L-hydroxyarginine; N(5)-(N-hydroxycarbamimidoyl)-L-ornithine; N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine; 53054-07-2; HAR; Nomega-hydroxy-L-arginine; NG-HYDROXY-L-ARGININE; CHEMBL260629; 1hqf; 6-Noha; N(G)-Hydroxy-L-arginine; (e)-n5-[amino(hydroxyamino)methylidene]-l-ornithine; omega-hydroxy-l-arginine; AC1L3XHY; AC1Q5QLG; Lopac-H-7278; Lopac0_000615; SCHEMBL448333	123895	C6H14N4O3	Investigative
M6APDG00264	"1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole"	"CHEMBL376371; 1H-1,2,4-Triazole, 1-(9-phenyl-9H-fluoren-9-yl)-; 828265-51-6; Fluorenyl deriv. 17; BDBM9468; 1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole; CTK3D6011"	11232117	C21H15N3	Investigative
M6APDG02038	UNC0638	UNC0638; 1255580-76-7; UNC-0638; UNC 0638; UNII-26A103L2FO; 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine; CHEMBL1231795; 26A103L2FO; 2-Cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; 1255517-77-1; 2-cyclohexyl-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine; 2-Cyclohexyl-N-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine	46224516	C30H47N5O2	Investigative
M6APDG01719	4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one	CHEMBL373210; 4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one	44403404	C16H21N3O2	Investigative
M6APDG03838	C326	.	.	.	Phase 1
M6APDG00852	NDP-alpha-MSH	.	16154396	C78H111N21O19	Investigative
M6APDG03118	ITF2357	"Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)"	9804992	C24H27N3O4	Phase 3
M6APDG03059	Balixafortide	"1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2-&gt;9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2-&gt;9)-disulfide"	91864511	C80H112N22O21S2	Phase 3
M6APDG00723	"(11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid"	CHEMBL33814; ZINC29223313	13640144	C15H12O4	Investigative
M6APDG04149	KN035	Envafolimab	.	.	Phase 2
M6APDG01582	Nitroarginine	"Arginine, N(G)-nitro-; L-Ornithine, N5-[imino(nitroamino)methyl]-; C6H13N5O4; omega-Nitroarginine; .omega.-Nitroarginine; Arginine, omega-nitro-; N(G)-Methyl-L-arginine; L-Ornithine, N5-(imino(nitroamino)methyl)-; Arginine, .omega.-nitro-; N(sup G)-Nitro-L-arginine; Arginine, omega-nitro-, L-; nitroarginin; EINECS 218-418-9; n5-(n-nitrocarbamimidoyl)ornithine; Dl-Nitro Arginine; NO2Arg; AI3-62168; NOARG; Norvaline, (+)-; N(omega)-Nitroarginine"	440005	C6H13N5O4	Investigative
M6APDG03652	ARX-AHD	"Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx"	.	.	Investigative
M6APDG03448	STAUROSPORINONE	.	.	.	Investigative
M6APDG04080	SNN-0031	"Platelet derived growth factor (parkinson's disease), NeuroNova; PDGF-BB (parkinson's disease), NeuroNova"	.	.	Phase 1/2
M6APDG00675	2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one	.	135463623	C15H13N3O	Investigative
M6APDG04114	ESBA-105	"ESBA-105 (ophthalmic liquid formulation); ESBA-105 (ophthalmic liquid formulation), ESBATech; Anti-cytokine single-chain antibody (inflammation), ESBATech"	.	.	Phase 2
M6APDG00944	"5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one"	"5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one; CHEMBL448743; 5-(pyridin-3-yl)-2,3-dihydroinden-1-one; 5-Pyridin-3-yl-1-indanone; 5-(3-Pyridyl)-1-indanone; SCHEMBL6205709; CTK8E5276; QNSOPUXDEXJMIY-UHFFFAOYSA-N; BDBM50273704; ZINC40829496; 255895-87-5; TX-011073"	18407230	C14H11NO	Investigative
M6APDG01130	NSC-57893	NSC-57893; MLS002667915; 7399-94-2; 4-[(1h-benzimidazol-2-ylmethyl)(formyl)amino]benzoic acid; NSC57893; AC1L6GFK; AC1Q5TWY; NCIOpen2_002368; CHEMBL599366; 4-[1H-benzimidazol-2-ylmethyl(formyl)amino]benzoic acid; CTK5D9099; DTXSID30288854; HMS3089M13; ZINC1688755; AKOS030547711	245689	C16H13N3O3	Investigative
M6APDG03428	Neutralase	"Heparinase I, IBEX"	.	.	Discontinued in Phase 3
M6APDG02339	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine	5328245	C18H12BrN3	Investigative
M6APDG00926	eicosatetranoic acid	"ETYA; 5,8,11,14-eicosatetraynoic acid; 1191-85-1; icosa-5,8,11,14-tetraynoic acid; Octadehydroarachidonic acid; eicosatetranoic acid; MLS000069514; SMR000058640; MLS-0002886.0001; Ro 31428; Ro 3-1428; Opera_ID_402; AC1Q5VYB; Spectrum5_001952; cid_1780; CBiol_001864; SCHEMBL68751; KBioSS_000169; BSPBio_001449; KBioGR_000169; GTPL2669; CHEMBL458328; BML2-F04; AC1L1C80; CTK0H5766; CHEBI:94483; KBio3_000338; KBio2_002737; KBio3_000337; KBio2_005305; KBio2_000169; BDBM31752; DTXSID20152318; MGLDCXPLYOWQRP-UHFFFAOYSA-N; HMS3402I11; Bio1_001128"	1780	C20H24O2	Investigative
M6APDG00561	SC-47643	CHEMBL129921; BDBM50035970; 3-(8-Guanidino-octanoylamino)-N-[2-(4-methoxy-phenyl)-ethyl]-succinamic acid	124392	C22H35N5O5	Terminated
M6APDG03628	ISIS 175510	.	.	.	Investigative
M6APDG01247	L-Tryptophan-L-glutamine	CHEMBL476173; L-Tryptophan-L-glutamine; SCHEMBL5970454	25187914	C16H20N4O4	Investigative
M6APDG01749	Cyclo(RGDfV) (control)	CHEMBL206344; cyclo(RGDfV) (control)	44409460	C26H38N8O7	Investigative
M6APDG03051	COTI-2	"Coti-2; UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide"	91810660	C19H22N6S	Phase 1
M6APDG03592	ISIS 114170	.	.	.	Investigative
M6APDG00884	Fedratinib	TG101348	16722836	C27H36N6O3S	Approved
M6APDG03857	ONYX-015	"Dl1520; E1B-deleted adenovirus (cancer), ONYX"	.	.	Phase 1
M6APDG03459	VX-467	"JAK 3 inhibitor (inflammation), Vertex"	.	.	Investigative
M6APDG01773	3-(3-(benzamido)-5-nitrobenzamido)propanoic acid	CHEMBL218226	44418282	C20H20N4O6	Investigative
M6APDG02432	Meloxicam	"Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica"	54677470	C14H13N3O4S2	Approved
M6APDG00795	Amediplase	"Amediplase [INN]; Trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol"	154656	C22H18O4	Phase 3
M6APDG00904	Fucose	L-galactomethylose; 6-Desoxygalactose; SCHEMBL13092958; AKOS030212707	17106	C6H12O5	Investigative
M6APDG00850	DiaPep-277	"Diaccine; AVE-0277; AVE-277; Antidiabetic, Peptor"	16138701	C106H180N28O34	Phase 3
M6APDG00147	"6,7-Dimethoxy-3-phenyl-quinoline"	"CHEMBL66063; 6,7-dimethoxy-3-phenyl-quinoline; SCHEMBL8177777; ZINC3834036"	10422972	C17H15NO2	Investigative
M6APDG01095	1-Naphthalen-2-yl-1H-imidazole	"1-(naphthalen-2-yl)-1H-imidazole; 1-(2-naphthyl)-1h-imidazole; 25372-01-4; 1H-Imidazole, 1-(2-naphthalenyl)-; SCHEMBL2071832; CHEMBL195996; BDBM8916; MolPort-009-323-053; Imidazole-substituted naphthalene 23; ZINC13674480; AKOS034336039; MCULE-9753314459"	23644748	C13H10N2	Investigative
M6APDG01374	Vandetanib	"Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)"	3081361	C22H24BrFN4O2	Approved
M6APDG04362	LG-2293	LG-121100	.	.	Terminated
M6APDG00077	Di(1H-indol-2-yl)methanone	"CHEMBL207483; 200706-56-5; di(1H-indol-2-yl)methanone; indolyl ketone; Di(1H-indole-2-yl) ketone; SCHEMBL370573; Methanone, di-1H-indol-2-yl-; ZINC24262; CTK0J0872; DTXSID70436953"	10220822	C17H12N2O	Investigative
M6APDG00653	9-(4-Hydroxybutyl)-N2-Phenylguanine	"9-(4-HYDROXYBUTYL)-N2-PHENYLGUANINE; HBPG; CHEMBL406254; BPG; 6H-Purin-6-one, 1,9-dihydro-9-(4-hydroxybutyl)-2-(phenylamino)-; 161363-19-5; 1QHI; AC1L9LM8; SCHEMBL1506775; SCHEMBL17485742; CTK0A9784; BDBM21866; DTXSID00332272; AKOS030558959; N2-Phenyl-9-(4-hydroxybutyl) guanine; DB02495; 9-(4-Hydroxybuthyl)-N2-Phenylguanine; 2-anilino-9-(4-hydroxybutyl)-1H-purin-6-one; 2-anilino-9-(4-hydroxybutyl)-3H-purin-6-one; 9-(4-hydroxybutyl)-2-(phenylamino)-1,9-dihydro-6H-purin-6-one"	135415618	C15H17N5O2	Investigative
M6APDG00686	8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one	.	135492389	C14H9N3O4	Investigative
M6APDG04162	Saruplase	"Rescupase; CG-4509; PUK, Grunenthal; Pro-urokinase, Grunenthal; Rscu-PA, Grunenthal"	.	.	Phase 2
M6APDG01014	Amlexanox	"ANW; Amlenanox; Amlexanoxo; Amlexanoxum; Amoxanox; Aphthasol; Aptheal; Apthera; Elics; OraDisc; OraRinse; Solfa; Amlexanoxo [Spanish]; Amlexanoxum [Latin]; GlaxoSmithKline brand of amlexanox; OraDisc A; AA 673; CHX 3673; AA-673; Aphthasol (TN); CHX-3673; Solfa (TN); Amlexanox [USAN:INN:JAN]; Amlexanox (JAN/USAN/INN); 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid; 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-(1-methylethyl)-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3b)pyridine-3-carboxylic acid"	2161	C16H14N2O4	Approved
M6APDG00374	WAY-255348	"WAY-255348; 872141-23-6; CHEMBL407848; WAY255348; KIOOLNRTWPFVHX-UHFFFAOYSA-N; GTPL8664; SCHEMBL1537222; BCP21063; ZINC29133439; BDBM50375827; WAY 255348; SB18886; KB-81484; 5-(7-fluoro-3,3-dimethyl-2-oxo-1H-indol-5-yl)-1-methylpyrrole-2-carbonitrile"	11543746	C16H14FN3O	Investigative
M6APDG04220	[131I]-BC8	.	.	.	Phase 2
M6APDG04128	MGAH22	.	.	.	Phase 2
M6APDG02824	PINOCEMBRIN	"Pinocembrin; 480-39-7; (+)-Pinocembrin; (2S)-pinocembrin; Dihydrochrysin; UNII-8T7C8CH791; NSC 43318; NSC 279005; NSC 661207; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (2S)-; (S)-5,7-dihydroxyflavanone; (S)-5,7-dihydroxy-2-phenylchroman-4-one; CHEMBL399910; CHEBI:28157; (2s)-5,7-dihydroxy-2-phenyl-2,3-dihydro-4h-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one; 8T7C8CH791; Pinocembrin (6CI); 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (-)-"	68071	C15H12O4	Phase 2
M6APDG00968	"3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine"	"CHEMBL185161; 3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine; 3,4-dimethylpyrrolidin-2-on imine; BDBM50150928"	19049163	C6H12N2	Investigative
M6APDG03412	XL784	.	.	.	Discontinued in Phase 2
M6APDG02872	ABT-510	N-Acetyl-N-methyl-glycyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-argininyl-L-proline N-ethylamide	6918562	C46H83N13O11	Phase 2
M6APDG02373	1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea	Diarylurea deriv. 14a; AC1NS9HT; BDBM6656; CHEMBL143759; ZINC13471116; AKOS027814075; 3-1H-indazol-6-yl-1-pyridin-2-ylurea; 1-(1H-indazol-6-yl)-3-pyridin-2-ylurea; N-(1H-Indazol-6-yl)-N -pyridin-2-ylurea	5330597	C13H11N5O	Investigative
M6APDG00766	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	CHEMBL76958; 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid	14862522	C15H11NO7S	Investigative
M6APDG04099	AGN-208397	.	.	.	Phase 1/2
M6APDG03463	PF-00614435	"PF-00658968; PF-00851623; PF-02311803; PF-4254644; PF-851623; PF-899555; C-Met (HGFR) inhibitors (cancer), Pfizer"	.	.	Investigative
M6APDG02235	KAEMPFEROL	"kaempferol; 520-18-3; Kaempherol; Kempferol; Trifolitin; Populnetin; Robigenin; Rhamnolutein; Pelargidenolon; Rhamnolutin; Swartziol; Indigo Yellow; Kampherol; Nimbecetin; Kampferol; Campherol; Kaemferol; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; CCRIS 41; NSC 407289; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphe"	5280863	C15H10O6	Investigative
M6APDG02507	GSK2636771	GSK2636771; 1372540-25-4; GSK-2636771; 2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid; UNII-DW94IAT0LS; DW94IAT0LS; GSK 2636771; 2-Methyl-1-((2-methyl-3-(trifluoromethyl)phenyl)methyl)-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid; 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid; lic acid; XTKLTGBKIDQGQL-UHFFFAOYSA-N	56949517	C22H22F3N3O3	Phase 1
M6APDG03544	ISIS 105987	.	.	.	Investigative
M6APDG00606	RU-56187	"RU-56187; 143782-25-6; CHEMBL1099140; 4-(3,4,4-Trimethyl-5-oxo-2-thioxo-1-imidazolidinyl)-2-(trifluoromethyl)benzonitrile; Benzonitrile,2-(trifluoromethyl)-4-(3,4,4-trimethyl-5-oxo-2-thioxo-1-imidazolidinyl)-; RU 56187; ACMC-20n377; AC1L318J; SCHEMBL1435262; CTK4C3806; DTXSID90162545; BDBM50317664; 2-(trifluoromethyl)-4-(3,4,4-trimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)benzonitrile; 2-(trifluoromethyl)-4-(3,4,4-trimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile; Benzonitrile, 2-(trifluoromethyl)-4-(3,4,4-trimet"	132581	C14H12F3N3OS	Investigative
M6APDG00380	AdPEDR	.	11557063	C38H41IN14O9	Phase 2
M6APDG02864	PMX-53	"YOKBGCTZYPOSQM-HPSWDUTRSA-N; PMX53; CHEMBL41547; (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[1630]henicosan-3-yl]-3-phenylpropanamide; PMX 53; AcF-[OP(D-Cha)WR]; Ac-Phe-[Orn-Pro-cha-Trp-Arg]; C5aR-AP; AC1OCFH0; GTPL579; SCHEMBL16492460; SCHEMBL12971688; 219639-75-5; BDBM50111445;  AcF-[OP(D-Cha)WR]; N-Acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-D-arginine N-52-C-16-lactam"	6918468	C47H65N11O7	Phase 2
M6APDG01985	KT-5720	"KT 5720; KT5720; 108068-98-0; GTPL337; ZINC3873013; KT 5720, &gt; hexyl (15R,16R,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaene-16-carboxylate; (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3 inverted exclamation marka,2 inverted exclamation marka,1 inverted exclamation marka-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-c"	454202	C32H31N3O5	Investigative
M6APDG01631	Di-Benzyloxycarbonyl-guanidino acetylryanodine	CHEMBL416926; Di-Benzyloxycarbonyl-guanidino acetylryanodine	44275895	C44H52N4O14	Investigative
M6APDG02171	"2,3,5-Trimethoxy-4'-amino-trans-stilbene"	CHEMBL1170663; BDBM50322054	49799657	C17H19NO3	Investigative
M6APDG02932	(S)-FLURBIPROFEN	"51543-39-6; esflurbiprofen; (S)-(+)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; UNII-J5ZZK9P7MX; (S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; (S)-2-(2-Fluoro-[1,1'-biphenyl]-4-yl)propanoic acid; (2S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; J5ZZK9P7MX; CHEMBL435298; CHEBI:42446; SYTBZMRGLBWNTM-JTQLQIEISA-N; (2S)-2-(3-fluoro-4-phenylphenyl)propanoic acid; BTS-24332; (S)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (S)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic ac"	72099	C15H13FO2	Preregistration
M6APDG02782	aminopurvalanol A	NG-97	6604931	C19H26ClN7O	Investigative
M6APDG01460	Indirubin-5-sulfonate	"indirubin-5-sulphonate; CHEMBL1207227; 2',3-DIOXO-1,1',2',3-TETRAHYDRO-2,3'-BIINDOLE-5'-SULFONIC ACID; INR; AC1NRBUE; AC1NZHHM; 1v0o; AC1O8NUW; Indirubin derivative, 20; SCHEMBL490806; BDBM84534; A05-A11B1-I; NSC717821; BDBM50023871; NSC-717821; DB02519; NCI60_040625; 2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (3Z)-2-oxo-3-(3-oxoindolin-2-ylidene)indoline-5-sulfonic acid; (3E)-2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (2Z)-2',3-dioxo-1,1',2',3-tetrahydro-2,3'-biindole-5'-sulfonic acid; Indirubin-5-Sulphonate"	3708	C16H10N2O5S	Investigative
M6APDG04082	EGFR CART	.	.	.	Phase 1/2
M6APDG04171	Testogen TDS	"OriTex; OriTex); TDS-testosterone; Testosterone (oral, testosterone deficiency), Clarus; Testosterone (transdermal, TDS), TransDermal Technologies"	.	.	Phase 2
M6APDG00160	"6,7-Dimethoxy-3-thiophen-2-yl-quinoline"	"CHEMBL304336; 6,7-dimethoxy-3-thiophen-2-yl-quinoline; SCHEMBL8501345; ZINC3834034"	10468421	C15H13NO2S	Investigative
M6APDG03227	UK-356202	"compound 13j [PMID: 15149680]; UK-356,202"	9885167	C17H13ClN4O2	Clinical trial
M6APDG01804	"3,2'-bis-trifluoromethyl-biphenyl-4-carbonitrile"	"CHEMBL396656; BDBM50220379; 582293-27-4; 3,2''-bis-trifluoromethyl-biphenyl-4-carbonitrile"	44434099	C15H7F6N	Investigative
M6APDG01760	(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone	CHEMBL210425; (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone	44411967	C23H16N2O2	Investigative
M6APDG03222	"6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline"	"CHEMBL70130; 6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline; SCHEMBL8501467; ZINC8074; BDBM50039071"	9882618	C18H17NO3	Investigative
M6APDG01607	AMG 337	.	44181686	C23H22FN7O3	Phase 2
M6APDG00905	"2-methylisoquinoline-1,3,4-trione"	"2-methylisoquinoline-1,3,4(2H)-trione; 21640-33-5; 2-methyl-isoquinoline-1,3,4-trione; 2-methylisoquinoline-1,3,4-trione; 2-methyl-1,2,3,4-tetrahydroisoquinoline-1,3,4-trione; N-methylphthalonimide; AC1LVZDH; AC1Q3XNZ; 1,3,4(2H)-Isoquinolinetrione, 2-methyl-; CHEMBL381480; SCHEMBL13442852; Isoquinoline-1,3,4-trione 2a; CTK4E7387; BDBM10248; DTXSID90364926; MolPort-001-798-932; ZINC2030689; CS-D0370; FCH830488; STK368698; AKOS005444509; MCULE-7985115369; ACM21640335; 2-methyl-1,3,4(2H)-isoquinolinetrione; AK325966"	1714901	C10H7NO3	Investigative
M6APDG03798	Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy	"Thymidine kinase-expressing adenovirus and ganciclovir suicide genetherapy (cancer); Ad5-SSTR/TK-RGD; Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy (cancer), University of Alabama"	.	.	Phase 1
M6APDG03422	ISIS 104838	.	.	.	Discontinued in Phase 2
M6APDG00570	(RS)-(tetrazol-5-yl)glycine	"(RS)-(tetrazol-5-yl)glycine; 138199-51-6; Tet-glycine; Tetrazol-5-yl-gly; 5-Tetrazolyl-glycine; (Tetrazol-5-yl)glycine; Tetrazolylglycine; 2-amino-2-(1H-1,2,3,4-tetrazol-5-yl)acetic acid; 2-amino-2-(2H-tetrazol-5-yl)acetic acid; CHEBI:35003; alpha-tetrazolylglycine; LY 285 265; Biomol-NT_000191; C13738; AC1L2Q8Q; GTPL4068; BPBio1_001214; CHEMBL140784; SCHEMBL10231795; MolPort-023-275-877; HMS3266G07; AKOS006272482; AKOS024048687; NCGC00024531-02; RT-015857; 2-amino-2-(1H-tetrazol-5-yl)acetic acid; T-205"	126383	C3H5N5O2	Investigative
M6APDG04132	POL-6326	"CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor"	.	.	Phase 2
M6APDG02954	AC0010	"Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-"	72734520	C26H26FN7O2	Phase 3
M6APDG01074	"5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione"	.	23354226	C8H4Cl2N2O3	Investigative
M6APDG02773	MINAMESTANE	"FCE-24928; Minamestane; 4-Aminoandrosta-1,4,6-triene-3,17-dione"	65886	C19H23NO2	Terminated
M6APDG02532	"3,4-dihydroxyxanthone"	"3,4-Dihydroxyxanthone; 3,4-Dihydroxy-xanthone; 3,4-dihydroxyxanthen-9-one; CHEMBL446323; 39731-48-1; AC1NX8OR; SCHEMBL133422; 3,4-dihydroxy-xanthen-9-one; CTK4I1796; DTXSID20192815; YFVCSEXMOBEPQB-UHFFFAOYSA-N; 3,4-dihydroxy-9H-xanthen-9-one; 9H-Xanthen-9-one,3,4-dihydroxy-; ZINC15119047; BDBM50269645; 9H-Xanthen-9-one, 3,4-dihydroxy-"	5748382	C13H8O4	Investigative
M6APDG01777	Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)	CHEMBL384429; cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)	44418869	C33H40N8O6	Investigative
M6APDG01125	NSC-54162	"NSC-54162; NSC54162; AC1Q5WTA; AC1L6CM2; CHEMBL611994; 2,2'-{[(2-hydroxyphenyl)methanediyl]disulfanediyl}diacetic acid; ZINC1685025; Acetic acid, (salicylidenedithio)di-; 4265-51-4; Acetic acid, [(o-hydroxybenzylidene)dithio]di-; Acetic acid,2'-[[(2-hydroxyphenyl)methylene]bis(thio)]bis-; 2-[carboxymethylsulfanyl-(2-hydroxyphenyl)methyl]sulfanylacetic acid"	243918	C11H12O5S2	Investigative
M6APDG04172	RM-1929	.	.	.	Phase 2
M6APDG01849	"2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine"	"2,4-diamino-6-phenyl-5,6,7,8,-tetrahydropteridine; (6R)-6-phenyl-5,6,7,8-tetrahydropteridine-2,4-diamine; AC1L9HFU"	445109	C12H14N6	Investigative
M6APDG04071	KB-004	"Anti-EphA3 tyrosine kinase receptor monoclonal antibody (Humaneered, iv, cancer), KaloBios"	.	.	Phase 1/2
M6APDG04285	DE-766	.	.	.	Phase 3
M6APDG01209	2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide	CHEMBL402718; 2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide; SCHEMBL8152458	25065925	C20H24N2O4	Investigative
M6APDG00381	3-methoxy-4-(o-tolyloxy)benzonitrile	CHEMBL449867; 3-methoxy-4-(o-tolyloxy)benzonitrile; SCHEMBL4183144	11557752	C15H13NO2	Investigative
M6APDG00958	RPR-108514A	CHEMBL543669; RPR-108514A	18770833	C17H18ClN3O2	Investigative
M6APDG01429	"1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one"	"CHEMBL84044; 7403-93-2; NSC403412; AC1L83AN; 1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one; SCHEMBL6645911; DTXSID70323238; BDBM50131013; NSC-403412; 2,3,4,4a,5,10b-hexahydro-1H-phenanthridin-6-one; 1,3,4,4a,5,10b-Hexahydro-2H-phenanthridin-6-one"	345678	C13H15NO	Investigative
M6APDG04064	Sym013	.	.	.	Phase 1/2
M6APDG04217	Emibetuzumab	.	.	.	Phase 2
M6APDG00469	CEP-11981	"CEP-11981; UNII-J8AY0Z4CBP; 856691-93-5; J8AY0Z4CBP; CHEMBL2010872; BOL-303213X; compound 11b [PMID 22148921]; GTPL8189; SCHEMBL2439310; DTXSID80234942; CEP11981; BDBM50379186; CEP 11981; 4H-Indazolo(5,4-a)pyrrolo(3,4-C)carbazol-4-one, 2,5,6,11,12,13-hexahydro-2-methyl-11-(2-methylpropyl)-8-(2-pyrimidinylamino)-; Z-3152"	11751922	C28H27N7O	Phase 1
M6APDG02423	Altiratinib	.	54576299	C26H21F3N4O4	Phase 1
M6APDG00339	N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide	CHEMBL202471; N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide; SCHEMBL3294121; BDBM50182531	11493409	C13H20N2O5S	Investigative
M6APDG01717	3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one	CHEMBL194535; 3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one	44403357	C18H18N2O2	Investigative
M6APDG03748	ISIS 104257	.	.	.	Investigative
M6APDG03041	L-Homoarginine	"L-Homoarginine; homoarginine; 156-86-5; H-HoArg-OH; homo-l-arginine; L-N(sup 6)-Amidinolysine; n6-amidino-lysine; UNII-JF751CK38I; (S)-2-Amino-6-guanidinohexanoic acid; N6-amidino-L-Lysine; L-Lysine, N(sup 6)-(aminoiminomethyl)-; NSC 27429; LYSINE, N(sup 6)-AMIDINO-, L-; CHEMBL589752; JF751CK38I; N6-(Aminoiminomethyl)-L-lysine; CHEBI:27747; QUOGESRFPZDMMT-YFKPBYRVSA-N; AK-49431; L-Lysine, N6-(aminoiminomethyl)- (9CI); L-alpha-Amino-epsilon-guanidinohexanoic acid; Q-201303; h-Homoarginine; h-har-oh; L-N(6)-amidinolysine"	9085	C7H16N4O2	Investigative
M6APDG03287	Nelipepimut S	E75	9941306	C50H78N10O11	Phase 3
M6APDG01270	MONODICTYOCHROMONE B	"Monodictyochromone B; CHEMBL576579; CHEBI:66397; (2S,2'R)-5,5'-dihydroxy-2-[(2R,3R)-3-hydroxy-5-oxotetrahydrofuran-2-yl]-2,2',7-trimethyl-2'-[(2R,3S)-3-methyl-5-oxotetrahydrofuran-2-yl]-2,2',3,3'-tetrahydro-4H,4'H-6,6'-bichromene-4,4'-dione; Monodictyochromes B"	25256842	C30H30O11	Investigative
M6APDG00588	Lactoquinomycin	Lactoquinomycin; SCHEMBL12324296	12967404	C24H27NO8	Investigative
M6APDG00914	SB 203580	152121-47-6; SB-203580; SB203580; 4-(4-(4-fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-1H-imidazol-5-yl)pyridine; 4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-5-(4-pyridyl)-1H-imidazole; CHEBI:90705; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; CHEMBL10; RWJ 64809; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole; 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine; PB 203580; UNII-WS78QR6DSV	176155	C21H16FN3OS	Terminated
M6APDG00041	CD666	CD-666; CD 666	10090192	C24H28O3	Investigative
M6APDG03802	ARX-424	"Long-acting interferon beta (multiple sclerosis), Merck Serono/ Ambrx"	.	.	Phase 1
M6APDG02919	HE-2000	"Immunitin; Inactivin; Bromoepiandrosterone, Hollis-Eden; DHEA analogs, Hollis-Eden; Dehydroepiandrosterone, Hollis-Eden"	71613	C19H29BrO2	Discontinued in Phase 2
M6APDG01567	PNU-107859	"PNU-107859; 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE; CHEMBL249847; ATT; 3usn; AC1N9ZM9; SCHEMBL6954588; RKWXKADYTDWZIJ-VIFPVBQESA-N; ZINC6379443; BDBM50241372; DB07390; N-methyl-Nalpha-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]-L-phenylalaninamide; (2S)-N-methyl-3-phenyl-2-{[(5-sulfanyl-1,3,4-thiadiazol-2-yl)carbamoyl]amino}propanamide; (S)-1-(1-(methylamino)-1-oxo-3-phenylpropan-2-yl)-3-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)urea"	4369084	C13H15N5O2S2	Investigative
M6APDG03568	ISIS 122974	.	.	.	Investigative
M6APDG02879	N-Methylleucine	"N-Methyl-L-leucine; 3060-46-6; (S)-4-Methyl-2-(methylamino)pentanoic acid; N-Methylleucine; L-Leucine, N-methyl-; N-Me-Leu-OH; MeLeu; methyl-L-leucine; UNII-2YT9687ECD; 2YT9687ECD; H-ALPHA-METHYL-L-LEUCINE; AK107655; N-methyl-l-leu; Leucine, N-methyl-; AC1MCSAQ; SCHEMBL93452; AMGLY00163; CTK1A1168; MolPort-003-925-252; XJODGRWDFZVTKW-LURJTMIESA-N; ZINC160405; KS-00000J9G; FCH835634; ANW-74881; AKOS006282756; CS-W008140; ACM3060466; AJ-15591; SC-82208; KB-58630; AC-24158; AS-19192; DB-038132; TC-163626; AX8020112; X5243; ST24036190; FT-0695191"	6951123	C7H15NO2	Investigative
M6APDG01747	Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3	CHEMBL202699; Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3; BDBM50179459; (S)-2-{(R)-2-[(S)-2-acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid ((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-amide	44409240	C40H48N8O6	Investigative
M6APDG00166	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	CHEMBL297968; N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide	10494722	C18H16N4O	Investigative
M6APDG01807	(4-guanidino-benzyl)-carbamic acid benzyl ester	CHEMBL391969; (4-guanidino-benzyl)-carbamic acid benzyl ester	44436702	C16H18N4O2	Investigative
M6APDG00009	CGP61594	"4-[2-(4-Azidophenyl)acetamido]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid; 4-[2-(4-azidophenyl)acetamido]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid; CGP 61594; [3H]CGP61594; CGP-61594; [3H]CGP 61594; GTPL5474;  CGP-61594"	10025114	C18H15Cl2N5O3	Investigative
M6APDG02741	4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	"(4-Pyridylmethylene)indane 8b; SCHEMBL4231649; CHEMBL175799; BDBM8619; AC1O7061; ZINC100056323; 4-[(Z)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539793	C15H12ClN	Investigative
M6APDG00702	PMID27841036-Compound-37	2X-121	135565981	C18H15N5O	Phase 2
M6APDG03224	BMS-564929	"BMS-564929; 627530-84-1; UNII-9BLW27W4X7; BMS 564929; 9BLW27W4X7; C14H12ClN3O3; 2-Chloro-4-[(7r,7as)-7-Hydroxy-1,3-Dioxotetrahydro-1h-Pyrrolo[1,2-C]imidazol-2(3h)-Yl]-3-Methylbenzonitrile; 2-Chloro-3-methyl-4-[(7R,7AS)-tetrahydro-7-hydroxy-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]benzonitrile; KEJORAMIZFOODM-PWSUYJOCSA-N; 2nw4; SCHEMBL2967577; DTXSID50432357; ZINC3938678; 3500AH; AKOS027288930; CS-1381; DB07286; BMS-564,929; NCGC00378909-01; HY-12111; 8NH; KB-75607; BMS 564929;BMS564929; W-5594; S900006120"	9882972	C14H12ClN3O3	Investigative
M6APDG02905	CS-038	"Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences"	71402018	C36H29FN2O4	Phase 3
M6APDG00003	4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine	"4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine; Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872"	10017019	C12H9BrN4	Investigative
M6APDG00350	N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide	N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide; CHEMBL378980; SCHEMBL1145050; BDBM15960; Aminopyridine-Based Inhibitor 19d	11507052	C12H16N4O2	Investigative
M6APDG02067	4-Imidazol-1-ylmethylxanthen-9-one	CHEMBL1083971; 4-Imidazol-1-ylmethylxanthen-9-one	46867542	C17H12N2O2	Investigative
M6APDG02072	1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole	CHEMBL1085936; 1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole	46867547	C16H13N3O2S	Investigative
M6APDG01007	2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid	CHEMBL572947; 2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid	21496278	C16H16O3S	Investigative
M6APDG02166	"2,3-Dimethoxy-4'-amino-trans-stilbene"	CHEMBL1173700; BDBM50322050	49799640	C16H17NO2	Investigative
M6APDG03867	FP-025	.	.	.	Phase 1
M6APDG02078	AdoC(Aoc)Arg6	CHEMBL610876	46877392	C54H98N30O12	Investigative
M6APDG02840	4-(4-methyl-benzylideneamino)-benzenesulfonamide	CHEMBL429915; AC1LEQSK; SCHEMBL5312741; SOHFVFXITPDEDK-UHFFFAOYSA-N; ZINC95919525; ZINC18036434; BDBM50371763; ZINC253618240; AKOS016038193; AKOS003632590; MCULE-3900521489; ST009696; N-(4-Methylbenzylidene)-4-sulfamoylaniline; J3.552.121F; 4-[[(E)-4-Methylbenzylidene]amino]benzenesulfonamide; 4-[(4-methylphenyl)methylideneamino]benzenesulfonamide; 4-[(1E)-2-(4-methylphenyl)-1-azavinyl]benzenesulfonamide	690836	C14H14N2O2S	Investigative
M6APDG03348	DRF-2593	DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645	9889200	C20H17N3O4S	Phase 3
M6APDG04042	AVX901	HER2 cancer immunotherapy	.	.	Phase 1/2
M6APDG04250	Indium-111	ABT-806	.	.	Phase 2/3
M6APDG03381	Mecasermin	Increlex (TN)	.	.	Approved
M6APDG00913	Acetate Ion	"acetate; Acetate Ion; Acetic acid, ion(1-); Acetate ions; 71-50-1; monoacetate; MeCO2 anion; UNII-569DQM74SC; ethanoate; Acetat; 569DQM74SC; Shotgun; Ethanoat; CHEMBL1354; racemic acetate; Azetat; acetyl hydroxide; Acetic acid ion; Acetic cid glacial; TCLP extraction fluid 2; AC1Q1J9D; AC1Q1J2O; CH3-COO(-); AC1L18N9; DTXSID1037694; CTK5D4394; CHEBI:30089; MolPort-006-169-563; QTBSBXVTEAMEQO-UHFFFAOYSA-M; STL282721; CMC_13391; BDBM50159793; AKOS022101130; AN-25008; AN-23801; LS-189936; 1395-EP2380874A2; 1395-EP2380661A2; 1395-EP2316837A1"	175	C2H3O2-	Investigative
M6APDG03850	MEDI-573	.	.	.	Phase 1
M6APDG00427	NU-8231	NU-8231; SCHEMBL2454464; CHEMBL360944	11648438	C26H26ClNO5	Investigative
M6APDG01217	4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine	CHEMBL608095; 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine; SCHEMBL4438208	25074312	C13H13N5OS	Investigative
M6APDG01653	"4-(2,3-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline"	"CHEMBL98155; 4-(2,3-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline"	44331261	C19H19NO5	Investigative
M6APDG00736	(S)-sirtinol	.	1376645	C26H22N2O2	Investigative
M6APDG00785	Merimepodib	"Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid"	153241	C23H24N4O6	Approved
M6APDG03234	L-165461	"L-165461; CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9889841	C23H26ClNO4S	Investigative
M6APDG01715	N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide	CHEMBL193979	44401305	C10H12N2O2S	Investigative
M6APDG01870	"4,5-Bis(4-methoxyphenyl)isothiazole"	"4,5-Bis(4-methoxyphenyl)isothiazole; CHEMBL473946"	44564415	C17H15NO2S	Investigative
M6APDG00651	10Z-Hymenialdisine	"Hymenialdisine; (Z)-Hymenialdisine; CHEMBL361708; 95569-43-0; 82005-12-7; (4Z)-4-(2-amino-4-oxo-1H-imidazol-5-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; Hymenialdisine, 1; 4-(2-Amino-4-oxo-2-imidazolidin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; AC1MHZEP; SCHEMBL155899; STO156; BDBM7491; SCHEMBL15426167; MolPort-006-394-608; 4-(2-Amino-5-oxo-3,5-dihydro-imidazol-4-ylidene)-2-bromo-4,5,6,7-tetrahydro-1H-pyrrolo[2,3-c]azepin-8-one; NSC607173"	135413546	C11H10BrN5O2	Investigative
M6APDG03468	Thieno-phenanthridin-6-one	.	.	.	Investigative
M6APDG01553	N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea	"n-(1-adamantyl)-n'-(4-guanidinobenzyl)urea; AGB; 1ejn; AC1L1HTN; SCHEMBL4328331; WX293T; SCHEMBL14524522; CTK7G4253; BDBM16176; WX-293T; DB03782; 3-adamantan-1-yl-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(1-adamantyl)-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(adamantan-1-yl)-1-[(4-carbamimidamidophenyl)methyl]urea; 1-(1-adamantyl)-3-[[4-(diaminomethylideneamino)phenyl]methyl]urea; 1-{4-[(diaminomethylidene)amino]benzyl}-3-tricyclo[3.3.1.13,7]dec-1-ylurea"	4286	C19H27N5O	Investigative
M6APDG02857	Temsirolimus	Torisel	6918289	C56H87NO16	Approved
M6APDG03548	S-111	"PARP1 inhibitor (cancer), Sentinel Oncology"	.	.	Investigative
M6APDG02515	HTS-05058	"MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; HTS-05058; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988"	5714572	C12H9N3O	Investigative
M6APDG00554	pristanic acid	"UNII-6P06977L1A; 6P06977L1A; (2S,6R,10R)-2,6,10,14-tetramethylpentadecanoic acid; L,d,D-pristanic acid; GTPL2676; Pristanic acid, (2S,6R,10R)-; UNII-5FMQ2908AP component PAHGJZDQXIOYTH-KURKYZTESA-N; Pentadecanoic acid, 2,6,10,14-tetramethyl-, (2S,6R,10R)-"	123929	C19H38O2	Investigative
M6APDG03352	Teprotumumab	RV001	.	.	Approved
M6APDG00390	"3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL372076; SCHEMBL3822337	11572699	C17H13NO3	Investigative
M6APDG01312	Ciprofibrate	"Ciprofibrato; Ciprofibratum; Ciprol; Hiperlipen; Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; C 0330; WIN 35833; Ciprofibrato [INN-Spanish]; Ciprofibratum [INN-Latin]; Win 35,833; Win-35833; Ciprofibrate (USAN/INN); Ciprofibrate [USAN:BAN:INN]; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid"	2763	C13H14Cl2O3	Approved
M6APDG01174	AMG 900	AMG-900; AMG 900; 945595-80-2; AMG900; UNII-9R2G075611; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; 9R2G075611; N-(4-((3-(2-aminopyrimidin-4-yl)pyridin-2-yl)oxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen- 2-yl)phthalazin-1-amine; IVUGFMLRJOCGAS-UHFFFAOYSA-N	24856041	C28H21N7OS	Phase 1
M6APDG01975	GW-637185X	CHEMBL539663; GW-637185X; GW637185X; BDBM50297670	45268661	C16H18F3N3O2S	Investigative
M6APDG00866	"3-aminobenzo[c][1,5]naphthyridin-6(5H)-one"	"CHEMBL106154; 3-aminobenzo[c][1,5]naphthyridin-6(5H)-one; Benzo[c]-1,5-naphthyridin-6(5H)-one, 3-amino-; SCHEMBL12750402; BDBM50130580; 433726-73-9"	16221809	C12H9N3O	Investigative
M6APDG00123	"5,6-Bis-p-tolylamino-isoindole-1,3-dione"	"CHEMBL7914; 5,6-Bis-p-tolylamino-isoindole-1,3-dione; SCHEMBL8834183; BDBM50040920"	10360970	C22H19N3O2	Investigative
M6APDG03274	Tofacitinib	"Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; racemic-tofacitinib; 1259404-17-5; tofacitinibum; CP-690,550; UNII-87LA6FU830; 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; Tofacitinib (CP-690550,Tasocitinib); CHEMBL221959; CHEBI:71200;  Xeljanz (TN)"	9926791	C16H20N6O	Approved
M6APDG02464	Ro-31-4724	Ro-31-4724; CHEMBL92608; [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER; RO4; 112105-54-1; Ro 314724; ro 31-4724; AC1NUPD6; ZINC3801503; ro-314724; BDBM50146631; DB08482; RO314724; (R)-N-(N-(2-(2-(Hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)-L-leucyl)-L-alanine ethyl ester; ethyl N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-L-leucyl-L-alaninate; ethyl (2S)-2-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoate	5487313	C19H35N3O6	Terminated
M6APDG03787	ISIS 9003	.	.	.	Investigative
M6APDG02759	5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole	"Imidazolylmethyleneindane 9a; AC1O70GV; BDBM8883; SCHEMBL4231848; CHEMBL177293; 5-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]-1H-imidazole; 5-[(E)-(5-Bromo-2,3-dihydro-1H-inden-1-ylidene)methyl]-1H-imidazole"	6540042	C13H11BrN2	Investigative
M6APDG00183	"N,N'-Bis-(4-butoxy-phenyl)-guanidine"	"CHEMBL326502; SCHEMBL4983215; n,n'-bis(4-butoxyphenyl)guanidine; BDBM50066423"	10594376	C21H29N3O2	Investigative
M6APDG02594	Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate	AC1NVSSE; MLS000104229; CHEMBL3197417; MolPort-002-136-693; MolPort-019-735-612; HMS2400I13; CCG-2361; ZINC18045921; STL321690; AKOS022107323; SMR000051278; SR-01000198931; SR-01000198931-1; ethyl (2Z)-cyano(quinoxalin-2(1H)-ylidene)ethanoate; ethyl (2Z)-2-cyano-2-(1H-quinoxalin-2-ylidene)acetate	607092	C13H11N3O2	Investigative
M6APDG01802	2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile	CHEMBL233874; 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile	44430881	C18H14N4	Investigative
M6APDG03349	Urokinase	.	.	.	Approved
M6APDG00465	Octanedioic acid hydroxyamide pyridin-2-ylamide	Octanedioic acid hydroxyamide pyridin-2-ylamide; SCHEMBL8090513; CHEMBL164872; ZINC13472303	11747496	C13H19N3O3	Investigative
M6APDG03012	N-(6-ethoxypyridin-2-yl)acetamide	N-(6-ethoxypyridin-2-yl)acetamide; N-(6-ethoxy-pyridin-2-yl)-acetamide; 775-38-2; AC1LGO22; CHEMBL210256; BDBM15972; Aminopyridine-Based Inhibitor 46	824661	C9H12N2O2	Investigative
M6APDG01938	TI3	"RB106; CHEMBL419499; [(2S)-2-SULFANYL-3-PHENYLPROPANOYL]-GLY-(5-PHENYLPROLINE); TI3; 1qf2; AC1L9LL2; BDBM50051785; DB02669; N-[(S)-2-Mercapto-3-phenylpropionyl]-Gly-[(5R)-5-phenyl-L-Pro-]-OH; N-[(2S)-3-phenyl-2-sulfanylpropanoyl]glycyl-(5R)-5-phenyl-L-proline; (2S,5R)-5-phenyl-1-[2-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid; (2S,5R)-1-[2-((S)-2-Mercapto-3-phenyl-propionylamino)-acetyl]-5-phenyl-pyrrolidine-2-carboxylic acid"	448087	C22H24N2O4S	Investigative
M6APDG04067	SNN-0029	"VEGF (intracerebroventricular, amyotrophic lateral sclerosis), NeuroNova/VIB/Genentech"	.	.	Phase 1/2
M6APDG04072	OPB-31121	.	.	.	Phase 1/2
M6APDG02802	GED-0507-34-Levo	GED-0507; GED-0507-34; GED-0507-34E2	67008033	C10H13NO3	Phase 2
M6APDG00035	N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide	CHEMBL1086782; N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652	10085059	C16H16N4O	Investigative
M6APDG02993	CPI-1205	"HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-"	78320408	C27H33F3N4O3	Phase 1/2
M6APDG01136	AZD1236	"(S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; 459814-90-5; AZD1236; AZD-1236; UNII-B4OQY51WZS; B4OQY51WZS; (S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)-sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; SCHEMBL942315; GTPL7844; DTXSID30647184; SFJFBTPHDHUUPU-OAHLLOKOSA-N; AZD 1236; 6326AB; ZINC59688588; AKOS016011525; DB11961; AX8246058; KB-211575; AJ-113592; Piperidine, 4-((5-chloro-2-pyridinyl)oxy)-1-((((4S)-4-methyl-2,5-dioxo-4-imidazolidinyl)methyl)sulfonyl)"	24751752	C15H19ClN4O5S	Discontinued in Phase 2
M6APDG00388	R763	.	11569967	C24H30FN7O	Phase 1
M6APDG01192	"4,5-Bis(4-chlorophenyl)-1,2-selenazole"	"CHEMBL501676; 4,5-Bis(4-chlorophenyl)-1,2-selenazole"	24884694	C15H9Cl2NSe	Investigative
M6APDG01757	2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	CHEMBL378740; BDBM50185874; 2-(4''-chloro-biphenyl-4-sulfonyl)-pentanoic acid	44411812	C17H17ClO4S	Investigative
M6APDG00443	MSX-122	.	11687907	C16H16N6	Phase 1
M6APDG01471	WHI-P154	.	3795	C16H14BrN3O3	Investigative
M6APDG00936	3-(5-methoxy-1H-indol-3-yl)propanoic acid	"3-(5-methoxy-1H-indol-3-yl)propanoic acid; 39547-16-5; 3-(5-Methoxy-1H-indol-3-yl)-propionic acid; 1H-Indole-3-propanoic acid, 5-methoxy-; 3-(5-methoxyindol-3-yl)propanoic acid; CBMicro_030931; ChemDiv2_000435; AC1L48GT; Oprea1_046476; SCHEMBL3024961; CTK1C3093; 5-methoxyindole-3-propionic acid; ZLSZCJIWILJKMR-UHFFFAOYSA-N; MolPort-002-085-835; ZINC195148; HMS3604K06; HMS1370D17; 2429AE; STK984200; SBB028111; AKOS000300418; MCULE-1797370196; DB07723; CCG-108176; DS-3311; AK403360; SC-43672; BIM-0030775.P001; TR-055403; AX8188175"	181137	C12H13NO3	Investigative
M6APDG03252	RO-319790	"Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703"	9904965	C15H29N3O4	Terminated
M6APDG02322	ISOLICOFLAVONOL	"Isolicoflavonol; 94805-83-1; MLS000697735; CHEMBL457679; SMR000470986; 3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]chromen-4-one; AC1NSX1R; SCHEMBL5614138; cid_5318585; MolPort-039-052-689; PGCKDCPTJAQQSQ-UHFFFAOYSA-N; HMS2271L11; ZINC13130924; LMPK12111984; 9577AF; BDBM50251003; 5,7,4'-trihydroxy-3'-prenylflavonol; 4',5,7-Trihydroxy-3'-prenylflavonol; SR-01000765807; SR-01000765807-2; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-"	5318585	C20H18O6	Investigative
M6APDG03689	ISIS 114537	.	.	.	Investigative
M6APDG00695	8-Methyl-2-phenyl-3H-quinazolin-4-one	.	135531482	C15H12N2O	Investigative
M6APDG04173	Cixutumumab	LY3012217	.	.	Phase 2
M6APDG02215	SB-216995	PYRIDINYLIMIDAZOLE; CHEMBL96741; sb216995; 4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyridine; 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE; SB6; 4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyridine; 1bl6; SB-216995; AC1L1JR9; SCHEMBL4915662; CTK7C0283; BDBM15237; ZINC2047872; DB08522; SB216995; PYRIDINYLIMIDAZOLE	5171	C18H16FN3	Investigative
M6APDG01892	GSK1511931	GSK1511931A; GSK-1511931; compound 14 [PMID: 19081716]	44581765	C29H32N8O	Investigative
M6APDG03596	ISIS 113019	.	.	.	Investigative
M6APDG03042	6-Phosphogluconic Acid	"6-phosphogluconic acid; 6-Phosphogluconate; 921-62-0; 6-phospho-D-gluconic acid; 6-phospho-D-gluconate; 6-O-phosphono-D-gluconic acid; Gluconic acid-6-phosphate; (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(phosphonooxy)hexanoic acid; UNII-W31WK7B8U0; D-Gluconic acid 6-(dihydrogen phosphate); CHEBI:48928; W31WK7B8U0; CHEMBL1230513; BIRSGZKFKXLSJQ-SQOUGZDYSA-N; 1pgp; 6PG; 6-phosphogluconic acid barium salt; C6H13O10P; 6-p-gluconate; EINECS 213-069-9; D-Gluconic acid, 6-(dihydrogen phosphate); bmse000198; AC1Q6RV2; AC1L3M6P; SCHEMBL50297"	91493	C6H13O10P	Investigative
M6APDG03721	ISIS 113210	.	.	.	Investigative
M6APDG01623	Staurosporine	"staurosporine; Staurosporin; (+)-Staurosporine; Antibiotic 230; 62996-74-1; Antibiotic AM 2282; CCRIS 3272; AM-2282; UNII-H88EPA0A3N; Alkaloid AM-2282 from Streptomyces; H88EPA0A3N; CHEMBL388978; CHEBI:15738; CGP 39360; 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-"	44259	C28H26N4O3	Phase 2
M6APDG02205	SEN-196	"EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena"	5113032	C13H13ClN2O	Phase 2
M6APDG00440	N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide	CHEMBL204184; N-(2-n-propyloxy-4-nitrophenyl)methanesulfonamide; 880145-98-2; N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide; SCHEMBL3301465; CTK6E5797; BDBM50182536; AKOS015965877; N-(4-nitro-2-propoxyphenyl)methanesulfonamide	11680642	C10H14N2O5S	Investigative
M6APDG01159	MERIOLIN 7	MERIOLIN 7; SCHEMBL2239805; CHEMBL405074	24801186	C14H15N5O2	Investigative
M6APDG03420	NP-619	.	.	.	Discontinued in Phase 2
M6APDG01091	"12,13-DEHYDRO-8-O-ACETYLMANZAMINE A"	"12,13-dehydro-8-O-acetylmanzamine A; CHEMBL252520"	23643836	C38H44N4O2	Investigative
M6APDG00762	PD-128763	"5-Methyl-3,4-dihydroisoquinolin-1(2H)-one; 129075-56-5; 5-methyl-3,4-dihydroisoquinolin-1(2H)-one; 3,4-Dihydro-5-methyl-1(2H)-isoquinolinone; 3,4-DIHYDRO-5-METHYL-ISOQUINOLINONE; 1(2H)-Isoquinolinone, 3,4-dihydro-5-methyl-; CHEBI:41928; PD128763; CHEMBL125200; 5-methyl-3,4-dihydro-2H-isoquinolin-1-one; 3,4-dihydro-5-methylisoquinolinone; 1(2H)-Isoquinolinone,3,4-dihydro-5-methyl-; 5-methyl-1,2,3,4-tetrahydroisoquinolin-1-one; DHQ; PD 128763; dihydroisoquinolinone, 1; AC1L3WIO; ACMC-1C7L4; SCHEMBL831538; AMBZ0075; KS-00000QFP; CTK4B6146; BDBM27682; 3,4-Dihydro-5-Methyl-Isoquinolinone"	148140	C10H11NO	Investigative
M6APDG01445	"3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione"	"CHEMBL29338; 3-(4-aminophenyl)-3-heptylpiperidine-2,6-dione; NSC622730; AC1L7GXY; 3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione; AC1Q6G81; CTK6D7912; 2,3-(4-aminophenyl)-3-heptyl-; BDBM50025057; NSC-622730; NCI60_006748; 2,6-piperidinedione, 3-(4-aminophenyl)-3-heptyl-"	360578	C18H26N2O2	Investigative
M6APDG03417	RG7160	.	.	.	Discontinued in Phase 2
M6APDG03694	SB-2280	"SB-2602; Selective mTOR inhibitors (cancer); Selective mTOR inhibitors (cancer), S*BIO"	.	.	Investigative
M6APDG01546	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide"	"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide; CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-"	4262314	C13H14N2O	Investigative
M6APDG03095	SU11274	Met kinase Inhibitor; SU-11274	9549297	C28H30ClN5O4S	Investigative
M6APDG03761	ISIS 28472	.	.	.	Investigative
M6APDG01830	N-(4-hydroxybiphenyl-3-yl)benzamide	CHEMBL269935; N-(4-hydroxybiphenyl-3-yl)benzamide; SCHEMBL5724398; BDBM50232005	44454650	C19H15NO2	Investigative
M6APDG01249	"8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"SCHEMBL4661629; CHEMBL370673; BDBM27510; SWBDUXDIPMGDNO-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 1b; ZINC13652894; 5,6-dihydro-5-oxo-8-nitro-indeno[1,2-c]isoquinoline; 8-Nitro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one"	25190929	C16H10N2O3	Investigative
M6APDG01406	THIOCITRULLINE	Thiocitrulline; 2-amino-5-(carbamothioylamino)pentanoic acid; AC1MNJZG; Lopac0_001244; SCHEMBL3276661; CHEMBL1608298; CHEBI:139389; CCG-205318; NCGC00094485-01; NCGC00015991-03; NCGC00015991-02; NCGC00094485-02; EU-0101244; T-173; SR-01000075525	3353976	C6H13N3O2S	Investigative
M6APDG01213	DCC-2036	"REBASTINIB; DCC-2036; 1020172-07-9; DCC-2036 (Rebastinib); DCC 2036; CHEBI:62166; UNII-75017Q6I97; Rebastinib(DCC-2036); 4-(4-(3-(3-(tert-butyl)-1-(quinolin-6-yl)-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; DCC2036; DP-1919; 4-[4-({[3-Tert-Butyl-1-(Quinolin-6-Yl)-1h-Pyrazol-5-Yl]carbamoyl}amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide; 75017Q6I97; 4-[4-[(5-Tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide,4-methylbenzenesulfonic acid;4-[4-[("	25066467	C30H28FN7O3	Phase 1/2
M6APDG02812	P1446A-05	.	67409219	C22H19ClF3NO5	Phase 1
M6APDG02807	Darolutamide	"1297538-32-9; BAY-1841788; N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Darolutamide [USAN]; Darolutamide (JAN/USAN/INN); SCHEMBL1814935; SCHEMBL13733117; KS-00000TSX; EX-A759; BLIJXOOIHRSQRB-PXYINDEMSA-N; MolPort-046-033-692; MolPort-044-560-277; AKOS030526387; CS-5174; BAY1841788; DB12941; BAY 1841788; HY-16985; S7559; FT-0700158; J3.501.129C; D11045; J-690121; 1H-Pyrazole-3-carboxamide, N-((1S)-2-(3-(3-chloro-4-cyanophen"	67171867	C19H19ClN6O2	Approved
M6APDG03942	MEDI5117	.	.	.	Phase 1
M6APDG03961	AZD4785	IONIS-KRAS-2.5RX	.	.	Phase 1
M6APDG03609	ISIS 6434	.	.	.	Investigative
M6APDG02709	AZAKENPAULLONE	"1-Azakenpaullone; 676596-65-9; azakenpaullone; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, &gt; AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866"	6538897	C15H10BrN3O	Investigative
M6APDG04376	S-33516	.	.	.	Terminated
M6APDG01145	TG-C	"3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC"	24768536	C25H40N7O19P3S2	Phase 3
M6APDG03132	MR-20492	"MR-20492; CHEMBL9165; SCHEMBL6064449; BDBM50070097; 6-(4-Chloro-phenyl)-7-[1-pyridin-4-yl-meth-(Z)-ylidene]-6,7-dihydro-5H-indolizin-8-one; 6-(4-Chlorophenyl)-7-(4-pyridylmethylene)-5,6-dihydroindolizine-8(7H)-one"	9819080	C20H15ClN2O	Investigative
M6APDG02994	Niraparib Tosylate	1038915-73-9; MK-4827 (tosylate); MK-4827 tosylate; UNII-75KE12AY9U; MK-4827(Niraparib) tosylate; 75KE12AY9U; MK-4827-tosylate; MK 4827 tosylate; Niraparib(MK-4827) tosylate; KS-00000TSH; MolPort-044-556-849; s7625; HY-10619B; AKOS030632785; CS-2283; AC-30383; KB-335358; AX8326059	78357761	C26H28N4O4S	Approved
M6APDG03097	IN1535	220792-57-4; CTK8F1119; K00613a; ZINC00582597; NCGC00390411-01; RT-011271	9549304	C19H26ClN7O	Investigative
M6APDG02197	BMS-911543	"BMS-911543; 1271022-90-2; BMS 911543; BMS911543; UNII-7N03P021J8; 7N03P021J8; N,N-Dicyclopropyl-4-[(1,5-Dimethyl-1h-Pyrazol-3-Yl)amino]-6-Ethyl-1-Methyl-1,6-Dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-Carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide; JCINBYQJBYJGDM-UHFFFAOYSA-N"	50922691	C23H28N8O	Phase 2
M6APDG03512	GSK-280	"P38 kinase inhibitors (inflammation), GSK"	.	.	Investigative
M6APDG00180	7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one	CHEMBL158984; 7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one; ZINC13861991; BDBM50097369; 7-Imidazol-1-ylmethyl-chromen-4-one	10585323	C13H10N2O2	Investigative
M6APDG00807	Naproxen	NAPROXEN; 22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex	156391	C14H14O3	Approved
M6APDG03109	"4-Methyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine"	"CHEMBL75304; 479668-33-2; 5,6-dihydro-4-methyl-2-Pyridinamine; ZINC2002913; BDBM50116666; AKOS006359115; FCH1123804; ACM479668332; DB-070901; FT-0749169; 2-Pyridinamine,5,6-dihydro-4-methyl-(9CI)"	9793827	C6H10N2	Investigative
M6APDG03587	ISIS 138616	.	.	.	Investigative
M6APDG01328	"6,7-dimethoxy-N-m-tolylquinazolin-4-amine"	"CHEMBL56802; 6,7-dimethoxy-N-m-tolylquinazolin-4-amine; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine"	2808977	C17H17N3O2	Investigative
M6APDG00645	N-omega-allyl-L-arginine	.	135409360	C9H18N4O2	Investigative
M6APDG03919	CYT-609	Aurimune	.	.	Phase 1
M6APDG03880	GBR1302	.	.	.	Phase 1
M6APDG02977	C 82	N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82	75202656	C8H7ClN4	Phase 1/2
M6APDG01483	LAVENDUSTIN A	"Lavendustin A; 125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid"	3894	C21H19NO6	Investigative
M6APDG03764	ISIS 31963	.	.	.	Investigative
M6APDG00161	Bempedoic acid	"ETC-1002; bempedoic acid; 738606-46-7; 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid; ESP-55016; UNII-1EJ6Z6Q368; ETC 1002; Bempedoic acid; ESP-55016; 1EJ6Z6Q368; Bempedoate; Bempedoic acid [USAN:INN]; ETC1002; ESP 55016; Bempedoic acid (USAN/INN); SCHEMBL185768; GTPL8321; CHEMBL3545313; HYHMLYSLQUKXKP-UHFFFAOYSA-N; EX-A1243; ZINC3948738; BCP16083; s7953; AKOS027439916; CS-3952; DB11936; AK499358; AC-29040; AS-49804; HY-12357; Bempedoic Acid(ETC-1002;ESP-55016); D10691; Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl-"	10472693	C19H36O5	Approved
M6APDG00581	5-Methyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL182305; CHEMBL555587; 5-Methylpyrrolidine-2-imine; BDBM50066782; AKOS006365094; 5-Methyl-pyrrolidin-(2E)-ylideneamine	12778906	C5H10N2	Investigative
M6APDG00590	Atiprimod	"Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine"	129869	C22H44N2	Phase 1/2
M6APDG04295	PF-06438179	.	.	.	Phase 3
M6APDG02742	4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine	"CHEMBL179222; BDBM8621; (4-Pyridylmethylene)indane 10b; AC1O7065; 4-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539795	C15H12BrN	Investigative
M6APDG00112	VX-702	"ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide"	10341154	C19H12F4N4O2	Phase 2a
M6APDG02984	1-Benzyl-4-methyl-piperazine	"1-benzyl-4-methylpiperazine; 62226-74-8; 1-benzyl-4-methyl-piperazine; CHEMBL363603; Piperazine, 1-methyl-4-(phenylmethyl)-; 4-Benzyl-1-methylpiperazine; 1-Benzyl-4-methylpiperazinehydrochloride; PubChem10987; AC1LG1B6; Cambridge id 5263722; N-benzyl-N'-methylpiperazine; SCHEMBL221139; Methyl piperazine, polymer-bound; CTK2C4522; DTXSID90354100; Methyl piperazinomethyl polystyrene; MolPort-000-882-836; MLJOKPBESJWYGL-UHFFFAOYSA-N; HMS1579O15; BCP22253; MFCD00976530; ZINC19536830; STK115879; BDBM50174044"	763557	C12H18N2	Investigative
M6APDG03482	ARN34	.	.	.	Investigative
M6APDG01852	PF-05212384	"PKI-587; 1197160-78-3; Gedatolisib; PF-05212384; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-"	44516953	C32H41N9O4	Phase 2
M6APDG02747	4-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine	"CHEMBL371742; BDBM8629; AC1O706L; (4-Pyridylmethylene)indane 22a; 4-[(E)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539803	C16H15N	Investigative
M6APDG01897	Guttiferone I	Guttiferone I	44584005	C43H58O6	Investigative
M6APDG02368	(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone	"CHEMBL7602; Bis(1H-2-indolyl)methanone 12; AC1NS9C2; SCHEMBL6864570; BDBM6574; ZINC13472534; 6-Methoxy-[2,2'-carbonylbis(1H-indole)]; 2-(1H-indol-2-ylcarbonyl)-6-methoxy-1H-indole; 1H-indol-2-yl-(6-methoxy-1H-indol-2-yl)methanone"	5330528	C18H14N2O2	Investigative
M6APDG03076	Ser-Tyr-Ser-Nle-Glu-His-Dphe-Arg	.	91971100	C76H108N20O19	Investigative
M6APDG00093	3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol	CHEMBL301565; 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol; SCHEMBL7208687; BDBM50076589	10267279	C15H16O3S2	Investigative
M6APDG01393	4-Methyl-piperidin-(2E)-ylideneamine	"CHEMBL6808; 2-imino-4-methylpiperidine; 2-PYRIDINAMINE, 3,4,5,6-TETRAHYDRO-4-METHYL-; 165383-71-1; 4-Methyl-piperidin-(2E)-ylideneamine; AC1MMWW1; 4-methylpiperidin-2-imine; 4-methyl-3,4,5,6-tetrahydropyridin-2-amine; 4-Methyl-2-piperidinimine; SCHEMBL4103569; CTK0A9019; DTXSID00390857; BDBM50062133; 4-Methyl-piperidin-(2Z)-ylideneamine; AKOS006348873; FT-0722141; 4-methyl-2,3,4,5-tetrahydropyridin-6-amine"	3268009	C6H12N2	Investigative
M6APDG03588	ISIS 138647	.	.	.	Investigative
M6APDG02200	1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole	"CHEMBL491222; AC1LAA5O; 1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole; BDBM50263812; 1-[1-benzyl-2-(4-phenylphenyl)ethyl]imidazole; 1-[1-phenyl-3-(4-phenylphenyl)propan-2-yl]imidazole; 1H-Imidazole, 1-[2-[1,1'-biphenyl]-4-yl-1-(phenylmethyl)ethyl]-"	510040	C24H22N2	Investigative
M6APDG01274	L-5-(bromovinyl)deoxyuridine	CHEMBL261850; L-5-(bromovinyl)deoxyuridine; SCHEMBL4314668; BDBM50375781	25323027	C11H13BrN2O5	Investigative
M6APDG03558	ISIS 188778	.	.	.	Investigative
M6APDG00481	H3B-6527	"MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla"	118029202	C29H34Cl2N8O4	Phase 1
M6APDG01619	(Z)-2'-des-methyl sulindac sulfide	CHEMBL561959; SCHEMBL2697270; BDBM50293599; ZINC43075511; (Z)-2''-des-methyl sulindac sulfide	44224199	C19H15FO2S	Investigative
M6APDG02295	3-Amino-4-Oxybenzyl-2-Butanone	3-AMINO-4-OXYBENZYL-2-BUTANONE; AC1NRD4M; SCHEMBL15172323; CHEMBL1235900; DB02148	5289348	C11H15NO2	Investigative
M6APDG03454	PD-156	"PD-503; PF-152; PF-212; PF-80; MMP-13 inhibitors (inflammation); MMP-13 inhibitors (inflammation), Pfizer"	.	.	Investigative
M6APDG01470	"4,5-dibenzylbenzene-1,2-diol"	"4,5-dibenzylbenzene-1,2-diol; 4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154"	379493	C20H18O2	Investigative
M6APDG04290	QPI-1002	.	.	.	Phase 3
M6APDG01457	PAULLONE	"Paullone; 142273-18-5; 7,12-Dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; CHEMBL430574; NSC641166; NSC 641166; 7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 8,18-diazatetracyclo[9.7.0.0; {12,17}]octadeca-1(11),2,4,6,12(17),13,15-heptaen-9-one; AC1Q6O0K; AC1L7YZ4; BDBM7287; SCHEMBL3178594; CTK4C3026; DTXSID30327277; CHEBI:138487; ZINC1626613; AKOS024113922; NSC-641166; NCI60_013826; RT-014947; FT-0673529"	369401	C16H12N2O	Investigative
M6APDG03330	CYT-387	Cyt387; 1056634-68-4; MOMELOTINIB; Cyt-387; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide; CYT 387; CYT 11387; UNII-6O01GMS00P; N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide; 6O01GMS00P; CHEMBL1078178; AK102858; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide; CYT387 sulfate salt; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide	25062766	C23H22N6O2	Phase 3
M6APDG03481	PU24S	.	.	.	Investigative
M6APDG02376	K00024	indolocarbazole deriv. 4(d)	5330797	C20H10BrN3O2	Investigative
M6APDG01686	"4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one"	CHEMBL147398	44364764	C9H4BrCl2NO2	Investigative
M6APDG02312	HKI-9924129	.	5311104	C21H15Cl2FN4O	Investigative
M6APDG03170	"5-(azepan-1-ylsulfonyl)indoline-2,3-dione"	"1H-Azepine, 1-[(2,3-dihydro-2,3-dioxo-1H-indol-5-yl)sulfonyl]hexahydro-; 220510-14-5; Isatin Sulfonamide 22; 5-(azepan-1-ylsulfonyl)-1H-indole-2,3-dione; CHEMBL302461; SCHEMBL6535562; CTK0I8877; BDBM10311; DTXSID20431675; 5-(azepane-1-sulfonyl)-2,3-dihydro-1H-indole-2,3-dione"	9839586	C14H16N2O4S	Investigative
M6APDG03071	RGDechi	.	91936353	C84H134N30O29S	Investigative
M6APDG00221	"5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione"	"5,6,7-trichloro-1,4-dihydroquinoxaline-2,3-dione; CHEMBL43846; 172215-97-3; 5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione; SCHEMBL8904175"	10849325	C8H3Cl3N2O2	Investigative
M6APDG01664	PAI-2	"N-Butyryl-DL-homoserine lactone; N-butanoyl-lhomoserine lactone; N-(2-oxooxolan-3-yl)butanamide; N-(2-oxotetrahydrofuran-3-yl)butanamide; N-Butyrylhomoserine lactone; 98426-48-3; N-(2-Oxotetrahydro-3-furanyl)butanamide; AC1L9ENE; SCHEMBL787006; Homoserine lactone, N-butanoyl-; N-Butanoyl-DL-homoserine lactone; VFFNZZXXTGXBOG-UHFFFAOYSA-N; LMFA08030002; AN-38291; N-Butyryl-DL-homoserine lactone, &gt"	443433	C8H13NO3	Discontinued in Phase 2
M6APDG02117	SCH 727965	Dinaciclib; SCH-727965	46926350	C21H28N6O2	Discontinued in Phase 3
M6APDG02852	VOROZOLE	"Vorozole; Rivizor; 129731-10-8; R-83842; UNII-1E2S9YXV2A; 1E2S9YXV2A; Vorozol [INN-Spanish]; Vorozolum [INN-Latin]; (+)-Vorozole; CCRIS 7482; Vorozolum; Vorozol; Rivizor (TN); 6-[(S)-(4-chlorophenyl)-(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole; Vorozole (USAN/INN); AC1OCF4T; (S)-VOROZOLE; SCHEMBL4554; Vorozole [USAN:INN:BAN]; CHEMBL224060; DTXSID20156230; (+)-(S)-6-(p-Chloro-alpha-1H-1,2,4-triazol-1-ylbenzyl)-1-methyl-1H-benzotriazole; CHEBI:135387; 1H-Benzotriazole, 6-((4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl)-1-methyl"	6918191	C16H13ClN6	Discontinued in Phase 2
M6APDG03275	N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide	"N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide; N-(4-Sulphamoylphenyl)-1H-indazole-3-carboxamide; 660822-60-6; 2vti; indazole amide, 14; CHEMBL455946; SCHEMBL4524087; BDBM24635; MNHPHKFLWAPNOV-UHFFFAOYSA-N; ZINC15270554; DB08133; DA-41761; FT-0707176; 1H-Indazole-3-carboxylic acid (4-sulphamoyl-phenyl)-amide"	9926933	C14H12N4O3S	Investigative
M6APDG03897	Drug 2881078	2881078	.	.	Phase 1
M6APDG00613	"6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE"	"6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE; 6-(3-bromonaphthalen-2-yl)-1,3,5-triazine-2,4-diamine; 2qf6; HSP90 Inhibitor, 1; SCHEMBL10822557; BDBM81729; DB07319"	13373715	C13H10BrN5	Investigative
M6APDG01502	L-NAME	"N-Nitroarginine methyl ester; NG-NITROARGININE METHYL ESTER; N(G)-Nitroarginine methyl ester; N-Nitro-L-arginine methylester; Ngamma-Nitro-L-arginine methyl ester; N(G)-Nitro-L-arginine methyl ester; N(sup G)-Nitro-L-arginine methyl ester; N-omega-Nitro-O-arginine methyl ester; Methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate; Methyl N5-(N'-nitrocarbamimidoyl)-L-ornithinate; N(5)-(Imino(nitroamino)methyl)-L-ornithine methyl ester; N-.omega.-Nitro-O-arginine methyl ester; L-Ornithine, N(5)-(imino(nitroamino)methyl)-, methyl ester; Methyl (2S)-2-amino-5-[(amino-nitramido-methylidene)amino]pentanoate"	39836	C7H15N5O4	Phase 2
M6APDG00530	[3H]dizocilpine	[3H]MK-801	1207	C16H15N	Investigative
M6APDG03930	ASN007	.	.	.	Phase 1
M6APDG00928	5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL185585; 5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine; SCHEMBL12617784; BDBM50150915	17892465	C7H14N2	Investigative
M6APDG02581	Exemestane	"Aromasil; Aromasin; Aromasine; EXE; Exemestance; Exemestano; Exemestanum; Nikidess; Pfizer brand of exemestane; Curator_000009; Fce 24304; Aromasin (TN); Aromasin, Exemestane; Exemestano [INN-Spanish]; Exemestanum [INN-Latin]; FCE-24304; PNU-155971; Exemestane [USAN:INN:BAN]; Exemestane (JAN/USP/INN); (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; 6-Methylenandrosta-1,4-diene-3,17-dione; 6-Methyleneandrosta-1,4-diene-3,17-dione; 6-methylideneandrosta-1,4-diene-3,17-dione"	60198	C20H24O2	Approved
M6APDG01212	2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide	CHEMBL402719; 2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide; SCHEMBL8150833	25065931	C17H24N2O4	Investigative
M6APDG00401	5-Mercapto-pentanoic acid phenylamide	"5-Mercapto-pentanoic acid phenylamide; N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-"	11608171	C11H15NOS	Investigative
M6APDG01322	CGP74514A	CGP-74514A; CGP 74514A	2794188	C19H24ClN7	Investigative
M6APDG04044	Neu-120	"Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim"	.	.	Phase 1/2
M6APDG03446	Recombinant human pro-urokinase	Recombinant human pro-urokinase (myocardial infarction)	.	.	Investigative
M6APDG04315	ABX-0401	"ALX-0071; Nanobody therapeutics (inflammation/rheumatoid arthritis/inflammatory bowel disease), Ablynx/Pfizer; Nanobody therapeutics (inflammation/rheumatoid arthritis/inflammatory bowel disease), Ablynx/Wyeth"	.	.	Preclinical
M6APDG03945	Autologous T Cells Expressing MET scFv CAR	.	.	.	Phase 1
M6APDG01551	XL880	"GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors"	42642645	C34H34F2N4O6	Phase 2
M6APDG01435	Melanocortin-4 Receptor antagonist	"Methyl 16-hydroxyhexadecanoate; AOTMRIXFFOGWDT-UHFFFAOYSA-N; 36575-67-4; Methyl juniperate; MC4 Receptor antagonist; AC1MRQ5C; SCHEMBL1245383; Methyl 16-hydroxy-hexadecanoate; CTK1B6241; DTXSID80393043; Melanocortin 4 Receptor antagonist; HS028; AKOS005066798; 16-hydroxyhexadecanoic Acid Methyl Ester; Hexadecanoic acid, 16-hydroxy-, methyl ester"	3496888	C17H34O3	Investigative
M6APDG01158	MERIOLIN 6	MERIOLIN 6; CHEMBL406463; SCHEMBL2999009	24801185	C14H15N5O	Investigative
M6APDG03655	GI-3000	"GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune"	.	.	Investigative
M6APDG03016	Piperidin-(2E)-ylideneamine	"PIPERIDIN-2-IMINE; 2-Piperidinimine; Piperidin-(2E)-ylideneamine; Piperidin-(2Z)-ylideneamine; CHEMBL269058; 2-amino-4-piperidyl; 22780-54-7; EN300-77982; 2-iminopiperidine; 2IM; AMINOPIPERIDINYL; NCGC00024898-01; Tocris-0951; (2E)-piperidin-2-imine; 2-Iminopiperidine, Hydrochloride; CTK0J6105; DTXSID40275816; DHGUMNJVFYRSIG-UHFFFAOYSA-N; 3,4,5,6-tetrahydropyridine amine; ZINC2141055; AC1L3920; BDBM50049255; 2,3,4,5-tetrahydropyridin-6-amine; 3,4,5,6-Tetrahydropyridin-2-amine; AKOS005199122; AKOS002684133; MCULE-9735306041"	85237	C5H10N2	Investigative
M6APDG01030	NU-100	"BaroFeron; Interferon beta-1b (PreEMT, multiple sclerosis), BaroFold; Interferon beta-1b (PreEMT, multiple sclerosis), NuronBiotech"	21987656	C24H30N2O2	Phase 3
M6APDG03264	L-873724	"L-873724; UNII-29250PP3ON; 603139-12-4; CHEMBL437501; 29250PP3ON; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]Pentanamide; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide; VYFDSJLOCIGIKP-SFTDATJTSA-N; GTPL7860; SCHEMBL2157182; BDBM19489; (+)-L-873724; ZINC34802820; CS-6814; HY-50887; Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)eth"	9913088	C23H26F3N3O3S	Investigative
M6APDG01188	"4,5-Bis(4-methoxyphenyl)-1,2-selenazole"	"CHEMBL470304; 4,5-Bis(4-methoxyphenyl)-1,2-selenazole"	24884690	C17H15NO2Se	Investigative
M6APDG03659	FHT-2107	"EGFR-targeting siRNA agent, ForHumanTech"	.	.	Investigative
M6APDG01141	CHLOROCYCLINONE A	"CHLOROCYCLINONE A; CHEMBL253120; BDBM50228358; methyl 2-chloro-9-ethyl-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate"	24762579	C24H19ClO7	Investigative
M6APDG00029	1-(3-(4-fluorophenyl)propyl)-1H-imidazole	CHEMBL214932; 1-(3-(4-fluorophenyl)propyl)-1H-imidazole; 1-[3-(4-Fluorophenyl)propyl]-1H-imidazole	10081625	C12H13FN2	Investigative
M6APDG03437	ON-128	"ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova"	.	.	Investigative
M6APDG02649	CYC116	"693228-63-6; CYC-116; CYC116; CHEMBL482967; Kinome_636; 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine; 4-Methyl-5-(2-((4-morpholinophenyl)amino)-pyrimidin-4-yl)thiazol-2-amine; 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine; 4-methyl-5-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)thiazol-2-amine; 2uue; CYC 116; GPSZYOIFQZPWEJ-UHFFFAOYSA-N; 2c5t; AC1O4WKE; MLS006011244; SCHEMBL2074998; SYN1034; EX-A753; CYC-116/CYC116; MolPort-009-679-476; HMS3244O12; HMS3244P11; BCPP000273"	6420138	C18H20N6OS	Phase 1
M6APDG02113	UNC0321	UNC-0321; UNC 0321	46901937	C27H45N7O3	Investigative
M6APDG02058	Resveratrol Potassium3-Sulfate	Resveratrol Potassium3-Sulfate	46855054	C14H11KO6S	Investigative
M6APDG00595	"6,7-Dimethoxy-4-phenoxy-quinoline"	"CHEMBL327534; 6,7-Dimethoxy-4-phenoxy-quinoline; SCHEMBL17117826"	13085778	C17H15NO3	Investigative
M6APDG01127	S-Methylcysteine	"7728-98-5; H-DL-Cys(Me)-OH; H-D-HoCys-OH; S-Methyl-DL-cysteine; USAF CB-24; Methylcysteine; 2-amino-3-(methylsulfanyl)propanoic acid; 19651-44-6; 1-carboxy-2-methylthioethylamine; Methylcysteine, L-; ALANINE, 3-(METHYLTHIO)-, L-; EINECS 231-787-0; Methylcysteine #; S-Methyl cysteine; DL-S-Methylcysteine; DL-S-Methyl-Cys-OH; DL-Cysteine, S-methyl-; AC1Q5S9H; AC1L5E8F; SCHEMBL110459; ACMC-209a03; IDIDJDIHTAOVLG-UHFFFAOYSA-; CTK0E0884; IDIDJDIHTAOVLG-UHFFFAOYSA-N; MolPort-003-876-437; NSC15387; NSC-15387; AKOS022154885"	24417	C4H9NO2S	Investigative
M6APDG04236	A-6	"Angstrom-6; CD44 binding peptide (cancer), Angstrom"	.	.	Phase 2
M6APDG02968	HOMOERIODICTYOL	"Homoeriodictyol; (-)-Homoeriodictyol; 446-71-9; Eriodictyonone; UNII-EHE7H3705C; Eriodictyol 3'-methyl ether; 5,7,4'-Trihydroxy-3'-methoxyflavanone; CHEMBL490170; EHE7H3705C; CHEBI:74960; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; Q-100585; (+/-)-Homoeriodictyol; cyanidanon-3-methyl ether 1625; EINECS 207-173-3; AC1Q6KID; AC1L2K7J; SCHEMBL39497; DTXSID30196243; FTODBIPDTXRIGS-ZDUSSCGKSA-N; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; ZINC4098322; BDBM50325672"	73635	C16H14O6	Investigative
M6APDG04305	SYM-004	"Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen"	.	.	Phase 3
M6APDG03033	GSK3326595	"JLCCNYVTIWRPIZ-NRFANRHFSA-N; 1616392-22-3; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-2-hydroxy-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]pyrimidine-4-carboxamide; SCHEMBL15825290; MolPort-044-813-754; BDBM178166; AKOS030528008; ZINC220119494; CS-6451; AS-53150; HY-101563; GSK3326595(EPZ015938); US9675614, 208; (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide"	90241742	C24H32N6O3	Phase 2
M6APDG00499	4'-cyano-3-(imidazolylmethyl)flavone	CHEMBL209731; BDBM50191602; 4''-cyano-3-(imidazolylmethyl)flavone	11847319	C20H13N3O2	Investigative
M6APDG04165	Ad-p53	"P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough"	.	.	Phase 2
M6APDG03215	CP-724714	"CP 724714; CP-724,714; CP724,714, CP-724,714; 2-Methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide; 2-Methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propen-1-yl]acetamide"	9874913	C27H27N5O3	Phase 2
M6APDG00288	A-674563	A 674563; A674563	11314340	C22H22N4O	Investigative
M6APDG01687	Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2	.	44366173	C54H71N15O9	Investigative
M6APDG04207	Abicipar pegol	.	.	.	Phase 2
M6APDG03374	Pertuzumab	Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor)	.	.	Approved
M6APDG00080	Deschloroflavopiridol	.	102397231	C21H22NO5+	Investigative
M6APDG00090	"6,7-Dichloro-3-thiophen-3-yl-quinoline"	"CHEMBL66718; 6,7-dichloro-3-thiophen-3-yl-quinoline; SCHEMBL8503219; ZINC13737709"	10265642	C13H7Cl2NS	Investigative
M6APDG02319	SU 6656	"su6656; 330161-87-0; SU-6656; SU6656; CHEMBL605003; (3z)-N,N-Dimethyl-2-Oxo-3-(4,5,6,7-Tetrahydro-1h-Indol-2-Ylmethylidene)-2,3-Dihydro-1h-Indole-5-Sulfonamide; (3Z)-N,N-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indole-5-sulfonamide; SR-01000076237; 2,3-Dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1H-indole-5-sulfonamide; AC1NSM2X; Lopac-S-9692; Lopac0_000979; MLS002153475; GTPL6044; EX-A584; MolPort-003-959-609; HMS3229I04; HMS2232C04"	5312137	C19H21N3O3S	Investigative
M6APDG00921	Lysine Nz-Carboxylic Acid	Lysine Nz-Carboxylic Acid; N(6)-carboxylysine; N(6)-carboxy-L-lysine; (2S)-2-amino-6-(carboxyamino)hexanoic acid; N~6~-carboxy-L-lysine; SCHEMBL357483; CHEBI:43575; ZINC6753301	17754054	C7H14N2O4	Investigative
M6APDG03551	HYDAMTIQ	"PARP-1 inhibitor (brain ischemia), University of Perugia"	.	.	Investigative
M6APDG03363	Certolizumab	CDP-870; Cimzia; PHA-738144; Simziya	.	.	Approved
M6APDG03048	PT2385	"ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A"	91754484	C17H12F3NO4S	Phase 2
M6APDG00089	N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide	N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N	10265187	C12H12F3N3O	Investigative
M6APDG00222	"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one"	"CHEMBL7827; SCHEMBL3355884; 62845-10-7; 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-"	10850934	C15H9ClO4	Investigative
M6APDG03379	Aflibercept	Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye	.	.	Approved
M6APDG04159	AZD5312	.	.	.	Phase 2
M6APDG03712	ISIS 133242	.	.	.	Investigative
M6APDG03266	L-734115	"CHEMBL40502; L-734115; BDBM50058236; N-(Butylsulfonyl)-3-[[4,5,6,7-tetrahydro-4-oxo-5-[2-(4-piperidinyl)ethyl]pyrazolo[1,5-a]pyrazin]-2-ylcarbonylamino]-L-alanine; (S)-2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid; 2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid(L-734115)"	9913833	C21H34N6O6S	Investigative
M6APDG02750	5-[5-Methoxy-indan-(1E)-ylidenemethyl]-thiazole	"(5-Thiazolemethylene)indane 27a; BDBM8632; CHEMBL192155; AC1O706R; 5-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]-1,3-thiazole"	6539806	C14H13NOS	Investigative
M6APDG00376	Losmapimod	"585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod  pound&gt; HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587"	11552706	C22H26FN3O2	Phase 3
M6APDG00828	5-propyl-2'-deoxyuridine	"5-Propyl-2'-deoxyuridine; 27826-74-0; CHEMBL221982; 5-Propyldeoxyuridine; 2'-Deoxy-5-propyluridine; 5-Propyl-dUrd; 5-Propyl-2'-desoxyuridine; AC1L4N4W; 2'-deoxy-5-n-propyluridine; Uridine,2'-deoxy-5-propyl-; Uridine, 2'-deoxy-5-propyl-; SCHEMBL2396529; CTK4G0305; DTXSID30182141; MBERTAKFBYOAHR-IVZWLZJFSA-N; BDBM50375778; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-propylpyrimidine-2,4-dione"	160155	C12H18N2O5	Investigative
M6APDG01707	Ac-YR[CEHdFRWC]SPPKD-NH2	CHEMBL2373515; Ac-YR[CEHdFRWC]SPPKD-NH2; CHEMBL437086	44400369	C83H115N25O21S2	Investigative
M6APDG00738	Testolactone	"Fludestrin; Teolit; Teslac; Teslak; Testolacton; Testolactona; Testolactonum; Testolattone; Bristol Myers SquibbBrand of Testolactone; Testolattone [DCIT]; SQ 9538; Bristol-Myers Squibb Brand of Testolactone; DELTA1-Dehydrotestolactone; DELTA1-Dehydrotestololactone; DELTA1-Testololactone; SQ-9538; TESLAC (TN);Teslac (TN); Testolactona [INN-Spanish]; Testolactone [USAN:INN]; Testolactonum [INN-Latin]; Delta(1)-Dehydrotestolactone; Delta(1)-Testolactone; Delta(1)-Testololactone; Delta(1)-testololactone; Delta-1-testololactone; Testolactone (USP/INN); D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione; D-homo-17a-oxaandrosta-1,4-diene-3,17-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione; 1 Dehydrotestolactone; 1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone; 1,2-Dehydrotestololactone; 1,2-Didehydrotestololactone; 1,2-didehydrotestololactone; 1-Dehydrotestolactone; 1-Dehydrotestololactone; 1-dehydrotestololactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI); 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione; 17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione; 2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone; 3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone"	13769	C19H24O3	Approved
M6APDG02270	Ozagrel	"Ozagrel (ophthalmic, eye disorders); Ozagrel (ophthalmic, eye disorders), Kissei/ Teika"	5282440	C13H12N2O2	Phase 4
M6APDG03940	BCL201	.	.	.	Phase 1
M6APDG02583	"2,4-dimethoxy-2'-hydroxychalcone"	"3-(2,4-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one; 36685-63-9; AC1L5NE0; NCIOpen2_004691; CTK1C4388"	6041429	C17H16O4	Investigative
M6APDG03158	acetyl-podocarpic dimer	acetyl podocarpic acid anhydride	9830426	C38H46O7	Investigative
M6APDG00844	N-(2-benzyloxy-4-nitrophenyl)methanesulfonamide	CHEMBL223108; SCHEMBL3295792; MolPort-028-745-458; ZINC35324154	16125122	C14H14N2O5S	Investigative
M6APDG03656	AGT-2000	"Gene therapy (intravenous, brain cancer), ArmaGen"	.	.	Investigative
M6APDG02239	Alpha-linolenic acid	"Linolenic acid; linolenic acid; alpha-Linolenic acid; 463-40-1; linolenate; (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid; a-Linolenic acid; cis,cis,cis-9,12,15-Octadecatrienoic acid; all-cis-9,12,15-Octadecatrienoic acid; alpha-Linolenate; 9-cis,12-cis,15-cis-Octadecatrienoic acid; (Z,Z,Z)-9,12,15-Octadecatrienoic acid; Linolenic acid (8CI); 9,12,15-Octadecatrienoic acid, (Z,Z,Z)-; (9,12,15)-linolenic acid; alpha-Lnn; 9Z,12Z,15Z-Octadecatrienoic acid; Industrene 120; CCRIS 656; UNII-0RBV727H71; (9Z,12Z,15Z)-Octadecatrienoic acid;  linolenate; alpha-LA; C18:3; LINOLENIC ACID"	5280934	C18H30O2	Investigative
M6APDG02983	A-366	A 366; A366	76285486	C19H27N3O2	Preclinical
M6APDG02517	ERK inhibitor III	AC1NSSSU; 1-nitro-2-[(Z)-[5-(3-nitrophenyl)furan-2-yl]methylideneamino]guanidine	5721470	C12H10N6O5	Investigative
M6APDG03165	Disitertide	"NAFB-001; Disitertide cream (skin disorders), Digna"	9833838	C68H109N17O22S2	Phase 2
M6APDG01957	4-phospho-D-erythronate	"4-Phospho-D-erythronate; 4-phosphoerythronate; 4-phospho-D-erythronic acid; 4-Phospho D-Erythronate; 57229-25-1; CHEBI:49003; 4-O-phosphono-D-erythronic acid; (2R,3R)-2,3-dihydroxy-4-(phosphonooxy)butanoic acid; 2bet; AC1L9MYX; SCHEMBL420471; CHEMBL1160945; CTK1E1186; DTXSID70332305; ZINC3869897; DER; AKOS030570437; DB03108; FT-0673861; C03393; (2R,3R)-2,3-dihydroxy-4-phosphonooxybutanoic acid; [R-(R*,R*)]-2,3-Dihydroxy-4-(phosphonooxy)butanoic Acid; Butanoic acid, 2,3-dihydroxy-4-(phosphonooxy)-, (2R,3R)-"	449304	C4H9O8P	Investigative
M6APDG01342	NSC-154957	NSC-154957; NSC154957; AC1L6EF2; CHEMBL586418; 3-benzhydrylsulfanyl-2-formamidopropanoic acid	290753	C17H17NO3S	Investigative
M6APDG04261	XOMA 052	Gevokizumab	.	.	Phase 3
M6APDG03500	ISC-4	"ISC-6; Isoselenocyanate Akt3 inhibitors (cancer); Isoselenocyanate Akt3 inhibitors (cancer), Penn State Hershey Medical Center"	.	.	Investigative
M6APDG03898	DT-200	.	.	.	Phase 1
M6APDG04259	ThermoProfen	.	.	.	Phase 3
M6APDG02090	10-EPI-8-DEOXY-CUMAMBRIN B	10-Epi-8-deoxy-cumambrin B; CHEMBL1099308	46887018	C14H18O2	Investigative
M6APDG01308	"3,4-diphenyl-1H-pyrrole-2,5-dione"	"2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; 3,4-diphenyl-1H-pyrrole-2,5-dione; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556"	2752461	C16H11NO2	Investigative
M6APDG04287	Ulocuplumab	.	.	.	Phase 3
M6APDG04228	HER1-VSSP vaccine	HER1-VSSP vaccine (cancer)	.	.	Phase 2
M6APDG03403	CDP-1050	"Ryanodine receptor modulators (heart failure), Cordex; Ryanodine receptor modulators (heart failure), Duke University; Ryanodine receptor modulators (heart failure), Duska Therapeutics"	.	.	Discontinued in Phase 1
M6APDG00072	GW-788388	452342-67-5; GW788388; 4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide; GW-788388; GW 788388; UNII-N14114957J; CHEMBL202887; N14114957J; 4-[4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl]-N-(tetrahydropyran-4-yl)benzamide; N-(oxan-4-yl)-4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}benzamide; 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydropyran-4-yl)benzamide; cc-69; SCHEMBL373524; SCHEMBL17926774; CTK8C0589; DTXSID70196444; EX-A122; AOB2606	10202642	C25H23N5O2	Investigative
M6APDG00253	"4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole"	"CHEMBL393014; 5-(4-CHLORO-PHENYL)-3H-[1,2,3]TRIAZOLE-4-CARBONITRILE; 50710-06-0; 4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL17969183; CTK1G7781; BDBM50200758; ZINC22004877; AKOS015967718; FCH1390661; ACM50710060"	11183327	C9H5ClN4	Investigative
M6APDG03058	NP-G2-044	"1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6"	91844684	C21H16F3N3O2	Phase 1
M6APDG01648	"4-(3,5-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline"	"CHEMBL101733; 4-(3,5-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline"	44330968	C19H19NO5	Investigative
M6APDG03290	N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide	CHEMBL139999; N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide; SCHEMBL1232700; BDBM50082661; ZINC13472309	9943996	C13H17N3O5	Investigative
M6APDG02901	CPI-203	CPI203; CPI 203	71291068	C19H18ClN5OS	Investigative
M6APDG03633	ISIS 298700	.	.	.	Investigative
M6APDG03395	GR-253035	.	.	.	Discontinued in Phase 1
M6APDG03498	WAY-254011	.	.	.	Investigative
M6APDG00981	AG-270	"REOUTEBTFSILJY-UHFFFAOYSA-N; AG 270; 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride; 6-(m-Methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-3(2H)-pyridazinone hydrochloride; Morpholinoethyl-2 methyl-4 (m-methoxyphenyl)-6 pyridazone-3 chlorhydrate [French]; 13299-99-5; AC1L496O; DTXSID20157888; Morpholinoethyl-2 methyl-4 (m-methoxyphenyl)-6 pyridazone-3 chlorhydrate; LS-130006; 6-(3-methoxyphenyl)-4-methyl-2-(2-morpholin-4-ylethyl)pyridazin-3-one hydrochloride"	202785	C18H24ClN3O3	Phase 1
M6APDG02551	AMG 232	KRT-232	58573469	C28H35Cl2NO5S	Phase 2
M6APDG01487	Letrozole	"Femara; Femera; Letoval; Letrozol; Novartis Brand of Letrozole; CGS 20267; CGS-20267; FEM-345; Femara (TN); Letrozole [USAN:INN]; CGS 20267, Femara, Piroxicam, Letrozole; Letrozole (JAN/USP/INN); 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile"	3902	C17H11N5	Approved
M6APDG03528	SX-ARPC	"ADR-L09; Androgen receptor antagonists (small peptide mimetic, androgen independent prostate cancer),Serometrix"	.	.	Investigative
M6APDG04163	MDX-1100	.	.	.	Phase 2
M6APDG00580	Pyrrolidin-(2Z)-ylideneamine	"3,4-dihydro-2H-pyrrol-5-amine; 872-34-4; Pyrrolidin-2-imine; Pyrrolidin-(2Z)-ylideneamine; 4,5-DIHYDRO-3H-PYRROL-2-YLAMINE; CHEMBL161318; 2-Amino-1-pyrroline; iminopyrrolidine; 2-iminopyrrolidine; 2-imino pyrrolidine; 2-imino-pyrrolidine; 2-Amino-1-pyrrolin; PYR040; CTK5F8124; DTXSID60509645; NJBMZYSKLWQXLJ-UHFFFAOYSA-N; MolPort-004-968-713; 2-amino-4,5-dihydro-3H-pyrrole; 2H-Pyrrol-5-amine,3,4-dihydro-; BDBM50049251; BBL031757; ZINC12946088; STL283815; ANW-72957; 3788AC; 2H-Pyrrol-5-amine, 3,4-dihydro-; AKOS009098397; AKOS002684118"	12778904	C4H8N2	Investigative
M6APDG03762	ISIS 31982	.	.	.	Investigative
M6APDG00746	SC-558	CHEMBL602951; BDBM50308509	1396	C16H11BrF3N3O2S	Investigative
M6APDG00983	2-(2-(biphenyl-4-yl)ethylthio)acetic acid	CHEMBL572980; 2-(2-(biphenyl-4-yl)ethylthio)acetic acid	20348772	C16H16O2S	Investigative
M6APDG02693	ASN-11124542	AC1O5VPR; ASN 11124542	6490494	C13H8N4OS	Investigative
M6APDG00137	"6,7-Dimethoxy-3-p-tolyl-quinoline"	"CHEMBL67219; 6,7-Dimethoxy-3-p-tolyl-quinoline; ZINC13737715"	10401378	C18H17NO2	Investigative
M6APDG01073	Cyclostellettamine derivative	CHEMBL88332	23327627	C40H58F6N2O4	Investigative
M6APDG01193	NSC-66811	NSC 66811; 6964-62-1; NSC-66811; 2-METHYL-7-[PHENYL(PHENYLAMINO)METHYL]-8-QUINOLINOL; 7-[anilino(phenyl)methyl]-2-methylquinolin-8-ol; 7-(Anilino(phenyl)-methyl)-2-methyl-8-quinolinol; 2-methyl-7-(phenyl(phenylamino)methyl)quinolin-8-ol; 8-Hydroxy-2-methyl-7-[phenyl(phenylamino)methyl]quinoline; NSC66811; AC1L6NIN; AC1Q79MP; 7-(anilino(phenyl)methyl)-2-methyl-8-quinolinol; SCHEMBL1241576; CHEMBL210778; BDBM31206; CTK5D0724; DTXSID30290119; MolPort-008-431-978; BCP07490; 2152AH; AKOS003020553; AKOS016050521; AK260645; M2390	248986	C23H20N2O	Investigative
M6APDG04311	RO-26-2853	.	.	.	Preclinical
M6APDG01960	Nimesulide	"nimesulide; 51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin"	4495	C13H12N2O5S	Terminated
M6APDG03788	ISIS 9005	.	.	.	Investigative
M6APDG04140	Matuzumab	"EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals"	.	.	Phase 2
M6APDG03409	CRx-401	.	.	.	Discontinued in Phase 2
M6APDG02454	4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one	"CHEMBL377646; 4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one; SCHEMBL4456699; BDBM50189477; 2(1H)-Quinolinone, 4-hydroxy-8-nitro-3-phenyl-"	54737904	C15H10N2O4	Investigative
M6APDG00225	PDGF receptor tyrosine kinase inhibitor III	"PDGFR Tyrosine Kinase Inhibitor III; PDGF Receptor Tyrosine Kinase Inhibitor III; CHEMBL102346; 205254-94-0; 4-(6,7-dimethoxyquinazolin-4-yl)-N-(4-phenoxyphenyl)piperazine-1-carboxamide; 4-(6,7-Dimethoxy-4-quinazolinyl)-N-(4-phenoxyphenyl)-1-piperazinecarboxamide; N-(4-Phenoxyphenyl)-4-(6,7-dimethoxyquinazoline-4-yl)piperazine-1-carboxamide; SCHEMBL2592017; GTPL6019; CTK8E8815; DTXSID20447892; CHEBI:143127; HMS3229I09; IN1156; HSCI1_000345; BDBM50115301; CCG-206772; NCGC00185729-01; ACM205254940; RT-014972; J-013383"	10907042	C27H27N5O4	Investigative
M6APDG01876	4-(cyclobutylmethylthio)-2-methoxybenzonitrile	CHEMBL453244; 4-(cyclobutylmethylthio)-2-methoxybenzonitrile	44564584	C13H15NOS	Investigative
M6APDG03093	A-420983	"CHEMBL314627; A-420983; N-(4-{4-Amino-1-[4-(4-Methylpiperazin-1-Yl)-Trans-Cyclohexyl]-1h-Pyrazolo[3,4-D]pyrimidin-3-Yl}-2-Methoxyphenyl)-1-Methyl-1h-Indole-2-Carboxamide; SCHEMBL6221049; SCHEMBL5803074; SCHEMBL19999345; SCHEMBL14106773; SCHEMBL16752208; STVKLDUINKMZFE-RQNOJGIXSA-N; STVKLDUINKMZFE-PSWAGMNNSA-N; BDBM50145571; L1G; N-(4-(4-amino-1-((trans)-4-(4-methylpiperazin-1-yl)cyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide"	9549183	C33H39N9O2	Investigative
M6APDG03613	TP-801	"C-Met tyrosine kinase inhibitor (oral, cancer), Tiger Pharmatech"	.	.	Investigative
M6APDG04251	AMO-02	.	.	.	Phase 2/3
M6APDG00243	N-(3-phenoxy-4-pyridinyl)ethanesulfonamide	"CHEMBL376143; 833455-54-2; N-(3-phenoxy-4-pyridinyl)ethanesulfonamide; CTK3D2870; DTXSID30457028; BDBM50158446; AKOS030595655; Ethanesulfonamide, N-(3-phenoxy-4-pyridinyl)-"	11150126	C13H14N2O3S	Investigative
M6APDG00337	AZD8931	Sapitinib; AZD8931; 848942-61-0; AZD8931 (Sapitinib); AZD-8931; Sapitinib(AZD8931); UNII-3499328002; CHEMBL2408045; 2-(4-((4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-n-methylacetamide; 2-[4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidin-1-yl]-N-methylacetamide; Sapitinib [INN]; 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-((1-(n-methylcarbamoylmethyl)piperidin-4-yl)oxy)quinazoline	11488320	C23H25ClFN5O3	Phase 2
M6APDG03240	IPI-493	"[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851"	9893658	C28H39N3O8	Discontinued in Phase 1
M6APDG02560	GLPG-0492	"G-100192; Selective androgen receptor modulators, Galapagos; Selective androgen receptor modulators, ProSkelia; Selective androgen receptor modulators, ProStrakan; SARMs (osteoporosis), ProSkelia; SARMs (osteoporosis), ProStraken; SARMs (osteoporosis/cachexia), Galapagos"	59317190	C19H14F3N3O3	Preclinical
M6APDG01637	RS-39066	RS-39066; CHEMBL288896; GTPL8567; BDBM50287379; RS39066; RS 39066; methyl 4-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]benzoate; 4-[(S)-2-((R)-2-Hydroxycarbamoylmethyl-4-methyl-pentanoylamino)-4-methyl-pentanoylamino]-benzoic acid methyl ester	44288042	C22H33N3O6	Investigative
M6APDG02378	UNC0642	"1481677-78-4; UNC 0642; UNC-0642; CHEMBL2441082; 2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine; Barrett; GTPL7017; SCHEMBL17372593; AOB2595; MolPort-035-765-953; EX-A2241; BCP08266; ZINC96285772; BDBM50442103; AKOS024458509; SB19046; CS-5269; NCGC00189140-01; NCGC00189140-02; AS-16721; HY-13980; BC600721; AK547424; UNC0642, &gt; KB-146019; J-008448"	53315878	C29H44F2N6O2	Investigative
M6APDG01901	Cerdulatinib	"PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals"	44595079	C20H27N7O3S	Phase 2
M6APDG01781	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL376811; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)	44418879	C37H49N11O6	Investigative
M6APDG03084	6-Benzylsulfanyl-9H-purine	"Purine, 6-(benzylthio)-; 6-Benzothiopurine; 6-Benzyl MP; 724-34-5; 6-(Benzylthio)purine; 6-Benzylmercaptopurine; 6-benzylsulfanyl-9H-purine; 6-Benzyl-MP; SRI 673; NSC 29421; 6-(benzylsulfanyl)-9H-purine; Purine, 6-benzylthio-; 6-((Phenylmethyl)thio)-1H-purine; EINECS 211-965-4; 6-(benzylthio)-9H-purine; AI3-50277; 6-[BENZYLTHIO]-1H-PURINE; 1H-Purine, 6-[(phenylmethyl)thio]-; 1H-Purine, 6-((phenylmethyl)thio)-; 6-[(PHENYLMETHYL)THIO]-1H-PURINE; 6-benzylthiopurine; AC1Q4XUO; CBMicro_000185; 6-(phenylmethylthio)purine"	93558	C12H10N4S	Investigative
M6APDG04094	INCB62079	.	.	.	Phase 1/2
M6APDG01205	Gly-Pip-Glu	Gly-Pip-Glu; SCHEMBL2084204	25055596	C13H21N3O6	Investigative
M6APDG03047	Hydroxyflutamide	"HFT; Hydroxyniphtholide; PC1193; Sch 16423; Hydroxy-flutamide; OH-flutamide; Sch-16423; Alpha, alpha, alpha-trifluoro-2-methyl-4'-nitro-m-lactotoluidide; Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-lactotoluidide; 2-Hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide; 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide"	91649	C11H11F3N2O4	Approved
M6APDG04363	KRP-105	.	.	.	Terminated
M6APDG01160	MERIOLIN 4	MERIOLIN 4; SCHEMBL3001373; CHEMBL406464	24801697	C13H13N5O	Investigative
M6APDG03543	ISIS 106008	.	.	.	Investigative
M6APDG02019	GSK-2256098	"Focal adhesion kinase inhibitor (oral, cancer), GlaxoSmithKline"	46214930	C20H23ClN6O2	Phase 1
M6APDG03321	Aleglitazar	"RO7; Aleglitazar (USAN); 2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzothiophen-7-yl]propanoic Acid"	10274777	C24H23NO5S	Discontinued in Phase 3
M6APDG02863	CI-1040	.	6918454	C17H14ClF2IN2O2	Investigative
M6APDG01788	Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL375850; cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)	44418889	C37H49N11O6	Investigative
M6APDG00119	2-(3-hydroxyphenyl)-7-methoxychroman-4-one	"CHEMBL256407; 32274-72-9; CTK1B9323; DTXSID30438650; BDBM50374258; AKOS030552772; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-(3-hydroxyphenyl)-7-methoxy-"	10355761	C16H14O4	Investigative
M6APDG04020	MEDI-547	"MedImmune, MedImmune/AstraZeneca"	.	.	Phase 1
M6APDG03149	KRP-101	"PPAR alpha agonist (hyperlipidemia), Kyorin"	9825046	C26H26FNO5	Discontinued in Phase 2
M6APDG00417	"2-allylisoquinoline-1,3,4-trione"	"807334-89-0; 1,3,4(2H)-Isoquinolinetrione, 2-(2-propenyl)-; 2-allylisoquinoline-1,3,4-trione; CHEMBL381777; Isoquinoline-1,3,4-trione 2b; SCHEMBL13442855; CTK2I7309; BDBM10249; DTXSID20469711; ZINC13683126; AKOS015966148"	11629882	C12H9NO3	Investigative
M6APDG01769	Ac-His-D-Phe-Arg-2-Nal-NHCH3	CHEMBL211699; Ac-His-D-Phe-Arg-2-Nal-NHCH3; BDBM50189018; (S)-2-{(R)-2-[(S)-2-acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid ((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-amide	44413876	C37H46N10O5	Investigative
M6APDG00678	"3-Pyridin-4-yl-quinoline-6,7-diol"	.	135469328	C14H10N2O2	Investigative
M6APDG01808	"4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole"	"CHEMBL239895; 4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL17969081"	44437844	C12H12N4	Investigative
M6APDG03247	"5-(azetidin-1-ylsulfonyl)indoline-2,3-dione"	"5-[1-(Azetidinyl)sulfonyl]isatin; Isatin Sulfonamide 19; 1H-Indole-2,3-dione, 5-(1-azetidinylsulfonyl)-; CHEMBL64789; SCHEMBL6535690; BDBM10308; 220510-08-7; 5-(Azetidine-1-ylsulfonyl)indoline-2,3-dione"	9903426	C11H10N2O4S	Investigative
M6APDG00273	FORMESTANE	"formestane; 566-48-3; 4-Hydroxyandrost-4-ene-3,17-dione; 4-Hydroxyandrostenedione; Lentaron; CGP-32349; Lentaron(R); 4-OH-A; B, Aromatase inhibitor; 4-Hydroxy-4-androstene-3,17-dione; NSC 282175; 17-dione; 4-OHA; CGP 32349; Formestane [INN:BAN]; UNII-PUB9T8T355; CCRIS 7483; ANDROST-4-ENE-3,17-DIONE, 4-HYDROXY-; 4-Hydroxy-delta(sub 4)-androstenedione; BRN 1889793; MLS002153359; MLS000028826; PUB9T8T355; CHEBI:75172"	11273	C19H26O3	Withdrawn from market
M6APDG01373	homoquinolinic acid	HQA	3080554	C8H7NO4	Investigative
M6APDG03952	TEN010	.	.	.	Phase 1
M6APDG00725	"3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione"	"CHEMBL29863; 3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione"	13660218	C15H20N2O2	Investigative
M6APDG01925	2-Aminoethanimidic Acid	2-AMINOETHANIMIDIC ACID; 2-iminoethanamine; 2-aminoethylimine; 2-Aminoethanimine; AC1NBQ0B; (2E)-2-iminoethanamine; AKOS006363845	4471892	C2H6N2	Investigative
M6APDG03635	ISIS 298702	.	.	.	Investigative
M6APDG02002	6-Benzyloxy-9H-purin-2-ylamine	"6-O-Benzylguanine; 19916-73-5; 6-(Benzyloxy)-7H-purin-2-amine; 2-amino-6-benzyloxypurine; 6-(benzyloxy)-9H-purin-2-amine; 2-Amino-6-(benzyloxy)purine; O(6)-Bgua; 6-(Benzyloxy)guanine; 6-Benzyloxyguanine; 6-Benzyloxy guanine; 6-(Phenylmethoxy)-1H-purin-2-amine; 2-Amino-6-(phenylmethoxy)-9H-purine; O6-BG; UNII-01KC87F8FE; 1H-Purin-2-amine, 6-(phenylmethoxy)-; 6-BENZYLGUANINE; Purine, 2-amino-6-(benzyloxy)-; NSC 637037; CHEMBL407874; 01KC87F8FE; 6-benzyloxy-7H-purin-2-amine"	4578	C12H11N5O	Investigative
M6APDG03098	PQ401	PQ 401; IGF-1R inhibitor II; PQ-401	9549305	C18H16ClN3O2	Investigative
M6APDG01121	"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine"	"bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514"	2426	C14H12BrN5	Investigative
M6APDG03075	Ac-YRMEHdFRWGSPPKD-NH2	.	91936747	C84H119N25O21S	Investigative
M6APDG04076	Sym015	.	.	.	Phase 1/2
M6APDG04093	ISIS-STAT3	.	.	.	Phase 1/2
M6APDG00792	C(-GRGDfL-)	CHEMBL235999	15409414	C29H43N9O8	Investigative
M6APDG03219	"2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline"	"CHEMBL51594; 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline; SCHEMBL6441852; CIOBWNSCGKJAQU-UHFFFAOYSA-N; ZINC13489832; BDBM50127824; AKOS027557951"	9877750	C14H14N2	Investigative
M6APDG00317	6-Mercapto-hexanoic acid phenylamide	"6-Mercapto-hexanoic acid phenylamide; CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600"	11436024	C12H17NOS	Investigative
M6APDG00631	indirubin deriv. 8a	.	135398521	C18H12BrN3O3	Investigative
M6APDG01890	RXP470.1	"RXP470.1; CHEMBL507420; N-[(2s)-3-[(S)-(4-Bromophenyl)(Hydroxy)phosphoryl]-2-{[3-(3'-Chlorobiphenyl-4-Yl)-1,2-Oxazol-5-Yl]methyl}propanoyl]-L-Alpha-Glutamyl-L-Alpha-Glutamine; R47; GTPL7812; BDBM50265078; (4S)-5-amino-4-((2S)-2-((2S)-3-((4-bromophenyl)(hydroxy)phosphoryl)-2-((3-(3''-chlorobiphenyl-4-yl)isoxazol-5-yl)methyl)propanamido)-4-carboxybutanamido)-5-oxopentanoic acid"	44580458	C35H35BrClN4O10P	Investigative
M6APDG00404	JNJ-26854165	"Serdemetan; 881202-45-5; N1-(2-(1H-Indol-3-yl)ethyl)-N4-(pyridin-4-yl)benzene-1,4-diamine; JNJ-26854165 (Serdemetan); UNII-ID6YB4W3V8; ID6YB4W3V8; C21H20N4; n-(2-(1h-indol-3-yl)ethyl)-n'-(4-pyridinyl)-1,4-benzenediamine; N-[2-(1H-INDOL-3-YL)ETHYL]-N'-(4-PYRIDINYL)-1,4-BENZENEDIAMINE; Serdemetan [INN]; MLS006011022; SCHEMBL3012498; CHEMBL2137530; CTK8C1936; EX-A267; DTXSID30236830; MolPort-009-679-468; HMS3654A16; JNJ 26854165 (Serdemetan); BCP02124; AOB87702; QC-534; ANW-67474"	11609586	C21H20N4	Phase 1
M6APDG01670	7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one	"CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone"	44350718	C22H23NO3	Investigative
M6APDG00644	2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one	.	135407310	C16H14N2O2	Investigative
M6APDG01412	Flufenamic Acid	flufenamic acid; 530-78-9; Fluphenamic acid; Nichisedan; Achless; Arlef; Tecramine; Paraflu; Lanceat; Flufacid; Plostene; Fullsafe; Parlef; Surika; Parlif; Flufenaminsaeure; Reumajust A; Acido flufenamico; N-(3-Trifluoromethylphenyl)anthranilic acid; Ristogen; Sastridex; Meralen; Ansatin; 2-((3-(Trifluoromethyl)phenyl)amino)benzoic acid; Fluore-200; 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid; ANT-1; Acide flufenamique; Acidum flufenamicum; TVX 916; INF 1837; 3'-Trifluoromethyldiphenylamine-2-carboxylic acid; NSC-82699; CI 440	3371	C14H10F3NO2	Approved
M6APDG03542	ISIS 105990	.	.	.	Investigative
M6APDG01561	4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile	CHEMBL464764; 4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile; BDBM50248553	43320723	C15H10F3NO	Investigative
M6APDG02042	[(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone	CHEMBL590497; [(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone	46232967	C15H14BrN3S	Investigative
M6APDG01432	Glimepiride	"Amarel; Amaryl; Endial; Glimepirid; Glimepirida; Glimepiridum; Glimepride; Glimer; Glymepirid; Roname; Solosa; Glimepirida [Spanish]; Glimepiridum [Latin]; Sandoz glimepiride; HOE 490; Amaryl (TN); Hoe-490; Novo-glimepiride; PMS-glimepiride; Ratio-glimepiride; Amaryl, Glista OD, Glimepiride; Glimepiride [USAN:BAN:INN]; Glimepiride (JAN/USP/INN); 1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea; 1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea; 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro; 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide; 64598P"	3476	C24H34N4O5S	Approved
M6APDG04199	Her2-targeted autologous T-cell therapy	Her2-targeted autologous T-cell therapy (cancer)	.	.	Phase 2
M6APDG02950	Redoxal	"52962-95-5; MLS000736810; NSC73735; UNII-Q0VK2156M5; N,N'-BIS(o-CARBOXYPHENYL)-o-DIANISIDINE; Q0VK2156M5; SMR000528333; 2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-benzoic acid; Benzoic acid, 2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-; 2-[4-[4-(2-carboxyanilino)-3-methoxyphenyl]-2-methoxyanilino]benzoic acid; 2-[4-[4-(2-carboxyanilino)-3-methoxy-phenyl]-2-methoxy-anilino]benzoic acid; 2-[(4-{4-[(2-carboxyphenyl)amino]-3-methoxyphenyl}-2-methoxyphenyl)amino]benzoic acid; Mini-antibody(scFv)"	72571	C28H24N2O6	Investigative
M6APDG02418	"Thieno[2,3-B]Pyridine-2-Carboxamidine"	"thieno[2,3-b]pyridine-2-carboxamidine; amino(thieno[2,3-b]pyridin-2-yl)methaniminium; [amino(thieno[2,3-b]pyridin-2-yl)methylidene]azanium; AC1L1KCT; BDBM14171; CTK7D1810; APC-7538"	5438	C8H8N3S+	Investigative
M6APDG01799	Methotrexate gamma-hydroxamic acid	methotrexate gamma-hydroxamic acid; CHEMBL244883	44428664	C20H23N9O5	Investigative
M6APDG04377	L-768277	L-766112	.	.	Terminated
M6APDG03483	ISIS 10582	.	.	.	Investigative
M6APDG03236	LY-929	LY-510929; Dual PPAR-alpha/PPAR-gamma agonists	9890585	C26H25NO5S	Discontinued in Phase 1
M6APDG02338	HIF-1alpha	"Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; UNII-NA856793UT; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060"	5328127	C20H24N6O3	Phase 4
M6APDG00075	L-698544	"7-Chloro-3-nitro-3,4-dihydroquinolin-2(1H)-one; 147778-05-0; 7-chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one; 7-CHLORO-3-NITRO-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL102574; 2(1H)-Quinolinone,7-chloro-3,4-dihydro-3-nitro-; ACMC-1C9KO; SCHEMBL8271408; CTK4C5567; DTXSID50436916; BDBM50038176; 3697AJ; AKOS024260378; AB06846; AK153524; DB-063735; AX8026622; FT-0703007; Z-7553;  CNDQ; 7-Chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one"	10220180	C9H7ClN2O3	Terminated
M6APDG03845	CTCE-0214	"CTCE-0013; CTCE-0021; CXCR4 agonists, Chemokine Therapeutics; Stem cell transplant therapy, Chemokine Therapeutics"	.	.	Phase 1
M6APDG02729	3-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine	"CHEMBL175550; BDBM8604; AC1O705B; (3-Pyridylmethylene)indane 21a; 3-[(E)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539780	C16H15N	Investigative
M6APDG01920	GW-409544	"GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo"	446642	C31H30N2O5	Phase 1
M6APDG01656	"8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one"	CHEMBL112148; SCHEMBL7364383; BDBM50218532	44341053	C20H21F3O2	Investigative
M6APDG02069	2-Imidazol-1-ylmethylxanthen-9-one	CHEMBL1083354; 2-Imidazol-1-ylmethylxanthen-9-one	46867544	C17H12N2O2	Investigative
M6APDG00370	"4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl"	CHEMBL379687; BDBM50186763	11537051	C21H20O3	Investigative
M6APDG00849	AEKKDEGPYRMEHFRWGSPPKD	.	16135998	C118H174N34O35S	Investigative
M6APDG02823	Trilaciclib	"G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra"	68029831	C24H30N8O	Approved
M6APDG00140	"3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline"	"CHEMBL67424; 3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline; ZINC3834040"	10402592	C17H13F2NO2	Investigative
M6APDG00753	1400W	N-(3-(Aminomethyl)benzyl)acetamidine; N-(3-(AMINOMETHYL)BENZYL)ACETAMIDINE; 180001-34-7; N-(3-(aminomethyl)benzyl)-acetamidine; n-[3-(aminomethyl)benzyl]ethanimidamide; CHEMBL107251; CHEBI:90721; N-{[3-(aminomethyl)phenyl]methyl}ethanimidamide; RODUKNYOEVZQPR-UHFFFAOYSA-N; n-[3-(aminomethyl)benzyl]acetamidine; N-(3-(aminomethyl)benzyl)acetimidamide; N-(3-Aminomethyl-benzyl)-acetamidine; CHEMBL544788; 14W; N-[[3-(Aminomethyl)phenyl]methyl]ethanimidamide; Bio1_001405; Tocris-1415; AC1Q4SXP; AC1L1BGT; Lopac-W-4262; W 1400; SCHEMBL4467; Lopac0_001258;  W 1400; N-(3-(Aminomethyl)Benzyl)Acetamidine; N-(3-(aminomethyl)-benzyl)acetamidine	1433	C10H15N3	Investigative
M6APDG04322	ADC-03	.	.	.	Preclinical
M6APDG00724	"3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione"	"CHEMBL29864; 3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione; BDBM50025059"	13660216	C14H18N2O2	Investigative
M6APDG02673	Darbufelone	PD-136095	6444826	C18H24N2O2S	Phase 2/3
M6APDG00442	IMRECOXIB	"Imrecoxib; UNII-SGW6W5758V; SGW6W5758V; CHEMBL504535; 395683-14-4; Imricoxib; BAP-909; SCHEMBL3034253; BDBM50293282; AKOS032954049; DB12354; LS-194053; 2H-Pyrrol-2-one, 1,5-dihydro-3-(4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-1-propyl-; BAP-909; ; "	11682175	C21H23NO3S	Phase 4
M6APDG03759	ISIS 28465	.	.	.	Investigative
M6APDG01549	N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide	CHEMBL556532; N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide; SCHEMBL3292226; SCHEMBL3290139	42632368	C15H13NO2	Investigative
M6APDG03462	ISIS 23544	.	.	.	Investigative
M6APDG03685	ISIS 114527	.	.	.	Investigative
M6APDG01216	4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine	CHEMBL604876; 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine; SCHEMBL4439490	25074311	C13H13N5OS	Investigative
M6APDG02485	TAM-67	"CHEMBL16410; UNII-929J96FO8T; 82668-33-5; JPC-211; U-99194A maleate; 929J96FO8T; PNU-99194A free base; 5,6-dimethoxy-n,n-dipropylindan-2-amine; JPC 211; Tocris-1357; NCGC00016073-01; 2-Di-n-propylamino-5,6-dimethoxyindane; Lopac-U-116; 1H-Inden-2-amine, 2,3-dihydro-5,6-dimethoxy-N,N-dipropyl-; AC1L1KRQ; Biomol-NT_000031; AC1Q56MX; Lopac0_001207; ZINC7459; SCHEMBL2640137; BPBio1_001223; CHEBI:93232; DTXSID50274471; BDBM50107876; CCG-205281; PNU-99,194; API0008965; NCGC00025123-03; NCGC00025123-01; NCGC00016073-02"	5626	C17H27NO2	Investigative
M6APDG03739	ISIS 29201	.	.	.	Investigative
M6APDG03281	RM-6427	"RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark"	9931101	C18H13BrO6	Investigative
M6APDG02731	3-[4-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 23b; AC1O705F; SCHEMBL4224796; BDBM8606; CHEMBL176009; 3-[(Z)-(4-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539782	C16H15N	Investigative
M6APDG04175	MEDI-575	.	.	.	Phase 2
M6APDG04257	MBG453	.	.	.	Phase 3
M6APDG04156	SAR-113945	S-0100229; S-0100658	.	.	Phase 2
M6APDG03614	mab 224G11	"MAb 224G11; C-Met antagonist monoclonal antibody (cancer); C-Met antagonist monoclonal antibody (cancer), Pierre Fabre/Abbott"	.	.	Investigative
M6APDG03647	IPS-01003	"EGFR kinase antagonist (cancer), InnoPharmaScreen"	.	.	Investigative
M6APDG03453	PNT-500	"ERBB2 gene inhibitor (cancer), ProNAi"	.	.	Investigative
M6APDG02672	TAK165	"Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole"	6444692	C25H23F3N4O2	Discontinued in Phase 1
M6APDG00036	N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N	10085818	C17H18N4O	Investigative
M6APDG03202	SB-242235	193746-75-7; SB-242235; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03	9863367	C19H20FN5O	Discontinued in Phase 1
M6APDG01934	6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine	6-(N-PHENYLCARBAMYL)-2-NAPHTHALENECARBOXAMIDINE; CHEMBL104937; 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE; 6-carbamimidoyl-N-phenylnaphthalene-2-carboxamide; 1owe; uPa_7; AC1L9L6A; SCHEMBL4324160; ZINC2047486; BDBM50138670; 6-carbamimidoyl-N-phenyl-2-naphthamide; DB01977; 6-Carbamimidoyl-naphthalene-2-carboxylic acid phenylamide	447732	C18H15N3O	Investigative
M6APDG01710	Ac-[CEHdFRWC]-NH2	CHEMBL385556; Ac-[CEHdFRWC]-NH2	44400398	C45H58N14O10S2	Investigative
M6APDG01026	RDP58	"Delmitide; RDP58; RDP-58; UNII-5759XTJ706; 5759XTJ706; Delmitide [INN]; Allotrap-1258; Allotrap 1258; 287096-87-1; AC1L55WS; AC1Q5JM9; (2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-5-guanidino-pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-n-[(1r)-1-[[(1r)-1-[[(1r)-1-[[(1r)-1-[[2-[[(1r)-2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]pentyl]carbamoyl]pentyl]carbamoyl]pentyl]carbamoyl]-4-guanidino-butyl]hexanamide; RDP 58; RSP-58; SCHEMBL18758870; D-Tyrosinamide, D-arginyl-D-norleucyl-D-norleucyl-D-n"	219021	C59H105N17O11	Phase 2
M6APDG03700	EC-0845	"MTOR modulator (inflammatory disease), Endocyte"	.	.	Investigative
M6APDG03873	MSB2311	.	.	.	Phase 1
M6APDG00196	Palodesangren C	Palodesangren C	10696160	C30H26O6	Investigative
M6APDG00589	ON-044580	"ON-04 series (cancer), Onconova; JAK2/Bcr-Abl kinase inhibitors (cancer), Onconova"	129860730	C16H13BrO3S	Investigative
M6APDG03502	ISIS 3804	.	.	.	Investigative
M6APDG02165	"2,4-Dimethoxy-3'-amino-trans-stilbene"	CHEMBL1173641; BDBM50322048	49799639	C16H17NO2	Investigative
M6APDG03626	TAT-120	"MIP-120, Vasade; Peptide mammalian sterile 20-like kinase 1 inhibitors (ischemic heart disease); Peptide Mst-1 inhibitors (ischemia), Vasade; Peptide mammalian sterile 20-like kinase 1 inhibitors (ischemic heart disease), Vasade"	.	.	Investigative
M6APDG00536	ATI-2341	"ATI-2346; ATI-2756; ATI-2766; CXCR4 agonists (cancer/bone marrow transplantation), Ascent; Pepducins (cancer/bone marrow transplantation), Ascent"	121513892	C104H178N26O25S2	Investigative
M6APDG00424	CGP-57380	"CGP 57380; 522629-08-9; CGP-57380; MNK1 Inhibitor; N3-(4-fluorophenyl)-1h-pyrazolo[3,4-d]pyrimidine-3,4-diamine; CGP57380; CHEMBL1240885; C11H9FN6; 4-Amino-5-(4-fluoroanilino)-pyrazolo[3,4-d]pyrimidine; SCHEMBL987991; GTPL6010; CHEMBL576817; SCHEMBL16714452; CHEBI:92749; DTXSID50469941; MolPort-006-725-822; HMS3653G22; HMS3269P13; HMS3263L14; HMS3229K20; HMS3648M14; Tox21_501256; BDBM50130693; 2314AH; NSC741567; MFCD03861062; ZINC13816313; s7421; IN1236; BDBM50298223; AKOS024457265; CCG-206868; NSC-741567; LP01256; NCGC00162380-06"	11644425	C11H9FN6	Investigative
M6APDG03679	ISIS 5875	.	.	.	Investigative
M6APDG03309	"3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline"	"CHEMBL302491; 3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline; SCHEMBL8502238; ZINC3834024; BDBM50039084"	9971060	C17H14FNO2	Investigative
M6APDG01215	VS-4718	PND-1186	25073775	C25H26F3N5O3	Phase 1
M6APDG04226	Depatuxizumab	.	.	.	Phase 2
M6APDG00032	"7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline"	"CHEMBL69378; 7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline; ZINC3832255"	10083695	C14H9NO2S	Investigative
M6APDG02082	AdoCGlyArg6	CHEMBL611123	46877398	C48H86N30O12	Investigative
M6APDG00410	PTosyl-Glu(OtBu)-Ala-LeuVSMe	CHEMBL207016; pTosyl-Glu(OtBu)-Ala-LeuVSMe	11621347	C27H43N3O8S2	Investigative
M6APDG00393	3-(4-Phenylethynylbenzoyl)nonanoic acid	3-(4-Phenylethynylbenzoyl)nonanoic acid; CHEMBL201298	11581319	C24H26O3	Investigative
M6APDG03770	ISIS 32006	.	.	.	Investigative
M6APDG01508	4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL143734; NSC718168; 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid	403373	C13H17ClN2O3	Investigative
M6APDG00170	4-[3-(5-Phenyl-pentylamino)-propyl]-phenol	"CHEMBL334003; 771459-50-8; 4-[3-(5-Phenyl-pentylamino)-propyl]-phenol; CTK2G6876; DTXSID00441232; BDBM50066546; 4-[3-[(5-Phenylpentyl)amino]propyl]phenol; Phenol, 4-[3-[(5-phenylpentyl)amino]propyl]-"	10520673	C20H27NO	Investigative
M6APDG00801	XR-9544	XR-9544; CHEMBL444075; SCHEMBL14290581; BDBM50375811	15511440	C36H34N4O4	Investigative
M6APDG01918	MMI270	CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; MMI270; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1	446504	C18H23N3O5S	Investigative
M6APDG02771	PMID17935984C1	CHEBI:45030; 1you; AC1LCVYP; GTPL6526; BDBM50224854; DB08388	657061	C20H19FN2O6	Clinical trial
M6APDG03474	ISIS 7453	.	.	.	Investigative
M6APDG02985	(R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide	AC1LGDRI; SCHEMBL4372856; CHEMBL190952; ZINC250026; (2R)-2-(4-Isobutylphenyl)-N-phenylpropionamide	769367	C19H23NO	Investigative
M6APDG02052	N-(2-amino-5-(furan-3-yl)phenyl)benzamide	"CHEMBL1095095; N-(2-amino-5-(furan-3-yl)phenyl)benzamide; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000"	46830327	C17H14N2O2	Investigative
M6APDG04075	Anti-C-met CAR-T cells	.	.	.	Phase 1/2
M6APDG01292	NSC-106084	NSC-106084; CHEMBL597113; NSC106084; AC1L6H8Q; CTK7J5419; ZINC1868549; BDBM50308983; {4-[5-bromo-2-(carboxymethoxy)benzoyl]phenoxy}acetic acid; 2-(4-bromo-2-(4-(carboxymethoxy)benzoyl)phenoxy)acetic acid; 2-[4-[5-bromo-2-(carboxymethyloxy)benzoyl]phenoxy]acetic acid	266989	C17H13BrO7	Investigative
M6APDG00726	"3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione"	"CHEMBL25735; 3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione"	13660221	C16H22N2O2	Investigative
M6APDG02908	SR9238	"SR9238; SR 9238; 1416153-62-2; GTPL8692; SCHEMBL15773678; MolPort-042-624-584; AKOS027470306; ZINC145690538; HY-101442; CS-0021352; ethyl 5-[[[4-(3-methylsulfonylphenyl)phenyl]methyl-(2,4,6-trimethylphenyl)sulfonylamino]methyl]furan-2-carboxylate; Ethyl 5-[[[[3'-(Methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl][(2,4,6-trimethylphenyl)sulfonyl]amino]methyl]-2-furancarboxylate"	71478195	C31H33NO7S2	Investigative
M6APDG00010	COOH	LS-191838	10025649	C27H27NO4	Investigative
M6APDG01420	Flurbiprofen	"Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1&prime; -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid"	3394	C15H13FO2	Approved
M6APDG02182	Pyrophosphate 2-	pyrophosphate 2-; dihydrogen diphosphate; diphosphate(2-); AC1L1JDO; CHEBI:45212; H2P2O7(2-)	4995	H2O7P2-2	Investigative
M6APDG00728	KO-947	"ODIUJYZERXVGEI-UHFFFAOYSA-N; KO947; 1695533-89-1; GTPL9976; SCHEMBL16619993; EX-A1980; BCP25116; HY-112181; CS-0043627; 6-benzyl-3-pyridin-4-yl-2,5-dihydro-1H-pyrazolo[4,3-g]quinazolin-7-one; 6-benzyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[4,3-g]quinazolin-7-one; KO947,1695533-89-1,1,5,6,8-Tetrahydro-6-(phenylmethyl)-3-(4-pyridinyl)-7H-pyrazolo[4,3-g]quinazolin-7-one,KO947,KO-947,KO 947"	136653617	C21H17N5O	Phase 1
M6APDG02261	ELLAGIC ACID	"ellagic acid; 476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728"	5281855	C14H6O8	Investigative
M6APDG00989	RG-50810	"Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; RG-50810; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215"	2052	C10H6N2O2	Investigative
M6APDG01843	N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide	CHEMBL575895; N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide	44479457	C14H13NO5S	Investigative
M6APDG02944	2-Chlorophenol	"2-CHLOROPHENOL; o-Chlorophenol; 95-57-8; Phenol, 2-chloro-; 2-Hydroxychlorobenzene; o-Chlorphenol; o-Chlorophenic acid; Phenol, o-chloro-; 2-Chloro-1-hydroxybenzene; CHLOROPHENOL; Septi-Kleen; 2-chloro-phenol; RCRA waste number U048; Pine-O Disinfectant; Caswell No. 203; o-Chlorphenol [German]; UNII-K9KAV4K6BN; Phenol, chloro-; NSC 2870; CCRIS 640; HSDB 1415; EINECS 202-433-2; K9KAV4K6BN; RCRA waste no. U048; 1-Chloro-2-hydroxybenzene; EPA Pesticide Chemical Code 062204; AI3-09060; CHEBI:47083; ISPYQTSUDJAMAB-UHFFFAOYSA-N"	7245	C6H5ClO	Investigative
M6APDG00485	4-Benzoylamino-N-hydroxy-benzamide	SCHEMBL673678; CHEMBL191227	11817702	C14H12N2O3	Investigative
M6APDG04041	ChronSeal	"Antibiotic-free recombinant HGF, Linkoping; Recombinant HGF, Kringle/ChronTech; Recombinant HGF, Kringle/Tripep"	.	.	Phase 1/2
M6APDG01609	RAD-140	"RAD-35010; Selective androgen receptor modulators (oral, sarcopenia/osteoporosis), Radius Health"	44200882	C20H16ClN5O2	Phase 1
M6APDG01272	GW853606	GW853606X; compound 22 [PMID: 19097784]	25263088	C20H13BrF3N3O2S	Investigative
M6APDG00056	Isogemichalcone C	"isogemichalcone C; CHEMBL463638; 3'-(4-Feruloyloxy-3-methylbutyl-2(E)-enyl)-2,4,2',4'-tetrahydroxychalcone; BDBM50250978; LMPK12120123; 3-Methoxy-4-hydroxy-trans-cinnamic acid 2-methyl-4-[2,6-dihydroxy-3-[3-(2,4-dihydroxyphenyl)acryloyl]phenyl]-2-butenyl ester; 3-Methoxy-4-hydroxy-trans-cinnamic acid 2-methyl-4-[2,6-dihydroxy-3-[(E)-2,4-dihydroxycinnamoyl]phenyl]-2-butenyl ester"	10143276	C30H28O9	Investigative
M6APDG00498	4'-bromo-3-(imidazolylmethyl)flavone	CHEMBL377766; BDBM50191597; 4''-bromo-3-(imidazolylmethyl)flavone	11847318	C19H13BrN2O2	Investigative
M6APDG02722	3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	"CHEMBL176609; AC1O704P; SCHEMBL4226031; SCHEMBL4226036; BDBM8593; (3-Pyridylmethylene)indane 11a; 3-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539769	C16H15NO	Investigative
M6APDG03980	LY3321367	.	.	.	Phase 1
M6APDG03720	ISIS 113209	.	.	.	Investigative
M6APDG00283	6-Phenoxy-hexane-1-thiol	"CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089"	11298778	C12H18OS	Investigative
M6APDG03954	CYT-013-IL1bQb	"Immunodrug vaccines (IL-1 beta) (rheumatoid arthritis), Cytos"	.	.	Phase 1
M6APDG03003	N-(4-methyl-benzyl)-4-phenoxy-benzamide	CHEMBL199174; N-(4-methyl-benzyl)-4-phenoxy-benzamide; AC1OVMY0; BDBM50174096	7916852	C21H19NO2	Investigative
M6APDG02836	PT-14	"Erectide; PT-14 (transmucosal); PT-14 (transmucosal), Palatin/TheraTech"	6875	C14H20N2O2	Discontinued in Phase 2
M6APDG00972	3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol	CHEMBL175113; 3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol; SCHEMBL7212134	19366844	C13H20O3S2	Investigative
M6APDG00122	"(2S)-5,7,2',4'-tetrahydroxyflavanone"	"steppogenin; 56486-94-3; (2S)-5,7,2',4'-tetrahydroxyflavanone; CHEMBL458395; (+)-Norartocarpanone; SCHEMBL6822729; QBLQLKNOKUHRCH-ZDUSSCGKSA-N; MolPort-035-705-966; ZINC14728050; BDBM50251005; AKOS032962442; (2S)-5,7,2'',4''-tetrahydroxyflavanone; W1600; (S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxychroman-4-one; (2s)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydro-4h-chromen -4-one"	10356745	C15H12O6	Investigative
M6APDG03556	ISIS 188761	.	.	.	Investigative
M6APDG00309	Ro-4396686	SCHEMBL5809947; CHEMBL606964	11396738	C24H24FN5O3	Investigative
M6APDG04200	HER-2 Protein AutoVac	.	.	.	Phase 2
M6APDG03526	Testetrol	"Testetrol (oral, hypogonadism); T2 (oral, hypogonadism), Pantarhei; Testetrol (oral, hypogonadism), Pantarhei; Testosterone agonist (oral, hypogonadism), Pantarhei"	.	.	Investigative
M6APDG00664	VER 50589	.	135446210	C19H17ClN2O5	Phase 2
M6APDG00316	MK-0668	"MK-0668; UNII-S441P37178; CHEMBL506044; S441P37178; 865110-07-2; SCHEMBL13884454; BDBM50423686; N-(N-((3-Cyanophenyl)sulfonyl)-4(R)-cyclobutylamino-(l)-prolyl)-4-((3',5'-dichloroisonicotinoyl) amino)-(l)-phenylalanine; L-Phenylalanine, (4R)-1-((3-cyanophenyl)sulfonyl)-4-(cyclobutylamino)-L-prolyl-4-(((3,5-dichloro-4-pyridinyl)carbonyl)amino)-"	11433918	C31H30Cl2N6O6S	Investigative
M6APDG02505	PIRINIXIC ACID	"Pirinixic acid; 50892-23-4; WY-14643; [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid; WY-14,643; WY14643; Wyeth 14,643; Wy 14643; Pirinixic acid [INN]; WY-14643 (Pirinixic Acid); (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid; UNII-86C4MRT55A; C14H14ClN3O2S; CCRIS 133; Acidum pirinixicum [INN-Latin]; Acide pirinixique [INN-French]; Acido pirinixico [INN-Spanish]; NSC310038; NSC-310038; NSC 310038; BRN 0759945; ((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)acetic acid; Acetic acid, ((4-chloro-6-("	5694	C14H14ClN3O2S	Preclinical
M6APDG01709	Ac-YR[CEHFRWC]-NH2	CHEMBL410672; Ac-YR[CEHFRWC]-NH2	44400371	C60H79N19O13S2	Investigative
M6APDG02697	2'-deoxythymidine triphosphate	"Thymidine-5'-triphosphate; dTTP; thymidine 5'-triphosphate; Deoxy-TTP; Deoxythymidine 5'-triphosphate; 2'-Deoxythymidine triphosphate; 5'-TTP; THYMIDINE-5'-TRIPHOSPHATE; thymidine 5'-(tetrahydrogen triphosphate); TTP (nucleotide); thymidine triphosphate; pppdT; TTP; UNII-QOP4K539MU; 5-Methyl-dUTP; dThd5'PPP; CHEBI:18077; EINECS 206-669-7; QOP4K539MU; CHEMBL363559; 2'-Deoxythymidine 5'-triphosphate; 18423-43-3; [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate; DEOXYTHYMIDINE_TRIPHOSPHATE; Thymidine-5'-Triphosphate"	64968	C10H17N2O14P3	Investigative
M6APDG03771	ISIS 32008	.	.	.	Investigative
M6APDG03506	SGI-1252	"JAK2 inhibitors (cancer), SuperGen; Janus-activated kinase-2 inhibitors (cancer), SuperGen"	.	.	Investigative
M6APDG01182	"4,12,17-dehydroxyriccardin C"	"Deoxyriccardin C; 4,12,17-dehydroxyriccardin C; Riccardin C derivative, 22; CHEMBL410486; BDBM23854"	24860516	C28H24O	Investigative
M6APDG01499	EM-101	"EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH"	3971	C19H18N2O2	Investigative
M6APDG02085	MK-10	MK-10	46877881	C41H55N11O7	Investigative
M6APDG01180	"12,17-dehydroxyriccardin C"	"12,17-dehydroxyriccardin C; Riccardin C derivative, 20e; CHEMBL429324; BDBM23852"	24860514	C28H24O2	Investigative
M6APDG03847	Zemab	.	.	.	Phase 1
M6APDG00886	Cacodylate Ion	"Dimethylarsinate; Arsinic acid, dimethyl-, ion(1-); Bolate; Bolls; 15132-04-4; Dimethylarsonic Acid; rad-e-cat 25; Cacodylate ions; Cacodylic acid, free acid; Kakodylat; DMAV; Dimethylarsinic acidanion; AC1L4ZLM; CAC; Me2AsO2(-); AC1Q1WC3; CHEBI:16223; CTK4C7002; BDBM92451; DTXSID60164758; OGGXGZAMXPVRFZ-UHFFFAOYSA-M; Scotts Stop Weeds After They Start; Scotts Spot Grass and Weed Control; [As(CH3)2O2](-); AKOS032954710; Arsinic acid,dimethyl-, ion(1-) (9CI)"	167250	C2H6AsO2-	Investigative
M6APDG04238	Dusigitumab	.	.	.	Phase 2
M6APDG03456	ISIS 122991	.	.	.	Investigative
M6APDG02502	LDC1267	"LDC1267; 1361030-48-9; LDC-1267; CHEMBL3808844; SCHEMBL167963; GTPL8247; MolPort-035-944-330; EX-A2265; AOB87188; BCP14023; BDBM50172075; s7638; ZINC113241878; AKOS026750422; CS-3603; SB19391; NCGC00386431-02; HY-12494; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide"	56847486	C30H26F2N4O5	Investigative
M6APDG02297	"[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala"	"[2(R,S)-2-Sulfanylheptanoyl]-phe-ala; [2(R,S)-2-SULFANYLHEPTANOYL]-PHE-ALA; TI1; AC1NRDCJ; 1qf1; DB02597; N-[(2S)-2-sulfanylheptanoyl]-L-phenylalanyl-L-alanine; N-[N-[(S)-2-Mercaptoheptanoyl]-L-phenylalanyl]-L-alanine; (2S)-2-[[(2S)-3-phenyl-2-[[(2S)-2-sulfanylheptanoyl]amino]propanoyl]amino]propanoic acid; (2S)-2-[(2S)-3-phenyl-2-[(2S)-2-sulfanylheptanamido]propanamido]propanoic"	5289469	C19H28N2O4S	Investigative
M6APDG01726	N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide	CHEMBL198543; N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide	44404537	C15H14N2O4	Investigative
M6APDG01210	"N8,2-dihydroxy-N1-phenyloctanediamide"	"CHEMBL251009; N8,2-dihydroxy-N1-phenyloctanediamide; SCHEMBL8144564"	25065929	C14H20N2O4	Investigative
M6APDG02222	splitomicin	"splitomicin; 5690-03-9; 1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398"	5269	C13H10O2	Investigative
M6APDG03401	LG-101280	"LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly"	.	.	Discontinued in Phase 1
M6APDG00456	2-methoxy-4-(o-tolyloxy)benzonitrile	CHEMBL491493; 2-methoxy-4-(o-tolyloxy)benzonitrile; SCHEMBL4178171	11715659	C15H13NO2	Investigative
M6APDG03601	Hebervis	"CIGB-400; EGF (buccal local, mucositis), CIGB; EGF (rectal, proctitis), CIGB"	.	.	Investigative
M6APDG03262	Ro-0505124	RO0505124	9911652	C23H25N5O3S	Investigative
M6APDG01820	6-deoxymanzamine X	.	44445400	C36H44N4O2	Investigative
M6APDG03664	Anti-EGFR mab	.	.	.	Investigative
M6APDG03599	ISIS 113022	.	.	.	Investigative
M6APDG03957	EZN-4176	.	.	.	Phase 1
M6APDG02957	santacruzamate A	CAY10683	72946782	C15H22N2O3	Investigative
M6APDG00863	"4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole"	"CHEMBL428206; 4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL17969160; CTK8F9477; BDBM50200766"	16216595	C15H10N4O	Investigative
M6APDG03350	Olaratumab	LY3012207	.	.	Approved
M6APDG01036	"6,7-Dimethoxy-4-(3-methoxy-phenoxy)-quinoline"	"CHEMBL98583; 6,7-Dimethoxy-4-(3-methoxyphenoxy)quinoline; 6,7-Dimethoxy-4-(3-methoxy-phenoxy)-quinoline; SCHEMBL7481076; SORFICSDHDADIC-UHFFFAOYSA-N"	22132666	C18H17NO4	Investigative
M6APDG02137	Pentoxifylline	"Agapurin; Azupentat; Dimethyloxohexylxanthine; Durapental; Hemovas; Ikomio; Oxpentifylline; PENTOXYPHYLINE;PNX; Pentoxifilina; Pentoxifyllin; Pentoxifyllinum; Pentoxil; Pentoxiphyllin; Pentoxiphylline; Pentoxiphyllium; Pentoxyfylline; Pentoxyphyllin; Pentoxyphylline; Ralofect; Rentylin; Torental; Trental;Vasofirin; Vazofirin; Agapurin Retard; BL 191; BL191; EHT 0201; EHT0201; IN1161; P 1784; Artal (TN); BL-191; EHT-0201; EHT-201; Flexital (TN); Pentox (TN); Pentoxifilina [INN-Spanish]; Pentoxifyllinum [INN-Latin]; Pentoxil (TN); Pentoxin (TN); Trental (TN); Cis-9-Octadecenoyl coenzyme A; Pentoxifylline [USAN:INN:JAN]; Pentoxifylline (JAN/USP/INN); 1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion; 1-(5-Oxohexyl)-3,7-dimethylxanthine; 1-(5-Oxohexyl)theobromine; 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxo-hexyl)-3,7-dihydro-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl) xantine; 3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)xanthine; 3,7-Dimethyl-1-(5-oxohexyl)xantine; 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione"	4740	C13H18N4O3	Approved
M6APDG02758	5-Indan-(1Z)-ylidenemethyl-1H-imidazole	AC1O70GD; SCHEMBL4236847; CHEMBL178036; SCHEMBL4235344	6540033	C13H12N2	Investigative
M6APDG01076	CEP-5104	"C25H22N2O3; 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CEP-5104; CHEMBL460989; SCHEMBL3264941; BDBM24947; ZINC40861910; 5-oxo dihydronaphthylcarbazole analogue, 14; X7364"	23378546	C25H22N2O3	Investigative
M6APDG02150	viral macrophage inflammatory protein-II	"CFLTKRGRQVC; vMIP-II; Viral macrophage inflammatory protein-II; AC1LAF0N; GTPL768; vMIP-II (RESIDUE 41-51, CYCLIC); (4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid"	486830	C55H93N19O14S2	Investigative
M6APDG00617	Bis(5-methoxybenzo[b]furan-2-yl)methanone	CHEMBL225772; bis(5-methoxybenzo[b]furan-2-yl)methanone	13454368	C19H14O5	Investigative
M6APDG00861	CA-170	"3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097"	16212596	C4H12Cl2N2	Phase 1
M6APDG00344	"6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine"	"6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamine; CHEMBL311108; CTK7E1320; ZINC13588156; BDBM50137196; AKOS015965750; 6-phenylthieno[3,2-d]pyrimidin-4-ylamine"	11499583	C12H9N3S	Investigative
M6APDG00365	C-[-Arg-Gly-Asp-Acpca31-]	CHEMBL534934	11533023	C18H29N7O6	Investigative
M6APDG03710	ISIS 133208	.	.	.	Investigative
M6APDG01149	C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	CHEMBL253788; c[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	24774519	C49H57N11O7	Investigative
M6APDG01899	(2S)-euchrenone a7	(2S)-euchrenone a7; CHEMBL457686; JJOUBYOHNYJCOU-IBGZPJMESA-N	44593508	C20H20O5	Investigative
M6APDG01712	Ac-YK[CEHdFRWC]-NH2	CHEMBL412495; Ac-YK[CEHdFRWC]-NH2	44400400	C60H79N17O13S2	Investigative
M6APDG02367	(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone	"CHEMBL7296; Bis(1H-2-indolyl)methanone 11; AC1NS9BZ; BDBM6573; ZINC8571; SCHEMBL6865103; 5-Methoxy-[2,2'-carbonylbis(1H-indole)]; 2-(1H-indol-2-ylcarbonyl)-5-methoxy-1H-indole; 1H-indol-2-yl-(5-methoxy-1H-indol-2-yl)methanone"	5330527	C18H14N2O2	Investigative
M6APDG03297	LG-120838	"LG-120838; CHEMBL302362; SCHEMBL4175160; SCHEMBL4175162; BDBM50067684; 5-(2-Methylbenzylidene)-2,2,4-trimethyl-1,2-dihydro-5H-1-aza-6-oxachrysene"	9951771	C27H25NO	Investigative
M6APDG00308	Indeglitazar	PLX-204	11395145	C19H19NO6S	Discontinued in Phase 2
M6APDG02959	Fascaplysin	"Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6"	73292	C18H11ClN2O	Investigative
M6APDG03172	CC-486	"AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917;  Nucleoside analogue"	9840076	C19H20N4O	Phase 3
M6APDG00954	"3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine"	"CHEMBL185833; 3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine"	18721724	C7H14N2S	Investigative
M6APDG02574	Dromostanolone	"Drostanolo; Drostanolon; Drostanolona; Drostanolone; Drostanolonum; Medrosteron; Medrotestron; Methalone; Metholone; Prometholone; Drostanolo [DCIT]; SKI 27719; Drolban (TN); Drostanolona [INN-Spanish]; Drostanolone [INN:BAN]; Drostanolonum [INN-Latin]; Dihydro-2alpha-methyltestosterone; Dihydro-2-alpha-methyltestosterone; Dihydro-2.alpha.-methyltestosterone; Androstan-3-one, 17-hydroxy-2-methyl-, (2alpha,5alpha,17beta)-(9CI); (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; (2alpha,5alpha,17beta)-17-hydroxy-2-methylandrostan-3-one; 17 beta-hydroxy-2 alpha-methyl-5 alpha-androstan-3-one; 17-beta-Hydroxy-2-alpha-methyl-5-alpha-androstan-3-one; 17beta-Hydroxy-2alpha-methyl-5alpha-androstan-3-one; 2-alpha-Methyl-17-beta-hydroxy-5-alpha-androstan-3-one; 2-alpha-Methyldihydrotestosterone; 2.alpha.-Methyldihydrotestosterone; 2a-methylandrostan-17b-ol-3-one; 2alpha-Methyldihydrotestosterone"	6011	C20H32O2	Approved
M6APDG03557	ISIS 188763	.	.	.	Investigative
M6APDG04019	ICT-121	.	.	.	Phase 1
M6APDG01284	NSC-93358	"CHEMBL583076; NSC-93358; NCIOpen2_006063; AC1L655A; CTK7H3397; BDBM50298490; 3a,5b,10-trimethyl-1,2,4,5,5a,6,7,10,10a,10b-decahydrocyclopenta[a]fluorene-3,8-dione; 3a,5b,10-trimethyl-1,2,3a,4,5,5a,5b,6,7,10,10a,10b-dodecahydrocyclopenta[a]fluorene-3,8-dione"	261365	C19H26O2	Investigative
M6APDG04240	Pidilizumab	CT-011	.	.	Phase 2
M6APDG00811	"3,4,5-Trimethoxy-4'-amino-trans-stilbene"	"CHEMBL87477; SCHEMBL4263050; MWXBWYJFAGYFKS-SNAWJCMRSA-N; ZINC26575008; BDBM50322046; (E)-4'-Amino-3,4,5-trimethoxystilbene; 3,4,5-Trimethoxy-4''-amino-trans-stilbene; 4-[2-(3,4,5-Trimethoxy-phenyl)-vinyl]-phenylamine"	15696376	C17H19NO3	Investigative
M6APDG03836	ALX-0651	"Anti-CXCR4 nanobodies (cancer), Ablynx"	.	.	Phase 1
M6APDG00547	Etoricoxib	"Algix; Arcoxia; Etoricoxibe; Nucoxia; Tauxib; L791456; MK 0663; MK 663; Algix (TN); Arcoxia (TN); L-791456; MK-0663; MK-663; Merck Sharp & Dohme brand of etoricoxib; Tauxib (TN); Etoricoxib (USAN/INN); Etoricoxib [USAN:INN:BAN]; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; 5CH"	123619	C18H15ClN2O2S	Approved
M6APDG01191	"4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole"	"CHEMBL471171; 4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole"	24884693	C16H12ClNSe	Investigative
M6APDG03843	EDP-322	"EP-16322; Antibacterial (oral, Gram-positive infections), Enanta; EDP-MRSA-1 (oral), Enanta"	.	.	Phase 1
M6APDG00282	KU-0058948	"CHEMBL380648; KU-0058948; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one"	11291932	C21H21FN4O2	Approved
M6APDG02356	SU-11652	"SU11652; SU-11652; 5-[(Z)-(5-chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; UNII-1C7AZL970U; CHEMBL13485; 1C7AZL970U; 326914-10-7; 5-[(E)-(5-Chloro-2-Oxo-1,2-Dihydro-3h-Indol-3-Ylidene)methyl]-N-[2-(Diethylamino)ethyl]-2,4-Dimethyl-1h-Pyrrole-3-Carboxamide; 5-{[(3Z)-5-chloro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; AC1NS62M; SU11248 analog 12c; GTPL6043; BDBM4815; SCHEMBL2114096"	5329103	C22H27ClN4O2	Investigative
M6APDG01764	C(his-D-phe-arg-trp-Aoc)	CHEMBL264120	44413535	C40H54N10O4	Investigative
M6APDG00633	Cyclic Guanosine Monophosphate	.	135398570	C10H12N5O7P	Investigative
M6APDG03958	BI-831266	.	.	.	Phase 1
M6APDG00867	2-Amino-5-Hydroxy-Benzimidazole	.	162636	C7H7N3O	Investigative
M6APDG04286	Hu5F9-G4	.	.	.	Phase 3
M6APDG03239	L-796449	"L-796449; UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid"	9891946	C28H27ClO4S	Investigative
M6APDG02383	TAK-960	"TAK-960; 1137868-52-0; TAK960; TAK 960; CHEMBL2392545; AK172385; benzamide, 4-[(9-cyclopentyl-7,7-difluoro-6,7,8,9-tetrahydro-5-methyl-6-oxo-5h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methyl-4-piperidinyl)-; 4-[(9-Cyclopentyl-7,7-Difluoro-5-Methyl-6-Oxo-6,7,8,9-Tetrahydro-5h-Pyrimido[4,5-B][1,4]diazepin-2-Yl)amino]-2-Fluoro-5-Methoxy-N-(1-Methylpiperidin-4-Yl)benzamide"	53357478	C27H34F3N7O3	Phase 1
M6APDG03407	GW-275919	.	.	.	Discontinued in Phase 2
M6APDG02223	8-OH-MANZAMINE A	"8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; 8-OH-MANZAMINE A; (+)8-Hydroxymanzamine A; CHEBI:66669"	5270765	C36H44N4O2	Investigative
M6APDG00537	(R)-2-Amino-5-phosphono-pentanoic acid	"76326-31-3; 5-Phosphononorvaline; DL-AP5; 2-Amino-5-phosphonopentanoic acid; 2-Amino-5-phosphovaleric acid; DL-2-Amino-5-phosphonopentanoic acid; 2-Amino-5-phosphopentanoic acid; 2-Amino-5-phosphonovaleric Acid; 2-AMINO-5-PHOSPHONOVALERATE; DL-2-Amino-5-phosphonovaleric acid; dl-APV; 2-Amino-5-phosphonopentanoate; AP-5; Norvaline, 5-phosphono-; 76726-92-6; CHEMBL28862; CHEBI:138644; 2-Amino-5-phosphono-pentanoic acid; (+/-)-Amino-5-phosphono-pentanoic acid; (+/-)-2-Amino-5-phosphonopentanoic acid; App acid; C5H12NO5P; Apv acid"	1216	C5H12NO5P	Investigative
M6APDG04110	AZX-100	.	.	.	Phase 2
M6APDG03522	MG-28	"FAS inhibitor (cancer), Institut Catala d'Oncologia; Fatty acid synthase inhibitor (cancer), Institut Catala d'Oncologia"	.	.	Investigative
M6APDG04314	Cruentaren	.	.	.	Preclinical
M6APDG02212	SB220025	SB220025; 3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole	5164	C18H19FN6	Terminated
M6APDG00834	6-o-tolylquinazolin-2-amine	6-o-tolylquinazolin-2-amine; CHEMBL215952; SCHEMBL5494575; RAWAQXBVMDKSIO-UHFFFAOYSA-N; ZINC35049815	16086113	C15H13N3	Investigative
M6APDG00262	3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone	"CHEMBL193856; BDBM22344; ZINC13683316; 1,3-Diarylprop-2-yn-1-one, 13a"	11231439	C16H12O3S	Investigative
M6APDG03801	Anti-CD133-CAR vector-transduced T cells	.	.	.	Phase 1
M6APDG00610	Boldenone	"Boldenone; Dehydrotestosterone; 846-48-0; 1,2-Dehydrotestosterone; 1-Dehydrotestosterone; 1,2-Didehydrotestosterone; 17beta-Boldenone; delta1-Testosterone; Boldenonum; Boldenona; 17beta-Hydroxyandrosta-1,4-dien-3-one; 1,4-Androstadien-17beta-ol-3-one; Boldenonum [INN-Latin]; Boldenona [INN-Spanish]; Boldenone [INN:BAN]; UNII-5H7I2IP58X; 17beta-Hydroxyandrosta-1,4-diene-3-one; 17-beta-Hydroxyandrosta-1,4-dien-3-one; EINECS 212-686-0; NSC 79102; 17-beta-Hydroxy-17-alpha-1,4-androstadien-3-one; 5H7I2IP58X; CHEBI:34584"	13308	C19H26O2	Investigative
M6APDG02737	4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine	"(4-Pyridylmethylene)indane 6b; SCHEMBL4231108; CHEMBL179144; AC1O705T; BDBM8615; ZINC100056302; 4-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539789	C15H12FN	Investigative
M6APDG03471	ISIS 12884	.	.	.	Investigative
M6APDG01031	XR-9504	XR-9504; CHEMBL258896; SCHEMBL7168501	22004473	C34H35N3O4	Investigative
M6APDG03175	ML-253764	"CHEMBL40711; ML-253764; SCHEMBL3728758; ZINC3938671; BDBM50142895; 2-[2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1h-imidazole; 2-{2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-fluoro-phenyl}-4,5-dihydro-1H-imidazole"	9842665	C18H18BrFN2O	Investigative
M6APDG02743	4-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	"(4-Pyridylmethylene)indane 12a; CHEMBL359942; BDBM8622; AC1O7067; 4-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539796	C16H15NO	Investigative
M6APDG00549	4-((1H-imidazol-1-yl)methyl)benzonitrile	1-(4-Cyanobenzyl)-1H-imidazole; 4-Imidazol-1-ylmethyl-benzonitrile	1236449	C11H9N3	Investigative
M6APDG03683	Long-acting FSH conjugate	"HM-12160B; LAPS-FSH; Long-acting FSH conjugate (LAPS); Long-acting FSH conjugate (LAPS), Hanmi; Long-acting follicle-stimulating hormone conjugate (LAPS, female infertility), Hanmi"	.	.	Investigative
M6APDG03110	ML-3375	ML-3375; CHEMBL113419; SCHEMBL4460547; SCHEMBL13712659; ZINC13491685; BDBM50119524; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridine; 2-(Methylthio)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole	9795838	C15H12FN3S	Investigative
M6APDG00705	MS436	.	135566899	C18H17N5O3S	Investigative
M6APDG02330	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE; 3-(naphthalen-1-ylmethoxy)pyridin-2-amine; 2-amino-3-(1-naphthylmethyloxy)pyridine; LI4; 1wbw; CHEMBL195393; AC1NS185; SCHEMBL6080116; BDBM13340; AKOS009255557; DB08093; Pyridine derived fragment based inhibitor 5	5326871	C16H14N2O	Investigative
M6APDG01564	WAY-151693	WAY-151693; CHEMBL70176; n-hydroxy-2-[(4-methoxy-benzenesulfonyl)-pyridin-3-ylmethyl-amino]-3-methyl-benzamide; 1fls; WAY; AC1L1I0A; SCHEMBL6129930; BDBM50096463; DB02071; WAY 151693; N-hydroxy-3-methyl-2-[N-(pyridin-3-ylmethyl)4-methoxybenzenesulfonamido]benzamide; N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbenzamide; N-hydroxy-2-{[(4-methoxyphenyl)sulfonyl](pyridin-3-ylmethyl)amino}-3-methylbenzamide	4368	C21H21N3O5S	Investigative
M6APDG00358	"2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione"	"2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione; CHEMBL205983; SCHEMBL13442854; Isoquinoline-1,3,4-trione 2e; CTK7A3832; BDBM10252; AKOS015966190; 2-(4-METHOXY-BENZYL)-ISOQUINOLINE-1,3,4-TRIONE"	11522185	C17H13NO4	Investigative
M6APDG02786	"5-Methyl-5-phenyl-pyrimidine-2,4,6-trione"	"Heptobarbital; Mephebarbital; Eudan; Phenylmethylbarbituric acid; Rutonal; Methylphenylbarbital; 5-Methyl-5-phenylbarbituric acid; 5-Methyl-5-phenylbarbityric acid; 76-94-8; 5-Phenyl-5-methylbarbituric acid; NSC 80543; Barbituric acid, 5-methyl-5-phenyl-; UNII-GFR227X6YY; 5-Methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; EINECS 200-994-8; BRN 0201825; GFR227X6YY; CHEMBL329617; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-methyl-5-phenyl-; 5-methyl-5-phenyl-barbituric acid; C11H10N2O3; 5-methyl-5-phenyl-1,3-diazinane-2,4,6-trione"	66160	C11H10N2O3	Investigative
M6APDG04359	A-252444.0	A-155918; A-205804; A-241548	.	.	Terminated
M6APDG03351	Golimumab	Simponi (TN); Golimumab (USAN/INN)	.	.	Approved
M6APDG04269	GED-0301	"SMAD-7 inhibitor (oligonucleotide, Crohn's disease), Giuliani"	.	.	Phase 3
M6APDG00510	ELACRIDAR	"Elacridar hydrochloride; 143851-98-3; Elacridar HCl; Elacridar (hydrochloride); gf 120918a; UNII-NX2BHH1A5B; NX2BHH1A5B; Elacridar hydrochloride [USAN]; GF-120918A; Elacridar hydrochloride (USAN); GF 120918; AC1Q3EOG; AC1L55DX; C34H34ClN3O5; SCHEMBL15847793; CHEMBL2074730; AOB5938; MolPort-023-332-877; BCP14056; 7066AA; AKOS016005297; CS-1113; ACN-041487; 4CA-0489; HY-50880; AC-30266; FT-0696337; W-5457; D03968; N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide hydro"	119373	C34H33N3O5	Discontinued in Phase 1
M6APDG03261	MCC950	"MCC950; 210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea"	9910393	C20H24N2O5S	Investigative
M6APDG00713	4-(6-morpholino-9H-purin-2-yl)phenol	.	135955186	C15H15N5O2	Investigative
M6APDG03133	FUTOENONE	"Futoenone; 19913-01-0; (-)-Futoenone; SCHEMBL3468519; CHEMBL295191; SXHVHWXETMBKPP-KXXATPMCSA-N; CHEBI:132647; OAS 1136; BDBM50213210; ZINC29395822; AKOS032949051; (2S,4S,5R,5aS)-4-(2H-1,3-benzodioxol-5-yl)-7-methoxy-5-methyl-2,3,4,5-tetrahydro-8H-2,5a-methano-1-benzoxepin-8-one"	9819306	C20H20O5	Investigative
M6APDG00841	E-7050	"C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai"	16118392	C33H37F2N7O4	Phase 1
M6APDG03438	PNT-300	"KRAS gene inhibitor (cancer), ProNAi"	.	.	Investigative
M6APDG02855	CAP-232	"TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP-232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01"	6918265	C45H58N10O9S2	Phase 2a
M6APDG03034	3-(Benzyloxy)Pyridin-2-Amine	"2-Amino-3-benzyloxypyridine; 24016-03-3; 3-(BENZYLOXY)PYRIDIN-2-AMINE; 3-Benzyloxy-2-pyridylamine; 2-Pyridinamine, 3-(phenylmethoxy)-; 3-benzyloxypyridin-2-amine; 3-Benzyloxy-2-aminopyridine; 2-amino-3-benzyloxy pyridine; 3-phenylmethoxypyridin-2-amine; 2-Amino-3-(benzyloxy)pyridine; 3-(phenylmethoxy)-2-pyridinamine; MFCD00006316; 3IP; 3-(phenylmethoxy)-2-pyridylamine; 2-Amino-3-benzyloxypyridine, 98.5%; 3-(benzyloxy)pyridin-2-amin; 3fty; EINECS 245-983-9; PubChem2575; 1w7h; ACMC-1COKO; AC1L3JRI; Maybridge1_001801; AC1Q52WQ"	90334	C12H12N2O	Investigative
M6APDG01831	4-phenyliminomethyl-benzenesulfonamide	4-phenyliminomethyl-benzenesulfonamide; CHEMBL407019; SCHEMBL5311443	44456679	C13H12N2O2S	Investigative
M6APDG01147	LD-101	AKT-SI-1	24773090	C13H15N5O6	Investigative
M6APDG03636	ISIS 298743	.	.	.	Investigative
M6APDG03361	Rilonacept	Rilonacept (USAN/INN)	.	.	Approved
M6APDG02834	Methyl Mercury Ion	"Methylmercury(1+); Methylmercury II; Methyl Mercury Ion; Methylmercury ion; Methyl mercury; METHYLMERCURY(II) CATION; Monomethylmercury cation; Methylmercury ion(1+); CH3Hg+; Mercury(1+), methyl-; 22967-92-6; methylmercury(II); AC1L1NGS; Methyl mercury(II) cation; CH3Hg(+); [HgMe](+); Mercury(1+), methyl-, ion; DTXSID9024198; [HgCH3](+); CTK8D8906; HSDB 3930; CHEBI:49747; AKOS015903545; BRN 3902999; LS-89823; C18672; I14-18601; I14-114322"	6860	CH3Hg+	Investigative
M6APDG01576	(L-)-S-adenosyl-L-homocysteine	"S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; S-adenosyl-L-homocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH; S-Adenosylhomocysteine; S-Adenosyl-L-Homocysteine"	439155	C14H20N6O5S	Investigative
M6APDG00604	C188-9	"QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9"	1324494	C27H21NO5S	Phase 1
M6APDG04086	Triciribine prodrug	"TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL"	.	.	Phase 1/2
M6APDG00039	4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol	CHEMBL54778; 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol; SCHEMBL7402131; BDBM50079386; Co-101071; 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol(Co 101071)	10086803	C20H25NO2	Investigative
M6APDG00479	CK-101	"IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena"	117909640	C29H28F2N6O2	Phase 1/2
M6APDG04160	MEHD-7945A	"RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech"	.	.	Phase 2
M6APDG01046	(E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	CHEMBL1086176; (E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide	22319483	C14H17N3O	Investigative
M6APDG01997	NS398	"ns-398; 123653-11-2; NS398; NS 398; N-(2-Cyclohexyloxy-4-nitrophenyl)methanesulfonamide; N-[2-(Cyclohexyloxy)-4-nitrophenyl]methanesulfonamide; CHEMBL7162; CHEBI:73458; Methanesulfonamide, N-(2-(cyclohexyloxy)-4-nitrophenyl)-; n-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide; N-(2-Cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide; Taisho NS 398; SR-01000597479; N-[2-Cyclohexyloxy-4-nitrophenyl]methanesulfonamide; N-(2-(cyclohexyloxy)-4-nitrophenyl)methanesulfonamide; CCRIS 8523; KTDZCOWXCWUPEO-UHFFFAOYSA-N; Tocris-0942"	4553	C13H18N2O5S	Terminated
M6APDG02473	Tolmetin	"Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid"	5509	C15H15NO3	Approved
M6APDG00219	SB-201076	"CHEMBL324097; 154566-05-9; SB-201076; SCHEMBL2622309; ZINC13781097; BDBM50066692; KB-145947; (S)-2-((S)-8-(2,4-dichlorophenyl)-2-hydroxyoctyl)-2-hydroxysuccinic acid; (S)-2-[(S)-8-(2,4-Dichloro-phenyl)-2-hydroxy-octyl]-2-hydroxy-succinic acid"	10835222	C18H24Cl2O6	Investigative
M6APDG03024	AMI-1	AMI1; AMI 1	88489	C21H14N2Na2O9S2	Investigative
M6APDG02385	INCB039110	Examlpe 294 [WO2011112662]	53380437	C26H23F4N9O	Phase 2
M6APDG01825	Neo-kauluamine	neo-Kauluamine	44448144	C72H90N8O6	Investigative
M6APDG00302	"2-benzylisoquinoline-1,3,4-trione"	"21640-35-7; 2-benzylisoquinoline-1,3,4-trione; 2-BENZYL-ISOQUINOLINE-1,3,4-TRIONE; CHEMBL382859; SCHEMBL13442853; Isoquinoline-1,3,4-trione 2c; BDBM10250; CTK4E7388; DTXSID80463477; ZINC13683129; AKOS015966149; FCH2821819; ACM21640357; 2-Benzylisoquinoline-1,3,4(2H)-trione; 2-Benzylisoquinoline-1,3,4(2H,4H)-trione; 1,3,4(2H)-Isoquinolinetrione,2-(phenylmethyl)-"	11357566	C16H11NO3	Investigative
M6APDG02917	Ripretinib	"1442472-39-0; Ripretinib [USAN]; UNII-9XW757O13D; GTPL9175; SCHEMBL14999718; 9XW757O13D; HY-112306; CS-0044835; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-"	71584930	C24H21BrFN5O2	Approved
M6APDG03595	ISIS 114232	.	.	.	Investigative
M6APDG02769	2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide	"3-(4-CHLOROPHENYL)QUINOXALINE-5-CARBOXAMIDE; 2-(4-CHLOROPHENYL)-5-QUINOXALINECARBOXAMIDE; 4tju; 1wok; AC1LCVX7; quinoxaline analogue, 3b; SCHEMBL424209; 3-(4-chloro-phenyl)-quinoxaline-5-carboxylic acid amide; CTK8F4675; BDBM27720; ZINC1489510; DB03509; 489457-67-2"	657038	C15H10ClN3O	Investigative
M6APDG00364	3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine	CHEMBL197576; BDBM8910; SCHEMBL4509209; Pyridine-substituted naphthalene 9; ZINC13674461; 3-(5-chloro-6-methoxy-2-naphthyl)pyridine	11529133	C16H12ClNO	Investigative
M6APDG03185	PG-530742	PG 116800; PG 530742; PGE 530742; PGE 7113313; PG-116800	9848869	C24H27N3O7S	Discontinued in Phase 2
M6APDG01722	N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide	CHEMBL366010; N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide	44404461	C11H13NO4	Investigative
M6APDG01792	Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL376219; cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)	44418893	C37H49N11O6	Investigative
M6APDG03597	ISIS 113020	.	.	.	Investigative
M6APDG02054	N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide	CHEMBL1098337; SCHEMBL15398027; BDBM50317988	46830345	C19H15FN2O	Investigative
M6APDG03678	ISIS 5876	.	.	.	Investigative
M6APDG01762	PLSQETFSDLWKLLPEN-NH2	CHEMBL267823	44412124	C93H142N22O28	Investigative
M6APDG01184	SCH772984	SCH-772984	24866313	C33H33N9O2	Investigative
M6APDG01789	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)	CHEMBL219075; cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)	44418890	C27H43N11O6	Investigative
M6APDG02510	USL311	"Usl-311; UNII-2BTG5MX2Q2; 2BTG5MX2Q2; SCHEMBL15347153; USL-311; 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-; 1373268-67-7"	56961879	C24H34N6O	Phase 1/2
M6APDG01255	3-Methylquinoline-8-carboxamide	"CHEMBL504998; 3-Methylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-methyl-; BDBM50255267"	25208598	C11H10N2O	Investigative
M6APDG00791	reglitazar	JTT-501	154000	C22H20N2O5	Investigative
M6APDG04237	MRG-201	.	.	.	Phase 2
M6APDG02897	LY3039478	"LY3039478; Crenigacestat; 1421438-81-4; LY-3039478; UNII-923X28214S; 4,4,4-Trifluoro-N-((S)-1-(((S)-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5H-benzo[d]pyrido[2,3-b]azepin-7-yl)amino)-1-oxopropan-2-yl)butanamide; 923X28214S; butanamide, n-[(1s)-2-[[(7s)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5h-pyrido[3,2-a][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-; Butanamide, N-((1S)-2-(((7S)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5H-pyrido(3,2-a)(3)benzazepin-7-yl)amino)-1-methyl-2-oxoethyl)-4,4,4-trifluoro-"	71236992	C22H23F3N4O4	Phase 1/2
M6APDG04338	MC-3002	"PPAR dual agonists, MaxoCore"	.	.	Preclinical
M6APDG03687	ISIS 114531	.	.	.	Investigative
M6APDG00784	(5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone	"54606-37-0; (5-Amino-1-phenyl-1H-pyrazol-4-yl)phenyl methanone; (5-AMINO-1-PHENYL-1H-PYRAZOL-4-YL)(PHENYL)METHANONE; 4-benzoyl-5-aminopyrazole 1; CHEMBL203333; (5-amino-1-phenyl-1H-pyrazol-4-yl)-phenyl-methanone; SCHEMBL13662120; BDBM15714; 5-amino-4-benzoyl-1-phenylpyrazole; ZINC12365464; 1-Phenyl-4-benzoyl-1H-pyrazol-5-amine; 4-benzoyl-1-phenyl-1H-pyrazol-5-amine; KB-208557; FT-0728731; (5-Amino-1-phenyl-1H-pyrazol-4-yl)(phenyl)methanone, AldrichCPR"	15311937	C16H13N3O	Investigative
M6APDG00955	"3-Methyl-[1,4]thiazepan-(5E)-ylideneamine"	"CHEMBL364999; 3-Methyl-[1,4]thiazepan-(5E)-ylideneamine; BDBM50155779"	18721726	C6H12N2S	Investigative
M6APDG03141	BB-3644	SCHEMBL609641	9822724	C20H32N4O5	Terminated
M6APDG02853	GHRP-2	"Pralmorelin; D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide; KP-102; UNII-E6S6E1F19M; E6S6E1F19M; KP 102; WAY-GPA-748; L-Lysinamide, D-alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-; (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide; KP-102D; Pralmorelin [INN]; GHRP-2 Acetate/; GHRP Kaken 100; AC1OCF7D; (2R)-2-methyl-4-deoxy and 2,4-dideoxy"	6918245	C45H55N9O6	Approved
M6APDG01310	3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide	"3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide; 175137-05-0; CHEMBL444884; 515142-45-7; 2-Thiophenecarboxamide,3-amino-5-(4-chlorophenyl)-; AC1MBTGN; 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxamide; SCHEMBL4097325; CTK4D5319; DTXSID90373351; MQYJPACEBWKWEH-UHFFFAOYSA-N; MolPort-000-150-990; ZX-AT016871; ZINC2556119; SBB101177; BDBM50186632; 5704AD; AKOS022181810; AJ-39853; ACM175137050; RT-019539; FT-0704094; 3-Amino-5-(4-chloro-phenyl)-thiophene-2-carboxylic acid amide"	2756390	C11H9ClN2OS	Investigative
M6APDG03152	Edaglitazone	Edaglitazone sodium; BM-131258; BM-152054; R-483; Ro-205; BM-13.258; BM-15.2054; Ro-205-2349; Ro-2052349-602	9825701	C24H20N2O4S2	Terminated
M6APDG03510	EX5	.	.	.	Investigative
M6APDG02050	AKB-9778	.	46700782	C26H26N4O6S3	Phase 2
M6APDG00887	BMS-687453	"BMS-687453; 1000998-59-3; UNII-39TL5L7XDX; BMS 687453; 39TL5L7XDX; 2-{[(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}phenyl)methyl](methoxycarbonyl)amino}acetic acid; SCHEMBL2742714; CHEMBL1089501; BDBM28800; EX-A592; BCP14808; ZINC44460341; AKOS030526188; CS-5523; DA-48472; HY-10678; FT-0749275; J-690001; 2-[[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]methyl-methoxycarbonylamino]acetic acid; 7HA; N-(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}benzyl)-N-(methoxycarbonyl)glycine"	16725047	C22H21ClN2O6	Investigative
M6APDG01100	2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide	4-anilinopyrimidine 2a; CHEMBL428213; BDBM15995	23647253	C17H15N5O	Investigative
M6APDG02099	N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1097746; BDBM50317992	46887437	C21H18N2O2	Investigative
M6APDG00539	24(S)-hydroxycholesterol	24s-OHC	121948	C27H46O2	Investigative
M6APDG02394	2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone	"37910-79-5; n-(4-nitrophenacyl)imidazole; CHEMBL162549; 2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone; Ethanone, 2-(1H-imidazol-1-yl)-1-(4-nitrophenyl)-; AC1Q5DPC; 2-imidazol-1-yl-1-(4-nitrophenyl)ethanone; AC1Q1XG1; SCHEMBL5730977; AC1L1F83; CTK1A9243; DTXSID00275594; BDBM50240895; ZINC19595447; AKOS009984680; 2-Imidazol-1-yl-1-(4-nitro-phenyl)-ethanone; I90114; alpha-(1H-Imidazole-1-yl)-4'-nitroacetophenone; 2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)-ethanone"	53600	C11H9N3O3	Investigative
M6APDG02589	LIAROZOLE	"Liarozole; Liazal; 115575-11-6; R-75251; LIAROZOLE FUMARATE; Liarozole [INN:BAN]; Liarozolum [INN-Latin]; Liarozol [INN-Spanish]; R 75251; R-61405; R085246; R 61405; R-085246; R 085246; 6-((3-chlorophenyl)(1H-imidazol-1-yl)methyl)-1H-benzo[d]imidazole; UNII-17NYD2210B; CHEMBL389433; UNII-090Y06W08H; 17NYD2210B; 090Y06W08H; Liarozolum; Liarozol; 1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-; NCGC00181034-01; Liarozole, (-)-; Liarozole, (+)-; AC1L1TNN; AC1Q3M3B; SCHEMBL18597; GTPL5210; SCHEMBL15944205; DTXSID9048277"	60652	C17H13ClN4	Phase 2/3
M6APDG03906	MEDI4276	.	.	.	Phase 1
M6APDG00329	[3H]CGP39653	(E)-2-amino-4-(phosphonomethyl)hept-3-enoic acid; 132472-31-2; [3H]CGP39653; ACMC-20muiw; GTPL4078; CTK0H6852; 2-amino-4-(phosphonomethyl)hept-3-enoic acid	114756	C8H16NO5P	Investigative
M6APDG02497	Epidermal growth factor	"62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1;  Gentel (TN); EGF"	56841751	C257H381N73O83S7	Approved
M6APDG03852	RG7775	.	.	.	Phase 1
M6APDG02104	1-(2-phenoxybenzyl)-1H-imidazole	CHEMBL1082760; 1-(2-phenoxybenzyl)-1H-imidazole; SCHEMBL11704850	46889432	C16H14N2O	Investigative
M6APDG02123	S-(Dimethylarsenic)Cysteine	[[(S)-2-Amino-2-carboxyethyl]thio]dimethylarsenic	46936846	C5H12AsNO2S	Investigative
M6APDG00560	S-tubercidinylhomocysteine	"S-tubercidinylhomocysteine; CHEMBL552309; 57344-98-6; AC1L3YAS; AC1Q5QMO; (S)-7-(5-S-(3-amino-3-carboxypropyl)-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; (2s)-2-amino-4-({[(2s,3s,4r,5r)-5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid(non-preferred name); BDBM50294482; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid"	124349	C15H21N5O5S	Investigative
M6APDG00467	Clascoterone	CB-03-01	11750009	C24H34O5	Approved
M6APDG00111	"3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline"	"CHEMBL66100; 3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline; BDBM50039089"	10336427	C19H19NO4	Investigative
M6APDG02794	PF-543	sphingosine kinase 1 Inhibitor II; PF 543	66577038	C27H31NO4S	Investigative
M6APDG03769	ISIS 32005	.	.	.	Investigative
M6APDG01232	NKP-1339	197723-00-5; KP-1339; EX-A1916; BCP26252; Z-3126; 1H-indazole; tetrachlororuthenium(1-) sodium salt	25134754	C14H12Cl4N4NaRu	Phase 1
M6APDG03572	ISIS 122985	.	.	.	Investigative
M6APDG01190	"5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole"	"CHEMBL513405; 5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole"	24884692	C16H12ClNSe	Investigative
M6APDG03657	MT-062	"EGFR inhibitor (melanoma), Medisyn Technologies"	.	.	Investigative
M6APDG00823	GSK461364	GSK461364; 929095-18-1; GSK-461364; 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide; GSK 461364; UNII-8QO27TK6Q4; GSK-461364A; (R)-5-(6-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide; 8QO27TK6Q4; CHEMBL1908394; GSK461364A; ZHJGWYRLJUCMRT-QGZVFWFLSA-N; SCHEMBL310080; GTPL5684; C27H28F3N5O2S; CTK8B7590; CHEBI:91333; DTXSID60239197; MolPort-016-633-304; BCP01720; GSK 461364A	15983966	C27H28F3N5O2S	Phase 1
M6APDG03199	SC-54701A	"UNII-TN585Y92BI; SC-54701A; SC-54701; CHEMBL311572; TN585Y92BI; Xemilofiban acid; Xemilofiban acid [MI]; SCHEMBL7080314; BDBM50031565; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, (3S)-; 149193-61-3; (S)-3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid ethyl ester; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid (SC-54701A)"	9862322	C16H18N4O4	Investigative
M6APDG04193	PF-06823859	.	.	.	Phase 2
M6APDG01873	2-methoxy-4-(propylthio)benzonitrile	CHEMBL443970; 2-methoxy-4-(propylthio)benzonitrile	44564581	C11H13NOS	Investigative
M6APDG04102	Anti-HER2 CAR-T	.	.	.	Phase 1/2
M6APDG03283	L-783483	F3MethylAA	9935197	C22H21ClF3NO4S	Investigative
M6APDG02614	4-benzylphthalazin-1(2H)-one	"4-Benzyl-1(2H)-phthalazinone; 4-benzylphthalazin-1(2H)-one; 32003-14-8; 4-Benzyl-2H-phthalazin-1-one; 4-benzyl-1,2-dihydrophthalazin-1-one; CHEMBL66761; JUCCMEHWBGPJKS-UHFFFAOYSA-N; benzylphthalazinone; phthalazinone, 1; 4-benzyl-phthalazone; AC1LDDNC; SMR000135223; AC1Q6GZZ; ChemDiv2_000142; Cambridge id 5241846; Oprea1_151142; Oprea1_623913; CBDivE_015258; MLS000530246; SCHEMBL863462; CTK4G8063; BDBM27660; DTXSID30346948; MolPort-001-796-654; HMS2379K10; HMS1369G10; 4-benzyl-2-hydrophthalazin-1-one; 4-Benzyl-1(2H)-phthalazinone #"	616651	C15H12N2O	Investigative
M6APDG03449	BL-6020	"SNT-207707; SNT-207858; SNT-209858; MC4-R antagonists (anorexia), Santhera; MC4-R antagonists (cachexia), Santhera; Melanocortin 4 receptor antagonists (cachexia/anorexia), Santhera; MC4-R antagonists (cachexia/anorexia), Santhera; MC4-R antagonists (cachexia/anorexia), Santhera/ BioLineRx"	.	.	Investigative
M6APDG03301	nTzDpa	"nTzDpa; 118414-59-8; 5-Chloro-1-(4-Chlorobenzyl)-3-(Phenylthio)-1h-Indole-2-Carboxylic Acid; 5-CHLORO-1-[(4-CHLOROPHENYL)METHYL]-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID; CHEMBL370152; 1H-Indole-2-carboxylicacid, 5-chloro-1-[(4-chlorophenyl)methyl]-3-(phenylthio)-; NZA; ACMC-1CBOZ; SCHEMBL6709652; GTPL2699; CTK0H3131; DTXSID40433292; MolPort-003-983-790; HMS3268N03; ZINC1492396; BDBM50173365; BS0133; AKOS024456957; NCGC00092313-01; RT-014770; KB-245430; B6955; J-003750; BRD-K54708045-001-01-3"	9954280	C22H15Cl2NO2S	Investigative
M6APDG01070	KW-2478	"KW-2478; 819812-04-9; KW-2478 free base; 2-(2-ethyl-3,5-dihydroxy-6-(3-methoxy-4-(2-morpholinoethoxy)benzoyl)phenyl)-N,N-bis(2-methoxyethyl)acetamide; UNII-QY50S617NM; KW 2478; KW2478; QY50S617NM; 2-ethyl-3,5-dihydroxy-n,n-bis(2-methoxyethyl)-6-(3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl)benzeneacetamide; 2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide"	23116322	C30H42N2O9	Phase 2
M6APDG03975	BI 860585	.	.	.	Phase 1
M6APDG02723	3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 11b; AC1O704R; SCHEMBL4226034; CHEMBL176101; BDBM8594; 3-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539770	C16H15NO	Investigative
M6APDG02135	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	PhiKan 083; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine	4722579	C16H18N2	Investigative
M6APDG00220	6-Imidazol-1-yl-isoquinoline	6-(1H-imidazol-1-yl)isoquinoline	10845522	C12H9N3	Investigative
M6APDG03335	Rivoglitazone	"CS-011; DE-101; Rivoglitazone (ophthalmic); Rivoglitazone (ophthalmic), Santen; CS-011 (ophthalmic), Santen"	3055168	C20H19N3O4S	Phase 3
M6APDG03415	CDP-860	"MAb, PDGFr, Celltech"	.	.	Discontinued in Phase 2
M6APDG02172	"2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide"	"2-phenylpyrazolo[1,5-a]pyridine-7-carboxamide; 1196713-16-2; ZINC64337832; DA-47424"	49799912	C14H17N3O	Investigative
M6APDG03525	ART-144	"Anti-inflammatory agent (intra-articular/injectable, sustained release, osteoarthritis), Artyx pharmaceuticals"	.	.	Investigative
M6APDG00777	2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	2-(2-hydroxy-phenyl)-1h-indole-5-carboxamidine; amino[2-(2-hydroxyphenyl)-1H-indol-5-yl]methaniminium; AC1L1BMI; BDBM13942; CTK8A0256; APC-8328; DB02463; [amino-[2-(2-hydroxyphenyl)-1H-indol-5-yl]methylidene]azanium	1507	C15H14N3O+	Investigative
M6APDG02881	(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	"(4-methylphenyl)(3-nitro-1H-pyrazol-1-yl)methanone; AC1LF99H; N-Benzoylpyrazole deriv., 18; CHEMBL244939; ZINC78678; BDBM23710; A2012/0084499; MolPort-002-705-255; STK760276; AKOS001746005; 4-methylphenyl 3-nitropyrazolyl ketone; MCULE-9242110239; ST073763; (4-methylphenyl)-(3-nitropyrazol-1-yl)methanone; SR-01000524341; 1-[(4-methylphenyl)carbonyl]-3-nitro-1H-pyrazole"	699665	C11H9N3O3	Investigative
M6APDG04137	Ifabotuzumab	.	.	.	Phase 2
M6APDG02290	SC-74020	sc-74020; CHEMBL1233506; N-{4-[(1-HYDROXYCARBAMOYL-2-METHYL-PROPYL)-(2-MORPHOLIN-4-YL-ETHYL)-SULFAMOYL]-4-PENTYL-BENZAMIDE; I52; SC 74020; AC1NRBR8; BDBM50026872; DB01630; SC74020; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl](2-morpholin-4-ylethyl)sulfamoyl}phenyl)-4-pentylbenzamide; N-(4-{[(1R)-1-(hydroxycarbamoyl)-2-methylpropyl][2-(morpholin-4-yl)ethyl]sulfamoyl}phenyl)-4-pentylbenzamide	5288596	C29H42N4O6S	Investigative
M6APDG04168	MBX-2044	"MBX-102 analogs, Metabolex"	.	.	Phase 2
M6APDG03418	Testosterone glucoside	S-403-G	.	.	Discontinued in Phase 2
M6APDG00858	T134	T134; GTPL852	16197445	C94H152N38O19S2	Investigative
M6APDG01916	LEE011	"Ribociclib; LEE011; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013"	44631912	C23H30N8O	Phase 3
M6APDG03682	PRX-111	"FSH variants (female infertility), Protalix Biotherapeutics/ Compugen; Follicle stimulating hormone variants (female infertility), Protalix Biotherapeutics/ Compugen"	.	.	Investigative
M6APDG03291	NS-220	"R-1593; Cis-2-Methyl-5-[4-[5-methyl-2-(4-methylphenyl)oxazol-4-yl]butyl]-1,3-dioxane-2-carboxylic acid"	9947731	C21H27NO5	Discontinued in Phase 2
M6APDG02213	SB 239063	SB 239063; 193551-21-2; SB239063; SB-239063; UNII-HII3DC8CPI; HII3DC8CPI; CHEMBL97162; trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)imidazole; CHEBI:90681; TRANS-1-(4-HYDROXYCYCLOHEXYL)-4-(4-FLUOROPHENYL)-5-(2-METHOXYPYRIMIDIN-4-YL) IMIDAZOLE; trans-4-[4-(4-Fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol; 4-[4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazol-1-yl]cyclohexan-1-ol	5166	C20H21FN4O2	Investigative
M6APDG00289	Ryanodine	"ryanodine; Ryanodin; 15662-33-6; Ryania; Ryanodol, 3-(1H-pyrrole-2-carboxylate); Ryanadol; (3S,4R,4aR,6S,6aR,7S,8R,8aS,8bR,9S,9aS)-4,6,7,8a,8b,9a-hexahydroxy-7-isopropyl-3,6a,9-trimethyldodecahydro-6,9-methanobenzo[1,2]pentaleno[1,6-bc]furan-8-yl 1H-pyrrole-2-carboxylate; (3S,4R,4aR,6S,6aR,7S,8R,8aS,8bR,9S,9aS)-4,6,7,8a,8b,9a-hexahydroxy-3,6a,9-trimethyl-7-(propan-2-yl)dodecahydro-6,9-methanobenzo[1,2]pentaleno[1,6-bc]furan-8-yl 1H-pyrrole-2-carboxylate; 3-(1H-pyrrole-2-carboxylate; Ryanodine High Purity"	11317883	C25H35NO9	Investigative
M6APDG00788	L-738167	"L-738167; CHEMBL298655; L 738167; 163212-43-9; AC1L4BHI; SCHEMBL609722; DTXSID30167534; YLFFZEQHDMFOEC-NRFANRHFSA-N; BDBM50058239; L-Alanine, N-((4-methylphenyl)sulfonyl)-3-(((5,6,7,8-tetrahydro-4-oxo-5-(2-(4-piperidinyl)ethyl)-4H-pyrazolo(1,5-a)(1,4)diazepin-2-yl)carbonyl)amino)-; 3-{[4-Oxo-5-(2-piperidin-4-yl-ethyl)-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carbonyl]-amino}-2-(toluene-4-sulfonylamino)-propionic acid (L-738167)"	153986	C25H34N6O6S	Terminated
M6APDG01370	Diflunisal	"Adomal; Algobid; Citidol; Difludol; Diflunisalum; Dolisal; Dolobid; Dolobil; Dolobis; Dolocid; Flovacil; Fluniget; Fluodonil; Flustar; Noaldol; Reuflos; Unisal; Apotex Brand of Diflunisal; Cahill May Roberts Brand of Diflunisal; Diflunisal Novopharm Brand; Frosst SA Brand of Diflunisal; Merck Brand of Diflunisal; Novopharm Brand of Diflunisal; Nu Pharm Brand of Diflunisal; MK 647; MK647; Apo-Diflunisal; Diflunisalum [INN-Latin]; Dolobid (TN); MK-647; Merck Sharp & Dohme Brand of Diflunisal; Novo-Diflunisal; Nu-Diflunisal; Nu-Pharm Brand of Diflunisal; Diflunisal (JAN/USP/INN); Diflunisal [USAN:INN:BAN:JAN]; 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid; 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid; 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid; 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid; 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID; 5-(2,4-Difluorophenyl)salicylic acid; 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid; 5-[2,4-Difluorophenyl]salicylic acid"	3059	C13H8F2O3	Approved
M6APDG00139	"3-Cyclohexylethynyl-6,7-dimethoxy-quinoline"	"CHEMBL63575; 3-Cyclohexylethynyl-6,7-dimethoxy-quinoline; SCHEMBL8172563; MBQNQJQVMOFJOD-UHFFFAOYSA-N; ZINC8552727; BDBM50039040"	10402251	C19H21NO2	Investigative
M6APDG04294	AP12009	.	.	.	Phase 3
M6APDG00420	MERIOLIN 1	"MERIOLIN 1; 341998-55-8; 4-(1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIMIDIN-2-AMINE; 2-Pyrimidinamine, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-; SCHEMBL2241315; CHEMBL405665; HQHSJJZIICGOIX-UHFFFAOYSA-; CTK1B7876; DTXSID60469811; BDBM50371404; ZINC29135178; AKOS027252841; 4-(7-aza-indol-3-yl)-2-amino pyrimidine; 3-(2-Amino-4-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridine"	11637090	C11H9N5	Investigative
M6APDG01163	LGD-5552	LGD-5552; CHEMBL259820; SCHEMBL4166143	24816375	C28H26FNO3	Investigative
M6APDG03929	VAN-10-4-eluting stent	"INC-105-eluting stent, Inncardio/University of Strathclyde; VAN-10-4-eluting stent, University of Strathclyde; Marigold compound (drug-eluting stent, restenosis), Inncardio/University of Strathclyde"	.	.	Phase 1
M6APDG00708	"3,4'-(Ethane-1,2-diyl)dibenzenamine"	"CHEMBL1172396; 3,4'-Ethylenedianiline; BDBM50322062"	13580711	C14H16N2	Investigative
M6APDG04051	ART621	.	.	.	Phase 1/2
M6APDG04104	ABY-025	.	.	.	Phase 1/2
M6APDG03848	DS-3032	.	.	.	Phase 1
M6APDG00023	Microxine	microxine; CHEMBL478797; SCHEMBL18686351; BDBM50269842	10061827	C8H11N5O4S	Investigative
M6APDG03221	RWJ-63556	.	9882374	C11H10FNO3S2	Terminated
M6APDG00460	"6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline"	"CHEMBL69585; 6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline; ZINC3834037"	11722903	C17H14N2O4	Investigative
M6APDG03859	Cipatinib	"HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui"	.	.	Phase 1
M6APDG00964	2-(2-butoxypyrimidin-4-ylamino)benzoic acid	2-[(2-butoxypyrimidin-4-yl)amino]benzoic Acid; 4-anilinopyrimidine 1; AC1LZD2G; CHEMBL242488; BDBM15977; MolPort-002-549-430; ZINC2272106; STL297947; AKOS003630983; MCULE-6330252818	1897784	C15H17N3O3	Investigative
M6APDG03241	WX-UK1	"UKI-1; UNII-00LOF6890B; CHEMBL107955; WX-UK1; 00LOF6890B; 220355-63-5; Wx-uk1 free base; compound 2r-L; GTPL6498; BDBM23891; 3-amidinophenylalanine deriv., 35; ZINC4426028; AKOS030526723; CS-5726; HY-100415; 1-Piperazinecarboxylic acid, 4-((2S)-3-(3-(aminoiminomethyl)phenyl)-1-oxo-2-(((2,4,6-tris(1-methylethyl)phenyl)sulfonyl)amino)propyl)-, ethyl ester; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-{[2,4,6"	9895194	C32H47N5O5S	Discontinued in Phase 1/2
M6APDG02098	MR-16089	MR-16089; CHEMBL1095413; BDBM50318402	46887422	C20H13F3N2O2	Investigative
M6APDG01822	N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	CHEMBL402990; N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	44446277	C13H13NO5	Investigative
M6APDG03722	ABC-4	"FGFR4 targeted antibody (solid tumors), XOMA; Fibroblast growth factor receptor 4 targeted antibody (solid tumors), Xoma"	.	.	Investigative
M6APDG04011	LY3300054	.	.	.	Phase 1
M6APDG02195	(E)-2-(4-(methylsulfonyl)styryl)thiophene	CHEMBL1288781; (E)-2-(4-(methylsulfonyl)styryl)thiophene	50908698	C13H12O2S2	Investigative
M6APDG02765	"3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine"	"3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 8; AC1O70HF; SCHEMBL4505804; BDBM8894"	6540052	C16H15N	Investigative
M6APDG02017	ABT-348	"ILORASERTIB; ABT-348; 1227939-82-3; UNII-6L5D03D975; ABT 348; ABT348; 6L5D03D975; A-968660; Abbott-969660; Ilorasertib [USAN:INN]; Ilorasertib (USAN); Kinome_405; GTPL9914; A-968660.0; SCHEMBL3381224; CHEMBL1980297; DTXSID10153718; WPHKIQPVPYJNAX-UHFFFAOYSA-N; BCP07256; ZINC63298074; BDBM50381716; SB16853; CS-6804; DB11694; KB-74395; HY-16018; US8722890, 1; Z-3287; US8722890, 2; D10423; N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea"	46207586	C25H21FN6O2S	Phase 2
M6APDG00843	TAK-901	"TAK-901; 934541-31-8; TAK901; TAK 901; UNII-DM9UIR23R7; 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; DM9UIR23R7; 5-[3-(Ethylsulfonyl)phenyl]-3,8-dimethyl-N-(1-methyl-4-piperidinyl)-9H-pyrido[2,3-b]indole-7-carboxamide; C28H32N4O3S; 5-[3-(ethanesulfonyl)phenyl]-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; 5-(3-ethylsulfonylphenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; cc-11; MLS006010174"	16124208	C28H32N4O3S	Phase 1
M6APDG01752	"3-isopropyl-4-(phenylthio)naphthalene-1,2-dione"	"CHEMBL205381; 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione"	44409669	C19H16O2S	Investigative
M6APDG01385	DUP 697	"Dup 697; dup-697; 88149-94-4; MRWLZPOFPA; UNII-MRWLZPOFPA; CHEMBL42485; CHEBI:4720; 5-Bromo-2-(4-fluorophenyl)-3-(4-methysulfonylphenyl)thiophene; 5-bromo-2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)thiophene; CPD000466299; Thiophene, 5-bromo-2-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-; Thiophene, 5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]- [CAS]; 5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]thiophene; 5-Bromo-2-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)thiophene; SMR000466299"	3177	C17H12BrFO2S2	Discontinued in Phase 1
M6APDG01265	3-(4-aminophenyl)quinoxaline-5-carboxamide	"CHEMBL443077; quinoxaline analogue, 3f; 3-(4-aminophenyl)quinoxaline-5-carboxamide; SCHEMBL7112515"	25218519	C15H12N4O	Investigative
M6APDG02080	AdoC(Aun)Arg6	CHEMBL611121	46877396	C57H104N30O12	Investigative
M6APDG01886	2-methoxy-4-(2-methoxyphenylthio)benzonitrile	CHEMBL510145; 2-methoxy-4-(2-methoxyphenylthio)benzonitrile	44565206	C15H13NO2S	Investigative
M6APDG03248	6-N-propyl -4-trifluoromethylquinolin-2(1H)-one	"SCHEMBL1771502; CHEMBL405835; BDBM18527; ZINC14968235; 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-one, 4a; 4-(Trifluoromethyl)-6-(propylamino)quinoline-2(1H)-one"	9903530	C13H13F3N2O	Investigative
M6APDG01548	6-(3-Fluoropropyl)-4-methylpyridin-2-amine	6-(3-Fluoropropyl)-4-methylpyridin-2-amine; CHEMBL443862; 1146620-54-3; SCHEMBL13040676	42625617	C9H13FN2	Investigative
M6APDG03242	"2-phenyl-2,3-dihydrobenzo[h]chromen-4-one"	"ALPHA-NAPHTHOFLAVANONE; 2-phenyl-2H-benzo[h]chromen-4(3H)-one; CHEMBL404225; 6051-86-1; 2-phenyl-2,3-dihydrobenzo[h]chromen-4-one; SCHEMBL14027636; BDBM50345186; FT-0758804; 2-Phenyl-2H-naphtho[1,2-b]pyran-4(3H)-one"	9898204	C19H14O2	Investigative
M6APDG01195	MGCD265	"MGCD-265; 875337-44-3; MGCD265; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide"	24901704	C26H20FN5O2S2	Phase 2
M6APDG00194	"8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione"	"1H-1-Benzazepine-2,5-dione, 8-ethyl-3-hydroxy-; SCHEMBL9389409; CHEMBL143292; 183663-81-2"	10680274	C12H11NO3	Investigative
M6APDG00488	3-(naphthalen-2-yl)pyridine	3-(2-naphthyl)pyridine; CHEMBL365735; 3-(naphthalen-2-yl)pyridine; 2-(3-pyridyl)-naphthalene; SCHEMBL4510935; BDBM8904; Pyridine-substituted naphthalene 1	11845485	C15H11N	Investigative
M6APDG00497	3-(imidazolylmethyl)-4'-nitroflavone	CHEMBL213588; BDBM50191598; 3-(imidazolylmethyl)-4''-nitroflavone	11847317	C19H13N3O4	Investigative
M6APDG00482	FGF401	"Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341"	118036971	C25H30N8O4	Phase 1/2
M6APDG03168	3-Benzenesulfonyl-heptanoic acid hydroxyamide	CHEMBL263501; 3-Benzenesulfonyl-heptanoic acid hydroxyamide; BDBM50089196	9838786	C13H19NO4S	Investigative
M6APDG00731	Englitazone sodium	"Englitazone sodium < Rec INNM; CP-68722 (racemate); CP-72467-02; CP-72467-2; (-)-5-[2(R)-Benzyl-3,4-dihydro-2H-benzopyran-6-ylmethyl]thiazolidine-2,4-dione sodium salt"	13728795	C20H18NNaO3S	Phase 1
M6APDG01732	C[Ser-Tyr-Thr-His-Dphe-Arg-Trp-Thr-Ile-Pro]	CHEMBL438596; c[Ser-Tyr-Thr-His-Dphe-Arg-Trp-Thr-Ile-Pro]	44406905	C63H84N16O14	Investigative
M6APDG03179	ML-3163	ML 3163; CHEMBL111456; 4-[5-(4-Fluorophenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-3H-imidazol-4-yl]pyridine; SCHEMBL4106398; BDBM50114690; IN1229; 4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-1H-imidazol-4-yl]-pyridine; 4-(2-(4-(methylsulfinyl)benzylthio)-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridine	9845197	C22H18FN3OS2	Investigative
M6APDG01761	C(Arg-Gly-Asp-D-Phe-Val)	CHEMBL383412	44411994	C26H38N8O7	Investigative
M6APDG00938	N-(Chlorophenyl)-N'-Hydroxyguanidine	"130974-86-6; N-(CHLOROPHENYL)-N'-HYDROXYGUANIDINE; Guanidine, N-(4-chlorophenyl)-N'-hydroxy-; N-(4-chloro)phenyl-N'-hydroxyguanidine; Guanidine,N-(4-chlorophenyl)-N'-hydroxy-; C7H8ClN3O; ACMC-1CA1V; SCHEMBL2213727; CHEMBL323202; AC1L490B; CTK4B7016; DTXSID90156823; AKOS017474904; AKOS011771250; AKOS030602610; 1-(4-Chlorophenyl)-3-hydroxyguanidine; DB04559; 2-(4-chlorophenyl)-1-hydroxyguanidine"	181426	C7H8ClN3O	Investigative
M6APDG01818	C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2	CHEMBL411391; c[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2	44445084	C42H59N11O7	Investigative
M6APDG00402	4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile	CHEMBL499137; 4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile; SCHEMBL4163678; BDBM50248552	11608821	C15H10F3NO	Investigative
M6APDG01376	CPL-7075	"Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751;  Mixed CB agonist/sodim channel blocker (pain), Cervelo"	3083542	C25H36O4	Phase 3
M6APDG00706	BI-847325	.	135567102	C29H28N4O2	Phase 1
M6APDG01469	4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine	"4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine; 4-(2-methoxy-ethoxy)-6-methyl-pyrimidin-2-ylamine; 75435-54-0; 2wi1; AC1MWPG2; pyrimidin-2-amine, 11; CHEMBL538937; SCHEMBL10752783; BDBM33223; CCG-774; VCJHOFUOIQHNBC-UHFFFAOYSA-N; AKOS017529730; DB08786; 2-amino-4-(2-methoxyethoxy)-6-methylpyrimidine; 4-Methyl-6-(2-methoxyethoxy)pyrimidine-2-amine; 4-(2-methoxy-ethoxy)-6-methyl-pyrimidine-2-ylamine"	3777900	C8H13N3O2	Investigative
M6APDG00872	SKF-107260	"F 107260; CHEMBL18734; [(7s,13s)-13-{3-[(diaminomethylidene)amino]propyl}-14-methyl-6,9,12,15-tetraoxo-6,7,8,9,10,11,12,13,14,15-decahydro-5h-dibenzo[c,p][1,2,5,8,11,14]dithiatetraazacycloheptadecin-7-yl]acetic acid; 136620-00-3; Skf 107260; F-107260; AC1L4UPG; AC1Q6GV5; Cyclo-S,S-(mba-(N(alpha)-Me)arg-gly-asp-man); CTK4C0386; DTXSID70159857; BDBM50036088; BDBM50230131; Cyclo-S,S-(2-mercaptobenzoyl-N(alpha)-methylarginyl-glycyl-aspartyl-2-mercaptophenylamide)"	164393	C26H31N7O6S2	Terminated
M6APDG02105	AC430	152-97-6; SCHEMBL11862489; ZINC21981448; AKOS025402073	46892373	C19H16FN5O	Phase 1
M6APDG00346	C[RGDf-(R)-alpha-TfmV]	CHEMBL203077; c[RGDf-(R)-alpha-TfmV]	11505585	C27H37F3N8O7	Investigative
M6APDG00164	L-696418	CHEMBL8494; L-696418; BDBM50057083; (R)-2-[(S)-1-(3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid; (R)-2-((S)-1-((S)-4-methyl-1-oxo-1-(phenylamino)pentan-2-ylamino)-1-oxo-4-phenylbutan-2-ylamino)propanoic acid; (R)-2-[(S)-1-((S)-3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid	10478364	C25H33N3O4	Terminated
M6APDG00994	Lapatinib	"FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)"	208908	C29H26ClFN4O4S	Approved
M6APDG03014	D-aspartic acid	"D-Aspartic acid; 1783-96-6; (R)-2-aminosuccinic acid; D-Aspartate; H-D-Asp-OH; (-)-Aspartic acid; (R)-Aspartic acid; Aspartic acid D-form; (2R)-2-aminobutanedioic acid; Aspartic acid, D-; D-(-)-Aspartic acid; (R)-(-)-Aminosuccinic acid; D-Asp; D-Aminosuccinic acid; NSC 97922; D-Asparaginsaeure; UNII-4SR0Q8YD1X; BRN 1723529; Tocris-0213; EINECS 217-234-6; 4SR0Q8YD1X; (R)-2-aminobutanedioic acid; CHEMBL29757; CHEBI:17364; CKLJMWTZIZZHCS-UWTATZPHSA-N; MFCD00063081; NCGC00024498-02; (R)-2-Aminobutanedioate; D(-)-Aspartic acid, 99+%;  D-aspartate; [3H]D-aspartic acid"	83887	C4H7NO4	Investigative
M6APDG03698	X-387	"MTOR inhibitors (cancer), Shanghai Institute of Materia Medica"	.	.	Investigative
M6APDG03209	Ki-20227	Ki 20227; Ki20227	9869779	C24H24N4O5S	Investigative
M6APDG02692	Dihydro-quinolinone	"553-03-7; 3,4-Dihydro-2(1H)-quinolinone; 3,4-Dihydroquinolin-2(1H)-one; Hydrocarbostyril; 1,2,3,4-tetrahydroquinolin-2-one; 3,4-Dihydrocarbostyril; 3,4-dihydro-1H-quinolin-2-one; 2-Oxo-1,2,3,4-tetrahydroquinoline; Dihydro-quinolinone; 3,4-Dihydro-2-quinolinol; o-Aminohydrocinnamic acid lactam; UNII-2CKG6TX32F; 3,4-Dihydro-2(1H)quinolinone; 2(1H)-Quinolinone, 3,4-dihydro-; NSC 49170; 2CKG6TX32F; CHEMBL388582; TZOYXRMEFDYWDQ-UHFFFAOYSA-N; 3,4-DIHYDRO-2-QUINOLONE; MFCD00016722; 3,4-Dihydro-2(1H)-quinolinone, 98%"	64796	C9H9NO	Investigative
M6APDG04263	Iomab-B	Iomab-B (TN)	.	.	Phase 3
M6APDG02720	3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 9a; SCHEMBL4231367; BDBM8590; SCHEMBL4231363; AC1O704L; CHEMBL194440; 3-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539767	C15H12BrN	Investigative
M6APDG01422	NSC-368272	"NSC-368272; CHEMBL459503; 5242-64-8; NSC368272; AC1L7R16; DTXSID10321036; 6-(benzo[d][1,3]dioxol-5-ol; BDBM50254016; 6-[1,3-benzodioxol-5-yl(imidazol-1-yl)methyl]-1,3-benzodioxol-5-ol"	339906	C18H14N2O5	Investigative
M6APDG03546	INO-1002	"PARP inhibitors, Inotek; PARP inhibitor (erectile dysfunction), Inotek; PARP inhibitor (prostate nerve damage), Inotek; Poly (ADP ribose) polymerase inhibitor (erectile dysfunction), Inotek; Poly (ADP ribose) polymerase inhibitor (prostate nerve damage), Inotek"	.	.	Investigative
M6APDG00948	6-(Dihydroxy-Isobutyl)-Thymine	"6-(DIHYDROXY-ISOBUTYL)-THYMINE; DHBT; 6-(1,3-dihydroxyisobutyl)thymine; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methylpyrimidine-2,4(1H,3H)-dione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-2,4(1h,3h)-pyrimidinedione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]thymine; CCV; AC1L1CE0; CTK8A1595; CHEBI:41485; DB02500; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-1H-pyrimidine-2,4-dione"	1855	C9H14N2O4	Investigative
M6APDG04346	TK-DLI	"TBI-0301; Herpes simplex thymidine kinase suicide gene therapy, MolMed/Takara Bio; HSV thymidine kinase gene therapy (GvH, retroviral vector), Istituto Scientifico H San Raffaele; HSV-TK suicide gene therapy, MolMed/Takara Bio; TK cell therapy (haploidentical haematopoietic stem cell transplantation), MolMed/Takara Bio; HSV-TK gene therapy (haematological malignancies), MolMed/Takara Bio; TK-DLI, San Raffaele/MolMed/Takara Bio; TK gene/cell therapy (bone marrow transplantation-associated GvHD prevention), MolMed/Takara Bio; TK-expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed; Thymidine kinase expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed/Takara"	.	.	Preregistration
M6APDG03108	Azepan-(2Z)-ylideneamine	"Azepan-(2Z)-ylideneamine; 3,4,5,6-tetrahydro-2H-azepin-7-amine; CHEMBL315857; 2214-67-7; iminohomopiperidine; 2-Iminohexahydro-1H-azepine; SCHEMBL1575752; MolPort-007-996-393; GTLJSJNKRLFVSJ-UHFFFAOYSA-N; STL163828; ZINC13746433; BBL012958; BDBM50049257; AKOS002684184; AKOS006375172; MCULE-7781415779"	9793728	C6H12N2	Investigative
M6APDG01584	ERIODICTYOL	"(+/-)-Eriodictyol; 4049-38-1; MLS000877024; 5,7,3',4'-Tetrahydroxyflavanone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-4-one; SMR000440624; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one; Eriodictyol, (+/-)-; Eriodicytol; ERIODYCTOL; Flavanone, 3',4',5,7-tetrahydroxy-; AC1L1WLT"	440735	C15H12O6	Investigative
M6APDG02106	AZD-3514	.	46893585	C25H32F3N7O2	Phase 1
M6APDG02644	NSC-75308	"NSC-75308; NSC75308; AC1O4U40; 5,6-dichloro-N-[(E)-[(4-methoxyphenyl)-phenylmethylidene]amino]pyridazin-4-amine"	6415854	C18H14Cl2N4O	Investigative
M6APDG02744	4-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine	"CHEMBL175609; BDBM8623; (4-Pyridylmethylene)indane 12b; AC1O7069; 4-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539797	C16H15NO	Investigative
M6APDG00021	"5,7-Dimethyl-3-thiophen-3-yl-quinoline"	"CHEMBL304333; 5,7-dimethyl-3-thiophen-3-yl-quinoline; SCHEMBL8501282; ZINC3832218"	10060170	C15H13NS	Investigative
M6APDG04307	INOC-005	"Capridine beta (prostate cancer), Prostagenics"	.	.	Preclinical
M6APDG02748	4-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	"(4-Pyridylmethylene)indane 22b; AC1O706N; CHEMBL192077; BDBM8630; 4-[(Z)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539804	C16H15N	Investigative
M6APDG02217	Octanedioic acid bis-hydroxyamide	Suberohydroxamic acid	5173	C8H16N2O4	Investigative
M6APDG03226	BMS753	BMS-753; BMS 753	9884820	C21H21NO4	Investigative
M6APDG04361	SAN-61	"SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune"	.	.	Terminated
M6APDG02253	ISORHAMNETIN	"Isorhamnetin; 480-19-3; 3-Methylquercetin; Isorhamnetol; 3'-Methoxyquercetin; 3'-Methoxy-3,4',5,7-tetrahydroxyflavone; isorhamnetine; 3'-Methylquercetin; C.I. 75680; 3-Methylquercetine; UNII-07X3IB4R4Z; CCRIS 3791; C16H12O7; EINECS 207-545-5; Flavone, 3'-methoxy-3,4',5,7-tetrahydroxy-; BRN 0044723; 3,5,7,4'-Tetrahydroxy-3'-methoxyflavone; CHEMBL379064; CHEBI:6052; 07X3IB4R4Z"	5281654	C16H12O7	Investigative
M6APDG01966	Nitroglycerin	"nitroglycerin; Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong;  Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Nitro-dur (TN); Transderm-nitro (TN); DWP-401"	4510	C3H5N3O9	Approved
M6APDG03718	ISIS 113176	.	.	.	Investigative
M6APDG00503	EFT508	"Tomivosertib; eFT508; 1849590-01-7; EFT-508; UNII-U2H19X4WBV; U2H19X4WBV; Tomivosertib [INN]; Tomivosertib [USAN]; SCHEMBL17362622; GTPL10167; eFT-508 (eFT508); EFT 508; MolPort-044-560-418; BCP18993; EX-A2494; ZINC575623807; AKOS030627405; CS-5841; compound 23 [PMID: 29526098]; HY-100022; S8275; 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'(2'H)-dione; 6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione"	118598754	C17H20N6O2	Phase 2
M6APDG01857	N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide	CHEMBL575856; N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide; BDBM50298668	44537911	C23H19NO3	Investigative
M6APDG01591	Nafamostat	FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum	4413	C19H17N5O2	Approved
M6APDG01402	Fenofibrate	"Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate"	3339	C20H21ClO4	Approved
M6APDG03182	A-286982	"A-286982; 280749-17-9; UNII-5I8WFS075A; A 286982; CHEMBL19677; 5I8WFS075A; C24H27N3O4S; (2E)-1-(4-Acetyl-1-piperazinyl)-3-[4-[[2-(1-methylethyl)phenyl]thio]-3-nitrophenyl]-2-propen-1-one; SCHEMBL5829786; GTPL6592; SCHEMBL12063498; AOB1772; SYN5060; MolPort-023-277-110; ZINC602716; BDBM50092956; AKOS024458044; API0010263; Piperazine, 1-acetyl-4-((2E)-3-(4-((2-(1-methylethyl)phenyl)thio)-3-nitrophenyl)-1-oxo-2-propenyl)-; (E)-1-(4-acetylpiperazin-1-yl)-3-[3-nitro-4-(2-propan-2-ylphenyl)sulfanylphenyl]prop-2-en-1-one; AS-16426"	9846729	C24H27N3O4S	Investigative
M6APDG02096	N-(4-amino-3'-methylbiphenyl-3-yl)benzamide	CHEMBL1094108; BDBM50317995	46887381	C20H18N2O	Investigative
M6APDG00991	5-aminoisoquinolin-1(2H)-one	"5-aminoisoquinolin-1(2H)-one; 93117-08-9; 5-amino-2H-isoquinolin-1-one; 5-AMINOISOQUINOLIN-1-OL; 5-amino-1,2-dihydroisoquinolin-1-one; 5-AIQ; CHEMBL446240; 5-Amino-2H-isoquinoin-1-one; 5-AMINO-1(2H)-ISOQUINOLINONE; 5-aminoisoquinolinone; 4pnq; 32X; AC1Q6DVG; AC1L1CUR; 5-Amino-1-isoquinolinol; SCHEMBL215327; 5-Amino-1-hydroxyisoquinoline; BDBM27503; 5-amino-isoquinolin-1(2h)-one; 5-amino isoquinolin-1(2h)-one; CTK5H2122; DTXSID90274354; 1(2H)-Isoquinolinone,5-amino-; MolPort-008-423-043; MolPort-004-803-197"	2072	C9H8N2O	Investigative
M6APDG02790	GNF-PF-67	"Toxoflavin; Toxoflavine; Xanthothricin; Xanthotricin; 84-82-2; Xanthothricin (VAN); UNII-5N5YI4IP1P; GNF-Pf-67; NSC 67078; 1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,6-Dimethylpyrimido(5,4-e)-as-triazine-5,7(1H,6H)-dione; 1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; BRN 0021014; 5N5YI4IP1P; MLS000087831; CHEBI:80729; NSC67078; 1,6-Dimethyl-5,7-dioxo-1,5,6,7-tetrahydropyrimido(5,4-E)-as-triazine-5,7(1H,6H)-dione; SMR000024051; Pyrimido(5,4-e)-as-triazine-5,7-(1H,6H)-dione, 1,6-dimethyl-"	66541	C7H7N5O2	Investigative
M6APDG03578	Anti-Fas mabs	"Anti-Fas mAbs (misfolded proteins, cancer); Anticancer monoclonal antibodies (misfolded Fas receptor-targeting), Amorfix/Apexigen; Anticancer monoclonal antibodies (misfolded Fas receptor-targeting), Amorfix/Epitomics; Anti-Fas mAbs (misfolded proteins, cancer), Amorfix/Apexigen"	.	.	Investigative
M6APDG01428	NSC-401077	"NSC401077; MLS000757170; DNA Methyltransferase Inhibitor; CHEMBL383475; NSC-401077; 32675-71-1; 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid; 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propanoic acid; 2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(1H-indol-3-yl)propionic acid; SMR000413613; AC1Q71QA; Oprea1_475901; Oprea1_410805; MLS000777218; MLS006011919; SCHEMBL562060"	344265	C19H14N2O4	Investigative
M6APDG04365	ZD-3980	.	.	.	Terminated
M6APDG00767	Arsenic trioxide	Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+)	14888	As2O3	Approved
M6APDG02144	Phenylbutazone	"Alindor; Alkabutazona; Alqoverin; Anerval; Anpuzone; Antadol; Anuspiramin; Arthrizon; Artizin; Artrizin; Artrizone; Artropan; Azdid; Azobutyl; Azolid; Benzone; Betazed; Bizolin; Bunetzone; Busone; Butacompren; Butacote; Butadion; Butadiona; Butadione; Butadionum; Butagesic; Butalgina; Butalidon; Butaluy; Butaphen; Butapirazol; Butapirazole; Butapyrazole; Butarecbon; Butartril; Butartrina; Butatron; Butazina; Butazolidin; Butazolidine; Butazona; Bute; Butidiona; Butone; Butoz; Butylpyrin; Buvetzone; Buzon;Chembutazone; Cotylbutazone; Digibutina; Diossidone; Diozol; Diphebuzol; Diphenylbutazone; Ecobutazone; Elmedal; Equipalazone; Equiphen; Eributazone; Esteve; Febuzina; Fenartil; Fenibutal; Fenibutasan; Fenibutazona; Fenibutol; Fenilbutazon; Fenilbutazona; Fenilbutazone; Fenilbutina; Fenilbutine; Fenilidina; Fenotone; Fenylbutazon; Flexazone; Intalbut; Intrabutazone; Intrazone; Ipsoflame; Kadol; Lingel; Malgesic; Mephabutazon; Mephabutazone; Merizone; Nadazone; Nadozone; Novophenyl; Phebuzin; Phebuzine; Phenbutazol; Phenbutazone; Phenopyrine; Phenylbutaz; Phenylbutazon; Phenylbutazonum; Phenyzene; Phenyzone; Praecirheumin; Pyrabutol; Pyrazolidin; Rectofasa; Reudo; Reudox; Reumasyl; Reumazin; Reumazol; Reumune; Reumuzol; Reupolar; Robizone; Rubatone; Scanbutazone; Schemergen; Schemergin; Shigrodin; Tazone; Tencodyne; Tetnor; Tevcodyne; Therazone; Ticinil; Todalgil; Uzone; Wescozone; Zolaphen; Zolidinum; Alka Butazolidin; Art rizin; Buta phen; Butyl pyrin; Equi bute; Exrheudon N; Fe nilbutine; Fenilbutazone [DCIT]; Phenyl butazone; Phenylbutazon [German]; Pirarreumol B; A 7514; Bizolin 200; G 13871; P 8386; P1686; P1Z; AZOLID (TN); Apo-Phenylbutazone; Butiwas-Simple; Component of Azolid-A; DA-192; Fenilbutazona [INN-Spanish]; G 13,871; Ia-But; Mepha-Butazon; Neo-zoline; Phenyl-Mobuzon; Phenylbutazonum [INN-Latin]; Robizon-V; Robizone-V; Usaf ge-15; VAC-10; B.T.Z; Phen-Buta-Vet; R-3-ZON; B.t.z.; Bute, Butazolidin, Butatron, Phenylbutazone; Phenylbutazone (JP15/USP/INN); Phenylbutazone [USAN:INN:BAN:JAN]; 1,2-Diphenyl-2,3-dioxo-4-N-butylpyrazoline; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazoline; 3,5-Dioxe-4 buty-1, diphenyl-pyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-N-butylpyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine; 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione"	4781	C19H20N2O2	Approved
M6APDG01547	6-(2-Fluoropropyl)-4-methylpyridin-2-amine	"6-(2-Fluoropropyl)-4-methylpyridin-2-amine; CHEMBL450726; 1146620-35-0; SCHEMBL13040574; BDBM50267272; 2-Pyridinamine, 6-(2-fluoropropyl)-4-methyl-"	42625451	C9H13FN2	Investigative
M6APDG03782	CXCR4 gene disrupted T cells	CXCR4 gene disrupted T cells (HIV infection)	.	.	Investigative
M6APDG01737	C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL409144; BDBM50184350	44408400	C45H57N11O9	Investigative
M6APDG02660	3-Methoxyl-4'-amino-trans-stilbene	"4-Amino-3'-methoxystilbene; CCRIS 6787; CHEMBL1173573; 4-(2-(3-Methoxyphenyl)ethenyl)benzenamine; Benzenamine, 4-(2-(3-methoxyphenyl)ethenyl)-; 154028-32-7; AC1O5THI; 3'-Methoxystilben-4-amine; SCHEMBL3365675; SCHEMBL3365670; KQIPLUOUWQXDOT-AATRIKPKSA-N; BDBM50322058; 3-Methoxyl-4''-amino-trans-stilbene; AKOS030582815; LS-28359; 4-[(E)-2-(3-methoxyphenyl)ethenyl]aniline"	6440384	C15H15NO	Investigative
M6APDG03904	MM-302	.	.	.	Phase 1
M6APDG01740	C(RGDfMeF)	CHEMBL383747	44408450	C31H40N8O7	Investigative
M6APDG04145	ALRN-6924	.	.	.	Phase 2
M6APDG00360	SC-58125	"SC-58125; 162054-19-5; SC 58125; C17H12F4N2O2S; 1-((4-Methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole; CHEBI:8983; CHEMBL274990; 5-(4-fluorophenyl)-1-(4-methylsulfonylphenyl)-3-(trifluoromethyl)pyrazole; 1-[(4-METHYLSULFONYL)PHENYL]-3-TRIFLUOROMETHYL-5-(4-FLUOROPHENYL)PYRAZOLE; 5-(4-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-3-(trifluoromethyl)-1H-pyrazole; 5-(4-Fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)pyrazole; 1H-Pyrazole, 5-(4-fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-3-(tr"	115239	C17H12F4N2O2S	Terminated
M6APDG01574	TCN-P	"TRICIRIBINE PHOSPHATE; 61966-08-3; TCN-P; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594"	43860	C13H17N6O7P	Phase 1
M6APDG01221	PF-0998425	"PF-998425; 1076225-27-8; UNII-OY0E00K11M; PF 998425; OY0E00K11M; 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile; PF 0998425; 4-[(1R,2R)-2-hydroxycyclohexyl]-2-(trifluoromethyl)benzonitrile; arylcyclohexanol, (-)-6a; GTPL6698; CHEMBL458084; SCHEMBL16763727; BDBM25436; MolPort-023-276-993; MFCD17215970; ZINC40865778; AKOS024457876; SB19038; API0010282; NCGC00370969-01; KB-79880; PF0998425; FT-0673658; PF-998425, &gt; (R,R)-(-)-2-(4-Cyano-3-(trifluoromethyl)phenyl)cyclohexanol"	25093231	C14H14F3NO	Investigative
M6APDG00261	7-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one	Coumarin deriv. 29; CHEMBL390152; BDBM9480	11230598	C14H12N2O3	Investigative
M6APDG02089	N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide	CHEMBL1091737; N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide	46886448	C23H17FN2O	Investigative
M6APDG00520	APTO-253	.	11960271	C22H14FN5	Phase 1
M6APDG03434	Ro-40-0655	"RAR-alpha agonist, Roche"	.	.	Investigative
M6APDG03607	ISIS 6442	.	.	.	Investigative
M6APDG01759	"11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol"	"CHEMBL207706; 11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol"	44411876	C17H15NO	Investigative
M6APDG01476	1-(9H-fluoren-9-yl)-1H-imidazole	1-(9H-fluoren-9-yl)-1H-imidazole; CHEMBL225447; 35214-35-8; Fluorenyl deriv. 13; AC1MY9SZ; SCHEMBL9633309; BDBM9464; 1-(9H-fluoren-9-yl)imidazole; MolPort-002-538-233; ZINC4645069; STL321422; AKOS022141595; MCULE-5499035128; DA-06525	3828439	C16H12N2	Investigative
M6APDG04119	CDP-6038	.	.	.	Phase 2
M6APDG03072	Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2	.	91936743	C64H81N19O13S2	Investigative
M6APDG04230	RX-0201	.	.	.	Phase 2
M6APDG01805	2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid	CHEMBL236238; 2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid; BDBM50213563	44434500	C12H10FNO2	Investigative
M6APDG00086	His-DPhe-Arg-Trp	CHEMBL397413; 4289-02-5; His-DPhe-Arg-Trp; Hisetal; Characteristic MSH-Tetrapeptide; ZINC28707608; BDBM50211182; (MSH fragment H-His-Phe-Arg-Trp-OH)2-(2-{2-[2-Amino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoylamino)-3-(1H-indol-3-yl)-propionic acid	10258635	C32H40N10O5	Investigative
M6APDG00674	"2,8-Dimethyl-3H-quinazolin-4-one"	.	135463574	C10H10N2O	Investigative
M6APDG03870	Ferroportin mab	.	.	.	Phase 1
M6APDG01176	"N-hydroxy-2,3-bis(phenylsulfonamido)propanamide"	"CHEMBL496717; N-hydroxy-2,3-bis(phenylsulfonamido)propanamide"	24857837	C15H17N3O6S2	Investigative
M6APDG00496	3-(imidazolylmethyl)flavone	3-(imidazolylmethyl)flavone; CHEMBL213587; BDBM50191599	11847316	C19H14N2O2	Investigative
M6APDG03022	5-hydroxynaphthalene-1-sulfonamide	"5-hydroxynaphthalene-1-sulfonamide; 17286-26-9; 5-Hydroxynaphthalene-1-sulphonamide; NFVBVKHGDDDCEA-UHFFFAOYSA-N; 5-Hydroxy-1-naphthalenesulfonamide; 5-hydroxy-naphthalene-1-sulfonic acid amide; 2vth; EINECS 241-319-7; AC1L3CSX; AC1Q6ULI; SCHEMBL588923; CHEMBL457047; CTK4D4388; NFVBVKHGDDDCEA-UHFFFAOYSA-; BDBM24628; DTXSID50169414; ZINC2242749; 5-hydroxy-1-naphthalenesulphonamide; 1-Naphthalenesulfonamide,5-hydroxy-; 1-Naphthalenesulfonamide, 5-hydroxy-; 5-hydroxynaphthalene-1-sulfonamide, 7; AKOS030618521; DB08132; TX-017211"	87031	C10H9NO3S	Investigative
M6APDG01072	Benzamidine	benzamidine; Benzimidamide; Benzenecarboximidamide; 618-39-3; Phenylamidine; UNII-KUE3ZY3J1F; NSC 243704; CCRIS 2952; Benzamidine (Protonated); EINECS 210-546-3; KUE3ZY3J1F; CHEMBL20936; CHEBI:41033; PXXJHWLDUBFPOL-UHFFFAOYSA-N; BDN; 1oss; 2ast; 1bra; Benzenecarboxamidine; 1v2m; 1v2j; 1h4w; 1ce5; 1c5o; 2j9n; 1f5k; 1c5p; 1v2v; 1v2s; 1v2l; 1c5z; 1v2u; AC1L1DFX; Lopac-B-6506; ACMC-1B9LG; SCHEMBL9207; Lopac0_000203; MLS001066369; GTPL7566; AC1Q1U98; DTXSID8045012; 1670-14-0 (hydrochloride); ZINC36634; CTK2F5055; 1w80; 1j16; 1j15; MolPort-000-001-395	2332	C7H8N2	Investigative
M6APDG01739	C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	CHEMBL263822; c[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	44408443	C43H62N14O7	Investigative
M6APDG03347	Curcumin	"curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil"	969516	C21H20O6	Phase 3
M6APDG03299	E-6087	"E-6231 ((R)-(+)-isomer); E-6232 ((S)-(-)-isomer); Rac-4-[5-(2,4-Difluorophenyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl]benzenesulfonamide"	9953093	C16H12F5N3O2S	Discontinued in Phase 1
M6APDG01189	"5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole"	"CHEMBL452730; 5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole"	24884691	C17H15NOSe	Investigative
M6APDG01731	C[Thr-Tyr-Thr-His-DNaf-Arg-Trp-Thr-Ile-Pro]	CHEMBL267492; c[Thr-Tyr-Thr-His-DNaf-Arg-Trp-Thr-Ile-Pro]	44406884	C68H88N16O14	Investigative
M6APDG02966	ZK-thiazolidinone	"Zoledronate trisodium; Zoledronate trisodium hydrate; UNII-ARL915IH66; Zoledronate trisodium [USAN]; ARL915IH66; 165800-08-8; Zoledronate trisodium (USAN); CGP-42446B; CGP 42446B; CHEMBL3989655; D06379; Trisodium hydrogen (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonate, hydrate (5:2); Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-, trisodium salt hydrate (5:2)"	73442801	C23H30F3N5O2S	Preclinical
M6APDG03743	ISIS 104211	.	.	.	Investigative
M6APDG00178	4-[2-(3-Phenyl-propylamino)-ethyl]-phenol	CHEMBL333339; 4-[2-(3-Phenyl-propylamino)-ethyl]-phenol; SCHEMBL12009648; BDBM50066543; AKOS010487382	10565541	C17H21NO	Investigative
M6APDG01427	"4-ethoxynaphthalene-1,2-dione"	"4-ethoxynaphthalene-1,2-dione; 4-ethoxy-1,2-naphthoquinone; CHEMBL50620; 4-Ethoxy-[1,2]naphthoquinone; 7473-19-0; NSC400247; AC1L7Z1H; 4-Ethoxy-1,2-naphthalenedione; SCHEMBL5595641; DTXSID70322029; XPXODXIULRDWNT-UHFFFAOYSA-N; 1,2-Naphthalenedione, 4-ethoxy-; ZINC1593117; BDBM50099736"	343759	C12H10O3	Investigative
M6APDG01676	Z-Ala-Leu-Phe-Agly-Ile-Val-OMe	.	44355205	C39H57N7O9	Investigative
M6APDG00461	KU-58684	SCHEMBL863338; 623578-11-0	11725479	C19H14FN3O3	Investigative
M6APDG01168	Cyclo-[-Arg-Gly-Asp-Amp25-]	CHEMBL270690	24822784	C17H28N8O6	Investigative
M6APDG02621	4-(4-methoxy-benzylideneamino)-benzenesulfonamide	"CHEMBL271911; N-(4-Methoxybenzylidene)-4-sulfamoylaniline; 66667-56-9; AC1LCE5G; CBDivE_014997; SCHEMBL1517619; 4-[(4-methoxyphenyl)methylideneamino]benzenesulfonamide; CTK1J4463; DTXSID70347792; MolPort-000-519-122; MLUHDVSELBSKPI-UHFFFAOYSA-N; MLUHDVSELBSKPI-MHWRWJLKSA-N; ZINC131008; BDBM50371762; STK790787; AKOS001583663; MCULE-9167737347; MCULE-3795342438; ST016434; 4-(4-Methoxybenzylideneamino)benzenesulfonamide; Benzenesulfonamide, 4-(4-methoxybenzylideneamino)-; 4-((4-METHOXYBENZYLIDENE)AMINO)BENZENESULFONAMIDE"	625902	C14H14N2O3S	Investigative
M6APDG01883	3-methoxy-4-(p-tolyloxy)benzonitrile	CHEMBL464929; 3-methoxy-4-(p-tolyloxy)benzonitrile	44565152	C15H13NO2	Investigative
M6APDG03007	"6-Chloro-1,4-dihydro-quinoxaline-2,3-dione"	"6-chloroquinoxaline-2,3-diol; 6639-79-8; 2,3-Dihydroxy-6-chloroquinoxaline; 6-Chloro-1,4-dihydroquinoxaline-2,3-dione; 6-Chloroquinoxaline-2,3(1H,4H)-dione; 6-Chloro-2,3-dihydroxyquinoxaline; 6-Chloro-1,2,3,4-tetrahydroquinoxaline-2,3-dione; 169-14-2; 2,3-Quinoxalinedione, 6-chloro-1,4-dihydro-; CHEMBL21641; 6-CHLORO-2,3-DIOXO-1,2,3,4-TETRAHYDROQUINOXALINE; 6-chloro-1,4-dihydro-2,3-quinoxalinedione; Oprea1_205811; 2,3-Quinoxalinediol, 6-chloro-; EINECS 229-647-9; NSC 48940; PubChem15426; 2, 6-chloro-; AC1Q3ORE"	81143	C8H5ClN2O2	Investigative
M6APDG02715	3-Indan-(1Z)-ylidenemethyl-pyridine	"(3-Pyridylmethylene)indane 1b; BDBM8583; SCHEMBL4221374; CHEMBL363621; AC1O7048; 3-[(Z)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 3-[(1Z)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 3-[(Z)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Hydrochloride"	6539760	C15H13N	Investigative
M6APDG03705	ISIS 173848	.	.	.	Investigative
M6APDG00034	N-(6-phenyl-1H-indazol-3-yl)butyramide	CHEMBL1086174; N-(6-phenyl-1H-indazol-3-yl)butyramide; SCHEMBL4493121	10085013	C17H17N3O	Investigative
M6APDG04155	DE-098	"ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen"	.	.	Phase 2
M6APDG00174	1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one	CHEMBL421829; 1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one; BDBM50097367; 4-((1H-imidazol-1-yl)methyl)-1-bromo-9H-xanthen-9-one	10546089	C17H11BrN2O2	Investigative
M6APDG01388	NSC-289311	"CHEMBL459502; NSC-289311; AC1L8A89; SCHEMBL11697991; BDBM50254015; 1-[2-(3,4-dichlorophenyl)sulfanyl-2-(4-methoxyphenyl)ethyl]imidazole"	324288	C18H16Cl2N2OS	Investigative
M6APDG02973	CXCL8	Interleukin-8; CHEMBL411250;  interleukin-8; IL-8	74974005	C112H150N24O38S2	Investigative
M6APDG00428	AM7	"pyrimidone, 22; AM 7; AM-7"	11650194	C35H35FN4O5	Investigative
M6APDG01931	(South)-Methanocarba-Thymidine	"(SOUTH)-METHANOCARBA-THYMIDINE; south-methanocarbathymidine; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hex-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; SCT; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hexan-1-yl]thymine; (1S,3S,4R,5S)-3-hydroxy-4-hydroxymethyl-1-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)bicyclo[3.1.0]hexane; [(S)-Methanocarba-T]; South-Methanocarba-thymine; AC1L9L1U; 2'-exo-Methanocarbathymidine; CHEBI:45586; XRMLXZVSFIBRRJ-PEFMBERDSA-N; DB02921"	447628	C12H16N2O4	Investigative
M6APDG01495	1-Methyloxy-4-Sulfone-Benzene	1-METHYLOXY-4-SULFONE-BENZENE; 4-methoxybenzenesulfinate; AC1MZTZ7; SCHEMBL13838953; YVZWQPOTHRMEQW-UHFFFAOYSA-M; SBB082464; 1-(dioxidosulfanyl)-4-methoxybenzene; ZINC150339282; AKOS004898433; DB03033	3952261	C7H7O3S-	Investigative
M6APDG01235	Capmatinib	"1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O"	25145656	C23H17FN6O	Approved
M6APDG02131	GSK525762	GSK-525762	46943432	C22H22ClN5O2	Phase 1
M6APDG02825	N-phenyl-1H-pyrazole-3-carboxamide	"N-phenyl-1H-pyrazole-3-carboxamide; 124828-46-2; CHEMBL445420; N-phenyl-1H-pyrazole-5-carboxamide; 1H-Pyrazole-3-carboxylic Acid Phenylamide; MLS000519301; 2vtl; pyrazole amide, 15; pyrazole-5-carboxanilide; ChemDiv2_004267; AC1LE63W; SCHEMBL19748; N-phenylpyrazol-3-ylcarboxamide; SCHEMBL13373589; BDBM24636; MolPort-001-664-649; HMS2155C18; HMS3604B14; HMS1381B21; HMS3323C02; ALBB-018739; ZINC5286379; STK926745; BDBM50109707; AKOS000321787; DB08135; 1H-pyrazole-3-carboxamide, N-phenyl-; MCULE-7079696193; IDI1_002982; ST034406"	680935	C10H9N3O	Investigative
M6APDG01763	H-Gly-D-dmP-Glu-OH	CHEMBL212694	44413487	C14H23N3O6	Investigative
M6APDG01810	"5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione"	CHEMBL397849	44440475	C18H16ClNO2	Investigative
M6APDG01998	Purvalanol A	Purvalanola; AC1L1JD0; PURVALANOLA; IN1131; 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropyl-purine; SCHEMBL3311119; GTPL6030; CTK8F1120; CHEBI:93781; HMS3229M14; KS-00001DB0; HSCI1_000128; AKOS030238850; CCG-206875; RT-015158; K00014; 2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol	456214	C19H25ClN6O	Investigative
M6APDG01578	Glucosamine	"Chitosamine; GCS; Glucosamina; Glucosaminum; D-glucosamine; Glucosamina [INN-Spanish]; Glucosamine [USAN:INN]; Glucosaminum [INN-Latin]; Viartril-S; Beta-D-Glucosamine; Glucosamine (USAN/INN); Partially N-deacetylated poly-beta-1,6-N-acetyl-D-glucosamine; (2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (2S,5R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; 2-Amino-2-deoxy-D-glucose; 2-Amino-2-deoxy-beta-D-glucopyranose; 2-amino-2-deoxy-D-glucopyranose; 2-amino-2-deoxyglucose"	439213	C6H13NO5	Approved
M6APDG03590	ISIS 138649	.	.	.	Investigative
M6APDG03380	Siltuximab	.	.	.	Approved
M6APDG03703	P-2281	"MTOR inhibitor (ulcerative colitis), Piramal"	.	.	Investigative
M6APDG03516	AEZS-131	"ERK inhibitor (cancer), AEterna"	.	.	Investigative
M6APDG03541	WAY-644	"MMP-12 inhibitor (aortic abdominal aneurysm), Pfizer; MMP-12 inhibitor (aortic abdominal aneurysm), Wyeth"	.	.	Investigative
M6APDG03451	ISIS 32039	.	.	.	Investigative
M6APDG01543	C75	"C75 trans; C75 (trans); 191282-48-1; 3-Carboxy-4-octyl-2-methylenebutyrolactone; CHEMBL449993; trans-4-Carboxy-5-octyl-3-methylenebutyrolactone; Fatty Acid Synthase Inhibitor, C75; (+)-trans-C75; C75 (racemic); SCHEMBL3007085; CTK8E7727; MolPort-005-933-439; HMS3649D16; ZINC2009913; BCP11074; HY-12364A; BDBM50256128; trans-Tetrahydro-3-methylene-2-oxo-5-n-octyl-4-furancarboxylic acid; AKOS015960616; VC30664; CS-3561; AC-11808; RT-011885; SR-01000946704; SR-01000946704-1; J-012362; UNII-8E9A8CTX2H component VCWLZDVWHQVAJU-NEPJUHHUSA-"	4248455	C14H22O4	Investigative
M6APDG02653	MYRIOCIN	"Myriocin; thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid"	6438394	C21H39NO6	Investigative
M6APDG01608	SNX-5422	"908115-27-5; PF-04929113; SNX-5422; SNX 5422; SNX5422; UNII-BF52J69Q8T; PF 04929113; PF-04929113 (SNX-5422); BF52J69Q8T; PF04929113; PF-4929113; cc-40; MLS006011083; SCHEMBL1220791; SCHEMBL1220790; CHEMBL1195136; SCHEMBL15604989; DTXSID50238270; C25H30F3N5O4; MolPort-023-293-502; BCPP000065; HMS3656B09; EX-A2343; BCP02427; s2656; ZINC95616595; ABP000737; ZINC100071931; ZINC252517142; AKOS027276395; SB16643; DB06070; API0008143; RL05706; SNX-5422 /; CS-0272; NCGC00346640-01; NCGC00386184-02; Glycine, trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrah"	44195571	C25H30F3N5O4	Phase 1/2
M6APDG02079	AdoC(Dpr)2AlaArg6	CHEMBL611120	46877395	C58H101N31O13	Investigative
M6APDG01845	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	CHEMBL573935; [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	44479701	C20H16O4S	Investigative
M6APDG02276	N-oleoylethanolamide	n-Oleoylethanolamine; n-oleoylethanolamine; oleoylethanolamide; N-(2-Hydroxyethyl)oleamide; 111-58-0; Oleylethanolamide; N-oleoyl ethanolamine; Oleamide MEA; Oleoyl monoethanolamide; Oleoyl Ethanolamide; N-(2-Hydroxyethyl)-9-octadecenamide; N-(Hydroxyethyl)oleamide; UNII-1HI5J9N8E6; (Z)-N-(2-hydroxyethyl)octadec-9-enamide; Oleic acid ethanolamide; N-(9Z-octadecenoyl)-ethanolamine; EINECS 203-884-8; OEA; MLS002153155; CHEMBL280065; 1HI5J9N8E6; (9Z)-N-(2-hydroxyethyl)octadec-9-enamide; Monoethanolamine oleic acid amide; CHEBI:71466; N-oleoylethanolamine; oleylethanolamide; NOE; OLEOYLETHANOLAMIDE	5283454	C20H39NO2	Investigative
M6APDG00951	Alpha-D-Mannose	"alpha-D-Mannose; alpha-D-Mannopyranose; alpha-Mannose; alpha-D-Man; UNII-W3F28J9G0W; CHEBI:28729; 7296-15-3; W3F28J9G0W; 3h-mannose; Manalpha1,; 1rdl; 1rin; 29696-75-1; Epitope ID:130701; AC1Q59RC; AC1L4HD7; SCHEMBL76882; CHEMBL365590; WQZGKKKJIJFFOK-PQMKYFCFSA-N; ZINC3860903; FT-0773891; C00936; WURCS=2.0/1,1,0/[a1122h-1a_1-5]/1/"	185698	C6H12O6	Investigative
M6APDG02404	"5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione"	"CHEMBL176517; 219311-20-3; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(4-phenoxyphenyl)-; SCHEMBL6380971; CTK0J6997; DTXSID60470422; NNRYJLARUIVRRO-UHFFFAOYSA-N; 5-(4'-phenoxyphenyl)barbituric acid; 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione"	53742316	C16H12N2O4	Investigative
M6APDG02225	GALLOCATECHIN GALLATE	"(-)-Gallocatechin gallate; 4233-96-9; Gallocatechin gallate; (-)-Gallocatechol gallate; UNII-IRW3C4Y31Q; (2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Gallocatechin gallate (Gcg); IRW3C4Y31Q; CHEMBL264938; (-)-gallocatechin-3-O-gallate; (2S,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); [(2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; Benzoic acid, 3,4,5-trihydroxy-, 3,"	5276890	C22H18O11	Investigative
M6APDG03143	RU-43044	"CHEMBL78704; RU-43044; SCHEMBL14289561; 136959-96-1; BDBM50113782; RU43044; 17-Hydroxy-13-methyl-10-(4-methyl-benzyl)-17-prop-1-ynyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one(RU-43044)"	9823099	C29H34O2	Investigative
M6APDG00977	RU-59063	"155180-53-3; 4-(3-(4-Hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile; 4-[3-(4-Hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; RU-59063; RU 59063; CHEMBL331820; AK134187; AC1L53SM; SCHEMBL1714908; CTK4C8567; DTXSID50165850; MolPort-027-950-495; FIDNKDVRTLFETI-UHFFFAOYSA-N; ZINC1538191; BDBM50091400; 6064AJ; AKOS016845838; TRA0008920; RU59063; DS-4755; SY008557; CJ-05279; AJ-26835"	197655	C17H18F3N3O2S	Investigative
M6APDG01753	"3-isopropyl-4-phenylnaphthalene-1,2-dione"	"CHEMBL207833; 3-isopropyl-4-phenylnaphthalene-1,2-dione"	44409685	C19H16O2	Investigative
M6APDG01680	Z-Ala-Leu-lle-Agly-Ile-Val-NHBzl	.	44355522	C42H64N8O8	Investigative
M6APDG00471	"3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one"	"CHEMBL1098382; 3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one"	11760063	C20H20O6	Investigative
M6APDG00712	2-(6-morpholino-9H-purin-2-yl)phenol	.	135955185	C15H15N5O2	Investigative
M6APDG02360	6-(3-Amino-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 33; BDBM5493; CHEMBL270977; AC1NS705; 2-Amino-6-(3 -aminobenzyl)oxypurine; 6-[(3-aminophenyl)methoxy]-9H-purin-2-amine	5329517	C12H12N6O	Investigative
M6APDG00082	3-((E)-Styryl)-quinoline	CHEMBL65858; 3-((E)-Styryl)-quinoline; (e)-3-styrylquinoline; 3-[(E)-Styryl]quinoline; SCHEMBL3164863; ZINC3832235; BDBM50039053	10243001	C17H13N	Investigative
M6APDG03780	ND-401	"ND-4019; CCR5 and CXCR4 inhibitors (HIV infection), NeED Pharmaceuticals"	.	.	Investigative
M6APDG03944	Gerilimzumab	.	.	.	Phase 1
M6APDG00091	N-(6-benzyl-1H-indazol-3-yl)butyramide	CHEMBL1077260; N-(6-benzyl-1H-indazol-3-yl)butyramide; SCHEMBL6490520	10266409	C18H19N3O	Investigative
M6APDG00162	4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one	"CHEMBL78322; 331684-13-0; 4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one; CTK1B8690; DTXSID70440555; BDBM50097370; AKOS030562752; 1-(imidazol-1-ylmethyl)-4-bromo-9h-9-xanthenone; 1-(1H-Imidazole-1-ylmethyl)-4-bromo-9H-xanthene-9-one; 9H-Xanthen-9-one, 4-bromo-1-(1H-imidazol-1-ylmethyl)-"	10473365	C17H11BrN2O2	Investigative
M6APDG03140	BRL-48482	"BRL-48482; SCHEMBL1850299; ZYKPNHFCNSVFNF-UHFFFAOYSA-N; 5-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(benzoxazol-2-yl-methylamino)ethoxy] benzyl]thiazolidine-2,4-dione"	9822139	C20H19N3O4S	Investigative
M6APDG03145	CEP-6331	"2-Isopropoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CEP-6331; CHEMBL460990; BDBM24949; MolPort-027-637-287; ZINC33970297; 5-oxo dihydronaphthylcarbazole analogue, 16; X7365"	9823787	C27H26N2O3	Investigative
M6APDG02344	"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile"	"133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile"	5328753	C12H8N2O2	Investigative
M6APDG03831	DSP-8658	.	.	.	Phase 1
M6APDG01706	Ac-YR[CE(1-Me-H)dFRWC]-NH2	CHEMBL264132; Ac-YR[CE(1-Me-H)dFRWC]-NH2	44400322	C61H81N19O13S2	Investigative
M6APDG00014	"3,4-bis(indol-3-yl)maleimide derivative"	CHEMBL7364	10033891	C49H66N10O9S	Investigative
M6APDG00331	AEW-541	"AECDBHGVIIRMOI-UHFFFAOYSA-N; NVP-AEW541; 475489-16-8; 475488-34-7; AEW541; NVP-AEW 541; UNII-97QB5037VR; AEW 541; AVP-AEW541; 7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; CHEMBL1614712; 97QB5037VR; 7-[TRANS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; C27H29N5O; 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE, 7-[CIS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-"	11476171	C27H29N5O	Phase 1
M6APDG02146	Cdk4 inhibitor III	"Ryuvidine; Cdk4 Inhibitor III; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830"	481747	C15H12N2O2S	Investigative
M6APDG01098	2-(2-phenoxypyrimidin-4-ylamino)benzoic acid	4-anilinopyrimidine 6g; CHEMBL244626; BDBM15985; 2-[(2-phenoxypyrimidin-4-yl)amino]benzoic acid	23647245	C17H13N3O3	Investigative
M6APDG01866	CLEMATOMANDSHURICA SAPONIN A	CHEMBL526701; BDBM50241847; 6)-[(3-O-isoferuloyl)-beta-D-glucopyranosyl]-(1-&gt; 3)-alph-L-rhamnopyranosyl-(1-&gt; 2)-alpha-L-arabinopyranosyloleanolicacid 28-O-alph-L-rhamnopyranosyl-(1-&gt	44559170	C92H142O46	Investigative
M6APDG03638	ISIS 298745	.	.	.	Investigative
M6APDG00840	1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine	CHEMBL219905; 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine	16098875	C28H28N2O4	Investigative
M6APDG04047	PLX2853	.	.	.	Phase 1/2
M6APDG02861	PKI166	"PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, &gt; 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol"	6918403	C20H18N4O	Discontinued in Phase 2
M6APDG00113	SL422	analogue 55f [PMID: 11472217]	10344307	C23H34N4O6	Investigative
M6APDG01885	4-(mesitylthio)-2-(trifluoromethyl)benzonitrile	CHEMBL462234; 4-(mesitylthio)-2-(trifluoromethyl)benzonitrile	44565205	C17H14F3NS	Investigative
M6APDG00297	7-Mercapto-heptanoic acid pyridin-3-ylamide	"CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653"	11345433	C12H18N2OS	Investigative
M6APDG02221	XD14	"XD14; 1370888-71-3; XD 14; 4-acetyl-N-[5-(diethylsulfamoyl)-2-hydroxyphenyl]-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide; CHEMBL3787231; 4-acetyl-N-(5-(N,N-diethylsulfamoyl)-2-hydroxyphenyl)-3-ethyl-5-methyl-1H-pyrrole-2-carboxamide; 4lyw; GTPL7524; SCHEMBL16181763; AOB6049; MolPort-010-365-022; XD-14; EX-A1864; ZINC59367920; BDBM50158909; AKOS025293503; NE41584; MCULE-3472066147; Z606699744"	52670832	C20H27N3O5S	Investigative
M6APDG02610	2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one	CHEMBL10072; 2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one; AC1O1A27; BDBM50111271; 3-[(Z)-4-Pyridinylmethylene]flavanone	6116651	C21H15NO2	Investigative
M6APDG00257	ADOCIAQUINONE B	Adociaquinone B	11201041	C22H17NO6S	Investigative
M6APDG02607	XEMILOFIBAN	"Xemilofiban; Xemilofiban [INN]; 149820-74-6; UNII-P614JI3IYK; SC-54684A; SC 54684A; P614JI3IYK; SC-54684; CHEMBL76098; Ethyl-3S-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-4-pentynoate; C18H22N4O4; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, ethyl ester, (S)-; CS-551; AC1Q5MFX; AC1L1U8F; SCHEMBL50663; DTXSID60164410; ZINC1535967; BDBM50083460; KB-81502; LS-102305; ethyl(3s)-3-[3-[(p-amidinophenyl)carbamoyl]propionamido]-4-pentynoate"	60957	C18H22N4O4	Discontinued in Phase 3
M6APDG00384	Apremilast	"Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide"	11561674	C22H24N2O7S	Approved
M6APDG01714	Ac-dR[CEHdFRWC]-NH2	CHEMBL267900; Ac-dR[CEHdFRWC]-NH2	44400402	C51H70N18O11S2	Investigative
M6APDG02329	ARQ 092	Miransertib	53262401	C27H24N6	Phase 2
M6APDG00295	AT7519	"LZE; AT 7519, AT7519; AT-7519; 4-[(2,6-dichlorobenzoyl)amino]-N-(4-piperidyl)-2H-pyrazole-3-carboxamide"	11338033	C16H17Cl2N5O2	Phase 1
M6APDG00182	"5,7-Dibromo-1,4-dihydro-quinoxaline-2,3-dione"	"CHEMBL336017; 5,7-Dibromo-1,4-dihydro-2,3-quinoxalinedione; 153504-78-0; 5,7-dibromo-1,4-dihydroquinoxaline-2,3-dione; Oprea1_150165; SCHEMBL2638792; SCHEMBL8557193; KAMOVQVEAFPAHG-UHFFFAOYSA-N"	10591750	C8H4Br2N2O2	Investigative
M6APDG02921	Ivosidenib	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767	71657455	C28H22ClF3N6O3	Approved
M6APDG01330	HTS-02876	HTS-02876; AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609	2810910	C24H20F3N3O4S2	Investigative
M6APDG00224	1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one	CHEMBL307160; 1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one; BDBM50097363; 1-(imidazol-1-ylmethyl)-4-nitro-9h-9-xanthenone; 4-Nitro-1-(1H-imidazole-1-ylmethyl)-9H-xanthene-9-one	10853186	C17H11N3O4	Investigative
M6APDG00098	2H-Isoquinolin-1-one	"1-Hydroxyisoquinoline; 491-30-5; Isoquinolin-1(2H)-one; isoquinolin-1-ol; 1-Isoquinolinol; 2H-Isoquinolin-1-one; Isocarbostyril; 1(2H)-ISOQUINOLINONE; Isoquinolin-1-one; 489453-23-8; 1(2H)-Isoquinolone; 1,2-dihydroisoquinolin-1-one; 1-hydroxyisoquinolin; isoquinolinol; 87602-67-3; 1(2H)-ISOQUINILONE; Isocarbostyril, 98%; UNII-95EG3HGG1P; 95EG3HGG1P; Isoquinolinone; CHEMBL339695; CHEBI:18350; VDBNYAPERZTOOF-UHFFFAOYSA-N; 1-isoquinolone; oxidoisoquinolinium; EINECS 207-732-1; Isocarbostyril(1-hydroxyisoquinoline); NSC 27273"	10284	C9H7NO	Investigative
M6APDG01506	[3H]MDL105519	"AC1L1H8N; GTPL4088; CTK6G6780; CTK0I1827; HMS3370K17; (E)-3-(2-Carboxy-2-phenylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acid; 3-(2-carboxy-2-phenylethenyl)-4,6-dichloro-1H-indole-2-carboxylic acid; (Z)-3-(2-carboxy-2-phenylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acid; 1H-Indole-2-carboxylicacid, 3-[(1E)-2-carboxy-2-phenylethenyl]-4,6-dichloro-"	4023	C18H11Cl2NO4	Investigative
M6APDG03620	Anti-cMET mab	"Anti-cMET mAb (undisclosed indication); Anti-cMET mAb (undisclosed indication), PharmAbcine; CMET inhibitor (mAb, undisclosed indication), PharmAbcine"	.	.	Investigative
M6APDG00154	"6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline"	"CHEMBL308466; 6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline; ZINC13737704"	10447210	C18H17NO3	Investigative
M6APDG03731	ISIS 29159	.	.	.	Investigative
M6APDG00640	Penciclovir	penciclovir; 39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2	135398748	C10H15N5O3	Approved
M6APDG03197	"6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine"	"CHEMBL121479; 127116-64-7; 2,4-Pyrimidinediamine, 5-nitro-6-(phenylmethoxy)-; ACMC-20msby; 6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine; SCHEMBL3309544; CTK0F6457; DTXSID40431990; VLVHHGNPHBVEIG-UHFFFAOYSA-N; BDBM50062813; AKOS030620964; 6-Benzyloxy-5-nitropyrimidine-2,4-diamine; 2,4-Diamino-6-benzyloxy-5-nitropyrimidine"	9860003	C11H11N5O3	Investigative
M6APDG00671	8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one	.	135457978	C15H11N3O3	Investigative
M6APDG02093	N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	CHEMBL1095096; N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide	46887378	C18H15N3O	Investigative
M6APDG01251	"9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"CHEMBL190895; BDBM27513; indeno[1,2-c]isoquinolinone, 1e; 9-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one"	25190932	C16H10FNO	Investigative
M6APDG00239	Bis(5-aminobenzo[b]furan-2-yl)methanone	CHEMBL376787; bis(5-aminobenzo[b]furan-2-yl)methanone	11098310	C17H12N2O3	Investigative
M6APDG03427	Segard	Afelimomab	.	.	Discontinued in Phase 3
M6APDG01243	SAR-125844	"Met inhibitor (iv, cancer), sanofi-aventis"	25182860	C25H23FN8O2S2	Phase 2
M6APDG00813	5-Phenyl-pentanoic acid benzyl-hydroxy-amide	"N-benzyl-N-hydroxy-5-phenylpentanamide; 158999-12-3; N-Benzyl-N-hydroxy-5-phenylpentamide; CHEMBL301253; N-Bhpp; AC1L4IPK; N-Hydroxy-N-(phenylmethyl)benzenepentanamide; 5-Phenyl-pentanoic acid benzyl-hydroxy-amide; SCHEMBL1271129; DTXSID60166550; ZINC5138973; BDBM50016680; KB-301817; Benzenepentanamide, N-hydroxy-N-(phenylmethyl)-"	157806	C18H21NO2	Investigative
M6APDG00598	LY-292223	"2-(4-Morpholinyl)-4H-1-benzopyran-4-one; 2-morpholinochromone; LY-292223; CHEMBL367315; 2-morpholino-4H-chromen-4-one; 130735-56-7; U67154; AC1L2YUR; U-67154; SCHEMBL3361567; 2-morpholin-4-ylchromen-4-one; DTXSID30156701; 2-Morpholin-4-yl-chromen-4-one; QNFWERYZJLBANZ-UHFFFAOYSA-N; BDBM50098118; 2-(4-Morpholinyl)-4H-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-"	131255	C13H13NO3	Investigative
M6APDG02895	(4-Phenoxy-phenyl)-quinazolin-4-yl-amine	CHEMBL304760; N-(4-phenoxyphenyl)quinazolin-4-amine; (4-Phenoxy-phenyl)-quinazolin-4-yl-amine; AC1LEH7Z; Neuro1_000298; Oprea1_168469; SCHEMBL5568872; MolPort-000-668-533; ZINC104659; BDBM50092231; STK918072; (4-phenoxyphenyl)quinazolin-4-ylamine; AKOS002241807; N-(4-Phenoxyphenyl)-4-quinazolinamine; MCULE-2087445269; ST50197248; EU-0074581; SR-01000459365	712152	C20H15N3O	Investigative
M6APDG00776	Quinoline-8-carboxamide	Quinoline-8-carboxamide; 8-Quinolinecarboxamide; 55706-61-1; CCRIS 6967; CHEMBL502330; HPQRQAOVNXWEEQ-UHFFFAOYSA-N; 8-Carbamoylquinoline; 8-Quinolinecarboxamide #; AC1L44SC; SCHEMBL460456; CTK5A4047; quinoline-8-carboxylic acid amide; DTXSID00204243; MolPort-005-722-305; ZINC6095019; BDBM50255266; AKOS008969900; NE38855; MCULE-7978956907; LS-188644; KB-259682	150664	C10H8N2O	Investigative
M6APDG00519	1-(4-(methylsulfonyl)phenyl)-1H-indole	CHEMBL1240964; 1-(4-(methylsulfonyl)phenyl)-1H-indole; 1-[4-(Methylsulfonyl)phenyl]-1H-indole; ZINC64475267	11958319	C15H13NO2S	Investigative
M6APDG02086	RESCOVITINE	Rescovitine; CHEMBL1087791	46881287	C19H28N6O	Investigative
M6APDG02457	URMC-099	compound 1 [PMID 24044867]	54764565	C27H27N5	Investigative
M6APDG04208	AEM-28	"Apo-E peptide mimetic (acute coronary syndrome), University of Alabama at Birmingham/LipimetiX"	.	.	Phase 2
M6APDG01119	BOHEMINE	bohemine; 189232-42-6; 3-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol; 3-{[6-(benzylamino)-9-(propan-2-yl)-9h-purin-2-yl]amino}propan-1-ol; CHEMBL83980; CHEBI:86007; 2-(3-Hydroxypropylamino)-6-benzylamino-9-isopropylpurine; [6-Benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine; 2-[(3-hydroxypropyl)amino]-6-benzylamino-9-isopropylpurine; 3-{[6-(benzylamino)-9-isopropyl-9H-purin-2-yl]amino}propan-1-ol; purine deriv. 1; AC1L1DN2; SCHEMBL1443403; GTPL5938; BDBM10633; CTK8A4395; DTXSID00274365; EX-A931	2422	C18H24N6O	Investigative
M6APDG04222	PNT-2258	.	.	.	Phase 2
M6APDG00437	3-chloro-4-(o-tolyloxy)benzonitrile	CHEMBL490955; 3-chloro-4-(o-tolyloxy)benzonitrile; SCHEMBL4168825; BDBM50248505	11673174	C14H10ClNO	Investigative
M6APDG03020	MLN0415	SCHEMBL3805703	86630595	C27H36ClN5O7S	Discontinued in Phase 1
M6APDG00265	PX-478	"PX-478; 685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di"	11234794	C13H20Cl4N2O3	Phase 1
M6APDG00377	Ki-11502	Ki 11502; PDGF Receptor Tyrosine Kinase Inhibitor V	11554659	C26H23N3O4S	Investigative
M6APDG00155	LY-326449	"LY-326449; CHEMBL292495; BDBM50052039; 3,4-[[(S)-3-Oxa-4-(hydroxymethyl)hexane-1,6-diyl]bis(1H-indole-1,3-diyl)]-3-pyrroline-2,5-dione"	10455969	C26H23N3O4	Investigative
M6APDG03517	KAR-1880	"Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus"	.	.	Investigative
M6APDG00058	Y-39041	SCHEMBL4603503	10151575	C27H30ClNO3	Investigative
M6APDG00516	AT13387	AT-13387	11955716	C24H31N3O3	Phase 1
M6APDG01047	N-(6-phenethyl-1H-indazol-3-yl)butyramide	CHEMBL1084684; N-(6-phenethyl-1H-indazol-3-yl)butyramide; SCHEMBL6489338	22319484	C19H21N3O	Investigative
M6APDG02826	NSC-26745	"5-Hydroxyflavone; 491-78-1; Primuletin; 5-hydroxy-2-phenyl-4H-chromen-4-one; 5-hydroxy-2-phenylchromen-4-one; NSC-26745; 5-Hydroxy-2-phenyl-chromen-4-one; NSC 26745; 5-Hydroxy-2-phenylchromone; UNII-378AE9MHL3; CHEMBL16807; MLS002639146; 378AE9MHL3; IYBLVRRCNVHZQJ-UHFFFAOYSA-N; NSC26745; MFCD00016944; 4H-1-Benzopyran-4-one,5-hydroxy-2-phenyl-; Primuliten; 5-hydroxy-flavone; 5-Hydroxy-2-phenyl-4-benzopyrone; EINECS 207-743-1; 5-hydroxy-2-phenyl-4h-chromen-4-on; AC1Q6AKC; ACMC-209kf5; Oprea1_688541; 5-Hydroxyflavone, &gt;=97%"	68112	C15H10O3	Investigative
M6APDG01230	Hydroxydimethylarsine Oxide	"Cacodylic acid; cacodylic acid; Dimethylarsinic acid; 75-60-5; Hydroxydimethylarsine oxide; Chexmate; Silvisar; Phytar; Arsan; Erase; DIMETHYLARSENIC ACID; Silvisar 510; Arsinic acid, dimethyl-; Phytar 560; Ansar 138; Sylvicor; Moncide; Dilic; Rad-e-cate 35; Agent Blue; Acide cacodylique; Alkargen; Phytar 138; Acide dimethylarsinique; Cotton aide HC; Kyselina kakodylova; RCRA waste number U136; Phytar 600; Caswell No 133; Arsine oxide, hydroxydimethyl-; Ansar; UNII-AJ2HL7EU8K; Acide cacodylique [French]; Kyselina kakodylova [Czech]"	2513	C2H7AsO2	Investigative
M6APDG02482	Troglitazone	"Noscal; Prelay; Resulin; Rezulin; Romglizone; Romozin; Troglitazona; Troglitazonum; Parke Davis brand of troglitazone; CS 045; GR 92132X; CS-045; GR-92132X; Resulin (TN); Rezulin (TN); Romozin (TN); Warner-Lambert brand of troglitazone; Troglitazone [USAN:BAN:INN]; Troglitazone (JAN/USAN/INN); (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-(9CI); 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione); 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione"	5591	C24H27NO5S	Approved
M6APDG00351	Dacomitinib	PF-00299804	11511120	C24H25ClFN5O2	Approved
M6APDG03796	CAR-T Cells targeting HER2	.	.	.	Phase 1
M6APDG04293	CBT-1	.	.	.	Phase 3
M6APDG00276	4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide	CHEMBL324126	11277483	C15H24N2OS	Investigative
M6APDG02575	Testosterone	"AndroGel; Androderm; Androlin; Andronaq; Andropatch; Androsorb; Andrusol; Depotest; Halotensin; Homosteron; Homosterone; Intrinsa; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Striant; Sustanon; Sustanone; Teslen; Testandrone; Testaqua; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testolin; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testrone; Testryl; Virormone; Virosterone; Beta testosterone; Cristerona T; Cristerone T; Malogen in Oil; Oreton F; Percutacrine androgenique; Synandrol F; Testoderm Tts; Testopel Pellets; Testosterone and its esters; Testosterone hydrate; Testosterone solution; Testoviron Schering; Testoviron T; Testro AQ; Virilon IM; AA 2500; Andro 100; Andronate 100; Andronate 200; Andropository 200; Andryl 200; CDB 111C; CMC_13449; COL 1621; CP 601B; Everone 200; Sustason 250; Testamone 100; Testred Cypionate 200; Androderm (TN); Androgel (TN); Geno-cristaux gremy; Malestrone (amps); Malogen, aquaspension injection; Neo-Hombreol F; Neo-testis; Oreton-F; Scheinpharm Testone-Cyp; Striant (TN); T-Cypionate; Testim (TN); Testoject-50; Testosterona [INN-Spanish]; Testosterone [Androgenic steroids, anabolic]; Testosterone [INN:BAN]; Testosteronum [INN-Latin]; Trans-Testosterone; Testosterone (JAN/USP); Testrin-P.A; Delta4-Androsten-17beta-ol-3-one; Delta4-androsten-17b-ol-3-one; Androst-4-en-17beta-ol-3-one; Delta(sup 4)-Androsten-17(beta)-ol-3-one; (17beta)-17-Hydroxyandrost-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17-Hydroxy-4-androsten-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 17b-hydroxy-4-androsten-3-one; 17beta-Hydroxy-3-oxo-4-androstene; 17beta-Hydroxy-4-androsten-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; 17beta-Hydroxyandrost-4-en-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 4-Androsten-17-ol-3-one; 4-Androsten-17beta-ol-3-one; 4-androstene-17beta-ol-3-one; 7-beta-Hydroxyandrost-4-en-3-one"	6013	C19H28O2	Approved
M6APDG04227	ABT-414	.	.	.	Phase 2
M6APDG02162	"2,5-dichloro-N-p-tolylthiophene-3-sulfonamide"	"CHEMBL1171972; 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide"	49798484	C11H9Cl2NO2S2	Investigative
M6APDG01907	Icotinib hydrochloride	Conmana; Conmanna; Icotinib; BPI-2009-H	44609731	C22H22ClN3O4	Registered
M6APDG00494	4'-bromo-3-(imidazolylmethyl)-7-methoxyflavone	CHEMBL209047; BDBM50191596; 4''-bromo-3-(imidazolylmethyl)-7-methoxyflavone	11847170	C20H15BrN2O3	Investigative
M6APDG00600	Rova-T	rovalpituzumab tesirine; Rovalpituzumab Tesirine; Rova-t; Rovalpituzumab-Tesirin; UNII-P256HB60FF; Rovalpituzumab tesirine [INN]; P256HB60FF; Rovalpituzumab tesirine [WHO-DD]; Rovalpituzumab tesirine [USAN:INN]; SC0002; 1613313-09-9	131954443	C78H108N10O25S	Phase 3
M6APDG04081	TKM-PLK1	.	.	.	Phase 1/2
M6APDG01601	"4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile"	"CHEMBL448454; 4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile"	44157041	C16H15NOS	Investigative
M6APDG00129	"5-Ethyl-3,4-diphenyl-isoxazole"	"CHEMBL361504; 5-Ethyl-3,4-diphenyl-isoxazole; 3,4-diphenyl-5-ethylisoxazole; SCHEMBL2279510; MXTWADCRLRQMDW-UHFFFAOYSA-N; ZINC13583259"	10377376	C17H15NO	Investigative
M6APDG03296	L-779450	"303727-31-3; L-779450; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol"	9950176	C20H14ClN3O	Investigative
M6APDG00892	AZD-5438	"602306-29-6; AZD5438; AZD-5438; AZD 5438; 4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine; CHEMBL488436; UNII-276Z913G29; MMV676604; 4-[2-METHYL-1-ISOPROPYL-1H-IMIDAZOL-5-YL]-N-[4-(METHYLSULFONYL)PHENYL]-2-PYRIMIDINAMINE; 2-Pyrimidinamine,4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-; 276Z913G29; 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine"	16747683	C18H21N5O2S	Phase 1
M6APDG01240	[3H]mibolerone	"Mibolerone; MIBOLERONE; 3704/9/4; Miboleronum; Mibolerona; Cheque; U-10,997; UNII-9OGY4BOR8D; NSC 72260; 9OGY4BOR8D; U 10997; Matenon; Miboleron; 17-beta-Hydroxy-7-alpha,17-dimethylestr-4-en-3-one; CHEBI:34849; U-10997; 17beta-Hydroxy-7alpha,17-dimethylestr-4-en-3-one; (7alpha,17beta)-17-hydroxy-7,17-dimethylestr-4-en-3-one; 7alpha-17alpha-dimethyl-19-nortestosterone; CDB 904; Cheque (Veterinary)"	251636	C20H30O2	Investigative
M6APDG00070	"(S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine"	"CHEMBL186431; (S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine; SCHEMBL7678842"	10198539	C8H16N2S	Investigative
M6APDG00046	"3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan"	"CHEMBL43396; 3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan; SCHEMBL7047273; SCHEMBL7047277; 3-[(E)-3,5-Dimethoxystyryl]furan; ZINC13471767; BDBM50108047; AKOS015967552"	10105252	C14H14O3	Investigative
M6APDG03582	DOM-0215	"dual anti-TNFalpha/unspecified target human dAb (rheumatoid arthritis), Domantis; dual-targeting domain antibody therapy (rheumatoid arthritis), Domantis"	.	.	Investigative
M6APDG01408	NSC-348926	"NSC-348926; NSC348926; 2-phthalimidoadipic acid; AC1L7IP1; SCHEMBL9741723; CHEMBL599367; 2-(1,3-dioxoisoindol-2-yl)hexanedioic acid"	336008	C14H13NO6	Investigative
M6APDG01181	"4,17-dehydroxyriccardin C"	"4,17-dehydroxyriccardin C; Riccardin C derivative, 20f; CHEMBL411912; BDBM23853"	24860515	C28H24O2	Investigative
M6APDG00038	"3-Benzyloxy-6,7-dimethoxy-quinoline"	"CHEMBL66932; 3-Benzyloxy-6,7-dimethoxy-quinoline; SCHEMBL8172572; ZJIOVLLLFWQBKA-UHFFFAOYSA-N; 3-benzyloxy-6,7-dimethoxyquinoline; ZINC3834031"	10085863	C18H17NO3	Investigative
M6APDG03790	ISIS 12883	.	.	.	Investigative
M6APDG04077	EGFR antisense DNA	"Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh"	.	.	Phase 1/2
M6APDG00299	N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide	SCHEMBL676079	11347053	C17H18N2O3	Investigative
M6APDG02883	L-Tryptophan-L-aspartic acid	H-TRP-ASP-OH; 71835-78-4; CHEMBL476008; CHEBI:74868; L-TRYPTOPHYL-L-ASPARTIC ACID; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)Propanamido)succinic acid; Tryptophyl-Aspartate; tryptophylaspartic acid; L-Tryptophan-L-aspartic acid; L-Trp-L-Asp; SCHEMBL10434701; CTK7I5235; WD; ZINC2556664; BDBM50266632	7019108	C15H17N3O5	Investigative
M6APDG03740	ISIS 23559	.	.	.	Investigative
M6APDG00824	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	CHEMBL213560; (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin; SCHEMBL16693054; BDBM50187134	15984068	C18H16N2O3	Investigative
M6APDG04245	CAT 1004	.	.	.	Phase 2
M6APDG03303	CLX-0921	CLX-090502; CLX-090503; CLX-090717; CLX-092402	9958278	C28H25NO7S	Phase 1
M6APDG02178	CHR-3996	"CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma"	49857317	C20H19FN6O2	Phase 1/2
M6APDG00900	FLUORESCEIN	Ful-Glo; Fluoreseptic; 41935-48-2; NSC5070	16850	C20H12O5	Approved
M6APDG03985	DS-1205	.	.	.	Phase 1
M6APDG00042	LY2157299	"Galunisertib; 700874-72-2; LY2157299; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide"	10090485	C22H19N5O	Phase 2/3
M6APDG01643	"6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione"	"CHEMBL77569; 6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione"	44315523	C8H4Cl2N2O3	Investigative
M6APDG03577	MT-061	"MT-061; Fatty acid biosynthesis inhibitor (Gram positive bacterial infection), MaxThera; MT-061 lead series, Biota; MT-061 lead series, MaxThera"	.	.	Investigative
M6APDG03640	ISIS 2974	.	.	.	Investigative
M6APDG04313	Melanotetan II	"Monorden; UNII-I60EH8GECX; I60EH8GECX; CHEMBL414883; CHEBI:556075; (1aR,2Z,4E,14R,15aR)-8-chloro-9,11-dihydroxy-14-methyl-1a,14,15,15a-tetrahydro-6H-oxireno[e][2]benzoxacyclotetradecine-6,12(7H)-dione; Monorderne; RDC; C18H17ClO6; Radisicol; Radicolol; Monorden A; RHI-12648; Microlactone, 1; 3cgy; NSC-294404; 4egk; 2wer; NSC 294404; 2zbk; 1bgq; (+)-Monorden A; Radicicol R 2146; 2q8i; SCHEMBL868832; BDBM15361; MolPort-003-959-447; HMS3648C16; BDBM227589; 6H-Oxireno(e)(2)benzoxacyclotetradecin-6,12(7H)-dione, 8-chlor"	.	.	Preclinical
M6APDG00447	C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL413573; BDBM50184361	11700730	C46H61N11O7	Investigative
M6APDG01323	Fibrates	"clofibric acid; 882-09-7; 2-(4-Chlorophenoxy)-2-methylpropanoic acid; Chlorofibrinic acid; Clofibrinic acid; Chlorfibrinic acid; Clofibrin; 2-(4-CHLOROPHENOXY)-2-METHYLPROPIONIC ACID; Chlorophibrinic acid; PCIB; Clofibrate free acid; Clofibrinsaeure; Regulipid; Regadrin; PCPIB; 2-(p-Chlorophenoxy)-2-methylpropionic acid; 2-(4-Chlorophenoxy)isobutyric Acid; 4-CPIB; 2-(p-Chlorophenoxy)isobutyric acid; Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-; alpha-(p-Chlorophenoxy)isobutyric acid; Acido clofibrico; Acide clofibrique; Acidum c"	2797	C10H11ClO3	Investigative
M6APDG03750	ISIS 101952	.	.	.	Investigative
M6APDG01570	NSC-319745	"61629-60-5; HB 093; NSC-319745; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745"	43709	C19H20ClNO4	Investigative
M6APDG00739	"N,N'-Bis-(4-isopropyl-phenyl)-guanidine"	"CHEMBL81626; SCHEMBL6154563; BDBM50010754; ZINC13733773; 1,3-Bis(4-isopropylphenyl)guanidine"	13781937	C19H25N3	Investigative
M6APDG04358	MX-7065	"Cdc25 phosphatase inhibitors, Maxia Pharmaceuticals; MX-7102; MX-7174; MX-7214; MX-7306"	.	.	Terminated
M6APDG04022	HER2-specific T cells	.	.	.	Phase 1
M6APDG00208	4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol	"CHEMBL420530; 765883-50-9; 4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol; CTK2G7588; DTXSID10444870; BDBM50066547; 4-[2-[(6-Phenylhexyl)amino]ethyl]phenol; Phenol, 4-[2-[(6-phenylhexyl)amino]ethyl]-"	10782907	C20H27NO	Investigative
M6APDG01675	Z-leu-Val-Agly-Val-OBzl	Z-leu-Val-Agly-Val-OBzl; CHEMBL263061	44355152	C32H45N5O7	Investigative
M6APDG03455	OSI-75	.	.	.	Investigative
M6APDG04239	VDA-1102	.	.	.	Phase 2
M6APDG01915	PF-3644022	PF3644022; PF 3644022	44631903	C21H18N4OS	Investigative
M6APDG00203	GNF-PF-1399	GNF-PF-2708; GNF-PF-4643	107464	C17H21IN2	Investigative
M6APDG02256	TAMARIXETIN	"Tamarixetin; 603-61-2; 4'-Methoxyquercetin; 4'-O-Methylquercetin; Quercetin 4'-methyl ether; UNII-73WRA8Z8M8; 3,3',5,7-Tetrahydroxy-4'-methoxyflavone; 4'-O-Methyl Quercetin; Quercetin-4'-methylether; 73WRA8Z8M8; CHEMBL226034; CHEBI:67492; 3,5,7-Trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3,5,7-trihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 4'-Methoxy-3,3',5,7-tetrahydroxyflavone; Tamaraxetin; 3-O-rhamnopyranosyl-1-2-glucopyranoside; 3-O-alpha-L-rhamnopyranosyl-1-2-beta-D-glucopyranoside; AC1NQYX7"	5281699	C16H12O7	Investigative
M6APDG03983	SAM-6	.	.	.	Phase 1
M6APDG01879	3-chloro-4-(o-tolylthio)benzonitrile	CHEMBL490956; 3-chloro-4-(o-tolylthio)benzonitrile; BDBM50248506	44565102	C14H10ClNS	Investigative
M6APDG01238	BIX-01294	BIX01294; BIX 01294	25150857	C28H38N6O2	Preclinical
M6APDG01748	Tic-D-Phe-Arg-2-Nal-NHCH3	CHEMBL381357; Tic-D-Phe-Arg-2-Nal-NHCH3	44409257	C39H46N8O4	Investigative
M6APDG01242	GSK-1838705A	GSK 1838705A; GSK1838705A	25182616	C27H29FN8O3	Investigative
M6APDG00512	E-3030	"Dual PPAR alpha/gamma agonists, Eisai"	11949481	C44H44CaCl2F2N2O10	Discontinued in Phase 1
M6APDG01641	"4-Methyl-3,6-dihydro-1H-pyridin-(2Z)-ylideneamine"	AKOS006358726	44313256	C6H10N2	Investigative
M6APDG04270	IT-101	.	.	.	Phase 3
M6APDG01354	RWJ-67657	215303-72-3; RWJ-67657; RWJ 67657; RWJ67657; 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; CHEMBL190333; 4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol; 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-Phenylpropyl)-5-(4-Pyridyl)imidazole; 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridyl)imidazol-2-yl]but-3-yn-1-ol; 4-(4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl)-3-butyn-1-ol	3008319	C27H24FN3O	Phase 1
M6APDG00105	PNRI-299	"PNRI-299; 550368-41-7; UNII-2WW6I6D1Z1; 2WW6I6D1Z1; PNRI299; ZINC1489322; BCP16043; AKOS030526844; CS-3985; HY-15131; 1H-(1,2,4)Triazolo(1,2-a)pyridazine-5-carboxamide, 2-(3-cyanophenyl)-2,3,7,8-tetrahydro-1,3,7-trioxo-N-(phenylmethyl)-"	10318848	C21H15N5O4	Investigative
M6APDG00622	Tilarginine acetate	"53308-83-1; L-NMMA acetate; UNII-2FL3530AF2; 2FL3530AF2; DSSTox_RID_81122; DSSTox_CID_25780; DSSTox_GSID_45780; SMR000449329; CAS-53308-83-1; N-omega-Monomethyl-L-arginine monoacetate, 99%"	135242	C9H20N4O4	Phase 3
M6APDG02472	Tolbutamide	Aglicid; Arcosal; Arkozal; Artosin; Artozin; Beglucin; Butamid; Butamide; Butamidum; Diaben; Diabesan; Diabetamid; Diabetol; Diabuton; Diasulfon; Diaval; Dirastan; Dolipol; Drabet; Glyconon; Ipoglicone; Mobenol; Orabet; Oralin; Oramide; Orezan; Orinase; Orinaz; Oterben; Pramidex; Rastinon; Restinon; Tarasina; Tolbet;Tolbusal; Tolbutamid; Tolbutamida; Tolbutamidum; Tolbutone; Toluina; Tolumid; Toluran; Toluvan; Tolylsulfonylbutylurea; Willbutamide; Apotex Brand of Tolbutamide; Aventis Brand of Tolbutamide; BerlinChemie Brand of Tolbutamide; Butamide Brand of Tolbutamide; Hoechst Brand of Tolbutamide; Pfizer Brand of Tolbutamide; TOLBUTAMIDE USP; Tolbutamide Aventis Brand; Tolbutamide Butamide Brand; Tolbutamide Hoechst Brand; Tolbutamide Pfizer Brand; Valdecasas Brand of Tolbutamide; Yamanouchi Brand of Tolbutamide; D 860; HLS 831; T 0891; U 2043; Apo-Tolbutamide; Berlin-Chemie Brand of Tolbutamide; Novo-Butamide; Orinase (TN); Sk-tolbutamide; Tol-Tab; Tolbutamida [INN-Spanish]; Tolbutamidum [INN-Latin]; Tolbutamide [INN:BAN:JAN]; R.A.N. Brand of Tolbutamide; Tolbutamid R.A.N.; Tolbutamide (JP15/USP/INN); N-4-Methylbenzolsulfonyl-N-butylurea; N-4-(Methylbenzolsulfonyl)-n-butylurea; N-Butyl-N'-p-toluenesulfonylurea; N-n-Butyl-N'-tosylurea; N-(4-Methylbenzenesulfonyl)-N'-butylurea; N-(4-Methylphenylsulfonyl)-N'-butylurea; N-(p-Tolylsulfonyl)-N'-butylcarbamide; N-Butyl-N'-(4-methylphenylsulfonyl)urea; N-Butyl-N'-(p-tolylsulfonyl)urea; N-Butyl-N'-toluene-p-sulfonylurea; N-(p-tolylsulfonyl)-N'-n-butylurea; 1-Butyl-3-(4-methylphenylsulfonyl)urea; 1-Butyl-3-(p-methylphenylsulfonyl)urea; 1-Butyl-3-(p-tolylsulfonyl)urea; 1-Butyl-3-(para-tolylsulfonyl) urea; 1-Butyl-3-tosylurea; 1-butyl-3-(4-methylphenyl)sulfonylurea; 1-p-Toluenesulfonyl-3-butylurea; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; 3-(p-tolylsulfonyl)-1-butylurea; 3-[p-Tolyl-4-sulfonyl]-1-butylurea	5505	C12H18N2O3S	Approved
M6APDG03312	tirotundin	Tirotundin; 56377-67-4; MEGxp0_000078; GTPL8700; CHEMBL464453; MolPort-039-052-526; ZINC40393738; BDBM50394803; AKOS032948657	9975297	C19H28O6	Investigative
M6APDG01950	6-bromoindirubin-3-oxime	6-bromoindirubin-3'-oxime (BIO)	448949	C16H10BrN3O2	Investigative
M6APDG02700	"5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione"	"CHEMBL282003; 5,7-dichloroquinoxaline-2,3-diol; 5,7-Dichloro-quinoxaline-2,3-diol; BAS 01357242; 5,7-dichloro-1,4-dihydroquinoxaline-2,3-dione; 5,7-Dichloro-1,4-dihydro-2,3-quinoxalinedione; MLS000026787; AC1LCHFV; 5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione; Oprea1_426848; SCHEMBL7345532; SCHEMBL2639494; MolPort-002-737-915; DBSHFABBWSZJLZ-UHFFFAOYSA-N; HMS2397P18; ZINC12428297; STK782684; BDBM50008757; AKOS022421131; AKOS005619834; AKOS000543707; MCULE-5094494417; ST088493; ST042190; SMR000010423; 4029-54-3"	650260	C8H4Cl2N2O2	Investigative
M6APDG02789	2-Methoxyestradiol	"ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene"	66414	C19H26O3	Phase 2
M6APDG04214	PF-04236921	.	.	.	Phase 2
M6APDG03085	Nicotinamide	"Aminicotin; Amixicotyn; Amnicotin; Benicot; Dipegyl; Endobion; Enduramide; Hansamid; Mediatric; Niacevit; Niacinamide; Niacotinamide; Niamide; Nicamina; Nicamindon; Nicasir; Nicobion; Nicofort; Nicogen; Nicomidol; Nicosylamide; Nicota; Nicotamide; Nicotilamide; Nicotililamido; Nicotinamid; Nicotinamida; Nicotinamidum; Nicotinsaeureamid; Nicotinsaureamid; Nicotol; Nicotylamide; Nicotylamidum; Nicovit; Nicovitina; Nicovitol; Nicozymin; Nikasan; Nikazan; Nikotinamid; Nikotinsaeureamid; Niocinamide; Niozymin; Papulex; Pelmin; Pelmine; Savacotyl; Amid kyseliny nikotinove; Amid kyseliny nikotinove [Czech]; Amide PP; Astra Brand of Niacinamide; Austrovit PP; Delonin amide; Factor pp; Inovitan PP; Jenapharm Brand of Niacinamide; Merck Brand of Niacinamide; Niacinamide Astra Brand; Niacinamide Jenapharm Brand; Niacinamide Merck Brand; Niacinamide Pharmagenix Brand; Niacinamide [USAN]; Niavit PP; Nicotine acid amide; Nicotine amide; Nicotinic acid amide; Nicotinic amide; Nicotinsaureamid Jenapharm; Nicotinsaureamid [German]; Nikotinsaeureamid [German]; Pelonin amide; Pharmagenix Brand of Niacinamide; Vitamin B; Vitamin PP; Witamina PP; Nicosan 2; Vitamin H1; B 3, Vitamin; B3, Vitamin; Beta-Pyridinecarboxamide; Jenapharm, Nicotinsaureamid; Nandervit-N; Niacin-Vitamin B3; Niacinamide (USP); Nicotinamida [INN-Spanish]; Nicotinamide (Niacinamide); Nicotinamidum [INN-Latin]; Niko-tamin; PP-Faktor; Vi-Nicotyl; Vitamin B (VAN); M-(Aminocarbonyl)pyridine; Niacinamide, Nicotinic acid amide, Nicotinamide; Nicotinamide (JP15/INN); Nicotinamide, niacin, vitamin B3; Nicotinamide-carbonyl-14C; Pyridine-3-carboxamide; Pyridine-3-carboxylic acid amide; 3 Pyridinecarboxamide; 3-Carbamoylpyridine; 3-Pyridinecarboxamide; 3-Pyridinecarboxylic acid amide"	936	C6H6N2O	Approved
M6APDG03131	RWJ-68354	"RWJ-68354; CHEMBL115769; 2-(4-FLUOROPHENYL)-4-METHOXY-3-(PYRIDIN-4-YL)-1H-PYRROLO[2,3-B]PYRIDIN-6-AMINE; rwj68354; SCHEMBL149547; BDBM15457; BDBM50215267; AKOS000280165"	9819053	C19H15FN4O	Investigative
M6APDG01339	Cromoglicate	Crolom (TN); Intal (TN); Nasalcrom (TN); Opticrom (TN); Optrex Allergy (TN); Prevalin (TN); Rynacrom (TN)	2882	C23H16O11	Approved
M6APDG03150	NVP-ADW742	"NVP-ADW742; 475488-23-4; ADW-742; 475489-15-7; UNII-MXS2N5862L; ADW742; MXS2N5862L; CHEMBL399021; 5-(3-(Benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)-cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-(Benzyloxy)phenyl)-7-(cis-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; C28H31N5O; 5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine"	9825149	C28H31N5O	Investigative
M6APDG00661	8-Methoxy-2-phenyl-3H-quinazolin-4-one	.	135439437	C15H12N2O2	Investigative
M6APDG00199	4-[2-(4-Phenyl-butoxy)-ethyl]-phenol	CHEMBL119100; 4-[2-(4-phenylbutoxy)ethyl]phenol; 4-[2-(4-Phenyl-butoxy)-ethyl]-phenol; BDBM50066548	10707190	C18H22O2	Investigative
M6APDG03176	SB-213068	SB-213068; CHEMBL306229; SCHEMBL7822831; FJENKDXEWRLENI-UHFFFAOYSA-N; BDBM50085043; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid; alpha-Ethoxy-4-[2-[methyl(benzoxazole-2-yl)amino]ethoxy]benzenepropanoic acid; 3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-ethoxypropanoic acid; 3-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-ethoxy-propionic acid(SB-213068)	9843045	C21H24N2O5	Investigative
M6APDG00654	7-Methyl-Gpppa	.	135415790	C21H30N10O17P3+	Investigative
M6APDG00444	Ac-hPhe-Leu-Phe-LeuVSMe	CHEMBL379669; Ac-hPhe-Leu-Phe-LeuVSMe; BDBM50186702	11693148	C35H50N4O6S	Investigative
M6APDG03984	CIGB-128	"HeberPAG; IFN alpha2b + IFN gamma (injectable, skin cancer), CIGB"	.	.	Phase 1
M6APDG03812	LM-CD45	"Anti-CD45, Baxter; Anti-CD45, Cantab"	.	.	Phase 1
M6APDG04348	TNFQb therapeutic vaccines	"TNFQb; CYT-020-TNFQb; TNF-targeted vaccine (inflammation, Immunodrug), Cytos Biotechnology; TNFQb therapeutic vaccines (rheumatoid arthritis/psoriasis/Crohn's disease); TNFQb therapeutic vaccines (rheumatoid arthritis/psoriasis/Crohn's disease), Cytos; Immunodrug vaccines (TNF) (rheumatoid arthritis/psoriasis/Crohn's disease), Cytos"	.	.	Terminated
M6APDG01273	N-(biphenyl-4-ylsulfonyl)-D-leucine	N-(biphenyl-4-ylsulfonyl)-D-leucine; DB07446; (R)-2-(biphenyl-4-ylsulfonamido)-4-methylpentanoic acid; (2R)-4-methyl-2-(4-phenylbenzenesulfonamido)pentanoic acid	25271580	C18H21NO4S	Investigative
M6APDG00336	(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid	LT175; (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid; 862901-87-9; CHEMBL191275; LRG; (2S)-3-phenyl-2-(4-phenylphenoxy)propanoic Acid; SCHEMBL20553479; BDBM28759; SYN5198; AOB2972; MolPort-039-138-772; ZINC13671695; LT 175; DB08121; LT175 (S-1); NCGC00402292-03	11483970	C21H18O3	Investigative
M6APDG03310	"3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline"	"CHEMBL302545; 3-(1H-indol-3-yl)-6,7-dimethoxy-quinoline; SCHEMBL8172242"	9972296	C19H16N2O2	Investigative
M6APDG00251	isothiourea-1a	IT1a	11176403	C19H30N4S2	Investigative
M6APDG02816	(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone	"BAS 02052938; AC1LDSCA; N-Benzoylpyrazole deriv., 5; 4-nitropyrazolyl phenyl ketone; CHEMBL244908; 1-benzoyl-4-nitro-1H-pyrazole; ZINC37183; BDBM23703; AKOS000577075; (4-nitropyrazol-1-yl)-phenylmethanone; MCULE-3158742884; ST033219; (4-Nitro-pyrazol-1-yl)-phenyl-methanone; SR-01000312627"	674651	C10H7N3O3	Investigative
M6APDG00004	"6,7-Dimethoxy-3-((E)-styryl)-quinoline"	"CHEMBL70149; 6,7-Dimethoxy-3-((E)-styryl)-quinoline; ZINC3834019; BDBM50039041"	10017166	C19H17NO2	Investigative
M6APDG00266	PNU-282987	"Benzamide, N-(3R)-1-azabicyclo[222]oct-3-yl-4-chloro-; PNU282987; 123464-89-1; 711085-63-1; PNU 282987; UNII-27M563MU5U; N-(3R)-1-Azabicyclo[222]oct-3-yl-4-chlorobenzamide; CHEMBL177611; 27M563MU5U; Benzamide, N-(3R)-1-azabicyclo(222)oct-3-yl-4-chloro-; CHEMBL554984; PNU-282,987; PNU-282987 free base; SCHEMBL677422; PNU282987HCl; GTPL3988; CHEBI:92508; CTK2H4027; MolPort-023-219-197; MolPort-003-983-664; HMS3268J18; ZINC3990028; BDBM50161764; BDBM50161753; ABP000998; AKOS016339643; AKOS024457037; KS-1399; API0008100;  N-((3R)-1-Azabicyclo(222)oct-3-yl)-4-chlorobenzamide hydrochloride; ISIS 25302"	11243536	C14H18Cl2N2O	Terminated
M6APDG00550	Gly-Arg-Gly-Asp-Ser	"Gly-arg-gly-asp-ser; 96426-21-0; GRGDS; glycyl-arginyl-glycyl-aspartyl-serine; H-Gly-Arg-Gly-Asp-Ser-OH; CHEMBL417553; L-Serine, N-(N-(N-(N2-glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-; GRGDS Peptide; C17H30N8O9; AC1L3XCA; NH2-Gly-Arg-Gly-Asp-Ser; SCHEMBL17440322; RGNVSYKVCGAEHK-GUBZILKMSA-N; HY-P0295; ZINC13455558; MFCD00076459; BDBM50414896; BDBM50006330; AKOS030622941; NCGC00167212-01; Gly-Arg-Gly-Asp-Ser, &gt; LS-178299; FT-0772116; L-Serine,glycyl-L-arginylglycyl-L-a-aspartyl-"	123811	C17H30N8O9	Investigative
M6APDG03120	L-756568	CHEMBL96097; L-756568; BDBM50092097; (S)-2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid; 2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid(L-756568)	9805998	C24H28N4O6S	Investigative
M6APDG01401	FENBUFEN	"fenbufen; 36330-85-5; Lederfen; Cinopal; Napanol; Bufemid; 4-(4-Biphenylyl)-4-oxobutyric acid; 3-(4-Phenylbenzoyl)propionic acid; 3-(4-Biphenylylcarbonyl)propionic acid; 4-(biphenyl-4-yl)-4-oxobutanoic acid; gamma-Oxo(1,1'-biphenyl)-4-butanoic acid; 3-(4-Biphenylcarbonyl)propionic acid; Cinopol; Fenbufenum [INN-Latin]; Fenbufene [INN-French]; 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid; CL-82204; CL 82204; 4-biphenyl-4-yl-4-oxobutanoic acid; Butyric acid 4-(4-biphenyl)-4-oxo-; UNII-9815R1WR9B; 4-oxo-4-(4-phenylphenyl)butanoic a"	3335	C16H14O3	Approved
M6APDG04196	AG140699	.	.	.	Phase 2
M6APDG04062	HER-2-targeting CAR T Cells	.	.	.	Phase 1/2
M6APDG04177	DN24-02	Lapuleucel-T	.	.	Phase 2
M6APDG00431	LY2109761	LY-2109761; LY 2109761	11655119	C26H27N5O2	Investigative
M6APDG01842	TG-0054	"CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology"	44479007	C27H51N8O3P	Phase 2
M6APDG02487	Rogletimide	"ROGLETIMIDE; Pyridoglutethimide; 92788-10-8; 3-PYG; (+-)-Pyridoglutethimide; Racemic-pyridoglutethimide; 2-Ethyl-2-(4-pyridyl)glutarimide; 121840-95-7; 3-Ethyl-3-(4-pyridyl)piperidine-2,6-dione; 2,6-Piperidinedione, 3-ethyl-3-(4-pyridinyl)-; CHEMBL289116; 3-ethyl-3-pyridin-4-ylpiperidine-2,6-dione; 3-ethyl-3-(pyridin-4-yl)piperidine-2,6-dione; (+/-) 3-Ethyl-3-(4-pyridinyl)-2,6-piperidinedione; 3-ethyl-3-(4-pyridinyl)-2,6-piperidinedione; Rogletimida; Rogletimidum; Rogletimidum [INN-Latin]; Rogletimida [INN-Spanish]"	56487	C12H14N2O2	Terminated
M6APDG03169	LG-121071	LGD-121071	9839132	C15H15F3N2O	Investigative
M6APDG00355	C[-Arg-Gly-Asp-Acpca36-]	CHEMBL557157	11518823	C18H29N7O7	Investigative
M6APDG03786	ISIS 9002	.	.	.	Investigative
M6APDG00006	"5-thia-8,11,14,17-eicosatetraenoic acid"	"CHEMBL460444; 5-thia-8,11,14,17-eicosatetraenoic acid; BDBM50242353; (8Z,11Z,14Z,17Z)-5-Thia-8,11,14,17-icosatetraenoic acid"	10019057	C19H30O2S	Investigative
M6APDG03778	ISIS 32028	.	.	.	Investigative
M6APDG02100	N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide	CHEMBL1097747; BDBM50317991	46887438	C20H18N2O2	Investigative
M6APDG01375	"5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione"	.	3082127	C9H6OS3	Investigative
M6APDG01173	(E)-10-nitrooctadec-9-enoic acid	"10-nitrooleic acid; 10-nitro-9E-octadecenoic acid; 10-Nitro Oleic Acid; (E)-10-nitrooctadec-9-enoic acid; 10-nitroelaidic acid; 875685-46-4; UNII-1N19AGY57Y; CHEMBL561371; 1N19AGY57Y; CHEBI:86285; (9E)-10-nitrooctadecenoic acid; 10-Nitrooleate; 10-nitro-oleic acid; 10-Nitroelaidate; 88127-53-1; 9-Octadecenoic acid, 10-nitro-, (9E)-; E-10-nitrooleic acid; Oa-NO2; 10-nitro-9E-Octadecenoate; (9E)-10-Nitrooctadecenoate; 10-Nitro-9-octadecenoic acid; SCHEMBL1018141; CXA-10; (e)-10-Nitrooctadec-9-enoate; WRADPCFZZWXOTI-BMRADRMJSA-N"	24836820	C18H33NO4	Investigative
M6APDG03030	M2698	HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)	89808643	C21H19ClF3N5O	Phase 1
M6APDG00768	"2-Phenethyl-1,2-dihydro-indazol-3-one"	"CHEMBL3144586; 2-Phenethyl-1,2-dihydro-indazol-3-one; CHEMBL8415; BDBM50009007; ZINC138045731"	14898714	C15H14N2O	Investigative
M6APDG00754	LUDARTIN	"Ludartin; CHEMBL1097764; 36149-87-8; BDBM50318394; 6,8a-Dimethyl-3-methylene-3a,4,5,7,7a,8a,8b,8c-octahydro-3H-1,8-dioxa-cyclopenta[h]cyclopropa[a]azulen-2-one (Ludartin)"	14355826	C15H18O3	Investigative
M6APDG02749	5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine	"AC1O706P; CHEMBL195248; SCHEMBL4225537; SCHEMBL4225546; BDBM8631; (5-pyrimidylmethylene)indane 28a; ZINC13535842; 5-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyrimidine"	6539805	C14H11FN2	Investigative
M6APDG02269	"(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid"	"(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid; 12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid"	5282316	C18H31NO4	Investigative
M6APDG02999	"2-Methyl-2,4-Pentanediol"	"2-METHYL-2,4-PENTANEDIOL; 107-41-5; 2-Methylpentane-2,4-diol; Pinakon; 2,4-Dihydroxy-2-methylpentane; 2,4-Pentanediol, 2-methyl-; Diolane; Isol; 4-Methyl-2,4-pentanediol; 1,1,3-Trimethyltrimethylenediol; 2-Methyl pentane-2,4-diol; 2-Methyl-2,4-pentandiol; Caswell No. 574; alpha,alpha,alpha'-Trimethyltrimethylene glycol; 1,3-dimethyl-3-hydroxybutanol; Hexylene glycol [NF]; HSDB 1126; 1,3,3-trimethyl-1,3-propanediol; (+-)-2-Methyl-2,4-pentanediol; NSC 8098; EINECS 203-489-0; EPA Pesticide Chemical Code 068601; BRN"	7870	C6H14O2	Investigative
M6APDG01065	2-Methylamino-succinic acid(NMDA)	"N-Methyl-D-aspartic acid; N-methyl-D-aspartic acid; NMDA; 6384-92-5; N-Methyl-D-aspartate; N-Methylaspartate; D-Aspartic acid, N-methyl-; N-Me-D-Asp-OH; (R)-2-(Methylamino)succinic acid; NMDA (N-Methyl-D-aspartic acid); Methyl aspartic acid; n-methyl-d-aspartic acid (nmda); UNII-1903B9Q6PI; N-Methyl aspartic acid; (2R)-2-(methylamino)butanedioic acid; 2-Methylamino-succinic acid; BRN 1724431; CHEMBL291278; CHEBI:31882; HOKKHZGPKSLGJE-GSVOUGTGSA-N; 1903B9Q6PI; N-Methyl-D-aspartic Acid, Hydrate; AK-44365; W-203368; N-Methyl-D-aspartic acid, 98%"	22880	C5H9NO4	Investigative
M6APDG01414	NSC-356483	"NSC-356483; CHEMBL495563; NSC356483; AC1L7M6E; ZINC1583041; BDBM50265441; 1-(furan-2-ylmethyl)-5-(4-methoxyphenyl)triazole; 1-(furan-2-ylmethyl)-5-(4-methoxyphenyl)-1H-1,2,3-triazole"	337660	C14H13N3O2	Investigative
M6APDG00988	AG1295	"6,7-Dimethyl-2-phenylquinoxaline; 71897-07-9; ag1295; AG-1295; AG 1295; CHEMBL7724; TYRPHOSTIN AG 1295; BiomolKI_000019; Tyrphostin AG-1295; AC1Q4WCY; AC1L1CSX; ChemDiv2_000256; BiomolKI2_000029; AC1Q2O4Y; cid_2048; BMK1-C7; MLS001194710; SCHEMBL925674; IFLab1_005463; GTPL5914; AC1Q2E07; CHEBI:94668; BDBM33408; CTK2H8610; DTXSID10274351; MolPort-000-182-258; FQNCLVJEQCJWSU-UHFFFAOYSA-N; 2-Phenyl-6,7-dimethylquinoxaline; HMS1427I07; HMS3229M19; HMS2879L07; HMS1369L14; ZINC257983; HMS3428I13; API01003; 6,7-Dimethyl-2-phenyl-quinoxaline"	2048	C16H14N2	Terminated
M6APDG04178	RG7221	.	.	.	Phase 2
M6APDG04279	ABP 501	.	.	.	Phase 3
M6APDG03846	AMG 811	.	.	.	Phase 1
M6APDG03767	ISIS 32003	.	.	.	Investigative
M6APDG02000	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	"6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-7H-purin-2-amine; 444722-81-0; 1h1r; AC1L1IG7; CHEMBL341273; SCHEMBL6790651; BDBM5531; CTK1D2420; DTXSID10274437; O6-Cyclohexylmethylguanine deriv. 15; DB07203; 2-(3 -Chloroanilino)-6-cyclohexylmethoxypurine; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine; N-(3-Chlorophenyl)-6-(cyclohexylmethoxy)-9H-purine-2-amine; 1H-Purin-2-amine, N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-"	4565	C18H20ClN5O	Investigative
M6APDG01658	1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole	CHEMBL112074; 1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole	44341253	C20H19N3	Investigative
M6APDG03460	Gold trichloride sodium chloride	.	.	.	Investigative
M6APDG01199	ABT-263	"Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide"	24978538	C47H55ClF3N5O6S3	Phase 3
M6APDG02542	ASP-015K	"Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; ASP-015K; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; ASP015K; JNJ-54781532; D10653; Peficitinib pound A"	57928403	C18H22N4O2	Phase 3
M6APDG01904	LY2801653	"Merestinib; LY2801653; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N"	44603533	C30H22F2N6O3	Phase 2
M6APDG03781	CX-02	"CX-05; CXCR4 monoclonal antibodies (cancer); CXCR4 monoclonal antibodies (cancer), Northwest Biotherapeutics; CXCR4 therapeutics (cancer), Northwest Biotherapeutics"	.	.	Investigative
M6APDG01839	N-(3-phenylamino-4-pyridinyl)methanesulfonamide	N-(3-phenylamino-4-pyridinyl)methanesulfonamide; CHEMBL1079877; BDBM50311367	44475843	C12H13N3O2S	Investigative
M6APDG03255	TGX-221	TGX 221	9907093	C21H24N4O2	Investigative
M6APDG01505	MCI-186	"Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one"	4021	C10H10N2O	Approved
M6APDG00789	LY335979	"Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride"	153997	C32H34Cl3F2N3O2	Discontinued in Phase 3
M6APDG03398	V85546	.	.	.	Discontinued in Phase 1
M6APDG00879	4-chloro-1-guanidino-7-isoquinolinesulphonamide	223671-02-1; 1-GUANIDINO-4-CHLORO-7-SULFAMOYL-ISOQUINOLINE; 4-chloro-1-guanidino-7-isoquinolinesulphonamide; 2-(4-chloro-7-sulfamoylisoquinolin-1-yl)guanidine; CHEMBL227782; SCHEMBL6437735; CTK4E9305; BDBM16132; DTXSID90586545; FXVHAOFNNRNCRJ-UHFFFAOYSA-N; AKOS015966420; 1-guanidino-7-sulfonamidoisoquinoline 6; ACM223671021; 4-chloro-1-guanidino-7-sulphamoylisoquinoline	16658353	C10H10ClN5O2S	Investigative
M6APDG03834	ISIS-CRP	"1-(Tert-butyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; 172889-27-9; pp2; PP 2; 1-(tert-butyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; AG 1879; 1-tert-butyl-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; PP2; 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine; AG-1879; CHEMBL406845; CHEBI:78331; AK-60369; 1-tert-butyl-3-(4-chlorophenyl)pyrazolo[3,4-d]pyrimidin-4-amine; 3-(4-chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H16ClN5; 1qpe; 4few; PBBRWFOVCUAONR-UHFFFAOYSA-N; AG1879; PP 2 (AG 1879)"	.	.	Phase 1
M6APDG02885	2-amino-5-phenylthiophene-3-carboxamide	"2-amino-5-phenylthiophene-3-carboxamide; 4815-35-4; 2-Amino-5-phenyl-thiophene-3-carboxylic acid amide; CHEMBL382565; 2-AMINO-5-PHENYL-3-THIOPHENECARBOXAMIDE; EN300-04586; AC1LDZKQ; ACMC-209kch; 3-thiophenecarboxamide, 2-amino-5-phenyl-; AC1Q5DNT; CBMicro_037044; Cambridge id 5914467; AC1Q4Z6N; Oprea1_326775; Oprea1_445444; SCHEMBL3510525; ZINC87504; CTK4J0691; DTXSID60351580; UHEGYTDIDBFUJD-UHFFFAOYSA-N; MolPort-000-223-057; HMS1757A19; ZX-AL001522; ANW-30639; STK346852; SBB015475; BDBM50186655; AKOS000274130; ACM4815354"	703965	C11H10N2OS	Investigative
M6APDG01723	N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide	CHEMBL198055; N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide	44404478	C16H15NO4	Investigative
M6APDG00947	4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile	CHEMBL411829; 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile; SCHEMBL6033918	18516979	C17H12N4	Investigative
M6APDG00956	"1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane"	"1,2-DIBROMO-4-(1,2-DIBROMOETHYL)CYCLOHEXANE; 3322-93-8; Citex BCL 462; Saytex BCL 462; Cyclohexane, 1,2-dibromo-4-(1,2-dibromoethyl)-; 1-(1,2-Dibromoethyl)-3,4-dibromocyclohexane; Vinylcyclohexene tetrabromide; 1,2-DIBROMO-4-(1,2-DIBROMOETHYL)-CYCLOHEXANE; 4-(1,2-Dibromoethyl)-1,2-dibromocyclohexane; CCRIS 3743; HSDB 6146; EINECS 222-036-8; BRN 1927455; CHEMBL375107; AK-78933; C8H12Br4; TBECH; AC1L2COC; DSSTox_CID_4947; DSSTox_RID_77594; DSSTox_GSID_24947; MLS002454355; 3-05-00-00093 (Beilstein Handbook Reference); SCHEMBL332771"	18728	C8H12Br4	Investigative
M6APDG01662	"1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one"	CHEMBL117916; SCHEMBL7366611; BDBM50217945	44342905	C20H21F3O3	Investigative
M6APDG01154	4-amino-N-(4-iodophenyl)benzenesulfonamide	"6965-75-9; NSC63371; 4-amino-N-(4-iodophenyl)benzenesulfonamide; 4-amino-n-(4-iodo-phenyl)-benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(4-iodophenyl)-; 4-amino-N-(4-iodophenyl)benzene-1-sulfonamide; Benzenesulfonamide,4-amino-N-(4-iodophenyl)-; NSC 63371; Enamine_003086; AC1Q6VVM; AC1Q51XD; AC1L6LA2; AC1Q51XC; 4-IODOSULFANILANILIDE; CHEMBL227416; CTK5D0764; DTXSID00219913; MolPort-001-833-979; HMS1402M06; ZINC537958; NSC-63371; STK063720; AKOS000115972; NE11209; MCULE-7780071880; KB-290010; EN300-02869; SR-01000033730"	247908	C12H11IN2O2S	Investigative
M6APDG03735	ISIS 29176	.	.	.	Investigative
M6APDG00687	NSC-131736	.	135494055	C17H14N2O4	Investigative
M6APDG00677	"5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine"	.	135468219	C16H11N5O2	Investigative
M6APDG04252	Rinfabate	"RhIGFBP-3; Rinfabate, Insmed; RhIGF-BP3, Insmed; Insulin-like growth factor binding protein-3, Insmed"	.	.	Phase 2/3
M6APDG00793	"3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione"	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide	15422868	C18H12N2O2	Investigative
M6APDG03732	ISIS 29160	.	.	.	Investigative
M6APDG02661	Lithospermic acid	"Lithospermic acid; 28831-65-4; UNII-100IP83JAC; CHEMBL518243; 100IP83JAC; Lithospermic-acid; AC1O5VFB; 4-(3-(1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxo-1-propenyl)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-3-benzofurancarboxylic acid; SCHEMBL13284084; MolPort-020-005-934; ZINC4097774; BDBM50250808; AKOS026674259; 4-{(E)-2-[1-Carboxy-2-(3,4-dihydroxy-phenyl)-ethoxycarbonyl]-vinyl}-2-(3,4-dihydroxy-phenyl)-7-hydroxy-2,3-dihydro-benzofuran-3-carboxylic acid; 3-Benzofurancarboxylic acid, 4-(3-(1-carboxy-2-(3,4-dihydr"	6441498	C27H22O12	Investigative
M6APDG00717	Indirubin-3-acetoxime	.	136043837	C18H13N3O3	Investigative
M6APDG02280	Cyproterone	"Ciproterona; Ciproterone; CyPat; Cyproteron; Cyproteronum; Ciproterona Servycal; Ciproterone [DCIT]; SH 80881; Apo-cyproterone; Ciproterona Servycal (TN); Ciproterona [INN-Spanish]; Cyproterone (INN); Cyproterone [INN:BAN]; Cyproteronum [INN-Latin]; Dianette (TN); Gen-Cyproterone; Novo-cyproterone; Diane-35 (TN); (1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-1-hydroxy-8b,10a-dimethyl-2,3,3a,3b,7a,8,8a,8b,8c,9,10,10a-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-7(1H)-one; 6-Chlor-delta(6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron [German]; 6-chloro-17-hydroxy-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-diene-3,20-dione"	5284537	C22H27ClO3	Approved
M6APDG03612	ISIS 6581	.	.	.	Investigative
M6APDG01425	3-Hydroxy-benzamide	"3-hydroxybenzamide; 618-49-5; benzamide, 3-hydroxy-; 3-Hydroxy-benzamide; CHEMBL419424; 3-Hydroxy benzamide; NSC379289; 3-hydroxybenzenecarboxamide; AC1Q4ZB3; AC1L7W2U; ACMC-1B71B; Oprea1_435073; SCHEMBL161861; 3-Hydroxybenzamide, AldrichCPR; CTK2F7291; DTXSID90321635; NGMMGKYJUWYIIG-UHFFFAOYSA-N; MolPort-001-791-593; ZINC1590754; KM0548; BDBM50068769; 9282AB; ANW-33964; 3-HYDROXY-BENZOIC ACID,AMIDE; SBB079277; AKOS000207073; VZ26952; NSC-379289; MB00281; MCULE-9599926365; NCGC00323509-01; KB-32185; CJ-25437; AJ-27681; CJ-05592; SC-47787"	342403	C7H7NO2	Investigative
M6APDG00960	7-hydroxy-2-phenylchroman-4-one	"7-Hydroxyflavanone; 6515-36-2; 7-Hydroxy-2-phenylchroman-4-one; 7-Hydroxyflavanone, 98%; CHEMBL97542; CHEBI:34483; SWAJPHCXKPCPQZ-UHFFFAOYSA-N; 7-hydroxy-2-phenyl-2,3-dihydro-4H-chromen-4-one; MFCD00017487; 2,3-dihydro-7-hydroxy-2-phenyl-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-2-phenyl-; 7-hydroxy-2-phenyl-4-chromanone; 2545-13-3; 7-hydroxy-flavanone; AC1L1CGO; AC1Q6KJV; ACMC-1B5B3; Oprea1_401356; MLS001181922; SCHEMBL130266; DTXSID0022430; CTK4F5779; MolPort-002-903-717; HMS2865F07; HMS1664L06"	1890	C15H12O3	Investigative
M6APDG02817	(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	"AC1LDSCF; N-Benzoylpyrazole deriv., 7; CHEMBL244909; ZINC37188; BDBM23705; MolPort-002-174-815; AKOS000576906; 4-bromopyrazolyl 4-methylphenyl ketone; MCULE-8194486011; ST033225; AB00100488-01; (4-bromopyrazol-1-yl)-(4-methylphenyl)methanone; SR-01000521427; SR-01000521427-1"	674656	C11H9BrN2O	Investigative
M6APDG01279	7-Phenoxy-heptanoic acid hydroxyamide	7-Phenoxy-heptanoic acid hydroxyamide; CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid	25798548	C13H19NO3	Investigative
M6APDG02406	1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one	"2'-Hydroxy-4-methylchalcone; 1-(2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one; (2E)-1-(2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one; AC1NTAGW; 2-Propen-1-one, 1-(2-hydroxyphenyl)-3-(4-methylphenyl)-; 4-Methyl-2'-hydroxychalcone; MLS000777737; CHEMBL476598; SCHEMBL2807968; MolPort-000-648-204; OOEWKJHFFYCQBM-ZHACJKMWSA-N; Chalcone, 2'-hydroxy-4-methyl-; HMS2760H03; ZX-AT026696; ZINC4252606; 2'-Hydroxy-4-methyl-trans-chalcone; STK530118; AKOS005463239; SMR000414122; ST098968; 2'-Hydroxy-4-methylchalcone, AldrichCPR"	5376916	C16H14O2	Investigative
M6APDG03092	DAP-81	.	9548005	C25H20N6O4	Preclinical
M6APDG02738	4-Indan-(1E)-ylidenemethyl-pyridine	"(4-Pyridylmethylene)indane 2a; SCHEMBL4230787; BDBM8616; CHEMBL175962; SCHEMBL4230798; AC1O705V; ZINC13610822; 4-[(E)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 4-[(1E)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 4-[(E)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Oxalate"	6539790	C15H13N	Investigative
M6APDG03421	Her-2-Bi-armed ATC	"Her-2Bi-armed ATC (cancer), Roger Williams Medical Center; Anti-CD3 + anti-Her2/neu bispecific antibody armed T-cells (cancer), Roger Williams Medical Center; T-cells plus anti-CD3 + anti-Her2/neu antibody (cancer), Roger Williams Medical Center"	.	.	Discontinued in Phase 2
M6APDG03776	ISIS 32021	.	.	.	Investigative
M6APDG02469	GARCINONE D	"GARCINONE D; 107390-08-9; CHEMBL462879; Q-100046; Garcinone-D; AC1NUY2Y; Garcinia mangostana (Mangosteen); DTXSID00420547; MolPort-039-142-002; ZINC14727633; 9439AF; BDBM50250510; AB3000023; N2173; FT-0686619; 1,3,6-trihydroxy-8-(3-hydroxy-3-methylbutyl)-7-methoxy-2-(3-methylbut-2-enyl)xanthen-9-one; 1,3,6-trihydroxy-8-(3-hydroxy-3-methyl-butyl)-7-methoxy-2-(3-methylbut-2-enyl)xanthen-9-one; 9H-Xanthen-9-one, 1,3,6-trihydroxy-8-(3-hydroxy-3-methylbutyl)-7-methoxy-2-(3-methyl-2-butenyl)-"	5495926	C24H28O7	Investigative
M6APDG01794	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)	CHEMBL374862; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)	44418895	C37H49N11O6	Investigative
M6APDG03371	Recombinant human endostatin	"Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn"	.	.	Approved
M6APDG01713	Ac-R[CEHdFRWC]-NH2	CHEMBL408257; Ac-R[CEHdFRWC]-NH2	44400401	C51H70N18O11S2	Investigative
M6APDG03032	EPZ015666	EPZ-015666; EPZ 015666	90241673	C20H25N5O3	Investigative
M6APDG03113	AG-014376	"AG-014376; CHEMBL361489; SCHEMBL7159231; BDBM50154730; 6-(4-Dimethylaminomethyl-phenyl)-3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-one"	9797108	C20H21N3O	Investigative
M6APDG04300	VM-501	"IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed"	.	.	Phase 3
M6APDG00368	"6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol"	"CHEMBL362997; 6-(3,5-Dimethoxy-phenyl)-naphthalen-2-ol; BDBM50186758"	11536458	C18H16O3	Investigative
M6APDG00321	7-Mercapto-heptanoic acid biphenyl-3-ylamide	CHEMBL320323	11449823	C19H23NOS	Investigative
M6APDG00223	4-[3-(4-Phenyl-butylamino)-propyl]-phenol	CHEMBL42414; 4-[3-(4-Phenyl-butylamino)-propyl]-phenol; BDBM50066538	10853103	C19H25NO	Investigative
M6APDG01718	4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one	CHEMBL194684; 4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one	44403402	C17H23N3O2	Investigative
M6APDG00330	Galarubicin	"DA-125; Metalloprotease inhibitors (cancer), Dong-A"	114759	C30H32FNO13	Discontinued in Phase 2
M6APDG00375	"(2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine"	"CHEMBL175596; 872872-12-3; (2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine; SCHEMBL4045943; CTK3C4931; DTXSID20468426; BDBM50179205; AKOS030605024; Indeno[1,2-c]pyrazol-3-amine, 1,4-dihydro-N-phenyl-"	11550535	C16H13N3	Investigative
M6APDG00658	HESPERADIN	.	135421442	C29H32N4O3S	Investigative
M6APDG00356	C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL383250; BDBM50184354	11520823	C46H59N11O9	Investigative
M6APDG01202	Ro5203280	"Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394"	25015677	C27H35F2N7O3	Investigative
M6APDG00508	Marimastat	"Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide"	119031	C15H29N3O5	Phase 3
M6APDG02160	PTC299	"6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002"	49787172	C25H20Cl2N2O3	Phase 2
M6APDG01644	"7-chloro-3-hydroxyquinazoline-2,4-dione"	"CHEMBL80594; 3-hydroxy-7-chloro-1H-quinazoline-2,4-dione; 705977-20-4; 7-chloro-3-hydroxyquinazoline-2,4-dione; BDBM50144806"	44315786	C8H5ClN2O3	Investigative
M6APDG01236	isothiourea-1t	IT1t	25147749	C21H34N4S2	Investigative
M6APDG00333	TESTOSTERONE BUCICLATE	CDB-1781; Testosterone buciclate; Testosterone trans-4-n-butylcyclohexylcarboxylate; [17beta(trans)]-(4-Butylcyclohexylcarbonyloxy)androst-4-en-3-one; 20 Aet-1	114819	C30H46O3	Phase 1
M6APDG03257	BB-1101	BB-1101; CHEMBL432079; SCHEMBL1844243; BDBM50070453	9908389	C21H31N3O4	Terminated
M6APDG02193	Rofecoxib	Ceoxx; Refecoxib; Vioxx; Cahill May Roberts brand of rofecoxib; MSD brand of rofecoxib; Merck Frosst brandof rofecoxib; Merck brand of rofecoxib; Vioxx Dolor; MK 0966; MK 0996; MK 966; MK0966; Ceeoxx (TN); Ceoxx (TN); KS-1107; MK-0966; MK-966; Merck Sharp & Dhome brand of rofecoxib; Vioxx (TN); Vioxx (trademark); Rofecoxib (JAN/USAN/INN); 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one; 3-Phenyl-4-(4-(methylsulfonyl)phenyl))-2(5H)-furanone; 3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone; 4-(4-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one; 4-(p-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one	5090	C17H14O4S	Approved
M6APDG01634	N-methyl ryanodine-succinamidate	N-methyl ryanodine-succinamidate; CHEMBL432278	44275929	C30H42N2O11	Investigative
M6APDG01669	7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL127328	44350703	C20H21NO3	Investigative
M6APDG00378	Ac-hPhe-Leu-Ala-LeuVSMe	CHEMBL207579; Ac-hPhe-Leu-Ala-LeuVSMe	11556056	C29H46N4O6S	Investigative
M6APDG04310	DX-2802	.	.	.	Preclinical
M6APDG00453	C-[-Arg-Gly-Asp-Acpca30-]	CHEMBL540622	11712622	C18H29N7O6	Investigative
M6APDG01103	RM65	CHEMBL61824; RM65; GTPL7029; SCHEMBL17767405; BDBM50215479; 2-(9H-xanthen-9-ylsulfanyl)-N-{2-[2-(9H-xanthen-9-ylsulfanyl)propanamido]ethyl}propanamide	23656549	C34H32N2O4S2	Investigative
M6APDG02293	9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine	"9-BUTYL-8-(4-METHOXYBENZYL)-9H-PURIN-6-AMINE; CHEMBL112834; 9-butyl-8-[(4-methoxyphenyl)methyl]purin-6-amine; 376629-53-7; PU4; AC1NRCWI; 1uy7; Purine-Based Inhibitor 2; SCHEMBL4320278; CTK1A9432; BDBM15375; DTXSID80415355; AKOS030562187; DB03899; 8-(4-Methoxybenzyl)-9-butyl-9H-purine-6-amine; 9-butyl-8-[(4-methoxyphenyl)methyl]-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl-8-[(4-methoxyphenyl)methyl]-"	5289227	C17H21N5O	Investigative
M6APDG02615	4-benzyloxy-2'-hydroxychalcone	CHEMBL242078; (E)-3-(4-(benzyloxy)phenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one; AC1O2DDI; SCHEMBL10768190; 4-benzyloxy-2''-hydroxychalcone; 2'-Hydroxy-4-(benzyloxy)chalcone; ZINC4775332; BDBM50241204; AKOS024335342; (E)-1-(2-hydroxyphenyl)-3-(4-phenylmethoxyphenyl)prop-2-en-1-one	6172473	C22H18O3	Investigative
M6APDG01970	muramyl dipeptide	"Muramyl Dipeptide; N-Acetylmuramyl-L-alanyl-D-isoglutamine; muramyldipeptide; CHEBI:59414; MurNAc-L-Ala-gamma-D-Glu; Acetylmuramyl-L-alanyl-D-isoglutamine; Acetylmuramyl-alanyl-isoglutamine; 87420-48-2; 53678-77-6; (4r)-4-[[(2s)-2-[[(2r)-2-[(2r,3s,4r,5r,6r)-5-Acetamido-2-(Hydroxymethyl)-3,6-Bis(Oxidanyl)oxan-4-Yl]oxypropanoyl]amino]propanoyl]amino]-5-Azanyl-5-Oxidanylidene-Pentanoic Acid"	451714	C19H32N4O11	Investigative
M6APDG03320	Afatinib	"Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens"	10184653	C24H25ClFN5O3	Approved
M6APDG03501	YK-3237	"Angiogenesis inhibitors (cancer); Angiogenesis inhibitors (cancer), Georgetown University"	.	.	Investigative
M6APDG02018	LY2784544	"LY2784544; 1229236-86-5; GANDOTINIB; LY 2784544; LY-2784544; Gandotinib (LY2784544); UNII-ANC71R916O; LY2784544(Gandotinib); ANC71R916O; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine; C23H25ClFN7O; 3-[(4-Chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)imidazo[1,2-b]pyridazin-6-amine; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-1H-pyrazol-5-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine"	46213929	C23H25ClFN7O	Phase 2
M6APDG01841	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	CHEMBL574589; 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	44478925	C19H15NO4S	Investigative
M6APDG00643	BMS-265246	BMS 265246; BMS265246	135402864	C18H17F2N3O2	Investigative
M6APDG03545	KR-33889	"KR-34285; PARP-1 inhibitors (myocardial infarction), KRICT"	.	.	Investigative
M6APDG01262	IM-12	"IM-12; 1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587"	25209788	C22H20FN3O2	Investigative
M6APDG04379	SCR-44001	"MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget"	.	.	Terminated
M6APDG03695	SX-MTR1	"MTOR modulators (small peptide mimetics, bladder cancer), Serometrix"	.	.	Investigative
M6APDG00135	7-Fluoro-3-thiophen-3-yl-quinoline	CHEMBL307093; 7-fluoro-3-thiophen-3-yl-quinoline; ZINC3834021	10398928	C13H8FNS	Investigative
M6APDG01940	SK1-I	BML-258	44815217	C17H27NO2	Investigative
M6APDG02023	LY2835219	Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);	46220502	C27H32F2N8	Approved
M6APDG00940	"5-amino-3,4-dihydroisoquinolin-1(2H)-one"	"5-amino-3,4-dihydroisoquinolin-1(2H)-one; 129075-53-2; CHEMBL594759; SCHEMBL7581623; RTPKPVYTPRJRBY-UHFFFAOYSA-N; ZINC45353622; BDBM50306284; AKOS023598631; AB53700; FCH1123505; KS-9128; CM10348; AJ-110485; 5-amino-3,4-dihydro-1(2H)-isoquinolinone; EN300-254419"	18369509	C9H10N2O	Investigative
M6APDG02092	N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide	CHEMBL1096397; BDBM50318002	46887334	C21H18N2O	Investigative
M6APDG03062	17-desmethoxy-17-aminogeldanamycin	"UNII-SLQ1AJG3VB; SLQ1AJG3VB; 17-Aminogeldanamycin; 17-Amino-17-demethoxygeldanamycin; Geldanamycin, 17-amino-17-demethoxy-; 17-Amino Geldanamycin; SCHEMBL8250568; SCHEMBL16226317; XYFFWTYOFPSZRM-TWNAANEASA-N; DB13023; 1174669-94-3"	91929099	C28H39N3O8	Investigative
M6APDG03404	AME-527	.	.	.	Discontinued in Phase 1/2
M6APDG03697	PF-03772304	"MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth"	.	.	Investigative
M6APDG01742	Phe-Pro-Glu	Phe-Pro-Glu	44408683	C19H25N3O6	Investigative
M6APDG01083	HQK-1004	"Arginine butyrate; VX-105; VX-105); Arginine butyrate (hematological malignancies), HemaQuest"	23622962	C34H74N12O14	Phase 2
M6APDG00506	Oblimersen	.	118984457	C172H204N62Na17O91P17S17	Phase 3
M6APDG02809	MK-1496	.	67313626	C14H24N2O	Phase 1
M6APDG02898	Flosulide	CGP-28238; CGP-28328; CGS-28238; SH-459; ZK-38997	71246	C16H13F2NO4S	Terminated
M6APDG03570	ISIS 122976	.	.	.	Investigative
M6APDG03567	ISIS 122971	.	.	.	Investigative
M6APDG02043	MLN-0905	"PLK-1 inhibitor (lymphoma), Millennium"	46235922	C24H25F3N6S	Investigative
M6APDG01649	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	"CHEMBL101581; 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline"	44331083	C17H14BrNO3	Investigative
M6APDG00684	FR167653	"HMPQTEPEMQZWQH-ROUUACIJSA-N; 2-(5-AMINO-6-OXO-2-PHENYL-6H-PYRIMIDIN-1-YL)-N-[2-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-1-(METHYLETHYL)-2-HYDROXYETHYL]ACETAMIDE; AC1NR9VL; SCHEMBL15034365; 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-N-[(1S,2S)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-hydroxy-3-methylbutan-2-yl]acetamide; ONO-6818"	135484078	C24H20FN5O6S	Discontinued in Phase 1
M6APDG01626	GLYCYLRYANODINE	glycylryanodine; CHEMBL283836	44275859	C27H38N2O10	Investigative
M6APDG02278	Acitretin	"Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid"	5284513	C21H26O3	Approved
M6APDG00062	CP-673451	"CP-673,451"	10158940	C24H27N5O2	Investigative
M6APDG03004	"4-(2,2'-bithiophen-5-ylmethyleneamino)phenol"	MLS000106248; SMR000103217; CHEMBL504791; 4-[(5-thiophen-2-ylthiophen-2-yl)methylideneamino]phenol; AC1LGKRK; cid_796420; BDBM29642; HMS2448D05; MCULE-1982148585; SR-01000609337; SR-01000609337-2; 4-[[5-(2-thienyl)-2-thienyl]methyleneamino]phenol	796420	C15H11NOS2	Investigative
M6APDG00625	AT9283	.	135398495	C19H23N7O2	Phase 3
M6APDG00495	4'-cyano-3-(imidazolylmethyl)-7-methoxyflavone	CHEMBL377626; BDBM50191601; 4''-cyano-3-(imidazolylmethyl)-7-methoxyflavone	11847171	C21H15N3O3	Investigative
M6APDG03708	ISIS 133206	.	.	.	Investigative
M6APDG02125	N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide	N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide; DB07920; N-oxo-2-(4-phenylbenzenesulfonamido)acetamide; N~2~-(biphenyl-4-ylsulfonyl)-N-oxoglycinamide	46937106	C14H12N2O4S	Investigative
M6APDG03862	BIWA 4	.	.	.	Phase 1
M6APDG01969	MK-8033	"MK-8033; 1001917-37-8; UNII-350H6PBQ5Q; 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide; 350H6PBQ5Q; CHEMBL2323775; MK8033; 1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide; 1-[2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridin-9-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide"	45142457	C25H21N5O3S	Phase 1
M6APDG04060	CAR-T cells targeting EphA2	.	.	.	Phase 1/2
M6APDG03400	ALS-00T2-0501	"TNF Blocker (Intradel, psoriasis), Apollo Life Sciences; TNF Blocker (TransD, psoriasis), Apollo Life Sciences; TNF Blocker (transdermal cream, psoriasis), Apollo Life Sciences; TNF receptor antagonist (Intradel, psoriasis), Apollo Life Sciences; TNF receptor antagonist (TransD, psoriasis), Apollo Life Sciences; TNF receptor antagonist (transdermal cream, psoriasis), Apollo Life Sciences"	.	.	Discontinued in Phase 1
M6APDG00898	alsterpaullone 2-cyanoethyl	alsterpaullone derivative7	16760286	C19H14N4O3	Investigative
M6APDG02734	3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 25b; CHEMBL369623; SCHEMBL4231092; BDBM8609; AC1O705L; 3-[(Z)-(4-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539785	C15H12ClN	Investigative
M6APDG00911	4-iodobenzo[b]thiophene 2-carboxamidine	amino(4-iodo-1-benzothiophen-2-yl)methaniminium; ESI; AC1L1C5C; CTK7C3490; BDBM14169; APC-6860; CRA-6860; DB03136; [amino-(4-iodo-1-benzothiophen-2-yl)methylidene]azanium	1746	C9H8IN2S+	Investigative
M6APDG01693	E[c(RGDyK)]2	E[c(RGDyK)]2; CHEMBL414385	44388431	C62H91N19O20	Investigative
M6APDG01905	Atropisomer 1	CHEMBL584052; atropisomer 1; Atropisomer 2; SCHEMBL2601123; BDBM50300196	44605611	C21H15N3O2	Investigative
M6APDG02557	Epitinib	"HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma"	59142777	C24H26N6O2	Investigative
M6APDG03365	Enbrel	.	.	.	Approved
M6APDG04276	FP-1201	"Traumagen; Traumakine; MR-11-A-8; CD73 agonist (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/MaruishiPharmaceutical; Interferon beta-1a (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/Maruishi Pharmaceutical"	.	.	Phase 3
M6APDG03839	AMG 595	.	.	.	Phase 1
M6APDG00280	4-Butyrylamino-N-hydroxy-benzamide	"CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262"	11287488	C11H14N2O3	Investigative
M6APDG00343	C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL204310; BDBM50184355	11498895	C46H60N12O8	Investigative
M6APDG03827	HPP-607	.	.	.	Phase 1
M6APDG01486	DNQX	"dnqx; 2379-57-9; 6,7-dinitro-1,4-dihydroquinoxaline-2,3-dione; FG-9041; FG 9041; UNII-62T278S1MX; 6,7-Dinitroquinoxaline-2,3-dione (DNQX); 2,3-Quinoxalinedione, 1,4-dihydro-6,7-dinitro-; 6,7-Dinitroquinoxaline-2,3(1H,4H)-dione; 62T278S1MX; 6,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione; SR-01000075442; 1ftl; Tocris-0189; AC1MZKE9; Lopac-D-0540; Biomol-NT_000182; Oprea1_127694; Lopac0_000345; MLS000705107; SCHEMBL594575; SCHEMBL8128055; BPBio1_001176; CHEMBL155265; C8H4N4O6; CHEBI:93492; CTK8F7031; DTXSID60178476; MolPort-003-846-931"	3899541	C8H4N4O6	Investigative
M6APDG02810	NSC-27236	.	67316	C13H11N3O5S	Investigative
M6APDG01730	4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid	CHEMBL373275; 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid; BDBM50180608	44406790	C20H26O3	Investigative
M6APDG03783	KUR-CXCR4	.	.	.	Investigative
M6APDG02426	Gamma-mangostin	"gamma-Mangostin; 31271-07-5; 1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one; CHEMBL260553; CHEBI:67548; Q-100393; 1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one; 9H-Xanthen-9-one, 1,3,6,7-tetrahydroxy-2,8-bis(3-methyl-2-butenyl)-; Normangostin; g-Mangostin; gamma- Mangostin; Mangostin, gamma-; AC1NUYXQ; 1,3,6,7-Tetrahydroxy-2,5-bis(3-methyl-2-butenyl)-9H-xanthen-9-one; SCHEMBL3753526; DTXSID50185194; VEZXFTKZUMARDU-UHFFFAOYSA-N; MolPort-019-937-259; ZINC5195818; gamma-Mangostin, &gt"	5464078	C23H24O6	Investigative
M6APDG04374	ALN-VEG01	"RNAi therapeutics (ocular disease), Alnylam; VEGF-silencing siRNAs, Alnylam; Vascular endothelial growth factor gene-silencing siRNAs, Alnylam; RNAi therapeutics (ocular disease), Alnylam/Merck; VEGF-silencing siRNAs, Alnylam/Merck; Vascular endothelial growth factor-silencing siRNAs, Alnylam/Merck"	.	.	Terminated
M6APDG01092	P276-00	CHEMBL2312181; SCHEMBL1180418	23643975	C21H21Cl2NO5	Phase 2
M6APDG03171	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol	CHEMBL63200; SCHEMBL7453649	9839919	C20H16N2O2	Investigative
M6APDG00601	ABBV-744	"OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318"	132010322	C28H30FN3O4	Phase 1
M6APDG00889	BIIB-021	"CNF-2024; CNF-3647; EC-129; EC-137; EC-138; EC-141; EC-144; EC-146; EC-147; EC-151; EC-78; EC-89; EC-145, Conforma; EC-82, Conforma; Hsp90 inhibitor (cancer), Biogen Idec; Synthetic Hsp90 inhibitors (cancer), Conforma; Hsp90 inhibitors (synthetic, cancer), Conforma"	16736529	C14H15ClN6O	Phase 2
M6APDG02226	GSK-644784	AC1NQWGT	5280119	C24H36F3N5O7	Discontinued in Phase 2
M6APDG00714	"3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione"	"CHEMBL149238; 3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-3-methyl-; SCHEMBL19074638; BDBM50025155"	13596072	C11H12N2O2	Investigative
M6APDG00778	2-Hexadecynoic acid	2-Hexadecynoic acid; hexadec-2-ynoic acid; 2834-03-9; 2-Hexadecynoate; N-2-Hexadecynoic acid; AC1L45K9; SCHEMBL2818253; CTK4G1266; DTXSID00182577; MECFGCCEVOFCNS-UHFFFAOYSA-N; NSC289580; LMFA01030494	151047	C16H28O2	Investigative
M6APDG01834	Hydroxyaminovaline	"HYDROXYAMINOVALINE; (2R)-2-amino-N-hydroxy-3-methylbutanamide; 88244-32-0; HAV; n-hydroxy-d-valinamide; AC1L9GKY; SCHEMBL2512211; CTK3B5308; DTXSID10332162; ZINC3997609; AKOS006348422; DB02697; (R)-2-Amino-N-hydroxy-3-methylbutanamide; FT-0772977; Butanamide, 2-amino-N-hydroxy-3-methyl-, (2R)-"	444599	C5H12N2O2	Investigative
M6APDG00052	"2,3-dihydro-1H-benzo[de]isoquinolin-1-one"	"CHEMBL594596; 2,3-dihydro-benzo[de]isoquinolin-1-one; 2,3-dihydro-1H-benzo[de]isoquinolin-1-one; SCHEMBL832168; ZINC24216; BDBM50306285; FCH1866210"	10130246	C12H9NO	Investigative
M6APDG03271	Rilapladib	.	9918381	C40H38F5N3O3S	Phase 1
M6APDG01167	Cyclo-[-Arg-Gly-Asp-Amp26-]	CHEMBL406680	24822444	C24H32N8O7	Investigative
M6APDG00270	Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester	CHEMBL111806; SCHEMBL14812153	11254470	C15H21NO2S	Investigative
M6APDG03618	LA-480	"Bispecific c-Met monoclonal antibody (cancer), Lilly"	.	.	Investigative
M6APDG01734	"4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione"	"CHEMBL380940; 4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione; SCHEMBL5828673"	44407566	C15H10N2O2	Investigative
M6APDG00214	ZEARALANONE	"Zearalanone; Zanone; 5975-78-0; (S)-Zearalanone; UNII-133DU2F2VS; CCRIS 9235; MLS000069626; P 1502; SMR000058193; CHEMBL491499; 133DU2F2VS; CHEBI:35051; beta-Resorcylic acid, 6-(10-hydroxy-6-oxoundecyl)-, mu-lactone; (S)-3,4,5,6,9,10,11,12-Octahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione; 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,5,6,9,10,11,12-octahydro-14,16-dihydroxy-3-methyl-, (S)-; 2,4-DIHYDROXY-6-[10-HYDROXY-6-OXO-UNDECYL]BENZOIC ACID MICRO-LACTONE"	108003	C18H24O5	Investigative
M6APDG00133	Manzamine Y	"manzamine Y; CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol"	10393120	C36H44N4O2	Investigative
M6APDG03362	HEGF	.	.	.	Approved
M6APDG00429	"2-phenethylisoquinoline-1,3,4-trione"	"2-phenethylisoquinoline-1,3,4-trione; CHEMBL382860; SCHEMBL13442858; Isoquinoline-1,3,4-trione 2d; BDBM10251; CTK7H5068; AKOS015966189; 2-PHENETHYL-ISOQUINOLINE-1,3,4-TRIONE"	11652039	C17H13NO3	Investigative
M6APDG00081	3-Thiophen-3-yl-quinoline	3-(3-Thienyl)quinoline; 56421-85-3; 3-(Thiophen-3-yl)quinoline; CHEMBL304310; 3-thiophen-3-ylquinoline; 3-Thiophen-3-yl-quinoline; 3-(3-thiophenyl)quinoline; SCHEMBL19180724; ZINC2392505; BDBM50039081; AKOS004118779; BB 0223675	10242258	C13H9NS	Investigative
M6APDG03406	CDP-484	"Anti-IL-1 beta FAb-PEG, Celltech"	.	.	Discontinued in Phase 1/2
M6APDG01514	Mefenamic acid	"ApoMefenamic; Bonabol; Contraflam; Coslan; Dysman; Lysalgo; Mefac; Mefacit; Mefedolo; Mefenacid;Mefenamate; Mefenaminsaeure; Mefic; Mycasaal; Namphen; NuMefenamic; Parkemed; Pinalgesic; Ponalar; Ponalgic; Ponmel; Ponstan; Ponstel; Ponstil; Ponstyl; Ponsyl; Pontal; Rolan; Tanston; Vialidon; APS Brand of Mefenamic Acid; Acide mefenamique; Acide mefenamique [French]; Acido mefenamico; Acidum mefenamicum; Antigen Brand of Mefenamic Acid; Apo Mefenamic; Apotex Brand of Mefenamic Acid; Ashbourne Brand of Mefenamic Acid; Chemidex Brand of Mefenamic Acid; Clonmel Brand of Mefenamic Acid; Elan Brand of Mefenamic Acid; Farmasierra Brand of Mefenamic Acid; First Horizon Brand of Mefenamic Acid; Godecke Brand of Mefenamic Acid; Mefanamic acid; Mefenaminic Acid; Mefenaminsaeure [German]; Mephenamic acid; Mephenaminic acid; Methenamic acid; Nu Mefenamic; Nu Pharm Brand of Mefenamic Acid; PMS Mefenamic Acid; Parke Davis Brand of Mefenamic Acid; Pfizer Brand of Mefenamic Acid; Pharmascience Brand of Mefenamic Acid; Pinewood Brand of Mefenamic Acid; Ponstan forte; Rowa Brand of Mefenamic Acid; Tamany Bonsan; Warner Lambert Brand of Mefenamic Acid; CL 473; CN 35355; HL 1; ID8; INF 3355; M1782; AGN-1255; Ac. mefenamico; Ac. mefenamico [Italian]; Acid, Mefenamic; Acid, Mefenaminic; Acide mefenamique [INN-French]; Acido mefenamico [INN-Spanish]; Acidum mefenamicum [INN-Latin]; Apo-Mefenamic; Bafameritin-M; Bafhameritin-M; CN-35355; Dyfenamic (TN); F0850-6853; Forte, Ponstan; INF-3355; In-M; Mafepain (TN); Meftal (TN); Mephadolor (TN); Nu-Mefenamic; Nu-Pharm Brand of Mefenamic Acid; PMS-Mefenamic Acid; Parkemed (TN); Ponstal (TN); Ponstan (TN); Ponstel (TN); Potarlon (TN); Warner-Lambert Brand of Mefenamic Acid; Mefenamic acid (JP15/USP/INN); Mefenamic acid [USAN:INN:BAN:JAN]; N-2,3-Xylylanthranilic acid; N-(2,3-Dimethylphenyl)anthranilic acid; N-(2,3-Xylyl)anthranilic acid; N-(2,3-Xylyl)-2-aminobenzoic acid; 2-((2,3-Dimethylphenyl)amino)benzoic acid; 2-(2,3-Dimethylanilino)benzoic acid; 2-(2,3-Xylidino)benzoic Acid; 2-(2,3-dimethylphenylamino)benzoic acid; 2-[(2,3-dimethylphenyl)amino]benzoic acid"	4044	C15H15NO2	Approved
M6APDG04266	Rindopepimut	.	.	.	Phase 3
M6APDG04241	M7824	.	.	.	Phase 2
M6APDG01874	4-(butylthio)-2-methoxybenzonitrile	CHEMBL455566; 4-(butylthio)-2-methoxybenzonitrile	44564582	C12H15NOS	Investigative
M6APDG03593	ISIS 114184	.	.	.	Investigative
M6APDG02828	GSK2816126	GSK 126; GSK-126	68210102	C31H38N6O2	Phase 1
M6APDG00750	1-(4-Cyanobenzyl)-5-methyl-1H-imidazole	4-(5-Methyl-imidazol-1-ylmethyl)-benzonitrile	14231155	C12H11N3	Investigative
M6APDG00386	HDS-029	HDS 029	11566580	C17H11ClFN5O	Investigative
M6APDG03046	"5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol"	"9-Hydroxyellipticine; 9-Hydroxyellipticin; 51131-85-2; 5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol; Hydroxyellipticine; ELLIPTICINE, 9-HYDROXY-; UNII-9G4A3ET6XG; IGIG 929; Hydroxy-9 ellipticine [French]; EINECS 257-000-0; NSC 237070; NSC 210717; 9G4A3ET6XG; CHEMBL26559; CHEBI:88297; C17H14N2O; 5,11-Dimethyl-6H-pyrido(4,3-b)carbazol-9-ol; 6H-Pyrido(4,3-b)carbazol-9-ol, 5,11-dimethyl-; 6H-Pyrido[4,3-b]carbazol-9-ol, 5,11-dimethyl-; 9-hydroxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole; Hydroxy-9 ellipticine"	91643	C17H14N2O	Investigative
M6APDG01660	"9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one"	SCHEMBL7373122; CHEMBL116578	44342872	C21H23F3O2	Investigative
M6APDG03117	L-745337	"Thioflosulide; L-745337; CHEMBL287919; 158205-05-1; L 745337; L 745,337; L-745,337; SCHEMBL2464202; ZINC1887701; BDBM50029603; CS-6783; N-(6-((2,4-Difluorophenyl)thio)-2,3-dihydro-1-oxo-1H-inden-5-yl)methanesulfonamide; HY-19217; L745,337"	9799453	C16H13F2NO3S2	Terminated
M6APDG02547	CC-223	"GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661"	58298316	C21H27N5O3	Phase 1/2
M6APDG00143	C[RGDf-(S)-alpha-TfmV]	CHEMBL203693; c[RGDf-(S)-alpha-TfmV]	10416726	C27H37F3N8O7	Investigative
M6APDG04033	SN-32793	"PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha"	.	.	Phase 1/2
M6APDG03745	ISIS 104254	.	.	.	Investigative
M6APDG00037	"6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline"	"CHEMBL419248; 6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline; ZINC13737710"	10085862	C18H17NO3	Investigative
M6APDG03136	B-623	149732-37-6	9820186	C18H14N2O2S	Investigative
M6APDG03916	Dendritic cell vaccine	"Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute"	.	.	Phase 1
M6APDG03210	GSK-9578	"KYQNYMXQHLMADB-UHFFFAOYSA-N; GW 9578; GW9578; 247923-29-1; GW-9578; UNII-H32ABL87X4; H32ABL87X4; CHEMBL278590; SCHEMBL68327; GTPL2673; BDBM28799; CTK8E7867; GSK9578; DTXSID10179493; MolPort-009-019-367; ZINC14115100; Propanoic acid, 2-((4-(2-((((2,4-difluorophenyl)amino)carbonyl)heptylamino)ethyl)phenyl)thio)-2-methyl-; RT-013144; J-015674; 289722-11-8; 2-{[4-(2-{[(2,4-difluorophenyl)carbamoyl](heptyl)amino}ethyl)phenyl]sulfanyl}-2-methylpropanoic acid; 2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenyl]sulfanyl-2-methylpropanoic"	9870304	C26H34F2N2O3S	Investigative
M6APDG01585	Nabumetone	"NNB-001; NNB-004; NNB-005; Nabumetone (oral); Nabumetone (oral), Nobex; 6-MNA (oral), Nobex"	4409	C15H16O2	Approved
M6APDG04205	DLX-105	"DLX-106; ESBA-105 (intra-articular formulation), ESBATech; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), Delenex; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), ESBATech"	.	.	Phase 2
M6APDG02159	PA-799	MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134	49784945	C15H19N7O3S	Phase 1/2
M6APDG00696	NVP-AUY922	"Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide"	135539077	C26H31N3O5	Phase 2
M6APDG03245	"3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol"	CHEMBL541643	9901372	C16H15N3O2S	Investigative
M6APDG01263	MGCD516	Sitravatinib	25212148	C33H29F2N5O4S	Phase 2/3
M6APDG04364	Maxy-10	"Optimized interferon beta, Maxygen; Beta-interferon (optimized), Maxygen"	.	.	Terminated
M6APDG00230	Phosphonothreonine	"phosphothreonine; O-phospho-L-threonine; 1114-81-4; L-Threonine O-phosphate; (2S,3R)-2-amino-3-(phosphonooxy)butanoic acid; O-Phosphothreonine; L-Threonine phosphate; Threoninium dihydrogen phosphate; O-phosphono-L-threonine; L-Threonine O-3-phosphate; O3-phosphothreonine; PHOSPHONOTHREONINE; 27530-80-9; threonine phosphate ester; (2S,3R)-2-amino-3-hydroxybutanoic acid 3-phosphate; Threonine, O-phosphono-; H-Thr(PO3H2)-OH; C4H10NO6P; phospho-l-threonine; EINECS 214-217-5; Synonyms    Sources; (S)-2-Amino-3-hydroxybutanoic acid "	10976469	C4H10NO6P	Investigative
M6APDG03736	ISIS 29177	.	.	.	Investigative
M6APDG02833	MX-4509	"17alpha-Estradiol; 57-91-0; Alfatradiol; Epiestradiol; 17-alpha-Estradiol; 3,17-Dihydroxyestratriene; 17a-estradiol; Estradiol-17alpha; Epiestrol; 17-Epiestradiol; Estra-1,3,5(10)-triene-3,17alpha-diol; 17alpha estradiol; NSC 20293; UNII-3VQ38D63M7; Alfatradiol [INN]; Oestradiol-17alpha; 17alpha-Oestradiol; Estradiol, 17alpha-; CHEBI:17160; VOXZDWNPVJITMN-SFFUCWETSA-N; 3VQ38D63M7; 17-epi-Estradiol; Alfatradiol (INN); Oestradiol-17-alpha; MITO-4509; Parkinsons therapeutics, MitoKor; Drug screening (Parkinsons), MitoKor; Estrogen analogs (Parkinsons), Mitokor"	68570	C18H24O2	Discontinued in Phase 1
M6APDG03901	MVA HER-2 AutoVac	"MVA-BN HER-2 AutoVac; MVA-BN-HER2; PX-103.2; MVA-BN Breast (cancer vaccine), Bavarian Nordic; MVA-BN breast cancer vaccine, BN ImmunoTherapeutics/ Pharmexa; MVA-BN/Her-2/Neu"	.	.	Phase 1
M6APDG02337	"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine"	"CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882"	5328077	C14H13N5	Investigative
M6APDG00626	Akt inhibitor VIII	"isozyme-selective, Akti-1/2"	135398501	C34H29N7O	Investigative
M6APDG03547	ANG-2684	"ANG-3038; PARP-1 inhibitors (acute pancreatitis/stroke); PARP-1 inhibitors (acute pancreatitis/stroke), Angion Biomedica"	.	.	Investigative
M6APDG02955	Cysteinesulfonic Acid	"Cysteic Acid; 3-Sulfoalanine; 2-amino-3-sulfopropanoic acid; DL-CYSTEIC ACID; 13100-82-8; beta-Sulfoalanine; Alanine, 3-sulfo-; Cysteinic acid; Cysteric acid; Cipteic acid; Cepteic acid; 3024-83-7; CHEBI:21260; C-9550; 2-amino-3-sulfopropanoate; cysteinsaure; Cepteate; Cysterate; Cipteate; Cysteinesulfonate; NSC 254030; (2R)-2-amino-3-sulfo-propanoic acid; L-Cysteic acid, 8; ACMC-209kii; 3-Sulfoalanine, (L)-; 2-Amino-3-sulfopropionate; AC1L19KC; SCHEMBL44030; CHEMBL1171434; 2-amino-3-sulfopro-panoic acid; BDBM85473; CTK8G7889"	72886	C3H7NO5S	Investigative
M6APDG02544	XL019	"XL019; 945755-56-6; UNII-4L1AM42NVA; (S)-N-(4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide; 4L1AM42NVA; (2S)-N-[4-[2-[[4-(4-Morpholinyl)phenyl]amino]-4-pyrimidinyl]phenyl]-2-pyrrolidinecarboxamide; 945750-13-0; (2S)-N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide; (2S)-N-[4-(2-{[4-(MORPHOLIN-4-YL)PHENYL]AMINO}PYRIMIDIN-4-YL)PHENYL]PYRROLIDINE-2-CARBOXAMIDE; C25H28N6O2; 2-Pyrrolidinecarboxamide, N-(4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)phe"	57990869	C25H28N6O2	Phase 3
M6APDG00389	6-benzenesulfonylhexanoic acid hydroxamide	6-benzenesulfonylhexanoic acid hydroxamide; CHEMBL203207	11572583	C12H17NO4S	Investigative
M6APDG03410	INGN-234	"P53 tumor suppressor (topical formulation), Introgen"	.	.	Discontinued in Phase 2
M6APDG00464	L-750034	L-750034; CHEMBL326492; BDBM50076058; 2-((S)-Benzenesulfonylamino)-3-(4-piperazin-1-yl-benzoylamino)-propionic acid; 2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid(L-750034); (S)-2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid	11743533	C20H24N4O5S	Investigative
M6APDG03326	Roscovitine	"Seliciclib; roscovitine; 186692-46-6; R-Roscovitine; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; Roscovitine; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine"	160355	C19H26N6O	Phase 2
M6APDG03442	ATF-HI-8	"urokinase/urinary trypsin inhibitor chimera, Nissin/Hamamatsu University"	.	.	Investigative
M6APDG02387	CHIR-98014	CHIR98014; CHIR 98014	53396311	C20H17Cl2N9O2	Investigative
M6APDG02839	(E)-N-(4-Phenylthiazol-2-yl) cinnamamide	"CHEMBL452100; 2-Cinnamamido-4-phenylthiazole; (2E)-3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)prop-2-enamide; 1107621-03-3; AC1LEPJR; (E)-N-(4-Phenylthiazol-2-yl) cinnamamide; ZINC60264; WOJRHCOBUKJCAJ-VAWYXSNFSA-N; MolPort-019-760-060; MolPort-001-931-977; HMS1397P15; STK173781; BDBM50255301; N-(4-phenylthiazol-2-yl)cinnamamide; AKOS000523355; MCULE-8934603681; BAS 00417267; ST4016450; 3-Phenyl-N-(4-phenyl-thiazol-2-yl)-acrylamide; AG-690/11629440; 3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)acrylamide; F0298-0058; A0793/0037152"	690181	C18H14N2OS	Investigative
M6APDG00136	"8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione"	SCHEMBL9007836; CHEMBL143380	10400801	C10H6BrNO3	Investigative
M6APDG04135	TNF alpha kinoid	"TNFa Kinoid; Debio-0512; TNF-K; TNF-kinoid; Anti-TNF alpha vaccine, Neovacs"	.	.	Phase 2
M6APDG00176	"5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline"	"CHEMBL293122; dihydroquinoline 31; BDBM10027; ZINC13808192; 5-[2-(Imidazol-1-yl)ethyl]-7,8-dihydroquinoline; 5-[2-(1H-imidazol-1-yl)ethyl]-7,8-dihydroquinoline"	10561174	C14H15N3	Investigative
M6APDG03128	2-(4-Phenoxy-benzyl)-1H-benzoimidazole	CHEMBL67249; SCHEMBL7510229	9817808	C20H16N2O	Investigative
M6APDG00263	N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide	SCHEMBL675474	11231829	C17H18N2O3	Investigative
M6APDG01817	C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	CHEMBL398665; c[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	44445083	C52H63N11O7	Investigative
M6APDG03367	PEGylated IFN beta 1-a	"BIIB-017; PEG-Avonex; PEGylated IFN beta 1-a (multiple sclerosis); PEGylated IFN beta 1-a (multiple sclerosis), Biogen Idec; PEGylated interferon beta 1-a (multiple sclerosis), Biogen Idec"	.	.	Approved
M6APDG03723	ISIS 29135	.	.	.	Investigative
M6APDG03314	"5-Methyl-3,4-diphenyl-isoxazole"	"5-Methyl-3,4-diphenylisoxazole; 37928-17-9; 5-Methyl-3,4-diphenyl-isoxazole; 5-methyl-3,4-diphenyl-1,2-oxazole; CHEMBL365033; Isoxazole, 5-methyl-3,4-diphenyl-; AK110518; SCHEMBL2277199; 3,4-Diphenyl-5-methylisoxazole; DTXSID40433813; 3,4-diphenyl-5-methyl isoxazole; 5-methyl-3,4-diphenyl isoxazole; 3,4-diphenyl-5-methyl-isoxazole; ZXIRUKJWLADSJS-UHFFFAOYSA-N; MolPort-027-835-429; KS-00000PQ9; Isoxazole, 5-Methyl-3,4-diphenyl- (Parecoxib sodiuM inteMediate); ZINC12352313; BDBM50153036; AKOS016008848; VO10067; DS-4629; LS40778"	9991673	C16H13NO	Investigative
M6APDG00780	Lumiracoxib	Joicela; Prexige; Novartis brand of lumiracoxib; COX 189; COX189; COX-189; Lumiracoxib [USAN:INN]; Prexige (Novartis); Prexige (TN); Lumiracoxib (USAN/INN); 2-((2-Chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid; 2-((2-Chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid; 2-(2-((2-chloro-6-fluoro-phenyl)amino)-5-methyl-phenyl)acetic acid; 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid	151166	C15H13ClFNO2	Approved
M6APDG03611	ISIS 6553	.	.	.	Investigative
M6APDG00312	R-1487	"449811-92-1; 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-IO0DCY55NQ; R-1487; IO0DCY55NQ; CHEMBL1230122; 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one; Kinome_3762; SCHEMBL5120612; KKKRKRMVJRHDMG-UHFFFAOYSA-N; HMS3401C13; BDBM50341342; ZINC58633224; AKOS027420928; NCGC00262195-02; KB-80224; ACM449811921"	11406590	C19H18F2N4O3	Discontinued in Phase 1
M6APDG03791	PS-178990	"SARMs (muscle wasting disease), BMS; SARMs (muscle wasting disease), Ligand; SARMs (muscle wasting disease), Pharmacopeia; Selective androgen receptor modulators (muscle wasting disease), BMS; Selective androgen receptor modulators (muscle wasting disease), Ligand; Selective androgen receptor modulators (muscle wasting disease), Pharmacopeia"	.	.	Phase 1
M6APDG03950	CBT-101	L-Asparaginyl-L-leucyl-glycyl-L-valyl-L-[S-(acetamidomethyl)]cysteinamide hydrochloride	.	.	Phase 1
M6APDG01645	RWJ-53419	RWJ-53419; CHEMBL421547; BDBM50104598; 2-Benzyloxycarbonylamino-3-{[(R)-1-(3-piperidin-4-yl-propionyl)-piperidine-3-carbonyl]-amino}-propionic acid	44322318	C25H36N4O6	Investigative
M6APDG01784	Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)	CHEMBL219135; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)	44418885	C37H49N11O6	Investigative
M6APDG00371	C[-Arg-Gly-Asp-Acpca35-]	CHEMBL534713	11540460	C18H29N7O7	Investigative
M6APDG00181	3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one	CHEMBL350922; 3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one; BDBM50097364; 3-Imidazol-1-ylmethyl-xanthen-9-one	10588478	C17H12N2O2	Investigative
M6APDG00071	NU6140	"Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide"	10202471	C23H30N6O2	Investigative
M6APDG03373	Trastuzumab	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	.	.	Approved
M6APDG02149	PJ34	"PJ34; 344458-19-1; pj-34; N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE; CHEMBL372303; P34; 2-(dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide; Acetamide, N-(5,6-dihydro-6-oxo-2-phenanthridinyl)-2-(dimethylamino)-; UYJZZVDLGDDTCL-UHFFFAOYSA-N; PJ34(free base); 1xk9; SCHEMBL422317; ZINC8960; AC1L1J45; BDBM27497; CTK1B7701; MolPort-035-395-737; Ibrutinib (PCI32765 pound(c); HMS3651B06; BCP07990; HY-13688A; 2662AH; AKOS030229047; SB19292; DB08348; CS-1463; NCGC00370866-10; DA-42692; BC600341"	4858	C17H17N3O2	Preclinical
M6APDG00865	PAMAPIMOD	"Pamapimod; 449811-01-2; RO 4402257; UNII-8S2C9V11K4; Pamapimod (R-1503, Ro4402257); CHEMBL1090089; CHEBI:90685; 8S2C9V11K4; Ro4402257; Ro-4402257; R1503; R 1503; R-1503; 6-(2,4-Difluorophenoxy)-2-{[3-Hydroxy-1-(2-Hydroxyethyl)propyl]amino}-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Pamapimod [USAN:INN]; 6-(2,4-Difluorophenoxy)-2-((3-hydroxy-1-(2-hydroxyethyl)propyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,4-Difluorophenoxy)-2-[[3-hydroxy-1-(2-hydroxyethyl)propyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one"	16220188	C19H20F2N4O4	Discontinued in Phase 2
M6APDG03357	Menotropins	Humegon; Human Menopausal Gonadotrophin; Human Menopausal Gonadotrophin (JP15); Humegon (TN); Menotropins (USP)	.	.	Approved
M6APDG04289	Act1	51-34-3; UNII-DL48G20X8X; alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester; DL48G20X8X; CHEBI:16794	.	.	Phase 3
M6APDG00493	3-(imidazolylmethyl)-7-methoxy-4'-nitroflavone	CHEMBL212168; BDBM50191603; 3-(imidazolylmethyl)-7-methoxy-4''-nitroflavone	11847169	C20H15N3O5	Investigative
M6APDG04268	NeuVax	NeuVax (TN)	.	.	Phase 3
M6APDG03405	CYT-007-TNFQb	.	.	.	Discontinued in Phase 1/2
M6APDG00148	N-(6-bromo-1H-indazol-3-yl)butyramide	"CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; N-(6-bromo-1H-indazol-3-yl)butyramide; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708"	10423871	C11H12BrN3O	Investigative
M6APDG00292	N-(2-aminophenyl)nicotinamide	N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)nicotinamide; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6	1133083	C12H11N3O	Investigative
M6APDG00396	4-(mesityloxy)-2-(trifluoromethyl)benzonitrile	CHEMBL513768; 4-(mesityloxy)-2-(trifluoromethyl)benzonitrile; SCHEMBL4163778	11587567	C17H14F3NO	Investigative
M6APDG00281	"9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one; CHEMBL194155; SCHEMBL4078284; BDBM27515; BIBLEFNXUYTZIB-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2b; ZINC13652899; 5,6-Dihydro-5-oxo-9-amino-indeno[1,2-c]isoquinoline"	11288114	C16H12N2O	Investigative
M6APDG01122	"4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine"	.	242623	C9H10N6	Investigative
M6APDG01993	5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	CHEMBL574666; SCHEMBL5613445; BDBM50300481; 5-(3''-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid	45483018	C18H17NO3	Investigative
M6APDG00511	Nitroflurbiprofen	Flurbinitroxybutylester; Flurbiprofen nitroxybutylester; HCT 1026; NO-flurbiprofen	119387	C19H20FNO5	Investigative
M6APDG02224	Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)	"Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-); Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine"	5275843	C36H47N11O6	Investigative
M6APDG01786	Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL374421; cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)	44418887	C37H49N11O6	Investigative
M6APDG01261	2-(4-methoxyphenyl)quinoline-8-carboxamide	"2-(4-methoxyphenyl)quinoline-8-carboxamide; CHEMBL481591; 655222-47-2; CTK1J6622; DTXSID70649086; BDBM50255383; AKOS030560276; 8-Quinolinecarboxamide, 2-(4-methoxyphenyl)-"	25209058	C17H14N2O2	Investigative
M6APDG00118	"11BETA,13-DIHYDRO-10-EPI-8-DEOXYCUMAM-BRIN B"	"CHEMBL1097371; 11beta,13-Dihydro-10-epi-8-deoxycumam-brin B; BDBM50318411; LS-23585; 11betaH,13-Dihydro-10-epi-8-deoxycumambrin B"	10354739	C15H22O3	Investigative
M6APDG03078	APG-115	"15Qau0SI9J; 15QAU0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-"	91972012	C34H38Cl2FN3O4	Phase 2
M6APDG04368	FR-133605	.	.	.	Terminated
M6APDG00836	"N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide"	"CHEMBL214965; N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide; SCHEMBL15313847"	16090304	C20H17NO4	Investigative
M6APDG04318	FAS1	.	.	.	Preclinical
M6APDG04301	MEDI4736	.	.	.	Phase 3
M6APDG00935	"6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine"	"101724-61-2; 2,4-Pyrimidinediamine, 5-nitroso-6-(phenylmethoxy)-; CHEMBL71484; 6-(benzyloxy)-5-nitrosopyrimidine-2,4-diamine; pyrimidine deriv. 1g; NU 6039; 6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine; AC1L48AH; 5-nitroso-6-phenylmethoxypyrimidine-2,4-diamine; BDBM5573; SCHEMBL2054835; DTXSID50144145; MBQPVHNJEDDVCF-UHFFFAOYSA-N; ZINC6096446; AKOS028111161; 2,4-diamino-6-benzyloxy-5-nitrosopyrimidine; 2,6-Diamino-4-benzyloxy-5-nitrosopyrimidine; 2,4-Diamino-5-nitroso-6-benzyloxypyrimidine"	181029	C11H11N5O2	Investigative
M6APDG04213	Clazakizumab	.	.	.	Phase 2
M6APDG00764	Tariquidar	"Tariquidarth; XR 9576; XR9576; Tariquidar (USAN/INN); N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide; N-(2-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)carbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide"	148201	C38H38N4O6	Discontinued in Phase 2
M6APDG02075	SYMBIOPOLYOL	SYMBIOPOLYOL	46872950	C60H99NaO23S	Investigative
M6APDG02752	5-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyrimidine	"(5-pyrimidylmethylene)indane 28b; SCHEMBL4225541; AC1O706V; CHEMBL364956; BDBM8634; 5-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyrimidine"	6539808	C14H11FN2	Investigative
M6APDG01438	GW-8510	.	3536	C21H15N5O3S2	Investigative
M6APDG03738	ISIS 29200	.	.	.	Investigative
M6APDG02561	VX-509	"Decernotinib; Adelatinib; 944842-54-0; VX-509; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK"	59422203	C18H19F3N6O	Phase 2/3
M6APDG04122	PF-446687	PF-00446687; PF-2336652	.	.	Phase 2
M6APDG00704	ME0328	ME-0328; compound 5b [PMID 24188023]	135566764	C19H19N3O2	Investigative
M6APDG02732	3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 24a; SCHEMBL4221248; SCHEMBL4221241; AC1O705H; CHEMBL366490; BDBM8607; 3-[(E)-(4-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539783	C15H12FN	Investigative
M6APDG02918	FV-100	"CF-1001; CF-1094; CF-1368; CF-1369; CF-1449; CF-1452; CF-1698; CF-1712; CF-1743; CF-1821; CF-1835; CF-1837; CF-1838; CF-1851; CF-2004; CF-2160; CF-2161; CF-2200; BCNAs (antiviral), FermaVir Pharmaceuticals; Bicyclic nucleoside analogs (VZV infection), FermaVir; Bicyclic nucleoside analogs (VZV infection), Inhibitex; Antivirals (nucleoside derivatives), Welsh School of Pharmacy/Rega; BCNAs (antiviral), Rega/Welsh School of Pharmacy; Bicyclic nucleoside analogs (antiviral), Rega/Welsh School of Pharmacy"	71587897	C27H36ClN3O6	Phase 3
M6APDG01633	(O10eq)-beta-alanyl-anhydro-ryanodine	CHEMBL28261; (O10eq)-beta-alanyl-anhydro-ryanodine	44275928	C28H38N2O9	Investigative
M6APDG00362	Pemafibrate	K-877	11526038	C28H30N2O6	Approved
M6APDG03476	GTx-027	.	.	.	Investigative
M6APDG00048	AS-601245	"JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673"	10109823	C20H16N6S	Investigative
M6APDG01557	4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile	CHEMBL465539; 4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile; BDBM50248554	43138559	C15H10F3NO	Investigative
M6APDG03765	ISIS 32000	.	.	.	Investigative
M6APDG03123	DP-b99	"DP-b99; 343340-21-6; 222315-88-0; SCHEMBL720046; DP-b 99; DTXSID20187908; DP-BAPTA-99, DP-b99; ZINC162948634; 2,2'-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis((2-(2-(octyloxy)ethoxy)-2-oxoethyl)azanediyl))diacetic acid"	9810955	C42H64N2O12	Phase 3
M6APDG02856	FINROZOLE	"MPV-2213ad; Finrozole; Rac-(R*,S*)-4-[3-(4-Fluorophenyl)-2-hydroxy-1-(1,2,4-triazol-1-yl)propyl]benzonitrile"	6918277	C18H15FN4O	Discontinued in Phase 2
M6APDG00116	6-Methoxy-3-pyridin-4-yl-quinoline	CHEMBL90780; 6-methoxy-3-pyridin-4-yl-quinoline; 6-Methoxy-3-(4-pyridyl)quinoline	10354094	C15H12N2O	Investigative
M6APDG00349	2-chloro-4-(o-tolyloxy)benzonitrile	CHEMBL470204; 2-chloro-4-(o-tolyloxy)benzonitrile; SCHEMBL4175953; BDBM50278226	11507014	C14H10ClNO	Investigative
M6APDG01778	Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)	CHEMBL387120; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)	44418872	C37H49N11O6	Investigative
M6APDG04342	MC-3001	"MC-3004; PPAR-alpha agonists, MaxoCore"	.	.	Preclinical
M6APDG01900	N5-(1-iminopropyl)-L-ornithine	"N5-(1-iminopropyl)-L-ornithine; CHEMBL507472; L-IPO, 13; BDBM152699; ZINC40380536; BDBM50254450; N~5~-[(1Z)-propanimidoyl]-L-ornithine; (S)-2-Amino-5-propionimidoylamino-pentanoic acid; (S)-2-Amino-5-propionimidamidopentanoic acid (8); (2S)-2-azanyl-5-(propanimidoylamino)pentanoic acid"	44593548	C8H17N3O2	Investigative
M6APDG00862	Methotrexate gamma-L-phenylalaninehydroxamic acid	CHEMBL396296; methotrexate gamma-L-phenylalaninehydroxamic acid	16216218	C29H32N10O6	Investigative
M6APDG03825	PF-04840082	.	.	.	Phase 1
M6APDG01134	AST-1306	Allitinib; Allitinib tosylate	24739943	C24H18ClFN4O2	Phase 1
M6APDG02684	cmp5	ChemBridge ID 9033823	6462334	C21H22ClN3	Investigative
M6APDG00237	4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide	CHEMBL167455	11086699	C13H18N2O4	Investigative
M6APDG03178	ZANOTERONE	"ZANOTERONE; 107000-34-0; UNII-XQ5V1W49JG; XQ5V1W49JG; WIN-49596; Zanoterone [USAN:INN]; Win 49,596; Zanoterone (USAN/INN); win49596; SCHEMBL60980; CHEMBL1908363; DTXSID50147873; BDBM50368314; 1'-(Methylsulfonyl)-1'H-5alpha,17alpha-pregn-20-yno(3,2-c)pyrazol-17-ol; D06357; 34004-EP2305642A2; 34004-EP2298765A1; 34004-EP2275420A1; 34004-EP2311453A1; 34004-EP2298764A1; 34004-EP2298748A2; 34004-EP2295416A2; 34004-EP2295055A2; 1'H-Pregn-20-yno(3,2-c)pyrazol-17-ol, 1'-(methylsulfonyl)-, (5alpha,17alpha)-"	9844827	C23H32N2O3S	Phase 3
M6APDG03343	JNJ 7706621	"JNJ-7706621; 443797-96-4; JNJ7706621; 4-((5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl)amino)benzenesulfonamide; UNII-74GK72DON8; RWJ-387252; 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide; CHEMBL191003; 74GK72DON8; 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide; JNJ 7706621; 4-(5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-ylamino)benzenesulfonamide"	5330790	C15H12F2N6O3S	Preclinical
M6APDG02088	"4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine"	"CHEMBL1089985; 4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine; SCHEMBL2239177; 1H-Pyrrolo[2,3-b]pyridine, 4-(1H-pyrazol-4-yl)-; BDBM50315770"	46885627	C10H8N4	Investigative
M6APDG03565	DL-3	.	.	.	Investigative
M6APDG03066	Cypate-[(RGD)2-NH2]2	.	91936295	C88H121N28O22+	Investigative
M6APDG01816	"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	"CHEMBL251123; 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline"	44442183	C23H26N2O2	Investigative
M6APDG01066	7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide	CHEMBL114184; SCHEMBL3383144	22915465	C19H23NO3	Investigative
M6APDG01228	Ruxolitinib	Ruxolitinib (JAK inhibitor)	25126798	C17H18N6	Approved
M6APDG02492	5-deoxy-5-phosphono-D-arabinonate	.	56603745	C5H8O8P-3	Investigative
M6APDG01535	BZ6	.	41673734	C20H18N4O	Investigative
M6APDG02174	Gilteritinib	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199	49803313	C29H44N8O3	Approved
M6APDG04143	ASCJ-9	"Dimethylcurcumin; ASC-JMX1; ASCJ-9; ASCJ-9 (systemic), AndroScience; ASCJ-9 (topical), AndroScience; Androgen antagonist (alopecia/acne), AndroScience; Androgen receptor degradation enhancers (oral, spinal bulbar muscular atrophy), AndroScience"	.	.	Phase 2
M6APDG01880	2-methoxy-4-(m-tolyloxy)benzonitrile	CHEMBL490957; 2-methoxy-4-(m-tolyloxy)benzonitrile	44565104	C15H13NO2	Investigative
M6APDG02529	PG-545	"PG-457; PG-500; PG-501; PG-502; PG-503; PG-504; PG-505; PG-506; PG-507; PG-508; PG-509; PG-510; PG-511; PG-512; PG-513; PG-514;PG-536; PG-546; PG-547; PG-554; PG-562; PG-500 series (heparan sulfate mimetics), Progen"	57412324	C51H75Na13O60S13	Phase 1
M6APDG03369	Bevacizumab	Bevacizumab (ophthalmic slow-release tissue tablet)	.	.	Approved
M6APDG02059	"Resveratrol Potassium4,-Sulfate"	"Resveratrol Potassium4,-Sulfate"	46855201	C14H11KO6S	Investigative
M6APDG00710	"(6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin"	.	135905887	C9H15N5O3	Investigative
M6APDG04355	AKP-320	"Bis(ethylmaltolato)oxovanadium (IV) + rosiglitazone (type 2 diabetes), Akesis"	.	.	Terminated
M6APDG01029	PX-12	"PX12, PX 12, IV-2"	219104	C7H12N2S2	Phase 2
M6APDG04336	CAR-T cells targeting CD133	.	.	.	Preclinical
M6APDG03154	TZD18	TZD 18; TZD-18	9827261	C27H27NO5S	Investigative
M6APDG01986	PROSTRATIN	.	454217	C22H30O6	Investigative
M6APDG01224	GSK2245840	"Gepirone hydrochloride; GEPIRONE HYDROCHLORIDE; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,"	25108829	C26H24N6O2S2	Phase 2
M6APDG00760	"N,N'-Bis-(4-ethyl-phenyl)-guanidine"	"CHEMBL78083; Guanidine, N,N'-bis(4-ethylphenyl)-; 128413-47-8; ACMC-20msu7; SCHEMBL6155127; SCHEMBL10825147; CTK0C1708; DTXSID70563854; 1,3-Bis(4-ethylphenyl)guanidine; N,N''-Bis(4-ethylphenyl)guanidine; BDBM50010736; ZINC13733770; AKOS030602502"	14771671	C17H21N3	Investigative
M6APDG03142	BMS-191095	BMS-199080	9822753	C22H21ClN4O2	Discontinued in Phase 1
M6APDG03447	Bimetopyrole	.	.	.	Investigative
M6APDG00632	leucettine L41	.	135398522	C17H13N3O3	Investigative
M6APDG03538	CA-327	.	.	.	Investigative
M6APDG01278	4-Fluoren-9-ylidenemethyl-pyridine	"MLS002694154; 4-(9H-fluoren-9-ylidenemethyl)pyridine; 4-Fluoren-9-ylidenemethyl-pyridine; NSC83319; AC1L5UM6; NCIOpen2_004593; Oprea1_438447; Oprea1_732020; BDBM8644; CHEMBL383145; 9-(4-pyridylmethylene)fluorene; SCHEMBL8276094; CTK7D1435; (4-Pyridylmethylene)fluorene 34; HMS3088F22; 4-(fluoren-9-ylidenemethyl)pyridine; ZINC13283063; NSC-83319; AKOS000634958; Pyridine, 4-(fluoren-9-ylidenemethyl)-; 4-(9H-Fluorene-9-ylidenemethyl)pyridine; SMR001560085; BAS 00004846; SR-01000321373"	256445	C19H13N	Investigative
M6APDG03733	ISIS 29161	.	.	.	Investigative
M6APDG00408	3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine	SCHEMBL4508450; CHEMBL196328; BDBM8911; Pyridine-substituted naphthalene 10; ZINC13674462; 3-(5-bromo-6-methoxy-2-naphthyl)pyridine	11616637	C16H12BrNO	Investigative
M6APDG03212	Talmapimod	"Talmapimod; SCIO-469; 309913-83-5; Scios 469; UNII-B1E00KQ6NT; SCIO 469; B1E00KQ6NT; CHEMBL514201; SCIO 469 hydrochloride; CHEBI:90683; Talmapimod hydrochloride; 2-(6-Chloro-5-{[(2r,5s)-4-(4-Fluorobenzyl)-2,5-Dimethylpiperazin-1-Yl]carbonyl}-1-Methyl-1h-Indol-3-Yl)-N,N-Dimethyl-2-Oxoacetamide; 2-[6-chloro-5-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine-1-carbonyl]-1-methylindol-3-yl]-N,N-dimethyl-2-oxoacetamide; 750646-72-1; Talmapimod [USAN]; Talmapimod [USAN:INN]"	9871074	C27H30ClFN4O3	Investigative
M6APDG01449	"4-(3,4,5-Trimethoxyphenethyl)aniline"	"CHEMBL86928; 4-(3,4,5-Trimethoxyphenethyl)aniline; 110997-90-5; Benzenamine, 4-[2-(3,4,5-trimethoxyphenyl)ethyl]-; 4-[2-(3,4,5-Trimethoxy-phenyl)-ethyl]-phenylamine; 4-[2-(3,4,5-Trimethoxyphenyl)Ethyl]Aniline; NSC631359; ACMC-20mdvn; AC1L7PCU; AC1Q56FF; SCHEMBL6483085; CTK0G1952; DTXSID30327095; BPIQFCQFIYIISU-UHFFFAOYSA-N; ZINC1622338; BDBM50322061; 4'-Amino-3,4,5-trimethoxybibenzyl; AKOS030581735; NSC-631359; NCI60_010236; 4-[2-(3,5-Trimethoxyphenyl)Ethyl]Aniline; 4-[2-(3,4,5-trimethoxy-phenyl)ethyl]-phenylamine"	364705	C17H21NO3	Investigative
M6APDG00320	N-(6-Mercapto-hexyl)-benzamide	CHEMBL112364; BDBM50223650	11447748	C13H19NOS	Investigative
M6APDG03965	IMGN289	.	.	.	Phase 1
M6APDG01133	SB-9200	SB 9200	24737742	C25H34N7O13PS	Phase 2
M6APDG04117	"AZ-01, PEGylated interferon-beta"	"PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne; AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis); AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne"	.	.	Phase 2
M6APDG01329	HTS-00213	"HTS-00213; CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole"	2809539	C19H12Cl2F3N5O2S	Investigative
M6APDG03600	WL-276	.	.	.	Investigative
M6APDG00800	XR-9456	XR-9456; CHEMBL346292; SCHEMBL7170174; BDBM50375810	15511439	C33H33N3O4	Investigative
M6APDG01959	5-Iodo-2'-Deoxyuridine-5'-Monophosphate	"AC1L52UF; [(2R,3S)-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate"	449489	C9H12IN2O8P	Investigative
M6APDG04130	Pegsunercept	STNF-R1	.	.	Phase 2
M6APDG03603	ISIS 6958	.	.	.	Investigative
M6APDG00049	"N1,N3-bis(3-methoxybenzyl)isophthalamide"	"CHEMBL605201; N1,N3-bis(3-methoxybenzyl)isophthalamide; SCHEMBL5332068"	10111838	C24H24N2O4	Investigative
M6APDG00229	Octanedioic acid hydroxyamide pyridin-4-ylamide	Octanedioic acid hydroxyamide pyridin-4-ylamide; SCHEMBL8082656; CHEMBL165162; ZINC13472304	10967421	C13H19N3O3	Investigative
M6APDG03648	Bmab-200	"Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon"	.	.	Investigative
M6APDG04260	Contusugene ladenovec	"Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR"	.	.	Phase 3
M6APDG01613	(E)-9-Nitrohexadec-9-enoicAcid	CHEMBL560513; (E)-9-Nitrohexadec-9-enoicAcid; 9-nitropalmitoleic acid; E-9-nitropalmitoleic acid; SCHEMBL15633556; YZNSJIAWRWPQGX-NTCAYCPXSA-N; (E)-9-Nitro-9-hexadecenoic acid; BDBM50295047	44220886	C16H29NO4	Investigative
M6APDG03402	AR-H049020	.	.	.	Discontinued in Phase 1
M6APDG03594	ISIS 114197	.	.	.	Investigative
M6APDG02877	R547	"LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone"	6918852	C18H21F2N5O4S	Discontinued in Phase 1
M6APDG03378	Ranibizumab	"Ranibizumab (nasal spray, hereditary hemorrhagic telangiectasia)"	.	.	Approved
M6APDG01661	"1,1,1-Trifluoro-8-phenoxy-octan-2-one"	CHEMBL114796; BDBM50217940	44342886	C14H17F3O2	Investigative
M6APDG02719	3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 7b; AC1O704J; CHEMBL193652; BDBM8589; SCHEMBL4220785; ZINC13610777; 3-[(Z)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539766	C15H12ClN	Investigative
M6APDG00426	N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide	CHEMBL202469; N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide; SCHEMBL3295100; BDBM50182532	11646165	C16H26N2O5S	Investigative
M6APDG02254	KAEMPFERIDE	"Kaempferide; 491-54-3; Kaempferid; 4'-Methylkaempferol; 4'-O-Methylkaempferol; Kaempferol 4'-methyl ether; Kaemperide; Campheride; Kempferide; UNII-508XL61MPD; 4'-Methoxy-3,5,7-trihydroxyflavone; NSC 407294; KAMPFERIDE; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-; 5,7-Dihydroxy-4'-methoxyflavonol; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; EINECS 207-738-4; BRN 0305378; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Flavone, 3,5,7-trihydroxy-4'-methoxy-; CHEMBL40919; CHEBI:6099; 508XL61MPD"	5281666	C16H12O6	Investigative
M6APDG02706	GW1929	GW 1929; GW-1929	6518171	C30H29N3O4	Investigative
M6APDG02526	S-2474	"158089-95-3; CTK4C9584; DTXSID20724630; PHENOL, 2,6-BIS(1,1-DIMETHYLETHYL)-4-[(E)-(2-ETHYL-1,1-DIOXIDO-5-ISOTHIAZOLIDINYLIDENE)METHYL]-"	57370228	C20H31NO3S	Discontinued in Phase 2
M6APDG03918	PMI-005	.	.	.	Phase 1
M6APDG04254	Emapalumab	emapalumab; Gamifant; emapalumab-lzsg; GTPL9295; Ni-0501; NI0501	.	.	Phase 2/3 Trial
M6APDG03923	ABBV-257	.	.	.	Phase 1
M6APDG02941	HONOKIOL	"Honokiol; 35354-74-6; 5,3'-Diallyl-2,4'-dihydroxybiphenyl; NSC 293100; Honokiol,(S); UNII-11513CCO0N; 3,5'-Diallyl-4,2'-dihydroxybiphenyl; 3',5-Diallylbiphenyl-2,4'-diol; CPD000387107; CHEMBL16901; CHEBI:5759; 4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol; 3',5-diallyl-[1,1'-biphenyl]-2,4'-diol; 11513CCO0N; 3',5-diallyl-2,4'-biphenyldiol; AK-25837; 5,3&amp; -Diallyl-2,4&amp; Q-100425; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-; SMR000387107; 3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol; houpa"	72303	C18H18O2	Investigative
M6APDG04131	Xentuzumab	.	.	.	Phase 2
M6APDG03322	Dihydrotestosterone	"Androstanolone; STANOLONE; dihydrotestosterone; 521-18-6; Andractim; Androlone; Proteina; Anaboleen; Stanaprol; Anabolex; Protona; Neodrol; Cristerona MB; 4-Dihydrotestosterone; 17beta-Hydroxy-5alpha-androstan-3-one; 5alpha-Dihydrotestosterone; Androstanolonum; Androstanolona; DHT; 5-alpha-Dihydrotestosterone; Dihydrotestosteron; Testosterone, dihydro-; 4,5alpha-Dihydrotestosterone; 5alpha-Androstan-17beta-ol-3-one; Stanorone; Stanolon; 17beta-Hydroxyandrostan-3-one; 5alpha-DHT; LG 152; 17beta-Hydroxy-3-androstanone; [3H]dihydrotestosterone"	10635	C19H30O2	Phase 4
M6APDG04105	CART-EGFR	.	.	.	Phase 1/2
M6APDG00925	"5,7-Dichlorokynurenic Acid"	Dcka	1779	C10H5Cl2NO3	Investigative
M6APDG00715	Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone	.	136002679	C14H11Br2N3OS	Investigative
M6APDG03091	6-Phenylsulfanyl-9H-purine	"Purine, 6-(phenylthio)-; 6-(Phenylthio)purine; 1H-Purine, 6-(phenylthio)-; 5450-35-1; NSC 15746; UNII-3KH11DU8DY; 6-phenylsulfanyl-7H-purine; BRN 0013668; 3KH11DU8DY; AI3-52068; AC1Q4XUH; AC1L3TI0; 4-26-00-01985 (Beilstein Handbook Reference); 9H-Purine,6-(phenylthio)-; SCHEMBL796397; 6-(phenylsulfanyl)-7H-purine; CHEMBL175600; 9H-Purine, 6-(phenylthio)-; CTK5A1336; DTXSID20202908; NSC15746; ZINC13608565; NSC-15746; AKOS030562402"	95065	C11H8N4S	Investigative
M6APDG02726	3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine	"SCHEMBL4224799; BDBM8599; CHEMBL368305; SCHEMBL4224793; (3-Pyridylmethylene)indane 23a; AC1O7051; 3-[(E)-(4-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539775	C16H15N	Investigative
M6APDG01793	Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)	CHEMBL426169; cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)	44418894	C37H49N11O6	Investigative
M6APDG03232	Naveglitazar	"LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand"	9888484	C25H26O6	Phase 2
M6APDG00415	C[Nle-Asp-D-Phe-Arg-Trp-Glu]-NH2	CHEMBL203170; c[Nle-Asp-D-Phe-Arg-Trp-Glu]-NH2	11629290	C41H55N11O9	Investigative
M6APDG00917	ROXIFIBAN	"Roxifiban; UNII-Q476FMZ72G; DMP754; 170902-47-3; CHEMBL18301; Q476FMZ72G; DMP-754; Roxifiban [INN]; AC1L42MF; SCHEMBL344302; DTXSID70168969; BDBM50075579; methyl (2S)-2-(butoxycarbonylamino)-3-[[2-[(5R)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]propanoate; L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-; L-Alanine, 3-((((5R)-3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methy"	177230	C21H29N5O6	Investigative
M6APDG03153	Lobeglitazone	"Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang"	9826451	C24H24N4O5S	Approved
M6APDG01926	P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate	"p1-(5'-adenosyl)p5-(5'-thymidyl)pentaphosphate; CHEMBL1236157; T5A; 3tmk; 1mrn; 4TMK; AC1L9KL2; BDBM50366828; DB03280; adenosine 5'-(hexahydrogen pentaphosphate), P"""" 5'-ester with thymidine; 103137-88-8; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy-[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]oxyphosphoryl]oxyphosphoryl] hydrogen phosphate"	447202	C20H30N7O23P5	Investigative
M6APDG03214	EB-47	"EB 47; 366454-36-6; 5'-Deoxy-5'-[4-[2-[(2,3-dihydro-1-oxo-1H-isoindol-4-yl)amino]-2-oxoethyl]-1-piperazinyl]-5'-oxoadenosine Dihydrochloride; DTXSID40692822; ZINC98052573; NCGC00370771-01; KB-76747; FT-0667818; 4-[1-(6-Amino-9H-purin-9-yl)-1-deoxy-; A-D-ribofuranuronoyl]-N-(2,3-dihydro-1-oxo-1H-isoindol-4-yl)-1-piperazineacetamide Dihydrochloride; 2-{4-[(2R,3R,4S,5S)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]piperazin-1-yl}-N-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)acetamide (non-preferred name)"	9871899	C24H27N9O6	Investigative
M6APDG00391	8-Octyl-benzolactam-V9	CHEMBL206866; 8-Octyl-benzolactam-V9; 8-Octylbenzolactam-V9	11574614	C24H40N2O2	Investigative
M6APDG00462	"8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one"	"SCHEMBL4662780; CHEMBL363363; BDBM27514; LQEYAIKMIJUZNT-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2a; ZINC13652898; 5,6-Dihydro-5-oxo-8-amino-indeno[1,2-c]isoquinoline"	11736764	C16H12N2O	Investigative
M6APDG03784	AT-009	.	.	.	Investigative
M6APDG00131	N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N	10380885	C17H16ClN3O	Investigative
M6APDG04333	CPH-102	"IABP; INH2BP, Crimson Pharmaceutical; INH2BP, Octamer; PARP inhibitors, Crimson Pharmaceutical; PARP inhibitors, Octamer; CPH-101, Crimson Pharma"	.	.	Preclinical
M6APDG04255	Olokizumab	OLOKIZUMAB; CHEMBL1743050; CDP-6038	.	.	Phase 2/3 Trial
M6APDG01389	PAI-1	"PA Autoinducer; Pseudomonas aeruginosa autoinducer; N-(3-Oxododecanoyl)homoserine lactone; 3-Oxo-N-(tetrahydro-2-oxo-3-furanyl)dodecanamide; 152833-54-0; CHEBI:29639; 3-oxo-N-(2-oxotetrahydrofuran-3-yl)dodecanamide; N-(3-ketododecanoyl)homoserine lactone; 3-oxo-C12-AHL; 3-oxo-N-(2-oxooxolan-3-yl)dodecanamide; AC1L2SRN; CHEMBL482476; SCHEMBL10076544; BCP19350; AN-30880; RT-014202; 3-(3-Oxododecanoylamino)tetrahydrofuran-2-one; C11840; Dodecanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)-"	3246941	C16H27NO4	Phase 4
M6APDG03441	ICR 62	.	.	.	Investigative
M6APDG02267	Cerulenin	"Helicocerin; Cerulenin, Cephalosporium caerulens; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2-alpha,3-alpha(4E,7E)))-(9CI); (2R,3S)-2,3-Epoxy-4-oxo-7E,10E-dodecadienamide; (2R,3S)-3-((4E,7E)-Nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide; (2R,3S)-3-((4E,7E)-nona-4,7-dienoyl)oxirane-2-carboxamide; (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; (2R,3S)-3-nona-4,7-dienoyloxirane-2-carboxamide; (2R,3S,E,E)-2,3-Epoxy-4-oxo-7,10-dodecadienamide; (2R-(2alpha,3alpha(4E,7E)))-3-(1-Oxonona-4,7-dienyl)oxirane-2-carboxamide; (2S)(3R)-2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; (2S,3R)-2,3-epoxy-4-oxy-7,10-dodecadienoylamide; (2r,3s)-3-(nona-4,7-dienoyl)oxirane-2-carboxamide; 2,3-Epoxy-4-oxo-7,10-dodecadienamide; 2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; 3-(1-Oxo-4,7-nonadienyl)oxiranecarboxamide; 3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; 3-nona-4,7-dienoyloxirane-2-carboxamide"	5282054	C12H17NO3	Approved
M6APDG01756	Carboxylated glucosamine	carboxylated glucosamine	44411803	C13H23NO7	Investigative
M6APDG02399	Methylnaltrexone bromide	"Relistor; Methylnaltrexone (Bromide); Naltrexone methobromide; 73232-52-7; N-Methylnaltrexone Bromide; MRZ-2663BR; N-Cyclopropylmethyl-noroxymorphone Methobromide; Methylnaltrexone; MNTX; C21H26NO4Br; MOA-728; Relistor (TN); MRZ 2663BR; Naltrexone Methyl Bromide; N-Methyl Naltrexone Bromide; MNTX-302; SCHEMBL2798188; CHEMBL1201770; IFGIYSGOEZJNBE-KNLJMPJLSA-N; ONO-3849; Methylnaltrexone bromide (JAN/USAN); 3844AH; AKOS015896214; CS-0762; AN-37324; HY-75766; Methylnaltrexone bromide, &gt; W-5330; CHIR-01020"	5361917	C21H26BrNO4	Approved
M6APDG02450	Cdk1 inhibitor	"cdk1 inhibitor; 3-(2-Chloro-3-indolylmethylene)-1,3-dihydroindol-2-one; CHEMBL261425; 220749-41-7; K00028; AC1NV88J; SCHEMBL1394886; GTPL5944; CHEBI:113538; HMS3229C12; NSC720148; BDBM50375670; HSCI1_000249; CCG-206822; NSC-720148; RT-011955; J-014469; BRD-K81836716-001-01-7; 3-[(2-Chloro-1H-indole-3-yl)methylene]-1H-indole-2(3H)-one; (3E)-3-[(2-chloro-1H-indol-3-yl)methylidene]-1H-indol-2-one"	5472558	C17H11ClN2O	Investigative
M6APDG00430	AZ12260493	AZ 12260493; AZ-12260493	11655079	C24H29N3O3S	Investigative
M6APDG02389	SAR-405838	"AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis"	53476877	C29H34Cl2FN3O3	Phase 1
M6APDG01028	Phenoxodiol	"Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran"	219100	C15H12O3	Phase 1/2
M6APDG01169	Cyclo-[-Arg-Gly-Asp-Amp21-]	CHEMBL411863; BDBM50372589	24822953	C17H28N8O6	Investigative
M6APDG03964	DS-8895	.	.	.	Phase 1
M6APDG01011	PIPERROLEIN B	"Piperolein B; PIPERROLEIN B; Piperoleine B; 30505-89-6; CHEMBL256214; MEGxp0_000205; SCHEMBL15471329; ACon1_000259; FAXXHNWVMKTOFF-UXBLZVDNSA-N; MCULE-4025815326; NCGC00180733-01; BRD-K04771916-001-01-8; Piperidine, 1-[(8E)-9-(1,3-benzodioxol-5-yl)-1-oxo-8-nonenyl]-; (8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)non-8-en-1-one; Piperidine, 1-[9-[3,4-(methylenedioxy)phenyl]-8-nonenoyl]-, (E)-; (E)-9-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)non-8-en-1-one; Piperidine, 1-[9-(1,3-benzodioxol-5-yl)-1-oxo-8-nonenyl]-, ("	21580213	C21H29NO3	Investigative
M6APDG02308	(E)-3-(4-(methylsulfonyl)styryl)thiophene	CHEMBL1288782; (E)-3-(4-(methylsulfonyl)styryl)thiophene	52949357	C13H12O2S2	Investigative
M6APDG00294	9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine	SCHEMBL6659707	11336624	C18H13FN4S	Investigative
M6APDG02936	SGC-CBP30	"SGC-CBP30; 1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256"	72201027	C28H33ClN4O3	Investigative
M6APDG01657	8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid	"CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-"	44341224	C20H22O4	Investigative
M6APDG02304	APR-246	Eprenetapopt	52918385	C10H17NO3	Phase 2
M6APDG03520	PF-05094037	"PF-05171310; PF-05181059; MTOR inhibitors (cancer), Pfizer"	.	.	Investigative
M6APDG02359	6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine	O6-Substituted Guanine Deriv. 32; CHEMBL405773; BDBM5492; AC1NS702; SCHEMBL12227591; O6-[3-(Methyl)Benzyl]Guanine; ZINC13475147; 2-Amino-6-(3 -methylbenzyl)oxypurine; 6-[(3-methylphenyl)methoxy]-9H-purin-2-amine	5329516	C13H13N5O	Investigative
M6APDG02377	"(2,6-Diamino-pyridin-3-yl)-phenyl-methanone"	"(2,6-Diaminopyridin-3-yl)(phenyl)methanone; 157924-28-2; 3-Acyl-2,6-diaminopyridine deriv. 3c; (2,6-diamino-3-pyridinyl)phenylmethanone; AC1NS9QT; SCHEMBL4419093; BDBM6908; CHEMBL193590; 3-benzoylpyridine-2,6-diamine; 852997-66-1"	5330842	C12H11N3O	Investigative
M6APDG02445	L-695902	"L-695902; CHEMBL104297; SCHEMBL8018550; AKOS022507211; methyl 7-chloro-2,4-dihydroxy-3-quinolinecarboxylate; methyl 7-chloro-2,4-dihydroxyquinoline-3-carboxylate"	54695867	C11H8ClNO4	Terminated
M6APDG02439	RG-13022	"RG-13022; RG 13022; CHEMBL67027; NSC666257; (Z)-3-(3,4-Dimethoxy-phenyl)-2-pyridin-3-yl-acrylonitrile; 136831-48-6; DBGZNJVTHYFQJI-RIYZIHGNSA-N; 149286-90-8; Tyrphostin RG13022; AC1NV4OE; SCHEMBL241869; SCHEMBL1959494; CHEBI:93448; MolPort-009-019-306; BDBM50039091; ZINC37858694; HSCI1_000158; AKOS032947325; NSC-666257; NCGC00018297-02; NCGC00018297-01; J-006919; BRD-K82688027-001-01-5; 3-(3,4-Dimethoxyphenyl)-2-(3-pyridinyl)acrylonitrile; (Z)-3-(3,4-dimethoxyphenyl)-2-pyridin-3-ylprop-2-enenitrile"	5468216	C16H14N2O2	Terminated
M6APDG03419	AVT-02 UE	.	.	.	Discontinued in Phase 2
M6APDG03385	Necitumumab	LY3012211	.	.	Approved
M6APDG00962	7-nitro-1H-indazole	"7-Nitroindazole; 7-nitroindazole; 7-Nitro-1H-indazole; 2942-42-9; 1H-Indazole, 7-nitro-; 7-nitro-indazole; 7-NI; UNII-UX0N37CMVH; CCRIS 3309; EINECS 220-934-4; NSC 72843; UX0N37CMVH; BRN 0006809; MLS000028452; CHEMBL247378; PQCAUHUKTBHUSA-UHFFFAOYSA-N; MFCD00022789; SMR000058266; 7NI; 2h-indazole,7-nitro-; SR-01000075512; 7- Nitroindazole; 7-Nitroisoindazole; Tocris-0602; PubChem14009; AC1L1CGU; Spectrum3_001980; Spectrum2_001715; Opera_ID_1690; Lopac-N-7778; ACMC-209h8w; AC1Q1Y3U; 7-Nitroindazole, &gt; NCIOpen2_000477; Lopac0_000839; BSPBio_003580"	1893	C7H5N3O2	Investigative
M6APDG03814	RG-7010	"R-7010; PEGylated IGF1 (amyotrophic lateral sclerosis), Roche"	.	.	Phase 1
M6APDG00837	6-amino-4-trifluoromethylquinolin-2(1H)-one	"6-amino-4-trifluoromethylquinolin-2(1H)-one; 328955-57-3; 6-amino-4-(trifluoromethyl)quinolin-2(1H)-one; 2(1H)-Quinolinone, 6-amino-4-(trifluoromethyl)-; SCHEMBL1770828; CHEMBL385509; SCHEMBL19680530; CTK8B4763; BDBM18526; DTXSID60582115; LMXZMEMPGRLDIG-UHFFFAOYSA-N; ANW-46096; ZINC12349446; AKOS015951346; AK-41783; AC-27434; SC-50493; AJ-61229; AB1009151; AB0024239; ST2406401; AX8208563; W5464; CS-0084832; FT-0688581; 6-Amino-4-trifluoromethyl-2(1H)-quinolinone; 6-Amino-4-(trifluoromethyl)-quinolin-2(1h)-one"	16090308	C10H7F3N2O	Investigative
M6APDG00457	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	CHEMBL382537	11717472	C16H13BrN2O3	Investigative
M6APDG01511	4-(4-hydroxy-benzylideneamino)-benzenesulfonamide	4-(4-hydroxybenzylideneamino)benzenesulfonamide	404202	C13H12N2O3S	Investigative
M6APDG01877	4-(isopentylthio)-2-methoxybenzonitrile	CHEMBL462663; 4-(isopentylthio)-2-methoxybenzonitrile	44564585	C13H17NOS	Investigative
M6APDG00450	AN0128	"Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane"	11704019	C20H16BCl2NO3	Phase 2
M6APDG01735	"Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione"	"CHEMBL373066; pyrroloisoindoledione; pyrrolo[3,4-e]indole-1,3(2H,6H)-dione"	44407700	C10H6N2O2	Investigative
M6APDG03375	Pro-urokinase	Thrombolyse (TN)	.	.	Approved
M6APDG04154	NI-0801	"Anti-interferon inducible protein 10, NovImmune"	.	.	Phase 2
M6APDG01678	Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe	.	44355267	C40H59N7O10	Investigative
M6APDG02811	GSK2194069	GSK-2194069; GSK 2194069	67376285	C25H24N4O3	Investigative
M6APDG03000	N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide	CHEMBL521733; N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide; N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-carboxamide; AC1LG1FS; Oprea1_829316; Oprea1_192683; MolPort-001-987-537; ZINC285233; STK129364; BDBM50272836; AKOS000554028; MCULE-1062167425; NCGC00304458-01; BAS 03049800; ST45172084; AB01300868-01; N-[2-(1H-indol-3-yl)ethyl]-4-phenylbenzamide; N-(2-indol-3-ylethyl)(4-phenylphenyl)carboxamide; Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide	787236	C23H20N2O	Investigative
M6APDG00614	Bis(6-hydroxybenzo[b]furan-2-yl)methanone	CHEMBL225827; bis(6-hydroxybenzo[b]furan-2-yl)methanone	13393486	C17H10O5	Investigative
M6APDG01099	2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid	4-anilinopyrimidine 7a; CHEMBL394869; BDBM15986; AKOS029246132; 2-{[2-(butylamino)pyrimidin-4-yl]amino}benzoic acid	23647246	C15H18N4O2	Investigative
M6APDG00538	L-689560	"trans-2-Carboxy-5,7-dichloro-4-(((phenylamino)carbonyl)amino)-1,2,3,4-tetrahydroquinoline; C17H15Cl2N3O3; L 689560; L-689,560; 4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline; 139051-78-8; (2S,4R)-5,7-dichloro-4-(phenylcarbamoylamino)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid; 2-Quinolinecarboxylic acid, 5,7-dichloro-1,2,3,4-tetrahydro-4-(((phenylamino)carbonyl)amino)-, trans-(+-)-; [3H]L689560; AC1L3TN7; SCHEMBL193615; GTPL4239; GTPL4086; ZINC2567729; compound 35"	121918	C17H15Cl2N3O3	Terminated
M6APDG04249	Clazakizumab	Clazakizumab; ALD518; CHEMBL2108589; BMS-945429	.	.	Phase 2 Trial
M6APDG03939	AI-850	.	.	.	Phase 1
M6APDG02757	5-Indan-(1E)-ylidenemethyl-1H-imidazole	"Imidazolylmethyleneindane 2a; AC1O70GB; SCHEMBL4235335; BDBM8873; CHEMBL177468; SCHEMBL13877092; 5-[(E)-2,3-dihydroinden-1-ylidenemethyl]-1H-imidazole; 5-[(E)-2,3-Dihydro-1H-inden-1-ylidenemethyl]-1H-imidazole"	6540032	C13H12N2	Investigative
M6APDG01208	N7-hydroxy-N1-phenyl-2-propoxyheptanediamide	CHEMBL251406; N7-hydroxy-N1-phenyl-2-propoxyheptanediamide; SCHEMBL8144856	25065713	C16H24N2O4	Investigative
M6APDG04063	AU105	.	.	.	Phase 1/2
M6APDG01207	N7-hydroxy-2-methoxy-N1-phenylheptanediamide	CHEMBL251206; N7-hydroxy-2-methoxy-N1-phenylheptanediamide; SCHEMBL8143763	25065710	C14H20N2O4	Investigative
M6APDG04216	LY-2875358	"C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly"	.	.	Phase 2
M6APDG02678	2-(biphenyl-4-ylsulfonamido)pentanedioic acid	CHEMBL475540; 2-(Biphenyl-4-sulfonylamino)-pentanedioic acid; SR-01000365325; BAS 07869980; AC1LD9LY; 2-(biphenyl-4-ylsulfonamido)pentanedioic acid; MLS000075919; CHEBI:91838; HMS2373B21; ML034; BDBM50247207; AKOS000737926; AKOS024284065; MCULE-3770968562; ST072428; SMR000014780; 2-[(4-phenylphenyl)sulfonylamino]pentanedioic acid; SR-01000365325-1; SR-01000365325-3; 2-{[(4-phenylphenyl)sulfonyl]amino}pentanedioic acid	644601	C17H17NO6S	Investigative
M6APDG03390	GSK2849466	.	.	.	Discontinued in Phase 1
M6APDG01290	Celecoxib	"CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide"	2662	C17H14F3N3O2S	Approved
M6APDG02674	Oxeglitazar	EMD-336340; EML-16156; EML-4156; LM-4156	6445229	C19H22O4	Phase 1
M6APDG04248	Sirukumab	Sirukumab (USAN); Sirukumab (genetical recombination) (JAN); D10080; 1194585-53-9	.	.	Phase 2 Trial
M6APDG01418	"1,2,4-Triazole-Carboxamidine"	"1,2,4-TRIAZOLE-CARBOXAMIDINE; AC1MPLO2; TZC; ZINC162503468; DB02048; CJ-13028; amino(1H-1,2,4-triazol-1-yl)methaniminium"	3387240	C3H6N5+	Investigative
M6APDG00078	RXP-470	"MMP-12 inhibitors (atherosclerosis); MMP-12 inhibitors (atherosclerosis), CEA; RXP-470 derivatives (atherosclerosis), CEA"	102258832	C35H35BrClN4O10P	Investigative
M6APDG00902	CGP-52411	DAPH	1697	C20H15N3O2	Terminated
M6APDG00458	GSK-812397	"CXCR4 receptor antagonists (HIV-1 infection); CXCR4 receptor antagonists (HIV-1 infection), GlaxoSmithKline"	11718722	C24H32N6O	Investigative
M6APDG03282	Ro-43-8857	"Ro-43-8857; CHEMBL290497; SCHEMBL8381416; BDBM50003852; alpha,alpha'-[[4-[[Methyl(4-amidinobenzoyl)amino]acetyl]-o-phenylene]bis(oxy)]diacetic acid; (4-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid; (5-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid"	9933077	C21H21N3O8	Terminated
M6APDG04273	Golnerminogene pradenovac	TNFerade (TN)	.	.	Phase 3
M6APDG01335	NSC-138419	NSC-138419; NSC138419; n-[4-(methylamino)benzoyl]glutamic acid; AC1Q5SG8; AC1L5YW4; SCHEMBL5925511; CHEMBL591443; CTK1H0013; 2-[(4-methylaminobenzoyl)amino]pentanedioic acid; A816490; 2-[[4-(methylamino)benzoyl]amino]pentanedioic acid; 2-[[4-(methylamino)phenyl]carbonylamino]pentanedioic acid; 2-[[[4-(methylamino)phenyl]-oxomethyl]amino]pentanedioic acid	283555	C13H16N2O5	Investigative
M6APDG03010	3-amino-benzo[b]thiophene-2-carboxylic acid amide	"3-amino-1-benzothiophene-2-carboxamide; 37839-59-1; 3-Aminobenzo[b]thiophene-2-carboxamide; CHEMBL211002; Benzo[b]thiophene-2-carboxamide, 3-amino-; 3-aminobenzo[b]thiophene-2-carboxylic acid amide; AC1LGIJV; 3-amino-benzo[b]thiophene-2-carboxylic acid amide; SCHEMBL6609258; CTK1B5350; DTXSID80356350; MolPort-002-798-643; ZINC339150; STL134701; BDBM50186634; AKOS001782516; CCG-127335; MCULE-9206749194; NE38914; EN300-88534"	821974	C9H8N2OS	Investigative
M6APDG04306	Siltuximab	Sylvant (TN); Siltuximab (USAN/INN); D09669; 541502-14-1	.	.	Phase 3 Trial
M6APDG03956	ISIS-AR	.	.	.	Phase 1
M6APDG00392	"[1,1':2',1'']-terphenyl-4,3'',5''-triol"	CHEMBL208098; BDBM50186757; ZINC35856323	11579996	C18H14O3	Investigative
M6APDG02289	Geldanamycin	"GDM; GMY; Geldanamicin; Geldanomycin; Geldaramycin; Antibiotic U 29135; BODIPY-labeled Geldanamycin; Geldanamycin (9CI); Geldanamycin, Streptomyces hygroscopicus; U-29135; Antibiotic (U-29,135); [(8E,12E,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(8E,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(8Z,12Z,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5R,6S,7R,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,10S,11S)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3S,5S,6R,7S,8E,10R,11S,12Z,14E)-6-Hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3S,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate; (6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl) carbamate; [8S-(4E,6Z,8R*,9R*,10E,12R*,13S*,14R*,16S*)]-9-[(Aminocarbonyl)oxy]-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-2-azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione; 2-Azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9,13-dihydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-, 9-carbamate (8CI); 2-Azabicyclo[16.3.1]docosane, geldanamycin deriv."	5288382	C29H40N2O9	Discontinued in Phase 2
M6APDG03111	RPR-118723	RPR-118723; CHEMBL80649	9796571	C14H11ClN2O4	Investigative
M6APDG03709	ISIS 133207	.	.	.	Investigative
M6APDG04283	Belagenpumatucel-L	Lucanix (TN)	.	.	Phase 3
M6APDG02147	Pioglitazone	"111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; Pioglitazone [INN:BAN]; Pioglitazone [BAN:INN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; U 72107; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; C19H20N2O3S; AD 4833; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A;  Actos; Actost; Glustin (TN); HS-0047; Pioglitazone (INN); U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; Linagliptin + pioglitazone; PCG1"	4829	C19H20N2O3S	Approved
M6APDG01052	N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide	CHEMBL1084681; N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680	22319694	C17H16FN3O	Investigative
M6APDG03204	SC-236	"SC-791; SC-872; COX-2 inhibitors (anticancer), Pfizer; COX-2 inhibitors (anticancer), Pharmacia"	9865808	C16H11ClF3N3O2S	Terminated
M6APDG01746	Ala-Pro-Glu	"Ala-Pro-Glu; 71190-92-6; CHEMBL381831; CTK2G2707; DTXSID10658778; L-Alanyl-L-prolyl-L-glutamic acid; L-Glutamic acid, L-alanyl-L-prolyl-"	44408970	C13H21N3O6	Investigative
M6APDG01924	PD-0173955	PD-17395	447077	C21H16Cl2N4OS	Investigative
M6APDG00934	"(2R)-1-(2,6-dimethylphenoxy)propan-2-amine"	"94991-73-8; (R)-1-(2,6-dimethylphenoxy)propan-2-amine; (2R)-1-(2,6-dimethylphenoxy)propan-2-amine; 2-Propanamine, 1-(2,6-dimethylphenoxy)-, (2R)-; CHEMBL147507; zlchem 1301; (R)-MEXILETINE; (R)-(-)-Mexiletine; AC1L47IL; SCHEMBL16082; BIDD:GT0498; ZINC20257; ZLE0076; DTXSID50241709; BDBM50135883; AKOS017529564; DB07129; AJ-08428; KB-209407; (2R)-1-(2,6-dimethylphenoxy)-2-propanamine; A821017; (R)-2-(2,6-Dimethyl-phenoxy)-1-methyl-ethylamine; UNII-1U511HHV4Z component VLPIATFUUWWMKC-SNVBAGLBSA-N"	180621	C11H17NO	Investigative
M6APDG02795	SF1126	"CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt"	66577114	C39H48N8O14	Phase 2
M6APDG02982	PCO371	"Pco-371; UNII-TE53TU0WSQ; TE53TU0WSQ; PCO-371; 1613373-33-3; SCHEMBL17104864; CHEMBL3976807; US9428505, Compound 7; BDBM64562; PC-0371; J3.591.565F; 2,4-Imidazolidinedione, 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethyl-"	76283707	C29H32F3N5O6S	Phase 1
M6APDG03691	ISIS 114559	.	.	.	Investigative
M6APDG00923	8-chloro-quinoline-3-carbonitrile	"CHEMBL436817; Cyanoquinoline, 11; SCHEMBL6071997; BDBM21898; CHEBI:94979; BRD-K00088062-001-01-3; 4-[(3-Chloro-4-fluorophenyl)amino]-6-[(1H-imidazole-5-ylmethyl)amino]-8-chloro-3-quinolinecarbonitrile"	17759555	C20H13Cl2FN6	Investigative
M6APDG03646	LA22-radioimmunoconjugates	"LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22"	.	.	Investigative
M6APDG03719	ISIS 113187	.	.	.	Investigative
M6APDG00084	"4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid"	"CHEMBL66868; 4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid; SCHEMBL8172493; ZINC13737718"	10244811	C18H15NO4	Investigative
M6APDG01875	4-(cyclopropylmethylthio)-2-methoxybenzonitrile	CHEMBL504110; 4-(cyclopropylmethylthio)-2-methoxybenzonitrile	44564583	C12H13NOS	Investigative
M6APDG00296	SKI-758	"SCHEMBL3992463; CHEMBL219557; BDBM13047; SKI-758; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile"	11341869	C28H27Cl2N5O3	Approved
M6APDG02736	4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine	"(4-Pyridylmethylene)indane 6a; BDBM8614; AC1O705R; SCHEMBL4231103; CHEMBL424960; SCHEMBL4231111; ZINC13535834; 4-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539788	C15H12FN	Investigative
M6APDG03621	APS-3010	"Hepatic growth factor inhibitor (cancer), Atlas Pharmaceuticals"	.	.	Investigative
M6APDG01743	Nle-Pro-Glu	Nle-Pro-Glu	44408687	C16H27N3O6	Investigative
M6APDG03190	Alvespimycin hydrochloride	"Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG"	9852573	C32H49ClN4O8	Phase 1
M6APDG02900	PFI-1	QCR-192; HY-16586; PF-6405761	71271629	C16H17N3O4S	Investigative
M6APDG00745	GW841819X	KB-75882	13953710	C25H21N5O2	Investigative
M6APDG01333	Calusterone	"CALUSTERONE; Methosarb; Dimethyltestosterone; Calusteronum; Calusterona; 7-beta,17-Dimethyltestosterone; Calusteronum [INN-Latin]; Calusterona [INN-Spanish]; 7beta,17alpha-Dimethyltestosterone; 17021-26-0; 7beta,17-Dimethyltestosterone; Calusteron; 7-beta,17-alpha-Dimethyl testosterone; Calusterone [USAN:INN]; NSC-88536; UNII-0678G6Q58A; HSDB 3210; 17-beta-Hydroxy-7-beta,17-alpha-dimethylandrost-4-ene-3-one; U 22550; U-22,550; BRN 3212336; 17beta-Hydroxy-7beta,17-dimethylandrost-4-en-3-one"	28204	C21H32O2	Investigative
M6APDG00893	LGD2941	"LGD2941; CHEMBL467888; SCHEMBL3015188; BDBM18522; DB05234; 6-(1-Pyrrolidine)quinolin-2(1H)-one, 6a"	16750192	C17H16F6N2O2	Discontinued in Phase 1
M6APDG03206	L-761000	CHEMBL352174; L-761000; SCHEMBL7070915; AXFSURYONUFFTK-UHFFFAOYSA-N; BDBM50289087; 4-(1-(4-Bromobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)-3-methylbutanoic acid; 4-[1-(4-Bromo-benzyl)-5-methoxy-2-methyl-1H-indol-3-yl]-3-methyl-butyric acid	9867333	C22H24BrNO3	Investigative
M6APDG01166	Cyclo-[-Arg-Gly-Asp-Amp22-]	CHEMBL406912	24822283	C24H32N8O7	Investigative
M6APDG00313	1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole	"1H-Imidazole, 1-(3-methoxy-2-naphthalenyl)-; 674309-81-0; CHEMBL194472; SCHEMBL4508354; BDBM8917; CTK1H7855; DTXSID70465102; Imidazole-substituted naphthalene 24; ZINC13674482; AKOS030619217; 1-(3-methoxy-2-naphthyl)-1h-imidazole"	11413434	C14H12N2O	Investigative
M6APDG00611	AM-92016	"COMPOUND II; N-(4-(3-((2-(3,4-Dichlorophenyl)ethyl)methylamino)-2-hydroxypropoxy)phenyl)methanesulfonamide; AM-92016; Bio2_000288; AC1L1CZF; Msaph-2ClPhEA-2-propanol; CBiol_001738; KBioGR_000288; BSPBio_001568; KBioSS_000288; CHEMBL43527; AC1Q3O93; SCHEMBL9655059; KBio3_000575; CHEBI:91532; KBio3_000576; KBio2_002856; KBio2_005424; KBio2_000288; Bio1_000513; HMS1791O10; Bio1_001002; Bio1_000024; HMS1989O10; Bio2_000768; AC-115; IDI1_034038; NCGC00024837-04; NCGC00024837-03; NCGC00024837-02; BRD-A11813248-003-01-6; BRD-A11813248-001-02-8"	133104	C26H30Cl2N2O6S	Terminated
M6APDG03159	Upamostat	WX-671	9830667	C32H47N5O6S	Phase 2
M6APDG00812	1-(phenyl(p-tolyl)methylene)thiosemicarbazide	CHEMBL402465; 1-(phenyl(p-tolyl)methylene)thiosemicarbazide	15722900	C15H15N3S	Investigative
M6APDG00087	"4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine"	"CHEMBL185584; 4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine; BDBM50150924"	10261068	C6H12N2	Investigative
M6APDG00908	"4-amino-1,8-naphthalimide"	"4-Amino-1,8-naphthalimide; 1742-95-6; 4-Aminonaphthalimide; 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE; 6-Amino-1H-benzo[de]isoquinoline-1,3(2H)-dione; 4-Aminonaphthalene-1,8-dicarboximide; Naphthalimide, 4-amino-; DFP 1; 1H-Benz[de]isoquinoline-1,3(2H)-dione, 6-amino-; EINECS 217-110-1; BRN 0177185; 6-aminobenzo[de]isoquinoline-1,3-dione; PARP Inhibitor V, 4-ANI; CHEMBL338790; CHEBI:40071; SSMIFVHARFVINF-UHFFFAOYSA-N; 6-Amino-1H-benz(de)isoquinoline-1,3(2H)-dione; 4-AMINO-1,8 NAPHTHALIMIDE"	1720	C12H8N2O2	Investigative
M6APDG03668	IKI-1	"IKK inhibitors (cancer); I kappa B kinase inhibitors (cancer), Pfizer; IKK inhibitor (cancer), Wyeth; IKK inhibitors (cancer), Pfizer"	.	.	Investigative
M6APDG00707	AZ10417808	AZ-10417808; AZ 10417808	135665263	C18H13Cl2N5O4	Investigative
M6APDG02822	ME-344	"NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards"	68026984	C22H20O4	Phase 1/2
M6APDG01034	"4-(3-Fluoro-phenoxy)-6,7-dimethoxy-quinoline"	"CHEMBL102191; 4-(3-Fluoro-phenoxy)-6,7-dimethoxy-quinoline; SCHEMBL7490337; LQOBRLFNSGKIFO-UHFFFAOYSA-N; BDBM50290841"	22132626	C17H14FNO3	Investigative
M6APDG03430	HBP-347	"HBP-347 (oral, cancer/autoimmunity/ocular disease); Hypericin (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; HBP-347 (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; Hypericin (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University; HBP-347 (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University"	.	.	Discontinued in Phase 3
M6APDG03755	ISIS 101987	.	.	.	Investigative
M6APDG02161	PCM-075	Onvansertib	49792852	C24H27F3N8O3	Phase 2
M6APDG01652	"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	"CHEMBL98798; 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline"	44331231	C16H13BrN2O3	Investigative
M6APDG03922	AVX-470	"Anti-TNF antibody (oral, IBD), Avaxia Biologics"	.	.	Phase 1
M6APDG04281	DWP-431	"Recombinant bone morphogenetic protein 2 (bone synthesis), Daewoong; RBMP-2 (bone synthesis), Daewoong"	.	.	Phase 3
M6APDG03333	ADD-3878	"ciglitazone; 74772-77-3; Ciglitizone; ADD-3878; Ciglitazonum; Ciglitazona; Ciglitazonum [Latin]; Ciglitazona [Spanish]; Ciglitazone [USAN:INN]; ADD 3878; CHEBI:64227; U-63287; (+-)-5-(p-((1-Methylcyclohexyl)methoxy)benzyl)-2,4-thiazolidinedione; C18H23NO3S; 5-(4-((1-methylcyclohexyl)methoxy)benzyl)thiazolidine-2,4-dione; YZFWTZACSRHJQD-UHFFFAOYSA-N; (+/-)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione; U 63287; 5-{4-[(1-methylcyclohexyl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione; NCGC00164446-01"	2750	C18H23NO3S	Discontinued
M6APDG02689	Manzamine E	Manzamine E	6474830	C36H44N4O2	Investigative
M6APDG01847	Fumaric acid	"Fum; Fumarsaeure; Acidum fumaricum; Allomaleic acid; Allomalenic acid; Ammonium fumarate; Boletic acid; Butenedioic acid; Kyselina fumarova; Kyselina fumarova [Czech]; Lichenic acid; Tumaric acid; F0067; OR17920; FC 33 (acid); Fumarate, 10; Fumaric acid (8CI); Fumaric acid (NF); Lichenic acid (VAN); S04-0167; Trans-Butenedioic acid; U-1149; E-2-Butenedioic acid; Trans-2-Butenedioic acid; USAF EK-P-583; Trans-1,2-Ethylenedicarboxylic acid; Trans-but-2-enedioic acid; (2E)-2-butenedioic acid; (2E)-but-2-enedioic acid; (E)-2-Butenedioic acid; 1,2-Ethylenedicarboxylic acid, (E); 2-(E)-Butenedioic acid; 2-Butenedioic acid; 2-Butenedioic acid (2E-(9CI)"	444972	C4H4O4	Phase 3
M6APDG01691	AdcAhxArg4Lys(biotin)-PEG-OMe	CHEMBL413173	44387501	C61H107N27O14S	Investigative
M6APDG03490	C-myb	.	.	.	Investigative
M6APDG03228	L-709780	"CHEMBL32960; L-709780; BDBM50078448; l709780; N-[2-[2-(4-Piperidinyl)ethyl]-3-oxoisoindoline-5-ylcarbonyl]-beta-alanine; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid(L-709780); 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid"	9885190	C19H25N3O4	Terminated
M6APDG00583	"4,6-Dichloro-1H-indole-2-carboxylic acid"	"101861-63-6; 4,6-dichloro-1H-indole-2-carboxylic acid; 4,6-Dichloroindole-2-carboxylic acid; CHEMBL301556; 1H-Indole-2-carboxylicacid, 4,6-dichloro-; 3-(4,6-Dichloro-2-carboxyindol-3-yl)propionic acid; 3-Dccip; KBio2_007460; PubChem7197; Spectrum_001822; SpecPlus_000800; 4,6-Dichloro-1H-indole-2-carboxylicacid; ACMC-1BPUR; AC1Q3MQM; AC1L2SZE; Maybridge1_006804; AC1Q73TA; Oprea1_268024; KBioSS_002327; SCHEMBL727389; DivK1c_006896; KBio2_004892; KBio2_002324; KBio1_001840; CTK0H4782; HMS560N06; DTXSID80144299; MolPort-000-147-351; Mdl-29951"	127988	C9H5Cl2NO2	Investigative
M6APDG02486	4-(4-nitro-benzylideneamino)-benzenesulfonamide	"CHEMBL255175; 66667-60-5; 4-[(1E)-2-(4-nitrophenyl)-1-azavinyl]benzenesulfonamide; AC1LBU0E; 4-[(4-nitrophenyl)methylideneamino]benzenesulfonamide; SCHEMBL12416808; CTK5I3043; CTK1J4461; DTXSID10340363; IJEQJCKQAKELNC-OQLLNIDSSA-N; MolPort-001-818-097; ZINC131032; BDBM50371746; STK790732; SBB006116; AKOS001719928; MCULE-1611993564; MCULE-9098092341; ST016439; EU-0084260; 4-(4-Nitrobenzylideneamino)Benzenesulfonamide; 4-[(4-Nitrobenzylidene)amino]benzenesulfonamide; Benzenesulfonamide, 4-(4-nitrobenzylidenamino)-"	564225	C13H11N3O4S	Investigative
M6APDG00068	2-Amino-5-(N-nitro-guanidino)-pentanoic acid	CHEMBL353794; N-nitro-l-arg; KSC911C9L; SCHEMBL5271958; CTK8B1195; BDBM50049252; ANW-24471; ZINC27740002	10198326	C6H13N5O4	Investigative
M6APDG01671	Z-Arg-Leu-Val-Agly-Ile-Val-Trp-NH2	.	44355091	C49H74N12O10	Investigative
M6APDG00804	1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol	CHEMBL176319; 1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol; SCHEMBL7212147	15516781	C14H22O3S2	Investigative
M6APDG01650	"4-(3-Ethyl-phenoxy)-6,7-dimethoxy-quinoline"	"CHEMBL100765; 4-(3-Ethyl-phenoxy)-6,7-dimethoxy-quinoline"	44331127	C19H19NO3	Investigative
M6APDG03192	Novolimus	.	9854320	C50H77NO13	Approved
M6APDG02164	"3,5-Diamino-4'-amino-trans-stilbene"	CHEMBL1171091; BDBM50322064	49798900	C14H15N3	Investigative
M6APDG03734	ISIS 29112	.	.	.	Investigative
M6APDG02180	4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine	CHEMBL1215664; BDBM50324611	49864181	C18H15NO2	Investigative
M6APDG01682	Z-Ala-Leu-His-Agly-Ile-Val-OMe	.	44355524	C36H55N9O9	Investigative
M6APDG01995	Nectamazin C	Nectamazin C; CHEMBL570290	45487137	C23H32O7	Investigative
M6APDG01196	PP121	PP-121; PP 121	24905142	C17H17N7	Investigative
M6APDG01898	3-Bromo-1H-indazole-7-carbonitrile	"3-Bromo-1H-indazole-7-carbonitrile; 945762-00-5; CHEMBL451541; 1H-Indazole-7-carbonitrile,3-bromo-; AK-27881; CTK8B8302; KS-00000HFF; DTXSID00659577; MolPort-009-197-290; 3-bromo-2H-indazole-7-carbonitrile; ZINC40448363; BDBM50270530; ANW-59984; AKOS015898261; FCH1406736; VI20021; RP05214; SC-35603; QC-11297; KB-70485; DS-11111; CJ-20125; TC-148729; ST2417498; AX8158454; AB0037522; AJ-102668; AJ-102669; FT-0646755; Y4808; 4CH-016057; A15929; J-511797"	44585510	C8H4BrN3	Investigative
M6APDG01267	SRT1720	"925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; SRT1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N"	25232708	C25H24ClN7OS	Investigative
M6APDG00690	"6s-5,6,7,8-Tetrahydrobiopterin"	.	135509079	C9H15N5O3	Investigative
M6APDG03339	INK128	"1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)"	45375953	C15H15N7O	Phase 2
M6APDG00278	RGB-286638	"GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech"	11285001	C29H37Cl2N7O4	Phase 1
M6APDG02370	D-65476	bis(1H-2-indolyl)methanone deriv. 52	5330548	C21H18N2O3	Investigative
M6APDG01848	BMS614	BMS 614; BMS-614	445091	C29H24N2O3	Investigative
M6APDG02990	ONC1-13B	.	77461273	C22H16F4N4O3S	Phase 1/2
M6APDG01815	"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	"CHEMBL399371; 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline"	44442182	C22H24N2O2	Investigative
M6APDG04360	CS-207	"CS-307; PPAR alpha agonists (cardiovascular disease associated with dyslipidemia); PPAR alpha agonists (cardiovascular disease associated with dyslipidemia), Chipscreen Biosciences"	.	.	Terminated
M6APDG02448	L-698532	"28563-19-1; 3-Phenyl-4-hydroxy-7-chloroquinolin-2(1H)-one; L-698532; CHEMBL31661; 7-Chloro-4-hydroxy-3-phenyl-2(1H)-quinolone; 7-chloro-4-hydroxy-3-phenyl-2(1H)-quinolinone; 7-Chloro-4-hydroxy-3-phenyl-1H-quinolin-2-one; Mdl 104,653; ZINC5910; AC1MD767; SCHEMBL1612505; CTK4G1708; DTXSID80182777; RDXQSWLUXKUQSI-UHFFFAOYSA-N; BCP18252; BDBM50041467; AKOS032961557; 7-chloro-4-hydroxy-3-phenylquinolin-2(1H)-one; 7-chloro-2-hydroxy-3-phenyl-1H-quinolin-4-one; 3-phenyl-4-hydroxy-7-chloro-quinolin-2(1h)-one"	54697468	C15H10ClNO2	Terminated
M6APDG00128	7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine	CHEMBL315194; 7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine; SCHEMBL6980573; BDBM50104649	10375155	C8H15N3O2	Investigative
M6APDG00110	4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol	"CHEMBL119778; 790642-63-6; 4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol; CTK2G4587; DTXSID40438363; BDBM50066544; 4-[2-[(5-Phenylpentyl)amino]ethyl]phenol; Phenol, 4-[2-[(5-phenylpentyl)amino]ethyl]-"	10336113	C19H25NO	Investigative
M6APDG02375	"PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE"	"PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE; 4-{[6-(2,6-Dichlorobenzoyl)imidazo[1,2-A]pyridin-2-Yl]amino}benzenesulfonamide; 1ykr; 4-[[6-(2,6-dichlorobenzoyl)imidazo[1,2-a]pyridin-2-yl]amino]benzenesulfonamide; aminoimidazo[1,2-a]pyridine deriv. 2i; AC1NS9IQ; CHEMBL182260; BDBM6670; DB04607; 4-({6-[(2,6-dichlorophenyl)carbonyl]imidazo[1,2-a]pyridin-2-yl}amino)benzenesulfonamide"	5330608	C20H14Cl2N4O3S	Investigative
M6APDG03581	ATN-658	"ATN-291; ATN-292; HuATN-658; UPA mAbs, Attenuon; MAb (urokinase plasminogen activator system), Attenuon/Kyowa Hakko Kirin"	.	.	Investigative
M6APDG03514	ISIS 28477	.	.	.	Investigative
M6APDG03625	NMS-1	.	.	.	Investigative
M6APDG01318	T0070907	"2-Chloro-5-nitro-N-4-pyridinylbenzamide; 313516-66-4; 2-CHLORO-5-NITRO-N-4-PYRIDINYLBENZAMIDE; 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide; T 0070907; T-0070907; 2-chloro-5-nitro-N-pyridin-4-ylbenzamide; 2-Chloro-5-nitro-N-(4-pyridyl)benzamide; CHEMBL510698; Benzamide, 2-chloro-5-nitro-N-4-pyridinyl-; 2-chloro-5-nitro-n-4-pyridinyl-benzamide; SR-01000392700; AC1MCROG; Oprea1_586106; ZINC3381; GTPL3444; SCHEMBL2128178; CTK6H1028; KS-00000MYU; CHEBI:92553; DTXSID30380504; MolPort-001-763-336; FRPJSHKMZHWJBE-UHFFFAOYSA-N; HMS3268J16; HMS3651P21; HMS3262J21;  T 0070907"	2777391	C12H8ClN3O3	Investigative
M6APDG01403	RS-130830	CTS-1027; 193022-04-7; RS-130830; UNII-2QD3F58224; CHEMBL440498; 2QD3F58224; 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE; 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide; 4-(4-(4-Chloro-phenoxy)-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; Ro-1130830; AC1MOE9A; SCHEMBL2381112; BDBM11863; DTXSID90172907; 830c; CTS 1027; ZINC1488366; BCP13018; 3563AH; alpha-tetrahydropyran beta-sulfone 1B; AKOS030526690	3342298	C19H20ClNO6S	Discontinued in Phase 2
M6APDG03096	EGFR inhibitor	EGFR Inhibitor; 879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01	9549299	C21H18F3N5O	Investigative
M6APDG02302	AZD8186	"AZD8186; 1627494-13-6; AZD-8186; AIQ4OWD0RA; UNII-AIQ4OWD0RA; CHEMBL3408248; AZD 8186; 8-[(1R)-1-(3,5-difluoroanilino)ethyl]-N,N-dimethyl-2-morpholin-4-yl-4-oxochromene-6-carboxamide; SCHEMBL1636956; GTPL8527; MolPort-039-137-739; EX-A1649; BDBM50070322; s7694; AKOS025404922; ZINC116734639; CS-4975; ACN-037528; SB16709; KS-0000063L; AK174916; AC-29024; HY-12330; KB-334360; B5950; AZD8186; 1627494-13-6; AZD-8186; AIQ4OWD0RA; UNII-AIQ4OWD0RA;"	52913813	C24H25F2N3O4	Phase 1
M6APDG02405	R1507	.	5376617	C17H12N2O2	Phase 2
M6APDG01218	Ac-YRMEHdFRWG-NH2	CHEMBL266879; Ac-YRMEHdFRWG-NH2	25078192	C61H83N19O13S	Investigative
M6APDG03180	SR13668	.	9845566	C25H22N2O5	Phase 1
M6APDG02133	PD-158780	"171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; PD 158780; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-"	4707	C14H12BrN5	Investigative
M6APDG03186	SR-973	"SR-973; CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide"	9849669	C30H41N3O5	Investigative
M6APDG00597	ATLIPROFEN METHYL ESTER	IDPH-8261; Atliprofen methyl ester; 2-[4-(3-Thienyl)phenyl]propionic acid methyl ester	130978	C14H14O2S	Terminated
M6APDG02361	"6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine"	"6-(cyclohexylmethoxy)pyrimidine-2,4,5-triamine; pyrimidine deriv. 16; AC1NS76Q; CHEMBL71036; BDBM5588; SCHEMBL6263731; IMNSQZHRHASLAR-UHFFFAOYSA-N"	5329597	C11H19N5O	Investigative
M6APDG02083	AdoC(GABA)Arg6	CHEMBL611125	46877400	C50H90N30O12	Investigative
M6APDG02386	Sulfasalazine	sulfasalazine; 599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; SAS-500; Sulfasalizine	5339	C18H14N4O5S	Approved
M6APDG02967	(3-Bromo-phenyl)-quinazolin-4-yl-amine	"N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-"	735125	C14H10BrN3	Investigative
M6APDG03639	ISIS 1931	.	.	.	Investigative
M6APDG03424	Reglixane	.	.	.	Discontinued in Phase 2
M6APDG00008	GSK-3beta inhibitor XI	GSK-3b inhibitor XI	10020713	C18H15N5O3	Investigative
M6APDG01220	2'-Hydroxy-3-methoxy-biphenyl-4-carbonitrile	"diarylphenol, 5b; CHEMBL503575; BDBM25431"	25093227	C14H11NO2	Investigative
M6APDG02949	UNC1999	UNC 1999; UNC-1999	72551585	C33H43N7O2	Investigative
M6APDG04352	B-5354a	"B-5354b; B-5354c; Sphingosine kinase inhibitors, Sankyo"	.	.	Terminated
M6APDG03284	OTX-015	MK 8628	9936746	C25H22ClN5O2S	Phase 1/2
M6APDG02779	GW-974	"GW-282974; GW-2974; GW-449; GW-734; GW-9263; Erb B-2 inhibitor, Glaxo Wellcome"	6603857	C23H21N7	Terminated
M6APDG02753	"3-(2,2-Diphenyl-vinyl)-pyridine"	"3-(2,2-diphenylethenyl)pyridine; 3-Pyridylmethylene 33; BDBM8638; CHEMBL370317; 3-(2,2-Diphenylvinyl)Pyridine"	6539811	C19H15N	Investigative
M6APDG02468	VX-680	"Tozasertib; MK 0457; VX 680; VX6; L-001281814; MK-045; MK-0457; Tozasertib (USAN); VX-68; MK-0457, Tozasertib, VX680, VX-680; N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid N-(4-((4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl)sulfanyl)phenyl)amide; Cyclopropane carboxylic acid{4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulphanyl]-phenyl}-amide; Cyclopropanecarboxylic Acid {4-[4-(4-Methyl-Piperazin-1-Yl)-6-(5-Methyl-2h-Pyrazol-3-Ylamino)-Pyrimidin-2-Ylsulfanyl]-Phenyl}-Amide"	5494449	C23H28N8OS	Phase 2
M6APDG04139	BGS-649	.	.	.	Phase 2
M6APDG01733	"5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione"	"CHEMBL201723; 5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione"	44407565	C15H10N2O2	Investigative
M6APDG02341	5-Methoxy-1-phenyl-1H-benzoimidazole	"1H-Benzimidazole, 5-methoxy-1-phenyl-; 38205-85-5; 1-Phenylbenzimidazole deriv. 64; AC1NS4LX; CHEMBL76202; BDBM3847; SCHEMBL8006768; 5-methoxy-1-phenylbenzimidazole; CTK1B5049; DTXSID40416161; 5-Methoxy-1-phenyl-1H-benzimidazole; AKOS023169650; 5-Substituted 1-Phenylbenzimidazole 6"	5328466	C14H12N2O	Investigative
M6APDG00104	5-Methylsulfanyl-thiophene-2-carboxamidine	"CHEMBL28890; 5-Methylsulfanyl-thiophene-2-carboxamidine; 2-Thiophenecarboximidamide, 5-(methylthio)-; SCHEMBL5982145; AXSQTCBARFBKPH-UHFFFAOYSA-N; BDBM50099912; 5-methylthiothiophene-2-carboxamidine"	10313318	C6H8N2S2	Investigative
M6APDG02760	5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole	AC1O70GX; SCHEMBL4231849; CHEMBL174579	6540043	C13H11BrN2	Investigative
M6APDG01947	aloisine A	"ALOISINE A; 4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131"	448912	C16H17N3O	Investigative
M6APDG01667	7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one	CHEMBL126355; BDBM50222394	44350626	C22H23NO3	Investigative
M6APDG03681	ISIS 3801	.	.	.	Investigative
M6APDG01203	E-3810	"Lucitanib; AL-3810; E-3810, EOS"	25031915	C26H25N3O4	Phase 3
M6APDG02960	"1,3-ditolylguanidine"	"1,3-Di-o-tolylguanidine; 97-39-2; Di-o-tolylguanidine; DOTG; Vulkacite DOTG; 1,3-Ditolylguanidine; Vulkacit DOTG; Eveite DOTG; ditolylguanidine; Vulkacit dotg/C; Nocceler DT; Sanceler DT; DOTG accelerator; Soxinol DT; Akrochem DOTG; Vulcafor DOTG; 1,3-Bis(o-tolyl)guanidine; Guanidine, N,N'-bis(2-methylphenyl)-; Diorthotolylguanidine; 1,3-Di-o-tolyguanidine; N,N'-Di-o-tolylguanidine; Guanidine, 1,3-di-o-tolyl-; USAF A-6598; NSC 473; CNS 1001; N,N'-Di-o-tolueylguanidine; UNII-LL2P01I17O; 1,3-di-(2-tolyl)guanidine; NSC 132023; [3H]-di-o-tolylguanidine; DITOLYLGUANIDINE"	7333	C15H17N3	Investigative
M6APDG02619	Cycloserine	"D-cycloserine; cycloserine; 68-41-7; Seromycin; orientomycin; Oxamycin; Cyclorin; Cyclo-D-serine; Wasserina; Farmiserina; Tisomycin; Cicloserina; Miroseryn; Closina; D-4-amino-3-isoxazolidinone; (R)-4-AMINOISOXAZOLIDIN-3-ONE; alpha-Cycloserine; (+)-4-Amino-3-isoxazolidinone; Miroserina; Cycloserinum; D-4-amino-3-isoxazolidone; Oxamicina; (4R)-4-aminoisoxazolidin-3-one; PA 94; (+)-Cycloserine; (4R)-4-amino-1,2-oxazolidin-3-one; Oxamicina [Italian]; Cycloserin; Micoserina; Cicloserina [Italian]; PA-94; Tebemicina; Novoserin; D-Oxamycin;  Cicloserina; Closerin; Orientomycin; C 3909; Alpha-Cycloserine; C-9390; C-9400; Cicloserina [INN-Spanish]; Cycloserinum [INN-Latin]; D-CS; DRG-0195; I-1431; K-300; SC-49088; Seromycin (TN); Cycloserine [INN:BAN:JAN]; E-733-A; RO-1-9213; Cycloserine (JP15/USP/INN); D-amino-3-isoxazolidinone; D-(+)-Cycloserine; D-4-Amino-3-isossazolidone; D-4-Amino-3-isossazolidone [Italian]; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; R-(+)-Cycloserine; R-4-Amino-3-isoxazolidinone; R(+)-4-Amino-3-isoxazolidinone; (4R)-4-Amino-3-isoxazolidinone; (R)-(+)-4-Amino-3-isoxazolidinone; (R)-(+)-Cycloserine; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; (R)-4-Amino-3-isoxazolidinone; (R)-4-Amino-3-isoxazolidone; (R)-Cycloserine; 3-Isoxazolidinone, 4-amino-, (+)-(8CI); 3-Isoxazolidinone, 4-amino-, (4R)-(9CI); 3-Isoxazolidinone, 4-amino-, (R); 3-Isoxazolidinone, 4-amino-, D; (R)-4-Amino-Isoxazolidin-3-One"	6234	C3H6N2O2	Approved
M6APDG01520	Pirfenidone	Deskar; Esbriet; Pirespa; Pirfenidona; Pirfenidonum; AMR 69; P 2116; AMR-69; F-647; KS-5041; Pirfenidona [INN-Spanish]; Pirfenidone (Deskar); Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; S-7701; Pirfenidone (JAN/USAN/INN); 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-Methyl-1-phenyl-2-(1H)-pyridone; 5-methyl-1-phenylpyridin-2(1H)-one; 5-methyl-1-phenylpyridin-2-one	40632	C12H11NO	Approved
M6APDG02194	(E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide	CHEMBL1288801; (E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide	50908697	C12H11NO2S2	Investigative
M6APDG01394	NBQX	"nbqx; 118876-58-7; FG 9202; 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline; 6-Nitro-7-sulfamoylbenzo(f)quinoxaline-2,3-dione; CHEMBL222519; CHEBI:31073; SBB066176; 6-nitro-2,3-dioxo-1,4-dihydrobenzo[f]quinoxaline-7-sulfonamide; 1,2,3,4-Tetrahydro-6-nitro-2,3-dioxobenzo(f)quinoxaline-8-sulfonamide; 6-Nitro-7-sulphamoylbenzo[f]quinoxaline-2,3-dione; 6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione; 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline"	3272524	C12H8N4O6S	Phase 1
M6APDG01367	Biricodar	"Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate"	3037617	C34H41N3O7	Discontinued in Phase 2
M6APDG03256	PKF-241-466	"PKF-241-466; CHEMBL306090; BDBM50240611; N*4*-(2,2-Dimethyl-1-methylcarbamoyl-propyl)-N*1*-hydroxy-2-hydroxymethyl-3-p-tolyl-succinamide"	9907830	C19H29N3O5	Investigative
M6APDG02421	NSC-1771	Thiram	5455	C6H12N2S4	Investigative
M6APDG02623	B-Octylglucoside	"29836-26-8; Octyl-beta-D-glucopyranoside; OCTYL BETA-D-GLUCOPYRANOSIDE; Octyl beta-D-glucoside; Octyl glucoside; Octyl b-D-Glucopyranoside; n-Octyl-beta-D-Glucoside; 1-O-n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-glucoside; beta-D-Octyl glucoside; 1-O-Octyl-beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(octyloxy)tetrahydro-2H-pyran-3,4,5-triol; UNII-V109WUT6RL; n-Octyl glucoside; n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-Glucopyranose; Octyl; V109WUT6RL"	62852	C14H28O6	Investigative
M6APDG00291	N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide	CHEMBL143674; SCHEMBL673760	11323577	C16H16N2O3	Investigative
M6APDG01277	"6,7-dibromoquinoline-5,8-dione"	"6,7-dibromoquinoline-5,8-dione; CHEMBL488961; 18633-05-1; 6,7-Dibrom-5,8-dihydrochinolin-5,8-dion; NSC82128; AC1L5TKN; SCHEMBL6866292; AC1Q6K93; 6,7-dibromo-5,8-quinolindion; CTK4D9216; DTXSID40292366; CPZKOUMVYNIHQE-UHFFFAOYSA-N; BDBM50264041; NSC-82128"	255964	C9H3Br2NO2	Investigative
M6APDG03724	ISIS 29136	.	.	.	Investigative
M6APDG00409	TAK-285	"TAK-285; 871026-44-7; TAK 285; TAK285; UNII-70CCB438L6; N-(2-(4-(3-CHLORO-4-(3-(TRIFLUOROMETHYL)PHENOXY)PHENYLAMINO)-5H-PYRROLO[3,2-D]PYRIMIDIN-5-YL)ETHYL)-3-HYDROXY-3-METHYLBUTANAMIDE; CHEMBL1614725; 70CCB438L6; N-{2-[4-({3-Chloro-4-[3-(Trifluoromethyl)phenoxy]phenyl}amino)-5h-Pyrrolo[3,2-D]pyrimidin-5-Yl]ethyl}-3-Hydroxy-3-Methylbutanamide; n-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5h-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide; C26H25ClF3N5O3"	11620908	C26H25ClF3N5O3	Phase 1
M6APDG01791	Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)	CHEMBL218806; cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)	44418892	C37H49N11O6	Investigative
M6APDG02892	D-serine	"D-serine; 312-84-5; (R)-2-amino-3-hydroxypropanoic acid; (2R)-2-amino-3-hydroxypropanoic acid; Serine D-form; (R)-Serine; Serine, D-; d-(+)-serine; D-2-Amino-3-hydroxypropionic Acid; D-Serin; D-Ser; UNII-1K77H2Z9B1; EINECS 206-229-4; MFCD00004269; NSC 77689; (2R)-2-amino-3-hydroxy-propanoic acid; AI3-18476; CHEMBL285123; CHEBI:16523; MTCFGRXMJLQNBG-UWTATZPHSA-N; 1K77H2Z9B1; (R)-2-Amino-3-hydroxypropionic acid; DSN; NCGC00094363-03; D-Serine, 98%; D-2-Amino-3-hydroxypropanoic acid; NSC77689; serine d-; [3h]-d-serine; (2R)-serine"	71077	C3H7NO3	Phase 4
M6APDG01700	"[1,4]Thiazepan-(3E)-ylideneamine"	"CHEMBL186856; [1,4]Thiazepan-(3E)-ylideneamine; BDBM50155780"	44396204	C5H10N2S	Investigative
M6APDG01692	6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine	SCHEMBL6660879	44387948	C13H9FN4	Investigative
M6APDG02899	GSK343	compound 6 [PMID 24900432]; GSK 343	71268957	C31H39N7O2	Investigative
M6APDG00484	PF-06651600	"CBRJPFGIXUFMTM-WDEREUQCSA-N; 1792180-81-4; UNII-2OYE00PC25; 2OYE00PC25; PF06651600; 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; GTPL9559; SCHEMBL16764638; BCP24778; EX-A2613; ZINC526061581; example 5 [WO2015083028]; ACN-040697; compound 11 [PMID: 28139931]; HY-100754; CS-0020243; 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one"	118115473	C15H19N5O	Phase 2/3
M6APDG01599	Debio 0932	.	44156921	C22H30N6O2S	Phase 1
M6APDG02463	YM-90K	"154164-30-4; YM 90K hydrochloride; YM 90K; YM-90K; UAEXCLWI0Q; YM-90K hydrochloride; UNII-UAEXCLWI0Q; 6-(1H-Imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione; 2,3-Quinoxalinedione, 1,4-dihydro-6-(1H-imidazol-1-yl)-7-nitro-, monohydrochloride; 1,4-Dihydro-6-(1H-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione monohydrochloride; 6-(1h-imidazol-1-yl)-7-nitro-2,3(1h,4h)-quinoxalinedione hydrochloride; YM-900; YM90K hydrochloride; AC1NUOLT; YM90KHYDROCHLORIDE; YM 90K HCl; YM-90K HCl; CHEMBL3400490; C11H7N5O4; EX-A113; DTXSID00165547"	5486547	C11H8ClN5O4	Discontinued in Phase 2
M6APDG00825	N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide	CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365	15986508	C15H12ClNO2	Investigative
M6APDG03676	ISIS 3792	.	.	.	Investigative
M6APDG03477	AMSH	.	.	.	Investigative
M6APDG03193	4-methyl-6-propylpyridin-2-amine	"4-Methyl-6-propylpyridin-2-amine; CHEMBL302657; 2-amino-4-methyl-6-propylpyridine; 179555-24-9; SCHEMBL7051196; QGCCHDIBMYPTPX-UHFFFAOYSA-N; BDBM50091817; 4-Methyl-6-propyl-pyridin-2-ylamine; 2-Pyridinamine, 4-methyl-6-propyl-; AKOS027400844; 4-Methyl-6-propylpyridin-2-amine, 7"	9855524	C9H14N2	Investigative
M6APDG03642	ISIS 3224	.	.	.	Investigative
M6APDG00985	Netoglitazone	"Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione"	204109	C21H16FNO3S	Phase 2
M6APDG01888	C-16-(S)-3-methylindolerapamycin	CHEMBL503885; C-16-(S)-3-methylindolerapamycin	44576240	C59H84N2O12	Investigative
M6APDG03273	1-(9-Phenyl-9H-fluoren-9-yl)1H-imidazole	"CHEMBL223874; 1H-Imidazole, 1-(9-phenyl-9H-fluoren-9-yl)-; 27608-12-4; Fluorenyl deriv. 14; BDBM9465; CTK0J2505; DTXSID90432952"	9926623	C22H16N2	Investigative
M6APDG02622	Urofollitropin	"Bravelle; Fertinex; Metrodin; Urofollitrophin; Fertinorm HP; Bravelle (TN); Fertinex (TN); Follistim (TN); Gonal-F(TN); (4-Threonine)oxytocin; 1,2-Dithia-5,8,11,14,17-penaazacycloeicosane, cyclic peptide deriv.; 4-(L-Threonine)oxytocin"	62819	C42H65N11O12S2	Approved
M6APDG00563	AZD4769	"Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic"	124437	C28H27NO3S	Discontinued in Phase 1
M6APDG03521	ASC-JMX2	"ASCJ-M12; ASCJ-M5; Q-103; Q-49; Androgen antagonist (prostate tumor/benign prostatic hyperplasia), AndroScience; ARD enhancers (oral, prostate tumor/benign prostatic hyperplasia), AndroScience"	.	.	Investigative
M6APDG02787	bisphenol A	BPA	6623	C15H16O2	Investigative
M6APDG01962	Se-Ethyl-Isoselenourea	SE-ETHYL-ISOSELENOUREA; ISU; ethyl imidoselenocarbamate; ethyl carbamimidoselenoate; AC1L9NBX; SCHEMBL5003626	449633	C3H8N2Se	Investigative
M6APDG00318	PHA-739358	"Danusertib; PHA 739358; Danusertib, PHA-739358; (R)-N-(5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide; 5-Amido-pyrrolopyrazole 9d"	11442891	C26H30N6O3	Phase 2
M6APDG02345	"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile"	"(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile"	5328755	C12H8N2O2	Investigative
M6APDG00782	KRP-297	"KRP-297; MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384"	151183	C20H17F3N2O4S	Discontinued in Phase 2
M6APDG01859	2-Benzyl-2H-indazole-7-carboxamide	CHEMBL1094951; 2-Benzyl-2H-indazole-7-carboxamide; SCHEMBL2268172	44549372	C15H13N3O	Investigative
M6APDG01152	BMS-754807	"BMS-754807; 1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin"	24785538	C23H24FN9O	Phase 1
M6APDG01423	NSC-368280	"NSC-368280; CHEMBL513615; NSC368280; AC1Q4NLW; AC1L7R1U; BDBM50254017; 6-[(4-fluorophenyl)-imidazol-1-ylmethyl]-1,3-benzodioxol-5-ol; 6-((4-fluorophenyl)(1H-imidazol-1-yl)methyl)benzo[d][1,3]dioxol-5-ol; 6-((4-fluorophenyl)(1H-imidazol-1-yl)methyl) benzo[d][1,3]dioxol-5-ol; 1,3-benzodioxol-5-ol, 6-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-"	339914	C17H13FN2O3	Investigative
M6APDG01035	"3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine"	"CHEMBL321572; 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine; SCHEMBL7478985; ZINC13859457; BDBM50290846"	22132655	C17H16N2O3	Investigative
M6APDG00405	PF-228	"869288-64-2; PF-573228; PF 573228; PF573228; PF-228; CHEMBL514554; 3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone; 6-((4-((3-(Methylsulfonyl)benzyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3,4-dihydroquinolin-2(1H)-one; 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"	11612883	C22H20F3N5O3S	Investigative
M6APDG00473	7-Methoxy-3-pyridin-4-yl-quinoline	CHEMBL329622; 7-methoxy-3-pyridin-4-yl-quinoline; 7-Methoxy-3-(4-pyridyl)quinoline	11776270	C15H12N2O	Investigative
M6APDG03921	AST-005	.	.	.	Phase 1
M6APDG01639	3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol	CHEMBL51013; 3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol	44294636	C12H16O3S2	Investigative
M6APDG01951	PU3	"PU3; 9-BUTYL-8-(3,4,5-TRIMETHOXYBENZYL)-9H-PURIN-6-AMINE; 352519-21-2; CHEMBL113690; 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]purin-6-amine; 1uym; 1uy6; Purine-Based Inhibitor 1; AC1L9MK5; PU-3; SCHEMBL2604975; BDBM15374; CTK1B7081; DTXSID40332291; ZINC3832013; AKOS030562182; DB02754; KB-275186; 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]-"	448965	C19H25N5O3	Phase 1
M6APDG00311	Obatoclax	CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7	11404337	C20H19N3O	Phase 2
M6APDG01937	I-5	"SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; I-5; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid"	448008	C17H10Cl2N2O4	Investigative
M6APDG01655	SC-57666	SC-57666; CHEMBL274893; AC1L9EJK; SC57666; CHEBI:8982; 1-fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene; SureCN213008; SCHEMBL213008; ZINC18527; GJGZQTGPOKPFES-UHFFFAOYSA-N; HY-U00129; BDBM50029614; DNC003789; CS-7166; C11706; 1-[2(4-Flurophenyl)-1-cyclopentyl]4-methylsulfonylbenzene; 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene; 1-[2-(4-fluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl)benzene; 1-fluoro-4-[2-(4-methylsulfonylphenyl)-1-cyclopentenyl]benzene	443373	C18H17FO2S	Discontinued in Phase 1
M6APDG00618	Bis(5-hydroxybenzo[b]furan-2-yl)methanone	CHEMBL225826; bis(5-hydroxybenzo[b]furan-2-yl)methanone	13454380	C17H10O5	Investigative
M6APDG01068	AGN193836	AGN-193836; AGN 193836	23001780	C22H22BrF2NO4	Investigative
M6APDG03278	Pifithrin-alpha	"P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta"	9929138	C16H19BrN2OS	Terminated
M6APDG02056	GSK2110183	.	46843057	C18H17Cl2FN4OS	Phase 2
M6APDG01324	4-Phenylbutyrohydroxamic acid	"N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; 4-Phenylbutyrohydroxamic acid; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596"	279980	C10H13NO2	Investigative
M6APDG00821	KU-60019	"KU-60019; 925701-49-1; ku60019; 925701-46-8; KU 60019; UNII-IAN358A69K; IAN358A69K; CHEMBL2140173; 2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-N-[5-(6-morpholin-4-yl-4-oxopyran-2-yl)-9H-thioxanthen-2-yl]acetamide; C30H33N3O5S; 2-((2S,6R)-2,6-dimethylmorpholino)-N-(5-(6-morpholino-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl)acetamide; 2-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-N-{5-[6-(morpholin-4-yl)-4-oxo-4H-pyran-2-yl]-9H-thioxanthen-2-yl}acetamide; MLS006011020; cc-509; SCHEMBL3681453; GTPL8041; EX-A658; DTXSID00580453; AOB3627"	15953870	C30H33N3O5S	Clinical trial
M6APDG03604	ISIS 6432	.	.	.	Investigative
M6APDG01368	VX-745	"5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One;  VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)"	3038525	C19H9Cl2F2N3OS	Phase 2
M6APDG00853	CBP-501	"UNII-XH2662798I; 565434-85-7; XH2662798I; Cdc25C phosphatase (211-221); CBP501; CBP 501; SCHEMBL17101340; Z-3278; D-Arginine, 4-benzoyl-D-phenylalanyl-D-seryl-D-tryptophyl-D-seryl-2,3,4,5,6-pentafluoro-D-phenylalanyl-3-cyclohexyl-D-alanyl-D-arginyl-D-  arginyl-D-arginyl-D-glutaminyl-D-arginyl-"	16156006	C86H122F5N29O17	Phase 1/2
M6APDG04182	SFX-01	.	.	.	Phase 2
M6APDG02216	SB-218655	1bmk; 4-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyrimidin-2-amine; SB-218655; 4-(FLUOROPHENYL)-1-CYCLOPROPYLMETHYL-5-(2-AMINO-4-PYRIMIDINYL)IMIDAZOLE; 165806-51-9; SB 218655; C14316; 4-[3-(cyclopropylmethyl)-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine; SB5; AC1L1JRC; AC1Q4ON9; SCHEMBL4323457; CHEMBL590753; BDBM15238; CTK4D2173; DTXSID50274456; sb218655; AKOS030547879	5172	C17H16FN5	Investigative
M6APDG01928	Ragaglitazar	Ragaglitazar; DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid	447458	C25H25NO5	Phase 3
M6APDG04335	IMX-942	"IDR-1; IMX-001; IMX-502; IMX-502001; IMX-503; IMX-602; IMX-602001; IMX-606; IMX-606001; IMX-735; IMX-775; Innate immune system upregulators, Inimex; Innate defense-regulatory peptides (infection), Ininmex"	.	.	Preclinical
M6APDG02718	3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 7a; CHEMBL383807; SCHEMBL4220789; AC1O704H; SCHEMBL4220782; BDBM8588; ZINC13610774; 3-[(E)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539765	C15H12ClN	Investigative
M6APDG03584	ISIS 25237	.	.	.	Investigative
M6APDG02880	Golotimod	"229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812;  Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta"	6992140	C16H19N3O5	Phase 2
M6APDG03276	6-(2-Bromo-acetylamino)-hexanoic acid phenylamide	"CHEMBL344920; 651767-99-6; 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-"	9927379	C14H19BrN2O2	Investigative
M6APDG00367	C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2	CHEMBL446185; c[Nle-His-D-Phe-Arg-Trp-Glu]-NH2	11535237	C43H57N13O7	Investigative
M6APDG03184	3-Methoxybenzamide	"3-Methoxybenzamide; 5813-86-5; m-Methoxybenzamide; m-Anisamide; 3-Methoxy-benzamide; Benzamide, 3-methoxy-; UNII-M8502TLK98; EINECS 227-379-7; NSC 28589; NSC 209527; BRN 2206857; CHEMBL123978; VKPLPDIMEREJJF-UHFFFAOYSA-N; M8502TLK98; 3MB; 3pax; 5-methoxybenzamide; 3-methoxy-benzamid; ACMC-1ASRE; AC1Q5DMC; M-METHOXY BENZAMIDE; bmse000775; 3-Methoxybenzamide, 97%; Oprea1_695428; MLS001066418; 4-10-00-00326 (Beilstein Handbook Reference); cid_98487; SCHEMBL283787; AC1L407F; KS-00000VVU; CTK1H2082; VKPLPDIMEREJJF-UHFFFAOYSA-; DTXSID00206848"	98487	C8H9NO2	Investigative
M6APDG04309	ON-01135	"Amerliorex; CDK1 inhibitors, Onconova; Novonex analogs, Onconova; ON-01060; ON-01130; ON-01220; ON-01250; ON-01300; ON-01330; ON-01370; ON-01500; ON-01560; ON-01590; ON-01620; Cell cycle checkpoint activators (cytoprotection), Onconova; ON-01060 derivatives, Onconova; ON-01500 series, Onconova; ON-01910 analogs, Onconova; Styryl benzyl sulfones (cell cycle checkpoint activators), Onconova"	.	.	Preclinical
M6APDG04129	WT1-targeted autologous dendritic cell vaccine	WT1-targeted autologous dendritic cell vaccine (cancer)	.	.	Phase 2
M6APDG00007	MR-20494	MR-20494; CHEMBL1098737; BDBM50318405	10019821	C20H15ClN2O	Investigative
M6APDG01084	T-5224	AKOS003047196; T5224	23626877	C29H27NO8	Discontinued in Phase 2
M6APDG02350	AG 112	tyrphostin A48; tyrphostin AG 112; AG-112; AG112	5328804	C13H8N4O	Investigative
M6APDG04378	ON-09300	"Oncoxib; ON-09310; COX2/lipoxygenase inhibitors (cancer), Onconova; ON-09 pyrazoline series (dual COX2/lipoxygenase inhibitors), Onconova"	.	.	Terminated
M6APDG00932	DIZOCILPINE	"DIZOCILPINE; 77086-21-6; MK-801 (Dizocilpine); UNII-7PY8KH681I; MK-801; Lopac-M-108; Lopac-M-107; MK 801; Prestwick0_000109; (5S,10R)-5-methyl-10,11-dihydro-5H-5,10-epiminodibenzo[a,d][7]annulene; 7PY8KH681I; CHEMBL284237; CHEBI:34725; Dizocilpine [INN]; Dizocilpinum [INN-Latin]; Dizocilpina [INN-Spanish]; Dizocilpinum; Dizocilpina; MK801; MK-801(Dizocilpine); HSDB 7641; (+)MK-801; (+)-MK-801; (+/-)-MK801; Prestwick2_000109; Prestwick3_000109; Prestwick1_000109; Biomol-NT_000210; SCHEMBL34528; Lopac0_000872; BSPBio_000098; SPBio_002037"	180081	C16H15N	Terminated
M6APDG01175	MK-1775	"MK-1775; 955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219"	24856436	C27H32N8O2	Phase 2
M6APDG01741	C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL204263; BDBM50184365	44408515	C47H64N14O7	Investigative
M6APDG03450	ANG-2864	"PARP inhibitor (ischemia/cancer), Angion Biomedica"	.	.	Investigative
M6APDG03479	ISIS 16518	.	.	.	Investigative
M6APDG02247	7-hydroxycoumarin	"Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510; UMBELLIFERONE"	5281426	C9H6O3	Investigative
M6APDG03937	GSK-2130579A	"Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline"	.	.	Phase 1
M6APDG02237	Prostaglandin G2	"prostaglandin G2; PGG2; 51982-36-6; 9S,11R-epidioxy-15S-hydroperoxy-5Z,13E-prostadienoic acid; (5Z)-7-{(1R,4S,5R,6R)-6-[(1E,3S)-3-hydroperoxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]hept-5-yl}hept-5-enoic acid; Endoperoxide G2; (5Z)-7-{(1R,4S,5R,6R)-6-[(1E,3S)-3-hydroperoxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]hept-5-yl}hept-5-enoate; GTPL5245; SCHEMBL16782384; CHEBI:27647; SGUKUZOVHSFKPH-YNNPMVKQSA-N; ZINC8220097; MFCD00036971; LMFA03010009; 2013AH; DB03866; C05956; Prostaglandin G2, &gt;=95% (HPLC), acetone solution"	5280883	C20H32O6	Investigative
M6APDG03493	KOSN1559	.	.	.	Investigative
M6APDG03779	ISIS 32035	.	.	.	Investigative
M6APDG03408	RQ-00317076	"COX-2 inhibitor (oral, pain), RaQualia"	.	.	Discontinued in Phase 2
M6APDG04349	CDP-845	.	.	.	Terminated
M6APDG00216	Tamibarotene	"Tamibarotene (oral, Alzheimer's disease)"	108143	C22H25NO3	Phase 3
M6APDG03294	CEP-6800	"CEP-6800; UNII-0X7U7SRK9H; 0X7U7SRK9H; CHEMBL247374; 609848-02-4; SCHEMBL12256417; BDBM50197585; 1H-Cyclopenta(a)pyrrolo(3,4-C)carbazole-1,3(2H)-dione, 10-(aminomethyl)-4,5,6,7-tetrahydro-; 8-aminomethyl-1,2,3,11-tetrahydro-5,11-diaza-benzo[a]trindene-4,6-dione"	9948440	C18H15N3O2	Investigative
M6APDG04351	Heparin-EGF-like factor	"HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova"	.	.	Terminated
M6APDG01689	AdcAhxArg4Lys-PEGOMe	CHEMBL426336	44387499	C51H93N25O12	Investigative
M6APDG03457	PD182905	.	.	.	Investigative
M6APDG02307	(E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide	CHEMBL1288783; (E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide	52946892	C12H11NO3S	Investigative
M6APDG03439	Recombinant follicle stimulating hormone	.	.	.	Investigative
M6APDG01806	2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid	CHEMBL398087; 2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid	44434501	C12H10FNO2	Investigative
M6APDG03663	AFM-21	"Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed"	.	.	Investigative
M6APDG01513	4-(3-methoxy-benzylideneamino)-benzenesulfonamide	CHEMBL271930; NSC720589; AC1L8N6O; CTK7A8689; BDBM50371745; NSC-720589; 4-[(3-Methoxy-benzylidene)-amino]-benzenesulfonamide; 4-[(3-methoxyphenyl)methylideneamino]benzenesulfonamide	404378	C14H14N2O3S	Investigative
M6APDG00737	(R)-sirtinol	.	1376646	C26H22N2O2	Investigative
M6APDG03949	ABBV-399	.	.	.	Phase 1
M6APDG04203	SGT-53	"P53 gene stimulator (solid tumor), Synergene Therapeutics"	.	.	Phase 2
M6APDG00201	4-Ethyl-pyrrolidin-(2Z)-ylideneamine	CHEMBL360616; CHEMBL543886; 4-Ethylpyrrolidine-2-imine; SCHEMBL7593608; BDBM50066783; AKOS006353400; 4-Ethyl-pyrrolidin-(2E)-ylideneamine	10725313	C6H12N2	Investigative
M6APDG03702	HM-5016699	"Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison"	.	.	Investigative
M6APDG00212	L-NIO	"n5-Iminoethyl-l-ornithine; n5-iminoethyl-l-ornithine; N5-(1-Iminoethyl)-L-ornithine; N(G)-Iminoethylornithine; CHEMBL11471; 36889-13-1; L-Ornithine, N5-(1-iminoethyl)-; ILO; C7H15N3O2; (e)-n5-(1-aminoethylidene)-l-ornithine; Tocris-0546; AC1Q5QLF; Lopac-I-8768; Lopac0_000683; SCHEMBL1569333; AC1L333Z; l-n5-(1-iminoethyl)-ornithine; L-NIO, 12; MolPort-006-394-636; UYZFAUAYFLEHRC-LURJTMIESA-N; BDBM152697; ZINC1886324; BDBM50072297; HSCI1_000259; AKOS030623044; (S)-5-Acetimidoylamino-2-amino-pent; CCG-204768; DB03305; NCGC00024644-01; NCGC00015568-01; N5-Iminoethyl-L-Ornithine"	107984	C7H15N3O2	Investigative
M6APDG00175	PD-169469	CHEMBL42420; PD-169469; SCHEMBL7404078; BDBM12074; alpha-arylsulfonylamino carboxylate 2R; (2R)-2-{[4-(4-bromophenyl)benzene]sulfonamido}-3-methylbutanoic acid	10549609	C17H18BrNO4S	Investigative
M6APDG01949	PF-00356231	PF-00356231; CHEMBL508461; (2R)-3-({[4-[(PYRIDIN-4-YL)PHENYL]-THIEN-2-YL}CARBOXAMIDO)(PHENYL)PROPANOIC ACID; 3-PHENYL-3-({[4-(4-PYRIDIN-4-YLPHENYL)THIEN-2-YL]CARBONYL}AMINO)PROPANOIC ACID; 1utz; AC1L9MIX; SCHEMBL8298104; MolPort-042-665-664; ZINC6744035; BDBM50264813; DB03367; NCGC00386512-01; (3R)-3-phenyl-3-({4-[4-(pyridin-4-yl)phenyl]thiophen-2-yl}formamido)propanoic acid; (3R)-3-phenyl-3-({[4-(4-pyridin-4-ylphenyl)thiophen-2-yl]carbonyl}amino)propanoic acid	448942	C25H20N2O3S	Investigative
M6APDG02768	Ruthenium red	.	656819	Cl6H42N14O2Ru3	Investigative
M6APDG03194	SC-75416	.	9858913	C15H14ClF3O3	Phase 2
M6APDG03001	4-amino-N-(4-chlorophenyl)benzenesulfonamide	"4-amino-N-(4-chlorophenyl)benzenesulfonamide; 16803-92-2; 4-Amino-N-(4-chloro-phenyl)-benzenesulfonamide; CHEMBL227413; Benzenesulfonamide, 4-amino-N-(4-chlorophenyl)-; 4-amino-n-(4-chlorophenyl)benzene-1-sulfonamide; Benzenesulfonamide,4-amino-N-(4-chlorophenyl)-; [(4-aminophenyl)sulfonyl](4-chlorophenyl)amine; BAS 02102352; AC1Q3REH; AC1LG33E; ARONIS021171; AC1Q51X9; SCHEMBL14093755; KS-00003SYR; CTK4D2850; DTXSID90354963; MolPort-000-164-113; ZINC286765; ALBB-000053; BDBM50197705; 5394AD; BBL037004; SBB009347; STK091555"	788021	C12H11ClN2O2S	Investigative
M6APDG03559	ISIS 188780	.	.	.	Investigative
M6APDG00551	"N,N-dimethylarginine"	"N,N-dimethylarginine; ADMA; Asymmetric dimethylarginine; 30315-93-6; Dimethyl-L-arginine; NG,NG-dimethyl-L-arginine; N(G)-Dimethylarginine; Guanidino-N,N-dimethylarginine; N(G),N(G)-Dimethylarginine; (S)-2-Amino-5-(3,3-dimethylguanidino)pentanoic acid; N(G1),N(G1)-Dimethylarginine; Lopac-D-4268; N(5)-((Dimethylamino)iminomethyl)-L-ornithine; N(omega),N(omega)-dimethyl-L-arginine; NG,NG-DIMETHYLARGININE HYDROCHLORIDE; CHEBI:17929; YDGMGEXADBMOMJ-LURJTMIESA-N; N5-[(Dimethylamino)iminomethyl]-L-ornithine"	123831	C8H18N4O2	Investigative
M6APDG03519	SJ-8002	"Piperazine derivative (anticancer), Samjin/ImQuest"	.	.	Investigative
M6APDG02710	PYRAZOLOPYRIDAZINE 1	"PYRAZOLOPYRIDAZINE 1; 551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine"	6539361	C17H14N6O	Investigative
M6APDG04181	LY-2189102	"Anti-IL-1 beta mAb (cardiovascular disease), Lilly; Anti IL-1 beta antibody (non-insulin dependent diabetes, rheumatoid athritis), Lilly"	.	.	Phase 2
M6APDG03499	ISIS 133245	.	.	.	Investigative
M6APDG01882	3-methoxy-4-(m-tolyloxy)benzonitrile	CHEMBL447604; 3-methoxy-4-(m-tolyloxy)benzonitrile	44565151	C15H13NO2	Investigative
M6APDG00149	"Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine"	"CHEMBL65850; Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine; ZINC3834030"	10424517	C18H18N2O2	Investigative
M6APDG02735	4-Indan-(1Z)-ylidenemethyl-pyridine	"(4-Pyridylmethylene)indane 2b; SCHEMBL4230792; CHEMBL179149; BDBM8612; AC1O705N; 4-[(Z)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 4-[(1Z)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 4-[(Z)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Oxalate"	6539786	C15H13N	Investigative
M6APDG04150	OPI-1002	.	.	.	Phase 2
M6APDG02935	EI1	KB-145943	72199293	C23H26N4O2	Investigative
M6APDG02986	Abaloparatide	Tymlos	76943386	.	Approved
M6APDG01774	1-[6-(triphenylmethoxy)hexyl]thymine	"1-[6-(triphenylmethoxy)hexyl]thymine; CHEMBL216998; 921587-93-1; CTK3G1844; DTXSID00658828; BDBM50200990; 5-Methyl-1-[6-(triphenylmethoxy)hexyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[6-(triphenylmethoxy)hexyl]-"	44418795	C30H32N2O3	Investigative
M6APDG01085	"2-(2,3,4-trimethoxyphenyl)-1H-indene"	"CHEMBL228561; 2-(2,3,4-trimethoxyphenyl)-1H-indene"	23627032	C18H18O3	Investigative
M6APDG02922	ASP8273	.	71667668	C30H42N8O3	Phase 2
M6APDG02755	3-[3-Methyl-indan-(1Z)-ylidenemethyl]-pyridine	"CHEMBL373074; AC1O707F; BDBM8647; (3-Pyridylmethylene)indane 36b; 3-[(Z)-(3-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539818	C16H15N	Investigative
M6APDG03126	3-Benzenesulfinyl-heptanoic acid hydroxyamide	CHEMBL75433; 3-Benzenesulfinyl-heptanoic acid hydroxyamide; BDBM50089197	9816867	C13H19NO3S	Investigative
M6APDG03472	ISIS-1939	136216-59-6	.	.	Investigative
M6APDG02576	EPZ005687	EPZ-005687; EPZ 005687	60160561	C32H37N5O3	Investigative
M6APDG00747	"2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione"	"CHEMBL611665; 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)"	1403654	C11H6N2O3	Investigative
M6APDG01635	(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine	CHEMBL287591; (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine; SCHEMBL8554934; BDBM50099967	44279279	C23H18N4	Investigative
M6APDG03487	ISIS 104258	.	.	.	Investigative
M6APDG02878	4-methoxy-N'-(2-phenylacetyl)benzohydrazide	"4-methoxy-N'-(phenylacetyl)benzohydrazide; 4-methoxy-N'-(2-phenylacetyl)benzohydrazide; benzohydrazide, 15; AC1LEZHC; CHEMBL244921; ARONIS002261; BDBM23731; ZINC68809; KS-00003VJE; MolPort-000-681-545; STK056698; AKOS000492246; MCULE-6943344531; ST040019; 4-methoxy-N -(phenylacetyl)benzohydrazide; KB-115318; 4-methoxy-N''-(2-phenylacetyl)benzohydrazide"	695069	C16H16N2O3	Investigative
M6APDG04369	Apolipoprotein E	"Apolipoprotein E, Bio-Technology General; Apo-A4, Bio-Technology General; Apo-E, Bio-Technology General; Apolipoprotein-A4, Bio-Technology General"	.	.	Terminated
M6APDG03082	Naringenin	"naringenin; 5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 67604-48-2; 4',5,7-Trihydroxyflavanone; Naringenine; (+/-)-Naringenin; naringetol; 480-41-1; salipurpol; (-)-Naringenin; NARIGENIN; Salipurol; 5,7,4'-Trihydroxyflavanone; 93602-28-9; (S)-Naringenin; BE-14348A; NSC 34875; ( inverted exclamation markA)-Naringenin; CHEMBL32571; MLS000738094; MLS000028739; CHEBI:50202; Flavanone, 4',5,7-trihydroxy-; FTVWIRXFELQLPI-UHFFFAOYSA-N; NSC34875; NSC11855; MFCD00006844; SMR000059039; AK122638; NSC 11855; 4',7-Trihydroxyflavanone"	932	C15H12O5	Phase 1
M6APDG01771	3-(3-(carbamoyl)benzamido)propanoic acid	CHEMBL219603; 3-(3-(carbamoyl)benzamido)propanoic acid	44418280	C20H21N3O4	Investigative
M6APDG00603	MDL-201112	"Carbocyclic nucleoside, Hoechst; MDL-201449; MDL-201449A"	132408	C10H13N5O	Terminated
M6APDG03488	ISIS 298746	.	.	.	Investigative
M6APDG01266	AZD5363	"AZD5363; 1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1"	25227436	C21H25ClN6O2	Phase 3
M6APDG03353	Margetuximab	.	.	.	Approved
M6APDG02523	isoxazole azepine compound 3	.	57345400	C20H18ClN3O2S	Investigative
M6APDG03610	ISIS 6445	.	.	.	Investigative
M6APDG00779	2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide	"2-(3'-methoxyphenyl) benzimidazole-4-carboxamide; 2-(3-methoxyphenyl)-1H-benzimidazole-4-carboxamide; CHEMBL134022; BZC; 1efy; AC1L1BMO; SCHEMBL4321727; CTK7A9229; NVVWVYYHTKCIAE-UHFFFAOYSA-N; ZINC11565446; BDBM50093373; DB04010; 2-(3'-Methoxyphenyl)-1-H-benzimidazole-4-carboxamide; 2-(3-methoxyphenyl)-1H-1,3-benzodiazole-4-carboxamide; 2-(3''-METHOXYPHENYL) BENZIMIDAZOLE-4-CARBOXAMIDE; 2-(3-Methoxy-phenyl)-1H-benzoimidazole-4-carboxylic acid amide"	1511	C15H13N3O2	Investigative
M6APDG00657	PAC1	PAC-1	135421197	C23H28N4O2	Phase 1
M6APDG03835	G1T28-1	.	.	.	Phase 1
M6APDG00256	N-Hydroxy-4-phenylacetylamino-benzamide	"CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-"	11196500	C15H14N2O3	Investigative
M6APDG00259	7-Mercapto-heptanoic acid biphenyl-4-ylamide	CHEMBL112311	11220728	C19H23NOS	Investigative
M6APDG00574	"3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione"	"144040-48-2; 2,5-Dihydro-2,5-dioxo-3-hydroxy-8-methyl-1H-benzazepine; 8-Me-Ddhb; AC1L2QYL; 5-hydroxy-8-methyl-1H-1-benzazepine-2,3-dione; 1H-1-Benzazepine-2,5-dione, 3-hydroxy-8-methyl-; CHEMBL143519; SCHEMBL9387738; CTK4C3913; 8-Methyl-3-hydroxy-1H-1-benzazepine-2,5-dione; 1H-1-Benzaepine-2,5-dione, 3-hydroxy-8-methyl-"	126810	C11H9NO3	Investigative
M6APDG04284	Sirukumab	.	.	.	Phase 3
M6APDG03304	L-739758	"CHEMBL78760; L-739758; BDBM50078437; 3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-739758); (S)-3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid; (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[5-[2-(4-piperidinyl)ethyl]thieno[2,3-b]thiophen-2-yl]carbonylamino]propanoic acid"	9958398	C22H26N4O5S3	Investigative
M6APDG01698	"(5-Imino-[1,4]thiazepan-3-yl)-methanol"	"CHEMBL361722; (5-Imino-[1,4]thiazepan-3-yl)-methanol"	44396191	C6H12N2OS	Investigative
M6APDG01532	"5-(piperidin-1-ylsulfonyl)indoline-2,3-dione"	"329905-79-5; 5-(piperidin-1-ylsulfonyl)indoline-2,3-dione; 5-(piperidin-1-ylsulfonyl)-1H-indole-2,3-dione; 5-(Piperidine-1-sulfonyl)-1H-indole-2,3-dione; 5-[1-(Piperidinyl)sulfonyl]isatin; Isatin Sulfonamide 21; AC1N3S5Q; CHEMBL61320; BDBM10310; DTXSID40399501; MolPort-000-149-258; ZX-BK002316; ZINC2944779; MIX-0755; STK894352; BBL021638; 2990AJ; AKOS005144288; MCULE-6394963078; 5-(Piperidinosulfonyl)indoline-2,3-dione; AJ-44313; ACM329905795; AX8291419; H8238; 5-(piperidinosulfonyl)-1H-indole-2,3-dione"	4117383	C13H14N2O4S	Investigative
M6APDG01062	MJN228	MJN228; SCHEMBL602647; GTPL8515; MolPort-044-561-486; ZINC114193322	22660592	C20H20N4O3	Investigative
M6APDG02829	R348	.	68254	C8H11N	Terminated
M6APDG01037	"6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline"	"CHEMBL415501; 6,7-Dimethoxy-4-(2-methoxyphenoxy)quinoline; 190726-38-6; 6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline; SCHEMBL7487419; CTK0E1594; DTXSID50622690; ZTLZYKICAWTOKI-UHFFFAOYSA-N; BDBM50290848; Quinoline, 6,7-dimethoxy-4-(2-methoxyphenoxy)-"	22132763	C18H17NO4	Investigative
M6APDG03319	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244	9995195	C18H16N4O	Investigative
M6APDG01814	"6,7-diethoxy-4-styrylquinazoline"	"CHEMBL250925; 6,7-diethoxy-4-styrylquinazoline"	44442181	C20H20N2O2	Investigative
M6APDG04219	ABT-981	.	.	.	Phase 2
M6APDG00326	N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide	"CHEMBL224122; N-(3-phenylsulfanyl-4-pyridinyl)methanesulfonamide; 833455-58-6; N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide; CTK3D2868; DTXSID10466638; BDBM50158452; Methanesulfonamide, N-[3-(phenylthio)-4-pyridinyl]-"	11460185	C12H12N2O2S2	Investigative
M6APDG02048	Aminosalicylic Acid	"4-Aminosalicylic acid; 65-49-6; Aminosalicylic acid; P-AMINOSALICYLIC ACID; Rezipas; Aminopar; Pamisyl; Parasalindon; Ferrosan; Deapasil; Apacil; Parasal; Paser; Paramycin; Gabbropas; Parasalicil; Pasnodia; Osacyl; Aminox; Pasolac; Pasmed; Propasa; Pasalon; Entepas; Pasdium; Pasara; Pamacyl; Pasem; Pasa; 2-Hydroxy-4-aminobenzoic acid; PASK; APAS; Para-Pas; Sanipirol-4; Hellipidyl; Pascorbic; PAS-C; Benzoic acid, 4-amino-2-hydroxy-; PAS (acid); Aminosalicylic Acid Resin Complex; Aminosalicylate Sodium"	4649	C7H7NO3	Approved
M6APDG02778	Benzyl-quinazolin-4-yl-amine	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; Benzyl-quinazolin-4-yl-amine; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine	6603129	C15H14ClN3	Investigative
M6APDG00669	DEBROMOHYMENIALDISINE	.	135451156	C11H11N5O2	Investigative
M6APDG04115	PF-04523655	.	.	.	Phase 2
M6APDG01871	"4,5-Bis(4-chlorophenyl)isothiazole"	"4,5-Bis(4-chlorophenyl)isothiazole; CHEMBL491088"	44564456	C15H9Cl2NS	Investigative
M6APDG01444	NSC-622444	"NSC622444; NSC-622444; CHEMBL116347; AC1Q3LXD; AC1L7GK5; SCHEMBL9755151; dichlorinated diacylmethane fragment; ZINC1616868; BDBM50048522; 5,3'-dicarboxy-4,4'-dihydrodiphenylmethane; 5,5''-methylenebis(3-chloro-2-hydroxybenzoic acid); 5,5'-Methylenebis(3-chloro-2-hydroxybenzoic acid); 3,3'-methanediylbis(5-chloro-6-hydroxybenzoic acid); 5-(3-carboxy-5-chloro-4-hydroxybenzyl)-3-chloro-2-hydroxybenzoic acid; 3',3-Dichloro-4',4-dimethoxy-5',5-bis(methoxycarbonyl)-1,1-diphenylmethane"	360384	C15H10Cl2O6	Investigative
M6APDG04112	ARI-3037MO	.	.	.	Phase 2
M6APDG02980	ITdU	"3-Hydroxyandrost-5-en-17-one; Diandron, 17-Hormoforin; A-hydroxy-5-androsten-17-one; Spectrum_000661; SpecPlus_000094; Androst-5-en-17-one, 3-hydroxy-, (3.beta.)-; Spectrum3_000116; Spectrum5_000130; Spectrum4_001395; Spectrum2_000359; AC1L18FD; KBioSS_001141; KBioGR_001750; CHEMBL31399; DivK1c_006190; SPBio_000457; SCHEMBL9969169; KBio1_001134; KBio3_000872; KBio2_006277; KBio2_003709; KBio2_001141; CHEBI:95212; MolPort-003-891-893; ALBB-023670; CCG-38634; Androst-5-en-17-one, 3-hydroxy-"	76	C19H28O2	Investigative
M6APDG02134	PD-168393	"PD168393; 194423-15-9; pd 168393; PD-168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide"	4708	C17H13BrN4O	Investigative
M6APDG04111	AVI-5126	"Resten-CP; NeuGene (CABG), AVI"	.	.	Phase 2
M6APDG03760	ISIS 28466	.	.	.	Investigative
M6APDG00475	"5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one"	"CHEMBL66981; SCHEMBL8176516; 5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one; ZINC9633633; BDBM50039067"	11778521	C16H14N2O3	Investigative
M6APDG02249	Chrysin	"chrysin; 480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0"	5281607	C15H10O4	Investigative
M6APDG00937	tagitinin A	tagitinin A; 59979-61-2; GTPL8701; CHEMBL518700; AC1L48P2; MEGxp0_000075; ACon0_000437; ACon1_000272; BDBM50394802; NCGC00180721-01	181254	C19H28O7	Investigative
M6APDG02332	Ro 31-7453	"Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione"	5327686	C22H16N4O4	Phase 2
M6APDG03794	AVE0897	.	.	.	Phase 1
M6APDG04197	CTP-543	.	.	.	Phase 2
M6APDG02095	N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide	CHEMBL1099078; BDBM50317997	46887380	C21H18N2O2	Investigative
M6APDG00856	CTCE-9908	"Anticancer therapy, Chemokine Therapeutics; CTCE-9908/0019"	16186350	C86H147N27O23	Phase 1/2
M6APDG01872	4-(mesitylthio)-2-methoxybenzonitrile	CHEMBL462022; 4-(mesitylthio)-2-methoxybenzonitrile	44564580	C17H17NOS	Investigative
M6APDG01677	Z-Ala-Leu-lle-Agly-Ile-Val-OMe	.	44355206	C36H59N7O9	Investigative
M6APDG03894	Unacylated ghrelin	"AZP-01; Diabetes therapeutic peptide, Theratechnologies; TH-0332; Un-octanoylated ghrelin; Unacylated ghrelin (diabetes); Ghrelin inhibitor peptides (diabetes), Theratechnologies; UAG (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Theratechnologies; Un-octanoylated ghrelin (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Alize Pharma/Eli Lilly"	.	.	Phase 1
M6APDG01431	S-Ethyl-N-Phenyl-Isothiourea	"S-ETHYL-N-PHENYL-ISOTHIOUREA; 19801-34-4; 2-ETHYL-1-PHENYL-ISOTHIOUREA; S-Ethyl N-Phenylisothiourea; CHEMBL451666; Carbamimidothioic acid,N-phenyl-, ethyl ester; CHEMBL545673; S-Ethyl N-Phenylisothio Urea; S-ethyl-N-phenylisothiourea; AC1L87NW; 1-Phenyl-2-ethylisothiourea; SCHEMBL1387773; CTK4E2382; ethyl N'-phenylimidothiocarbamate; ethyl N'-phenylcarbamimidothioate; DTXSID00324314; LAXNJIWNBHHMDO-UHFFFAOYSA-N; ZINC6001367; FCH829155; BDBM50058459; 2-Ethyl-1-phenyl-2-thio-pseudourea; N-phenyl(ethylsulfanyl)methanimidamide"	347590	C9H12N2S	Investigative
M6APDG02173	CMX-2043	.	49802864	C16H26N2O6S2	Phase 2
M6APDG02070	1-Imidazol-1-ylmethylxanthen-9-one	CHEMBL1083652; 1-Imidazol-1-ylmethylxanthen-9-one	46867545	C17H12N2O2	Investigative
M6APDG02714	3-Indan-(1E)-ylidenemethyl-pyridine	"(3-Pyridylmethylene)indane 1a; SCHEMBL4221377; SCHEMBL4221371; CHEMBL364080; BDBM8581; AC1O7046; 3-[(E)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 3-[(1E)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 3-[(E)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Hydrochloride"	6539759	C15H13N	Investigative
M6APDG01197	PI-3065	PI 3065	24937012	C27H31FN6OS	Investigative
M6APDG03650	HM-61713B	"EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi"	.	.	Investigative
M6APDG00995	Firocoxib	"Firocoxib; 189954-96-9; Equioxx; Previcox; Equixx; Librens; UNII-Y6V2W4S4WT; Y6V2W4S4WT; CHEMBL69998; CHEBI:76136; 3-(CYCLOPROPYLMETHOXY)-5,5-DIMETHYL-4-[4-(METHYLSULFONYL)PHENYL]-2(5H)-FURANONE; ML 1785713; 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one; 3-(Cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one; Firocoxib [USAN:INN]; firocoxibum; 3-(cyclopropylmethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2(5H)-one; Firocoxib (USAN/INN); AC1L4LLA; ML-1,785,713"	208910	C17H20O5S	Investigative
M6APDG00454	PF-562271	PF-00562271	11713159	C21H20F3N7O3S	Phase 1
M6APDG02943	AXL-1717	"BVT-51004; IGF-1 inhibitors, Axelar/Biovitrum; IGF-1 inhibitors, Karolinska/Biovitrum; Insulin-like growth factor 1 inhibitors, Axelar/Biovitrum"	72435	C22H22O8	Phase 2
M6APDG01477	TRANSTORINE	"kynurenic acid; 492-27-3; 4-Hydroxyquinoline-2-carboxylic acid; 13593-94-7; Kynurenate; Quinurenic acid; 4-oxo-1,4-dihydroquinoline-2-carboxylic acid; Transtorine; Kynuronic acid; Kinurenic acid; 4-Hydroxyquinaldic acid; 4-Hydroxy-2-quinolincarboxylic acid; 1,4-Dihydro-4-oxoquinoline-2-carboxylic acid; 2-Quinolinecarboxylic acid, 4-hydroxy-; 4-Hydroxyquinaldinic acid; 4-Hydroxy-2-quinolinecarboxylic acid; Quinaldic acid, 4-hydroxy-; NSC 58973; 4-oxo-1H-quinoline-2-carboxylic acid; UNII-H030S2S85J; KYNA; CCRIS 4428; NSC58973"	3845	C10H7NO3	Investigative
M6APDG00741	BZ3	"5-METHOXYINDOLE; 1006-94-6; 5-Methoxy-1H-indole; 1H-Indole, 5-methoxy-; Femedol; 5-Methoxy indole; Indole, 5-methoxy-; Methoxy-5 indole; Indol-5-yl methyl ether; UNII-DQM3AS43PQ; Methoxy-5 indole [French]; 5-Methoxyindole, 99%; EINECS 213-745-3; DQM3AS43PQ; NSC 521752; CHEMBL280311; DWAQDRSOVMLGRQ-UHFFFAOYSA-N; MFCD00005674; 916979-77-6; BZ3; 5Methoxyindole; 5-methoxyindol; 5-methoxy-indole; 3img; 3imc; PubChem7432; 1,3-dihydro-5-methyl-2H-Indol-2-one; ACMC-1BMAQ; 5-(methyloxy)-1H-indole; AC1Q4F1F; AC1L22NW; SCHEMBL74720; KSC177G3N; WLN: T"	13872	C9H9NO	Investigative
M6APDG00425	(E)-9-nitrooctadec-9-enoic acid	(E)-9-Nitrooctadec-9-enoic Acid; 9-nitro-9E-octadecenoic acid; 9-Nitro Oleic Acid; (E)-9-nitrooctadec-9-enoic Acid; 9-Nitrooleic acid; Nitroleic Acid; 875685-44-2; 9-Nitrooleate; CHEMBL550762; (9E)-9-nitrooctadecenoic acid; CHEBI:86329; 9-nitro-9E-Octadecenoate; (9E)-9-Nitrooctadecenoate; 9-Nitro-9-octadecenoic acid; (e)-9-Nitrooctadec-9-enoate; GTPL6296; SCHEMBL1015108; MolPort-027-641-228; CQOAKBVRRVHWKV-SAPNQHFASA-N; (e)-9-nitro-octadec-9-enoic acid; (9E)-9-nitrooctadec-9-enoic acid; (9E)-9-Nitro-9-octadecenoic Acid; BDBM50295048; 1573AH; LMFA01120004; nitrooleic acid	11645581	C18H33NO4	Investigative
M6APDG01581	desmosterol	"DESMOSTEROL; 24-Dehydrocholesterol; 313-04-2; UNII-ANP93865R8; cholest-5,24-dien-3beta-ol; Cholesta-5,24-dien-3beta-ol; NSC 226126; CHEBI:17737; 3beta-cholesta-5,24-dien-3-ol; ANP93865R8; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Cholesta-5,24-dien-3-ol; desmesterol; EINECS 206-236-2; 24-dehydro Cholesterol; 24,25-Dehydrocholesterol; AC1L97ME; Cholesta-5,24-dien-3b-ol; 5,24-Cholestadien-3beta-ol; 5,24-Cholestadien-3"	439577	C27H44O	Investigative
M6APDG01089	8-O-(4-bromobenzenesulfonyl)manzamine F	CHEMBL414128; 8-O-(4-bromobenzenesulfonyl)manzamine F	23643732	C42H47BrN4O5S	Investigative
M6APDG01666	7-Biphenyl-4-yl-heptanoic acid hydroxyamide	CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid	44349481	C19H23NO2	Investigative
M6APDG02111	"4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol"	CHEMBL1172779; SCHEMBL18770369; BDBM50322793	46901610	C18H15NO2	Investigative
M6APDG03861	TAK-114	.	.	.	Phase 1
M6APDG00876	Buparlisib	BKM120	16654980	C18H21F3N6O2	Phase 3
M6APDG03155	RPR 200765A	CHEMBL68211; SCHEMBL5770288; SCHEMBL13819552; SCHEMBL20555598; SCHEMBL18797648	9828952	C24H25FN4O4	Terminated
M6APDG01724	4-Butoxy-N-hydroxycarbamoylmethyl-benzamide	CHEMBL371715; 4-Butoxy-N-hydroxycarbamoylmethyl-benzamide	44404479	C13H18N2O4	Investigative
M6APDG04142	Tarextumab	.	.	.	Phase 2
M6APDG01019	NUTLIN-3	"Nutlin-3; 548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one"	216345	C30H30Cl2N4O4	Investigative
M6APDG04319	ATL-1101	.	.	.	Preclinical
M6APDG02354	Romiplostim	.	5329098	C15H14N2O	Approved
M6APDG00976	RPR-104632	"RPR-104632; RPR104632; 154106-92-0; Rpr 104632; Rpr 104,632; AC1L53RY; CHEMBL80741; SCHEMBL9280756; 2H-1,2,4-Benzothiadiazine-1-dioxide-3-carboxylate acid; CTK0H7515; BCP08875; CS-6717; RPR-110750; RPR-110754; HY-101600; 2-[(3-bromophenyl)methyl]-6,8-dichloro-1,1-dioxo-3,4-dihydro-1; 2H-1,2,4-Benzothiadiazine-3-carboxylicacid, 2-[(3-bromophenyl)methyl]-6,8-dichloro-3,4-dihydro-, 1,1-dioxide"	197644	C15H11BrCl2N2O4S	Terminated
M6APDG02770	GW-2331	"190844-95-2; PPAR ligand, Glaxo Wellcome"	657048	C27H36F2N2O4	Investigative
M6APDG02313	"15-deoxy-Delta(12, 14)-prostaglandin J(2)"	"15d-PGJ2; 15-Deoxy-PGJ2; 15-Deoxy-delta-12,14-prostaglandin J2; 15-deoxy-delta12,14-prostaglandin J2; delta12,14-PGJ 2; UNII-ALI977775J; 87893-55-8; CHEMBL482477; CHEBI:34159; (5Z,12E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid; ALI977775J; delta-12,14-15-Deoxy-PGJ2; 15-Deoxy-delta12,14-prostaglandin; 15-deoxy-Delta(12,14)-prostaglandin J2; Prostaglandin J2, 15-Deoxy-Delta12,14; 15-Deoxy-delta 12, 14-Prostaglandin J2"	5311211	C20H28O3	Investigative
M6APDG00842	SAR245409	.	16123056	C13H14N6O	Phase 2
M6APDG01157	MERIOLIN 8	MERIOLIN 8; SCHEMBL2991886; CHEMBL406102	24801181	C12H11N5O	Investigative
M6APDG03817	Cyclolignan picropodophyllin	"PPP; IGF-1R inhibitor (cancer), Karolinska"	.	.	Phase 1
M6APDG03305	ALBANOL A	"Mulberrofuran G; Albanol A; 87085-00-5; NSC649229; iso-mulbel-rochromene; NSC 649229; AC1L51ZD; SCHEMBL4926236; AKOS032948258; 3aH-Benzo[3,4][2]benzopyrano[1,8-bc][1]-benzopyran-4,11-diol, 8a-(2,4-dihydroxphenyl)-1,8a,13b,13c-tetrahydro-6-(6-hydroxy-2-benzofuranyl)-2-methyl-, (3a,S,8aS,13bS,13cR)-"	9959532	C34H26O8	Investigative
M6APDG02016	4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide	CHEMBL601040; 4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide	46207013	C18H20Cl2N2O	Investigative
M6APDG02712	"3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione"	"SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01"	6539451	C16H12N2O2	Investigative
M6APDG00802	METHYLHONOKIOL	"4-O-Methylhonokiol; 68592-15-4; METHYLHONOKIOL; 4-O-Methyl honokiol; 4-methoxyhonokiol; HONOKIOL MONO-METHYL ETHER; CHEMBL89700; (1,1'-Biphenyl)-2-ol, 4'-methoxy-3',5-di-2-propenyl-; [1,1'-Biphenyl]-2-ol, 4'-methoxy-3',5-di-2-propenyl-; Magreth-14a; NSC293101; 4'-O-Methylhonokiol; AC1L4DQF; 4'-O-methylhonokiol, MH; SCHEMBL12391677; CTK5C8246; DTXSID50218693; ZINC1566147; HY-U00450; BDBM50295926; AKOS028111321; NSC-293101; CS-0035406; 5,3''-Diallyl-4''-methoxy-biphenyl-2-ol; 3,5'-diallyl-2'-hydroxy-4-methoxybiphenyl"	155160	C19H20O2	Investigative
M6APDG00986	AG 1024	tyrphostin AG 1024; AG-1024; AG1024	2044	C14H13BrN2O	Investigative
M6APDG00973	3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol	CHEMBL368972; 3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol; SCHEMBL7207764	19366856	C12H18O3S2	Investigative
M6APDG00314	5-Bromo-6-methoxy-9H-beta-carboline	5-bromo-6-methoxy-beta-carboline; CHEMBL310975; 5-Bromo-6-methoxy-9H-beta-carboline; SCHEMBL6465779; BDBM50130233	11414735	C12H9BrN2O	Investigative
M6APDG04202	Mydicar	Mydicar (TN)	.	.	Phase 2
M6APDG04299	Granexin gel	alphaCT1	.	.	Phase 3
M6APDG02348	"2-cyano-3-(3,4-dihydroxyphenyl)acrylamide"	"Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR"	5328768	C10H8N2O3	Investigative
M6APDG02204	GSK2141795	"Uprosertib; 1047634-65-0; GSK2141795; UNII-ZXM835LQ5E; Uprosertib (GSK2141795); GSK2141795C; ZXM835LQ5E; GSK795; GSK-2141795; 2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-;2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-; Uprosertib [USAN:INN]; Uprosertib (USAN/INN); Uprosertib, GSK2141795; SCHEMBL168584; GTPL7902; CHEMBL3137336; MolPort-044-560-307; AXTAPYRUEKNRBA-JTQLQIEISA-N"	51042438	C18H16Cl2F2N4O2	Phase 2
M6APDG03969	MM-151	.	.	.	Phase 1
M6APDG04246	LR3001	.	.	.	Phase 2
M6APDG04100	WT-4869	.	.	.	Phase 1/2
M6APDG02340	4-Benzoimidazol-1-yl-phenylamine	"4-(1H-benzimidazol-1-yl)aniline; 52708-36-8; 4-(1H-Benzo[d]imidazol-1-yl)aniline; 4-(1H-1,3-benzodiazol-1-yl)aniline; 4-benzimidazolylphenylamine; AC1NS4KU; 4-(benzimidazol-1-yl)aniline; AC1Q51W1; SCHEMBL1208951; BDBM3829; CHEMBL346870; CTK1H4832; DTXSID80416160; 1-Phenylbenzimidazole deriv. 46; MolPort-000-892-003; ZINC2538824; 7454AB; STK122023; 1-(4-Aminophenyl)-1H-benzimidazole; SBB022485; AKOS000200797; MCULE-3811873515; AJ-38769; DA-18573; Benzenamine, 4-(1H-benzimidazol-1-yl)-; KB-237102; ST45055167; FT-0748937; EN300-14992"	5328453	C13H11N3	Investigative
M6APDG00186	"3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione"	SCHEMBL9389021	10633414	C10H6N2O5	Investigative
M6APDG00542	"3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione"	"CHEMBL357775; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-1-methyl-; 59512-13-9; 3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione; CTK1E7233; DTXSID50490593; BDBM50025151; AKOS022647888"	12331302	C11H12N2O2	Investigative
M6APDG01627	Benzyloxycarbonyl-glycylryanodine	Benzyloxycarbonyl-glycylryanodine; CHEMBL28383	44275860	C35H44N2O12	Investigative
M6APDG00394	C-[-Arg-Gly-Asp-Acpca32-]	CHEMBL556402	11583738	C18H29N7O6	Investigative
M6APDG01716	N-(2-Mercapto-ethyl)-N'-phenyl-succinamide	CHEMBL193959	44401339	C12H16N2O2S	Investigative
M6APDG03254	DFU	"Deoxyfuconojirimycin; 1,2,6-Trideoxy-2,6-imino-D-galactitol; (2S,3R,4S,5R)-2-methylpiperidine-3,4,5-triol; 99212-30-3; 1,5-Dideoxy-1,5-iminofucitol; CHEMBL314772; 1-Deoxyfuconojirimycin HCl; 1,5-Dideoxy-1,5-imino-L-fucitol; L-fuco-Deoxynojirimycin; Fucosidase Inhibitor, 3; AC1L3UXS; AC1Q59GC; SCHEMBL4378188; 3,4,5-Piperidinetriol, 2-methyl-, (2S,3R,4S,5R)-; CHEBI:132866; 1-Deoxyfuconojirimycin hydrochloride; ZINC2585424; BDBM50065258; AKOS006283710; D-Galactitol, 1,2,6-trideoxy-2,6-imino-; FT-0624513"	9906892	C19H17FO4S	Investigative
M6APDG02713	GSK-3beta inhibitor II	GSK-3b inhibitor II	6539732	C14H10IN3OS	Investigative
M6APDG02528	CPI-0610	.	57389999	C20H16ClN3O2	Phase 3
M6APDG03316	4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide	"4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide; CHEMBL487738; 4-(6-chloropyrazin-2-ylamino)benzenesulfonamide; 642459-21-0; 2vtj; SCHEMBL6659290; BDBM24631; ZINC16052861; DB08134; FT-0723597; 4-[(6-chloropyrazin-2-yl)amino]benzene-1-sulfonamide; 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide, 10"	9994066	C10H9ClN4O2S	Investigative
M6APDG01053	4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one	aromatase inhibitor i; CHEMBL159073; 4-(Imidazolylmethyl)-1-nitro-9H-9-xanthenone; 4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one; AC1L1D8C; CTK5I3006; BDBM50097366; 4-(imidazol-1-ylmethyl)-1-nitroxanthen-9-one; 4-(1H-imidazol-1-ylmethyl)-1-nitro-9H-xanthen-9-one; 4-((1H-imidazol-1-yl)methyl)-1-nitro-9H-xanthen-9-one; 1-Nitro-4-(1H-imidazole-1-ylmethyl)-9H-xanthene-9-one	2238	C17H11N3O4	Investigative
M6APDG03810	BLY719	.	.	.	Phase 1
M6APDG00854	(R)-2-Amino-7-phosphono-heptanoic acid	"81338-23-0; UNII-89FET0690I; (2R)-2-amino-7-phosphonoheptanoic acid; D(-)-2-Amino-7-phosphonoheptanoic acid; Heptanoic acid, 2-amino-7-phosphono-, (2R)-; CHEMBL302783; 89FET0690I; D-(-)-2-Amino-7-phosphonoheptanoic acid; (R)-AP7; D-(-)-2-Amino-7-phosphonoheptanoate; AC1LUTYN; Tocris-0164; Tocris-0104; Lopac-A-167; Lopac-A-5157; Lopac0_000157; SCHEMBL9848541; ZINC1856281; BDBM50017226; STL526509; BN0090; AKOS024456719; CCG-204252"	1617430	C7H16NO5P	Investigative
M6APDG01930	CRA_10655	AC1O4QGF	447480	C19H20N4O2	Investigative
M6APDG00922	PF-4217903	"2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N;  PF-04217903"	17754438	C19H16N8O	Phase 1
M6APDG02924	HDM201	.	71678098	C26H24Cl2N6O4	Phase 1
M6APDG03507	ISIS 113048	.	.	.	Investigative
M6APDG00141	CP-775146	CP775146	10410059	C26H33NO4	Investigative
M6APDG02266	NSC-94258	"7-Hydroxyflavone; 6665-86-7; 7-Hydroxy-2-phenyl-4H-chromen-4-one; Flavone, 7-hydroxy-; 7-Hydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 7-hydroxy-2-phenyl-; 7-hydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-; 7-Hydroxy-2-phenyl-chromen-4-one; NSC 94258; UNII-ZE72458E4L; EINECS 229-705-3; NSC-94258; MLS002695239; CHEBI:2268; CHEMBL276915; MQGPSCMMNJKMHQ-UHFFFAOYSA-N; ZE72458E4L; NSC94258; MFCD00006835; 7-Hydroxy-2-phenyl-4H-1-benzopyran-4-one; H-5100; SR-01000359106; 7-Hydroxyflavone, 11; 7-Hydroxy-flavone, "	5281894	C15H10O3	Investigative
M6APDG03464	ISIS 114563	.	.	.	Investigative
M6APDG01391	"2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl"	"CHEMBL89828; 68592-18-7; NSC293102; AC1L6VMD; HONOKIOL DIMETHYL ETHER; SCHEMBL13978616; CTK2F6825; DTXSID00315202; ZINC1566148; BDBM50295927; 3',5-diallyl-2,4'-dimethoxybiphenyl; NSC-293102; 5,3''-Diallyl-2,4''-dimethoxy-biphenyl; 3,3'-Diallyl-4',6-dimethoxy-1,1'-biphenyl; 2,4''-Dimethoxy-5,3''-di-(2-propenyl)-biphenyl; 1-methoxy-2-(4-methoxy-3-prop-2-enylphenyl)-4-prop-2-enylbenzene"	325144	C20H22O2	Investigative
M6APDG00353	H-Gly-dmP-Glu-OH	SCHEMBL2085656; CHEMBL193486	11515428	C14H23N3O6	Investigative
M6APDG03119	Sodelglitazar	"Sodelglitazar; 447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac"	9805950	C23H21F4NO3S2	Discontinued in Phase 2
M6APDG01049	N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide	CHEMBL1086639; N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706	22319573	C17H17N3O2	Investigative
M6APDG00810	2-Aminothiazoline	"2-Amino-2-thiazoline; 1779-81-3; 4,5-dihydrothiazol-2-amine; 2-Iminothiazolidine; 2-Thiazolidinimine; 2-Thiazolamine, 4,5-dihydro-; 2-Amino-4,5-dihydrothiazole; 2-Thiazoline, 2-amino-; 4,5-Dihydro-1,3-thiazol-2-amine; USAF PD-57; 2-Amino-4,5-dihydrothiazoline; 4,5-DIHYDRO-2-THIAZOLAMINE; 2-Thiazolin-2-ylamine; 2-Aminothiazoline (VAN); UNII-5JC2YZG56Q; NSC 3110; NSC 24626; Thiazolidin-(2E)-ylideneamine; 2-Amino-DELTA2-thiazoline; EINECS 217-224-1; 5JC2YZG56Q; CHEMBL362148; 2-Amino-2-thiazoline, 97%"	15689	C3H6N2S	Investigative
M6APDG00173	1-(2-(benzo[b]thiophen-4-yl)ethyl)-1H-imidazole	CHEMBL460382; Benzo[b]thiophene 32; BDBM10038; ZINC13808220; 1-[2-(1-benzothiophen-4-yl)ethyl]-1H-imidazole; 4-[2-(1H-Imidazole-1-yl)ethyl]benzo[b]thiophene	10537337	C13H12N2S	Investigative
M6APDG03948	LY3164530	.	.	.	Phase 1
M6APDG00108	Napabucasin	"83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919"	10331844	C14H8O4	Phase 3
M6APDG00459	BVD-523	.	11719003	C21H22Cl2N4O2	Phase 2
M6APDG04272	VP-102	.	.	.	Phase 3
M6APDG02519	Ribociclib Succinate	1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739	57334219	C27H36N8O5	Approved
M6APDG00451	C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2	CHEMBL380638; c[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2	11707715	C43H61N11O7	Investigative
M6APDG01800	Methotrexate gamma-L-proline-hydroxamic acid	CHEMBL388879; methotrexate gamma-L-proline-hydroxamic acid	44428667	C25H30N10O6	Investigative
M6APDG04032	HTU-PA	"Human tissue urokinase type plasminogen activator, Global Biotech"	.	.	Phase 1/2
M6APDG03496	CHR-4125	"CHR-4146; CHR-5010; PLK-1 inhibitors (cancer), Chroma Therapeutics; Polo-like kinase-1 inhibitors (cancer); Polo-likekinase-1 inhibitors (cancer), Chroma Therapeutics"	.	.	Investigative
M6APDG03167	"2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione"	"CHEMBL11516; 63586-13-0; 2-Benzyl-4,5,6,7-tetrachloro-isoindole-1,3-dione; 2-benzyl-4,5,6,7-tetrachloro-1H-isoindole-1,3(2H)-dione; AC1LK1ZO; Oprea1_023833; 2-benzyl-4,5,6,7-tetrachloroisoindole-1,3-dione; 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione; SCHEMBL10675358; CTK2A8819; DTXSID60359687; MolPort-001-020-850; ZINC630019; STK246502; BDBM50088678; AKOS003243470; MCULE-7798575308; N-Benzyl-3,4,5,6-tetrachlorophthalimide; ST50854964; AK-918/11423009; 4,5,6,7-tetrachloro-2-benzylbenzo[c]azolidine-1,3-dione"	983732	C15H7Cl4NO2	Investigative
M6APDG01096	2-(2-propoxypyrimidin-4-ylamino)benzoic acid	4-anilinopyrimidine 6b; CHEMBL242489; BDBM15980; 2-[(2-propoxypyrimidin-4-yl)amino]benzoic acid	23647240	C14H15N3O3	Investigative
M6APDG02541	Deoxythymidine	"Thymidine; thymidine; 50-89-5; deoxythymidine; 2'-Deoxythymidine; Beta-Thymidine; 5-Methyldeoxyuridine; Thymidin; DThyd; 5-Methyl-2'-deoxyuridine; Thymine-2-deoxyriboside; Thyminedeoxyriboside; Thymine-2-desoxyriboside; 5-Methyldeoxyurindine; dThd; Uridine, 2'-deoxy-5-methyl-; Thymine deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; dT; UNII-VC2W18DGKR; Deoxyribothymidine; AI3-52267; 2'-thymidine; beta-D-Ribofuranoside, thymine-1 2-deoxy-; CCRIS 1283; CHEBI:17748"	5789	C10H14N2O5	Investigative
M6APDG02294	9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine	9-BUTYL-8-(3-METHOXYBENZYL)-9H-PURIN-6-AMINE; CHEMBL109612; AC1NRCWL; 1uy8; Purine-Based Inhibitor 3; SCHEMBL1966787; BDBM15376; BWLWUGBHOXIUBP-UHFFFAOYSA-N; DB03809; 8-(3-Methoxybenzyl)-9-butyl-9H-purine-6-amine; 9-butyl-8-[(3-methoxyphenyl)methyl]purin-6-amine; 9-Butyl-8-(3-methoxy-benzyl)-9H-purin-6-ylamine	5289228	C17H21N5O	Investigative
M6APDG01101	N-(2-aminophenyl)quinoxaline-6-carboxamide	"N-(2-aminophenyl)quinoxaline-6-carboxamide; benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424"	23648267	C15H12N4O	Investigative
M6APDG02591	1-Phenyl-1H-benzoimidazole	"1-Phenyl-1H-benzoimidazole; 2622-60-8; 1-phenyl-1H-benzo[d]imidazole; 1-phenylbenzimidazole; 1-Phenyl-1H-benzimidazole; 97542-80-8; 1H-Benzimidazole,1-phenyl-; BAS 00350928; 1H-Benzimidazole, 1-phenyl-; XNCMQRWVMWLODV-UHFFFAOYSA-N; 1-PHENYL-1H-1,3-BENZODIAZOLE; AK123264; AC1LCTXI; PubChem19972; 1-Phenyl benzoimidazole; 1-Phenylbenzimidazole 3; phenyl-1H- Benzimidazole; 1-phenyl-1,3-benzodiazole; MLS000765952; SCHEMBL157265; 1-Phenyl-1H-benzimidazole #; CHEMBL310080; BDBM3794; CTK4F7433; DTXSID10345732; 1-Phenylbenzimidazole deriv. "	606669	C13H10N2	Investigative
M6APDG03946	REGN5093	.	.	.	Phase 1
M6APDG03715	(D-Arg)(9)-p19(ARF) 26-44 peptide	.	.	.	Investigative
M6APDG00373	5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide	"5-amino-2-(4-methylphenyl)-1,3-oxazole-4-carboxamide; CHEMBL382993; 5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide; CTK6B8237; MolPort-000-894-518; SBB024037; BDBM50186628; STK351079; ZINC12394806; AKOS000313592; MCULE-2038651256"	11543063	C11H11N3O2	Investigative
M6APDG01151	AP-Cav	AP-Cav	24779772	C33H51ClN2O6	Investigative
M6APDG00829	ISOSAKUTANETIN	"Isosakuranetin; 480-43-3; 4'-Methylnaringenin; Isosakutanetin; UNII-U02X7TF8UA; naringenin 4'-methyl ether; U02X7TF8UA; CHEMBL470266; CHEBI:27552; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Citrifoliol; (S)-5,7-dihydroxy-2-(4-methoxyphenyl)chroman-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-, (2S)-; 4'-Methoxy-5,7-dihydroxyflavonone"	160481	C16H14O5	Investigative
M6APDG02358	6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine	"CHEMBL115498; O6-Substituted Guanine Deriv. 27; AC1NS6ZQ; 9H-Purin-2-amine, 6-(3-cyclohexen-1-ylmethoxy)-; SCHEMBL6267556; BDBM5487; 220035-95-0; 6-(cyclohex-3-en-1-ylmethoxy)-9H-purin-2-amine"	5329512	C12H15N5O	Investigative
M6APDG02234	CHRYSOERIOL	"Chrysoeriol; 491-71-4; Chryseriol; Luteolin 3'-methyl ether; 3'-O-Methylluteolin; 3'-O-Methyluteolin; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-chromen-4-one; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; UNII-Q813145M20; EINECS 207-742-6; BRN 0295004; CHEMBL214321; CHEBI:16514"	5280666	C16H12O6	Investigative
M6APDG03934	OPB-51602	.	.	.	Phase 1
M6APDG00709	5-Chloro-2-methyl-3H-quinazolin-4-one	.	135875707	C9H7ClN2O	Investigative
M6APDG00765	BMS 275291	"D 2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide"	148203	C23H41N5O5S	Discontinued in Phase 3
M6APDG01283	[3H]methyltrienolone	"Methyltrienolone; METRIBOLONE; 965-93-5; R1881; Metribolona; 17alpha-Methyltrienolone; Metribolonum; RU 1881; Ru-1881; R 1881; UNII-2C323EGI97; 17beta-Hydroxy-17-methylestra-4,9,11-trien-3-one; 17-beta-Hydroxy-17-methylestra-4,9,11-trien-3-one; R-1881; R1881 (synthetic androgen); CHEBI:379896; 2C323EGI97; (17BETA)-17-HYDROXY-17-METHYLESTRA-4,9,11-TRIEN-3-ONE; 17-methyloestra-4,9,11-trien-3-one,17beta-ol; 17-beta-hydroxy-17-methylestra-4,9,11-trien-3-one (9CI); Estra-4,9,11-trien-3-one, 17-hydroxy-17-methyl-, (17b)-;  [3H]-R1881; [3H]R1881"	261000	C19H24O2	Investigative
M6APDG00805	"7-Methyl-[1,4]thiazepan-(5E)-ylideneamine"	"CHEMBL365202; 7-Methyl-[1,4]thiazepan-(5E)-ylideneamine; SCHEMBL7682273; BDBM50155792"	15552206	C6H12N2S	Investigative
M6APDG03714	ISIS 133244	.	.	.	Investigative
M6APDG01077	XD1	colchicein; colchiceine; NSC33411	234105	C21H23NO6	Investigative
M6APDG03777	ISIS 32024	.	.	.	Investigative
M6APDG03637	ISIS 298744	.	.	.	Investigative
M6APDG03996	TTI-621	.	.	.	Phase 1
M6APDG00290	3-(2-propyn-1-yl)thymidine	3-(2-propyn-1-yl)thymidine; 3-Propargylthymidine; SCHEMBL1619074; CHEMBL524872	11323459	C13H16N2O5	Investigative
M6APDG01320	Small molecule 34	3-(2-(4-pyridyl)ethyl)indole; 3-(2-PYRIDIN-4-YLETHYL)-1H-INDOLE; INHIBITOR OF P38 KINASE; 3-(2-(Pyridin-4-yl)ethyl)-1H-indole; 3-[2-(pyridin-4-yl)ethyl]-1H-indole; 3-(2-Pyridin-4-yl-ethyl)-1H-indole; L12; Maybridge1_000718; Cambridge id 5373101; AC1L1E9J; Oprea1_574113; Oprea1_420786; SCHEMBL735580; CHEMBL193156; HMS543I14; ZINC94256; BDBM13346; UUEYCHLWAOBOHG-UHFFFAOYSA-N; 1w84; MolPort-001-886-488; HMS3604M06; 3-[2-(4-pyridyl)-ethyl]-indole; STL328644; CCG-45397; 3-[2-(4-Pyridyl)ethyl]-1H-indole; AKOS000545583; MCULE-4657429599	27934	C15H14N2	Investigative
M6APDG00406	C[-Arg-Gly-Asp-Acpca21-]	CHEMBL534711	11613122	C18H29N7O8	Investigative
M6APDG01337	aminooxyacetic acid	"Aminooxyacetic acid; (aminooxy)acetic acid; 2-(Aminooxy)acetic acid; AOAA; carboxymethoxylamine; 645-88-5; Carboxymethoxyamine; ACETIC ACID, (AMINOOXY)-; Aminooxyacetate; Aminooxy-acetic acid; (Carboxymethoxy)amine; (o-Carboxymethyl)hydroxylamine; aminoxyacetic acid; UNII-14I68GI3OQ; BRN 0878238; C2H5NO3; 14I68GI3OQ; U 7524; NQRKYASMKDDGHT-UHFFFAOYSA-N; u-7524; AOA; Aminooxyacetic acid hemihydrochloride; Carboxymethoxylamine hemihydrochloride; aminoxy-acetic acid; amino-oxyacetic acid; AOA hemihydrochloride; 2-aminooxyacetic acid;  AOAA"	286	C2H5NO3	Investigative
M6APDG03225	2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine	CHEMBL65119	9883372	C20H17N3O	Investigative
M6APDG01679	Z-Arg-Leu-Val-Agly-Trp-Val-Ala-NH2	.	44355268	C45H67N13O9	Investigative
M6APDG00472	Ac-Asp-Arg-Leu-Asp-Ser-OH	CHEMBL238484; Ac-Asp-Arg-Leu-Asp-Ser-OH; Acetyl-Asp-Arg-Leu-Asp-Ser-OH; ZINC28869420	11764797	C25H42N8O12	Investigative
M6APDG01211	N8-hydroxy-2-methoxy-N1-phenyloctanediamide	CHEMBL251010; N8-hydroxy-2-methoxy-N1-phenyloctanediamide; SCHEMBL8158442	25065930	C15H22N2O4	Investigative
M6APDG03465	DB-900	.	.	.	Investigative
M6APDG03467	Rapamycin complexed with immunophilin FKBP12	.	.	.	Investigative
M6APDG00445	6-benzenesulfinylhexanoic acid hydroxamide	6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4; 6-benzenesulfinylhexanoic acid hydroxamide	11694528	C12H17NO3S	Investigative
M6APDG01523	NSC-12999	CHEMBL495567; NSC-12999; AC1L8UK1; ZINC4366490; BDBM50265443; 6-chloro-2-methoxy-N-pyridin-3-ylacridin-9-amine; 6-chloro-2-methoxy-N-(3-pyridyl)acridin-9-amine	408350	C19H14ClN3O	Investigative
M6APDG00541	[3H]CPP	"100828-16-8; 4-(3-phosphonopropyl)piperazine-2-carboxylic acid; (RS)-CPP; 3-2-Cpp; CARBOXYPEPTIDASE P; 3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid; (+/-)-CPP; 4-(3-Phosphonopropyl)-2-piperazinecarboxylic acid; CHEMBL22304; DL-3-(2-Carboxypiperazin-4-yl)-propyl-1-phosphonic acid; 4-(3-Phosphono-propyl)-piperazine-2-carboxylic acid; 2-Piperazinecarboxylic acid, 4-(3-phosphonopropyl)-; (+)-3-(2-Carboxypiperazin-4-yl)-propyl-1-phosphoric Acid; 2-Piperazinecarboxylic acid, 4-(3-phosphonopropyl)-, (+-)-; 108549-42-4"	1228	C8H17N2O5P	Investigative
M6APDG03250	Nandrolone	"Decadura; Estrenolone; Menidrabol; Nadrolone; Nandrolon; Nandrolona; Nandrolonum; Norandrostenolon;Norandrostenolone; Nortestonate; Nortestosterone; Nortestosteronum; Oestrenolon; LT03330030; U 2410; Decadura (TN); Durabolin (TN); Nandrolona [INN-Spanish]; Nandrolone (INN); Nandrolonum [INN-Latin]; Estr-4-en-3-one, 17beta-hydroxy-(8CI); Estr-4-en-3-one, 17-hydroxy-, (17beta)-(9CI); Estr-4-en-3-one, 17-hydroxy-, (17-beta)-(9CI); (17-beta)-17-Hydroxyestr-4-en-3-one; (17beta)-17-hydroxyestr-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; 17-Hydroxy-Estr-4-Ene-3-One; 17-beta-Hydroestr-4-en-3-one; 17beta-Hydroxy-19-nor-4-androsten-3-one; 17beta-Hydroxy-19-norandrost-4-en-3-one; 17beta-Hydroxy-4-estren-3-one; 17beta-hydroxy-19-nor-4-androsten-3-one; 17beta-hydroxy-4-estren-3-one; 17beta-hydroxyestr-4-en-3-one; 19-Norandrostenolone; 19-Nortestosterone; 4-Estren-17beta-ol-3-one; 4-estren-17beta-ol-3-one"	9904	C18H26O2	Approved
M6APDG04210	BMS-936557	"Anti-CXCL10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Medarex/BMS; Anti-IP-10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Bristol-Myers Squibb/Medarex"	.	.	Phase 2
M6APDG03666	UCB-1277763	"P38 kinase inhibitors (inflammation), UCB"	.	.	Investigative
M6APDG02978	VPC-94075	"Sphingosine kinase inhibitor (vascular disease); Sphingosine kinase inhibitor (vascular disease), University of Virgina"	753704	C15H11ClN2OS	Investigative
M6APDG03188	M826	compound 4sx	9851134	C28H45N7O6	Investigative
M6APDG03480	XB-387	"PDGFRB-targeted mAb (cancer), X-BODY; Platelet-derived growth factor receptor beta-targeted monoclonal antibody (cancer), X-BODY"	.	.	Investigative
M6APDG03181	SB-219994	SB-219993	9845965	C21H21F3N2O5	Terminated
M6APDG02248	BAICALEIN	"baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Noroxylin; Biacalein; BaiKalein; Baicelein; UNII-49QAH60606; NSC661431; NSC 661431; CHEMBL8260; 5,6,7-trihydroxy-2-phenylchromen-4-one; CHEBI:2979; FXNFHKRTJBSTCS-UHFFFAOYSA-N; MFCD00017459; 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl-; 49QAH60606; 5,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-chromen-4-one; Sho-saiko-to; SMR000112462; SR-01000597499; Baicalein, 8; Baicalein,(S); 3WL; Baicalein, 14; Baicalein, 98%; AC1NQYPP; Tocris-1761"	5281605	C15H10O5	Phase 2
M6APDG01229	HM-78136B	"Pan-Her/EGFR inhibitors (cancer), Hanmi"	25127713	C23H21Cl2FN4O3	Phase 2
M6APDG02800	1-Phenyl-1H-benzoimidazol-5-ol	"1-Phenyl-5-hydroxybenzimidazole; 1-phenyl-1H-Benzimidazol-5-ol; 69445-45-0; 1-Phenylbenzimidazole deriv. 65; AC1LDIKP; 1-phenylbenzimidazol-5-ol; CHEMBL80873; SCHEMBL4280861; BDBM3848; 5-hydroxy-1-phenylbenzimidazole; CTK5C9901; ZINC17525; DTXSID70349872; 1-Phenyl-1H-benzimidazole-5-ol; 1H-Benzimidazol-5-ol,1-phenyl-; OQAPWZCMAFFBBL-UHFFFAOYSA-N; 1-phenyl-1H-1,3-benzodiazol-5-ol; AKOS022650144; 5-Substituted 1-Phenylbenzimidazole 5; DA-04176; KB-219704; FT-0734974"	667662	C13H10N2O	Investigative
M6APDG00197	C(RGDfF)	CHEMBL380434	10699123	C30H38N8O7	Investigative
M6APDG02179	N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	CHEMBL1210476; N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide	49863103	C17H16N6O	Investigative
M6APDG00755	1-Methyl-4-(1-phenyl-ethyl)-piperazine	CHEMBL195009; 1-Methyl-4-(1-phenyl-ethyl)-piperazine; SCHEMBL2625061; BDBM50174064	14364677	C13H20N2	Investigative
M6APDG00452	5-amino-2-phenyl-oxazole-4-carboxylic acid amide	CHEMBL207987; 5-amino-2-phenyloxazole-4-carboxylic acid amide; 99185-68-9; 5-amino-2-phenyl-oxazole-4-carboxylic acid amide	11708263	C10H9N3O2	Investigative
M6APDG01790	Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)	CHEMBL375993; cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)	44418891	C37H49N11O6	Investigative
M6APDG01812	"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline"	"CHEMBL250523; 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline; BDBM50222432"	44442168	C19H16N2O3	Investigative
M6APDG03002	N-(4-Phenylthiazol-2-yl)isonicotinamide	"N-(4-phenyl-1,3-thiazol-2-yl)pyridine-4-carboxamide; CHEMBL482012; 5245-66-9; N-(4-Phenylthiazol-2-yl)isonicotinamide; BAS 03572091; AC1Q5OBS; AC1LG7OX; CBMicro_015073; n-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Cambridge id 5245669; Oprea1_303023; Oprea1_553111; SCHEMBL17107144; CTK4J5937; DTXSID30355050; MolPort-001-992-732; ZINC290573; STK483947; BDBM50255300; AKOS000569765; MCULE-9247268363; BIM-0015234.P001; N-(4-Phenyl-thiazol-2-yl)-isonicotinamide; ST50017829; N~4~-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Z27772062"	790259	C15H11N3OS	Investigative
M6APDG02815	(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone	"BAS 02052986; AC1LDSC0; N-Benzoylpyrazole deriv., 20; CHEMBL244072; ZINC37170; BDBM23712; MolPort-001-971-782; AKOS000577347; 2-methylphenyl 4-nitropyrazolyl ketone; MCULE-4726161589; ST033205; (4-Nitro-pyrazol-1-yl)-o-tolyl-methanone; (2-methylphenyl)-(4-nitropyrazol-1-yl)methanone"	674641	C11H9N3O3	Investigative
M6APDG01488	Bezafibrate	"Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid"	39042	C19H20ClNO4	Approved
M6APDG02347	"2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile"	"Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile"	5328763	C16H11NO3	Investigative
M6APDG01708	Ac-YR[CEHdFRWC]-NH2	CHEMBL264352; Ac-YR[CEHdFRWC]-NH2	44400370	C60H79N19O13S2	Investigative
M6APDG02728	3-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine	"(3-Pyridylmethylene)indane 15a; CHEMBL366772; BDBM8601; AC1O7055; 3-[(E)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine"	6539777	C16H15NO	Investigative
M6APDG04116	VPI-2690B	.	.	.	Phase 2
M6APDG03099	octanol	"1-octanol; Octan-1-ol; octanol; 111-87-5; N-octanol; Capryl alcohol; Octyl alcohol; caprylic alcohol; n-Octyl alcohol; Heptyl carbinol; 1-Hydroxyoctane; Primary octyl alcohol; Alcohol C-8; n-Octan-1-ol; Octilin; Sipol L8; Alfol 8; Lorol 20; Dytol M-83; n-Caprylic alcohol; 1-Octyl alcohol; n-Heptyl carbinol; EPAL 8; octyl-alcohol; Alcohols, C6-12; N-octyl-alcohol; Octyl alcohol, normal-primary; C8 alcohol; Fatty alcohol(C8); Octyl alcohol, primary; Caswell No. 611A; Octyl alcohol (natural); FEMA Number 2800; Lorol C 8-98; n-Capryl alcohol"	957	C8H18O	Investigative
M6APDG00577	2-(p-Methylsulfonylbenzoyl)furan	2-(p-Methylsulfonylbenzoyl)furan; CHEMBL1240887; SCHEMBL7814046; BDBM50326535	12701751	C12H10O4S	Investigative
M6APDG02566	ZK 304709	ZK 304709; 1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701	59733314	C22H29ClN6O2	Discontinued in Phase 1
M6APDG02363	Palbociclib	"571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE;  LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934"	5330286	C24H29N7O2	Approved
M6APDG02142	Terameprocol	"EM-1421; Terameprocol (INN/USAN); Meso-Tetra-O-methylnordihydroguaiaretic acid; Meso-Tetramethoxy-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol; Meso-1,4-Bis-(3,4-dimethoxyphenyl)-2,3-dimethylbutane; 4-[(2S,3R)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene"	476861	C22H30O4	Phase 2
M6APDG01316	CL-387785	"cl-387785; 194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide"	2776	C18H13BrN4O	Investigative
M6APDG00680	2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one	.	135471356	C14H11N3O2	Investigative
M6APDG00436	C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2	CHEMBL425591; BDBM50184356	11672424	C47H59N13O7	Investigative
M6APDG03773	ISIS 32014	.	.	.	Investigative
M6APDG01045	1-(4-(methylsulfonyl)phenyl)-1H-pyrrole	CHEMBL1240963; 1-(4-(methylsulfonyl)phenyl)-1H-pyrrole; 1-[4-(Methylsulfonyl)phenyl]-1H-pyrrole; ZINC35120168; BDBM50326521; AKOS008961779; 1-(4-methanesulfonylphenyl)-1H-pyrrole	22316981	C11H11NO2S	Investigative
M6APDG00483	"N4-(3-chlorophenyl)quinazoline-4,6-diamine"	"CHEMBL343352; Anilinoquinazoline, 4c; N4-(3-chlorophenyl)quinazoline-4,6-diamine; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline"	11807783	C14H11ClN4	Investigative
M6APDG01419	GW7647	GW-7647; GW 7647	3392731	C29H46N2O3S	Investigative
M6APDG04332	TV-1390	"Multiple sclerosis therapy, Teva Pharmaceuticals"	.	.	Preclinical
M6APDG01801	1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea	CHEMBL397745; 1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea	44430622	C10H12N4S2	Investigative
M6APDG00157	PHA-665752	"PHA-665752; 477575-56-7; PHA 665752; PHA665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate"	10461815	C32H34Cl2N4O4S	Investigative
M6APDG03828	ARQ-171	"ARQ-550RP; ARQ-580; E2F modulators (anticancer); E2F modulators (anticancer), ArQule; 550 series (E2F modulators), Arqule; 550 series (anticancer), Arqule; 550 series, Arqule"	.	.	Phase 1
M6APDG00305	7-Mercapto-heptanoic acid phenylamide	7-Mercapto-heptanoic acid phenylamide; Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692	11379392	C13H19NOS	Investigative
M6APDG01447	aloisine	IN1538; RP106	3641059	C17H19N3O	Investigative
M6APDG00894	SB-1578	.	16750271	C26H30N4O4	Phase 1
M6APDG03163	GW-406381	"GW 406381; GW406381; 8-(4-ethoxyphenyl)-7-(4-methylsulfonylphenyl)-1,2,9-triazabicyclo[4.3.0]nona-2,4,6,8-tetraene"	9832687	C21H19N3O3S	Discontinued in Phase 3
M6APDG01821	N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	"CHEMBL252674; N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide; 2H-1-Benzopyran-3-propanamide, N-hydroxy-2-oxo-; BDBM50224963"	44446270	C12H11NO4	Investigative
M6APDG02867	BIBX-1382	"Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; BIBX-1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047"	6918508	C18H19ClFN7	Phase 1
M6APDG02230	APIGENIN	"apigenin; 520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di"	5280443	C15H10O5	Investigative
M6APDG02250	DIOSMETIN	"Diosmetin; 520-34-3; Luteolin 4'-methyl ether; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; Salinigricoflavonol; 4'-Methylluteolin; 5,7,3'-Trihydroxy-4'-methoxyflavone; UNII-TWZ37241OT; Luteolin 4-methyl ether; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3',5,7-trihydroxy-4'-methoxyflavone; CHEBI:4630; TWZ37241OT; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-; MFCD00017425; AK111246"	5281612	C16H12O6	Investigative
M6APDG02514	(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol; YC-1	5712	C19H16N2O2	Investigative
M6APDG00152	"6,7-Dimethoxy-3-pyridin-3-yl-quinoline"	"CHEMBL304668; 6,7-dimethoxy-3-pyridin-3-yl-quinoline; SCHEMBL8170900; KYJQMVJJOORKLO-UHFFFAOYSA-N; ZINC3832247; BDBM50039050; 3-(6,7-dimethoxyquinolin-3-yl)pyridine; 6,7-dimethoxy-3-(3-pyridinyl)quinoline"	10445611	C16H14N2O2	Investigative
M6APDG03053	DS-437	DS437	91827358	C15H23N7O4S	Investigative
M6APDG04109	WT1 peptide vaccine	"WT1 peptide vaccine (cancer); WT1 peptide vaccine (cancer), Charity Medical School of the Humboldt University of Berlin; Cancer vaccine (Wilms tumor gene 1 + KLH + GM-CSF advuvants), Humboldt University of Berlin"	.	.	Phase 2
M6APDG01758	"6,11-dihydrothiochromeno[4,3-b]indol-8-ol"	"CHEMBL210924; 6,11-dihydrothiochromeno[4,3-b]indol-8-ol; SCHEMBL1986592; BVGUKMAMOJMOFD-UHFFFAOYSA-N; BDBM50185203"	44411868	C15H11NOS	Investigative
M6APDG01381	3-(4-dimethylamino-benzylidenyl)-2-indolinone	"dmbi; 3-(4-Dimethylaminobenzylidenyl)-2-indolinone; CHEMBL296455; (Z)-3-[4-(Dimethylamino)benzylidenyl]indolin-2-one; 3-[4-(dimethylamino)benzylidene]-1,3-dihydro-2H-indol-2-one; SU-4312; Tocris-1459; trans-SU 4312; AC1NS4CN; Lopac-S-8567; AC1Q6J0Q; SCHEMBL644678; GTPL5958; SCHEMBL13394695; ZINC21786; MolPort-019-728-327; MolPort-002-894-447; 3-[[(4-Dimethyl-amino)phenyl]methylene]-1,3-dihydro-2H-indol-2-one, E/Z mixture; HMS3229C19; HSCI1_000057; MFCD00118147; BDBM50111603; AKOS001034409; CCG-206747; NCGC00025170-01"	3135	C17H16N2O	Investigative
M6APDG00594	SRI-62-834	"CRC-8605; Rac-2-[Hydroxy[2-(octadecyloxymethyl)tetrahydrofuran-2-ylmethoxy]phosphinyloxy]-N,N,N-trimethylethylamminium hydroxyde,inner salt P-oxide"	130724	C29H60NO6P	Discontinued in Phase 2
M6APDG02783	CGK733	"CGK733; 905973-89-9; CGK 733; CGK-733; 2,2-Diphenyl-N-(2,2,2-trichloro-1-(3-(4-fluoro-3-nitrophenyl)thioureido)ethyl)acetamide; CHEMBL1221601; 2,2-Diphenyl-n-(2,2,2-trichloro-1-[3-(4-fluoro-3-nitrophenyl)thioureido]ethyl)acetamide; UNII-L3DGZ99QYM; 2,2-diphenyl-N-(2,2,2-trichloro-1-{[(4-fluoro-3-nitrophenyl)carbamothioyl]amino}ethyl)acetamide; 2,2-diphenyl-N-[2,2,2-trichloro-1-[(4-fluoro-3-nitrophenyl)carbamothioylamino]ethyl]acetamide; L3DGZ99QYM"	6605258	C23H18Cl3FN4O3S	Investigative
M6APDG00449	N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide	CHEMBL198563; N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide	11703439	C21H16F3NO2	Investigative
M6APDG01952	"8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-"	"8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-; CHEMBL326564; PU6; 8-(1,3-benzodioxol-5-ylmethyl)-9-butyl-9H-purin-6-amine; 1uy9; Purine-Based Inhibitor 4; AC1L9MK7; BDBM15377; DB08436; 8-(1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine; 8-(2H-1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine; 8-(1,3-Benzodioxole-5-ylmethyl)-9-butyl-9H-purine-6-amine"	448968	C17H19N5O2	Investigative
M6APDG03208	FK-614	"ATx08-001; ATx08-001); PPAR gamma agonist (oral, neuropathic pain), Aestus"	9869229	C21H23Cl2N3O3S	Phase 2
M6APDG00880	1-guanidino-N-phenyl-7-isoquinolinesulphonamide	SCHEMBL6435184; CHEMBL227781; BDBM16131; NNEJXIJKGKRBBF-UHFFFAOYSA-N; 1-guanidino-7-sulfonamidoisoquinoline 5; 1-guanidino-7-phenylsulphamoylisoquinoline	16658631	C16H15N5O2S	Investigative
M6APDG03340	Venetoclax	.	49846579	C45H50ClN7O7S	Approved
M6APDG01256	3-Ethynylquinoline-8-carboxamide	"CHEMBL501330; 3-Ethynylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-ethynyl-; BDBM50255268"	25208746	C12H8N2O	Investigative
M6APDG02865	Imisopasem manganese	"KM-4403; M-40403; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis); Imisopasem manganese (dermatological,psoriasis/atopic dermatitis), ActivBiotics; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis), Metaphore; M-40403 (dermatological, psoriasis/atopic dermatitis), Metaphore"	6918487	C21H35Cl2MnN5	Phase 2
M6APDG03383	ISIS 1570	.	.	.	Approved
M6APDG00300	9-Benzyl-6-phenylsulfanyl-9H-purine	SCHEMBL6662063	11347708	C18H14N4S	Investigative
M6APDG01690	AdcAhxArg4NH(CH2)6NH2	CHEMBL263964	44387500	C46H84N24O9	Investigative
M6APDG03173	CCT-018159	"CCT 018159; CCT018159; (6Z)-6-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1,2-dihydropyrazol-3-ylidene]-4-ethyl-3-hydroxycyclohexa-2,4-dien-1-one; 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethylbenzene-1,3-diol"	984170	C20H20N2O4	Preclinical
M6APDG00228	"3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione"	"1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388"	10946795	C18H15NO4	Investigative
M6APDG01552	Varlitinib	"VARLITINIB; 845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine"	42642648	C22H19ClN6O2S	Phase 2/3
M6APDG02518	ZM-336372	ZM 336372; 208260-29-1; ZM336372; ZM-336372; 3-(dimethylamino)-N-(3-(4-hydroxybenzamido)-4-methylphenyl)benzamide; N-[5-(3-Dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide; CHEMBL186526; n-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide; 3-(dimethylamino)-N-{3-[(4-hydroxybenzoyl)amino]-4-methylphenyl}benzamide; 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]benzamide; 3-(dimethylamino)-N-[3-(4-hydroxybenzamido)-4-methylphenyl]benzamide; Bio1_001346; compound 1 [PMID: 15454231	5730	C23H23N3O3	Investigative
M6APDG01681	Z-Ala-Leu-Nal-Agly-Ile-Val-OMe	.	44355523	C43H59N7O9	Investigative
M6APDG04296	Olokizumab	.	.	.	Phase 3
M6APDG04158	XL-820	EXEL-9820	.	.	Phase 2
M6APDG03492	ISIS 29202	.	.	.	Investigative
M6APDG03515	MMP-408	"MMP-118; MMP-145; MMP-12 inhibitors (COPD); MMP-12 inhibitors (COPD), Pfizer; MMP-12 inhibitors (COPD), Wyeth"	.	.	Investigative
M6APDG02665	MK-11	"Menaquinone 11; Vitamin MK 11; 19228-10-5; MK-11; menaquinone-11; 2-METHYL-3-[(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-UNDECAMETHYLTETRATETRACONTA-2,6,10,14,18,22,26,30,34,38,42-UNDECAEN-1-YL]NAPHTHALENE-1,4-DIONE; AC1O5WR2; MK11; SCHEMBL14164358; MK 11; ZINC150341901; 2-methyl-3-[(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2,6,10,14,18,22,26,30,34,38,42-undecaenyl]naphthalene-1,4-dione"	6442190	C66H96O2	Investigative
M6APDG00691	7n-Methyl-8-Hydroguanosine-5'-Diphosphate	.	135509116	C11H19N5O11P2	Investigative
M6APDG02063	NS-018	"NS-018; ilginatinib; 1239358-86-1; UNII-56R994WX4L; 56R994WX4L; GTPL7839; SCHEMBL14954406; UQTPDWDAYHAZNT-AWEZNQCLSA-N; NS018; ZINC68245917; HY-19631A; AKOS030526348; DB12784; CS-5358; SB16921; 2,6-Pyridinediamine, N2-((1S)-1-(4-fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-; (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2yl)pyridine-2,6-diamine; (S)-N-(1-(4-Fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-2,6-diamine"	46866319	C21H20FN7	Phase 1/2
M6APDG02257	Wogonin	"Wogonin; 632-85-9; 5,7-Dihydroxy-8-methoxyflavone; Vogonin; Norwogonin 8-methyl ether; UNII-POK93PO28W; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-methoxy-2-phenyl-; BRN 0287152; POK93PO28W; 5,7-dihydroxy-8-methoxy-2-phenyl-4H-chromen-4-one; CHEMBL16171; FLAVONE, 5,7-DIHYDROXY-8-METHOXY-; CHEBI:10043; XLTFNNCXVBYBSX-UHFFFAOYSA-N; 5,7-dihydroxy-8-methoxy-2-phenylchromen-4-one; 5,7-Dihydroxy-8-methoxy-2-phenyl-chromen-4-one; ST077088; Q-100730; 5,7-dihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one"	5281703	C16H12O5	Investigative
M6APDG02049	Prinomastat	"AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide"	466151	C18H21N3O5S2	Approved
M6APDG03552	AMG-JAK2-01	"JAK2 inhibitor (myeloproliferative disorder), Amgen"	.	.	Investigative
M6APDG00673	Meta-sirtinol	.	135461039	C26H22N2O2	Investigative
M6APDG02989	3-Bromo-2'-hydroxy-4-methoxychalcone	AC1ORO2M; CHEMBL492941; MolPort-000-648-211; ZINC5549056; STL192121; AKOS025268524; (E)-3-(3-bromo-4-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one	7729032	C16H13BrO3	Investigative
M6APDG00146	"3-Cyclopentyl-6,7-dimethoxy-quinoline"	"CHEMBL66785; 3-cyclopentyl-6,7-dimethoxy-quinoline; SCHEMBL8801444; ZINC3834044"	10422592	C16H19NO2	Investigative
M6APDG00324	TW-37	"TW-37; 877877-35-5; N-[4-(2-tert-Butylphenylsulfonyl)phenyl]-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; tw 37; CHEMBL217354; N-(4-((2-(tert-butyl)phenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-[4-[(2-tert-Butylphenyl)sulfonyl]phenyl]-2,3,4-trihydroxy-5-[(2-isopropylphenyl)methyl]benzamide; N-(4-((2-Tert-Butylphenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-((2-isopropylphenyl)methyl)benzamide"	11455910	C33H35NO6S	Investigative
M6APDG02496	TP-0903	"YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide"	56839178	C24H30ClN7O2S	Phase 1/2
M6APDG03580	UPA-targeted oncolytic Sendai virus	"BioKnife; RSeV/Fct14(uPA2)dM; UPA-targeted oncolytic Sendai virus, DNAVEC"	.	.	Investigative
M6APDG00838	1-[5-(triphenylmethoxy)pentyl]thymine	"1-[5-(triphenylmethoxy)pentyl]thymine; CHEMBL216997; 921587-92-0; CTK3G1845; DTXSID10582665; BDBM50201001; 5-Methyl-1-[5-(triphenylmethoxy)pentyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[5-(triphenylmethoxy)pentyl]-"	16098859	C29H30N2O3	Investigative
M6APDG02444	Salirasib	"162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-;  FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032"	5469318	C22H30O2S	Phase 2
M6APDG00945	3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol	CHEMBL51638; 3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol; SCHEMBL7076532; JIFLEYNNNKKNOQ-UHFFFAOYSA-N; BDBM50076592; 3-(4-Methoxyphenylsulfonyl)propane-1-thiol	18411961	C10H14O3S2	Investigative
M6APDG03806	BI-853520	.	.	.	Phase 1
M6APDG03968	SYN004	.	.	.	Phase 1
M6APDG01684	4-Bromo-3-hydroxy-1H-quinolin-2-one	"2(1H)-Quinolinone, 4-bromo-3-hydroxy-; CHEMBL146520; SCHEMBL15690621; BSYFERFWIZPSKL-UHFFFAOYSA-N; BDBM247011; 4-Bromo-3-hydroxyquinolin-2(1H)-one; 4-Bromo-3-hydroxyquinoline-2(1H)-one; 176170-14-2; US9701638, 2"	44364603	C9H6BrNO2	Investigative
M6APDG03223	"9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide"	"9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553"	9882812	C15H18F3NO2	Investigative
M6APDG03629	ISIS 298697	.	.	.	Investigative
M6APDG02891	p-nitrophenyl glutamyl anilide	gamma-glutamyl-p-nitroanilide; p-nitrophenyl glutamyl anilide; AC1OF0UB; GTPL4508; (2S)-2-azaniumyl-5-(4-nitroanilino)-5-oxopentanoate	7090494	C11H13N3O5	Investigative
M6APDG03925	Navicixizumab	.	.	.	Phase 1
M6APDG01397	AMP-PNP	"Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; phosphoaminophosphonic acid-adenylate ester; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine; Phosphoaminophosphonic Acid-Adenylate Ester"	33113	C10H17N6O12P3	Investigative
M6APDG03832	CDT-fenofibrate	.	.	.	Phase 1
M6APDG00026	Riccardin C	Riccardin C; Riccardi C; CHEMBL411317; BDBM23839	10070992	C28H24O4	Investigative
M6APDG00411	Aminopyridine deriv. 2	"JNK Inhibitor VIII; TCS JNK 6o; 894804-07-0; aminopyridine deriv. 2; N-(4-Amino-5-cyano-6-ethoxypyridin-2-yl)-2-(2,5-dimethoxyphenyl)acetamide; Kinome_3020; SCHEMBL157014; GTPL5998; CHEMBL210618; BDBM15908; Aminopyridine-Based Inhibitor 6o; CTK8E8164; DTXSID20469650; MolPort-023-276-703; HMS3229K06; IN1283; ZINC14959960; AKOS024457488; CCG-206859; NCGC00387087-01; RT-013406; B7321"	11624601	C18H20N4O4	Investigative
M6APDG02107	"N,8-diphenyl-9H-purin-6-amine"	"CHEMBL1210175; N,8-diphenyl-9H-purin-6-amine; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492"	46894037	C17H13N5	Investigative
M6APDG00095	PIK-75	PIK75; PIK 75; imidazopyridine derivative 8c [PMID 17601739]	10275789	C16H14BrN5O4S	Investigative
M6APDG01946	Niflumic Acid	"Actol; Donalgin; Flunir; Forenol; Landruma; NFL; Niflactol; Niflam; Niflugel; Niflumate; Nifluril; Acide niflumique; Acide niflumique [French]; Acido niflumico; Acido niflumico [Italian]; Acidum niflumicum; Nifluminic acid; UPSA Conseil Brand of Niflumic Acid; Upsamedica Brand of Niflumic Acid; N 0630; SC 1332; UP 83; UPSA Brand 1 of Niflumic Acid; UPSA Brand 2 of Niflumic Acid; Acid, Niflumic; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; Niflugel (TN); Niflumic acid (INN); Niflumic acid [INN:DCF]; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; 2-(A,A,A-Trifluoro-m-toluidino)nicotinic acid; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 39690A"	4488	C13H9F3N2O2	Approved
M6APDG03116	6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole	CHEMBL67196	9797585	C21H18N2O2	Investigative
M6APDG02961	Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2	.	73347136	C49H63FN10O9	Investigative
M6APDG01214	(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol	CHEMBL594669; (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol; SCHEMBL4442909	25069592	C16H17N5O2	Investigative
M6APDG03829	OMP-18R5	"Vantictumab; Wnt inhibitors (mAb, cancer), OncoMed Pharmaceuticals"	.	.	Phase 1
M6APDG01787	Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)	CHEMBL436536; cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)	44418888	C37H49N11O6	Investigative
M6APDG00742	3-Fluoren-9-ylidenemethyl-pyridine	3-(9h-fluoren-9-ylidenemethyl)pyridine; 3-(fluoren-9-ylidenemethyl)pyridine; 3239-00-7; NSC83320; AC1Q4YVX; AC1L5UM9; NCIOpen2_004633; CHEMBL194928; BDBM8637; SCHEMBL8276088; CTK1C4120; (3-Pyridylmethylene)fluorene 32; DTXSID10292510; NSC-83320; ZINC13283158; AKOS030540073; 3-(9H-Fluorene-9-ylidenemethyl)pyridine	139138079	C38H26N2	Investigative
M6APDG02874	MCL0129	MCL-0129; TCMDC-134847	6918688	C34H47FN4O	Investigative
M6APDG04090	CEQ-508	"CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina"	.	.	Phase 1/2
M6APDG02930	Prifelone	"Prifelone; Prifelonum [INN-Latin]; Prifelone [USAN:INN]; Prifelona [INN-Spanish]; R-830; S-16820; UNII-0414BW860U; R-830T; BRN 3620438; CHEMBL8846; 69425-13-4; R 830; 3,5-Di-tert-butyl-4-hydroxyphenyl 2-thienyl ketone; 0414BW860U; (3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl)-2-thienylmethanone; Prifelonum; Prifelona; Methanone, (3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-2-thienyl-; Butafen; C19H24O2S; Prifelone (USAN/INN); AC1L2GQY; SCHEMBL42678; 5-18-02-00065 (Beilstein Handbook Reference); ZINC1977; DTXSID90219583; BDBM50012780"	71751	C19H24O2S	Investigative
M6APDG04078	Beclanorsen	"SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris"	.	.	Phase 1/2
M6APDG03623	ALD-805	.	.	.	Investigative
M6APDG00656	7-Methyl-Guanosine-5'-Triphosphate	.	135419182	C11H19N5O14P3+	Investigative
M6APDG04350	KRH-2731	.	.	.	Terminated
M6APDG03644	ISIS 11159	.	.	.	Investigative
M6APDG00067	6-isobutyl-4-methylpyridin-2-amine	"CHEMBL294609; 6-isobutyl-4-methylpyridin-2-amine; SCHEMBL7052362; VMTPVCVORKDABN-UHFFFAOYSA-N; BDBM50091801; 2-Amino-4-methyl-6-isobutylpyridine; 6-Isobutyl-4-methyl-pyridin-2-ylamine; 179555-28-3; 2-amino-4-methyl-6-(2-methylpropyl)pyridine; 2-Pyridinamine, 4-methyl-6-(2-methylpropyl)-"	10197851	C10H16N2	Investigative
M6APDG00543	Gallopamil	"16662-47-8; methoxyverapamil; 5-((3,4-Dimethoxyphenethyl)(methyl)amino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)pentanenitrile; Galopamilo; Galopamilo [INN-Spanish]; Gallopamillum [INN-Latin]; Gallopamil [INN:BAN]; D600; D 600; C28H40N2O5; CHEBI:34772; (+/-)-Methoxyverapamil hydrochloride; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4,5-trimethoxy-alpha-(1-methylethyl)-; Methoxyverapamil; GSK 796406"	1234	C28H40N2O5	Phase 2
M6APDG02792	Tazemetostat	"EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-"	66558664	C34H44N4O4	Approved
M6APDG01954	PMID18163548C4	"7IN; 1vja; AC1L9MNX; GTPL6545; BDBM50231520; US8476306, 6.12"	449051	C21H27N5O6S	Clinical trial
M6APDG03300	AD-5061	AD-7057; AD7057; AD 7057; AD5061; AD 5061	9953271	C22H20N2O4S	Investigative
M6APDG02422	TT-301	"Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics"	54576073	C23H21N7	Phase 1
M6APDG01002	Norleucine	"L-Norleucine; 327-57-1; H-Nle-OH; NORLEUCINE; (S)-2-Aminohexanoic acid; Glycoleucine; Caprine; L-(+)-Norleucine; L-2-Aminohexanoic acid; 2-Aminocaproic acid; L-2-Aminohexanoate; L-Aminohexanoate; alpha-Aminocaproic acid; (2S)-2-aminohexanoic acid; (S)-(+)-2-Aminohexanoic acid; Norleucine (VAN); L-Aminohexanoic acid; Hexanoic acid, 2-amino-, (S)-; 2S-amino-hexanoic acid; (S)-2-Aminocaproic acid; (S)-Norleucine; NSC 10378; L(+)-Norleucine; UNII-832C8OV84S; EINECS 206-321-4; BRN 1721750; NLE; CHEBI:18347; LRQKBLKVPFOOQJ-YFKPBYRVSA-N"	21236	C6H13NO2	Phase 1/2
M6APDG00703	ischemin	MS120	135566302	C15H17N3O4S	Investigative
M6APDG03837	LYS-6KAKT1	.	.	.	Phase 1
M6APDG01595	MK-2461	MK 2461	44137946	C24H25N5O5S	Phase 1/2
M6APDG00831	GSK-9772	"GSK-9772; CHEMBL493241; 928035-84-1; GSK9772; 4-[[Butyl[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]amino]methyl]-2,6-dichlorophenol; 4-[(Butyl{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}amino)methyl]-2,6-dichlorophenol; SCHEMBL4629551; GTPL8693; GSK 9772; BDBM50252940; ZINC34946707; KB-71932"	16049480	C20H19Cl2F6NO2	Investigative
M6APDG01434	"2-Amino-N,3,3-Trimethylbutanamide"	"2-AMINO-N,3,3-TRIMETHYLBUTANAMIDE; AC1MRP6C; SCHEMBL343358; DTXSID30393038; BPKJNEIOHOEWLO-UHFFFAOYSA-N; 2-amino-N,3,3-trimethyl-butanamide; 2-azanyl-N,3,3-trimethyl-butanamide; AKOS022475747; AN-25241"	3496445	C7H16N2O	Investigative
M6APDG00730	2'-Deoxyuridine	"2'-DEOXYURIDINE; 951-78-0; deoxyuridine; Uracil deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 2-Deoxyuridine; Deoxyribose uracil; 2'-Desoxyuridine; UNII-W78I7AY22C; CCRIS 2832; dURD; EINECS 213-455-7; BRN 0024433; 1-(2-Deoxy-beta-D-ribofuranosyl)uracil; W78I7AY22C; CHEBI:16450; 2 -Deoxyuridine; 1-(2-Deoxy-beta-D-erythro-pentofuranoxyl)uracil; MFCD00006527; AK-54658; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-; NSC 23615; DEOXYURIDINE"	13712	C9H12N2O5	Investigative
M6APDG00952	6-Hydroxypropylthymine	"6-hydroxypropylthymine; 6-(3-hydroxypropyl)thymine; 6-(3-hydroxypropyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 6-(3-hydroxypropyl)-5-methyl-; 156569-47-0; AC1L1CEO; SCHEMBL4315838; CHEBI:43299; CTK8A4001; DB04139"	1865	C8H12N2O3	Investigative
M6APDG03148	andarine	GTX007; GTX-007	9824562	C19H18F3N3O6	Investigative
M6APDG00156	Volasertib	"Volasertib; 755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947"	10461508	C34H50N8O3	Phase 3
M6APDG00500	3-(imidazolylmethyl)-4'-methoxyflavone	CHEMBL212473; BDBM50191600; 3-(imidazolylmethyl)-4''-methoxyflavone	11847320	C20H16N2O3	Investigative
M6APDG04224	MM-141	.	.	.	Phase 2
M6APDG04106	COVA322	.	.	.	Phase 1/2a
M6APDG03423	AVE-1642	"EM-164; Anti-IGF-1 receptor antibody (cancer), Aventis; Anti-IGF-1 receptor antibody (cancer), ImmunoGen; Anti-insulin-like growth factor-1 receptor antibody, Aventis; Anti-insulin-like growth factor-1 receptor antibody, ImmunoGen; Anti-IGF-1 receptor antibody (cancer), sanofi-aventis; Anti-insulin-like growthfactor-1 receptor antibody, sanofi-aventis"	.	.	Discontinued in Phase 2
M6APDG02004	Olomoucine	"olomoucine; 101622-51-9; 4erk; UNII-6A839B2HYS; 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6A839B2HYS; CHEMBL280074; 2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol; 6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; Ethanol,2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-; OLO; 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6-Benylamino-2-(2-hydroxyethylamino)-9-methylpurine"	4592	C15H18N6O	Terminated
M6APDG01602	4-(isopropylthio)-2-methoxybenzonitrile	CHEMBL445429; 4-(isopropylthio)-2-methoxybenzonitrile	44157042	C11H13NOS	Investigative
M6APDG01620	KH-CB19	KH CB19	44237094	C15H13Cl2N3O2	Investigative
M6APDG03489	MR-20814	.	.	.	Investigative
M6APDG02556	(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one	"oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one; Oxindole I"	5908088	C13H10N2O	Investigative
M6APDG02912	WO2013026806C72 	EHT 5372; compound 8c [PMID 25264830]; GTPL8166; BDBM50434338	71529770	C17H12ClN5OS	Investigative
M6APDG04223	AMG 479	.	.	.	Phase 2
M6APDG02260	"(E)-4-(3,5-dimethoxystyryl)phenol"	"Pterostilbene; 537-42-8; 4-(3,5-Dimethoxystyryl)phenol; 3',5'-Dimethoxy-4-stilbenol; trans-pterostilbene; 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; pterostilben; 4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]phenol; UNII-26R60S6A5I; 3,5-Dimethoxy-4'-hydroxy-trans-stilbene; 3,5-Dimethoxy-4'-hydroxystilbene; 18259-15-9; trans-3,5-dimethoxy-4'-hydroxystilbene; CHEMBL83527; CHEBI:8630; VLEUZFDZJKSGMX-ONEGZZNKSA-N; 4-((E)-2-(3,5-dimethoxyphenyl)ethenyl)phenol; 26R60S6A5I; Pterostilbene, Pterocarpus; pterostilbene"	5281727	C16H16O3	Investigative
M6APDG02662	2-chloro-5-nitro-N-phenylbenzamide	"2-Chloro-5-nitro-N-phenylbenzamide; GW9662; 22978-25-2; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; benzamide, 2-chloro-5-nitro-N-phenyl-; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Tocris-1508; Spectrum5_001989; Lopac-M-6191; AC1LD8S0; DSSTox_RID_79570; DSSTox_CID_20723; DSSTox_GSID_40723; Lopac0_000798; KBioGR_000361; KBioSS_000361; BSPBio_001021; SCHEMBL420231; CHEMBL375270; GTPL3442; cid_644213"	644213	C13H9ClN2O3	Investigative
M6APDG03399	Opterone	SEPA testosterone cream	.	.	Discontinued in Phase 1
M6APDG01088	8-O-(4-chlorobenzenesulfonyl)manzamine F	CHEMBL400717; 8-O-(4-chlorobenzenesulfonyl)manzamine F	23643731	C42H47ClN4O5S	Investigative
M6APDG00814	Hombreol	"Dihydroandrosterone; Etiocholane-3alpha,17beta-diol; Hombreol; J34MX0M30Y; (3alpha,5alpha,17beta)-androstane-3,17-diol; 1852-53-5; 3alpha androstanediol; 3alpha,17beta-Dihydroxy-5alpha-androstane; 3alpha-androstanediol; 5-alpha-ANDROSTANE-3-alpha,17-beta-DIOL; 5a-Androstane-3a,17b-diol; 5alpha-Androstan-3alpha,17beta-diol; 5alpha-Androstane-3alpha,17beta-androstanediol; 5alpha-Androstane-3alpha,17beta-diol; BRN 2694353; CHEBI:36713; CHEMBL335062; EINECS 217-447-4; MLS000028362; NSC 9899; UNII-J34MX0M30Y"	15818	C19H32O2	Investigative
M6APDG02694	Fenofibric acid	"Fenofibric acid; Procetofenic acid; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid; NSC 281318; Trilipix; alpha 1081; LF 178 acid; UNII-BGF9MN2HU1; LF 153; C17H15ClO4; CCRIS 7302; EINECS 255-626-9; BGF9MN2HU1; CHEMBL981; BRN 2058973; CHEBI:83469; NSC-281318; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid; ABT-335; AK117112; Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-; 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoic acid; FNF Acid; W-106287; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropionic acid; 2-[4-(4-Chloro-benzoyl)-phenoxy]-2-methyl-propionic acid (Fenofibric acid); ABT 335; Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-; feno-fibric acid; Fibricor (TN); Fenofibrate free acid; FENOFIBRIC ACID; SCHEMBL16377; Fenofibrate related compound b; GTPL2662; ZINC1984; DTXSID8041030; BDBM28700; MQOBSOSZFYZQOK-UHFFFAOYSA-N; BCP22437; HY-B0760; KS-00000MR0; Fenofibric acid, analytical standard; LF-153; NSC281318; s4527; AKOS015889489; API0000561; 42017-89-0"	64929	C17H15ClO4	Approved
M6APDG02582	Uridine	"Uracil riboside; Uracil, 1-beta-D-ribofuranosyl-; DRTQHJPVMGBUCF-XVFCMESISA-N; Uracil-1-beta-d-ribofuranoside; Uridin; WHI7HQ7H85; b-Uridine; beta-Uridine; d-uridine; uridine; uridine-1'-13C; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 1-.beta.-D-Ribofuranosyluracil; 1-beta-D-Ribofuranosyluracil; 58-96-8; AI3-52690; C9H12N2O6; CHEBI:16704; EINECS 200-407-5; MFCD00006526; MLS000069625; NSC 20256; SMR000058222; UNII-WHI7HQ7H85; Urd"	6029	C9H12N2O6	Approved
M6APDG02616	Cytidine	"Cytidin; Cytosine riboside; Cytosine, 1-beta-D-ribofuranosyl-; Zytidin; beta-D-Ribofuranoside, cytosine-1; cytidine; 1-beta-D-Ribofuranosylcytosine; 1-beta-Ribofuranosylcytosine; 1beta-2'-Ribofuranosylcytosine, d-; 1beta-Ribofuranosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-beta-D-ribofuranosyl-; 4-Amino-1-beta-D-ribofuranosyl-2(1H)-pyrimidinone; 4-Amino-1beta-D-ribofuranosyl-2(1H)-pyrimidinone; 65-46-3; CHEBI:17562; Cyd; EINECS 200-610-9; MFCD00006545; NSC 20258; UNII-5CSZ8459RP"	6175	C9H13N3O5	Investigative
M6APDG03008	Decanal	"Aldehyde C-10; Aldehyde C10; Capraldehyde; Capric aldehyde; Caprinaldehyde; Caprinic aldehyde; DECALDEHYDE; Decanal; Decanal (natural); Decanaldehyde; Decyl aldehyde; Decyl aldehyde, 95%; Decylic aldehyde; KSMVZQYAVGTKIV-UHFFFAOYSA-N; decylaldehyde; n-DECYLALDEHYDE; n-Decaldehyde; n-Decanal; n-Decyl aldehyde; 1-Decanal; 1-Decanal(mixed isomers); 1-Decyl aldehyde; 112-31-2; 31Z90Q7KQJ; AC1L1QFM; AI3-04860; BRN 1362530; C-10 aldehyde; CHEBI:31457; EINECS 203-957-4; FEMA No. 2362; HSDB 288; MFCD00007031; NSC 6087; NSC6087; UNII-31Z90Q7KQJ"	8175	C10H20O	Investigative
M6APDG02634	All-trans-retinal	"E-Retinal; RR725D715M; Retinal, all-trans-; Retinaldehyde (VAN); Retinene 1; Retinyl aldehyde; TOCOPHEROL, ALPHA; Vitamin A1 aldehyde; all-E-Retinal; all-trans-Retinal; all-trans-Retinaldehyde; all-trans-Retinene; all-trans-Vitamin A aldehyde; axerophthal; retinal; retinaldehyde; retinene; trans-Retinal; trans-Vitamin A aldehyde; vitamin A aldehyde; .alpha.-Retinene; 116-31-4; BRN 1914183; CHEBI:17898; EINECS 204-135-8; MFCD00001550; NCYCYZXNIZJOKI-OVSJKPMPSA-N; NSC 122757; NSC 626581; NSC626581; UNII-RR725D715M"	638015	C20H28O	Investigative
M6APDG02238	Gamma-linolenic acid	"Acide gamolenique [French]; Acido gamolenico [Spanish]; Acidum gamolenicum [Latin]; GAMOLENIC ACID; Gamolenic acid [INN:BAN]; gamma-Linolenic acid; (6,9,12)-linolenic acid; (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid; (Z,Z,Z)-6,9,12-Octadecatrienoic acid; 506-26-3; 6,9,12-Octadecatrienoic acid, (Z,Z,Z)-; 6Z,9Z,12Z-octadecatrienoic acid; 78YC2MAX4O; CCRIS 7668; CHEBI:28661; CHEMBL464982; Ligla; UNII-78YC2MAX4O; all-cis-6,9,12-Octadecatrienoic acid; cis,cis,cis-6,9,12-Octadecatrienoic acid; cis-Delta(6,9,12)-octadecatrienoic acid"	5280933	C18H30O2	Phase 4
M6APDG02232	Icosatrienoic acid	"Bishomo-gamma-linolenic acid; Cis-8,11,14-eicosatrienoic acid; Dihomo-gamma-linolenic acid; Homo-gamma-linolenic acid; Ro 12-1989; cis-8,11,14-Eicosatrienoic Acid; gamma-Homolinolenic acid; (8Z,11Z,14Z)-Icosatrienoic acid; (8Z,11Z,14Z)-icosa-8,11,14-trienoic acid; (Z,Z,Z)-8,11,14-Eicosatrienoic acid; (Z,Z,Z)-8,11,14-Icosatrienoic acid; 1783-84-2; 8,11,14-Eicosatrienoate; 8,11,14-Eicosatrienoic acid; 8,11,14-Icosatrienoate; 8Z,11Z,14Z-eicosatrienoic acid; DGLA; UNII-FC398RK06S; all-cis-8,11,14-Eicosatrienoic acid; cis,cis,cis-8,11,14-Eicosatrienoic acid"	5280581	C20H34O2	Investigative
M6APDG02470	BML3-C01	"Adrenic acid; TWSWSIQAPQLDBP-DOFZRALJSA-N; (7Z,10Z,13Z,16Z)-Docosa-7,10,13,16-tetraenoic acid; 28874-58-0; 7,10,13,16-Docosatetraenoate; 7,10,13,16-Docosatetraenoic acid; 7,10,13,16-Docosatetraenoic acid, (all-Z)-; 7,10,13,16-docosatetraenoic acid, (7Z,10Z,13Z,16Z)-; 7Z,10Z,13Z,16Z-Docosatetraenoic acid; AC1NUZMR; Cis-7,10,13,16-docosatetraenoic acid; BSPBio_001499; CHEBI:53487; CHEMBL1491103; HMS1791K21; HMS1989K21; SCHEMBL19452; all-cis-7,10,13,16-Docosatetraenoic acid; all-cis-docosa-7,10,13,16-tetraenoic acid; cis-7,10,13,16-Docosatetraenoic acid"	5497181	C22H36O2	Investigative
M6APDG01913	Icosapentum	"Eicosapentaenoic acid; Icosapent; Icosapent [INN]; Icosapentaenoic acid; Icosapento; Cis-5,8,11,14,17-eicosapentaenoic acid; Timnodonic acid; (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid; (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid; 10417-94-4; 5,8,11,14,17-EICOSAPENTAENOIC ACID; 5,8,11,14,17-Icosapentaenoic acid; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid; AAN7QOV9EA; C20:5 omega-3; CCRIS 3279; CHEBI:28364; CHEMBL460026; EPA; UNII-AAN7QOV9EA; cis-5,8,11,14,17-Eicosapentaenoic acid"	446284	C20H30O2	Investigative
M6APDG02656	Eicosadienoic acid	"Eicosadienoic acid; HOMO-GAMMA-LINOLEICACID; Homo-gamma-linoleic acid; Icosadienoic acid; SCHEMBL416181; cis-11,14-Eicosadienoic acid; cis-11,14-eicosadienoicacid; (11Z,14Z)-Eicosa-11,14-dienoic acid; (11Z,14Z)-Icosa-11,14-dienoic acid; (11Z,14Z)-icosadienoic acid; 11, 14-icosadienoate; 11, 14-icosadienoic acid; 11,14-Eicosadienoate; 11,14-Eicosadienoic acid, (Z,Z)-; 11,14-Icosadienoic acid; 11C,14C-Eicosadienoic acid; 11Z,14Z-eicosadienoic acid; 2091-39-6; 5598-38-9; AC1O5SJA; BSPBio_001326; CHEBI:73731; CHEMBL464983; FA 20:2"	6439848	C20H36O2	Investigative
M6APDG01081	HSDB-3466	"BERGAPTAN; Bergapten; Bergaptene (DCF); Heraclin; Majudin; O-Methylbergaptol; Pentaderm; Psoraderm; bergaptene; 4-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 4-Methoxy-7H-furo[3,2-g]chromen-7-one; 4-Methoxyfuro[3,2-g]benzopyran-7-one; 4-methoxyfuro[3,2-g]chromen-7-one; 484-20-8; 5-Methoxy psoralen; 5-Methoxy-6,7-furanocoumarin; 5-Methoxyfuranocoumarin; 5-Methoxypsoralen; 5-Mop; 5-methoxypsoralene; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-methoxy-; CCRIS 4348; HSDB 3466; NSC 95437; UNII-4FVK84C92X"	2355	C12H8O4	Phase 3
M6APDG02838	LAS-17177	Blaston; Cidine; Cinitaprida; Cinitaprida [INN-Spanish]; Cinitapride; Cinitapride (INN); Cinitapride [INN]; Cinitapride hydrogen tartrate; Cinitapridum; Cinitapridum [INN-Latin]; Cinmove; Cintapro; Paxapride; Paxapride (TN); R8I97I2L24; SCHEMBL476454; cinitapride tartrate; (non-labelled)Cinitapride-d5; 4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide; 66564-14-5; AC1L2AM4; AC1Q1YMD; AKOS015909742; BCP04096; C21H30N4O4; CHEBI:135642; CHEMBL2104523; DB08810; SCHEMBL19235643; UNII-R8I97I2L24; cidin	68867	C21H30N4O4	Phase 3
M6APDG03324	BNP-1350	"Cositecan; Cositecan (USAN); Cositecan [USAN:INN]; Karenitecin; Karenitecin (TN); POADTFBBIXOWFJ-VWLOTQADSA-N; SCHEMBL2315201; Z-3161; ZINC169746728; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-(2-trimethylsilyl)ethyl)-, (4S)-; 203923-89-1; 24R60NVC41; 7-Trimethylsilylethylcamptothecin; 923K891; AC1L3WN8; AN-29989; BNP 1350; BNP-1350; BNP1350; CHEMBL1997373; CS-0003573; D09327; DB 172; DB05806; DTXSID90174340; HY-14812; NCI60_038797; NSC-710270; NSC710270; UNII-24R60NVC41"	148202	C25H28N2O4Si	Phase 3
M6APDG02288	LAU-7b	"FENRETINIDE; Fenretinida; Fenretinida [Spanish]; Fenretinide [USAN:INN]; Fenretinidum; Fenretinidum [Latin]; McN-R-1967; N-(4-Hydroxyphenyl)retinamide; Retinamide, N-(4-hydroxyphenyl)-; Retinoic acid p-hydroxyanilide; all-trans-4'-Hydroxyretinanilide; 15-[(4-hydroxyphenyl)amino]retinal; 4-(hydroxyphenyl)retinamide; 4-HPR; 4-Hydroxyphenyl retinamide; 4-hydroxy(phenyl)retinamide; 4-hydroxyphenylretinamide; 4HPR; 65646-68-6; CCRIS 3260; N-(4-Hydroxyphenyl)all-Trans Retinamide; Retinoic acid p-hydroxyphenylamide; UNII-187EJ7QEXL"	5288209	C26H33NO2	Phase 3
M6APDG02176	LY-2484595	"Evacetrapib; Evacetrapib (LY2484595); Evacetrapib (USAN); Evacetrapib [USAN:INN]; IHIUGIVXARLYHP-YBXDKENTSA-N; LY 2484595; LY-2484595; LY2484595; SCHEMBL108367; SCHEMBL108602; SCHEMBL141340; Tube726; evacetrapib-ly2484595; (1S,4r)-4-(((S)-5-((3,5-bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino)-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)methyl)cyclohexanecarboxylic acid; 1186486-62-3; 51XWV9K850; AK172427; C31H36F6N6O2; CHEMBL2017179; EX-A621; GTPL8401; HMS3651J12; KS-000007CQ; UNII-51XWV9K850"	49836058	C31H36F6N6O2	Phase 3
M6APDG02860	EMD-128130	"Sarizotan; Sarizotan [INN]; ZINC21067; (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman; (r)-(+)-2-[5-(4-fluorphenyl)-3-pyridylmethylaminomethyl]-chromane; 1-(5-(4-Fluorophenyl)pyridin-3-yl)-N-((2R)-3,4,4a,8a-tetrahydro-2H-chromen-2-ylmethyl)methanamine; 3-Pyridinemethanamine, 5-(4-fluorophenyl)-N-(((2R)-3,4,4a,8a-tetrahydro-2H-1-benzopyran-2-yl)methyl)-; 351862-32-3; 467LU0UCUW; AC1OCFD8; ACM177975085; BDBM50027256; CHEMBL220808; HKFMQJUJWSFOLY-OAQYLSRUSA-N; SCHEMBL120080; UNII-467LU0UCUW"	6918388	C22H21FN2O	Phase 2/3
M6APDG00279	TAK-652	"Cenicriviroc; Cenicriviroc (USAN/INN); SB16976; SCHEMBL3157748; SCHEMBL3157768; TAK-652; TAK652; TBR-652; TBR652; 1-Benzazocine-5-carboxamide, 8-[4-(2-butoxyethoxy)phenyl]-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-[4-[[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (5E)-; 15C116UA4Y; 497223-25-3; AS-35184; BDBM50422828; CHEMBL2110727; CS-6148; D09878; DB11758; EX-A1608; HY-14882; MFCD28502076; UNII-15C116UA4Y; UNII-15C116UA4Y component PNDKCRDVVKJPKG-WHERJAGFSA-N"	11285792	C41H52N4O4S	Phase 2
M6APDG03043	GSK-1278863	"Daprodustat; Daprodustat (GSK1278863); Daprodustat (JAN/USAN/INN); Daprodustat [USAN:INN]; Daprodustat(GSK1278863); JVR38ZM64B; ZINC231226004; 2-[(1,3-dicyclohexyl-2,4,6-trioxo-1,3-diazinan-5-yl)formamido]acetic acid; 960539-70-2; AKOS027439964; BCP16766; CHEMBL3544988; EX-A1121; GSK 1278863; GSK-1278863; GSK1278863; GTPL8455; KS-00000M8Z; MFCD29924726; N-((1,3-Dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl)carbonyl)glycine; UNII-JVR38ZM64B; s8171"	91617630	C19H27N3O6	Phase 2
M6APDG03341	YP-005	"D-erythro-Sphingosine-1-phosphate; D-erythro-sphingosine 1-phosphate; DUYSYHSSBDVJSM-KRWOKUGFSA-N; Sphing-4-enine 1-phosphate; Sphing-4-enine-1-phosphate; Sphingosine 1-phosphate; Sphingosine 1-phosphic acid; YVE187NJ1U; sphingosine-1-phosphate; (2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate; 26993-30-6; 4-Octadecene-1,3-diol, 2-amino-, 1-(dihydrogen phosphate), (2S,3R,4E)-; C18-Sphingosine 1-phosphate; CHEBI:37550; CHEMBL225155; S1P; UNII-YVE187NJ1U"	5283560	C18H38NO5P	Phase 1
M6APDG03018	AZD-9496	"AZD-9496; AZD-9496 maleate; AZD9496; DA9P7LN909; DFBDRVGWBHBJNR-BBNFHIFMSA-N; (E)-3-(3,5-Difluoro-4-((1r,3r)-2-(2-Fluoro-2- Methylpropyl)-3-Methyl-2,3,4,9-Tetrahydro-1h-Pyrido(3,4-B)indol-1-Yl)phenyl)acrylic Acid; (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid; 1639042-08-2; CHEMBL3623004; UNII-DA9P7LN909"	86287635	C25H25F3N2O2	Phase 1
M6APDG00559	H3B-6545	EX-A2942; H3B-6545; HY-112596;2052130-80-8; CS-0047714;  SCHEMBL18261010	124091040	C30H29F4N5O2	Phase 1
M6APDG02595	Bromfenac	"BromSite; Bromday; Bromfenac; Bromfenac (INN); Bromfenac [INN]; Bromfenaco; Bromfenaco [Spanish]; Bromfenacum; Bromfenacum [Latin]; Duract; ISV-303; Prolensa; Xibrom; 120638-55-3; 2-(2-Amino-3-(4-bromobenzoyl)phenyl)acetic acid; 2-Amino-3-(4-bromobenzoyl)benzeneacetic acid; 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid; 4mjq; 864P0921DW; 91714-94-2; AHR 10282; AHR-10282; AHR-10282B; AK-85648; Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-; C15H12BrNO3; CHEBI:240107; UNII-864P0921DW; [2-amino-3-(4-bromobenzoyl)phenyl]acetic acid"	60726	C15H12BrNO3	Approved
M6APDG00558	Desloratadine	"Denosin; Descarboethoxyloratadine; Descarboethoxyoratidine; Desloratadine; Desloratidine; FVF865388R; JAUOIFJMECXRGI-UHFFFAOYSA-N; Aerius; Azomyr; Clarinex; Clarinex RediTabs; Neoclarityn; Sch 34117; Sch-34117; 100643-71-8; 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; CHEBI:291342; CHEMBL1172; MFCD00871949; MLS000559042; UNII-FVF865388R"	124087	C19H19ClN2	Approved
M6APDG02525	Zopiclone	"Zimovane; Zopiclona; Zopiclona [INN-Spanish]; Zopiclone [BAN:INN:JAN]; Zopiclonum; Zopiclonum [INN-Latin]; Amoban; Amovane; Imovane; RP 27267; RP-27267; Ximovan; zopiclone; (+-)-Zopiclone; 43200-80-2; 6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; BRN 0768704; C17H17ClN6O3; EINECS 256-138-9; MLS000083579; [6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate"	5735	C17H17ClN6O3	Phase 4
M6APDG01439	Zidovudine	"Zidovudina [Spanish]; Zidovudinum; Zidovudinum [Latin]; Azidothymidine; Compound S; Retrovir; Thymidine, 3'-azido-3'-deoxy-; ZIDOVUDINE [AZT]; zidovudin; zidovudine; 3'-Azido-3'-deoxythymidine; 3'-Azido-3'-deoxythymidine (AIDS); 3'-Deoxy-3'-azidothymidine; 30516-87-1; 4B9XT59T7S; AZT; Aztec; BW A509U; BW-A 509U; BW-A-509U; BW-A509U; BWA509U; CCRIS 105; CHEMBL129; DRG-0004; HSDB 6515; MFCD00006536; MLS000028548; NSC 602670; UNII-4B9XT59T7S; ZDV"	35370	C10H13N5O4	Approved
M6APDG02516	Zafirlukast	"Zafirlukast (Accolate); Aeronix; Olmoran; Vanticon; XZ629S5L50; zafirlukast; 107753-78-6; Accolate; Accoleit; C31H33N3O6S; CHEBI:10100; CHEMBL603; CPD000466316; Cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl)carbamate; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; DSSTox_CID_3746; DSSTox_GSID_23746; DSSTox_RID_77181; ICI 204,219; ICI 204219; ICI-204219; MFCD00864775; NCGC00164547-01; NCGC00164547-06; UNII-XZ629S5L50"	5717	C31H33N3O6S	Approved
M6APDG00860	Warfarin sodium	"Warcoumin; Warfarin sodium; Warfarin sodium [USP]; Warfarin sodium salt; Warfarin, sodium salt; Warfilone; Zoocoumarin sodium salt; Warfarat; Warfarine; Zoocoumarin; mice bait; Warfarin; 81-81-2; Athrombine-K; Brumolin; Coumadin; Coumafen; Coumafene; Coumaphene; Coumarins; Coumefene; D-Con; Dethmor; Dethnel; Frass-Ratron; Kumader; Kumadu; Kumatox; Kypfarin; Maag Rattentod Cum; Mar-Frin; Martin's mar-frin; Maveran; Panwarfin; Prothromadin; Rat &amp; Rat-B-gon; Rat-Gard; Rat-Kill; Rat-Mix; Rat-Ola; Rat-Trol; Rat-a-way; Ratorex; Ratoxin; Ratron; Rats-no-more; Ratten-Koederrohr; Rattentraenke; Rattunal; Ro-Deth; Rodafarin; Rosex; Solfarin; Temus W; Tox-hid; Vampirinip II; Vampirinip iii; (+-)-Warfarin sodium; 129-06-6; Aldocumar; Athrombin; C19H15NaO4; Caswell No. 903A; Coumadan Sodico; Coumadin sodium; Coumadine; Coumafene sodium; Dicusat; EINECS 204-929-4; EPA Pesticide Chemical Code 086003; Jantoven; Marevam; Marevan; Orfarin; Ratsul soluble; Simarc; Sodium 2-oxo-3-(3-oxo-1-phenylbutyl)-2H-chromen-4-olate; Sodium coumadin; Sodium warfarin; Tintorane; UniWarfin; Varfine; Waran"	16204922	C19H15NaO4	Approved
M6APDG03031	Voxilaprevir	Voxilaprevir; Voxilaprevir (USAN/INN); Voxilaprevir [USAN:INN]; 0570F37359;J3.665.048F;  1535212-07-7; CS-0017027; D10899; DB12026; GS-9857; HY-19840; L9P; SCHEMBL15412621; UNII-0570F37359	89921642	C40H52F4N6O9S	Approved
M6APDG02501	Vortioxetine hydrobromide	"Vortioxetine (Lu AA21004) HBr; Vortioxetine (hydrobromide); Vortioxetine HBr; Vortioxetine hydrobromide; Vortioxetine hydrobromide [USAN]; Vortioxetine monohydrobromide; 1-(2-((2,4-Dimethylphenyl)sulfanyl)phenyl)piperazine monohydrobromide; 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine hydrobromide; 1-[2-[(2,4-dimethylphenyl)thio]phenyl]piperazine hydrobromide; 960203-27-4; C18H22N2S.BrH; CHEBI:76015; Lu AA21004 hydrobromide; TKS641KOAY; Trintellix (TN); UNII-TKS641KOAY"	56843850	C18H23BrN2S	Approved
M6APDG01856	NSC-122758	Afaxin; Agiolan; Agoncal; Alcovit A; Alphalin; Alphasterol; Anatola; Anatola A; Apexol; Apostavit; Aquasynth; Avibon; Avitol; Axerol; Axerophthol; Bentavit A; Biosterol; Chocola A; Disatabs Tabs; Dofsol; Dohyfral A; Epiteliol; Lard Factor; Myvpack; Oleovitamin A; Ophthalamin; Plivit A; Prepalin; Testavol; Vaflol; Veroftal; Vi-Alpha; Vitamin A; Vitamin A alcohol; Vitamin A1; Vitpex; Vogan-Neu; all-trans-Retinol; all-trans-Retinyl alcohol; all-trans-Vitamin A alcohol; retinol; trans-retinol; 68-26-8; Aoral; Atars; Vafol; A-Mulsal; A-Vitan; Vogan	445354	C20H30O	Phase 3
M6APDG02629	Verapamil hydrochloride	"Vasopten; Verabeta; Veracor; Verahexal; Veraloc; Veramil; Verapamil Ebewe; Verapamil HCl; Verapamil hydrochloride; Verapin; Verasal; Verasifar; Veratensin; Verdilac; Veroptinstada; Vetrimil; Vortac; Veramex; Verapamil [USAN:INN:BAN]; Verapamilo; Verapamilo [INN-Spanish]; Verapamilum; Verapamilum [INN-Latin]; Verelan; Verelan PM; Verpamil; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 52-53-9; Berkatens; CCRIS 6749; CP-16533-1; Calan; Calcan; Cardiagutt; Covera-HS; D-365; Dignover; Dilacoran; Falicard; Finoptin; Geangin; Iproveratril; Isoptimo; Isoptin; Isoptine; Isotopin; Izoptin; Lekoptin; Novo-Veramil; Quasar; Securon; Tarka; Univer; VERAPAMIL; Vasolan; (+/-)-VERAPAMIL HYDROCHLORIDE; 152-11-4; Anpec; Calaptin; Calcan hydrochloride; Cardiabeltin; Cardioprotect; Caveril; Civicor; Coraver; Corpamil; Durasoptin; Elthon; Flamon; Harteze; Hexasoptin; Hormitol; Ikacor; Ikapress; Inselon; Isoptino; Jenapamil; Lodixal; Magotiron; Manidon; Ormil; Praecicor; Rapam; Robatelan; Univex; Vasomil"	62969	C27H39ClN2O4	Approved
M6APDG02820	Velpatasvir	"Velpatasvir; Velpatasvir [USAN:INN]; Verpatasvir; KCU0C7RS7Z; 1377049-84-7; GS 5816; GS-5816; GS5816; UNII-KCU0C7RS7Z; methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate"	67683363	C49H54N8O8	Approved
M6APDG02479	Trimethoprim	"Trimanyl; Trimethioprim; Trimethoprime; Trimethoprimum; Trimetoprim; Trimetoprima; Trimopan; Trimpex; Triprim; Trisulcom; Trisulfam; Uretrim; Apo-Sulfatrim; Bacticel; Bactramin; Chemotrin; Cotrimel; Espectrin; Fermagex; Lagatrim; Monoprim; Monotrim; Monotrimin; NIH 204; Novotrimel; Pancidim; Proloprim; Sinotrim; Sugaprim; Sulfamar; Sulfamethoprim; Sulfoxaprim; Syraprim; Urobactrim; Wellcoprim; Wellcoprin; Zamboprim; trimethoprim; 2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine; 5-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine; 738-70-5; Abaprim"	5578	C14H18N4O3	Approved
M6APDG02478	Trimethadione	"Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadione; Trimetadione [DCIT]; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; trimethadione; 127-48-0; 2,4-OXAZOLIDINEDIONE, 3,5,5-TRIMETHYL-; Convenixa; Convexina; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; 3,5,5-Trimethyloxazolidine-2,4-dione; Absentol; Absetil; Edion"	5576	C6H9NO3	Approved
M6APDG00354	Trifarotene	"Trifarotene; Trifarotene (USAN/INN); Trifarotene [USAN:INN]; CD 5789; CD5789; SCHEMBL381493; compound 15b [PMID: 29706423]; 0J8RN2W0HK; 3''-Tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)(1,1':3',1'')terphenyl-4-carboxylic acid; 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid; 895542-09-3; CHEMBL3707313; CS-0018407; D11225; DB12808; DTXSID30237781; EX-A2704; GTPL9962; HY-100256; UNII-0J8RN2W0HK"	11518241	C29H33NO4	Approved
M6APDG02850	Treprostinil	"Treprostinil; Treprostinil [USAN:INN]; Tresprostinil; Trevyent; Tyvaso; U 62840; U-62,840; Uniprost; treprostinilo; treprostinilum; LRX 15; LRX-15; Orenitram; PAJMKGZZBBTTOY-ZFORQUDYSA-N; RUM6K67ESG; Remodulin; Remodulin (TN); ((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate; 15AU81; 2-[[(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-Hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]acetic Acid; 81846-19-7; CHEBI:50861; UNII-RUM6K67ESG; UT-15"	6918140	C23H34O5	Approved
M6APDG00623	AK-602	Trastuzumab emtansine; GW-873140; SCHEMBL20530710	135353969	C25H21N7O4	Phase 3
M6APDG01536	Torasemide	"Torasemida; Torasemida [INN-Spanish]; Torasemide; Torasemide, Anhydrous; Torasemidum; Torasemidum [INN-Latin]; Torsemide (Demadex); Demadex; JDL 464; JDL-464; Luprac; TORSEMIDE; W31X2H97FB; 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; 56211-40-6; AC 4464; AC-4464; AC4464; BM 02015; BM-02015; BRN 0498515; CCRIS 6736; CHEBI:9637; MLS001165687; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide; Torem; UNII-W31X2H97FB"	41781	C16H20N4O3S	Approved
M6APDG01009	Theophylline	"Teofyllamin; Teolair; Theacitin; Theo-dur; Theobid; Theocin; Theocontin; Theofol; Theograd; Theolair; Theolix; Theophyl-225; Theophyllin; Theophylline anhydrous; Theovent; Uniphyl; Uniphyllin; Xantivent; theophylline; 1,3-Dimethylxanthine; Acet-theocin; Aerolate; Aerolate III; Armophylline; Bronkodyl; Doraphyllin; Elixex; Elixicon; Elixophyllin; Elixophylline; Lanophyllin; Liquophylline; Maphylline; Medaphyllin; Nuelin; Optiphyllin; Parkophyllin; Pseudotheophylline; Respbid; Slo-bid; Slo-phyllin; Solosin; Sustaire; Synophylate; 58-55-9; Accurbron"	2153	C7H8N4O2	Approved
M6APDG02705	Testosterone undecanoate	"Testosterone (undecanoate); Testosterone undecanoate; Testosterone undecanoate [USAN]; Testosterone undecylate; Testosterone, undecanoate (ester); UDSFVOAUHKGBEK-CNQKSJKFSA-N; UNII-H16A5VCT9C; Undestor; 17beta-Hydroxyandrost-4-en-3-one undecanoate; 3-Oxoandrost-4-en-17beta-yl undecanoate; 5-alpha-Androstan-3-one, 17-beta-hydroxy-, undecanoate; 5949-44-0; Andriol; Androst-4-en-3-one, 17-((1-oxoundecyl)oxy)-, (17-beta)-; BRN 3176734; EINECS 227-712-6; H16A5VCT9C; Nebido; Org 538; Pantestone; Restandol; T undecanoate"	65157	C30H48O3	Approved
M6APDG03089	Testosterone enanthate	"Testanthate; Testate; Testenate; Testinon; Testoenant; Testonenant; Testosterone 17-enanthate; Testosterone enantate; Testosterone heptanoate; Testosterone heptoate; Testosterone heptylate; Testosterone oenanthate; Testostroval; testosterone enanthate; 17-Hydroxyandrost-4-en-3-one, 17-heptanoate; 315-37-7; Andro L.A. 200; Andropository; Androtardyl; Atlatest; DePatestrye; Delatest; Depo-Testro Med; Ditate; Durathate; Everone; Exten test; Malogen L.A.; Malogen L.A.200; NSC-17591; Orquisteron-E; Primotestone; Reposo TMD; Reposo-TMD"	9416	C26H40O3	Approved
M6APDG01598	Testosterone cypionate	"Testodrin prolongatum; Testosterone 17beta-cyclopentylpropionate; Testosterone 17beta-cypionate; Testosterone cyclopentanepropionate; Testosterone cyclopentylpropionate; Testosterone cypionate [USP]; Testandrone; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testoviron Schering; Testoviron T; Testrone; Testryl; Virormone; Virosterone; testosterone; trans-Testosterone; 58-22-0; AndroGel; Androderm; Androlin; Andronaq; Andropatch; Andrusol; Cristerona T; Cristerone T; Homosteron; Homosterone; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Sustanon; Sustanone; Synandrol F; Teslen; UNII-M0XW1UBI14; depAndro 100; depAndro 200; 58-20-8; Andro-Cyp; Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17b)-; CHEBI:9463; DEPO; Dep-Test; Depo-Testadiol; Depo-Testosterone; Depotest; Depovirin; Durandro; Jectatest; M0XW1UBI14; Malogen CYP; NSC 9157; Pertestis; T-Ionate-P.A; TESTOSTERONE CYPIONATE"	441404	C27H40O3	Approved
M6APDG02274	Terbinafine hydrochloride	"Terbinafina [Spanish]; Terbinafine (hydrochloride); Terbinafine HCl; Terbinafine hydrochioride; Terbinafine hydrochloride; Terbinafinum [Latin]; UNII-012C11ZU6G; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; 91161-71-6; BRN 4256376; CHEBI:9448; CHEMBL822; Corbinal; DOMXUEMWDBAQBQ-WEVVVXLNSA-N; G7RIW8S0XP; Lamasil; Lamisil; Lamisil Tablet; NCGC00159346-02; SF 86-327; SF-86-327; UNII-G7RIW8S0XP; terbinafine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine hydrochloride; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine hydrochloride; 012C11ZU6G; 78628-80-5; C21H26ClN; CHEBI:77614; CPD000469152; DRG-0286; Lamisil Krem; MFCD00145430; MycoVa; SF 86-327 hydrochloride"	5282481	C21H26ClN	Approved
M6APDG02413	Temazepam	Temador; Temazepamum; Temazepamum [INN-Latin]; Temtabs; Uvamin Retard; WY 3917; Wy-3917; temazep von ct; temazepam; 3-Hydroxydiazepam; Cerepax; Crisonar; Dasuen; ER 115; Euhypnos; Euipnos; Gelthix; Hydroxydiazepam; K-3917; Levanxene; Levanxol; Levanzene; Mabertin; Methyloxazepam; N-Methyloxazepam; Neodorm SP; Nocturne; Nomapam; Norkotral Tema; Normison; Normitab; Nortem; Oxydiazepam; Perdorm; Planum; Pronervon T; Remestan; Restoril; Ro 5-5345; Signopam; 846-50-4; Lenal; Temaz; Tenox	5391	C16H13ClN2O2	Approved
M6APDG02411	Tegafur	"Tefsiel C; Tegafurum [INN-Latin]; Citofur; Coparogin; Exonal; Fental; Florafur; Fluorafur; Fluorofur; Franroze; Ftorafur; Fulfeel; Furafluor; Furflucil; Furofutran; Futraful; Lifril; MJF-12264; Neberk; Nitobanil; Phthorafur; Phthorafur [Czech]; Racemic Ftorafur; Sinoflurol; Sunfral; tegafur; 1-(2-Tetrahydrofuryl)-5-fluorouracil; 17902-23-7; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-; 5-Fluoro-1-(tetrahydro-2-furyl)uracil; 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; C8H9FN2O3; FT-207; Lamar; Riol"	5386	C8H9FN2O3	Phase 4
M6APDG02410	Tazarotene	"Tazarotene (Avage); Tazarotene [USAN:INN]; Tazorac; tazarotene; 118292-40-3; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; Fabior; OGQICQVSFDPSEI-UHFFFAOYSA-N; 81BDR9Y8PS; AGN 190168; AGN-190168; Avage; C21H21NO2S; CHEBI:32184; CHEMBL1657; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; NCGC00167525-01; UNII-81BDR9Y8PS; Zora; Zorac; ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]pyridine-3-carboxylate"	5381	C21H21NO2S	Approved
M6APDG02388	Sulfinpyrazone	"Sulfinpirazona [INN-Spanish]; Sulfinpyrazine; Sulfinpyrazon; Sulfinpyrazonum; Sulfinpyrazonum [INN-Latin]; Sulfoxyphenylpyrazolidine; Sulphinpyrazone; USAF GE-13; Anturan; Anturane; Anturane (TN); Anturanil; Anturano; Anturen; Anturidin; Apo-Sulfinpyrazone; Diphenylpyrazone; Enturan; Enturen; sulfinpyrazone; (+/-)-SULFINPYRAZONE; 1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)pyrazolidine-3,5-dione; 4-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione; 57-96-5; G 28315; NSC 75925"	5342	C23H20N2O3S	Approved
M6APDG02353	Sulfamethoxazole	Simsinomin; Sinomin; Solfametossazolo; Sulfamethalazole; Sulfamethoxazol; Sulfamethoxazolum; Sulfamethoxizole; Sulfamethylisoxazole; Sulfametoxazol; Sulfisomezole; Sulpha-methoxizole; Sulphamethoxazol; Sulphamethoxazole; Sulphamethylisoxazole; Sulphisomezole; Urobak; Azo-gantanol; Bactrimel; Gamazole; Gantanol; Gantanol-DS; Metoxal; Radonil; Ro 4-2130; sulfamethoxazole; 3-Sulfanilamido-5-methylisoxazole; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; 723-46-6	5329	C10H11N3O3S	Approved
M6APDG02219	Sulfadiazine	Sanodiazine; Spofadrizine; Sterazine; Sulfadiazene; Sulfadiazin; Sulfanilamidopyrimidine; Sulfapyrimidin; Sulfapyrimidine; Sulfatryl; Sulfazine; Sulfolex; Sulfonsol; Sulfose; Sulphadiazine; Terfonyl; Theradiazine; Tri-Sulfameth; Trifonamide; Adiazin; Adiazine; Cremodiazine; Cremotres; Debenal; Deltazina; Diazin; Diazolone; Diazyl; Eskadiazine; Honey diazine; Lipo-Levazine; Liquadiazine; Microsulfon; Neazine; Neotrizine; Palatrize; Piridisir; Pirimal; Pyrimal; Quadetts; Quadramoid; Trisem; Truozine; sulfadiazine; 2-Sulfanilamidopyrimidine; 68-35-9	5215	C10H10N4O2S	Approved
M6APDG01568	Sitagliptin	"Sitagliptan; Sitagliptin; Sitagliptin phosphate; Tesavel; Xelevia; Januvia; MK-0431; QFP0P1DV7Z; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; (3R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; (R)-3-AMINO-1-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; 486460-32-6; CHEBI:40237; UNII-QFP0P1DV7Z"	4369359	C16H15F6N5O	Approved
M6APDG02419	Simvastatin	Simcard; Simlup; Simovil; Simvacor; Simvastatin (Zocor); Simvastatin lactone; Simvastatina; Simvastatina [Spanish]; Simvastatine; Simvastatine [French]; Simvastatinum; Simvastatinum [Latin]; Simvoget; Sinvacor; Sivastin; Synvinolin; Cholestat; Coledis; Colemin; Corolin; Labistatin; Lipovas; Lodales; MK-0733; MK-733; Medipo; Nivelipol; Pantok; Rechol; Rendapid; Vasotenal; Velostatin; Zocord; Zorced; simvastatin; 79902-63-9; Denan; Lipex; Zocor	54454	C25H38O5	Approved
M6APDG01129	ABT-001	"Bronica; SERATRODAST; Seratrodast [USAN:INN]; (+-)-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid; 112665-43-7; 7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid; 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid; A 73001; A-73001; AA 2414; AA-2414; ABT 001; ABT-001; Abbott 73001; Abbott-73001; Benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+-)-; C22H26O4; CCRIS 8939; DSSTox_CID_1397; DSSTox_RID_76138; NCGC00181296-01"	2449	C22H26O4	Discontinued
M6APDG03265	Selexipag	"Selexipag; Selexipag [USAN:INN]; Selexipag(NS-304); Uptravi; Uptravi (TN); 2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide; 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide; 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide; 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide; 475086-01-2; 5EXC0E384L; ACT 293987; ACT-293987; NS 304; NS-304; UNII-5EXC0E384L"	9913767	C26H32N4O4S	Approved
M6APDG01294	Selegiline hydrochloride	"Selegiline Hcl; Selegiline hydrochloride; Selegilina; Selegilina [INN-Spanish]; Selegilinum; Selegilinum [INN-Latin]; Selegyline; UNII-2K1V7GP655; Zalapar; l-E 250; selegiline; selgene; (-)-Deprenil; (-)-selegiline; (R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine; (R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin; 14611-51-9; 2K1V7GP655; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-; CHEBI:9086; CHEMBL972; Carbex; Deprenyl; Emsam; Jumex; L-Deprenalin; N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine; UNII-6W731X367Q; l-Deprenyl hydrochloride; (-)-Deprenil hydrochloride; (-)-Deprenyl hydrochloride; (-)-E-250 hydrochloride; (-)-Phenylisopropylmethylpropynylamine; (R)-(-)-Deprenyl hydrochloride; (R)-N-Methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine hydrochloride; 14611-52-0; 6W731X367Q; Eldepryl hydrochloride; FPF1100; HSDB 7183; Jumex hydrochloride; R-(-)-Deprenyl (hydrochloride)"	26758	C13H18ClN	Approved
M6APDG01911	Rosuvastatin	"Rosuvastatin; Rosuvastatin calcium; ZD-4522; (3R,5R)-Rosuvastatin; Creston (TN); (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid; (E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid; 287714-41-4; 413KH5ZJ73; CHEBI:38545; CHEMBL1496; UNII-413KH5ZJ73"	446157	C22H28FN3O6S	Approved
M6APDG02992	Rosiglitazone	"Rosigilitazone; Rosiglitazone [INN:BAN]; Rosiglitazone maleate; Rosiglizole; TDZ 01; YASAKCUCGLMORW-UHFFFAOYSA-N; Avandamet; Avandaryl; Avandia; rosiglitazona; rosiglitazone; rosiglitazone (Avandia); rosiglitazonum; 122320-73-4; 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; BRL49653; Brl 49653; Brl-49653; C18H19N3O3S; CHEBI:50122"	77999	C18H19N3O3S	Approved
M6APDG00284	Riociguat	"Riociguat; Riociguat (BAY 63-2521); riociguatum; 625115-55-1; BAY 63-2521; BAY 632521; CHEBI:76018; Adempas; RU3FE2Y4XI; Methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate; Methyl N-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamate; N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester; UNII-RU3FE2Y4XI"	11304743	C20H19FN8O2	Approved
M6APDG02635	QLT-091001	"Crystalets; Davitan A 650; Myvak (VAN); Myvax (VAN); O~15~-acetylretinol; RETINYL ACETATE; RO 1-5275; Retinol acetate; Retinol, acetate; Retinol, acetate, all-trans-; Retinyl acetate, all-trans-; Vitamin A acetate; Vitamin A acetate (VAN); Vitamin A alcohol acetate; Vitamin A ester; Vitamin A1 acetate; all-trans-Retinol acetate; all-trans-Retinyl acetate; all-trans-Retinylacetate; all-trans-Vitamin A acetate; trans-Retinol Acetate; 127-47-9; Acetic acid, retinyl ester; CCRIS 1907; NSC 122045; UNII-3LE3D9D6OY"	638034	C22H32O2	Phase 2/3
M6APDG00514	Quinine sulfate	"Quinine bisulfate; Quinine bisulfate [NF]; Quinine hydrogen sulfate; Quinine hydrogen sulphate; Quinine, sulfate (1:1) (salt); Qualaquin; Quinine; Quinine HCl; Quinine anhydrous; Quinine sulphate; Quinine, Anhydrous; Quinine, tannate; Quinineanhydrous; Quinoline alkaloid; UNII-A7V27PHC7A; chininum; quinina; quinine bisulphate; (-)-Quinine; (8S,9R)-Quinine; (R)-(-)-quinine; 130-95-0; 6'-Methoxycinchonan-9-ol; 6'-Methoxycinchonidine; 6'-Methoxycinchonine; 6-Methoxycinchonine; A7V27PHC7A; Aflukin; CHEBI:15854; Chinin; Chinin [German]; Chinine; Cinchonan-9-ol, 6'-methoxy-, (8a,9R)-; Coco-Quinine; LOUPRKONTZGTKE-WZBLMQSHSA-N; MFCD00198096; NSC 192949; SCHEMBL29712; UNII-M201HC068W; (-)-Quinine Sulfate Dihydrate; (R)-(6-Methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol sulfate; 549-56-4; 6119-70-6; 804-63-7; 8alpha,9R-6'-Methoxycinchonan-9-ol, sulfate (1:1) salt; CHEMBL1201100; EC 208-970-9; EINECS 208-970-9; FEMA No. 2975; GNF-Pf-506; M201HC068W; QUININE SULFATE DIHYDRATE"	11949689	C20H26N2O6S	Approved
M6APDG01586	Quinidine	"Quinact; Quinaglute; Quinalan; Quinatime; Quindine; Quinicardine; Quinidex; Quinidine sulfate; Quiniduran; Quinora; beta-Quinine; Cardioquin; Chinidin; Chinidine; Cin-Quin; Cinchonan-9-ol, 6'-methoxy-, (9S)-; Conchinin; Conchinine; Conquinine; Duraquin; ITX08688JL; Kinidin; Pitayine; chinidinum; quinidina; quinidine; (+)-Quinidine; (8R,9S)-Quinidine; (9S)-6'-Methoxycinchonan-9-ol; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol; 56-54-2; CHEBI:28593; CHEMBL1294; MFCD00135581; UNII-ITX08688JL"	441074	C20H24N2O2	Approved
M6APDG02156	Propofol	"Propofolum; Propofolum [Latin]; Propovan; Rapinovet; Recofol; propofol; 2,6-Bis(1-methylethyl)phenol; 2,6-DIISOPROPYLPHENOL; 2,6-Diisopropyl phenol; 2,6-bis(propan-2-yl)phenol; 2,6-di(propan-2-yl)phenol; 2078-54-8; C12H18O; CCRIS 9000; Ampofol; Diisopropylphenol; Diprifusor; Diprivan; Diprivan 10; Diprivan Injectable emulsion; Diprofol; Disoprivan; Disoprofol; Fresofol; Ivofol; Phenol, 2,6-bis(1-methylethyl)-; Phenol, 2,6-diisopropyl-; Propofol-Lipuro; EINECS 218-206-6; HSDB 7123; ICI 35868; ICI-35868; NSC 5105; Pofol; UNII-YI7VU623SF"	4943	C12H18O	Approved
M6APDG02570	Progesterone	"Piaponon; Pregnenedione; Primolut; Progestasert; Progesterol; Progesteronum; Progestin; Progestone; Progestosol; Progestron; Progestronol; Prometrium; Protormone; Pregn-4-ene-3,20-dione; Syngesterone; Syntolutan; Utrogestan; progesterone; Agolutin; Corlutin; Corpus luteum hormone; Crinone; Cyclogest; Flavolutan; Gestone; Gestormone; Glanducorpin; Gynolutone; Hormoflaveine; Hormoluton; Lingusorbs; Luteogan; Luteohormone; Luteol; Luteopur; Luteosan; Luteostab; Luteovis; Lutociclina; Lutocylin; Lutromone; Methylpregnone; 4-Pregnene-3,20-dione; 57-83-0"	5994	C21H30O2	Approved
M6APDG02152	Procarbazine	Procarbazin; Procarbazin [German]; Procarbazina; Procarbazina [INN-Spanish]; Procarbazine [INN:BAN]; Procarbazinum; Procarbazinum [INN-Latin]; Ibenzmethyzine; Natulan; Ro 4-6467; procarbazine; 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; 671-16-9; Ibenzmethyzin; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; N-Isopropyl-4-((2-methylhydrazinyl)methyl)benzamide; p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide	4915	C12H19N3O	Approved
M6APDG02272	Pitavastatin calcium	"Pitavastatin; Pitavastatin [INN]; Zypitamag; ( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; C25H24FNO4; CHEBI:32020; UNII-M5681Q5F9P; Itavastatin; M5681Q5F9P; NK 104; Alipza; IYD54XEG3W; Itavastatin calcium; Livazo; Nisvastatin; Pitavastatin hemicalcium; 147526-32-7; 2C25H23FNO4.Ca; Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt; CHEBI:71258; Calcium (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate; UNII-IYD54XEG3W"	5282451	C50H46CaF2N2O8	Approved
M6APDG02431	Piroxicam	"Pirkam; Piroflex; Piroftal; Piroxicam (Feldene); Piroxicamum; Piroxicamum [INN-Latin]; Pyroxycam; Reudene; Riacen; Roxicam; Roxiden; Sasulen; Solocalm; Artroxicam; Bruxicam; CHF 1251; Caliment; Erazon; Feldene; Flogobene; Geldene; Improntal; Larapam; Zunden; piroxicam; piroxicam usp; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 36322-90-4; 4-Hydroxy-2-methyl-N-(pyridin-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide; BAXO; CCRIS 3719; CP 16171; CP-16171; NSC 666076; Roxam; UNII-13T4O6VMAM"	54676228	C15H13N3O4S	Approved
M6APDG02587	Pioglitazone hydrochloride	"Pioglitazona; Pioglitazona [INN-Spanish]; Pioglitazone; Pioglitazone (Actos); Pioglitazone [BAN:INN]; Pioglitazone [INN:BAN]; Pioglitazonum; Pioglitazonum [INN-Latin]; Pioditazone hydrochloride; Pioglitazone (hydrochloride); Pioglitazone HCl; U-72107A; U-72107E; pioglitazone hydrochloride; (+-)-5-(p-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione monohydrochloride; 112529-15-4; 5-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione hydrochloride; AD 4833; C19H21ClN2O3S; DSSTox_CID_24203; DSSTox_GSID_44203; DSSTox_RID_80116; MFCD04975446; NCGC00095131-01; [5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-] thiazolidinedione hydrochloride; U 72107; Zactos; 105355-27-9; 111025-46-8; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; AD-4833; Actos; C19H20N2O3S; CHEBI:8228; HSDB 7322; Duetact; Glustin"	60560	C19H21ClN2O3S	Approved
M6APDG00920	Phenytoin	"Phanantin; Phanatine; Phenatine; Phenatoine; Phentytoin; Phenytoine; Sodantoin; Sodanton; Sylantoic; Thilophenyl; Aleviatin; Dantoinal; Di-Hydan; Difenin; Dihycon; Dihydantoin; Dilabid; Dilantin; Diphantoin; Diphedan; Diphenine; Diphentyn; Diphenylan; Diphenylhydantoin; Diphenylhydatanoin; Ditoinate; Elepsindon; Epamin; Epilantin; Fenitoina; Fenylepsin; Fenytoine; Hidantilo; Hidantina; Hidantomin; Hydantoinal; Kessodanten; Lehydan; Lepitoin; Zentronal; Zentropil; phenytoin; 5,5-DIPHENYLHYDANTOIN; 5,5-diphenylimidazolidine-2,4-dione; 57-41-0"	1775	C15H12N2O2	Approved
M6APDG02438	Phenprocoumon	Phenprocoumarol; Phenprocoumarole; Phenprocoumone; Phenprocoumone [INN-French]; Phenprocoumonum; Phenprocoumonum [INN-Latin]; Phenprocumone; Phenprocumonum; Ro 1-4849; 3-(1'-Phenyl-propyl)-4-oxycoumarin; 3-(1-Phenylpropyl)-4-hydroxycoumarin; Falithrom; Fencumar; Fenprocoumona [INN-Spanish]; Fenprocumone; Fenprocumone [DCIT]; Liquamar; Marcoumar; Marcumar; PHENPROCOUMON; 3-(alpha-Ethylbenzyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one; 4-Hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one; 435-97-2	54680692	C18H16O3	Approved
M6APDG02141	Phenobarbital	Phenaemal; Phenemal; Phenobarbitol; Phenobarbitone; Phenobarbituric acid; Phenobarbyl; Phenolurio; Phenonyl; Phenoturic; Phenylethylbarbiturate; Phenylethylbarbituric acid; Phenylethylmalonylurea; Phenyral; Polcominal; Sedonettes; Adonal; Aphenylbarbit; Aphenyletten; Barbiphenyl; Cabronal; Cratecil; Dezibarbitur; Dormiral; Ensodorm; Fenobarbital; Gardenal; Glysoletten; Hypnogen; Hysteps; Lepinaletten; Lubrokal; Lumesettes; Luminal; Lumofridetten; Neurobarb; Solfoton; Sombutol; Somnolens; Somnoletten; Somnosan; phenobarbital; Nunol	4763	C12H12N2O3	Approved
M6APDG02139	Perphenazine	"Perfenazina; Perfenazina [INN-Spanish]; Perfenazina [Italian]; Perfenazine; Perphenan; Perphenazin; Perphenazinum; Perphenazinum [INN-Latin]; Perphenazine dimaleate; LS-112191; Perphenazine maleate; Perphenazine maleate (JP17); Perphenazine maleate [JAN]; (Z)-but-2-enedioic acid; 1-Piperazineethanol, 4-(3-(2-chlorophenothiazin-10-yl)propyl)-, maleate; 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol; 5352-90-9; 7K96LZ09JI; AC1O60XO; C13540; D02037; UNII-7K96LZ09JI; Sch 3940; Thilatazin; Tranquisan; Trifaron; Trilafon; Trilifan; Triphenot; perphenazine; 2-(4-(3-(2-Chloro-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol; 58-39-9; C21H26ClN3OS; F-mon; NSC 150866; PZC; UNII-FTA7XXY4EZ; Chlorperphenazine; Chlorpiprazine; Decentan; Emesinal; Etaperazin; Etaperazine; Ethaperazine; Fentazin"	4748	C21H26ClN3OS	Approved
M6APDG00369	M-813	"Lullan; Perospirone; Perospirone [INN]; (3aR,7aS)-2-[4-[4-(1,2-benzothiazol-3-yl)-1-piperazinyl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione; (3aR,7aS)-2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione; 129273-38-7; 150915-41-6; 1H-Isoindole-1,3(2H)-dione,2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]hexahydro-,(3aR,7aS)-rel-; C23H30N4O2S; N303OK87DT; UNII-N303OK87DT; cis-N-(4-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximide"	115368	C23H30N4O2S	Phase 1
M6APDG03023	Pentamidine isethionate	"Pentamidine (isethionate); Pentamidine diisethionate; Pentamidine isethionate salt; Pentamidine isothionate; Pentaminide isetionate; USAF XR-10; V2P3K60DA2; 1,5-Bis(p-amidinophenoxy)pentane bis(2-hydroxyethanesulfonate salt); 140-64-7; 4,4'-(Pentamethylenedioxy)dibenzamidine bis(2-hydroxyethanesulfonate); 4,4'-(Pentane-1,5-diylbis(oxy))dibenzimidamide bis(2-hydroxyethanesulfonate); CCRIS 1660; CHEBI:7977; MFCD00079213; UNII-V2P3K60DA2; PENTAMIDINE ISETHIONATE; Nebupent (as isethionate); Pentacarinat (as isethionate); Pentam 300 (as isethionate); Pentamide; Pentamidin; Pentamidina; Pentamidina [DCIT]; Pentamidine [INN:BAN:DCF]; Pentamidine mesylate; Pentamidinum; Pentamidinum [INN-Latin]; pentamidine; 100-33-4; 4,4'-(Pentamethylenedioxy)dibenzamidine; 4,4'-(Pentane-1,5-diylbis(oxy))dibenzimidamide; 4,4'-Diamidinodiphenoxypentane; CCRIS 3825; UNII-673LC5J4LQ; p,p'-(Pentamethylenedioxy)dibenzamidine"	8813	C23H36N4O10S2	Approved
M6APDG00050	Pazopanib	"Pazopanib; Pazopanib (GW-786034); 444731-52-6; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; 790713-33-6; 7RN5DR86CK; CHEBI:71219; DSSTox_CID_28659; DSSTox_GSID_48733; DSSTox_RID_82929; GW 78603; GW 786034; GW-786034; GW786034; MFCD11616589; NCGC00188865-01; UNII-7RN5DR86CK"	10113978	C21H23N7O2S	Approved
M6APDG03087	Paraoxon	"Chinorta; Chinorto; Diethyl 4-nitrophenyl phosphate; Diethyl p-nitrophenyl phosphate; Diethyl paraoxon; Diethyl-p-nitrophenyl phosphate; Diethylparaoxon; Ester 25; Ethyl paraoxan; Ethyl paraoxon; Eticol; Fosfakol; Mintaco; Mintacol; Miotisal; Miotisal A; Oxyparathion; PARAOXON; Paraoxon-ethyl; Paraoxone; Paroxan; Pestox 101; Phosphachole; Phosphacol; Phosphakol; Soluglacit; Soluglaucit; p-Nitrophenyl diethyl phosphate; 311-45-5; E 600 (pesticide); Phosphoric acid diethyl 4-nitrophenyl ester; Phosphoric acid, diethyl 4-nitrophenyl ester"	9395	C10H14NO6P	Investigative
M6APDG03231	Oxaliplatin	Oxaliplatin (Eloxatin); Oxaliplatin (JAN/USAN/INN); SC-17287; SCHEMBL4859; SW219151-1; 15171-EP2272827A1; 15171-EP2292617A1; 15171-EP2295055A2; Eloxatin (TN); 15171-EP2295416A2; 15171-EP2295427A1; 15171-EP2298748A2; 15171-EP2298764A1; 15171-EP2298765A1; 15171-EP2298768A1; 15171-EP2298778A1; 15171-EP2298780A1; 15171-EP2305642A2; 15171-EP2305671A1; 15171-EP2308855A1; 15171-EP2311453A1; 15171-EP2311825A1; 15171-EP2311829A1; 15171-EP2311840A1; 15171-EP2316832A1; 15171-EP2316833A1; AB01568250_01; AKOS015920125; BR-72813; D01790; O0372; s1224	9887054	C8H14N2O4Pt	Approved
M6APDG02005	Omeprazole	Omapren; Omepral; Omeprazon; Omeprol; Omezol; Omisec; Omizac; Ompanyt; Ozoken; Parizac; Pepticum; Peptilcer; Prazentol; Prazidec; Audazol; Belmazol; Ceprandal; Demeprazol; Dizprazol; Dudencer; Emeproton; Epirazole; Gastrimut; Gastroloc; Gibancer; Indurgan; Inhibitron; Inhipump; Logastric; Mepral; Miracid; Mopral; Prazolit; Prilosec; Prysma; Ramezol; Regulacid; Sanamidol; Secrepina; Ulceral; Ulcesep; Ulcometion; Ulcozol; Zefxon; Zegerid; Zoltum; omeprazole; 73590-58-6; Antra; Desec; Elgam; Lomac; Losec; Miol; OMEP; Ocid; Omed; Omid; Ulsen; Ultop; Zimor	4594	C17H19N3O3S	Approved
M6APDG02499	Omega-6-FA	"Fatty Acids, Omega-6; Omega-6 Fatty Acids; Omega-6 Polyunsaturates; N-6 Fatty Acids; SCHEMBL17080398"	56842208	C38H64O4	Phase 3
M6APDG02500	Omega-3 Fatty acids	"Omega-3 Fatty Acids; Omega-3 Polyunsaturates; Epanova; Fatty Acids, Omega-3; QPEOIOLHJXXJFN-GNGJDXFDSA-N; n-3 PUFA; n-3 PUFAs; n-3 Polyunsaturated Fatty Acid; Polyunsaturated Fatty Acids (PUFAs)"	56842239	C60H92O6	Phase 4
M6APDG02458	Ombitasvir	"Ombitasvir (USAN); Ombitasvir [USAN:INN]; Ombitasvir pound&gt;&gt;ABT-267; Ombitasvir(ABT-267); SB16895; SCHEMBL8542284; ABT-267; ZINC150601177; 1258226-87-7; 2302768XJ8; ABT 267; ABT-267;ABT267;ABT 267; ABT267; CHEBI:85183; CHEMBL3127326; CS-5330; DB09296; UNII-2302768XJ8; dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate"	54767916	C50H67N7O8	Phase 4
M6APDG00060	MK-0822	"MK 0822; MK-0822; MK0822; Odanacatib; Odanacatib (MK 0822); Odanacatib (MK-0822); (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]pentanamide; (S)-N-(1-CYANOCYCLOPROPYL)-4-FLUORO-4-METHYL-2-((S)-2,2,2-TRIFLUORO-1-(4'-(METHYLSULFONYL)BIPHENYL-4-YL)ETHYLAMINO)PENTANAMIDE; 603139-19-1; CHEMBL481611; N673F6W2VH; UNII-N673F6W2VH"	10152654	C25H27F4N3O3S	Phase 1
M6APDG00517	Nilotinib	Nilotinib [INN]; Nilotinib [USAN]; L-N6-(1-Iminoethyl)lysine; Lopac0_000663; ZINC2384265; (2R)-2-amino-6-ethanimidamidohexanoic acid; BDBM50030277; CCG-204749; CHEMBL340800; GTPL5231; N6-ethanimidoyl-D-lysine; NCGC00162216-01; NCGC00162216-02	11957582	C8H17N3O2	Approved
M6APDG03027	Nicotine	Nicoderm; Nicoderm Cq; Nicorette; Nicotina [Italian]; Nicotine polacrilex; Nicotrol; Nicotrol Inhaler; Nicotrol NS; Nikotin [German]; Nikotyna [Polish]; Destruxol orchid spray; Flux MAAG; Fumetobac; Habitrol; L-Nicotine; Micotine; NICOTINE AND SALTS; Niagara P.A. dust; Ortho N-4 dust; Ortho N-5 dust; Prostep; XL All Insecticide; nicotine; (-)-Nicotine; (S)-(-)-Nicotine; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; (S)-Nicotine; 3-(N-Methylpyrollidino)pyridine; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine	89594	C10H14N2	Approved
M6APDG01528	Nicardipine hydrochloride	"Nicardipine LA; Nicardipine [INN:BAN]; Nicardipino; Nicardipino [INN-Spanish]; Nicardipinum; Nicardipinum [INN-Latin]; Angioglebil; Bionicard; Cardene SR; Lincil; NICARDIPINE HYDROCHLORIDE; Nicardil; Nicardipine (Hydrochloride); Nicardipine HCl; Nicodel; Perdipina; Perdipine; RS-69216; RS-69216-XX-07-0; 2-(Benzylmethylamino)ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylatemonohydrochloride; 54527-84-3; Dafil; Dagan; EINECS 259-198-4; Loxen; MFCD00057327; MLS000069782; Nicardipine hydrochloride [USAN:JAN]; SMR000058487; YC 93; YC-93; ZBBHBTPTTSWHBA-UHFFFAOYSA-N; nicardipine; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 55985-32-5; BRN 0504321; C26H29N3O6; CHEBI:7550; DSSTox_CID_3363; EINECS 259-932-3; NCGC00015747-03"	41114	C26H30ClN3O6	Approved
M6APDG02282	Naloxone	"Nalone; Nalossone; Nalossone [DCIT]; Naloxona; Naloxona [INN-Spanish]; Naloxone [INN:BAN]; Naloxonum; Naloxonum [INN-Latin]; Narcan; Narcanti; Narcon; l-Naloxone; n-Allylnoroxymorphone; naloxone; (-)-Naloxone; 1-N-Allyl-14-hydroxynordihydromorphinone; EN 1530 base; N-Allyl-noroxymorphone; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; 465-65-6; HSDB 3279; UNII-36B82AMQ7N; l-N-Allyl-14-hydroxynordihydromorphinone"	5284596	C19H21NO4	Approved
M6APDG02244	Mycophenolate mofetil	"Mycophenolate mofetil (CellCept); Mycophenolatemofetil; Mycophenylate mofetil; Myfenax; RS 61443; RS-61443; TM-MMF; mycophenolate mofetil; CellCept; Cellcept (TN); Munoloc; 115007-34-6; 128794-94-5; 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 9242ECW6R0; C23H31NO7; CHEBI:8764; HSDB 7436; MFCD00867568; Mycophenolic acid morpholinoethyl ester; UNII-9242ECW6R0"	5281078	C23H31NO7	Approved
M6APDG02291	Morphine	Meconium; Morfina; Morfina [Italian]; Morphia; Morphin; Morphin [German]; Morphina; Morphina [Italian]; Morphine [BAN]; Morphinism; Morphinum; Morphium; Morpho; Moscontin; Ms Emma; Nepenthe; Oramorph SR; Ospalivina; Roxanol; Statex SR; Astramorph PF; Avinza; Cube juice; DepoDur; Dolcontin; Dreamer; Dulcontin; Duramorph; Duramorph PF; Duromorph; Hard stuff; Infumorph; Kadian; M-Eslon; MORPHINE SULFATE; MS Contin; l-Morphine; morphine; (-)-Morphine; 57-27-2; CCRIS 5762; HSDB 2134; Hocus; Unkie	5288826	C17H19NO3	Approved
M6APDG01106	Montelukast sodium	"Montelukast (sodium); Montelukast sodium [USAN]; Montelukast sodium salt; Montelukast [INN:BAN]; Singular; montelukast; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 158966-92-8; CHEBI:50730; CHEMBL787; UNII-MHM278SD3E; MHM278SD3E; U1O3J18SFL; 151767-02-1; CHEBI:6993; CPD000469188; Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, sodium salt (1:1); DSSTox_CID_26450; DSSTox_GSID_46450; DSSTox_RID_81624; UNII-U1O3J18SFL; MK 476; MK-0476; MK-476; MONTELUKAST Na; MONTELUKAST SODIUM; Montair"	23663996	C35H35ClNNaO3S	Approved
M6APDG01539	Mirtazapine	"Mepirzapin; Mepirzepine; Mirtazapina; Mirtazapina [INN-Spanish]; Mirtazapine [USAN:BAN:INN]; Mirtazapine [USAN:INN:BAN]; Mirtazapinum; Mirtazapinum [INN-Latin]; Mirtazepine; Mirtazipine; Norset; ORG 3770; Org-3770; Promyrtil; Remergil; Avanza; Remergon; Remeron; Remeron SolTab; Zispin; mirtazapine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 6-Azamianserin; 61337-67-5; 85650-52-8; CHEMBL654; EINECS 288-060-6; Rexer"	4205	C17H19N3	Approved
M6APDG00576	Methotrexate	"Metatrexan; Methotextrate; Methotrexat; Methotrexat-Ebewe; Methotrexate, L-; Methotrexatum; Methoxtrexate; Methylaminopterin; Methylaminopterinum; Metotressato [DCIT]; Metotrexato; Mexate; Mexate-Aq; N-Bismethylpteroylglutamic acid; A-Methopterin; A-Methpterin; Amethopterin; Amethopterin L-; Amethopterine; Antifolan; Emtexate; Folex-Pfs; L-Amethopterin; Maxtrex; Rasuvo; Rheumatrex; Trexall; methotrexate; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Abitrexate; Folex; Hdmtx; MTX; NCI-C04671"	126941	C20H22N8O5	Approved
M6APDG02612	Methionine	"Acimethin; Cymethion; L-(-)-Methionine; L-Homocysteine, S-methyl-; L-Methionin; L-Methioninum; L-methionine; Liquimeth; METHIONINE, L-; Methilanin; Methionine (VAN); Methioninum; Methioninum [INN-Latin]; Metionina [DCIT]; Neo-methidin; Poly-L-methionine; Polymethionine; S-Methionine; methionine; metionina; (2S)-2-amino-4-(methylsulfanyl)butanoic acid; (L)-Methionine; (S)-2-Amino-4-(methylthio)butanoic acid; (S)-methionine; 63-68-3; L-alpha-Amino-gamma-methylmercaptobutyric acid; h-Met-h; h-Met-oh"	6137	C5H11NO2S	Investigative
M6APDG01043	Methadone	"Levometadona; Levometadona [INN-Spanish]; Levomethadone; Levomethadone (INN); Levomethadone [INN]; Levomethadonum; Levomethadonum [INN-Latin]; Levothyl; Polamivet; L-Polamidon; l-Polamivet; (-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (-)-Methadone; (6R)-Methadone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (R)-Methadone; 125-58-6; 3-HEPTANONE, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-, L-; 3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)- (9CI); 6Y75Z4E8NS; L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; UNII-6Y75Z4E8NS"	22267	C21H27NO	Approved
M6APDG02626	Mestranol	Menophase; Mestranolo [DCIT]; Mestranolum; Mestranolum [INN-Latin]; Norquen; Ovastol; Devocin; EE(sub3)ME; Ethinylestradiol 3-methyl ether; Ethynylestradiol 3-methyl ether; Ethynylestradiol methyl ether; Ethynyloestradiol 3-methyl ether; Inostral (steroid); SC 4725; delta-MVE; mestranol; 3-Methoxy-17alpha-ethynylestradiol; 3-Methoxyethynylestradiol; 3-Methoxyethynyloestradiol; 3-Methylethynylestradiol; Compound 33355; 3-Methylethynyloestradiol; 3-O-Methylethynylestradiol; 72-33-3; Caswell No. 547A; EE3ME	6291	C21H26O2	Phase 4
M6APDG01519	Mephenytoin	"Mefenitoina; Mephenetoinum; Mephenytoine; Mephenytoinum; Mesantoin; Mesdontoin; Mesontoin; Methoin; Methyl hydantoin; Methylphenetoin; Metydan; Phenantoin; Phenylethylmethylhydantoin; Sacerno; Sedantional; Sedantoin; Sedantoinal; Triantoin; Epiazin; Epilan; Fenantoin; Gerot-epilan; Insulton; MEPHENYTOIN; mephentoin; (+/-)-Mephenytoin; (S)-Mephenytoin; 3-Ethylnirvanol; 3-Methyl-5,5-phenylethylhydantoin; 3-Methyl-5-ethyl-5-phenylhydantoin; 5-Ethyl-3-methyl-5-phenylhydantoin; 5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione"	4060	C12H14N2O2	Approved
M6APDG01516	Menadione	"Menadion; Menadionum; Menaphthon; Menaphthone; Menaphtone; Menaquinone 0; Mitenon; Mitenone; Panosine; Prokayvit; Synkay; Aquakay; Aquinone; Hemodal; Juva-K; K-Thrombyl; K-Vitan; Kaergona; Kanone; Kappaxin; Karcon; Kareon; Kativ-G; Kayklot; Kaykot; Kayquinone; Kipca-Oil Soluble; Klottone; Koaxin; Kolklot; Thyloquinone; Vitamin K 3; Vitamin K0; Vitamin K2(0); Vitamin K3; menadione; 2-Methyl-1,4-naphthalenedione; 2-Methyl-1,4-naphthochinon; 2-Methyl-1,4-naphthoquinone; 2-Methylnaphthoquinone; 2-methylnaphthalene-1,4-dione; 58-27-5; Kipca"	4055	C11H8O2	Approved
M6APDG03028	Melatonin	"Melatonex; Melatonin; Melatonine; Melovine; Circadin; JL5DK93RCL; Melatol; N-Acetyl-5-methoxytryptamine; N-acetyl-5-methoxy-tryptamine; 5-Methoxy-N-acetyltryptamine; 73-31-4; Acetamide, N-(2-(5-methoxyindol-3-yl)ethyl)-; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-; BRN 0205542; CCRIS 3472; CHEMBL45; EINECS 200-797-7; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide; N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide; N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide; N-[2-(5-methoxyindol-3-yl)ethyl]acetamide; NSC 113928; UNII-JL5DK93RCL"	896	C13H16N2O2	Phase 4
M6APDG02324	Lovastatin	Lestatin; Lipdip; Lipivas; Lipofren; Lovalip; Lovalord; Lovastatina; Lovastatina [Spanish]; Lovastatine; Lovastatine [French]; Lovastatinum; Lovastatinum [Latin]; Lovasterol; Lovastin; Lozutin; MK 803; MK-803; MSD 803; Mevacor; Mevinacor; Altocor; Altoprev; Artein; Belvas; Cholestra; Closterol; Colevix; Hipolip; Hipovastin; Mevlor; Monacolin K; Nergadan; Paschol; Rodatin; Rovacor; Sivlor; Taucor; Tecnolip; Teroltrat; lovastatin; mevinolin; 6 alpha-Methylcompactin; 6-alpha-Methylcompactin; 6alpha-Methylcompactin; 75330-75-5; UNII-9LHU78OQFD	53232	C24H36O5	Approved
M6APDG00468	Losartan potassium	"Losartan [INN:BAN]; Losartan monopotassium salt; losartan; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; 114798-26-4; 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol; C22H23ClN6O; CHEBI:6541; MFCD00865831; UNII-JMS50MPO89; [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; DUP 89; JMS50MPO89; Lifezar; Lorzaan; Lorzaar; Losacar; Losacor; Losaprex; Losartan Potassium (DuP 753); MK 0954; MK 954; MK-0954; Neo Lotan; Ocsaar; Tenopres; losartan potassium salt; losartanpotassium; 124750-99-8; 2-Butyl-4-chloro-1-(2'-(tetrazol-5-yl)biphenyl-4-ylmethyl)-1H-imidazole-5-methanol potassium; 3ST302B24A; C22H22CIKN6OK; Lotim; Niten; UNII-3ST302B24A; Du Pont 753; ERYTHROPOIETIN; L-158086"	11751549	C22H22ClKN6O	Approved
M6APDG02929	Lorlatinib	"Loratinib; Lorbrena; Lorlatinib; Lorlatinib,PF-06463922; OSP71S83EU; PF 06463922; PF-06463922; PF06463922; (10R)-7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile; (10r)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2h-8,4-(Metheno)pyrazolo[4,3-H][2,5,11]benzoxadiazacyclotetradecine-3-Carbonitrile; 1454846-35-5; CHEMBL3286830; MFCD28144520; UNII-OSP71S83EU"	71731823	C21H19FN6O2	Approved
M6APDG01497	Loratadine	Lertamine; Lesidas; Lisino; Loracert; Loradex; Loradif; Loranox; Lorantis; Lorastine; Loratidine; Loratyne; Loraver; Lorfast; Loritine; Lowadina; Nularef; Optimin; Polaratyne; Restamine; Rhinase; Rinomex; Sanelor; Sch 29851; Sensibit; Aerotina; Alarin; Alavert; Alerpriv; Allertidin; Anhissen; Bedix Loratadina; Biloina; Bonalerg; Civeran; Claratyne; Clarinase; Claritin; Claritin Reditabs; Claritine; Clarityn; Clarityne; Fristamin; Histaloran; Sinhistan Dy; Sohotin; Tadine; Talorat Dy; Velodan; Versal; loratadine; 79794-75-5; Lergy; Pylor; Zeos	3957	C22H23ClN2O2	Approved
M6APDG02906	Loperamide hydrochloride	"Loperamida; Loperamida [INN-Spanish]; Loperamide [INN:BAN]; Loperamidum; Loperamidum [INN-Latin]; Maalox Anti-Diarrheal; Nu-Loperamide; PMS-Loperamide; R-18553; Rho-Loperamide; loperamide; 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide; 53179-11-6; 6X9OC3H4II; BRN 1558273; C29H33ClN2O2; CHEMBL841; EINECS 258-416-5; UNII-6X9OC3H4II; Apo-Loperamide; Imodium A-D Caplets; Ioperamide; Kaopectate II; Loperacap; Dissenten; Fortasec; Imosec; Lopemid; Lopemin; Loperamide (hydrochloride); Loperamide HCl; Loperamide hydrochloride; Loperyl; Maalox Antidiarrheal; R 18553; Suprasec; Tebloc; 34552-83-5; 4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-N,N-dimethyl-2,2-diphenylbutanamide hydrochloride; 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide hydrochloride; BLOX; BREK; CHEBI:6533; EINECS 252-082-4; MFCD00058581; MLS000069779; PJ185; UNII-77TI35393C"	71420	C29H34Cl2N2O2	Approved
M6APDG00819	CKD-501	Lobeglitazone sulfate; SB16870; BDBM50152829; CHEMBL3780740; CKD 501; CKD-501	15951505	C24H26N4O9S2	Phase 3
M6APDG01455	Lidocaine	"Leostesin; Lida-Mantle; Lidocaine (VAN); Lidoderm; Lignocaine; Lignocainum; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Alphacaine; Anestacon; Cappicaine; Cito optadren; Cuivasil; Dalcaine; Dentipatch; Duncaine; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; L-Caine; Xilocaina; Xllina; Xycaine; Xylestesin; Xylocain; Xylocaine; Xylocitin; Xyloneural (free base); Xylotox; lidocaine; 137-58-6; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide"	3676	C14H22N2O	Approved
M6APDG00609	ML-3000	"Licofelone; Licofelone [INN]; ML 3000; ML-3000; P5T6BYS22Y; 156897-06-2; 2,3-Dihydro-6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-1H-pyrrolizine-5-acetic acid; 2-[2-(4-chlorophenyl)-6,6-dimethyl-1-phenyl-5,7-dihydropyrrolizin-3-yl]acetic acid; 6-(4-Chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl-1H-pyrrolizine-5-acetic acid; BRN 6823674; C23H22ClNO2; CHEMBL300982; UNII-P5T6BYS22Y; [6-(4-CHLOROPHENYL)-2,2-DIMETHYL-7-PHENYL-2,3-DIHYDRO-1H-PYRROLIZIN-5-YL]ACETIC ACID"	133021	C23H22ClNO2	Discontinued
M6APDG02845	Levomilnacipran	"Levomilnacipran; Levomilnacipran (USAN/INN); Levomilnacipran [USAN:INN]; Milnacipram; SB17447; SCHEMBL1414867; UGM0326TXX; ZINC506; (+)-Milnacipran; Fetzima; GJJFMKBJSRMPLA-DZGCQCFKSA-N; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1S,2R)-milnacipran; 96847-54-0; 96847-55-1; AC1OCEN8; BDBM50032379; CHEBI:136040; CHEMBL99946; D10072; DB08918; F 2695; F-2695; GTPL7435; UNII-UGM0326TXX; f2-695"	6917779	C15H22N2O	Approved
M6APDG01494	Levomethadyl acetate hydrochloride	"Levacetilmetadol; Levacetilmetadol [INN-Spanish]; Levacetylmethadol; Levacetylmethadol (INN); Levacetylmethadol [INN]; Levacetylmethadolum; Levacetylmethadolum [INN-Latin]; Levomethadyl; Levomethadyl acetate; Levacetyl methadol hydrochloride; LAAM hydrochloride; Levomethadyl acetate HCl; MK 790; MK-790 hydrochloride; ORLAAM hydrochloride; l-Acetylmethadol hydrochloride; (-)-(3S,6S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester), hydrochloride; 43033-72-3; 6-Dimethylamino-4,4-diphenyl-3-heptanolacetate.HCl; B54CW5KG52; CCRIS 3321; Levomethadyl acetate hydrochloride; Levomethadyl acetate hydrochloride [USAN]; UNII-B54CW5KG52; alpha-l-Acetylmethadol hydrochloride; l-alpha-Acetylmethadol hydrochloride; N-alpha-Acetylmethadol; Orlaam; alpha-l-Acetylmethadol; l-alpha-Acetylmethadol; levo-Alphacetylmethadol; levo-Methadyl acetate; levo-alpha-Acetylmethadol; (-)-alpha-Acetylmethadol; 1-alpha-Acetylmethadol; 1477-40-3; DEA No. 9648; LAAM; UNII-R3B637Y991; alpha-(-)-Acetylmethadol"	39371	C23H32ClNO2	Approved
M6APDG03286	Lapatinib ditosylate	Lapatinib (GW-572016) Ditosylate; Lapatinib (ditosylate); Lapatinib Ditosylate; Tykerb Ditosylate; 388082-77-7; 4WK72K94MC; AK-47669; GW-57201; GW-572016F Ditosylate; N-(3-CHLORO-4-((3-FLUOROBENZYL)OXY)PHENYL)-6-(5-(((2-(METHYLSULFONYL)ETHYL)AMINO)METHYL)FURAN-2-YL)QUINAZOLIN-4-AMINE BIS(4-METHYLBENZENESULFONATE); N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine; UNII-4WK72K94MC; bis(4-methylbenzene-1-sulfonic acid)	9941095	C43H42ClFN4O10S3	Approved
M6APDG01481	Lansoprazole	Lancid; Lanproton; Lansopep; Lansoprazol; Lansoprazol [INN-Spanish]; Lansoprazole [USAN:BAN:INN]; Lansoprazolum; Lansoprazolum [INN-Latin]; Lansox; Lanston; Lanzol-30; Lanzopral; Lanzor; Lasoprol; Limpidex; Mesactol; Monolitum; Ogastro; Opiren; Agopton; Aprazol; Bamalite; Blason; Compraz; Ilsatec; Ketian; Prevacid; Prevacid 24HR; Prevacid Iv; Prevacid NapraPAC; Prevacid SoluTab; Prezal; Pro Ulco; Prosogan; Suprecid; Takepron; Zoprol; lansoprazole; 103577-45-3; A-65006; AG 1749; AG-1749; CHEBI:6375; Dakar; HSDB 7204; Lanz; Lanzo; Ogast; Promp; Ulpax; Zoton	3883	C16H14F3N3O2S	Approved
M6APDG01475	Ketorolac	"Ketoralac; Ketorolac [INN:BAN]; Ketorolaco; Ketorolaco [Spanish]; Ketorolacum; Ketorolacum [Latin]; Macril; OZWKMVRBQXNZKK-UHFFFAOYSA-N; RS 37619; RS-37619; Toradol (TN); ketorolac; (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; (+-)-Ketorolac; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-; 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 66635-83-4; 74103-06-3; CHEBI:76223"	3826	C15H13NO3	Approved
M6APDG03006	Ketobemidone	"Ketobemidone HCl; Ketobemidone hydrochloride; Ketobimedon hydrochloride; Ketogan (TN); Cliradon hydrochloride; LS-123062; SCHEMBL9706814; U9U6LTV80K; 1-Methyl-4-(m-hydroxyphenyl)piperidine-4-ethylketone hydrochloride; 1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)-, hydrochloride; 1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one hydrochloride(1:1); 5965-49-1; AC1L2YOJ; AC1Q5G7W; D08101; DTXSID00208327; EINECS 227-749-8; UNII-U9U6LTV80K"	80069	C15H22ClNO2	Phase 4
M6APDG01244	Ixazomib	"Ixazomib; Ixazomib (MLN2238); Ixazomib (USAN); Ixazomib Impurity; Ixazomib [INN]; Ixazomib [USAN:INN]; Ixazomib(MLN2238); Ixozamib; MLN 2238; MLN-2238; MLN2238; MLN2238(Ixazomib); SCHEMBL3742758; (R)-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)boronic acid; (R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid; 1072833-77-2; 71050168A2; C14H19BCl2N2O4; CHEBI:90942; CHEMBL2141296; CTK4A5116; EX-A547; GTPL8450; KS-00000PQX; UNII-71050168A2"	25183872	C14H19BCl2N2O4	Approved
M6APDG02311	Istradefylline	"Istradefylline; Istradefylline (KW-6002); KW 6002; KW-6002; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methyl-1H-purine-2,6(3H,7H)-dione; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine; 155270-99-8; 2GZ0LIK7T4; 8-[(E)-2-(3,4-Dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methyl-purine-2,6 -dione; 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione; CHEMBL431770; UNII-2GZ0LIK7T4"	5311037	C20H24N4O4	Approved
M6APDG01466	Irbesartan	"Irbesartan [USAN:INN]; J0E2756Z7N; Karvea; SR 47436; SR-47436; YOSHYTLCDANDAN-UHFFFAOYSA-N; irbesartan; 138402-11-6; Aprovel; Avapro; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one; 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one; AK-57149; BMS 186295; BMS-186295; C25H28N6O; CHEBI:5959; CHEMBL1513; MFCD00864464; NCGC00095122-01; UNII-J0E2756Z7N"	3749	C25H28N6O	Approved
M6APDG00544	Imatinib mesylate	"Imatinib; Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; Imatinib free base; Imatinib(STI571); Gleevec; Glivec; Imatinib (mesylate); Imatinib Mesylate (STI571); Imatinib mesilate; Imatinib mesylate; Imatinib mesylate (USAN); Imatinib mesylate, 98%; Imatinib, methanesulfonate salt; ST-1571 Mesylate; imatinib methanesulfonate; imatinib monomesylate; 220127-57-1; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate; 8A1O1M485B; AK-44930; CGP-57148B; CHEBI:31690; HSDB 7142; NSC-716051; UNII-8A1O1M485B; STI571; 152459-95-5; 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE; CCRIS 9076; CGP-57148; CHEMBL941; Cgp 57148; N-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; BKJ8M8G5HI; UNII-BKJ8M8G5HI"	123596	C30H35N7O4S	Approved
M6APDG01456	Ifosfamide	"Ifosfamid; Ifosfamida; Ifosfamida [INN-Spanish]; Ifosfamide Sterile; Ifosfamidum; Ifosfamidum [INN-Latin]; Ifosphamide; Ifsofamide; Iphosphamid; Iphosphamide; Isoendoxan; Isofosfamide; Isophosphamide; MJF 9325; MJF-9325; Mitoxana; Naxamide; ASTA Z 4942; Holoxan; Holoxan 1000; I-Phosphamide; Z 4942; Z-4942; ifomide; ifosfamide; isosfamide; 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; 3778-73-2; A 4942; CCRIS 352; Cyfos; Ifex; NCI-C01638; NSC 109724; NSC-109724; NSC109724; UNII-UM20QQM95Y; Z4942"	3690	C7H15Cl2N2O2P	Approved
M6APDG02996	Hydrogen peroxide	"Hydrogen dioxide; Hydrogen dioxide solution; Hydrogen peroxide (H2O2); Hydrogen peroxide solution; Hydrogen peroxide, 30%; Hydrogen peroxide, 90%; Hydrogen peroxide, solution; Inhibine; Interox; Kastone; Lensept; Perone; Perone 30; Perone 35; Albone; Dihydrogen dioxide; Elawox; Hioxyl; Perone 50; Peroxaan; Peroxan; Peroxide; Superoxol; T-Stuff; Wasserstoffperoxid; Waterstofperoxyde; hydrogen peroxide; hydroperoxide; oxydol; perhydrol; 7722-84-1; Albone 35; Albone 35CG; Albone 50; Albone 50CG; Albone 70; Albone 70CG; Albone DS; H2O2"	784	H2O2	Approved
M6APDG02987	Heparin	Heparin [BAN]; Heparina; Heparine; Heparinum; Hepathrom; Lipo-hepin; Liquaemin; Liquemin; Lovenox; Lovenox HP; Low molecular weight heparin; Multiparin; Nadroparin; Nadroparine; Normiflo; Novoheparin; Octaparin; PK-10169; Pabyrin; Parnaparin; Adomiparin; Ardeparin; Bemiparin; Clexane; Clivarin; Depo-Heparin; Eparina [DCIT]; Fluxum; Fragmin A; Fragmin B; Hed-heparin; Parvoparin; Pularin; Reviparin; SEMULOPARIN; Sandoparin; Subeparin; Sublingula; Tinzaparin; Triofiban; Vetren; Vitrum AB; enoxaparin; heparin; 9005-49-6; CY 216; FR 860; LMWH	772	C26H42N2O37S5	Approved
M6APDG01465	Halofantrine	"Halfan; Halofantrina; Halofantrina [INN-Spanish]; Halofantrine; Halofantrine (INN); Halofantrine HCl; Halofantrine [USAN]; Halofantrinum; Halofantrinum [INN-Latin]; R7ADS21FSN; dl-WR 171669; 3-(Dibutylamino)-1-(1,3-dichlor-6-(trifluormethyl)-9-phenanthryl)propanol; 3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol; 69756-53-2; MLS002154111; FOHHNHSLJDZUGQ-UHFFFAOYSA-N; UNII-R7ADS21FSN"	37393	C26H30Cl2F3NO	Approved
M6APDG00634	Folic acid	Folacid; Folacin; Folaemin [Netherlands]; Folasic (Australia); Folate; Folbal; Folcidin; Folcysteine; Foldine; Foldine [France]; Folettes; Foliamin; Folicet; Folico (Italy); Folina (Italy); Folipac; Folsan; Folsaure; Folsav; Folvite; Acifolic; Antianemia factor; Acfol (Spain); Cytofol; Factor U; Incafolic; Millafol; Mittafol; PteGlu; Pteroyl-L-glutamic acid; Pteroyl-L-monoglutamic acid; Pteroylglutamic acid; Pteroylmonoglutamate; Pteroylmonoglutamic acid; Vitamin B9; Vitamin Bc; Vitamin Be; Vitamin M; folic acid; 59-30-3; Facid; Folan	135398658	C19H19N7O6	Approved
M6APDG01104	Fluvastatin sodium	"Fluindostatin sodium; Fluvastatin (sodium); Fluvastatin sodium (Lescol); Fluvastatin sodium salt; Fluyastatin Sodium Salt; Fractal; Lescol XL; Lipaxan; Lochol; Prestwick_1032; Sri 62320; Sri-62320; Vastin; XU 62-320; XU-62-320; Xilep XL; 93957-55-2; 94061-80-0; AB01274723-01; C24H25FNNaO4; CAS-93957-55-2; CHEBI:77602; Canef; DSSTox_CID_24758; DSSTox_GSID_44758; DSSTox_RID_80451; Locol; SMR000550480; Sodium (3R,5S,E)-7-(3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoate; FLUVASTATIN SODIUM; Fluvastatin [INN:BAN]; XU 62320; XU-62320; fluvastatin; (+)-(3R,5S)-fluvastatin; (3R,5S)-fluvastatin; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 93957-54-1; C24H26FNO4; CHEBI:38565; EN300-51915; CHEMBL1078"	23663976	C24H25FNNaO4	Approved
M6APDG01448	Etoposide	"Eposin; Etopophos (phosphate salt); Etoposide (VP16); Etoposido; Etoposido [INN-Spanish]; Etoposidum; Etoposidum [INN-Latin]; Lastet; NK 171; Toposar; VP 16 (pharmaceutical); VP 16-213; VP 16213; VP-16-213; VePesid; Vepesid J; Zuyeyidal; etoposide; trans-Etoposide; (-)-Etoposide; 33419-42-0; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; CCRIS 2392; EINECS 251-509-1; HSDB 6517; NSC 141540; NSC-141540; UNII-6PLQ3CP4P3; VP 16; VP-16"	36462	C29H32O13	Approved
M6APDG02569	Ethinyl estradiol	Ertonyl; Esteed; Estigyn; Estinyl; Eston-E; Estoral; Estorals; Ethidol; Ethinoral; Ethinyloestradiol; Ethynyl estradiol; Ethynylestradiol; Eticyclin; Eticyclol; Etinestrol; Etinestryl; Etinoestryl; Etistradiol; Feminone; Follicoral; Amenoron; Diogyn E; Dyloform; ETHINYLESTRADIOL; Ginestrene; Inestra; Linoral; Lynoral; Menolyn; Neo-Estrone; Nogest-S; Novestrol; Oradiol; Orestralyn; Palonyl; Perovex; Primogyn; Primogyn C; Primogyn M; Progynon C; Spanestrin; ethinyl estradiol; 17-Ethinylestradiol; 17-Ethynylestradiol; 17alpha-Ethynylestradiol; 57-63-6	5991	C20H24O2	Approved
M6APDG03105	Eszopiclone	"Esopiclone; Estorra; Eszopiclone; Eszopiclone [USAN:INN]; Lunesta; SEP-190; SEP-225441; UZX80K71OE; ( )-Zopiclone; (+)-Zopiclone; (5S)-6-(5-CHLOROPYRID-2-YL)-5-(4-METHYLPIPERAZIN-1-YL)CARBONYLOXY-7-OXO-6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRAZINE; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (S)-Zopiclone; 138729-47-2; CHEBI:53760; HSDB 7472; UNII-UZX80K71OE; [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate"	969472	C17H17ClN6O3	Approved
M6APDG02553	Estrone	Endofolliculina; Estron; Estrone-A; Estrugenone; Estrusol; Femidyn; Folikrin; Folipex; Folisan; Follestrine; Follestrol; Folliculine; Aquacrine; Cristallovar; Crystogen; Destrone; Disynformon; Follicunodis; Glandubolin; Hiestrone; Hormestrin; Hormovarine; Kestrone; Ketodestrin; Ketohydroxyestrin; Ketohydroxyoestrin; Kolpon; Menagen; Menformon; Mestronaq; OESTRONE; Oestrin; Oestroform; Oestronum; Oestroperos; Ovifollin; Perlatan; Solliculin; Theelin; Thelykinin; Thynestron; Wynestron; estrone; estrovarin; follicular hormone; folliculin; 53-16-7; Unden	5870	C18H22O2	Approved
M6APDG00740	Estradiol valerate	Estradiol valerate; Delestrogen; 979-32-8; Progynova; Neofollin; Estraval; Femogex; Progynon-Depot; Estradiol valerianate; Estradiol 17-valerate; Oestradiol valerate; Pharlon; Duratrad; Deladiol; Climaval; Atladiol; Estate; Dura-estradiol; Exten strone; Repo-Estra; Depo estro med; Estraval PA; Delestrogen 4X; Estraval 2X; Estroval-10; Delahormone unimatic; Depo-Estro-Med; Femogen-L.A.; Ronfase; Pelanin; Merimono; Cyclocur; Postoval; Nuvelle; Primogyna; Gynokadin; Estradiol Depot; Primogyn-Depot; Gynogen L.A. 20; Gynogen L.A. 40; Gynogen L.A. 10	13791	C23H32O3	Approved
M6APDG03088	Estradiol cypionate	"Estradiol cypionate; Depofemin; Depoestradiol; Depo-Estradiol; 313-06-4; Estrapo; Estradep; Depoestra; Estro-Depo; Dep-Estro; Femogen CYP; depGynogen; Depoestradiol cypionate; beta-Estradiol 17-cypionate; Estradiol 17-cypionate; Estradiol cyclopentylpropionate; Pertradiol; Estradiol (cypionate); E. Ionate P.A.; Neoginon Depositum; Estradiol 17-cyclopentylpropionate; Depo-estradiol cyclopentylpropionate; ECP (VAN); Estradiol 17beta-cypionate; NSC 3354; UNII-7E1DV054LO; Cyclopentanepropionic acid, 17-ester with estradiol"	9403	C26H36O3	Approved
M6APDG03129	Estradiol acetate	"Estradiol 3-acetate; Estradiol acetate (USAN); Estradiol acetate [USAN]; Estradiol, 3-acetate; Estradiol-3-acetate; FHXBMXJMKMWVRG-SLHNCBLASA-N; Femring; Femring (TN); Menoring; UNII-5R97F5H93P; beta-Estradiol 3-acetate; 17beta-Estradiol 3-acetate; 17beta-Hydroxy-3-acetoxyestra-1,3,5(10)-triene; 3-Acetoxyestra-1,3,5(10)-trien-17beta-ol; 3-O-Acetylestradiol; 4245-41-4; 5R97F5H93P; CAS-4245-41-4; DSSTox_CID_25867; DSSTox_GSID_45867; DSSTox_RID_81186; E 3A; E3A; Estra-1,3,5(10)-triene-3,17beta-diyl 3-acetate"	9818306	C20H26O3	Approved
M6APDG00567	Erythromycin stearate	"Eratrex; Erypar; Erythrocin stearate; Erythromycin octadecanoate (salt); Erythromycin stearate (salt); Erythromycin stearate [BAN:JAN]; Erythromycin steraric acid salt; Erythromycin, stearate (salt); Ethril; Ethril 250; Gallimycin; HSDB 4178; LXW024X05M; Meberyt; NCI-C55674; OE 7; Octadecanoic acid, compd. with erythromycin (1:1); Pfizer-E; Qidmycin; Stearic acid, compd. with erythromycin (1:1); UNII-LXW024X05M; Wyamycin S; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erygel; Erymax; Erythra-Derm; Erythro-Statin; Erythrocin; Erythromycin; Erythrogran; Erythroguent; Erythromid; Erythromycin A; Erythromycin base; Erythromycine; Erythromycinum; Ilocaps; Ilotycin; Mephamycin; Pantomicina; Propiocine; R-P Mycin; Robimycin; Sansac; Stiemycin; Torlamicina; Wemid; Erythro; (-)-ERYTHROMYCIN; 114-07-8; Abboticin; Abomacetin; Akne-Mycin; Benzamycin; Dotycin; Dumotrycin; E-Base; E-Glades; E-Mycin; E-Solve 2; Emgel; Eritrocina; Eritromicina; Ery-Tab; Eryacne; Eryc 125; Eryc Sprinkles; 643-22-1; Abboticine; Bristamycin; CCRIS 1504; Dowmycin E; EINECS 211-396-1; ERYTHROMYCIN STEARATE; ETHRIL 500"	12559	C55H103NO15	Approved
M6APDG03029	Enasidenib	"Enasidenib; Enasidenib mesylate; IDHIFA; 1446502-11-9; 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol; 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-; 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol; 3T1SS4E7AG; AG-221; CC-90007; CC-90007 Free Base; UNII-3T1SS4E7AG"	89683805	C19H17F6N7O	Approved
M6APDG00666	Eltrombopag olamine	EltroMbopag diethanolaMine salt; Eltrombopag (Olamine); Eltrombopag olamine; Eltrombopag olamine (JAN/USAN); Eltrombopag olamine [USAN:JAN]; Eltrombopag-SB-497115-GR; FT-0773802; HY-15306A; MFCD22380664; PLILLUUXAVKBPY-SBIAVEDLSA-N; Promacta; Promacta (TN); Promacta Olamine; Revolade; SB 497115GR; SB-497115-GR; SB-497115GR; SB19102; SCHEMBL16207741; SCHEMBL210183; UNII-4U07F515LG; Z-3296; 3608AH; 496775-62-3; 4U07F515LG; AC-26286; AKOS025396658; BCP07055; C25H22N4O4.2C2H7NO; CHEMBL3989691; CHEMBL4097947; CS-1566; D03978	135449331	C29H36N6O6	Approved
M6APDG03336	Domperidone	"Domperidona; Domperidona [INN-Spanish]; Domperidone (Motilium); Domperidonum; Domperidonum [INN-Latin]; KW 5338; KW-5338; Lopac-D-122; Motilium; Motillium; Motinorm; Nauzelin; R 33,812; R-33812; R33812; domperidone; 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine; 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone; 57808-66-9; BRN 0903774; CHEBI:31515; CHEMBL219916; Costi; EINECS 260-968-7; MFCD00069256; MLS000069343; NSC299589; UNII-5587267Z69"	3151	C22H24ClN5O2	Approved
M6APDG01865	SC-411	"AquaGrow Advantage; Cervonic acid; Doconexent; Doconexento; Doconexentum; Docosahexaenoate; Docosahexaenoic acid; Docosahexaenoic acid (all-Z); Doxonexent; Martek DHA HM; Ropufa 60; ZAD9OKH9JC; all-Z-Docosahexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; 6217-54-5; CCRIS 7670; CHEMBL367149; UNII-ZAD9OKH9JC; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; all-cis-DHA; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; cis-4,7,10,13,16,19-Docosahexaenoic acid"	445580	C22H32O2	Phase 3
M6APDG02627	Diltiazem hydrochloride	Dilicardin; Dilpral; Diltahexal; Diltelan; Diltiasyn; Diltiazem HCl; Diltiazem hydrochloride; Diltikor; Diltime; Dilzem; Dilzene; Dilzicardin; Dinisor; Dodexen; Farmabes; Gadoserin; Helsibon; Herbesser; Incoril; Kaltiazen; Lacerol; Levozem; Longazem; Lytelsen; Masdil; Miocardie; Mono-Tildiem; Oxycardil; Poltiazem; Presoken; Surazem; Tilazem; Tildiem; Trumsal; Ziruvate; Diltiazem; Diltiazem [INN:BAN]; Diltiazemum; Diltiazemum [INN-Latin]; Diltiazen; Dilticard; Diltzac; Dilzen; EE92BBP03H; EINECS 255-796-4; Endrydil; HSDB 6528; HSUGRBWQSSZJOP-RTWAWAEBSA-N; Incoril AP; Tiamate; Tiazac XC; UNII-EE92BBP03H; d-cis-Diltiazem; (+)-cis-diltiazem; (+)-diltiazem; 42399-41-7; Acalix; Adizem; Anoheal; BRN 3573079; CHEBI:101278; CHEMBL23; Cardil; Cardizem; Dilacor; Dilacor-XR; Dilcontin; Dilren; Dilt-cd; Dilta-Hexal; (+)-cis-Diltiazem hydrochloride; 33286-22-5; Altiazem; Anginyl; Bi-Tildiem; Britiazim; CRD-401; Calnurs; Cardizem CD; Cardizem LA; Cirilen; Citizen; Clarute; Corazet; Deltazen	62920	C22H27ClN2O4S	Approved
M6APDG01944	Diethylstilbestrol	Diastyl; Diethylstilbesterol; Distilbene; Domestrol; Dyestrol; Estrobene; Estromenin; Estrosyn; Fonatol; Grafestrol; Iscovesco; Makarol; Menostilbeen; Micrest; Microest; Milestrol; OeKolp; Oestrogenine; Oestromenin; Oestromensyl; Oestromienin; Pabestrol; Palestrol; Serral; Sexocretin; Stilbestrol; Stilbestrone; Stilbetin; Stilboefral; Agostilben; Antigestil; Comestrol; Cyren A; Stilboestroform; Stilboestrol; Stilbofolin; Stilkap; Synestrin; Synthoestrin; Synthofolin; Syntofolin; Vagestrol; diethylstilbestrol; 56-53-1; Bufon; Cyren; Desma; Sibol	448537	C18H20O2	Approved
M6APDG02185	Diclofenac sodium	"Delimon; Delphimix; Dichronic; Diclofenac (Sodium); Diclofenac sodium; Diclofenac sodium salt; Diclophenac sodium; Dyloject; EINECS 239-346-4; Feloran; GP 45840; Kriplex; Neriodin; Olfen; Orthophen; Ortofen; Prophenatin; Sodium (o-(2,6-dichloroanilino)phenyl)acetate; Sodium diclofenac; Tsudohmin; UNII-QTG126297Q; Urigon; Valetan; Voltaren ophthalmic; Voltarene; Vonafec; Vurdon; Diclofenac; Diclofenac acid; Diclofenac resinate; Diclofenaco; Diclofenaco [INN-Spanish]; Diclofenacum; Diclofenacum [INN-Latin]; Diclophenac; Novapirina; Pennsaid; ProSorb-D; UNII-144O8QL0L1; Voltaren; Voltarol; Dichlofenac; 15307-86-5; 2-((2,6-Dichlorophenyl)amino)benzeneacetic acid; 2-(2,6-Dichloroanilino)phenylacetic Acid; 2-(2-((2,6-Dichlorophenyl)amino)phenyl)acetic acid; 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid; Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-; CHEBI:47381; Cataflam; 15307-79-6; Allvoran; Anthraxiton; Assaren; Ba 47210; Batafil; Blesin; C14H10Cl2NNaO2; CCRIS 1909"	5018304	C14H10Cl2NNaO2	Approved
M6APDG01357	Dibutylphthalate	"Butyl phthalate; Celluflex DPB; DBP (ester); DIBUTYLPHTHALATE; Di-n-butyl phthalate; Dibutyl 1,2-benzenedicarboxylate; Dibutyl o-phthalate; Dibutyl-o-phthalate; Ergoplast FDB; Ersoplast FDA; Genoplast B; Hatcol DBP; Hexaplas M/B; Kodaflex DBP; N-Butylphthalate; Palatinol C; Phthalate, di-n-butyl; Phthalic acid dibutyl ester; Polycizer DBP; RC Plasticizer DBP; Staflex DBP; Uniflex DBP; Unimoll DB; Witcizer 300; dibutyl benzene-1,2-dicarboxylate; dibutyl phthalate; n-Butyl phthalate; 84-74-2; Elaol"	3026	C16H22O4	Investigative
M6APDG01356	Diazepam	Diacepan; Diapam; Diazemuls; Diazepan; Diazetard; Dipezona; Domalium; Faustan; Kiatrium; Levium; Liberetas; Methyldiazepinone; Neurolytril; Paranten; Quetinil; Quiatril; Quievita; Relaminal; Relanium; Renborin; Ruhsitus; Sedipam; Seduksen; Amiprol; Ansiolin; Ansiolisina; Apaurin; Apozepam; Assival; Atensine; Atilen; Bensedin; Bialzepam; Calmocitene; Calmpose; Ceregulart; Condition; Seduxen; Serenack; Serenamin; Serenzin; Sibazon; Sonacon; Stesolid; Stesolin; Tensopam; Tranimul; Tranqdyn; Tranquirit; Umbrium; Unisedil; Valitran; Valium; diazepam; 439-14-5	3016	C16H13ClN2O	Approved
M6APDG01503	Dexibuprofen	Dexibuprofen [INN]; Dexibuprofen [USAN]; Dexibuprofen [BAN]; DEXIBUPROFEN; S(+)-Ibuprofen; S-(+)-ibuprofen; Seractil; d-Ibuproten; (+)-(S)-p-Isobutylhydratropic acid; (2S)-2-(4-isobutylphenyl)propanoic acid; (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid; (S)-(+)-2-(4-Isobutylphenyl)propionic acid; (S)-(+)-4-Isobutyl-alpha-methylphenylacetic acid; (S)-(+)-Ibuprofen; (S)-2-(4-Isobutylphenyl)propanoic acid; (S)-Ibuprofen; (S)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acid; 51146-56-6; 671DKG7P5S; CHEBI:43415; CHEMBL175; MFCD00069289; NCGC00016861-05; UNII-671DKG7P5S	39912	C13H18O2	Phase 4
M6APDG03344	Dasabuvir	"Dasabuvir; Dasabuvir [INN]; Dasabuvir [USAN:INN]; dasabuvir-abt-333; 1132935-63-7; ABT 333; ABT-333; ABT333; AK145466; C26H27N3O5S; CHEBI:85182; DE54EQW8T1; N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; N-(6-(3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide; UNII-DE54EQW8T1"	56640146	C26H27N3O5S	Phase 3
M6APDG01343	Dapsone	"Dapson; Dapsonum; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Diphenasone; Diphone; Disulone; Dubronax; Dumitone; Eporal; Metabolite C; Novophone; Sulfadione; Sulfona; Sulfona-MAE; Sulphadione; Sulphonyldianiline; Aczone; Avlosulfon; Avlosulfone; Avlosulphone; Bis(4-aminophenyl) sulfone; Croysulfone; Croysulphone; Sumicure S; Tarimyl; Udolac; dapsone; p-Aminophenyl sulfone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenylsulfone; 4,4'-Sulfonyldianiline; 4-Aminophenyl sulfone; 80-08-0; DADPS"	2955	C12H12N2O2S	Approved
M6APDG01851	Dabrafenib mesylate	"Dabrafenib (Mesylate); Dabrafenib Mesylate (GSK-2118436); Dabrafenib Mesylate (GSK-2118436B); Dabrafenib mesylate; Dabrafenib mesylate (USAN); Dabrafenib mesylate [USAN]; Dabrafenib methanesulfonate; METHANE SULFONATE SALT; Tafinlar (TN); Taflinar; 1195768-06-9; B6DC89I63E; CHEBI:75048; GSK 2118436B; GSK-2118436A; GSK-2118436B; GSK2118436 Methane sulfonate salt; GSK2118436B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate; UNII-B6DC89I63E"	44516822	C24H24F3N5O5S3	Approved
M6APDG01341	Cyclophosphamide	Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cyclofosphamide; Cyclophosphamid; Cyclophosphamide anhydrous; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxan R; Endoxan-Asta; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Lyophilized Cytoxan; Mitoxan; Neosar; Procytox; Rcra waste number U058; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; cyclophosphamide; (+-)-Cyclophosphamide; (RS)-Cyclophosphamide; 50-18-0	2907	C7H15Cl2N2O2P	Approved
M6APDG02624	Cyamemazine	Ciamatil; Ciamemazina [INN-Spanish]; Cianatil; Cyamemazin; Cyamemazine; Cyamemazine (INN); Cyamemazine [INN]; Cyamemazinum [INN-Latin]; Cyamepromazine; Cyamepromezine; Kyamepromazin; Kyamepromazine; RP-7204; TH 2602; Tercian; 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine-2-carbonitrile; 10-(3-dimethylamino-2-methylpropyl)phenothiazine-2-carbonitrile; 10-[3-(Dimethylamino)-2-methylpropyl]-10H-phenothiazine-2-carbonitrile; 3546-03-0; 7204 R.E.; 7204 RP; BRN 0093261; EINECS 222-594-2; F.I. 6229	62865	C19H21N3S	Investigative
M6APDG00636	Clozapine	"Clorazil; Clozapin; Clozapina; Clozapina [INN-Spanish]; Clozapinum; Clozapinum [INN-Latin]; Fazaclo; Fazaclo ODT; HF 1854; Asaleptin; CLOZARIL; HF-1854; LX 100-129; Leponex; Lepotex; clozapine; 5786-21-0; 5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)-; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; CCRIS 9171; HSDB 6478; Iprox; UNII-J60AR2IKIC; W-801"	135398737	C18H19ClN4	Approved
M6APDG01314	Cisapride	Cipride; Cisaprida [INN-Spanish]; Cisaprida [Spanish]; Cisapridum [INN-Latin]; Cisapridum [Latin]; Cisapron; Cisawal; Colinorm; Acpulsif; Alimix; Alimix Forte; Alipride; DCSUBABJRXZOMT-UHFFFAOYSA-N; Dispep; Enteropride; Esorid; Guptro; Kinestase; Prepulsid; Presid; Pridesia; Propulsid; Propulsid Quicksolv; Propulsin; Pulsid; R 51619; R-51619; Rapulid; Risamal; Syspride; Unamol; Unipride; Vomiprid; Vomipride; cisapride; 104860-73-3; 81098-60-4; Acenalin	2769	C23H29ClFN3O4	Approved
M6APDG01105	Cerivastatin sodium	"Cerivastatin sodium [USAN]; Cerivastatin, sodium salt; Certa; DSSTox_CID_26488; DSSTox_GSID_46488; DSSTox_RID_81659; Rivastatin; UNII-6Q18G1060S; Cerivastatin; Cerivastatin [INN:BAN]; HSDB 7357; UNII-AM91H2KS67; cerivastatin; cerivastatin acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; 145599-86-6; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; AM91H2KS67; CHEBI:3558; (+)-Sodium (3R,5S,6E)-7-(4-(p-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoate; 143201-11-0; 6Q18G1060S; 7-(4-(4-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyrid-3-yl)-3,5-dihydroxy-6-heptenoate sodium salt; Bay w 6228; Bay-w-6228; CERIVASTATIN Na; CERIVASTATIN SODIUM; CHEBI:3559; CPD000469148"	23663992	C26H33FNNaO5	Approved
M6APDG02540	Cefaloridine	Cefaloridin; Cefaloridina; Cefaloridina [INN-Spanish]; Cefaloridinum; Cefaloridinum [INN-Latin]; Cefalorizin; Ceflorin; Cepaloridin; Cepalorin; Cephalomycine; Cephaloridin; Cephaloridinum; Ceporan; Ceporin; Ceporine; Cilifor; Deflorin; Ampligram; Betaine cephaloridine; Faredina; Glaxoridin; Intrasporin; Keflodin; Keflordin; Kefloridin; Kefspor; Lloncefal; Loridine; Sasperin; Sefacin; Verolgin; Vioviantine; cefaloridine; cephaloridine; 50-59-9; CHEBI:3537; N-(7-(2'-Thienylacetamidoceph-3-ylmethyl))-pyridinium-2-carboxylate; UNII-LVZ1VC61HB	5773	C19H17N3O4S2	Phase 4
M6APDG01276	Carbamazepine	"Calepsin; Carbamazepen; Carbamazepin; Carbamazepina; Carbamazepinum; Carbamezepine; Carbatrol; Carbazepine; Carnexiv; Amizepin; Bipotrol; Biston; Epitol; Equetro; Finlepsin; Geigy 32883; Karbamazepin; Neurotol; Stazepin; Stazepine; Tegretal; Tegretol; Tegretol-Xr; Telesmin; Timonil; carbamazepine; 298-46-4; 5-Carbamoyl-5H-dibenz(b,f)azepine; 5-Carbamoyl-5H-dibenzo(b,f)azepine; 5-Carbamyl-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine-5-carboxamide; 5H-Dibenz[b,f]azepine-5-carboxamide; 5H-Dibenzo[b,f]azepine-5-carboxamide; Lexin; Teril"	2554	C15H12N2O	Approved
M6APDG00798	Capsaicin	"Capsaicin; Capsaicin (JAN/USP); Capsaicin [USAN]; Axsain; CAPSAICINE; E-CAPSAICIN; Isodecenoic acid vanillylamide; NGX-4010; Qutenza; Styptysat; Transacin; Vanilloid; ZOSTRIX (TN); Zostrix; trans-Capsaicin; (E)-8-Methyl-N-vanillyl-6-nonenamide; (E)-Capsaicin; 404-86-4; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)-; 8-Methyl-N-Vanillyl-6-Nonenamide; 8-Methyl-N-vanillyl-trans-6-nonenamide; C18H27NO3; CCRIS 1588; CHEBI:3374; Caswell No. 158; FEMA No. 3404; HSDB 954; NCI-C56564; NSC 56353; UNII-S07O44R1ZM; trans-8-Methyl-N-vanillyl-6-nonenamide"	1548943	C18H27NO3	Approved
M6APDG00927	AG-1549	"Capravirine; S 1153; S-1153; VHC779598X; 178979-85-6; 1H-Imidazole-2-methanol, 5-((3,5-dichlorophenyl)thio)-4-(1-methylethyl)-1-(4-pyridinylmethyl)-, carbamate (ester); 5-((3,5-Dichlorophenyl)thio)-4-isopropyl-1-(4-pyridylmethyl)imidazole-2-methanol carbamate (ester); 5-(3,5-dichlorophenyl)thio-4-isopropyl-1-(pyridin-4-yl-methyl)-1h-imidazol-2-yl-methyl carbamate; AG 1549; AG 549; AG-1549; CDIMI; S11; UNII-VHC779598X; {5-[(3,5-dichlorophenyl)sulfanyl]-4-isopropyl-1-(pyridin-4-ylmethyl)-1h-imidazol-2-yl}methyl carbamate"	1783	C20H20Cl2N4O2S	Phase 1
M6APDG01248	Caffeine	"Cafeina; Caffedrine; Caffein; Caffeine, synthetic; Caffine; Cafipel; Coffein; Coffeine; Coffeinum; Caffeine citrate; DHCplus; Dexitac; Durvitan; Eldiatric C; Guaranine; Hycomine; Koffein; Mateina; Methyltheobromide; Methyltheobromine; Nix Nap; No-Doz; Nodaca; Organex; Phensal; Quick-Pep; Refresh'n; Stim; Thein; Theine; Theophylline, 7-methyl; Tirend; Vivarin; Wigraine; caffeine; Caffeina citrate; Caffeine citrate (1:1); Caffeine citrated; Caffeine, Citrated; Citrated caffein; Citric acid, compd. with caffeine (1:1); DSSTox_CID_26938; DSSTox_GSID_46938; DSSTox_RID_82023; NCGC00015208-09; U26EO4675Q; UNII-U26EO4675Q; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione; 1,2,3-Propanetricarboxylic acid,2-hydroxy-,compounds,mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6- dione; 69-22-7; C8H10N4O2.C6H8O7; CAS-69-22-7; 1,3,7-Trimethyl-2,6-dioxopurine; 1,3,7-Trimethylxanthine; 1958/8/2; 3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione; 7-Methyltheophylline; Alert-pep; Anhydrous caffeine; Cafamil; Cafecon"	2519	C8H10N4O2	Approved
M6APDG03191	Cabazitaxel	Cabazitaxel (Jevtana); Cabazitaxel (USAN/INN); Cabazitaxel Injection; Cabazitaxel [USAN:INN]; Cabazitaxelum; Jevanta; Jevtana; Jevtana (TN); Jevtana Kit; RPR 116258A; RPR-116258A; SCHEMBL179674; TXD 258; TXD-258; TXD258; Taxoid XRP6258; XRP 6258; XRP-6258; CABAZITAXEL; Xrp6258; ZINC85536932; cabazitaxel-jevtana; 183133-96-2; 51F690397J; ABP001072; AKOS032947285; AN-1492; BMQGVNUXMIRLCK-OAGWZNDDSA-N; C45H57NO14; CHEBI:63584; CHEMBL1201748; CS-0972; DTXSID40171389; EX-A838; GTPL6798; MFCD18827611; NSC761432; UNII-51F690397J; s3022	9854073	C45H57NO14	Approved
M6APDG01361	Buprenorphine hydrochloride	"Belbuca; Buprenex (TN); Buprenorphine; Buprenorphine Depot; Buprex; CHEBI:652822; CL 112,302; CL 112302; CL-112302; EINECS 258-396-8; Finibron; MR 56; NIH 8805; NIH-8805; Norspan; RX 6029-M; RX 6029-M HCl; RX-6029-M; Transtec; UM 952; UM-952; UNII-56W8MW3EN1; Buprenex; Buprenophine; Buprenorfina; Buprenorfina [INN-Spanish]; Buprenorphinum; Buprenorphinum [INN-Latin]; CAM2038; CHEBI:3216; EINECS 257-950-6; Probuphenine; Probuphine; RX 6029M; Temgesic (TN); UNII-40D3SCR4GZ; (-)-buprenorphine; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 40D3SCR4GZ; 6029-M; Buprel; 21-Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine hydrochloride; 53152-21-9; 56W8MW3EN1; BEMA LA; BEMA-buprenorphine; BUPRENORPHINE HYDROCHLORIDE"	3033050	C29H42ClNO4	Approved
M6APDG02827	Brigatinib	"Brigatiib; Brigatinib; Brigatinib (AP26113); Brigatinib (USAN); Brigatinib [USAN]; HYW8DB273J; Alunbrig (TN); 1197953-54-0; 2,4-Pyrimidinediamine, 5-chloro-N4-(2-(dimethylphosphinyl)phenyl)-N2-(2-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)-; 5-Chloro-N~4~-[2-(Dimethylphosphoryl)phenyl]-N~2~-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl)piperidin-1-Yl]phenyl}pyrimidine-2,4-Diamine; UNII-HYW8DB273J"	68165256	C29H39ClN7O2P	Approved
M6APDG02847	Beraprost	"Beraprost [USAN:INN]; Beraprostum; Beraprostum [INN-Latin]; MDL-201229; ML-1229; beraprost; (+-)-(1R,2R,3aS,8bS)-2,3,3a,8b-Tetrahydro-2-hydroxy-1-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran-5-butyric acid; 2-Hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-5-butanoic acid; 88430-50-6; AC1OCEUA; CHEBI:135633; CHEMBL1207745; CTPOHARTNNSRSR-APJZLKAGSA-N; DTXSID7049136; SCHEMBL16904620; SCHEMBL34593"	6917951	C24H30O5	Phase 4
M6APDG01126	Benzyl alcohol	"Bentalol; Benzal alcohol; Benzenecarbinol; Benzoyl alcohol; Benzyl alcohol (natural); Benzylicum; Alcool benzilico [DCIT]; Alcool benzylique; BENZYL-ALCOHOL; Euxyl K 100; Hydroxytoluene; Itch-X; Methanol, phenyl-; Phenolcarbinol; Phenyl Methanol; Phenyl-Methanol; Phenylcarbinolum; Phenylmethyl alcohol; alpha-Toluenol; alpha-hydroxytoluene; benzenemethanol; benzyl alcohol; benzylalcohol; benzylic alcohol; hydroxymethylbenzene; phenylcarbinol; phenylmethanol; (Hydroxymethyl)benzene; .alpha.-Toluenol; 100-51-6; Caswell No. 081F"	244	C7H8O	Approved
M6APDG02400	Benazepril	"Benazepril [INN:BAN]; Benazeprilum; Benazeprilum [Latin]; UDM7Q7QWP8; XPCFTKFZXHTYIP-PMACEKPBSA-N; benazapril; benazepril; benzazepril; 1H-1-Benzazepine-1-acetic acid, 3-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (S-(R*,R*))-; 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid; 86541-75-5; CGS-14824-A; CGS-14824A; CHEBI:3011; CHEMBL838; UNII-UDM7Q7QWP8"	5362124	C24H28N2O5	Approved
M6APDG01063	Azelastine	Azelastina; Azelastina [INN-Spanish]; Azelastine [INN:BAN]; Azelastinum; Azelastinum [INN-Latin]; MBUVEWMHONZEQD-UHFFFAOYSA-N; Optilast; azelastine; 4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone hydrochloride; 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one; 58581-89-8; A-5610; BRN 0900747; C22H24ClN3O; CHEBI:2950; CHEMBL639	2267	C22H24ClN3O	Approved
M6APDG02598	Atorvastatin calcium	"Atorvastatin Hemicalcium; Atorvastatin calcium [USAN]; Atorvastatin calcium salt; Atorvastatin hemicalcium salt; Atorvastatin; Atorvastatin [INN:BAN]; C33H35FN2O5; CCRIS 7159; CHEBI:39548; CHEMBL1487; Cardyl; HSDB 7039; Lipitor (TN); Sotis; Tozalip; UNII-A0JWA85V8F; Xarator; Xavator; (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; 110862-48-1; 134523-00-5; A0JWA85V8F; C0GEJ5QCSO; CHEBI:50686; CI 981; CI-981; Calcium (betaR,deltaR)-2-(p-fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoate (1:2); DRG-0321; PD 134298-38A; Sortis; Tahor; UNII-C0GEJ5QCSO; YM 548; 134523-03-8"	60822	C66H68CaF2N4O10	Approved
M6APDG02393	Arsenic	"Agent SA; Arsen [German,Polish]; Arsenic; Arsenic Black; Arsenic Lump (Metals Basis); Arsenic and arsenic compounds; Arsenic compounds; Arsenic hydride (AsH3); Arsenic, elemental; Arsenic, inorganic; Arsenic, organic compounds; Arsenic-75; Arsenicals; Arsenowodor [Polish]; Arsenwasserstoff [German]; Colloidal arsenic; Gray arsenic; Grey arsenic; Metallic arsenic; UN 2188; UN1558; UN2188; V1I29R0RJQ; 7440-38-2; Arsen; As; CCRIS 55; EINECS 231-148-6; EINECS 232-066-3; HSDB 509; HSDB 510; N712M78A8G; UNII-N712M78A8G; UNII-V1I29R0RJQ"	5359596	As	Approved
M6APDG01846	Arachidonic acid	"Arachidonic Acid, 99%; Immunocytophyte; YZXBAPSDXZZRGB-DOFZRALJSA-N; arachidonate; arachidonic acid; (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid; (all-Z)-5,8,11,14-Eicosatetraenoic acid; 27YG812J1I; 5,8,11,14-Eicosatetraenoic acid; 5,8,11,14-Eicosatetraenoic acid, (all-Z)-; 506-32-1; 5Z,8Z,11Z,14Z-eicosatetraenoic acid; CHEBI:15843; CHEMBL15594; MFCD00004417; UNII-27YG812J1I; all-cis-5,8,11,14-eicosatetraenoic acid; cis,cis,cis,cis-5,8,11,14-Eicosatetraenoic acid; cis-5,8,11,14-Eicosatetraenoic acid"	444899	C20H32O2	Investigative
M6APDG00066	Apixaban	"Apixaban; Apixaban(BMS-562247-01); Eliquis; apixabanum; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; 3Z9Y7UWC1J; 503612-47-3; BMS 562247-01; BMS-562247; BMS-562247-01; BMS562247-01; CHEBI:72296; CHEMBL231779; UNII-3Z9Y7UWC1J"	10182969	C25H25N5O4	Approved
M6APDG01033	Antipyrine	"Analgesine; Anodynin; Anodynine; Antipirin; Antipyrin; Antipyrinum; Apirelina; Auralgan; Azophen; Azophene; Azophenum; Dimethyloxychinizin; Dimethyloxyquinazine; Fenazon; Fenazon [Czech]; Fenazona; Fenazona [INN-Spanish]; Fenazone; Methozin; Oxydimethylquinazine; Oxydimethylquinizine; Parodyne; Phenazon; Phenazone; Phenazone (pharmaceutical); Phenazonum; Phenozone; Phenylon; Phenylone; Pyrazophyl; Sedatin; Sedatine; antipyrine; 2,3-Dimethyl-1-phenyl-5-pyrazolone; 3-Antipyrine; 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl-; 60-80-0"	2206	C11H12N2O	Investigative
M6APDG01020	Amodiaquine	"Amodiachin; Amodiachinum; Amodiaquin; Amodiaquina; Amodiaquina [INN-Spanish]; Amodiaquine USP24; Amodiaquine hydrochloride; Amodiaquine, ring-closed; Amodiaquinum; Amodiaquinum [INN-Latin]; CAM-AQI; Cam-AQ1; Camochin; Camoquin; Camoquin Hcl; Camoquinal; Camoquine; Flavoquine; Miaquin; S. N. 10751; SN 10,751; amodiaquine; 4-[(7-CHLOROQUINOLIN-4-YL)AMINO]-2-[(DIETHYLAMINO)METHYL]PHENOL; 86-42-0; C20H22ClN3O; CHEBI:2674; NSC 13453; Phenol, 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl]-; UNII-220236ED28"	2165	C20H22ClN3O	Phase 4
M6APDG00235	Amitriptyline hydrochloride	Amavil; Ami-Anelun; Amilit; Amineurin; Amiplin; Amiprin; Amitid; Amitrip; Amitriptyline HCl; Amitriptyline hydrochloride; Amyline; Amyzol; Anapsique; Annoyltin; Apo-Amitriptyline; Belpax; Daprimen; Domical; Elatrol; Elatrolet; Elavil hydrochloride; Enafon; Etrafon; Etravil; Kyliran; Larozyl; Lentizol; Levate; Maxivalet; Miketorin; Mitaptyline; Novoprotect; Pinsanu; Pinsaun; Rantoron; Saroten; Sarotena; Syneudon; Teperin; Trepiline; Triavil; Tridep; Tripta; Triptizol; Trynol; Tryptine; Tryptizol; Trytomer; Vanatrip; Yamanouchi; Adepress; Adepril; Amitril; Amitriptyline; Amitriprolidine; Amitriptilina; Amitriptilina [INN-Spanish]; Amitriptilina [Italian]; Amitriptylin; Amitriptylin [German]; Amitriptyline [INN:BAN]; Amitriptylinum; Amitriptylinum [INN-Latin]; Amitryptiline; Amitryptyline; Amytriptiline; Amytriptylin; Damilan; Damilen; Damitriptyline; Elanil; Elavil; Flavyl; Lantron; Laroxil; MK 230; Proheptadiene; Redomex; Ro 4-1575; Sarotex; Seroten; Triptanol; Triptilin; Triptisol; Tryptanol; 50-48-6; 549-18-8	11065	C20H24ClN	Approved
M6APDG01593	Amiodarone hydrochloride	"Amiodar; Amiodarone (hydrochloride); Amiodarone HCL; Amiodarone hydrochloride; Amiodaronum hydrochloride; Angoron; Atlansil; Amiodarona; Amiodarone; Amiodarona [INN-Spanish]; Amiodarone Base; Amiodaronum; Amiodaronum [INN-Latin]; Amjodaronum; BRN 1271711; C25H29I2NO3; CHEMBL633; Cordarone; EINECS 217-772-1; L 3428; L-3428; N3RQ532IUT; UNII-N3RQ532IUT; (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone; 1951-25-3; 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran; CPD000058296; DSSTox_CID_17185; DSSTox_GSID_37185; DSSTox_RID_79304; EINECS 243-293-2; HSDB 6525; L 3428 labaz; MFCD00069204; MLS000028520; Miodrone; NSC 85442; Nexterone; Renodoron; Ritmocardyl; Rythmarone; SKF 33134 A; SMR000058296; Trangorex; UNII-976728SY6Z; (2-Butylbenzofuran-3-yl)(4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl)methanone hydrochloride; 19774-82-4; 51087 N HCl; 976728SY6Z"	441325	C25H30ClI2NO3	Approved
M6APDG02573	Aminophenazone	AMINOPYRINE; Amidazofen; Amidazophen; Amidazophene; Amidofebrin; Amidofen; Amidophen; Amidophenazone; Amidopyrazoline; Amidopyrin; Amidopyrine; Aminofenazone; Aminophenazon; Aminopyrin; Anafebrina; Brufaneuxol; Dereuma; Dimapyrin; Dimethylaminoantipyrine; Dimethylaminoazophene; Dimethylaminophenazone; Dipirin; Dipyrin; Dipyrine; Eufibron; Febrinina; Febron; Hyparon; Itamidone; Mamallet-A; Novamidon; Piramidon; Pirazon; Piridol; Piromidina; Polinalin; Pyradone; Pyramidon; Pyramidone; aminophenazone; 4-Dimethylaminoantipyrine; 58-15-1	6009	C13H17N3O	Phase 4
M6APDG00546	Almotriptan malate	"Almotriptan; Almotriptan (malate); Almotriptan malate; Almotriptan malate (USAN); Almotriptan malate [USAN]; Almotriptan maleate; CHEBI:53781; LAS 31416; LAS 31416 D,L-malate acid; PNU 180638E; PNU-180638E; Almogran; Almotriptan [USAN:INN:BAN]; Axert; CHEBI:520985; DSSTox_CID_24289; DSSTox_GSID_44289; DSSTox_RID_80142; LAS-31416; N,N-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1H-indol-3-yl)ethanamine; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; NCGC00095135-01; UNII-1O4XL5SN61; WKEMJKQOLOHJLZ-UHFFFAOYSA-N; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine; 154323-57-6; 1O4XL5SN61; 1-(((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)pyrrolidine, hydroxybutanedionate (1:1); 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine malate (1:1); 1-[[[2-(Dimethyl-amino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine Malate; 181183-52-8; AK110510"	123607	C21H31N3O7S	Approved
M6APDG00642	ISO-901	"FOLITIXORIN; Modufolin; Tetrahydromethylenefolate; 3432-99-3; 5,10-Methylene-tetrahydrofolate; 5,10-Methylenetetrahydrofolic acid; 5,10-methylenetetrahydrofolate; CH2H4folate; CHEBI:20502; L-Glutamic acid,N-[4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]-; MTHF; N-(4-(3-Amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo(1,5-f)pteridin-8(9H)-yl)benzoyl)-L-glutamic acid; N-{4-[3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9H)-yl]benzoyl}-L-glutamic acid"	135400185	C20H23N7O6	Phase 1
M6APDG02136	BRN-3548355	"NNK (carcinogen); 1-Butanone, 4-(methylnitrosoamino)-1-(3-pyridinyl)-; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; 4-(Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; 4-(N-Nitroso-N-methylamino)-1-(3-pyridyl)-1-butanone; 4-Methylnitrosoamino-1-(3-pyridinyl)-1-butanone; 4-[methyl(nitroso)amino]-1-(pyridin-3-yl)butan-1-one; 64091-91-4; 7S395EDO61; CCRIS 1150; CHEBI:32692; MFCD00274580; N-Methyl-N-nitroso-4-oxo-4-(3-pyridyl)butyl amine; NNK; UNII-7S395EDO61"	47289	C10H13N3O2	Investigative
M6APDG03345	Estradiol	Aerodiol; Altrad; Aquadiol; Bardiol; Climara; Corpagen; Dihydrofolliculin; Dihydromenformon; Dihydrotheelin; Dihydroxyestrin; Dimenformon; Diogyn; Diogynets; Divigel; Estrace; Estraderm TTS; Estroclim; Estrovite; Evorel; Femestral; Femogen; Follicyclin; Ginosedol; Gynergon; Gynoestryl; Lamdiol; Macrodiol; Oestergon; Oestradiol; Oestroglandol; Ovahormon; Ovasterol; Ovastevol; Ovocyclin; Perlatanol; Primofol; Profoliol; Syndiol; Trocosone; Vagifem; Vivelle; beta-Estradiol; cis-Estradiol; estradiol; estradiol-17beta; progynon; 17beta-Estradiol; 50-28-2	5757	C18H24O2	Approved
M6APDG02474	Gepirone	"Gepirone; 4,4-Dimethyl-1-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)piperidine-2,6-dione; Gepirone ER; Gepironum [Latin]; Gepirone [INN]; Gepirona [Spanish]; UNII-JW5Y7B8Z18; BMY-13805; JW5Y7B8Z18; CHEMBL284092; MJ-13805; Variza; Ariza; Gepironum; AK115965; Gepirona; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione; Travivo; 2,6-Piperidinedione, 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-; BMY 13805; MJ 13805; gepiron ER; MJ 13805-1; ORG-13011(Gepirone); AC1L1IK6; AC1Q6F8Q"	55191	C19H29N5O2	Phase 2
M6APDG02846	Saphris	"Asenapine maleate; Saphris; Asenapine (maleate); Org 5222; Sycrest; Org-5222; Asenapine maleate [USAN]; C17H16ClNO.C4H4O4; Asenapine/; Saphris (TN); EINECS 288-064-8; Org 5222 maleate; trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole maleate; (S,S)-Asenapine Maleate; SCHEMBL175228; Asenapine maleate (JAN/USAN); CHEBI:71248; GMDCDXMAFMEDAG-CHHFXETESA-N; ABP000604; s1283; MFCD00900588; Asenapine maleate, &gt;=98% (HPLC); AKOS015951084; SCH-900274; MK-8274; CS-0859; HY-11100; AC-24116"	6917875	C21H20ClNO5	Approved
M6APDG01366	Parabis	"Dichlorophen; dichlorophene; Dichlorofen; Dichlorphen; 2,2'-Methylenebis(4-chlorophenol); Didroxane; Didroxan; Trivex; Difentan; Dicestal; Antiphen; Vermithana; Teniatol; Prevental; Teniotol; Embephen; Anthiphen; Teniathane; Taeniatol; Panacide; Cordocel; Palacel; Halenol; Parabis; Korium; Hyosan; Antifen; Dichlorophen B; Dichlorophene 10; Dichloorfeen; Gingivit; Wespuril; Gefir; Fungicide M; Plath-Lyse; DDDM; Bis(5-chloro-2-hydroxyphenyl)methane; Preventol GD; Fungicide GM; Preventol GDC; Diphenthane 70; Sandocide; Super mosstox"	3037	C13H10Cl2O2	Withdrawn
M6APDG03220	S-licarbazepine	"Eslicarbazepine; (S)-10-Hydroxy-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; S-licarbazepine; UNII-S5VXA428R4; BIA 2-194; S-10-Monohydroxy-dihydro-carbamazepin; S5VXA428R4; S-(+)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide; (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide; (10S)-10,11-Dihydro-10-hydroxy-5H-Dibenz[b,f]azepine-5-carboxamide; (S)-Licarbazepine; S(+)-Liscarbazepine; (10S)-10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide"	9881504	15H14N2O2	Approved
M6APDG00505	Azidothymidine monophosphate	azidothymidine monophosphate; SCHEMBL17515060	118879755	C10H14N5O8P	Preclinical
M6APDG00979	Benzoylphenylurea	benzoylphenylurea; SCHEMBL83109	19851629	C14H12N2O2	Phase 1
M6APDG02461	Tenofovir disoproxil	Tenofovir disoproxil; PMPA prodrug; Bis(POC)PMPA; Tenofovir (Disoproxil); UNII-F4YU4LON7I; 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine; F4YU4LON7I; CHEBI:63717; tenofovir bis(isopropyloxycarbonyloxymethyl) ester; Tenofovir Disoproxil Fumarate; [[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate	5481350	C19H30N5O10P	Phase 4
M6APDG01386	Ebastine	"ebastine; Kestine; Ebastel; Ebastin; Evastel; Kestin; Bactil; Ebastinum [Latin]; LAS W-090; Ebastina [Spanish]; Estivan; UNII-TQD7Q784P1; RP 64305; 1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one; TQD7Q784P1; CHEMBL305660; 4-Diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine; C32H39NO2; MFCD00865661; 1-[4-(1,1-Dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone; NCGC00164603-01; RP-64305; 4'-tert-Butyl-4-(4-(diphenylmethoxy)piperidino)butyrophenone"	3191	C32H39NO2	Phase 4
M6APDG02010	Sitafloxacin	"Sitafloxacin; Gracevit; Sitafloxacin Sesquihydrate; UNII-3GJC60U4Q8; Sitafloxacin isomer II; DU-6859a; C19H18ClF2N3O3; 3GJC60U4Q8; 7-((S)-7-AMINO-5-AZASPIRO[2.4]HEPTAN-5-YL)-8-CHLORO-6-FLUORO-1-((1R,2S)-2-FLUOROCYCLOPROPYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; STFX; 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-quinoline-3-carboxylic acid"	461399	C19H18ClF2N3O3	Phase 2/3
M6APDG02687	Lovastatin acid	"Lovastatin acid; Mevinolinic acid; Monacolinic K acid; MSD 803 acid; MSD 803 free acid; UNII-5CLV35Y90C; MK 819; L-154819; L 154819; 5CLV35Y90C; CHEBI:82985; (3R,5R)-7-((1R,2R,6S,8R,8AS)-2,6-DIMETHYL-8-{[(2R)-2-METHYLBUTANOYL]OXY}-1,2,6,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL)-3,5-DIHYDROXYHEPTANOIC ACID; (3R,5R)-7-[(1S,2S,6R,8S,8aR)-2,6-dimethyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid"	64727	C24H38O6	Approved
M6APDG01945	Epothilone A	"Epothilone A; (-)-Epothilone A; Epo A; epothile; Epothilone-A; UNII-51E07YBX96; Epoa; 51E07YBX96; EP; Epothilones; Epothilon A; (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione; 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione,7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-,(1S,3S,7S,10R,11S,12S,16R)-"	448799	C26H39NO6S	Preclinical
M6APDG01021	Beclomethasone dipropionate	"BECLOMETHASONE DIPROPIONATE; Beclometasone dipropionate; Beconase; Beclovent; Vancenase; Beclorhinol; Becloforte; Sanasthmyl; Beclazone; Sanasthmax; Propaderm; Beclomet; Vanceril; Aerobec; Becloturmant; Beclacin; Respocort; Entyderma; Korbutone; Viarox; Rino-clenil; Clenil-A; Beclometasone 17,21-dipropionate; Becotide; Aldecin; Turbinal; Aldecina; Rhinosol; Beclate; Atomase; Alanase; Benconase; Aldecine; Clenil; Spir; Beclocort Nasel; Beclomet Nasal; Propaderm Forte; Rhino Clenil; Inalone O; Inalone R; Qvar; QNASL; Beconase AQ; Qvar 80"	21700	C28H37ClO7	Phase 4
M6APDG02427	Metkephamid	"METKEFAMIDE; UNII-MNL20FXH9Y; MNL20FXH9Y; Metkephamid; Metkephamide; Metkefamida; Metkefamidum; L-Methioninamide, L-tyrosyl-D-alanylglycyl-L-phenylalanyl-N2-methyl-; Metkefamidum [INN-Latin]; Metkefamida [INN-Spanish]; L-Tyrosyl-D-alanylglycyl-L-phenylalanyl-N2-methyl-L-methioninamide; Metkefamide [INN]; AC1NUZ1B; SCHEMBL329997; CHEMBL2220405; CTK2F4766"	5464184	C29H40N6O6S	Preclinical
M6APDG01611	Cephaeline	"Cephaeline; Cephaelin; 483-17-0; 7',10,11-Trimethoxyemetan-6'-ol; UNII-QA971541A1; Desmethylemetine; QA971541A1; Dihydropsychotrine; Cepheline; GNF-Pf-307; (1R)-1-[[(2S,3R,11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-ol; NSC32944; Cephaelinel; (-)-Cephaeline; EINECS 207-591-6; Prestwick2_000428; Prestwick3_000428; Prestwick1_000428; Prestwick0_000428; AC1L9CF2; BSPBio_000416; SCHEMBL181711; SPBio_002355; CHEMBL255708"	442195	C28H38N2O4	Preclinical
M6APDG01556	Bouvardin	"Bouvardin; MLS002703036; NSC259968; NSC 259968; NSC-259968; AC1L8NRS; Neuro_000123; SCHEMBL8739404; SMR001566844; From fraction F049 of Bouvardia ternifolia; Cyclic(D-alanyl-L-alanyl-N, cyclic(54.fwdarw.63)-ether, (S)-; 17,24-dihydroxy-10-(4-methoxybenzyl)-4,7,9,13,15,29-hexamethyl-22-oxa-3,6,9,12,15,29-hexaazatetracyclo[14.12.2.2~18,21~.1~23,27~]tritriaconta-18,20,23(31),24,26,32-hexaene-2,5,8,11,14,30-hexone"	429598	C40H48N6O10	Preclinical
M6APDG01720	Fluticasone propionate	FLUTICASONE PROPIONATE; Flovent; Cutivate; Flixotide; Flonase; Flixonase; Flovent HFA; Flunase; Flutide; Fluspiral; Flusonal; atemur; Flutivate; Fluinol; Axotide; Asmatil; Brethal; Flovent Diskus 50; Flixotide Disks; Flixotide Disk; Flovent Diskus; Flovent Diskus 100; Flovent Diskus 250; Flixotide Inhaler; Trialona; Rinosone; Inalacor; Cultivate; Ubizol; Zoflut; Flixonase Nasal Spray; Flonase Aq; Fluticasonpropionat Allen; Fluticasone (propionate); UNII-O2GMZ0LF5W; CCI-18781; CCI 18781; MFCD00866007; O2GMZ0LF5W	444036	C25H31F3O5S	Approved
M6APDG00949	Scutellarin	"Scutellarin; Breviscapin; Scutellarein-7-glucuronide; Scutellarin B; Breviscapine; Scutellarein-7beta-D-glucuronide; Scutellarein 7-beta-D-glucuronide; Scutellarein-7beta-D-glucuronoside; Scutellarein-7-O-beta-D-glucuronide; UNII-16IGP0ML9A; Scutellarein 7-b-D-glucuronide; Scutellarein 7-O-beta-D-glucuronide; 16IGP0ML9A; SCUTELLAREIN 7-O-GLUCURONIDE; beta-D-Glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl"	185617	C21H18O12	Preclinical
M6APDG00100	N-desethyl sunitinib	"N-Desethyl Sunitinib; N-DesethylSunitinib; UNII-42LJ35612R; 42LJ35612R; C20H23FN4O2; N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide; SCHEMBL2115189; CHEMBL3542344; DTXSID10437828"	10292573	C20H23FN4O2	Preclinical
M6APDG01437	Guanfacine	"GUANFACINE; Tenex; Guanfacinum [INN-Latin]; Guanfacina [INN-Spanish]; Estulic; Intuniv; N-amidino-2-(2,6-dichlorophenyl)acetamide; CHEBI:5558; INJOMKTZOLKMBF-UHFFFAOYSA-N; SPD 503; C9H9Cl2N3O; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; Guanfacine Monohydrochloride; NCGC00015469-05; Lon798; Guanfacine (INN); Estulic (TN); Tenex (Salt/Mix); Estulic (Salt/Mix); Tocris-1030; Prestwick1_000339; Prestwick3_000339; Prestwick2_000339; Prestwick0_000339; Lopac-G-1043"	3519	C9H9Cl2N3O	Phase 4
M6APDG00043	(Z)-endoxifen	"Endoxifen; Z-Endoxifen; 4-Hydroxy-N-desmethyltamoxifen; (E/Z)-Endoxifen; Endoxifen Z-Isomer; UNII-46AF8680RC; N-Desmethyl-4-hydroxytamoxifen; 110025-28-0; 4-Hydroxy-N-desmethyl-tamoxifen; CHEBI:80555; 46AF8680RC; 4OHNDtam; W-200834; N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture); (Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer); 4-hydroxy-N-desmethyltamoxifen, (Z)-isomer; (Z)-Endoxifen; Endoxifen(E/Z=1:1); 4-hydroxy-N-desmethyl tamoxifen; SCHEMBL10107920; CHEMBL1093458; GTPL10203; EX-A645"	10090750	C25H27NO2	Phase 2
M6APDG00101	Genz 644282	"GENZ-644282; Genz 644282; genz644282; UNII-717I541I2R; 717I541I2R; 2,3-dimethoxy-12-(2-(methylamino)ethyl)-[1,3]dioxolo[4',5':4,5]benzo[1,2-h]benzo[c][1,6]naphthyridin-13(12H)-one; SCHEMBL241696; CHEMBL191958; EX-A481; AOB87160; BCP20983; ZINC6718458; SAR402674; AKOS030526835; CS-1525; SAR 402674; SAR-402674; HY-16228; Benzo(C)(1,3)benzodioxolo(5,6-H)(1,6)naphthyridin-13(12H)-one, 2,3-dimethoxy-12-(2-(methylamino)ethyl)-; BC600645; DA-42192; GENZ-644282/GENZ644282; FT-0700324; A3434; W-6112; A13206"	10294813	C22H21N3O5	Phase 1
M6APDG00930	Eslicarbazepine acetate	"Eslicarbazepine acetate; BIA 2-093; Aptiom; Zebinix; Stedesa; Exalief; Eslicarbazepine (acetate); UNII-BEA68ZVB2K; BIA-2-093; (S)-5-Carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate; Sep 0002093; BIA 2093; BEA68ZVB2K; SEP-0002093; CHEMBL87992; Eslicarbazepine acetate [USAN]; CHEBI:87016; exelief; (S)-(-)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide; [(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate; Eslicarbazepine acetate (USAN)"	179344	C17H16N2O3	Approved
M6APDG01075	Benzo(a)pyrene	"benzo[a]pyrene; 3,4-Benzopyrene; benzo[pqr]tetraphene; BENZO(A)PYRENE; 3,4-Benzpyrene; Benzpyrene; benzo[def]chrysene; 6,7-Benzopyrene; Benz[a]pyrene; 3,4-BP; 3,4-Benz[a]pyrene; 3,4-Benzopirene; 3,4-Benzpyren; Benzo[d,e,f]chrysene; Benz(a)pyrene; (B(a)P); B(a)P; BP; 3,4 Benzpyrene; RCRA waste number U022; Benzo(d,e,f)chrysene; 3,4-Benz(a)pyrene; NSC 21914; 3,4-Benzo(a)pyrene; B[a]p; 3,4-Benzpyren [German]; CCRIS 76; Benzo[A]-Pyrene; Benzo(def)chrysene; 3,4-benzylpyrene; 3,4-Benzopirene [Italian]"	2336	C20H12	Phase 1
M6APDG00342	Norbuprenorphine	"Norbuprenorphine; N-Desalkylbuprenorphine; Des(cyclopropylmethyl)buprenorphine; UNII-7E53B4O073; 7E53B4O073; 6,14-Ethenomorphinan-7-methanol, alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-; AC1L3GBB; SCHEMBL14408877; CHEMBL1743323; YOYLLRBMGQRFTN-IOMBULRVSA-N; ZINC6031944; LS-67705; 6,14-ethenomorphinan-3-ol, 4,5-epoxy-18,19-dihydro-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-, (5alpha,6beta,14beta,18R)-"	114976	C25H35NO4	Phase 1
M6APDG02044	MG-132	MG-132; Z-Leu-leu-leu-al; MG132; Zlllal; MG 132; Z-LLL-CHO; Zlll-cho; Z-Leu-leu-leucinal; Z-Leu-Leu-Leu-H; Z-Leu-Leu-Leu-CHO; Carbobenzoxy-leucyl-leucyl-leucinal; UNII-RF1P63GW3K; Benzyloxycarbonyl-leu-leu-leu-aldehyde; Benzyloxycarbonyl-leucyl-leucyl-leucinal; Lll cpd; Carbobenzoxyl-leucinyl-leucinyl-leucinal-H; Cbz-Leu-Leu-Leu-H; Benzyloxycarbonylleucyl-leucyl-leucine aldehyde; benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate; RF1P63GW3K	462382	C26H41N3O5	Preclinical
M6APDG01605	Pancratistatin	"Pancratistatin; (+)-Pancratistatin; NSC349156; MLS002701837; AC1L9BE4; SCHEMBL93612; CHEMBL419335; VREZDOWOLGNDPW-ALTGWBOUSA-N; ZINC4097654; (1R,2S,3S,4S,4aR,11bR)-1,2,3,4,7-pentahydroxy-2,3,4,4a,5,11b-hexahydro-1H-[1,3]dioxolo[4,5-j]phenanthridin-6-one; NSC-349156; SMP1_000217; NCI60_003105; B844009K070; C08535"	441597	C14H15NO8	Preclinical
M6APDG00328	Desmethylsertraline	"Desmethylsertraline; Norsertraline; (1s,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine; UNII-CJJ71O9BE8; CJJ71O9BE8; CHEMBL40733; (1S,4S)-4-(3,4-Dichloro-phenyl)-1,2,3,4-tetrahydronaphthalen-1-amine; CHEMBL1743864; N-Demethylsertraline; N-Desmethylsertraline; Demethylsertraline; CP 62508; CP-53261; AC1L3FVW; AC1Q3O5M; SCHEMBL145234; NAP005; CTK8E0157; DTXSID60236666; SRPXSILJHWNFMK-ZBEGNZNMSA-N; ZINC6117444; PDSP2_001789; BDBM50367182; MFCD00871799; BDBM50028066; AKOS027382323"	114743	C16H15Cl2N	Preclinical
M6APDG02668	Mycophenolic acid glucuronide	"MPAG; Mycophenolic acid glucosiduronate; mycophenolic acid glucuronide; UNII-54TS5J9T0K; 54TS5J9T0K; AC1O5XMV; BYFGTSAYQQIUCN-HGIHDBQLSA-N; Mycophenolic Acid ; A-D-Glucuronide; ZINC13550000; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[[5-[(E)-6-hydroxy-3-methyl-6-oxohex-2-enyl]-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-4-yl]oxy]oxane-2-carboxylic acid; 5-[(2E)-5-Carboxy-3-methyl-2-penten-1-yl]-1,3-dihydro-6-methoxy-7-methyl-3-oxo-4-isobenzofuranyl"	6442661	C23H28O12	Phase 1
M6APDG03103	Selamectin	"selamectin; UNII-A2669OWX9N; A2669OWX9N; UK-124,114; 25-cyclohexyl-25-de(1-methylpropyl)-5-deoxy-22 23-dihydro-5-(hydroxyimino)-avermectin B1 monosaccharide; Stronghold; Revolution; 220119-17-5; 25-Cyclohexyl-4'-O-de(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-avermectin A1a"	9578507	C43H63NO11	Preclinical
M6APDG02650	Abamectin B1A	"AVERMECTIN B1A; abamectin component B1a; Avermectin B(1)a; Abamectine [French]; Abamectinum [Latin]; Abamectina [Spanish]; Caswell No. 063AB; Antibiotic C 076B1a; Abamectin komponente B1a; 5-O-Demethylavermectin A1a; UNII-K54ZMM929K; Avermectin; Avermectin A1a, 5-O-demethyl-; EINECS 265-610-3; Antibiotic C 076A1a, 5-O-demethyl-; K54ZMM929K; CHEBI:29534; Avermectin A(sub 1a), 5-O-demethyl-; DSSTox_CID_3892; DSSTox_RID_77221; DSSTox_GSID_23892; Abamectina; Abamectine; C48H72O14; Abamectin B1a"	6434889	C48H72O14	Preclinical
M6APDG00763	HPPH	"CHEMBL500853; SCHEMBL12722713; EX-A2655; 14-Ethyl-9-(1-(hexyloxy)ethyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbinepropanoic acid; HY-13722; 3-Phorbinepropanoic acid, 14-ethyl-9-[1-(hexyloxy)ethyl]-4,8,13,18-tetramethyl-20-oxo-, (3S,4S)-; CS-0007752"	148160	C39H48N4O4	Phase 2
M6APDG00192	Homocamptothecin	"homocamptothecin; UNII-5B3LFU8GLM; 5B3LFU8GLM; E-Homocamptothecin; E-Homocamptothecine; (20R)-Homocamptothecin; E-Homocamptothecin, (R)-; CHEMBL74190; SCHEMBL5860320; PAEZRCINULFAGO-OAQYLSRUSA-N; ZINC840834; 3H,15H-Oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (5R)-; 3H,15H-Oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (R)-"	10666346	C21H18N2O4	Preclinical
M6APDG02894	Enrofloxacin	"Enrofloxacin; 93106-60-6; Baytril; Enrofloxacine; CFPQ; Enrofloxacinum; Enrofloxacino; endrofloxicin; BAY VP 2674; Bay-Vp-2674; Enrofloxacine [French]; Enrofloxacinum [Latin]; Enrofloxacino [Spanish]; UNII-3DX3XEK1BN; N-Ethylciprofloxacin; Baytril (TN); ERFX; Enrofloxacin [USAN:BAN:INN]; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; HSDB 6952; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 3DX3XEK1BN; Enrofloxacin (USAN/INN)"	71188	C19H22FN3O3	Preclinical
M6APDG02947	Nonactin	"nonactin; Werramycin-A; Antibiotic from Actinomycete; Upjohn 170t (high melting); UPJOHN 170T, high melting; UNII-TTP24WX8P7; 5342 PFW 19; TA-25-M-I; EINECS 229-911-3; A 4426; NSC 56409; E-79-C; NSC 52141; N-329-A; BRN 0076434; TTP24WX8P7; CHEBI:7614; GNF-PF-1094; 3584-A; NSC52141; 4,13,22,31,37,38,39,40-Octaoxapentacyclo(32.2.1.1(sup 7,10).1(sup 16,19).1(sup 25,28))tetracontane-3,12,21,30-tetrone, 2,5,11,14,20,23,29,32-octamethyl-, (1R-(1R*,2R*,5R*,7R*,10S*,11S*,14S*,16S*,19R*,20R*,23R*,25R*,28S*,29S*,32S*,34S*))-"	72519	C40H64O12	Preclinical
M6APDG01525	Oxfendazole	Oxfendazole; Fenbendazole sulfoxide; Synanthic; Systamex; OFDZ; Systemax; Repidose; Oxfendazolum; Oxfendazol; Synanthic (Veterinary); RS-8858; fenbendazole S-oxide; RS 8858; 5-Phenylsulfinyl-2-carbomethoxyaminobenzimidazole; Oxfendazol [INN-Spanish]; Oxfendazolum [INN-Latin]; UNII-OMP2H17F9E; HOE 8105; methyl [5-(phenylsulfinyl)-1H-benzimidazol-2-yl]carbamate; Oxfendazole [USAN:BAN:INN]; Methyl 5-(phenylsulfinyl)-2-benzimidazolecarbamate; Oxfendazole (USP/INN)	40854	C15H13N3O3S	Phase 2
M6APDG02273	Pitavastatin	"Pitavastatin; Itavastatin; Livalo; NK 104; Pitavastatin [INN]; Pitavastatin calcium; UNII-M5681Q5F9P; NK-104; C25H24FNO4; M5681Q5F9P; Zypitamag; Flovas; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; P 872441; P-872441; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; ( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; NK 104 (acid); Pitavastatin calcium (JAN)"	5282452	C25H24FNO4	Approved
M6APDG02775	Pazufloxacin	"Pazufloxacin; T-3761; Pazufloxacin [INN]; UNII-4CZ1R38NDI; CCRIS 7312; T 3761; 4CZ1R38NDI; C16H15FN2O4; NCGC00167534-01; DSSTox_CID_26697; DSSTox_RID_81831; DSSTox_GSID_46697; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-; SMR000466380; (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid"	65957	C16H15FN2O4	Phase 3
M6APDG02686	Simvastatin acid	"Simvastatin acid; Tenivastatin; UNII-9L6M5TH46B; DIMETHYL-COMPACTIN; 9L6M5TH46B; (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethylbutanoyloxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; Tenivastatin [INN]; (3R,5R)-7-{(1S,2S,6R,8S,8aR)-8-[(2,2-dimethylbutanoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}-3,5-dihydroxyheptanoic acid"	64718	C25H40O6	Phase 3
M6APDG00663	Coelenterazine	"coelenterazine; Coelenteramine; Oplophorus luciferin; UNII-3O1CB88RRD; CLZN; 8-benzyl-2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one; coelenterate luciferin; Coelenterazine, native; 3O1CB88RRD; MFCD00467176; C-7001; C-7002; 8-benzyl-6-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)methyl]-7H-imidazo[1,2-a]pyrazin-3-one; 8-Benzyl-2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)imidazo-[1,2a]pyrazin-3(7H)-one; 2-(p-Hydroxybenzyl)-6-(p-hydroxyphenyl)-8-benzylimidazo[1,2-a]pyrazin-3-(7H)-one"	135445694	C26H21N3O3	Preclinical
M6APDG01580	Puromycin	"puromycin; Stylomycin; Puromycinum; Puromycine; Puromicina; UNII-4A6ZS6Q2CL; P-638; Stillomycin; CL 13900; 3123L; 4A6ZS6Q2CL; 3'-(L-alpha-Amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyladenosine; (S)-3'-((2-Amino-3-(4-methoxyphenyl)-1-oxopropyl)amino)-3'-deoxy-N,N-dimethyladenosine; GNF-PF-2016; Puromycinum [INN-Latin]; Puromycine [INN-French]; Puromicina [INN-Spanish]; 9-{3-deoxy-3-[(O-methyl-L-tyrosyl)amino]-beta-D-xylofuranosyl}-N,N-dimethyl-9H-purin-6-amine; Bacterenomycin"	439530	C22H29N7O5	Preclinical
M6APDG01132	Bunitrolol	"Bunitrolol; 2-(3-(tert-Butylamino)-2-hydroxypropoxy)benzonitrile; Bunitrolol [INN]; Stresson; Bunitrololum [INN-Latin]; KO-1366; Bunitrolol HCl; BRN 2374567; 2-Nitrilo-N-tert-butylphenoxypropanolamine; Koe 1366; o-(3-(tert-Butylamino)-2-hydroxypropoxy)benzonitrile; 2-Propanol, 3-(tert-butylamino)-1-(m-cyanophenoxy)-; (RS)-2-(3-(tert-Butylamino)-2-hydroxypropoxy)benzonitril; 2-[3-(tert-butylamino)-2-hydroxypropoxy]benzonitrile; Bunitrololum; BENZONITRILE, o-(3-(tert-BUTYLAMINO)-2-HYDROXYPROPOXY)-"	2473	C14H20N2O2	Preclinical
M6APDG00569	Dehydroepiandrosterone sulfate	Prasterone sulfate; DHEA sulfate; DEHYDROEPIANDROSTERONE SULFATE; Dehydroisoandrosterone sulfate; DHEAS; Dehydroepiandrosterone sulphate; Dehydroepiandrosterone monosulfate; 3-O-Sulfodehydroepiandrosterone; Dehydroepiandrosterone 3-sulfate; Dehydroandrosterone sulfate; Dehydroisoandrosterone-3-sulfate; 17-Ketoandrost-5-en-3beta-yl sulfate; DHEA-S; Androst-5-en-17-on-3beta-yl sulfuric acid; 3beta-Hydroxyandrost-5-en-17-one 3-sulfate; CCRIS 6746; (3-beta)-3-(Sulfooxy)androst-5-en-17-one; DHEA sulphate	12594	C19H28O5S	Approved
M6APDG03122	Dolastatin 10	"Dolastatin 10; Dolastatin-10; Dolostatin 10; UNII-EI946JT51X; CCRIS 7310; CHEBI:67357; NSC 376128; EI946JT51X; L-Valinamide, N,N-dimethyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-"	9810929	C42H68N6O6S	Phase 2
M6APDG00073	Cepharanthine	"CEPHARANTHINE; Cepharanthin; (+)-Cepharanthine; O-Methylcepharanoline; Cepharantin; Cepharanthine [JAN]; UNII-7592YJ0J6T; CCRIS 6539; NSC 623442; BRN 0075231; 6',12'-Dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))oxyacanthan; CHEBI:3546; 7592YJ0J6T; NSC623442; Cepharanthine (JAN); NSC-623442; ecaene (non-preferred name); DSSTox_RID_81253; DSSTox_CID_25957; DSSTox_GSID_45957; Oxyacanthan, 6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))-; CAS-481-49-2; SR-01000779734; Cepharanthin,(S)"	10206	C37H38N2O6	Approved
M6APDG01059	Azasetron	"Azasetron; Nazasetron; Azasetron [INN]; C17H20ClN3O3; 123039-99-6; WUKZPHOXUVCQOR-UHFFFAOYSA-N; Azasetron (INN); 6-Chloro-4-methyl-3-oxo-N-(quinuclidin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide; NCGC00024563-02; DSSTox_RID_81029; DSSTox_CID_25651; DSSTox_GSID_45651; (- )-6-Chloro-3,4-dihydro-4-methyl-3-oxo-N-3-quinuclidinyl-2H-1,4-benzoxazine-8-carboxamide; N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide"	2264	C17H20ClN3O3	Approved
M6APDG01027	BN-80915	"BN-80915; R-1536; Diflomotecan; (+)-5(R)-Ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione"	219023	C21H16F2N2O4	Phase 2
M6APDG02220	Spiperone	"Spiperone; spiperone; Spiroperidol; Spiropitan; 749-02-0; Espiperona; Spiperonum; [3H]-spiperone; R 5147; Spiperonum [INN-Latin]; Espiperona [INN-Spanish]; E 525; UNII-4X6E73CJ0Q; NSC 170983; MLS000028615; Spiperone [USAN:INN:BAN:JAN]; 8-(3-(p-Fluorobenzoyl)propyl)-1-phenyl-1,3,8-triazaspiro(45)decan-4-one; 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[45]decan-4-one; 8-(3-p-Fluorobenzoyl-1-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro(4,5)decane; EINECS 212-024-0; BRN 0632204; SMR000058674; [3H]-spiperone; SPIPERONE"	5265	C23H26FN3O2	Approved
M6APDG01958	4-Hydroxytamoxifen	"4-Hydroxytamoxifen; Afimoxifene; (Z)-4-Hydroxytamoxifen; Hydroxytamoxifen; 4-Monohydroxytamoxifen; Tamogel; 68047-06-3; trans-4-Hydroxytamoxifen; Ici 79280; 68392-35-8; 65213-48-1; 4-OH-TAM; (Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol; Z-4-hydroxytamoxifen; UNII-95K54647BZ; CHEMBL489; ICI 79,280; TAMOXIFEN, 4-HYDROXY-, (Z)-; BRN 4910749; (E/Z)-4-Hydroxy Tamoxifen; MLS000069742; C26H29NO2; CHEBI:44616; 95K54647BZ; SMR000058939; 4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol"	449459	C26H29NO2	Phase 3
M6APDG02774	Apafant	"Apafant; 105219-56-5; WEB-2086; Web 2086; Apafant [USAN:INN]; Apafantum [INN-Latin]; Apafanto [INN-Spanish]; WEB 2086BS; WEB2086; UNII-J613NI05SV; WEB 2086 BS; BRN 4302553; C22H22ClN5O2S; J613NI05SV; CHEMBL280164; NCGC00092377-03; NCGC00092377-02; Apafantum; Apafanto; DSSTox_CID_28900; DSSTox_RID_83168; DSSTox_GSID_48974; 4-(3-(4-(o-Chlorophenyl)-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-2-yl)propionyl)morpholine; [3H]apafant; Morpholine; Apafant (ophthalmic formulation), Santen"	65889	C22H22ClN5O2S	Discontinued in Phase 2
M6APDG02873	Ingenol-3-angelate	Picato; Ingenol 3-angelate; 75567-37-2; PEP-005; PEP005; 3-Angeloylingenol; UNII-7686S50JAH; PEP 005; 3-Ingenyl angelate; Ingenol-3-angelate; 7686S50JAH; Picato (TN); Euphorbia factor H1; Euphorbia factor An1; Ingenol mebutate [USAN:INN]; [dihydroxy-(hydroxymethyl)-tetramethyl-oxo-[?]yl] (Z)-2-methylbut-2-enoate; I3A; Ingenol-3- angelate; Ingenol mebutate (USAN); (Z)-2-methylbut-2-enoate; SCHEMBL2526605; GTPL7443; CHEMBL1863513; HSDB 8308; VDJHFHXMUKFKET-WDUFCVPESA-N; MolPort-003-941-761; AN-262; POL-103A	6918670	C25H34O6	Approved
M6APDG02657	E-guggulsterone	"Guggulsterone E; (E)-Guggulsterone; E-Guggulsterone; Guggulsterones E; trans-Guggulsterone; 39025-24-6; Pregna-4,17-diene-3,16-dione; UNII-9B259YE66O; (17E)-Pregna-4,17(20)-diene-3,16-dione; Z-Guggulsterone; CHEMBL402063; 95975-55-6; 9B259YE66O; (8R,9S,10R,13S,14S,17E)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; E-Guggulsteron; Pregna-4,17(20)-diene-3,16-dione; Guggulsterone, (E)-; Guglip; Z/E-Guggulsterone; Pregna-4,17(20)-diene-3,16-dione, (17E)-; Guggulsterone E; Guggulsterones Z; Cis-Guggulsterone; Trans-Guggulsterone; (17E)-pregna-4,17-diene-3,16-dione; (17Z)-Pregna-4,17(20)-diene-3,16-dione; (17Z)-pregna-4,17-diene-3,16-dione; (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; (Z)-Guggulsterone; 4,17(20)-cis-Pregnadiene-3,16-dione; E-GUGGULSTERONE"	6439929	C21H28O2	Preclinical
M6APDG01344	Debrisoquine	"Debrisochinum; Debrisoquina; Debrisoquine; Debrisoquinum; Declinax; Equitonil; Isocaramidine; Tendor; DEBRISOQUIN SULFATE; Debrisoquin hemisulfate; Debrisoquine sulfate; Isocaramidine sulfate; Debrisoquina [INN-Spanish]; Debrisoquine [INN:BAN]; Debrisoquinum [INN-Latin]; Ro 5-3307/1; Sulfuric acid compound with 3,4-dihydro-2(1H)-isoquinolinecarboximidamide (1:1); 1,2,3, 4-Tetrahydro-isoquinoline-2-carboxamidine sulfate; 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-(7CI,8CI); 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-, sulfate (2:1); 2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro-, sulfate (2:1); 2-Amidino-1,2,3,4-tetrahydroisoquinoline; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine sulfate (2:1); 3,4-Dihydro-2(1H)-isoquinolinecarboximidamide; 3,4-Dihydro-2(1H;)-isoquinoline carboxamidine sulfate; 3,4-dihydro-1H-isoquinoline-2-carboximidamide; 3,4-dihydroisoquinoline-2(1H)-carboximidamide"	2966	C10H13N3	Approved
M6APDG01109	Quinacrine	"quinacrine; mepacrine; atabrine; Acrinamine; Acriquine; 83-89-6; Quinactine; Antimalarina; Haffkinine; Akrichin; Italchine; acrichine; Erion; Mepacrinum; Quinacrine hydrochloride; Mepacrine [INN:BAN]; St 439; Mepacrinum [INN-Latin]; Mepacrina [INN-Spanish]; atebrin; Malaricida; Methoquine; Palacrin; Italchin; Pentilen; Palusan; Atebrine; Metochin; Mecryl; Quinacrine, Mepacrine; 3-Chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine; 2-Methoxy-6-chloro-9-diethylaminopentylaminoacridine; HSDB 3253"	237	C23H30ClN3O	Phase 2
M6APDG00163	Butyrate	butyric acid; butanoic acid; n-Butyric acid; 107-92-6; n-Butanoic acid; propylformic acid; ethylacetic acid; 1-propanecarboxylic acid; Butanic acid; butyrate; 1-Butyric acid; Buttersaeure; butanoate; Kyselina maselna; Butyric acid (natural); Propanecarboxylic acid; Buttersaeure [German]; 1-butanoic acid; FEMA Number 2221; Kyselina maselna [Czech]; FEMA No. 2221; CCRIS 6552; HSDB 940; butoic acid; Ethyacetic Acid; 2-butanoate; NSC 8415; UNII-40UIR9Q29H; UN2820; AI3-15306; EINECS 203-532-3; BRN 0906770; CH3-[CH2]2-COOH; 40UIR9Q29H	104775	C4H7O2-	Phase 2/3
M6APDG02854	Exatecan mesylate	Exatecan mesylate; DX-8951; DX-8951a; DX-8951f; UM-1; UM-2	6918249	C25H26FN3O7S	Phase 3
M6APDG02241	Amphotericin B	amphotericin b; Amphotericine B; Amphotericin; Amfotericina B; Amphotericinum B; Fungizone; Halizon; Amphocin; AMPH-B; Liposomal Amphotericin B; Fungilin; Amphozone; Ambisome; Abelcet; Ampho-Moronal; Amphotericin-B; Amphortericin B; UNII-7XU7A7DROE; Amphotec; Abelecet; Mysteclin-F; MFCD00877763; 7XU7A7DROE; NCGC00090808-01; DSSTox_CID_2601; NSC 527017; DSSTox_RID_76653; DSSTox_GSID_22601; Amphomoronal; Fungisome; Fungisone; Amphotericinum B [INN-Latin]; Amfotericina B [INN-Spanish]; Amphotericine B [INN-French]; CCRIS 5963	5280965	C47H73NO17	Approved
M6APDG00552	Geneticin	"Geneticin; geneticin; antibiotic G 418; antibiotic G-418; UNII-A08F5XTI6G; 49863-47-0; BRN 1669188; A08F5XTI6G; O-2-Amino-2,7-dideoxy-D-glycero-alpha-D-gluco-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-D-streptamine; G 418 sulfate; G 418; G-418; C20H40N4O10; GET; D-Streptamine, O-2-amino-2,7-dideoxy-D-glycero-alpha-D-gluco-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-; AC1L3XFV; SCHEMBL5006573; CHEMBL215226; DTXSID10198129"	123865	C20H40N4O10	Preclinical
M6APDG00065	Cinchonidine	"CINCHONIDINE; Cinchonan-9-ol; cinchonine; alpha-Quinidine; 485-71-2; GNF-PF-5411; 118-10-5; MLS002637808; NSC5364; .alpha.-Quinidine; NSC 5364; Cinchonan-9-ol, (8.alpha.,9R)-; Cinchonan-9-ol, (9S)-; (8alpha,9R)Cinchonan-9-ol; a-quinidine; (8-alpha,9R)-Cinchonan-9-ol; EINECS 207-622-3; {5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl}(quinolin-4-yl)methanol; SMR001488502; AI3-15317; 4-quinolyl-(5-vinylquinuclidin-2-yl)methanol; 2-Quinuclidinemethanol, alpha-4-quinolyl-5-vinyl-; (+)-Quinolin-4-yl(5-vinylquinuclidin-2-yl)methanol"	101744	C19H22N2O	Approved
M6APDG00646	AG 337	"Thymitaq; AG-337; ZX-337; Nolatrexed (intravenous), EXIMIAS"	135409535	C14H14Cl2N4OS	Phase 3
M6APDG00891	Phenethyl isothiocyanate	Phenethyl-isothiocyanate	16741	C9H9NS	Phase 3
M6APDG00602	C-1311	"XF-02; NSC-645809; C-1311; Imidacrine; Symadex; CHEMBL3545337; XJYNBZQTAZDMHZ-UHFFFAOYSA-N; Imidazoacridone dihydrocheloride hydrate; 138154-55-9; 5-((2-(diethylamino)ethyl)amino)-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one dihydrochloride hydrate"	132127	C20H22N4O2	Phase 2
M6APDG01903	Hydroxybupropion	Hydroxybupropion	446	C13H18ClNO2	Discontinued in Phase 2
M6APDG02157	Protoporphyrin	"protoporphyrin IX; protoporphyrin; 553-12-8; Ooporphyrin; Protoporpyrin IX; Porphyrinogen IX; Protoporphyrin IX disodium; Kammerer's prophyrin; ppIX; Protoporphyrin IX (VAN); H2ppIX; Kammerer's porphyrin; MLS001074731; UNII-C2K325S808; NSC2632; NSC 2632; EINECS 209-033-7; 3,7,12,17-Tetramethyl-8,13-divinyl-2,18-porphinedipropionic acid; SMR000127405; 21H,23H-Porphine-2,18-dipropanoic acid, 7,12-diethenyl-3,8,13,17-tetramethyl-; CHEMBL267548; CHEBI:15430; C34H34N4O4"	4971	C34H34N4O4	Preclinical
M6APDG01493	SJG-136	SG-2000; SJG-136; SP-2001	393111	C31H32N4O6	Phase 2
M6APDG00209	S9788	"S-9788; S9788; S 9788; CHEMBL85156; 140945-01-3; 6-(4-(2,2-di(4-Fluorophenyl)ethylamino)-1-piperidinyl)-N,N'-di-2-propenyl-1,3,5-triazine-2,4-diamine; 1,3,5-Triazine-2,4-diamine, 6-(4-((2,2-bis(4-fluorophenyl)ethyl)amino)-1-piperidinyl)-N,N'-di-2-propenyl-; AC1L32YH; SCHEMBL1527824; DTXSID80161502; GERNFWKTMKWULM-UHFFFAOYSA-N; BDBM50053888; LS-187603; LS-186957; N,N''-Diallyl-6-{4-[2,2-bis-(4-fluoro-phenyl)-ethylamino]-piperidin-1-yl}-[1,3,5]triazine-2,4-diamine; H2O"	107903	C28H33F2N7	Discontinued in Phase 2
M6APDG03121	J-107088	Edotecarin; Edotecarinum; UNII-1V8X590XDP; J-107088; PF-804950; CHEMBL435191; 1V8X590XDP; Edotecarina; E'dotecarine; Edotecarin [USAN:INN]; Edotecarinum [INN-Latin]; E'dotecarine [INN-French]; C29H28N4O11; Edotecarin (USAN/INN); J 107088; SCHEMBL5177060; ZINC3946372; BDBM50086570; DB04882; CS-6688; HY-13618; Z1880; D03954	9808998	C29H28N4O11	Phase 3
M6APDG01647	E3040	"E-3040; E 3040; CHEMBL105139; 145096-30-6; E3040; AC1L9EDQ; CHEBI:4732; 6-Hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole; SCHEMBL6009376; DTXSID80162877; CHEBI:271098; 5,7-Dimethyl-2-(methylamino)-4-(3-pyridinylmethyl)-6-benzothiazolol; BDBM50037037; 6-Benzothiazolol, 5,7-dimethyl-2-(methylamino)-4-(3-pyridinylmethyl)-; C11593; L001447; 5,7-Dimethyl-2-methylamino-4-pyridin-3-ylmethyl-benzothiazol-6-ol; 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole"	443292	C16H17N3OS	Discontinued in Phase 2
M6APDG01453	Hypericin	"Hypericin; VIMRxyn; Synthetic hypericin, Nexell"	3663	C30H16O8	Phase 4
M6APDG02022	NSC325663	21-Cyanosaframycin-B; NSC 325663; 66082-27-7; C29H30N4O8; 21-cyanosaframycin B; AC1L2P2O; SCHEMBL637953; CHEMBL452709	462199	C29H30N4O8	Phase 2
M6APDG00168	Norverapamil	"Arverapamil; (R)-norverapamil; Agi-003; UNII-3J8P56R04P; (R)-(+)-Nor Verapamil Hydrochloride; 123932-43-4; 3J8P56R04P; Rezular; (+)-norverapamil; (R)-desmethylverapamil; (+)-desmethylverapamil; CHEBI:134082; ZINC13492624; AKOS030532539; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, (alphaR)-; UNII-957Z3K3R56 component UPKQNCPKPOLASS-AREMUKBSSA-N"	104972	C26H36N2O4	Phase 2
M6APDG02682	Belotecan	"Belotecan hydrochloride; 213819-48-8; Belotecan; CKD-602; Belotecan HCl; Camtobell hydrochloride; Belotecan (hydrochloride); CKD 602; UNII-01DZ4127G7; 01DZ4127G7; Belotecan hydrochloride (USAN); Belotecan Hydrochloride [USAN]; CHEMBL2107315; DTXSID60175647; BCP28717; HY-13566A; AKOS027420465; API0009359; CS-6955; (S)-4-ethyl-4-hydroxy-11-(2-(isopropylamino)ethyl)-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione hydrochloride; AN-29684; ACM213819488; FT-0662513; D03225; 819C488; J-014022"	6456014	C25H27N3O4	Phase 3
M6APDG02938	UCN-01	"UCN; UCN01; Ucn 01; KRX-0601; KW-2401; UCN-02; (5s,6r,7r,9r,16r)-16-hydroxy-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; 7-Hydroxystaurosporine; 7-hydroxystaurosporine (UCN-01)"	72271	C28H26N4O4	Phase 2
M6APDG02537	Estriol	"Aacifemine; Destriol; Estratriol; Estriel; Estriolo; Gynaesan; Hemostyptanon; Holin; Hormomed; Hormonin; Klimoral; Oestratriol; Oestriol; Oestriolum; Orestin; Orgastyptin; Overstin; Ovestin; Ovestrion; Stiptanon; Synapause; Theelol; Thulol; Tridestrin; Trihydroxyestrin; Trihydroxyoestrin; Triodurin; Triovex; Deuslon A; Estriolo [Italian]; Folicular hormone; Follicular hormone hydrate; Oestriol [Steroidal oestrogens]; A 13610; E0218; OE3; Deuslon-A; Estriel (TN); Estriol [USAN:JAN]; Estriol, unconjugated; Ortho-Gynest; Estriol (JP15/USP); Estra-1,3,5(10)-trien-3,16alpha,17beta-triol; Estra-1,3,5(10)-triene-3,16,17-triol; Estra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16-alpha,17-beta-triol; Estra-1,3,5(10)-trien-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-trien-3,16.alpha.,17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; (16.alpha.,17.beta.)-Estra-1,3,5(10)-triene-3,16,17-triol; (16.alpha.,17.beta.)-Oestra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Estra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Oestra-1,3,5(10)-triene-3,16,17-triol; 1,3,5(10)-ESTRATRIENE-3,16,17-TRIOL; 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol; 1,3,5(10)-Estratriene-3,16.alpha., 17.beta.-triol; 1,3,5(10)-Estratriene-3,16.alpha.,17.beta.-triol; 1,3,5(10)-Estratriene-3,16alpha,17beta-Triol; 1,3,5-Estratriene-3.beta.,16-.alpha.,17-.beta.-triol; 1,3,5-Estratriene-3beta,16alpha,17beta-triol; 1,3,5-Oestratriene-3-.beta.,16.alpha.,17.beta.-triol; 1,3,5-Oestratriene-3beta,16alpha,17beta-triol; 16,17-Epiestriol; 16-Epiestriol; 16-Hydroxyestradiol; 16-alpha,17-beta-Estriol; 16-alpha,17-beta-Oestriol; 16-alpha-Hydroxyestradiol; 16-alpha-Hydroxyoestradiol; 16.alpha.,17.beta.-Estriol; 16.alpha.,17.beta.-Oestriol; 16.alpha.-Estriol; 16.alpha.-Hydroxy-17.beta.-estradiol; 16.alpha.-Hydroxyestradiol; 16.alpha.-Hydroxyoestradiol; 16alpha,17beta-Estriol; 16alpha,17beta-Oestriol; 16alpha-Hydroxy-17beta-estradiol; 16alpha-Hydroxyestradiol; 16alpha-Hydroxyoestradiol; 3,16-alpha,17-beta-Estriol; 3,16-alpha,17-beta-Oestriol; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-estratriene; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16-alpha,17-beta-Trihydroxyestra-1,3,5(10)-triene; 3,16-alpha,17-beta-Trihydroxyoestra-1,3,5(10)-triene; 3,16.alpha.,17.beta.-Estriol; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-estratriene; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-oestratriene; 3,16.alpha.,17.beta.-Trihydroxy-1,3,5(10)-estratriene; 3,16.alpha.,17.beta.-Trihydroxyestra-1,3,5(10)-triene; 3,16alpha,17beta-Estriol; 3,16alpha,17beta-Trihydroxy-1,3,5(10)-estratriene; 3,16alpha,17beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16alpha,17beta-trihydroxy-Delta(1,3,5)-estratriene"	5756	C18H24O3	Approved
M6APDG02480	Trimetrexate	"TMQ; Trimetrexato; Trimetrexatum; JB 11; Jb-11; Trimetrexato [INN-Spanish]; Trimetrexatum [INN-Latin]; Trimetrexate (USAN/INN); Trimetrexate [USAN:BAN:INN]; 2,4-Diamino-5-methyl-6-((3,4,5-trimethoxyanilino)methyl)quinazoline; 5-Methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-2,4-quinazolinediamine; 5-methyl-6-({[3,4,5-tris(methyloxy)phenyl]amino}methyl)quinazoline-2,4-diamine; 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; 6-[((3,4,5-Trimethoxyphenyl)amino)methyl]-5-methyl-2,4-quinazolinediamine"	5583	C19H23N5O3	Approved
M6APDG01399	Famciclovir	"FCV; Famciclovirum; Famvir; Oravir; BRL 42810; IN1338; Anti-Farnesyl Rabbit pAb; BRL-42810; Famciclovirum [INN-Latin]; Famvir (TN); Famciclovir [USAN:BAN:INN]; Famciclovir (JAN/USAN/INN); [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate; Diacetyl 6-deoxy-9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine; 1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester); 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate (ester); 2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate; 2-(acetoxymethyl)-4-(2-amino-4,5-dihydro-9H-purin-9-yl)butyl acetate; 2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate; 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate; 9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine; 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine"	3324	C14H19N5O4	Approved
M6APDG02633	Pirarubicin	pirarubicin; Theprubicin; MFCD00869742; THP-doxorubicin; C32H37NO12; NCGC00167982-01; AC1LCS5T; Pirarubicin (JP17/INN); SCHEMBL15472856; CHEMBL1398373; EX-A494; AOB5649; KMSKQZKKOZQFFG-HSUXVGOQSA-N; ZINC3913909; AKOS015895621; NCGC00167982-02; BC225325; K234; D01885; 15207-EP2316833A1; 15207-EP2311829A1; 15207-EP2298765A1; 15207-EP2298748A2; 15207-EP2295427A1; 15207-EP2295416A2; 15207-EP2272827A1; 15207-EP2316832A1; 15207-EP2298778A1; 15207-EP2298768A1; 15207-EP2295426A1; 15207-EP2295055A2; 15207-EP2311808A1	636397	C32H37NO12	Approved
M6APDG03139	CP-122721	"CP-122721; UNII-R7OYP6N58F; R7OYP6N58F; CHEMBL319118; CHEMBL1917847; DSSTox_CID_27251; DSSTox_RID_82210; DSSTox_GSID_47251; SCHEMBL156646; DTXSID9047251; Tox21_300205; BDBM50067935; ZINC22441997; AKOS030542331; DB05421; NCGC00254228-01; NCGC00247927-01; CAS-145742-28-5; (2S,3S)-N-(2-methoxy-5-(trifluoromethoxy)benzyl)-2-phenylpiperidin-3-amine"	9821217	C20H23F3N2O2	Phase 2
M6APDG02148	Pirenzepine	"Gasteril; Gastrotsepin; Gastrozepin; Pirenzepin; Pirenzepina; Pirenzepinum; Pyrenzepine; Ulcosan; Pirenzepine Gastrozepin; Gastrozepin (TN); L-S 519; Pirenzepina [INN-Spanish]; Pirenzepine (INN); Pirenzepine [INN:BAN]; Pirenzepinum [INN-Latin]; 11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one; 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 5,11-Dihydro-11-((4-methyl-1-piperazinyl)acetyl)-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one"	4848	C19H21N5O2	Approved
M6APDG01275	Calphostin C	"calphostin C; CHEMBL460433; UNII-I271P23G24; I271P23G24; CHEMBL1256495; Ucn 1028 C; UCN 1028C; BSPBio_001520; GTPL5156; SCHEMBL15185703; HSDB 7592; SRJYZPCBWDVSGO-NHCUHLMSSA-N; HMS1989L22; HMS3402L22; HMS1791L22; BDBM213748; Carbonic acid, 2-(12-(2-(benzoyloxy)propyl)-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl)-1-methylethyl 4-hydroxyphenyl ester; Carbonic acid, (1R)-2-(12-((2R)-2-(benzoyloxy)propyl)-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl)-1-methylethyl 4-hydroxy"	2533	C44H38O14	Terminated
M6APDG00213	Ramosetron	"132036-88-5; UNII-7ZRO0SC54Y; Ramosetron [INN]; 7ZRO0SC54Y; CHEMBL1643895; Ramosetron (INN); (1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone; Nor-YM 060; SCHEMBL16701; GTPL2301; DTXSID0043842; NTHPAPBPFQJABD-LLVKDONJSA-N; MolPort-019-991-383; CHEBI:135156; ZINC5116719; AC1L3355; BDBM50334454; 8235AH; AKOS015896003; SB19072; DB09290; SC-92398; AJ-53160; LS-187182; TL8000762; R-146; FT-0651831; D08466; A806353; (-)-(R)-1-Methylindol-3-yl-4,5,6,7-tetrahydro-5-benzimidazolyl ketone; Nasea (TN); YM060"	108000	C17H17N3O	Approved
M6APDG01363	Droloxifene	E-droloxifene; FK-435; K-060; K-060E; RP-60850; K-21.060E; 3-hydroxytamoxifen	3033767	C26H29NO2	Discontinued in Phase 2
M6APDG02606	Lurtotecan	"OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan"	60956	C28H30N4O6	Discontinued in Phase 2
M6APDG03104	Methysergide	"Deseril; Desernil; Desernyl; Deseryl; Desril; Dimethylergometrin; Methylmethylergonovine; Methysergid; Methysergidum; Metisergide; Metisergido; Sansert; Methyllysergic acid butanolamide; Metisergide [DCIT]; UML 491; Deseril (TN); Methysergidum [INN-Latin]; Metisergido [INN-Spanish]; Sansert (TN); UML-491; Methysergide (USAN/INN); Methysergide [USAN:INN:BAN]; N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; (+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide; (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide; (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide; 1-Methyl-D-lysergic acid butanolamide; 1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide; 1-Methylmethylergonovine; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide"	9681	C21H27N3O2	Approved
M6APDG02279	Acrivastine	"Acrivastin; Acrivastina; Acrivastinum; Semprex; Acrivastina [Spanish]; Acrivastinum [Latin]; Benadryl allergy relief; BW 0270C; BW 825C; BW A825C; BW-825C; Acrivastine (USAN/INN); Acrivastine [USAN:INN:BAN]; E-(9CI); (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; (E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid; (E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure; (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid; 3-{6-[1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid"	5284514	C22H24N2O2	Approved
M6APDG00059	Becatecarin	"BMS-181176; Becatecarin < USAN; DEAE-Rebeccamycin; XL-119; BMY-27557-01 (HCl); BMY-27557-14 (tartrate); 1,11-Dichloro-6-[2-(diethylamino)ethyl]-12-(4-O-methyl-beta-D-glucopyranosyl)-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	101524	C33H34Cl2N4O7	Discontinued in Phase 3
M6APDG02231	beta-Carotene	"beta-carotene; 7235-40-7; beta Carotene; beta,beta-Carotene; Betacarotene; Provitamin A; Solatene; Carotaben; Provatene; all-trans-beta-Carotene; Serlabo; Natural Yellow 26; Karotin; KPMK; C.I. Food Orange 5; Solatene (caps); Karotin [Czech]; Food orange 5; Zlut prirodni 26; Betacarotenum [Latin]; Betacaroteno [Spanish]; Lucaratin; BetaVit; beta-Karotin; beta-Carotin; beta;-Carotene; beta-Carotene, all-trans-; .beta. Carotene; .beta.-Carotene; Betacarotenum [INN-Latin]; C.I. 75130; Betacaroteno [INN-Spanish]; Zlut prirodni 26 [Czech]"	5280489	C40H56	Approved
M6APDG00115	beta-Acetyldigoxin	Novodigal (TN)	10350481	C43H66O15	Approved
M6APDG02512	Guanabenz	"GBZ; Guanabenzo; Guanabenzum; Wytensin; Guanabenz acetate; Guanabenz monoacetate; Wy 8678; Wy 8678 base; BR-750; Guanabenz [USAN:INN]; Guanabenz(USAN); Guanabenzo [INN-Spanish]; Guanabenzum [INN-Latin]; Wy-8678; Wytensin (TN); Guanabenz (USAN/INN); [(2,6-Dichlorobenzylidene)amino]guanidine; N-((2,6-Dichlorobenzylidene)amino)guanidine; Guanidine, ((2,6-dichlorobenzylidene)amino)-(8CI); N-(2,6-Dichlorobenzylidene)-N'-amidinohydrazine; ((2,6-Dichlorobenzylidene)amino)guanidine; 2,6-Dichlorobenzylideneaminoguanidine;2-((2,6-Dichlorophenyl)methylene)-hydrazinecarboximidamide; 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine"	5702063	C8H8Cl2N4	Approved
M6APDG02868	vildagliptin	"Equa; Galvu; Galvus; Jalra; Xiliarx; Galvus (TN); Vidagliptin (see Vildagliptin); Vildagliptin (JAN/USAN/INN); (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile; (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 2-Pyrrolidinecarbonitrile, 1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)-(9CI)"	6918537	C17H25N3O2	Approved
M6APDG02851	Ciclesonide	"Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate"	6918155	C32H44O7	Approved
M6APDG02538	Pemirolast	"Pemirolastum; Pemirox; Pemirolast [INN]; Pemiroplast Potassium; Alamast (TN); Alegysal (TN); Pemirolast (INN); Pemirolastum [INN-Latin]; Pemirox (TN); 9-TBX; 9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; 9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one"	57697	C10H8N6O	Approved
M6APDG02654	Phosphatidylserine	distearoylphosphatidylserine; LifeExtension PS Caps	6438639	C42H78NO10P	Phase 2
M6APDG03100	Ximelagatran	"Exanta; Exarta; H 376/95; Ximelagatran [USAN:INN]; 192939-46-1; H 376-95; H 37695; Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-, ethyl ester; NCGC00183598-01; Ethyl (((1R)-1-cyclohexyl-2-((2S)-2-((4-(hydroxycarbamimidoyl)benzyl)carbamoyl)azetidin-1-yl-2-oxoethyl)amino)acetate; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-(hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ethyl ester; H 376 95; Exanta (TN); Exarta (TN); Xi-melagatran; H-376/95; Ximelagatran (JAN/USAN/INN); Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; Glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-((hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ester ester; H376/95"	9574101	C24H35N5O5	Withdrawn
M6APDG01450	Substance P	Substance P; 33507-63-0; Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2; CCRIS 7229; UNII-675VGV5J1D; EINECS 251-545-8; CHEMBL235363; 675VGV5J1D; 12769-48-1; P substance; Neurokinin P; Substanz-P; C63H98N18O13S; Substance P analogue; AC1Q5IQE; AC1L1VX3; tachykinin substance P (SP); SCHEMBL1116347; GTPL2098; ArgProLysProGlnGlnPhePheGlyLeuMet; MolPort-023-276-010; ADNPLDHMAVUMIW-CUZNLEPHSA-N; 2053AH; BDBM50001450; AKOS024456424; NCGC00167123-01; 11035-08-8; LS-147256; Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-amine	36511	C63H98N18O13S	Phase 1
M6APDG03268	NB-506	"J-107185; L-753000; N-[12-(beta-D-Glucopyranosyl)-1,11-dihydroxy-5,7-dioxo-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-6-yl]formamide; 6-(Formamido)-12-(beta-D-glucopyranosyl)-1,11-dihydroxy-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione"	9915861	BN	Discontinued in Phase 2
M6APDG00869	Mithramycin	NCGC00181319-05; NCGC00181319-01; DSSTox_CID_3492; DSSTox_RID_77052; Plicatomycin; DSSTox_GSID_23492; CAS-18378-89-7; AC1NR4RB; SCHEMBL4516; DTXSID6023492; Tox21_112787; Tox21_112751; NCGC00181319-08; NCGC00181319-06; NCGC00181319-03; NCGC00181319-04; NCGC00181319-02; NCGC00181319-07	163659	C52H76O24	Withdrawn
M6APDG00650	Aprepitant	"Aprepitant [USAN]; L 754030; MK 0869; Emend (TN); L-754030; MK-0869; ONO-7436; Aprepitant (JAN/USAN/INN); MK-869, L-754030, Emend, Aprepitant; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one; 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one"	135413536	C23H21F7N4O3	Approved
M6APDG02831	Nifurtimox	"NIFURTIMOX; Lampit; Bayer 2502; 23256-30-6; BAY 2502; Nifurtimox [INN:BAN]; Nifurtimoxum [INN-Latin]; CCRIS 2201; EINECS 245-531-0; CHEBI:7566; C10H13N3O5S; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide; 3-Methyl-N-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-dioxide; 3-Methyl-4-(5'-nitrofurylidene-amino)-tetrahydro-4H-1,4-thiazine-1,1-dioxide"	6842999	C10H13N3O5S	Phase 4
M6APDG02271	Triprolidine	"Actidil; Actidilat; Entra; Histafed; Myidyl; Tripolidina; Triprolidin; Triprolidinum; Venen; Triprolidine HCL; Triprolidine Monohydrochloride; Triprolidine hydrochloride; Triprolidine hydrochloride anhydrous; T 6764; Actidil (TN); Myidil (TN); Pro-Actidil; Pro-Entra; Tripolidina [INN-Spanish]; Triprolidine (INN); Triprolidine Hydrochloride (anhydrous); Triprolidine Monohydrochloride, Monohydrate; Triprolidine [INN:BAN]; Triprolidinum [INN-Latin]; Venen (TN); Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine; Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride; Trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene; Trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, monohydrochloride, monohydrate, stereoisomer; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl)-, hydrochloride (1:1); (E)-2-(1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)pyridine; (E)-2-[3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]pyridine hydrochloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ium-1-ylprop-1-enyl]pyridine chloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine hydrochloride"	5282443	C19H22N2	Approved
M6APDG03107	Betamethasone	"betamethasone; 378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Beta-Methasone; Beta-Methasone alcohol; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate"	9782	C22H29FO5	Approved
M6APDG00799	Clomifene	"Androxal; Chlomaphene; Chloramifene; Cisclomifenum; Cisclomiphene; Clomifen; Clomifeno; Clomifenum; Clomifert; Clomiphene; Clostilbegit; Enclomifene; Enclomifeno; Enclomifenum; Enclomiphen; Enclomiphene; Klostilbegit; Transclomifenum; Transclomiphene; Zuclomifene; Zuclomifeno; Zuclomifenum; Zuclomiphene; Clomiphene B;Enclomiphene [USAN]; ISOMER B; Zuclomiphene [USAN]; Cis-Clomifene; Cis-Clomiphene; Clomid (TN); Clomifene (INN); Clomifene (TN); Clomifene [INN:BAN]; Clomifeno [INN-Spanish]; Clomifenum [INN-Latin]; En-Clomiphene; Enclomifeno [INN-Spanish]; Enclomifenum [INN-Latin]; Enclomiphene (USAN); Milophene (TN); RMI 16,289; RMI-16289; RMI-16312; Serophene (TN); Trans-Clomifene; Trans-Clomiphene; Zuclomifeno [INN-Spanish]; Zuclomifenum [INN-Latin]; Zuclomiphene (USAN); Cis-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Trans-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Cis-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; Trans-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; (E)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-isomer; 1-(p-(beta-Diethylaminoethoxy)-phenyl)-1,2-diphenylchloroethylene; 2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; 2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; 2-(p-(beta-Chloro-alpha-phenylstyryl)phenoxy)-triethylamine; 2-(p-(beta-chloro-alpha-phenylstyryl)phenoxy)triethylamine; 2-({4-[(Z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-N,N-diethylethanamine; 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine; 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-{4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy}-N,N-diethylethanamine"	1548953	C26H28ClNO	Approved
M6APDG00477	Silvestrol	"Naturally derived compounds (cancer); Naturally derived compounds (cancer), Bristol-Myers Squibb/National Cancer Institute"	11787114	C34H38O13	Preclinical
M6APDG02849	Dexniguldipine	Dexniguldipine hydrochloride; BY-935; B-8509-035; B-859-35	6918097	C36H39N3O6	Discontinued in Phase 2
M6APDG02310	Cefotetan	"Cefotetanum; Apatef (TN); Cefotan (TN); Cefotetan (JP15/USP/INN); (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid"	53025	C17H17N7O8S4	Approved
M6APDG01478	Labetalol	Albetol; Ibidomide; Labetalolum; Labetolol; NORMOZIDE; AH 5158; AH-5158; Labetalol (INN); Labetalol [INN:BAN]; Labetalolum [INN-Latin]; Normodyne (TN); Sch-19927; Trandate (TN); 2-Hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)benzamide; 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide; 2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide; 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol; 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide	3869	C19H24N2O3	Approved
M6APDG01124	Camptothecin	"camptothecin; Camptothecine; 7689-03-4; (S)-(+)-Camptothecin; Campathecin; d-Camptothecin; (+)-Camptothecine; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; (S)-Camptothecin; Camptothecine (8CI); 20(S)-Camptothecin; Camptothecine (S,+); CHEMBL65; UNII-XT3Z54Z28A; MLS000766223; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; XT3Z54Z28A; CHEBI:27656; VSJKWCGYPAHWDS-FQEVSTJZSA-N; Camptothecin, Camptotheca acuminata; NSC-94600; Camptothecin derivat"	24360	C20H16N2O4	Phase 3
M6APDG00996	Alfuzosin	"Alfusosine; Alfuzosina; Alfuzosine; Alfuzosinum; Alphuzosine; Alfuzosina [Spanish]; Alfuzosine [French]; Alfuzosinum [Latin]; Alfuzosin (INN); Alfuzosin [INN:BAN]; Xatral (TN); N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide"	2092	C19H27N5O4	Approved
M6APDG01521	Mequitazine	"Butix; Instotal; Kitazemin; Mequitazina; Mequitazinum; Metaplexan; Mircol; Primalan; Quitadrill; Vigigan; Virginan; Zesulan; Italfarmaco brand of mequitazine; Mequitazina [Spanish]; Mequitazine hydrochloride; Pierre Fabre brand of mequitazine; LM 209; Kitazemin (TN); LM-209; Mequitazina [INN-Spanish]; Mequitazinum [INN-Latin]; Mequitazine (JP15/INN); Mequitazine [INN:BAN:DCF:JAN]; Mequitazine tartrate, (R-(R*,R*))-isomer; 10-(1-Azabicyclo[2.2.2]oct-3-ylmethyl)-10H-phenothiazine; 10-(1-azabicyclo(2.2.2)oct-8-ylmethyl)phenothiazine; 10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine; 10-(3-Quinuclidinylmethyl)phenothiazine; 10H-Phenothiazine, 10-(1-azabicyclo(2.2.2)oct-3-ylmethyl)-(9CI); 3-Methylquinuclidinyl-10-phenothiazine"	4066	C20H22N2S	Approved
M6APDG02416	Piritrexim	"Piritrexim; 72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine"	54369	C17H19N5O2	Phase 2
M6APDG01867	Neostigmine	"Eustigmin; Eustigmine; Intrastigmina; Juvastigmin; Neostigmin; Neostigminum; Prostigmin; Prostigmine; Prozerin; Sulfonatooxymethane; Synstigmin; Syntostigmine; Vagostigmin; Vagostigmine; Neostigmine [BAN]; Neostigmine omega; M-Trimethylammoniumphenyldimethylcarbamate; Neostigmine (BAN); Prostigmin (TN); Vagostigmin (TN); [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide; Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester); Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-(9CI); (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester); 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium; 3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium"	4456	C12H19N2O2+	Approved
M6APDG02283	Topiramate	"Epitoma; Epitomax; TOR; Tipiramate; Tipiramato; Topamac; Topamax; Topimax; Topina; Topiramato; Topiramatum; Topomax; Cilag brandof topiramate; Janssen brand of topiramate; Ortho brand of topiramate; Tipiramate [French]; Tipiramato [Spanish]; Topamax Sprinkle; Topiramate tablet; Topiramatum [Latin]; Topiramic acid; McN 4853; RWJ 17021; KS-1122; KW-6485; McN-4853; RWJ-17021; Topamax (TN); Topamax, Topiramate; Topiramate (TPM); Topiramate / Placebo; Topiramato [INN-Spanish]; Topiramatum [INN-Latin]; USL-255; RWJ-17021-000; Topiramate [USAN:BAN:INN]; Topiramate (JAN/USAN/INN); Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI);Beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-(beta)-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, beta"	5284627	C12H21NO8S	Approved
M6APDG02942	9-Aminocamptothecin	"IDEC-132; (S)-10-Amino-4-ethyl-4-hydroxy-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione; 9-Amino-20(S)-camptothecin"	72402	C20H17N3O4	Phase 2
M6APDG03156	Midostaurin	"PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251"	9829523	C35H30N4O4	Approved
M6APDG02236	Prostaglandin A2	medullin; PGA2	5280880	C20H30O4	Phase 1
M6APDG00987	Beclomethasone	"Anceron; Beclocort; Beclometason; Beclometasona; Beclometasonum; Becloval; Becodisks; Beconasol; Becotide; Inalone; Viarex; Beclometasondipropionat Mikron; Beclometasone [INN]; Vancenase AQ; B 0385; BMJ 5800; Beclometason (TN); Beclometasona [INN-Spanish]; Beclometasone (INN); Beclometasonum [INN-Latin]; Beconase (TN); Clipper (TN); Propaderm (TN); Vancenase (TN); (11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8R,9S,10S,11S,13R,14R,16R,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9alpha-Chloro-16beta-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione; 9alpha-Chloro-16beta-methylprednisolone"	20469	C22H29ClO5	Approved
M6APDG02617	Cycloheximide	naramycin A; NSC 185; FT 3422-2; NM-MCD 80	6197	C15H23NO4	Preclinical
M6APDG02688	Dirithromycin	"Dirithromycine; Dirithromycinum; Diritromicina; Divitross; Dynabac; Noriclan; Valodin; Dirithromycine [French]; Dirithromycinum [Latin]; Diritromicina [Spanish]; LY 237216; AS-E 136; ASE-136; Dynabac (TN); LY-237216; Dirithromycin (USP/INN); Dirithromycin [USAN:BAN:INN]; (9S)-9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)ethylidene]erythromycin"	6473883	C42H78N2O14	Approved
M6APDG02777	Tolafentrine	BY-4070	65990	C28H31N3O4S	Discontinued in Phase 2
M6APDG02600	Befloxatone	MD-370503	60824	C15H18F3NO5	Discontinued in Phase 3
M6APDG02477	Triflupromazine	"Adazine; Fluopromazine; Fluorofen; Neoprin; Nivoman; Psyquil; Siquil; Trifluopromazine; Triflupromazina; Triflupromazinum;Vesprin; Vetame; Fluopromazine monohydrochloride; Trifluopromazine hydrochloride; Triflupromazine [INN]; Triflupromazina [INN-Spanish]; Triflupromazinum [INN-Latin]; Vesprin (TN); Triflupromazine (USP/INN); N,N-Dimethyl-2-(trifluoromethyl)-10H-phenothiazine-10-propanamine; N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine; N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine hydrochloride; N,N-dimethyl-3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propan-1-amine; N,N-dimethyl-3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)-1-propanamine; 10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine; 10-3-(Dimethylamino)propyl-2-(trifluoromethyl)phenothiazine; 2-(Trifluoromethyl)promazine; 2-Trifluoromethyl-10-(gamma-dimethylaminopropyl)phenothiazine"	5568	C18H19F3N2S	Approved
M6APDG00545	Niguldipine	"NIGULDIPINE; S(+)-niguldipine; UNII-Z81N45O25Z; S(+)-Niguldipine hydrochloride; 113165-32-5; Z81N45O25Z; (+)-NIGULDIPINE; Niguldipine [INN]; niguldipine[inn]; (S)-Niguldipine; Tocris-1123; Tocris-1124; AC1Q1ZUF; AC1L1TKT; S(+)-1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(4,4-diphenyl-1-piperidinyl)-propyl methyl ester hydrochloride; GTPL487; SCHEMBL245992; CHEMBL41929; CHEMBL405355; DTXSID60274008; CHEBI:103931; MFCD00873564; BDBM50034683; BDBM50453799; ZINC100001967; DB09239; NCGC00025015-01"	1236	C36H39N3O6	Terminated
M6APDG02243	Olopatadine	"Allelock; Opatanol; Pataday; Patanase; Patanol; OLOPATADINE HCl; OLOPATADINE HYDROCHLORIDE; ALO4943A; HCl of KW 4679; KW 4679; O0361; AL-4943A; ALO-4943A; Allelock (TN); KW-4679; KW-4943A; Olopatadine [INN:BAN]; Pataday (TN); Patanase (TN); Patanol S (TN); {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride; 11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride"	5281071	C21H23NO3	Approved
M6APDG02292	Nogalamycin	AC1MBPR2	5289019	C39H49NO16	Preclinical
M6APDG02435	Isoxicam	"isoxicam; 34552-84-6; Maxicam; Isoxicamo; Isoxicamum; UNII-8XU734C4NG; Pacyl (antiinflammatory); Isoxicamum [INN-Latin]; Isoxicamo [INN-Spanish]; EINECS 252-084-5; W 8495; BRN 0577221; 8XU734C4NG; CHEBI:76163; C14H13N3O5S; NCGC00016829-05; CAS-34552-84-6; 4-Hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; 4-Hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; DSSTox_CID_25462; DSSTox_RID_80893; DSSTox_GSID_45462"	54677972	C14H13N3O5S	Withdrawn
M6APDG02893	Pafenolol	H-138/03; Pafenolol; Rac-N-[2-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]ethyl]-N'-isopropylurea	71144	C18H31N3O3	Discontinued in Phase 1
M6APDG02524	Flesinoxan	Flesinoxan hydrochloride; DU-29373	57347	C22H26FN3O4	Discontinued in Phase 3
M6APDG02187	Raloxifene	"Raloxifene (extended-release, CDT)"	5035	C28H27NO4S	Approved
M6APDG02397	Morphine-6-glucuronide	"Morphine-6-glucuronide; Morphine 6-glucuronide; 20290-10-2; UNII-64Y9KYM60R; Morphine 6-beta-D-glucopyranosiduronide; 64Y9KYM60R; CHEBI:80581; MORPHINE GLUCURONIDE; MORPHINE 6-GLUCURONIDE(MINOR); beta-D-Glucopyranosiduronic acid, (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl; Morphine 6-beta-D-Glucuronide; Glucopyranosiduronic acid, 7,8-didehydro-4,5-alpha-epoxy-3-hydroxy-17-methylmorphinan-6-alpha-yl-, beta-D-; Morphine glucuronide [INN]; morphine-glucuronide"	5360621	C23H27NO9	Phase 3
M6APDG01919	Okadaic acid	"78111-17-8; CHEMBL280487; CHEBI:44658; C44H68O13; 9,10-Deepithio-9,10-didehydroacanthifolicin; Ocadaic Acid; OKA; (2R)-3-[(2S,5R,6R,8S)-8-[(2R,3E)-4-[(2R,4'aR,5R,6'S,8'R,8'aS)-8'-hydroxy-6'-[(1S,3S)-1-hydroxy-3-[(2S,3R,6S)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-7'-methylidene-hexahydro-3'H-spiro[oxolane-2,2'-pyrano[3,2-b]pyran]-5-yl]but-3-en-2-yl]-5-hydroxy-10-methyl-1,7-dioxaspiro[5.5]undec-10-en-2-yl]-2-hydroxy-2-methylpropanoic acid; UNII-1W21G5Q4N2; CCRIS 3329; HSDB 7243; 1W21G5Q4N2; 1jk7"	446512	C44H68O13	Preclinical
M6APDG02314	Nalbuphine	"Intapan; Nalbufina; Nalbuphinum; Intapan (TN); Nalbuphine (INN); Nubain (TN); (5alpha,6alpha)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol; 17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alpha,14-triol"	5311304	C21H27NO4	Approved
M6APDG02315	Vinorelbine	"Eunades; Exelbine; NVB; Navelbine; Vinorelbin; Vinorelbina; Vinorelbinum; Navelbine base; Vinorelbina [Spanish]; Vinorelbine Ditartarate; Vinorelbine ditartrate; Vinorelbine tartrate; Vinorelbinum [Latin]; KW 2307; KW 2307 base; ANX-530; KW-2307; Navelbine (TN); SDP-012; Vinorelbine (INN); Vinorelbine [INN:BAN]; Aspidospermidine-3-carboxylic acid; Nor-5'-anhydrovinblastine; Methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate"	5311497	C45H54N4O8	Approved
M6APDG01606	Nafoxidine	"Nafoxidine; 1845-11-0; Nafoxidine [INN]; Nafoxidinum [INN-Latin]; Nafoxidina [INN-Spanish]; UNII-4RIY10WM82; U-11000A; BRN 1440873; CHEMBL28211; 4RIY10WM82; CHEBI:34881; NSC 70735; C29H31NO2; JEYWNNAZDLFBFF-UHFFFAOYSA-N; 1-(2-(p-(3,4-Dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)ethyl)pyrrolidine; Pyrrolidine, 1-(2-(4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy)ethyl)-; 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine; Pyrrolidine, 1-(2-(p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl"	4416	C29H31NO2	Preclinical
M6APDG03102	Gimatecan	"LBQ-707; ST-1480; ST-1481; Camptothecin analogs, Sigma-Tau; 7-cyano-camptothecin"	9577124	C25H25N3O5	Phase 1/2
M6APDG03101	Tenofovir alafenamide	"(S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; AK109983; EL9943AG5J; GS 7340; GS-7339; GS-7340; GS7340; J4414G3BUK; L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester; TENOFOVIR ALAFENAMIDE; Tenofovir Alafenamide (GS-7340); Tenofovir Alafenamide [USAN:INN]; UNII-EL9943AG5J; UNII-J4414G3BUK; Vemlidy"	9574768	C21H29N6O5P	Phase 3
M6APDG00099	Binimetinib	"181R97MR71; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; 606143-89-9; ARRY 162; ARRY 438162; ARRY-162; ARRY-438162; Binimetinib (JAN/USAN); Binimetinib (MEK162, ARRY-162, ARRY-438162); Binimetinib [USAN:INN]; D0C4LF; MEK 162; MEK-162; MEK162; MEK162 (ARRY-162, ARRY-438162); MEK162(Binimetinib); NVP-ME; UNII-181R97MR71"	10288191	C17H15BrF2N4O3	Approved
M6APDG00107	Boceprevir	"(1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide; 394730-60-0; 89BT58KELH; Boceprevir; CHEBI:68621; EBP 520; SCH 503034; SCH-503034; UNII-89BT58KELH; Victrelis"	10324367	C27H45N5O5	Approved
M6APDG00509	Clofarabine	"(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048; CAFdA; CFB; Cl-F-Ara-A; Clofarabina; Clofarabine (USAN/INN); Clofarabine [USAN]; Clofarabinum; Clofarex; Clolar; Clolar (TN); Clolar, Evoltra, Clofarabine; Evoltra; Evoltra (TN)"	119182	C10H11ClFN5O3	Approved
M6APDG01300	Thiamphenicol	(+)-Thiamphenicol; 15318-45-3; Armai (TN); C12H15Cl2NO5S; D-Thiocymetin; D-Thiophenicol; Descocin; Dexawin; Dextrosulphenidol; EINECS 239-355-3; Efnicol; Hyrazin; Igralin; Macphenicol; Masatirin; Neomyson; RACEPHENICOL; Raceophenidol; Rincrol; SW 5063; Thiamcol; Thiamphenicol (Thiophenicol); Thiamphenicol [USAN:INN:BAN:JAN]; Thiamphenicolum; Thiamphenicolum [INN-Latin]; Thiocymetin; Thiocymetin (TN); Thiophenicol; Tiamfenicol [INN-Spanish]; Tiamfenicolo [DCIT]; UNII-FLQ7571NPM; Unaseran-D; Urfamicina; Urfamycine; WIN-5063-2; thiamphenicol	27200	C12H15Cl2NO5S	Approved
M6APDG00379	Carfilzomib	(S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; 72X6E3J5AR; 868540-17-4; CHEBI:65347; CHEMBL451887; Carfilzomib; Carfilzomib (PR-171); DSSTox_CID_28616; DSSTox_GSID_48690; DSSTox_RID_82886; Kyprolis; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide; NCGC00249613-01; PR-171; UNII-72X6E3J5AR	11556711	C40H57N5O7	Approved
M6APDG00992	Albendazole	"((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole; Albendazol; Albendazol [INN-Spanish]; Albendazole (JAN/USP/INN); Albendazole Armstrong Brand; Albendazole Diba Brand; Albendazole Fustery Brand; Albendazole Hormona Brand; Albendazole Liferpal Brand; Albendazole Monohydrochloride; Albendazole Noe-Socopharm Brand; Albendazole Pfizer Brand; Albendazole Sanicoopa Brand; Albendazole Valdecasas Brand; Albendazole [USAN:INN:BAN:JAN]; Albendazolum; Albendazolum [INN-Latin]; Albendoral; Albenza; Albenza (TN); Albenza, Eskazole, Zentel, Andazol, Albendazole; Armstrong Brand of Albendazole; Bendapar; Bilutac; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Diba Brand of Albendazole; Digezanol; Disthelm; Disthelm, Mediamix V; Endoplus; Eskazole; Eskazole (TN); Fustery Brand of Albendazole; Gascop; Hormona Brand of Albendazole; Liferpal Brand of Albendazole; Lurdex; Mediamix V Disthelm; Methyl 5-(propyl-thio)-2-benzimidazolecarbamate; Methyl 5-(propylthio)-2-benzimidazolecarbamate; Methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; Methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; Methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; Methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Methyl-5-[propylthio]-2-benzimidazole carbamate; MethylN-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; Metiazol; Monohydrochloride, Albendazole; Noe Socopharm Brand of Albendazole; Noe-Socopharm Brand of Albendazole; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; Pfizer Brand of Albendazole; Proftril; SK&F 62979; SK&F-62979; SK&F62979; SKF 62979; SKF-62979; SKF62979; Sanicoopa Brand of Albendazole; Smith Kline & French Brand of Albendazole; SmithKline Beecham Brand of Albendazole; V Disthelm, Mediamix; Valbazen; Valdecasas Brand of Albendazole; Zental; Zentel; Zentel (TN); [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester"	2082	C12H15N3O2S	Approved
M6APDG01967	Paritaprevir	"(2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; ABT 450; ABT-450; ABT450; CHEMBL3391662; EX-A2278; OU2YM37K86; Paritaprevir; Paritaprevir [USAN:INN]; Paritaprevir(ABT-450); Paritaprevir(Veruprevir ABT-450); SCHEMBL3069964; UNII-OU2YM37K86; Veruprevir; Veruprevir [INN]; Veruprevir anhydrous"	45110509	C40H43N7O7S	Phase 2
M6APDG02801	Glecaprevir	A-1282576.0; ABT 493; ABT-493; ABT-493(Glecaprevir); CS-8098; D10814; DB13879; EX-A1940; Glecaprevir; Glecaprevir (USAN/INN); Glecaprevir [USAN]; HY-17634; J3.646.120I; K6BUU8J72P; SB19760; SCHEMBL883097; UNII-K6BUU8J72P; glecaprevirum	66828839	C38H46F4N6O9S	Phase 2
M6APDG02390	Bisantrene	"39C34M111K; 78186-34-2; 9,10-Anthracendicarbaldehyde bis(2-imidazolin-2-ylhydrazon); 9,10-Anthracenedicarboxaldehyde, bis((4,5-dihydro-1H-imidazol-2-yl)hydrazone)-; BISANTRENE HYDROCHLORIDE; BRN 0966309; Bisantrene; Bisantrene [INN]; Bisantreno; Bisantreno [INN-Spanish]; Bisantrenum; Bisantrenum [INN-Latin]; CHEMBL25336; CL 216942; N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazono)methyl]-9-anthryl]methyleneamino]-4,5-dihydro-1H-imidazol-2-amine; NSC 337766; UNII-39C34M111K"	5351322	C22H22N8	Phase 2
M6APDG02323	Bcecf-Am	"117464-70-7; 2',7'-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester; 2',7'-bis(2-Carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester Mixed isomers; AKOS015916474; BCECF-AM solution; BCECF-AM solution (5 mM in DMSO), 1 mg in 0.25 ml DMSO; BCECF-acetoxymethyl; FT-0622598; I14-51975; J-100048; MFCD00036969; SCHEMBL15570087; Spiro(isobenzofuran-1(3H),9'-(9H)xanthene)-2',7'-dipropanoic acid; ZINC169730836"	53229972	C42H40O21	Investigative
M6APDG01042	Deoxycholic acid	"(3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-oic acid; 3,12-Dihydroxycholanic acid; 3alpha,12alpha-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,12alpha-Dihydroxy-5beta-cholanic acid; 5-beta-Deoxycholic acid; 7-Deoxycholic acid; 7alpha-Deoxycholic acid; ATX-101; Choleic acid; Cholerebic; Cholic acid, deoxy-; Cholorebic; DEOXYCHOLIC ACID; Degalol; Deoxy cholic acid; Deoxycholatic acid; Desoxycholic acid; Desoxycholsaeure; Dihydroxycholanoic acid; Droxolan; Pyrochol; Septochol; Sodium deoxycholate; deoxycholate"	222528	C24H40O4	Approved
M6APDG02683	Sunitinib malate	"(Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate; LVX8N1UT73; MFCD08282795; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate; PHA-290940AD; SU 011248; SU010398; SU011248; SU011248 L-malate salt; SUNITINIB MALEATE; Sunitinib malate; Sunitinib malate [USAN]; UNII-LVX8N1UT73"	6456015	C26H33FN4O7	Approved
M6APDG02263	Flupentixol	2-[4-[(3Z)-3-[2-(Trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol; 4-(3-(2-(Trifluoromethyl)thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 53772-82-0; ALPHA-FLUPENTHIXOL; EINECS 220-304-9; EINECS 258-756-4; Emergil; FA0UYH6QUO; FLUPENTHIXOL; Fluanxol; Flupenthixole; Flupentixol; Flupentixolum [INN-Latin]; Fluphenthixol; Fluxanxol; LC 44; N 7009; Siplaril; Siplarol; UNII-FA0UYH6QUO; cis-(Z)-Flupenthixol; cis-(Z)-Flupenthixol dihydrochloride; cis-Flupenthixol; cis-Flupentixol; flupentixolum	5281881	C23H25F3N2OS	Approved
M6APDG01319	Clobazam	"Onfi; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine; 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-; 22316-47-8; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione; 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione; BRN 0758410; CCRIS 7506; Chlorepin; Clobazam - Lundbeck; Clobazamum; Clobazamum [INN-Latin]; Clorepin; EINECS 244-908-7; Frisium; H 4723; H-4723; HR 376; LM 2717; LM-2717; NSC 336279; Onfi; RU-4723; UNII-2MRO291B4U; Urbadan; Urbanyl"	2789	C16H13ClN2O2	Approved
M6APDG02262	Trans-flupentixol	"(E)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; (E)-Flupenthixol; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-, (E)-; 2-[4-[(3E)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol; 2709-56-0; 53772-85-3; 895OJP78MJ; EINECS 258-759-0; FLUPENTHIXOL, Alpha; FLUPENTIXOLE; Flupenthixol, Beta; Flupentiol; UNII-895OJP78MJ; beta-Flupenthixol; trans-(E)-Flupentixol; trans-Flupentixol; trans-flupenthixol"	5281878	C23H25F3N2OS	Withdrawn
M6APDG02459	Pepstatin A	26305-03-3; 39324-30-6; Ahpatinin C; C34H63N5O9; CCRIS 3603; CHEMBL296588; DSSTox_CID_26095; DSSTox_GSID_46095; DSSTox_RID_81334; FAXGPCHRFPCXOO-LXTPJMTPSA-N; Ia Quinidine; Iboctadekin + rituximab; Iva-Val-Val-Sta-Ala-Sta-OH; MLS002222329; NCGC00161670-06; Pepstatin (VAN); Pepstatin (nonspecific); Pepstatina; Pepstatine; Pepstatinum; UNII-V6Y2T27Q1U; V6Y2T27Q1U	5478883	C34H63N5O9	Preclinical
M6APDG00757	Hoechst 33342	"2'-(4'-Ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bis-1H-benzimidazole trihydrochloride trihydrate; 2'-(4-Ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-1H,1'H-2,5'-bibenzo[d]imidazole; 2'-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-1H-benzimidazole; 2'-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-benzimidazole; 99KZS6CNZX; Bisbenzimide; Bisbenzimide (Hoechst 33258); CHEBI:51232; CHEMBL343002; EINECS 245-691-1; Ho 342; UNII-99KZS6CNZX; hoechst33342"	1464	C27H28N6O	Investigative
M6APDG02545	Pibrentasvir	"2WU922TK3L; A-1325912.0; ABT 530; ABT-530; ABT-530;Pibrentasvir; CHEMBL3545123; CS-8135; D10816; DB13878; Dimethyl N,N'-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis((6-fluoro-1H-benzimidazole-5,2-diyl)((2S)-pyrrolidine-2,1-diyl)((2S,3R)-3-methoxy-1-oxobutane-1,2-diyl)))biscarbamate; EX-A865; J-690144; J3.646.121G; Pibrentasvir; Pibrentasvir (JAN/USAN/INN); Pibrentasvir [USAN]; SCHEMBL17639956; SCHEMBL2756579; UNII-2WU922TK3L"	58031952	C57H65F5N10O8	Approved
M6APDG02818	Ledipasvir	"013TE6E4WV; 1256388-51-8; CHEBI:85089; CHEMBL2374220; DTXSID90154829; EX-A411; GS 5885; GS-5885; GS5885; Ledipasvir (GS5885); Ledipasvir (USAN); Ledipasvir [USAN:INN]; MolPort-039-138-665; SCHEMBL15116943; SCHEMBL2706494; UNII-013TE6E4WV; WHO 9796; methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate"	67505836	C49H54F2N8O6	Approved
M6APDG01590	Pentazocine	"(2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; (2R,6R,11R)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; (2alpha,6alpha,11R*)-(1)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan; 2-(3,3-Dimethylallyl)cyclazocine; 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol; Algopent (free base); Fortal (TN); Fortalgesic; Fortalin; Fortral; Fortral (TN); Fortwin (TN); II-C-2; KF-1820; L-pentazocine; Lexir; Liticon; NIH 7958; Pentagin; Pentazocaine; Pentazocin; Pentazocina; Pentazocina [DCIT]; Pentazocine (JP15/USP/INN); Pentazocine [USAN:INN:BAN:JAN]; Pentazocine, Pentazocin, Sosegon, WIN 20228; Pentazocinum; Pentazocinum [INN-Latin]; Sosegon; Soseton; Sosigon; Talacen; Talacen (TN); Talwan; Talwin (TN); Talwin NX (TN); Talwin PX (TN); WIN 20228"	441278	C19H27NO	Approved
M6APDG02675	Ixabepilone	Azaepothilone B; BMS-247550; Ixempra (TN)	6445540	C27H42N2O5S	Approved
M6APDG02284	Trospium chloride	trospium chloride; Sanctura; Trospium (chloride); Spasmex; Spasmo-lyt; UNII-1E6682427E; Trospium chloride (Sanctura); Relaspium; Santura; Keptan; Azoniaspiro Compound XVII; Spasmo 3; IP631; AS Xvii; 1E6682427E; DSSTox_CID_3724; DSSTox_RID_77166; DSSTox_GSID_23724; Trospii chloridum [INN-Latin]; Uraplex; Cloruro de trospio [INN-Spanish]; Chlorure de trospium [INN-French]; EINECS 233-875-4; Trospium Cl; Trospii chloridum; Sanctura XR; Cloruro de trospio	5284631	C25H30ClNO3	Approved
M6APDG01540	Tiapamil	"ORE-5002; Tiapamil (CNS disease); Tiapamil (CNS disease), Ore Pharmaceuticals"	42107	C26H37NO8S2	Investigative
M6APDG02604	Zolmitriptan	"(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone; (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one; (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one; AscoTop; AscoTop (TN); BW-311C90; Flezol; KS-5072; Zolmitriptan RapidFilm; Zolmitriptan [USAN]; Zolmitriptane; Zolmitriptanum; Zomig; Zomig (TN); Zomig Nasal Spray; Zomig ZMT; Zomig, Zomigon, AscoTopand, Zomigoro, Zolmitriptan; Zomig-ZMT; Zomigon; Zomigon (TN); Zomigoro (TN)"	60857	C16H21N3O2	Approved
M6APDG00627	Entecavir	"2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one-water (1/1); 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]; 9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate; BMS-200475; Baraclude; Baraclude (TN); ETV; Entecavir (INN); Entecavir (USAN); Entecavir hydrate; Entecavir hydrate (JAN); Entecavir monohydrate; SQ-34676"	135398508	C12H15N5O3	Approved
M6APDG02963	Gramicidin D	"1,10-anhydro(L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithine); Cyclo(L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl); Gramacidine S; Gramacidine S [INN-French]; Gramicidin A(1); Gramicidin C; Gramicidin Dubos; Gramicidin J; Gramicidin K; Gramicidin P; Gramicidin S; Gramicidin S [INN]; Gramicidin [INN:BAN]; Gramicidina D; Gramicidina S; Gramicidina S [INN-Spanish]; Gramicidina [INN-Spanish]; Gramicidine [INN-French]; Gramicidins; Gramicidinum S; Gramicidinum S [INN-Latin]; Gramicidinum [INN-Latin]; Gramicin S 1; Gramicin S-A; Gramoderm; Neosporin Ophthalmic Solution"	73357	C60H92N12O10	Approved
M6APDG02245	Entacapone	"(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide; COM-998; Comtan; Comtan (TN); Comtess; Entacapona; Entacapona [INN-Spanish]; Entacapone (JAN/USAN/INN); Entacapone [USAN:INN]; Entacaponum; Entacaponum [INN-Latin]; KB475572; N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; Novartis brand of entacapone; OR 611; OR-611; Orion brand of entacapone; Stalevo (TN)"	5281081	C14H15N3O5	Approved
M6APDG00599	Fosamprenavir	"((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide; (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester; Amprenavir phosphate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester; Fosamprenavir (INN); Fosamprenavir [INN]; GW 433908; GW433908; GW433908A (*Sodium Salt*); GW433908G (*Calcium Salt*); Lexiva (TM); Lexiva (TN); Telzir; Telzir (TN); Telzir(TM); VX 175; VX-175; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate"	131536	C25H36N3O9PS	Approved
M6APDG02767	Azidopine	"3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-(trifluoromethyl)phenyl)-, 2-((4-azidobenzoyl)amino)ethyl ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-2-[(4-azidobenzoyl)amino]ethyl ethyl ester (9CI); 90523-31-2; AC1LCUW1; Azidopine; C11282; CHEBI:2952; CHEMBL1993397; GTPL6980; NCI60_005410; NSC-617999; NSC617999; O5-[2-[(4-azidobenzoyl)amino]ethyl] O3-ethyl 2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3,5-dicarboxylate"	656406	C27H26F3N5O5	Investigative
M6APDG02181	Pyrimethamine	"2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE; 5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine; 5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine; 5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine; AZT + Pyrimethamine combination; Aventis Brand of Pyrimethamine; BW 50-63; BW 5063; CRL-8131 & Pyrimethamine; CRL-8142 & Pyrimethamine; Chloridin; Chloridine; Chloridyn; Darachlor; Daraclor; Darapram; Daraprim; Daraprim (TN); Daraprime; Daraprin; Diaminopyritamin; EXR-101; Erbaprelina; Ethylpyrimidine; Fansidar (Pyrimethamine/Sulfadoxine); Glaxo Wellcome Brand of Pyrimethamine; GlaxoSmithKline Brand of Pyrimethamine; Khloridin; Lactoferrin B & Pyrimethamine; Lactoferrin H & Pyrimethamine; M alocid; Malacid; Malocid; Malocide; Maloprim; Pirimecidan; Pirimetamin; Pirimetamina; Pirimetamina [INN-Spanish]; Pirimetamina [Spanish]; Primethamine; Pyremethamine; Pyrimethamin; Pyrimethamine (JAN/USP/INN); Pyrimethamine (Pyr); Pyrimethamine Hcl; Pyrimethamine [USAN:INN:BAN:JAN]; Pyrimethaminum; Pyrimethaminum [INN-Latin]; RP 4753; TCMDC-123831; TCMDC-125860; Tindurin; Tindurine; Tinduring; WR 2978; Wellcome Brand of Pyrimethamine"	4993	C12H13ClN4	Approved
M6APDG02940	Levomepromazine	2-Methoxytrimeprazine; 60-99-1; 9G0LAW7ATQ; Arc-VI-C-5; Bayer 1213; CL 36467; CL 39743; Dedoran; EINECS 200-495-5; F-5116; Hirnamine; Levomepromazin; Levomepromazina; Levomepromazina [INN-Spanish]; Levomepromazinum; Levomepromazinum [INN-Latin]; Levopromazioni; Levoprome; Levotomin; METHOTRIMEPRAZINE; Methotrimeprazine; Methotrimeprazine (USP); Methotrimeprazine [USP]; Methoxytrimeprazine; Milezin; Minozinan; Neozine; Nirnamine; Nocinan; Nomizan; Nosinan; Nozinan; RP-7044; UNII-9G0LAW7ATQ; Veractil; XP03	72287	C19H24N2OS	Approved
M6APDG01164	Ibrutinib	Ibrutinib (BTK inhibitor); PCI-32765	24821094	C25H24N6O2	Approved
M6APDG01579	Leupeptin	"(2S)-2-acetamido-N-[1-[[5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide; 2-(2-Acetamido-4-methylvaleramido)-N-(1-formyl-4-guanidinobutyl)-4-methylvaleramide; 24365-55-7; AC1L97IT; Valeramide, 2-(2-acetamido-4-methylvaleramido)-N-(1-formyl-4-guanidinobutyl)-4-methyl-"	439527	C20H38N6O4	Investigative
M6APDG00929	Asimadoline	"Asimadoline [INN]; EMD 61753; N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide"	179340	C27H30N2O2	Phase 3
M6APDG02509	Naloxegol	NKTR-118	56959087	C34H53NO11	Approved
M6APDG02138	Perazine	"PERAZINE; Pernazine; Taxilan; Psytomin; N-(3-(4-Methyl-1-piperazinyl)propyl)phenothiazine; P 725; 10-(3-(4-Methyl-1-piperazinyl)propyl)-10H-phenothiazine; N-Methyl-piperazinyl-N'-propyl-phenothiazin; UNII-8915147A2B; EINECS 201-578-9; Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-; 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-; NSC638694; N-Methyl-piperazinyl-N'-propyl-phenothiazin [German]; N-Methyl-piperazinylpropyl-phenothiazine; NCGC00159492-02; 10H-Phenothiazine"	4744	C20H25N3S	Approved
M6APDG02804	Actinomycin D	AC1O8OFK; CCG-35952; CCG-36086; NCIMech_000599	6713178	C62H86N12O16	Approved
M6APDG01489	Nadolol	"(2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; 2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol; 5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol; Alti-Nadolol (TN); Anabet; Anabet (TN); Apo-Nadol (TN); Corgard; Corgard (TN); Corgaretic; Corzide (TN); Nadic; Nadolol (JP15/USP/INN); Nadolol [USAN:BAN:INN:JAN]; Nadololum; Nadololum [INN-Latin]; Novo-Nadolol (TN); SQ 11725; SQ-11725; SQ11725; Solgol; Solgol (TN)"	39147	C17H27NO4	Approved
M6APDG00233	Tadalafil	"(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; ADCIRCA; Acdirca; Cialis; Cialis (TN); Cialis, GF 196960, IC 351, ICOS 351, Tadalafil; GF 196960; GF-196960; IC 351; IC-351; ICOS 351; Ic351; KS-1117; Lilly brand of tadalafil; Tadalafil (JAN/USAN/INN); Tadalafil [USAN]; Tadanafil"	110635	C22H19N3O4	Approved
M6APDG01012	Amisulpride	"4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide; Aminosultopride; Amisulpiride; Amisulprida; Amisulprida [INN-Spanish]; Amisulpride (INN); Amisulpride [INN]; Amisulpridum; Amisulpridum [INN-Latin]; DAN 2163; DAN-2163; Deniban; Deniban (TN); SL-91.1077; Socian; Solian; Solian (TN); Solian, Amisulpride"	2159	C17H27N3O4S	Approved
M6APDG01291	Celiprolol	"3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea; BRN 2776298; CCRIS 3400; Celectol; Celiprolol [INN:BAN]; Celiprololum; Celiprololum [INN-Latin]; EINECS 260-497-7; N'-(3-Acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethylurea; RHC 5320 A; RHC-5320A; ST-1396; Selectol; UL/1677; Urea, N'-(3-acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethyl-; celiprolol"	2663	C20H33N3O4	Approved
M6APDG02531	Mitomycin	"Ametycin; 1950/7/7; 7-Amino-9alpha-methoxymitosane; Ametycin; Ametycine; C15H18N4O5; CCRIS 414; EINECS 200-008-6; HSDB 3239; MMC; Mit-C; Mitamycin; Mito-C; Mitocin C; Mitocin-C; Mitomicina; Mitomicina [INN-Spanish]; Mitomycin (TN); Mitomycin (USP/INN); Mitomycin C; Mitomycin C (JP15); Mitomycin C from Streptomyces caespitosus; Mitomycin C,; Mitomycin C, Streptomyces caespitosus; Mitomycin C, Streptomyces caespitosus, Carrier-Free; Mitomycin [USAN:INN:BAN]; Mitomycin-C; Mitomycine; Mitomycine [INN-French]; Mitomycins; Mitomycinum; Mitomycinum C; Mitomycinum [INN-Latin]; Mitomycyna C; Mitomycyna C [Polish]; Mitosol; Mitozytrex; Muamycin; Muamycin (TN); Mutamycin; Mytomycin; Mytozytrex; NCI-C04706; NSC 26980; NSC-26980; NSC26980; RCRA waste number U010; UNII-50SG953SK6; mitomycin C"	5746	C15H18N4O5	Approved
M6APDG01963	Nimodipine	"1,4-Dihydro-2,6-dimethyl-4-(3&prime;-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl Ester; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester;1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-Methoxyethyl-1-methylethyl ester; 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), 2-methoxyethyl 1-methylethyl ester; 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide; Admon; Almirall Brand of Nimodipine; Alpharma Brand of Nimodipine; Andromaco Brand of Nimodipine; Bay-E 9736; Bay-e-9736; Bayer Brand of Nimodipine; Bayvit Brand of Nimodipine; Brainal; Calnit; Cantabria Brand of Nimodipine; DRG-0139; EG-1961; Elan Brand of Nimodipine; Esteve Brand of Nimodipine; Hexal Brand of Nimodipine; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; Kenesil; Modus; N-149; NIMOTOP (TN); NimoGel; Nimodipin Hexal; Nimodipin ISIS; Nimodipin-ISIS; NimodipinISIS; Nimodipine (USAN/INN); Nimodipine [USAN:BAN:INN]; Nimodipino; Nimodipino Bayvit; Nimodipino [INN-Spanish]; Nimodipinum; Nimodipinum [INN-Latin]; Nimotop; Nimotop (TN); Nimotop(TM); Nimotop, Nimodipine; Periplum; Periplum, Nimotop, BRN 0459792, DRG-0139; Remontal; Vita Brand of Nimodipine"	4497	C21H26N2O7	Approved
M6APDG01983	Norfloxacin	"1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; AM 0715; AM 715; AM-0715; AM-715; AM0715; Apo-Norflox (TN); Baccidal; Barazan; Chibroxin; Chibroxin (TN); Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; Fulgram; Insensye (TN); Lexinor; MK 0366; MK 366; MK-0366; MK-366; MK0366; MK366; Merck Brand of Norfloxacin; NFLX; Norflo; Norflohexal (TN); Norfloxacin (JP15/USP/INN); Norfloxacin Merck Brand; Norfloxacin [USAN:BAN:INN:JAN]; Norfloxacine; Norfloxacine [INN-French]; Norfloxacino; Norfloxacino [INN-Spanish]; Norfloxacinum; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin; Noroxin (TN); Nufloxib (TN); Roxin (TN); Sebercim; Utin (TN); Utinor (TN)"	4539	C16H18FN3O3	Approved
M6APDG00980	Dactinomycin	"1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; ACT D; ACTINOMYCIN D AMP; AD (VAN); Actactinomycin A IV; Actinomycin 11 cosmegen; Actinomycin 7; Actinomycin A IV; Actinomycin Aiv; Actinomycin C (sub1); Actinomycin C(sub1); Actinomycin C1; Actinomycin D (JP15); Actinomycin D deriv. of 3H-phenoxaocardazine; Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin I; Actinomycin I (sub1); Actinomycin I(sub 1); Actinomycin I(sub1); Actinomycin I1; Actinomycin IV; Actinomycin X 1; Actinomycin X1; Actinomycin cl; Actinomycin x i; Actinomycin-(threo-val-pro-sar-meval); Actinomycin-IV; Actinomycin-[threo-val-pro-sar-meval]; Actinomycindioic D acid, dilactone; Actinomyein-theo-val-pro-sar-meval; Acto-D; Antibiotic from Streptomyces parvullus; COSMEGEN (TN); Chounghwamycin B; Cosmegen; D Actinomycin; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; Dactinomicina; Dactinomicina [INN-Spanish]; Dactinomycin (USP); Dactinomycin D; Dactinomycin [USAN:BAN]; Dactinomycine; Dactinomycine [INN-French]; Dactinomycinum; Dactinomycinum [INN-Latin]; Dactinomyein d; Dilactone actin omycindioic D acid; Dilactone actinomycin D acid; Dilactone actinomycindioic D acid; GNF-PF-1977; HBF 386; HBF 386 meractinomycin; Lyovac cosmegen; Meractinomycin; NP-005932; O)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; Oncostatin K; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; X 97"	2019	C62H86N12O16	Approved
M6APDG02186	Rabeprazole	2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole; Aciphex (TN); CL23619; Dexrabeprazole; Eraloc; Eraloc (TN); LY307640; Pariet (TN); Rabeprazole (INN); Rabeprazole [BAN:INN]; Rabeprazole [INN:BAN]; Rablet (TN); Rebeprazole sodium	5029	C18H21N3O3S	Approved
M6APDG00756	Nitric oxide	"HNO; ()NO; 10102-43-9; AC1L3QHF; Bioxyde d'azote; Bioxyde d'azote [French]; CHEBI:16480; CHEMBL1200689; CTK0H7679; DTXSID1020938; EDRF; Endogenous Nitrate Vasodilator; Endothelium-Derived Nitric Oxide; Endothelium-derived relaxing factor (EDRF); INOmax; INOmax (TN); Mononitrogen monoxide; Monoxide, Mononitrogen; Monoxide, Nitrogen; Monoxido de nitrogeno; Monoxyde d'azote; NITRIC-OXIDE; NO(); Nitrate Vasodilator, Endogenous; Nitric Oxide, Endothelium Derived; Nitric Oxide, Endothelium-Derived; Nitric oxide; Nitric oxide (JAN); Nitric oxide 10% by volume or more; Nitric oxide trimer; Nitric oxide, 985%; Nitric oxide, compressed [UN1660] [Poison gas]; Nitrogen monoxide; Nitrogen oxide (NO); Nitrogen(II) oxide; Nitrosoradical; Nitrosyl; Nitrosyl hydride; Nitrosyl hydride ((NO)H); Nitrosyl radical; Nitroxide radical; Nitroxyl; OHM 11771; Oxide, Nitric; Oxido de nitrogeno(II); Oxido nitrico; Oxidonitrogen; Oxoazanyl; Oxyde azotique; Oxyde nitrique [French]; Stickmonoxyd; Stickmonoxyd [German]; Stickstoff(II)-oxid; Stickstoffmonoxid; Vasodilator, Endogenous Nitrate; [NO]; endothelium-derived relaxing factor; monoxido de nitrogeno; monoxyde d'azote; nitric oxide; nitrogen monoxide; nitrogen protoxide; nitrosyl; oxido de nitrogeno(II); oxido nitrico; oxidonitrogen; oxoazanyl; oxyde azotique"	145068	NO	Phase 2/3
M6APDG01452	Hydroxyurea	"1-HYDROXYUREA; Biosupressin; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; DRG-0253; Droxia; Droxia (TM); Droxia (TN); H 8627; HYDREA (TN); HYDROXY-UREA; Hidrix; Hidroxicarbamida; Hidroxicarbamida [INN-Spanish]; Hydrea; Hydrea (TM); Hydrea, Biosupressin, Cytodrox, Hydroxyurea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamide (JAN/INN); Hydroxycarbamidum; Hydroxycarbamidum [INN-Latin]; Hydroxycarbamine; Hydroxyharnstoff; Hydroxyharnstoff [German]; Hydroxylurea; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); Hydura; Hydurea; Idrossicarbamide; Idrossicarbamide [DCIT]; Litaler; Litalir; Mylocel; N-(Aminocarbonyl) Hydroxyamine; N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; NHY; Onco-carbide; Oncocarbide; Oxyurea; S-phase/G-1 interface inhibitor; SK 22591; SQ 1089; SQ-1089; Siklos; Tetratogen: inhibits ribonucleoside diphosphate reductase"	3657	CH4N2O2	Approved
M6APDG01353	Toremifene	"(Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1); 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Acapodene; Acapodene (TN); Estrimex; FC-1157a; Fareston (TN); Farestone; GTX-006 (Acapodene); GTx 006; GTx-006; Toremifene (INN); Toremifene Base; Toremifene Citrate (1:1); Toremifene [INN:BAN]; Toremifeno; Toremifeno [Spanish]; Toremifenum; Toremifenum [Latin]; Z-Toremifene; {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine"	3005573	C26H28ClNO	Approved
M6APDG02409	Gatifloxacin	"(+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; AM 1155; AM-1155; AM-1155 (*Sesquihydrate*); BMS 206584-01; BMS-206584; BMS-206584-01; Bonoq; CG 5501;PD 135432; CG-5501; GTFX; Gaity; Gatiflo; Gatiflo (TN); Gatiflo,Tequin and Zymar, Gatifloxacin; Gatifloxacin & Gamma Interferon; Gatifloxacin (INN); Gatifloxacin (TN); Gatifloxacin [USAN:INN]; Gatilox; Gatiquin; Gatispan; PD-135432; PD135432; Tequin; Tequin (TN); Tequin in dextrose 5% in plastic container; Zymar; Zymar (TN); Zymaxid; Zymer; Zymer (TN)"	5379	C19H22FN3O4	Approved
M6APDG02609	Ajmaline	"Ajmaline; Cardiorythmine; Ajmalin; Raugalline; Tachmalin; Gilurytmal; (+)-Ajmaline; Aritmina; Rauwolfine; Rhytmaton; Rauwolfin; Merabitol; Takycor; Siddiqui; Rytmalin; Ignazin; Ritmos; 4360-12-7; UNII-1PON08459R; 1PON08459R; Takhmalin; Cartagine; Tajmalin; NSC 15627; Ajmaline [JAN]; Ajmalan-17,21-diol; EINECS 224-439-4; NSC 628054; (17R,21alpha)-Ajmalan-17,21-diol; (17R,21-alpha)-Ajmalan-17,21-diol; AI3-62668; Ajmalan-17,21-diol, (17R,21alpha)-, compound with methanol (1:1); ZINC898188"	6100671	C20H26N2O2	Approved
M6APDG02797	Taurocholic acid	"2-((3-alpha,7-alpha,12-alpha-Trihydroxy-24-oxo-5-be ta-cholan-24-yl)amino)ethanesulfonic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid 24-taurine; 81-24-3; Acidum cholatauricum; C26H45NO7S; Cholaic acid; Cholic acid taurine conjugate; Cholyltaurine; EINECS 201-336-2; Ethanesulfonic acid, 2-(((3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxy-24-oxocholan-24-yl)amino)-; HSDB 832; N-Choloyltaurine; NSC 25505; NSC25505; TAUROCHOLIC ACID; Taurine Cholate; Taurine, N-choloyl-; Taurocholate; Taurocholic acid; UNII-5E090O0G3Z; [3H]taurocholic acid"	6675	C26H45NO7S	Terminated
M6APDG01387	Epinastine	"(+-)-Epinastine; 3-Amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine; 3-amino-9,13b-dihydro-1H-benz(c,f)imidazo(1,5a)azepine; 9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-amine; Elestat (TN); Epinastina; Epinastina [Spanish]; Epinastine (INN); Epinastine [INN]; Epinastinum; Epinastinum [Latin]; Purivist; Purivist (TN); Relestat (TN); WAL 80; WAL 801; WAL 801CL; WAL-80 Cl"	3241	C16H15N3	Approved
M6APDG01044	Cortisone	11-dehydro-17-hydroxycorticosterone; 17-hydroxy-11-dehydrocorticosterone	222786	C21H28O5	Approved
M6APDG02562	Chloramphenicol	"Ak-chlor; Alficetyn; Alficetyn (TN); Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; Ambofen; Amphenicol; Amphicol; Amphicol (TN); Amseclor; Anacetin; Aquamycetin; Austracil; Austracol; Biocetin; Biomicin (TN); Biophenicol; Brochlor (TN); C.A.F; CAF; CAF (pharmaceutical); CHLOROPTIC S.O.P; CLM; Catilan; Cedoctine (TN); Ch loramex; Chemiceticol; Chemicetin; Chemicetina; Chlomin; Chlomycol; Chlora-tabs; Chloramex; Chloramex (TN); Chloramfenikol; Chloramfenikol [Czech]; Chloramficin; Chloramfilin; Chloramphenicol & VRC3375; Chloramphenicol (JP15/USP/INN); Chloramphenicol [INN:BAN:JAN]; Chloramphenicol crystalline; Chloramphenicolum; Chloramphenicolum [INN-Latin]; Chloramsaar; Chlorasol; Chlorbiotic (Veterinary); Chloricol; Chlormycetin R; Chlornitromycin; Chlornitromycin (TN); Chloro-25 vetag; Chloroamphenicol; Chlorocaps; Chlorocid; Chlorocid S; Chlorocide; Chlorocidin C; Chlorocidin C tetran; Chlorocol; Chlorofair; Chloroject L; Chloromax; Chloromycetin; Chloromycetin (TN); Chloromycetin&#174; Chloromycetny; Chloromycetny [Polish]; Chloromyxin; Chloronitrin; Chloroptic; Chloroptic S.O.P.; Chlorovules; Chlorsig; Chlorsig (TN); Cidocetine; Ciplamycetin; Cloramfen; Cloramfenicol; Cloramfenicol [INN-Spanish]; Cloramfenicolo; Cloramfenicolo [DCIT]; Cloramficin; Cloramical; Cloramicol; Cloramidina; Cloranfenicol; Cloroamfenicolo; Cloroamfenicolo [Italian]; Clorocyn; Cloromisan; Cloromissan; Clorosintex; Comycetin; Cylphenicol; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol; D(-)-threo-Chloramphenicol; D-(-)-Chloramphenicol; D-(-)-threo-Chloramphenicol; D-Chloramphenicol; D-threo-Chloramphenicol; Desphen; Detreomycin; Detreomycine; Dextromycetin; Dispersadron C (TN); Doctamicina; Duphenicol; Econochlor; Econochlor (TN); Elase-Chloromycetin; Embacetin; Emetren; Enicol; Enteromycetin; Erbaplast; Ertilen; F armicetina; Farmicetina; Fenicol; Fenicol (TN); Globenicol; Glorous; Golden Eye (TN); Halomycetin; Hortfenicol; I 337A; Interomycetine; Intramycetin; Intramyctin; Isicetin; Ismicetina; Isophenicol; Isopto fenicol; Isoptophenicol (TN); Juvamycetin; Kamaver; Kemicetina; Kemicetine; Kemicetine (TN); Kloramfenikol; Klorita; Klorocid S; Laevomycetin (TN); Laevomycetinum; Leukamycin; Leukomyan; Leukomycin; Levomicetina; Levomitsetin; Levomycetin; Loromicetina; Loromisan; Loromisin; Mastiphen; Mediamycetine; Medichol; Medicom (TN); Micloretin; Micochlorine; Micoclorina; Microcetina; Mychel; Mychel-Vet; Mycinol; Myscel; Nevimycin (TN); Normimycin V; Novochlorocap; Novomycetin; Novophenicol; Oftalent; Oftan Chlora (TN); Oleomycetin; Opclor; Opelor; Ophthochlor; Ophtochlor; Optomycin; Optrex Infected Eyes (TN); Orchadexoline (TN); Otachron; Otophen; Pantovernil; Paraxin; Pentamycetin; Phenicol (TN); Quemicetina; Renicol (TN); Rivomycin; Romphenil; Ronfenil; Ronphenil; Septicol; Sificetina; Silmycetin (TN); Sintomicetina; Sintomicetine R; Sno Phenicol; Sno-Phenicol; Stanomycetin; Synthomycetin; Synthomycetine; Synthomycine; Synthomycine (TN); Syntomycin; Tea-Cetin; Tega-Cetin; Tevcocin; Tevcosin; Tifomycin; Tifomycine (TN); Tifomycine;Tiromycetin; Treomicetina; U-6062; Unimycetin; Vernacetin (TN); Veticol; Veticol (TN); Vice ton; Viceton"	5959	C11H12Cl2N2O5	Approved
M6APDG02991	Eletriptan	(R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-Indole; (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole; 3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole; 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole; 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole; Eletriptan (INN); Eletriptan [INN:BAN]; Eletriptanum; Relpax; Relpax (TN); UK 116044; UK-116044; UK-116044-04; UK116044	77993	C22H26N2O2S	Approved
M6APDG00641	Raltitrexed	"(2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; 112887-68-0; C21H22N4O6S; CHEBI:5847; CHEMBL225071; D 1694; D-1694; D1694; DSSTox_CID_26482; DSSTox_GSID_46482; DSSTox_RID_81653; FCB9EGG971; ICI D1694; ICI-D-1694; ICI-D1694; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; NCGC00229704-01; NSC-639186; Raltitrexed (Tomudex); Tomudex; UNII-FCB9EGG971; ZD 1694; ZD-16; ZD-1694; ZD1694"	135400182	C21H22N4O6S	Approved
M6APDG00941	Melagatran	159776-70-2; 2A9QP32MD4; C22H31N5O4; CHEBI:43966; H-319/68; MEL; MELAGATRAN (ASTRA-ZENECA); Melagatran; Melagatran (INN); Melagatran [INN]; N-((R)-(((2S)-2-((-p-Amidobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine; N-((R)-(((2S)-2-((p-Amidinobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine; UNII-2A9QP32MD4; [((1R)-2-{(2S)-2-[({4-[AMINO(IMINO)METHYL]BENZYL}AMINO)CARBONYL]AZETIDINYL}-1-CYCLOHEXYL-2-OXOETHYL)AMINO]ACETIC ACID	183797	C22H31N5O4	Withdrawn
M6APDG02258	Coumestrol	"3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; 3,9-Dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one; 3,9-Dihydroxycoumestan; 479-13-0; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-; 6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-; 7,12-Dihydroxycoumestan; BRN 0266702; CCRIS 7311; CHEBI:3908; CHEMBL30707; COUMESTROL; Coumesterol; Cumoesterol; Cumoestrol; Cumostrol; EINECS 207-525-6; MLS000738006; NSC 22842; NSC22842; UNII-V7NW98OB34; V7NW98OB34; ZZIALNLLNHEQPJ-UHFFFAOYSA-N"	5281707	C15H8O5	Preclinical
M6APDG02007	Ondansetron	"(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; 9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; Apo-ondansetron; DESMETHYLONDANSETRON; GR 38032; GR 38032X; GR-38032F; GR38032F; Novo-ondansetron; Ondansetron (JAN/USP/INN); Ondansetron (Zofran); Ondansetron [USAN:INN:BAN]; Ondansetron, (+,-)-Isomer; PHL-ondansetron; PMS-ondansetron; Ratio-ondansetron; SN-307; Sandoz ondansetron; ZOFRAN IN PLASTIC CONTAINER; Zofran; Zofran (TN); Zofran ODT; Zofran ODT (TN); Zophren; Zudan"	4595	C18H19N3O	Approved
M6APDG00667	Eltrombopag	"Eltrombopag; Revolade; Promacta; (Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; UNII-S56D65XJ9G; SB497115; Eltrombopag-Isomer; SB-497115; SB 497115; S56D65XJ9G; CHEMBL461101; 1807882-48-9; SB-497115-GR; Eltrombopag (SB-497115-GR); 3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; NCGC00274067-01"	135449332	C25H22N4O4	Approved
M6APDG01410	Timolol	"(-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole; (2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol; (S)-timolol; Apo-Timol; Apo-Timol (TN); Apo-Timop; Apo-Timop (TN); Aquanil; Betim; Betimol; Betimol (TN); Blocadren; Blocadren (TN); Gen-Timolol (TN); Istalol; Istalol (TN); L-714,465; MK-950; Novo-Timol; Nu-Timolol; Nu-Timolol (TN); Optimol; PMS-Timolol (TN); Phoxal-timolol; Phoxal-timolol (TN); Proflax; S(-)-Timolol maleate; S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole; TIM; Temserin; Tenopt; Tim-AK; Tim-AK (TN); Timacar; Timolol (INN); Timolol (TN); Timolol GFS; Timolol Maleate, (1:1) Salt; Timolol [USAN]; Timololum; Timololum [INN-Latin]; Timopic; Timoptic (TN); Timoptic OcuDose; Timoptic OcuDose. (TN); Timoptic-XE; Timoptic-XE (TN); Timoptol"	33624	C13H24N4O3S	Approved
M6APDG01297	Chlorambucil	Ambochlorin; Amboclorin; C0253; CB 1348; CB-1348; CB1348; Cb l348; Chlocambucil; Chloorambucol; Chlorambucil (USP/INN); Chlorambucil [INN:BAN]; Chlorambucilum; Chlorambucilum [INN-Latin]; Chloraminophen; Chloraminophene; Chlorbutin; Chlorbutine; Chlorbutinum; Chloroambucil; Chlorobutin; Chlorobutine; Clorambucile; Clorambucile [DCIT]; Clorambucilo; Clorambucilo [INN-Spanish]; Ecloril; Elcoril; Elcorin; Glaxo Wellcome Brand of Chlorambucil; GlaxoSmithKline Brand of Chlorambucil; LEUKERAN (TN); Leuk ersan; Leukeran; Leukeran (TN); Leukeran tablets; Leukersan; Leukoran; Linfolizin; Linfolysin; Lympholysin; Phenylbuttersaeure-lost; Phenylbuttersaeure-lost[German]; Phenylbutyric acid nitrogen mustard; Wellcome Brand of Chlorambucil	2708	C14H19Cl2NO2	Approved
M6APDG02781	Nitrofurantoin	"1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-Nitrofurfurylidene)amino)hydantoin; 1-(5-Nitro-2-furfurylidenamino)hydantoin; 1-(5-Nitro-2-furfurylideneamino)hydantoin; 1-[(5-:nitrofurfurylidene)amino]hydantoin; 1-[(5-Nitrofurfurylidene)amino]hydantoin; 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione; 1-[[(5-Nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione; 1-{[(1E)-(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione; 1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; 5-Nitrofurantoin; Alfuran; Benkfuran; Berkfuran; Berkfurin; Ceduran; Chemiofuran; Cistofuran; Cyantin; Cystit; Dantafur; Fua Med; Fua-med; Fur-ren; Furabid; Furachel; Furadantin; Furadantin (TN); Furadantin Retard; Furadantina MC; Furadantine; Furadantine mc; Furadantine-MC; Furadantoin; Furadoine; Furadonin; Furadonine; Furadoninum; Furadontin; Furalan; Furaloid; Furantoin; Furatoin; Furedan; Furina; Furobactina; Furodantin; Furophen; Furophen T; Gerofuran; Ituran; Macpac; Macrobid; Macrobid (TN); Macrodantin; Macrodantin (TN); Macrodantina; Macrofuran; Macrofurin; N-(5-Nitro-2-furfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina [Polish]; N-(5-Nitrofurfurylidene)-1-aminohydantoin; N-(5-nitro-2-furfurylidene)-1-aminohyda ntoin; N-Toin; ND-3320; ND-7248; NITROFURANTION; NITROFURANTOIN MACROCRYSTALLINE; NITROFURANTOIN, MACROCRYSTALLINE; Nierofu; Nifurantin; Nifuretten; Nitoin; Nitrex; Nitro Macro (TN); Nitrofur-C; Nitrofuradantin; Nitrofurantoin (JAN/USP/INN); Nitrofurantoin [USAN:INN:BAN:JAN]; Nitrofurantoina; Nitrofurantoina [DCIT]; Nitrofurantoine; Nitrofurantoine [INN-French]; Nitrofurantoinum; Nitrofurantoinum [INN-Latin]; Novofuran; Orafuran; Parfuran; Phenurin; PiyEloseptyl; Ro-Antoin; Siraliden; Trantoin; Uerineks; Urantoin; Urantoin (TN); Urizept; Uro-Selz; Uro-Tablinen; Uro-tablineu; Urodil; Urodin; Urofuran; Urofurin; Urolisa; Urolong; Usaf ea-2; Welfurin; Zoofurin"	6604200	C8H6N4O5	Approved
M6APDG02183	Quetiapine	"111974-69-7; 2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol; 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol; 2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol; BGL0JSY5SI; C21H25N3O2S; CHEBI:8707; CHEMBL716; Co-Quetiapine; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-; Ketipinor (TN); NCGC00095911-03; Norsic; Norsic (TN); PD-172760; Quetiapina; Quetiapine (INN); Quetiapine [INN:BAN]; Quetiapine hemifumarate; Quetiapinum; Seroquel (Fumarate); Seroquel (TN); UNII-BGL0JSY5SI; URKOMYMAXPYINW-UHFFFAOYSA-N; quetiapine"	5002	C21H25N3O2S	Approved
M6APDG02259	Daidzein	"7-Dihydroxyisoflavone; 4',7-Dihydroxy-iso-flavone; 4',7-Dihydroxyisoflavone; 4,7-Dihydroxyisoflavone; 486-66-8; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-; 7,4'-Dihydroxyisoflavone; 7,4'-dihydroxyisoflavone; 7-Hydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one; BRN 0231523; CCRIS 7600; CHEMBL8145; DIADZEIN; Daidzein; Daidzeol; EINECS 207-635-4; K 251b; UNII-6287WC5J2L; d-(+)-alpha-methylbenzylamine"	5281708	C15H10O4	Phase 4
M6APDG01703	Bupropion	"Amfebutamon; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; (+-)-Bupropion; (-)-2-(tert-Butylamino)-3'-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chlorpropiophenon; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one; 1-Propanone; 2-(Tert-Butylamino)-3'-chloropropiophenone; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; 34841-39-9; 34911-55-2; AMFEBUTAMONE HCl; Alpha-(tert-Butylamino)-m-chloropropiophenone; Alpha-(tert-butylamino)-m-chloropropiophenone; Amfebutamon; Amfebutamona; Amfebutamona [INN-Spanish]; Amfebutamone; Amfebutamonum; Amfebutamonum [INN-Latin]; BRN 2101062; Bupropion (INN); Bupropion (Old RN); Bupropion (USAN); Bupropion Hcl; Bupropion SR; Bupropion [INN:BAN]; Bupropion hydrocloride; CHEBI:3219; CHEMBL894; Elont; Elontril; SNPPWIUOZRMYNY-UHFFFAOYSA-N; Wellbatrin; Zyban; alpha-(tert-butylamino)-m-chloropropiophenone; amfebutamonum; bupropion"	444	C13H18ClNO	Approved
M6APDG01968	Apatinib	"Apatinib; Apatinib Mesylate; YN968D1; YN-968D1; UNII-TK02X14ASJ; YN 968D1; TK02X14ASJ; 3-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-, methanesulfonate (1:1); Rivoceranib mesylate; 3-Pyridinecarboxamide, N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-, methanesulfonate (1:1); Apatinib-YN968D1; Apatinib - YN968D1; Apatinib (YN968D1); MLS006011286; CHEMBL3545414; KS-00000TST; DTXSID80153427; HMS3655H12; BCP15234; AOB87128; BDBM50152828; s2221; AKOS026750547"	45139106	C25H27N5O4S	Approved
M6APDG01000	Alprenolol	1-(2-Allylphenoxy)-3-isopropylamino-2-propanol; 1-(o-Allylphenoxy)-3-(isopropylamino)-2-propanol; 1-(o-Allylphenoxy)-3-isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol; 1-[2-(propen-2-ylphenoxy)]-3-(isopropylamino)propan-2-ol; Alfeprol; Alfeprol [Russian]; Alpheprol; Alprenolol (INN); Alprenolol [INN:BAN]; Alprenololum; Alprenololum [INN-Latin]; Apllobal (TN); Aptine (TN); Aptol (TN); Duriles (TN); Gubernal (TN); H-56-28; Regletin (TN); Yobir; Yobir (TN)	2119	C15H23NO2	Withdrawn
M6APDG02603	Ziprasidone	"Geodon; 146939-27-7; 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[430]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one; 6UKA5VEJ6X; C21H21ClN4OS; CHEBI:10119; CHEMBL708; CP 88059; CP 88059-01; CP-88,059; CP-88,059-01; CP-88,059-1; CP-88059-1; DSSTox_CID_3753; DSSTox_GSID_23753; DSSTox_RID_77186; Geodon; Geodon (TN); TC-5280; UNII-6UKA5VEJ6X; Zeldox; Zeldox (TN); Zipradon; Zipradon (TN); Ziprasidona; Ziprasidone (INN); Ziprasidone [INN:BAN]; Ziprasidone hydrochloride; Ziprasidone mesylate trihydrate; Ziprasidonum; Ziprazidone; ziprasidona; ziprasidonum; ziprazidone"	60854	C21H21ClN4OS	Approved
M6APDG02584	Sparfloxacin	"(cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid; AT 4140; AT-4140; CP 103826; CP-103826; Cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; DRG-0143; Esparfloxacino; Esparfloxacino [INN-Spanish]; Liposome-encapsulated sparfloxacin; PD 1315-1; PD 131501; PD-131501; PD131501; RP-64206; Respipac (TN); SPFX; Spara; Sparfloxacin & RU 40555; Sparfloxacin (JAN/USAN/INN); Sparfloxacin [USAN:BAN:INN:JAN]; Sparfloxacin, cis-isomer; Sparfloxacine; Sparfloxacine [INN-French]; Sparfloxacinum; Sparfloxacinum [INN-Latin]; Zagam; Zagam (TN)"	60464	C19H22F2N4O3	Approved
M6APDG02420	Thioridazine	"(+-)-Thioridazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine; Aldazine; Dl-Thioridazine; Mallorol; Malloryl; Meleril; Mellaril; Mellaril (*Hydrochloride*); Mellaril (TN); Mellaril-S; Mellaril-S (TN); Mellarit; Mellerets; Mellerette; Melleretten; Melleril; Melleril (liquid); Melleryl; Metlaril; Novoridazine; Novoridazine (TN); Orsanil; Ridazine; Sonapax; Stalleril; TP-21; Thioridazin; Thioridazine (USP/INN); Thioridazine Hcl; Thioridazine Hcl Intensol; Thioridazine [USAN:INN:BAN]; Thioridazine prolongatum; Thioridazine, prolongatum; Thioridazinum; Thioridazinum [INN-Latin]; Thioril (TN); Thioxidazine; Thoridazine hydrochloride; Tioridazin; Tioridazina; Tioridazina [INN-Spanish]"	5452	C21H26N2S2	Approved
M6APDG01313	Ciprofloxacin	85721-33-1; BAY q 3939; Bacquinor; Baflox; Bernoflox; Cifloxin; Cilab; Ciplus; Ciprecu; Ciprinol; Cipro IV; Cipro XR; Ciprobay; Ciprocinol; Ciprodar; Ciproflox; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy; Ciprofloxacina; Ciprofloxacine; Ciprofloxacino; Ciprofloxacinum; Ciprogis; Ciprolin; Ciprolon; Cipromycin; Ciproquinol; Ciprowin; Ciproxan; Ciproxina; Ciproxine; Ciriax; Citopcin; Cixan; Corsacin; Cycin; Fimoflox; GW1843; Ipiflox; Italnik; Loxan; Probiox; Proflaxin; Quinolid; Quintor; Rancif; Roxytal; Septicide; Spitacin; Superocin; Unex; Zumaflox; ciprofloxacin	2764	C17H18FN3O3	Approved
M6APDG02590	Mibefradil	"Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics"	60663	C29H38FN3O3	Withdrawn
M6APDG02414	Terfenadine	"1-(4-tert-Butylphenyl)-4-(4-(alpha-hydroxybenzhydryl)piperidino)-butan-1-ol; 1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol; 1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol; 1-(p-tert-Butylphenyl)-4-(4'-(alpha-hydroxydiphenylmethyl)-1'-piperidyl)butanol; 1-[4-(1,1-dimethylethyl)phenyl]-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butan-1-ol; Aldaban; Aliud Brand of Terfenadine; Allerplus; Alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol; Alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenyl-methyl)-1-piperidine butanol; Alpha-(4-[1,1-Dimethylethyl]phenyl)-4-[hydroxydiphenylmethyl]-1-piperidinebutanol; Alpha-(p-tert-Butylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-[4-(1,1-Dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Balkis Saft Spezial; Bial Brand of Terfenadine; Cantabria Brand of Terfenadine; Ct Arzneimittel Brand of Terfenadine; Ct-Arzneimittel Brand of Terfenadine; Cyater; Dolorgiet Brand of Terfenadine; Heumann Brand of Terfenadine; Hisfedin; Hoechst Brand of Terfenadine; MDL 9918; MDL-9918; Merck dura Brand of Terfenadine; Mundipharma Brand of Terfenadine; RMI 9918; RMI-9918; RMI9918; Rapidal; Ratiopharm Brand of Terfenadine; Seldane; Seldane (TN); Sigma Tau Brand of Terfenadine; Sigma-Tau Brand of Terfenadine; Stadapharm Brand of Terfenadine; T 9652; Teldane; Teldane (TN); Teldanex; Terdin; Terfedura; Terfemundin; Terfen; Terfenadin AL; Terfenadin Heumann; Terfenadin Stada; Terfenadin von ct; Terfenadin-ratiopharm; Terfenadina; Terfenadina [INN-Spanish]; Terfenadine (JAN/USAN/INN); Terfenadine [USAN:BAN:INN:JAN]; Terfenadinum; Terfenadinum [INN-Latin]; Terfenidine; Terfex; Ternadin; Triludan; Triludan (TN); Wolff Brand of Terfenadine"	5405	C32H41NO2	Withdrawn
M6APDG00044	Linagliptin	"(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione; BI 1356; BI-1356; BI-1356-BS; Ondero; Ondero (TN)"	10096344	C25H28N8O2	Approved
M6APDG01351	Maraviroc	"376348-65-1; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; CHEBI:63608; CHEMBL1201187; CHEMBL256907; Celsentri; Celsentri (TN); Celsentri(TM); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; MD6P741W8A; MVC; Maraviroc [USAN]; PRO 140 & Maraviroc; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; Selzentry; Selzentry (TN); Selzentry(TM); UK 427857; UK-427,857; UK-427,857 maraviroc (MVC); UK-427857; UNII-MD6P741W8A; [3H]maraviroc"	3002977	C29H41F2N5O	Approved
M6APDG01500	Vecuronium	"(2A,3A,5A,16A,17A)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; (2beta,3alpha,5alpha,16beta,17beta)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; Norcuron (TN); [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate"	39765	C34H57N2O4+	Approved
M6APDG03015	Clarithromycin	"clarithromycin; 81103-11-9; Biaxin; Clarithromycine; Klaricid; 6-O-Methylerythromycin; Clathromycin; 6-O-Methylerythromycin a; Abbott-56268; Macladin; Veclam; Kofron; Klacid; Clarith; Clarithromycinum; Naxy; A-56268; Erythromycin, 6-O-methyl-; TE-031; Claritromicina; Fromilid; Claridar; Bicrolid; Astromen; Claricide; Clacine; Abbotic; Mabicrol; Clambiotic; Klaciped; Heliclar; Claripen; Claribid; Clarem; Clacid; Clacee; Zeclar; Maclar; Klarid; Crixan; Klarin; Klabax; Cyllid; Mavid; Helas; Biaxin filmtab; Adel; Klax; Biaxin xl filmtab; Biaxin HP; Klaricid Pe"	84029	C38H69NO13	Approved
M6APDG01078	Bepridil	Bepadin; Bepadin (TN); Bepridil (INN); Beta-((2-Methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine; CERM 1978; N-Benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-yl-propyl]aniline hydrochloride; N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline; N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline; N-{3-[(2-methylpropyl)oxy]-2-pyrrolidin-1-ylpropyl}-N-(phenylmethyl)aniline; Vascor; Vascor (TN)	2351	C24H34N2O	Approved
M6APDG02843	Roxithromycin	"9-(O-((2-Methoxyethoxy)methyl)oxime)erythromycin; 9-[O-(2-methoxyethoxymethyl)-oxime] of erythromycin; Assoral; Biaxsig (TN); Coroxin (TN); Erythromycin 9-(-O-[2-methoxyethoxy]methyloxime);Erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime); Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime); Overall; RC2952; RU 28965; RU 965; RU-28965; RU-965; RXM; Rossitrol; Roxar (TN); Roximycin (TN); Roxithromycin & Tumor Necrosis Factor; Roxithromycin (JP15/USAN/INN); Roxithromycin [USAN:INN:JAN]; Roxithromycine; Roxithromycine [French]; Roxithromycinum; Roxithromycinum [Latin]; Roxitromicina; Roxitromicina [Spanish]; Roxl-150 (TN); Roxo (TN); Rulid; Rulide; Rulide (TN); Surlid; Surlid (TN); Tirabicin (TN)"	6915744	C41H76N2O15	Withdrawn
M6APDG01055	Astemizole	"1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole; AlacanBrand of Astemizole; Alermizol; Alonga Brand of Astemizole; Alonga, Astemizol; Astemina; Astemisan; Astemisol; Astemison; Astemizol; Astemizol Alonga; Astemizol [German]; Astemizol [INN-Spanish]; Astemizol ratiopharm; Astemizole (JAN/USP/INN); Astemizole Alacan Brand; Astemizole Alonga Brand; Astemizole Byk Brand; Astemizole Diba Brand; Astemizole Elfar Brand; Astemizole Esteve Brand; Astemizole Fustery Brand; Astemizole ICN Brand; Astemizole Janssen Brand; Astemizole Lesvi Brand; Astemizole McNeil Brand; Astemizole Medinsa Brand; Astemizole Merck Brand; Astemizole Senosiain Brand; Astemizole Septa Brand; Astemizole Smaller Brand; Astemizole Urbion Brand; Astemizole Vita Brand; Astemizole [USAN:BAN:INN]; Astemizole ratiopharm Brand; Astemizolum; Astemizolum [INN-Latin]; Astesen; Byk Brand of Astemizole; Diba Brand of Astemizole; Elfar Brand of Astemizole; Emdar; Esmacen;Fustermizol; Esteve Brand of Astemizole; Fustery Brand of Astemizole; GNF-PF-2461; HISMANAL (TN); Hestazol; Hestazol, Kelp, Laridal, Retolen, Wareezol, HSBD 6799, BRN 4830190; Hismanal; Histamen; Histaminos; Histazol; Hubermizol; ICN Brand of Astemizole; Janssen Brand of Astemizole; Kelp; Laridal; Lesvi Brand of Astemizole; MJD-30; McNeil Brand of Astemizole; Medinsa Brand of Astemizole; Merck Brand of Astemizole; Metodih; Metodik; Nono-Nastizol A; Novo-mastizol A; Paralergin; R 42512; R 43 512; R-43-512; R-43512; R43512; Ratiopharm Brand of Astemizole; Ratiopharm, Astemizol; Reig Jofre Brand of Astemizole; Retolen; Rifedot; Rimbol; Romadin; Senosiain Brand of Astemizole; Septa Brand of Astemizole; Simprox; Smaller Brand of Astemizole; Urbion Brand of Astemizole; Urdrim; Vita Brand of Astemizole; Wareezol; Waruzol; [3H]Astemizole"	2247	C28H31FN4O	Withdrawn
M6APDG01355	Telaprevir	"(1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-6-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide; 402957-28-2; 655M5O3W0U; CHEBI:68595; CHEMBL231813; Incivek; Incivo; LY-570310; MP-424; S-Telaprevir; Telaprevir (VX-950); Telavic; UNII-655M5O3W0U; VRT-111950; VX 950; VX-950; VX-950(Telaprevir)"	3010818	C36H53N7O6	Approved
M6APDG02151	Prazosin	"1-(3-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline; 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone; CP-12299; Furazosin; Hypovase (TN); Justac; Lentopres; Minipress (TN); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-(8CI); Piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-(9CI); Prazocin; Prazosin (INN); Prazosin HCl; Prazosin [INN:BAN]; Prazosina; Prazosina [INN-Spanish]; Prazosine; Prazosine [INN-French]; Prazosinum; Prazosinum [INN-Latin]; TNP00312; Vasoflex (TN); [3H]-Prazosin; [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone"	4893	C19H21N5O4	Approved
M6APDG01400	Felodipine	"(+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; (+/-)-ethylmethyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 1A Brand of Felodipine; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methylester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-,ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester; 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate; 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester; 4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester; 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester; 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; AE-641/11429675; AGON SR; AbZ Brand of Felodipine; Agon; Aliud Brand of Felodipine; Alphapharm Brand of Felodipine; Alpharma Brand of Felodipine; Astra Brand of Felodipine; AstraZeneca Brand of Felodipine; Aventis Brand of Felodipine; Azupharma Brand of Felodipine; BC Brand of Felodipine; Betapharm Brand of Felodipine; CGH-869; Ct Arzneimittel Brand of Felodipine; Ct-Arzneimittel Brand of Felodipine; Dl-Felodipine; Ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; F 9677; Felo Biochemie; Felo Puren; Felo-Puren; Felobeta; Felocor; Feloday; Felodipin 1A Pharma; Felodipin AL; Felodipin AZU; Felodipin AbZ; Felodipin Heumann; Felodipin Stada; Felodipin dura; Felodipin ratiopharm; Felodipin von ct; Felodipin-ratiopharm; Felodipina; Felodipina [INN-Spanish]; Felodipine (JAN/USP/INN); Felodipine [USAN:BAN:INN]; Felodipine [USAN:INN:BAN]; Felodipinum; Felodipinum [INN-Latin]; Felodur; FelodurER; Felogamma; Felogard; Fensel; Flodil; H 154 82; H 154-82; H 154/82; H 15482; H-154/82; Heumann Brand of Felodipine; Heumann, Felodipin; Hexal Brand of Felodipine; Hoechst Brand of Felodipine; Hydac; Lexxel; Logimax; Merck dura Brand of Felodipine; Modip; Munobal; Munobal Retard; Penedil; Perfudal; Pharmaceutica Astra Brand of Felodipine; Pharmacia Spain Brandof Felodipine; Plandil; Plendil; Plendil (TN); Plendil Depottab; Plendil ER; Plendil Retard; Plendil, Renedil, Feloday, Felodipine; Preslow; Prevex; Promed Brand of Felodipine; Ratiopharm Brand of Felodipine; Renedil; Splendil; Stadapharm Brand of Felodipine; TheraPharm Brand of Felodipine; Worwag Brand of Felodipine"	3333	C18H19Cl2NO4	Approved
M6APDG01281	Carvedilol	"(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol; Artist; Artist (TN); Atlana Pharma brand of carvedilol; BM 14190; BM-14-190; BM-14.190; BM-14190; Carloc (TN); Carvedilol (JAN/USAN/INN); Carvedilol [USAN:INN:BAN:JAN]; Carvedilol, (+-)-isomer; Carvedilol, (R)-isomer; Carvedilol, (S)-isomer; Carvedilol, 14C-labeled; Carvedilolum; Carvedilolum [Latin]; Coreg; Coreg (TN); Coreg CR; Coropres; Coropress; DQ 2466; DQ-2466; Dibloc; Dilatrend; Dilatrend (TN); EG-P042; Eucardic; Eucardic (TN); GlaxoSmithKline brand of carvedilol; Kredex; Lakeside brand of carvedilol; Querto; Roche brand of carvedilol; SK&F-105517; SKF 105517"	2585	C24H26N2O4	Approved
M6APDG02844	Itraconazole	"(+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one; (1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; Canadiol; Cis-Itraconazole; Hyphanox; ITCZ; ITZ; Intraconazole; Itraconazol; Itraconazol [Spanish]; Itraconazole & Bovine Lactoferrin; Itraconazole & Nyotran; Itraconazole & Nyotran(Liposomal Nystatin); Itraconazole (JAN/USAN); Itraconazole [USAN:BAN:INN:JAN]; Itraconazole oral solution; Itraconazolum; Itraconazolum [Latin]; Itrizole; Itrizole (TN); Oriconazole; Oriconazole, R51211, Sporanox; Orungal; Prokanazol; R 51211; R-51211; Sempera; Spherazole; Sporal; Sporanos; Sporanox; Sporanox (TN); Sporonox; Triasporn"	6917738	C35H38Cl2N8O4	Approved
M6APDG01538	Midazolam	"4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate; 8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride; 8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine; 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine; Dazolam; Dormicum; Dormicum (TN); Hypnovel (TN); Midacum (TN); Midanium; Midazolam (JAN/INN); Midazolam Base; Midazolam [INN:BAN:JAN]; Midazolamum; Midazolamum [INN-Latin]; Midosed; Ro 21-3981; Versed; Versed (TN)"	4192	C18H13ClFN3	Approved
M6APDG01360	Diclofenac	"Diclofenac (sodium matrix patch, pain)"	3033	C14H11Cl2NO2	Approved
M6APDG01321	Clofazimine	"(3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; B 663; B 663 (Pharmaceutical); B 663 (VAN); B 663, pharmaceutical; B-663; B. 663; CFZ; Chlofazimine; Clofazimina; Clofazimina [INN-Spanish]; Clofazimine (JAN/USP/INN); Clofazimine [USAN:INN:BAN]; Clofaziminum; Clofaziminum [INN-Latin]; G 30320; G-30,320; G-30320; Lampren; Lamprene; Lamprene (TN); Liposome-encapsulated clofazimine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; SMP2_000339"	2794	C27H22Cl2N4	Approved
M6APDG01964	Nisoldipine	"(+-)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester; 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Bay k 5552; Bay-k-5552; Baymycard; Isobutyl 1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-3-pyridincarboxylat;Methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Nisocor; Nisoldipin; Nisoldipine (JAN/USAN/INN); Nisoldipine [USAN:BAN:INN:JAN]; Nisoldipino; Nisoldipino [INN-Spanish]; Nisoldipinum; Nisoldipinum [INN-Latin]; Sular; Sular (TN); Syscor; Zadipina"	4499	C20H24N2O6	Approved
M6APDG02429	Doxycycline	"(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 5-Hydroxy-alpha-6-deoxytetracycline; 6-Deoxyoxytetracycline; 6-Deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; 6alpha-Deoxy-5-oxytetracycline; Alpha-6-Deoxy-5-hydroxytetracycline; Alpha-6-Deoxyoxytetracycline; Alpha-Doxycycline; Alti-Doxycycline; Apo-Doxy; Atridox; Azudoxat; BMY-28689; BU-3839T; DMSC (*Fosfatex); DOXCYCLINE ANHYDROUS; DOXY; DOXYCYCLINE CALCIUM; DOXYCYCLINE MONOHYDRATE; Deoxymykoin; Dossiciclina; Dossiciclina [DCIT]; Doxiciclina; Doxiciclina [INN-Spanish]; Doxiciclina [Italian]; Doxitard; Doxivetin; Doxy-Caps; Doxy-Puren; Doxy-Tabs; Doxycen; Doxychel; Doxychel (TN); Doxycin; Doxycyclin; Doxycycline (200mg/day) or Placebo; Doxycycline (INN); Doxycycline (TN); Doxycycline (anhydrous); Doxycycline (internal use); Doxycycline anhydrous; Doxycycline hyclate; Doxycycline-Chinoin; Doxycyclinum; Doxycyclinum [INN-Latin]; Doxysol; Doxytec; Doxytetracycline; GS-3065 (*monohydrate); Hydramycin; Investin; Jenacyclin; Liviatin; Monodox; Monodox (*monohydrate); Novo-Doxylin; Nu-Doxycycline; Oracea; Periostat (TN); Ronaxan; Spanor; Supracyclin; Vibra-tabs; Vibramycin; Vibramycin (*monohydrate); Vibramycin Novum; Vibramycine; Vibravenos; Vivox (*Hyclate)"	54671203	C22H24N2O8	Approved
M6APDG02476	Trifluoperazine	10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; Apo-Trifluoperazine; Apo-trifluoperazine (TN); Calmazine; Eskazine; Eskazine (TN); Eskazinyl (TN); Fluoperazine; Flurazine; Jatroneural (TN); Modalina; Modalina (TN); NCI17474; Novo-Trifluzine; PMS Trifluoperazine; RP 7623; SKF 5019; Stelazine; Stelazine (*Dihydrochloride*); Stelazine (TN); Stelazine Concentrate; Stellazine; TFP; Terfluzine (TN); Trifluoperaz (TN); Trifluoperazin; Trifluoperazina; Trifluoperazina [INN-Spanish]; Trifluoperazina [Italian]; Trifluoperazine (INN); Trifluoperazine HCl; Trifluoperazine [INN:BAN]; Trifluoperazine dihydrochloride; Trifluoperazinum; Trifluoperazinum [INN-Latin]; Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; Trifluoromethylperazine; Trifluoroperazine; Trifluoroperazine dihydrochloride; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Tripfluoperazine Hydrochloride; Triphtazin; Triphtazine; Triphthasine	5566	C21H24F3N3S	Approved
M6APDG01413	Fluphenazine	"1-(2-Hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine; 1-(2-Hydroxyethyl)-4-[3-(trifluoromethyl-10-phenothiazinyl)propyl]piperazine; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-(9CI); 10-(3'-(4""-(beta-Hydroxyethyl)-1""-piperazinyl)-propyl)-3-trifluoromethylphenothiazine; 10-(3'-(4''-(beta-Hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; 2-(4-(3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethanol; 2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-pipe razinyl)propyl)phenothiazine; 2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol dihydrochloride; 4-(3-(-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; 4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol; 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-Piperazineethanol; 4-(3-(2-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol; 4-[3-(2-Trifluoromethyl-10-phenothiazyl)-propyl]-1-piperazineethanol; Anatensol (TN); Apo-Fluphenazine; Dapotum; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Elinol; Enanthate (TN); Fludecate (TN); Flufenazin; Flufenazina; Flufenazina [DCIT]; Flunanthate (TN); Fluorfenazine; Fluorophenazine; Fluorphenazine; Fluphenazine (INN); Fluphenazine [INN:BAN]; Fluphenazine hydrochloride; Fluphenazinum; Fluphenazinum [INN-Latin]; Ftorphenazine; Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen (Tabl or elixir); Moditen Enanthate Injection (TN); Moditen Hcl; Omca (TN); Pacinol; Permitil (TN); Permitil Concentrate; Phthorphenazine; Prolixin (TN); Prolixin Concentrate; Prolixine; S94; SQ 4918; Sediten (TN); Selecten (TN); Sevinol; Sevinol (TN); Sinqualone (TN); Siqualine; Siqualon; Trancin (TN); Triflumethazine; Vespazine; Yespazine"	3372	C22H26F3N3OS	Approved
M6APDG01040	Cholic acid	"(R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; 3,7,12-Trihydroxycholanic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; BHQCQFFYRZLCQQ-OELDTZBJSA-N; CHEBI:16359; CHEMBL205596; Cholalic acid; Cholalin; Cholic acid [USAN]; Cholic acid, 5beta-; Cholsaeure; Colalin; G1JO7801AE; HSDB 982; NSC-6135; NSC6135; UNII-G1JO7801AE; cholate"	221493	C24H40O5	Approved
M6APDG01490	Diltiazem	"(+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one; Acalix; Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; Adizem; Adizem (TN); Aldizem; Altiazem (TN); Angiozem (TN); Angizem (TN); Angizem CD (TN); Anoheal; Apo-Diltiaz; Cardil; Cardizem; Cardizem (Hydrochloride); Cardizem (TN); Cardizen LA; Cartia XT (TN); Citizem; D-cis-Diltiazem; Dilacor; Dilacor-XR; Dilatam (TN); Dilatem (TN); Dilcardia (TN); Dilcontin; Dilcontin SR (TN); Dilren; Dilt-cd; Dilta-Hexal; Diltelan (TN); Diltia; Diltiazem (INN); Diltiazem [INN:BAN]; Diltiazemum; Diltiazemum [INN-Latin]; Dilticard; Diltime (TN); Diltzac; Dilzem (TN); Dilzen; Dyalec (TN); Endrydil; Filazem (TN); Herben (TN); Incoril AP; MK-793 (Malate); Nu-Diltiaz; Progor (TN); RG 83606 (Hydrochloride); Surazem (TN); Tiamate (TN); Tiazac (TN); Tiazac Tildiem; Tiazac XC; Tiazac XC (TN); Tildiem (TN); Vasmulax (TN); Viazem; Viazem (TN); Zandil (TN); Zemtrial (TN); [(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate"	39186	C22H26N2O4S	Approved
M6APDG01299	Chlorothiazide	"2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Aldoclor; Alurene; C 4911; Chloriazid; Chlorosal; Chlorothiazid; Chlorothiazide (JAN/USP/INN); Chlorothiazide [USAN:INN:BAN]; Chlorothiazidum; Chlorothiazidum [INN-Latin]; Chlorotiazida; Chlorthiazid; Chlorthiazide; Chlorthiazidum; Chlortiazid; Chlorurit; Chlotride; Chlrosal; Clorotiazida; Clorotiazida [INN-Spanish]; Clorotiazide; Clorotiazide [DCIT]; Clotride; Component of Aldoclor; Diupres; Diuresal; Diuril; Diuril (TN); Diuril Boluses; Diuril Boluses, Veterinary; Diuril, Chlotride, Chlorothiazide; Diurilix; Diurite; Diutrid; Flumen; Minzil; Neo-Dema; Salisan; Salunil; Saluretil; Saluric; Sk-chlorothiazide; Thiazide; Urinex; Warduzide; Yadalan"	2720	C7H6ClN3O4S2	Approved
M6APDG01010	Amiodarone	"(2-Butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone; (2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone; (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodophenyl]methanone; (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone; (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone; (2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine; 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(4'-beta-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran; 2-Butyl-3-[3,5-diiodo-4-(2-di; 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-((2-diethylamino)ethoxy)-m,m-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-[(2-diethylamino)ethoxy]-m,m-diiodophenyl ketone; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran; ASTA Medica Brand of Amiodarone Hydrochloride; Alphapharm Brand of Amiodarone Hydrochloride; Amidorone; Aminodarone; Amio-Aqueous IV; Amiobeta; Amiodarex; Amiodarona; Amiodarona [INN-Spanish]; Amiodarone (USAN/INN); Amiodarone Base; Amiodarone [USAN:BAN:INN]; Amiodarons; Amiodaronum; Amiodaronum [INN-Latin]; Amiohexal; Amjodaronum; Ancar; Aratac (TN); Aratac;Arycor; Armstrong Brand of Amiodarone Hydrochloride; Arycor (TN); Atlansil (TN); Berenguer Infale Brand of Amiodarone Hydrochloride; Betapharm Brand of Amiodarone Hydrochloride; Braxan; Corbionax; Cordarex; Cordarone; Cordarone (TN); Cordarone Intravenous; Ethylaminoethoxy)benzoyl]benzofuran; G Gam Brand of Amiodarone Hydrochloride; Hexal Brand of Amiodarone Hydrochloride; Ketone, 2-butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl; Ketone, 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl (7CI,8CI); Kordaron; L 3428; L-3428; L3428; Labaz; Leurquin Brand of Amiodarone Hydrochloride; Ortacrone; Pacerone; Pacerone (TN); Pharma Investi Brand of Amiodarone Hydrochloride; Pms-Amiodarone; Rytmarone; SKF 33134-A; SKF 33134A; Sanofi Winthrop Brand of Amiodarone Hydrochloride; Sedacoron; Sedacorone; Tachydaron; Wyeth Brand of Amiodarone Hydrochloride"	2157	C25H29I2NO3	Approved
M6APDG02240	Genistein	"4 inverted exclamation marka,5,7-Trihydroxyisoflavone; 4&prime;,5,7-Trihydroxyisoflavone; 4',5, 7-Trihydroxyisoflavone; 4',5,7-Trihydroxy isoflavone; 4',5,7-Trihydroxyisoflavone; 4,5,7-Trihydroxyiso-flavone; 4,6,7-Trihydroxyisoflavone; 5,7,4'-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one; Bonistein; C.I. 75610; Differenol A; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); G 6649; G10000; GEN; GENISTEIN (ENDOCRINE DISRUPTER); Genestein; Genisteol; Genisterin; IN1327; Lactoferrin-genistein; NPI 031L; PTI G4660 (Genistein); PTI-G4660; Prunetol; SIPI 807-1; SIPI-9764-I; STO514; Sophoricol; TNP00151"	5280961	C15H10O5	Phase 2
M6APDG02945	Grepafloxacin	"(+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; Grepafloxacin (unspecified); Grepafloxacin [INN]; Raxar; Raxar (TN)"	72474	C19H22FN3O3	Approved
M6APDG02539	Reserpine	"3P Reserp; Abesta; Abicol; Adelfan; Adelphin; Alkarau; Alkaserp; Alserin; Apoplon; Apoplon (TN); Apsical; Ascoserp; Ascoserpina; Austrapine; Banasil; Banisil; Benazyl; Bioserpine; Brinderdin; Briserine; Broserpine; Cam-Ap-Es; Cardioserpin; Carditivo; Carpacil; Carrserp; Darebon; Deserpine; Diupres 250; Diupres 500; Diupres-250; Diupres-500; Diurese-R; Diutensen-R; Dralserp; ENT 50146; Eberpine; Eberspine; Ebserpine; Elfanex; Elserpine; Enipresser; Esc aspere; Escaspere; Eserpine; Eskaserp; Eskaserpine; Gammaserpine; Gilucard; H 520; HYDRO-RESERP; Helfoserpin; Hexaplin; Hiposerpil; Hiserpia; Hydrap-ES; Hydromox R; Hydromox-R; Hydropine; Hydropres 25; Hydropres 50; Hydroserp; Hydrosine 25; Hypercal B; Hypersil; Hypersine; Hypertensan; Idoserp; Idsoserp; Interpina; Key-serpine; Kitine; Klimanosid; L""-Carpserp; L-Carpserp; Lemiserp; Loweser p; Loweserp; Mallopress; Maviserpin; Mayserpine; Mephaserpin; Modenol; Naquival; Nembuserpin; Neo-serp; Neose rfin; Neoserfin; Neoserp; Neoslowten; Orthoserpina; Perskleran; Pressimedin; Purserpine; Quiescin; R 0875; R-e-s; Rau sedyl; Rau-Sed; Raucap; Raudiford; Raudixin; Raudixoid; Raugal; Raulen; Rauloydin; Raumorine; Raunervil; Raunorine; Raunova; Raupasil; Raupoid; Raurine; Rausan; Rausedan; Rausedil; Rausedyl; Rauserpin; Rauserpine; Rauserpol; Rausingle; Rautrin; Rauvlid; Rauwasedin; Rauwilid; Rauwiloid; Rauwipur; Rauwita; Rauwoleaf; Rawilid; Recipin; Regroton; Renese R; Renese-R; Resaltex; Rese rpamed; Rese-lar; Resedrex; Resedril; Reser-ar; Reserbal; Resercaps; Resercen; Reserfia; Reserjen; Reserlor; Reserp; Reserpal; Reserpamed; Reserpanca; Reserpene; Reserpex; Reserpidefe; Reserpil; Reserpin; Reserpina; Reserpinum; Reserpka; Reserpoid; Reserpur; Reserutin; Resiatric; Residin; Residine; Resine; Resocalm; Resperin; Resperine; Respital; Restran; Rezerpin; Riserpa; Rivased; Rivasin; Rolserp; Roxel; Roxinoid; Roxynoid; Ryser; SK-Reserpine; Salupres; Sandril; Sandron; Se rpate; Sedaraupin; Sedaraupina; Sederaupin; Sedserp; Seominal; Ser-A-Gen; Serfin; Serfolia; Serolfia; Serpalan; Serpaloid; Serpaneurona; Serpanray; Serpasil; Serpasol; Serpate; Serpazil; Serpazol; Serpedin; Serpen; Serpena; Serpentil; Serpentin; Serpentina; Serpicon; Serpil; Serpiloid; Serpilum; Serpine; Serpipur; Serpivate; Serpivite; Serpogen; Serpoid; Serpone; Serpyrit; Sertabs; Sertens; Sertensin; Sertina; Supergan; T-Serp; Tefaserpina; Temposerpine; Tensanyl; Tenserpinie; Tensional; Tensionorme; Tepserpine; Terbolan; Transerpin; Triserpin; Tylandril; Unilord; Unipres; Usaf cb-27; V Serp; V-Serp; VI XO; VIXO; Veriloid; Vio-Serpine"	5770	C33H40N2O9	Approved
M6APDG02154	Propafenone	1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone; 1-(2-(2-Hydroxy-3-propylaminopropoxy)phenyl)-3-phenylpropan-1-one; 1-[2-(2-Hydroxy-3-(propylamino)propoxy)phenyl]-3-phenyl-1-propanone hydrochloride; 1-[2-(2-Hydroxy-3-[propylamino]-propoxy)phenyl]-3-phenyl-1-propanone; 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one; Propafenon Hexal; Propafenon hexal (TN); Propafenona; Propafenona [INN-Spanish]; Propafenone (INN); Propafenone [INN:BAN]; Propafenone-HCl; Propafenonum; Propafenonum [INN-Latin]; Rythmol; Rythmol SR (TN); Rytmonorm (TN)	4932	C21H27NO3	Approved
M6APDG02548	Aldosterone	"(+)-Aldosterone; (11BETA)-11,21-DIHYDROXY-3,20-DIOXOPREGN-4-EN-18-AL; (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde; 11.beta.,21-Dihydroxypregn-4-ene-3,18,20-trione; 11beta,21-Dihydroxy-3,20-diketo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-diketopregn-4-ene-18-al; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al, 18,11-halbacetal; 11beta,21-Dihydroxypregn-4-ene-3,18,20-trione; 11beta,21-dihydroxy-3,20-dioxo-pregn-4-ene-18-al; 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al; 18-Aldocorticosterone; 18-Formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione; 18-Oxocorticosterone; Aldocorten; Aldocortene; Aldocortin; Aldosterona; Aldosterona [INN-Spanish]; Aldosterone [INN:BAN:DCF]; Aldosterone, (+-)-Isomer; Aldosterone, (11 beta,17 alpha)-Isomer; Aldosteronum; Aldosteronum [INN-Latin]; D-Aldosterone; Electrocortin; Elektrocortin; Reichstein X"	5839	C21H28O5	Approved
M6APDG00978	Acebutolol	(+-)-3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; (+-)-Acebutolol; (+-)-N-(3-Acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)butanamide; 1-(2-Acetyl-4-n-butyramidophenoxy)-2-hydroxy-3-isopropylaminopropane; 3'-(Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)butyranilid; 5'-Butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone; Acebrutololum; Acebrutololum [INN-Latin]; Acebutolol (USAN/INN); Acebutolol HCL; Acebutolol [USAN:INN:BAN]; Acebutololo; Acebutololum; Acebutololum [INN-Latin]; Acetobutolol; Acetobutolol [INN-Spanish]; Dl-Acebutolol; M & B 17803A; M&B-17803 A; N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide; N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide; N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide; N-{3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}butanamide; Neptal; Prent; Prent (TN); RP 21823; Sectral; Sectral (TN)	1978	C18H28N2O4	Approved
M6APDG01522	Mefloquine	"(+)-(11R,2'S)-erythro-Mefloquine; (+)-Mefloquine; (+)-Threo-Mefloquine; (-)-(11S,2'R)-erythro-Mefloquine; (-)-Mefloquine; (-)-Threo-Mefloquine; (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol; Alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; Alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol; Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol; Lariam; Lariam (Hydrochloride); Lariam (TN); Mefaquin (TN); Mefloquin; Mefloquina; Mefloquina [INN-Spanish]; Mefloquine (USAN/INN); Mefloquine [USAN:INN:BAN]; Mefloquinone; Mefloquinum; Mefloquinum [INN-Latin]; Mephloquine; RO 13-7224; RO 13-7225; RTI1169-1-1; RTI1172-1-1; RTI1173-1-1; RTI1174-1-1; RTI1188-1-1; RTI1189-1-1; Racemic mefloquine; Ro 21-5998; Ro 21-5998 (Hydrochloride); Ro 215998; Ro-21-5998-001; SPB-80406; WR 142490; WR-142,490; WR-142490; WR-177,602; [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol"	40692	C17H16F6N2O	Approved
M6APDG02484	Delavirdine	"(1-(5-METHANSULPHONAMIDO-1H-INDOL-2-YL-CARBONYL)4-[METHYLAMINO)PYRIDINYL]PIPERAZINE; (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide); 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; 1-(5-Methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl]piperaz; 2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine; BHAP-U 90152; DELAVIRDINE MESYLATE; DLV; Delavirdine (*Mesylate salt*); Delavirdine (INN); Delavirdine [INN]; Delavirdine(U-90152) & .a.IFN; N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide; N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide; N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide; N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide; N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; PNU-90152-T; Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-& alpha-Interferon; Rescriptor; Rescriptor (TM);Rescriptor (TN); SPP; U 90152; U-90152; U-90152S; U90152S (*Mesylate salt*)"	5625	C22H28N6O3S	Approved
M6APDG01378	Dipyridamole	"2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; Agilease; Anginal; Antistenocardin; Apo-Dipyridamole; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Apotex Brand of Dipyridamole; Apricor; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin Chemie Brand of Dipyridamole; Berlin-Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; Cardioflux; Cardoxil; Cardoxin; Cerebrovase; Chilcolan; Cleridium; Cleridium 150; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantil; Curantyl; D 9766; Dipiridamol; Dipiridamol [INN-Spanish]; Dipyramidole; Dipyridamine; Dipyridamol; Dipyridamole (JP15/USP/INN); Dipyridamole [USAN:INN:BAN:JAN]; Dipyridamolum; Dipyridamolum [INN-Latin]; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; IPRAD Brand of Dipyridamole; Iv Persantine; Justpertin; Kurantil; Miosen; Natyl; Novo-Dipiradol; Novopharm Brand of Dipyridamole; Peridamol; Permiltin; Permole, Persantine, Dipyridan, Dipyridamole; Persantin; Persantine; Persantine (TN); Piroan; Prandiol; Prandiol 75; Protangix; RA-8; Stenocardil; Stenocardiol; Stimolcardio; Usaf Ge-12"	3108	C24H40N8O4	Approved
M6APDG01108	Cephalothin	Cephalothin; Cephalothin Sodium; Cephalothin Sodium W/ Dextrose In Plastic Container; Cephalothin Sodium W/ Sodium Chloride In Plastic Container; Keflin; Keflin In Plastic Container; Seffin	23675321	C16H15N2NaO6S2	Approved
M6APDG01288	Cefoperazone	"(6R,7R)-7-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6S,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl-3,4-didehydrocepham-4-carboxylic acid; CP 52640; Cefazone (TN); Cefobid; Cefobid (TN); Cefoperazon; Cefoperazone (INN); Cefoperazone [INN:BAN]; Cefoperazone sodium salt; Cefoperazono; Cefoperazono [INN-Spanish]; Cefoperazonum; Cefoperazonum [INN-Latin]; Peracef [veterinary]; Peracef [veterinary] (TN)"	2630	C25H27N9O8S2	Approved
M6APDG01473	Ketoconazole	"(+)-Ketoconazole; (+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine; (+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine; (+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone; 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine; CIS-1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE; Cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine; Fungarest; Fungoral; K 1003; KCZ; KS-1205; KTZ; KW-1414; Ketoconazol; Ketoconazole [USAN:INN:BAN:JAN]; Ketoderm; Nizoral (TN); Nizoral, Extina, Xolegel, Kuric, Ketoconazole; Perkhotal (TN); R 41,400; R 41400; R-41400; R41,400; R41400"	3823	C26H28Cl2N4O4	Approved
M6APDG01592	Abacavir	"(+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; (+/-)-Abacavir; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ABC; Abacavir (INN); Abacavir [INN]; Trizivir; Ziagen; Ziagen (TM)(*Succinate salt*); Ziagen (TN); [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol"	441300	C14H18N6O	Approved
M6APDG01965	Nitrendipine	"1A Pharma, Nitren; AL, Nitrendipin; AbZ, Nitre; Acis, Nitren; Atid, Nitrendipin; Basics, Nitrendipin; Bay-e-5009; Baylotensin; Bayotensin; Baypress; Baypress (TN); Bayvit, Nitrendipino; Beta, Nitrendipin; Biochemie, Nitrendi; Bylotensin; Ct, nitrendipin von; Deiten; Gericin; Heumann, Nitrendipin; Jutapress; KSK, Nitrend; Lich, Nitren; Lindo, Nitrendipin; N-144; Nidrel; Niprina; Nitre AbZ; Nitre Puren; Nitre-Puren; NitrePuren; Nitregamma; Nitren 1A Pharma; Nitren Lich;Nitren acis; Nitrend KSK; Nitrendepat; Nitrendi Biochemie; Nitrendidoc; Nitrendimerck; Nitrendipin; Nitrendipin AL; Nitrendipin Apogepha; Nitrendipin Atid; Nitrendipin Basics; Nitrendipin Heumann; Nitrendipin Lindo; Nitrendipin Stada; Nitrendipin beta; Nitrendipin corax; Nitrendipin von ct; Nitrendipin-corax; Nitrendipincorax; Nitrendipino; Nitrendipino Bayvit; Nitrendipinum; Nitrensal; Nitrepin; Nitrepress; Pharma, Nitren 1A; Stada, Nitrendipin; Tensogradal; Trendinol; Vastensium; Von ct, nitrendipin"	4507	C18H20N2O6	Approved
M6APDG02699	Amprenavir	"(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide; AMV; Agenerase; Agenerase (TM); Agenerase (TN); Amprenavir (JAN/USAN/INN); Amprenavir [USAN]; Amprenavir[usan]; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin(HHA); DRG-0258; GNA & Amprenavir; HHA & Amprenavir; KVX-478; Prozei; Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; VX 478; VX-478; VX478; Vertex; Vertex VX478; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER"	65016	C25H35N3O6S	Approved
M6APDG02264	Valspodar	3'-Keto-bmt(1)-val(2)-cyclosporin A; Amdray; Amdray (TN); PSC-833; PSC833; Psc 833; SDZ-PSC 833; Sdz psc 833; Sdz-psc-833; Valspodar (USAN/INN)	5281884	C63H111N11O12	Discontinued in Phase 3
M6APDG01372	Dihydroergocristine	Nehydrin	3065	C35H41N5O5	Approved
M6APDG01350	Telithromycin	"(1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; 11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A; HMR 3647; HMR-3647; HMR3647; Ketek; Ketek (TN); Levviax; RU 66647; RU-66647; RU66647; TEL; Telithromycin (JAN/USAN/INN); Telithromycin [USAN:BAN:INN]"	3002190	C43H65N5O10	Approved
M6APDG00055	Glycocholic acid	Glycocholate; cholylglycine	10140	C26H43NO6	Phase 3
M6APDG02939	Hesperetin	"(-)-hesperetin; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; (S)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 3',5,7-Trihydroxy-4'-methoxyflavanone; 3',5,7-Trihydroxy-4-methoxyflavanone; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-(9CI); 5,7,3'-Trihydroxy-4'-methoxyflavanone; Cyanidanon 4'-methyl ether 1626; Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN); Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN) (8CI); Hesperin; Hesperitin; TNP00238; YSO2"	72281	C16H14O6	Approved
M6APDG00074	Emetine	"EMETINE; Emetin; Cephaeline methyl ether; Methyl cephaeline; 6',7',10,11-Tetramethoxyemetan; Emetine hydrochloride; Emetine [BAN]; Cephaline-O-methyl ether; UNII-X8D5EPO80M; Emetan, 6',7',10,11-tetramethoxy-; HSDB 2150; TCMDC-125531; EINECS 207-592-1; BRN 0100829; X8D5EPO80M; CHEMBL50588; GNF-PF-196; Emetine dihydrochloride hydrate; Ipecine; Methylcephaeline; DSSTox_CID_2980; DSSTox_RID_76816; DSSTox_GSID_22980"	10219	C29H40N2O4	Approved
M6APDG02460	Ceftriaxone	"(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid; Biotrakson; CEFTRIAXONE SODIUM; CTRX; Cefatriaxone; Ceftriaxon; Ceftriaxona; Ceftriaxona [INN-Spanish]; Ceftriaxone (INN); Ceftriaxone (TN); Ceftriaxone [USAN:JAN]; Ceftriaxone intravenous; Ceftriaxone, Disodium Salt; Ceftriaxone, Disodium Salt, Hemiheptahydrate; Ceftriaxonum; Ceftriaxonum [INN-Latin]; Ceftriazone; DRG-0071; Longacef; Longaceph; Ro 139904; Ro-13-9904; Ro13-9904; Rocefin; Rocephin; Rocephin (TN); Rocephine"	5479530	C18H18N8O7S3	Approved
M6APDG01458	Imipramine	"1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; 5,6-Dihydro-N-[3-(dimethylamino)propyl]-11H-dibenz[b,e]azepine; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine,5-[3-(dimethylamino)propyl]-10,11-dihydro-mixed with ethyl alcohol; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-(9CI); Antideprin; Antideprin (TN); Berkomine; Censtim; Censtin; Declomipramine; Deprimin (TN); Deprinol (TN); Depsonil (TN); Dimipressin; Dpid; Dyna-zina; Dynaprin; Dynaprin (TN); Eupramin; Eupramin (TN); G-22355; Imavate; Imidobenzyle; Imipramil (TN); Imipramin; Imipramina; Imipramina [INN-Spanish]; Imipramina [Italian]; Imipramine (INN); Imipramine [INN:BAN]; Imipraminum; Imipraminum [INN-Latin]; Imiprin; Imizin; Imizinum; Impramine; Intalpram; Iramil; Irmin; Irmin (TN); Janimine; Janimine (TN); Janimine (hydrochloride); Melipramin; Melipramin (TN); Melipramine; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(gamma.-Dimethylaminopropyl)iminodibenzyl; Nelipramin; Norchlorimipramine; Norfranil; Pramine; Prazepine; Promiben;Psychoforin; SK-Pramine; Surplix; Surplix (TN); Timolet; Tofranil; Tofranil (free base); Tofranil (hydrochloride); Tofranil(TN); Tofranil, base; Tofraniln A"	3696	C19H24N2	Approved
M6APDG01379	Bromocriptine	"(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; 2-Bromo-alpha-ergocryptine; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; 2-Bromoergocryptine Methanesulfonate; 2-Bromoergokryptine; Alti-Bromocriptine; Apo-Bromocriptine; Bagren; Bromergocryptine; Bromocriptin; Bromocriptina; Bromocriptina [INN-Spanish]; Bromocriptine (USAN/INN); Bromocriptine [BAN]; Bromocriptine [USAN:BAN:INN]; Bromocriptine methanesulfonate; Bromocriptinum; Bromocriptinum [INN-Latin]; Bromocryptin; Bromocryptine; Bromoergocriptine; Bromoergocryptine; CB-154; Ergocryptine, 2-bromo-(8CI); Ergoset; Parlodel; Parlodel (TN); Parlodel Snaptabs"	31101	C32H40BrN5O5	Approved
M6APDG00998	Propranolol	"(+-)-Propranolol; (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; (R)-(+)-propranolol; (S)-(-)-PROPRANOLOL; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-(9CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-(9CI); 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol; AY 64043; AY-20694; Anaprilin; Anapriline; Anaprilinum (TN); Avlocardyl; Avlocardyl (TN); Bedranol; Berkolol; Beta Neg; Beta-Propranolol; Beta-Tablinen; Beta-Timelets; Betachron; Betadren; Betalong; Caridolol; Corpendol; D,L-Propranolol; DL-Propranolol hydrochloride; Deralin (TN); Dociton; Dociton (TN); Efektolol;Etalong; Euprovasin; Herzbase; INDERIDE-40/25; INDERIDE-80/25; Ikopal; Inderal; Inderal (TN); Inderal LA (TN); Inderal hydrochloride; Inderalici; Inderalici (TN); Inderex; Inderol; InnoPran XL (TN); Intermigran; Kemi; Kemi S; Migrastat; Naprilin; Obsidan; Obzidan; Pranolol; Pronovan; Propanalol; Propanix; Propanolol; Propanolol [INN-Spanish]; Propranalol; Propranolol (INN); Propranolol (TN); Propranolol Hcl Intensol; Propranolol [INN:BAN]; Propranololo; Propranololo [DCIT]; Propranololum; Propranololum [INN-Latin]; Proprasylyt; R,S-Propranolol Hydrochloride; Racemic propranolol; Reducor; Reducorline; Sawatal; Servanolol; Sumial; Sumial (TN)"	21138	C16H21NO2	Approved
M6APDG01326	Clonidine	"1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-(9CI); 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; 2,6-dichloro-N-(2-imidazolidinylidene)aniline; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; 2-((2,6-Dichlorophenyl)imino)imidazolidine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2);2-(2,6-Dichloroanilino)-2-imidazoline; 2-(2,6-Dichlorophenylamino)-2-imidazoline; 2-(2,6-Dichlorophenylimino)imidazolidine; 2-Imidazoline, 2-(2,6-dichloroanilino)-(7CI,8CI); 2-[(2,6-Dichlorophenyl)imino]imidazoline; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; 734571A; Adesipress; CATAPRES-TTS-1; CATAPRES-TTS-2; CATAPRES-TTS-3; Catapres (TN); Catapres-TTS; Catapresan; Catapressan; Catarpres; Catarpres-TTS; Catarpres-TTS (TN); Catarpresan; Chlornidinum; Clofenil; Clonidin; Clonidina; Clonidina [INN-Spanish]; Clonidine (JAN/USAN/INN); Clonidine [USAN:BAN:INN]; Clonidinhydrochlorid; Clonidinum; Clonidinum [INN-Latin]; Clopheline; Dixarit; Duraclon; Duraclont; Gemiton; Hemiton; Isoglaucon; Klofelin; Klofenil; M 5041T; M-5041T; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; SKF 34427; ST 155BS; ST-155-BS; ST-155BS; Tenso-Timelets"	2803	C9H9Cl2N3	Approved
M6APDG02003	Ofloxacin	"(+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (+/-)-Floxin; (-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; Bactocin; DEXTROFLOXACINE; DL 8280; DL-8280; DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin; Danoflox; Effexin; Exocin; Exocine; FLOXIN IN DEXTROSE 5%; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Flobacin; Flodemex; Flotavid; Flovid; Floxal; Floxil; Floxin; Floxin (TN); Floxin Otic (TN); Floxin otic; Floxstat; Fugacin; HOE 280; HOE-280;Hoe-280; Inoflox; Kinflocin; Kinoxacin; Liflox; Loxinter; Marfloxacin; Marfloxacin (TN); Medofloxine; Mergexin; Novecin; Nufafloqo; O 8757; O-Flox; OFLX; OFX; ORF 18489; ORF-28489; Obide; Occidal; Ocuflox; Ocuflox (TN); Ofcin; Oflin; Oflocee; Oflocet; Oflocin; Oflodal; Oflodex; Oflodura; Oflox; Ofloxacin (JP15/USP/INN); Ofloxacin Otic; Ofloxacin [USAN:BAN:INN:JAN]; Ofloxacin, (S)-Isomer; Ofloxacina; Ofloxacina [DCIT]; Ofloxacine; Ofloxacine [French]; Ofloxacino; Ofloxacino [Spanish]; Ofloxacinum; Ofloxacinum [Latin]; Ofloxin; Ofus; Onexacin; Operan; Orocin; Otonil; Oxaldin; PT 01; Pharflox; Praxin; Puiritol; Qinolon; Qipro; Quinolon; Quotavil; Rilox; Ru-43280; Sinflo; Tabrin; Taravid; Tariflox; Tarivid; Telbit; Tructum; Uro Tarivid; Viotisone; Visiren; WP-0405; XED; Zanocin"	4583	C18H20FN3O4	Approved
M6APDG01004	Darunavir	"(3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; AIDS073035; Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; Darunavir (USAN/INN); Darunavir [USAN]; Darunavirum; Darunavirum [INN-Latin]; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide; Prezista; Prezista(TM); TMC 114; TMC-114; TMC114; UIC 94017; UIC-94017; UIC-96017; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester"	213039	C27H37N3O7S	Approved
M6APDG01301	Thioguanine	"2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; BW 5071; DX4; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Guanine, thio-(VAN); LT00455187; Lanvis; Lanvis (TN); Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; THG; Tabloid; Thioguanin GSK; Thioguanin-GSK; ThioguaninGSK; Thioguanine (Guanine analog); Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Thioguanine [USAN:BAN]; Tioguanin; Tioguanina; Tioguanina Wellcome; Tioguanina[INN-Spanish]; Tioguanine; Tioguanine (INN); Tioguanine GlaxoSmithKline Brand; Tioguaninum; Tioguaninum [INN-Latin]; Wellcome Brand of Thioguanine; Wellcome U3B"	2723601	C5H5N5S	Approved
M6APDG01304	Chlorpromazine	"10-(3-Dimethylaminopropyl)-2-chlorophenothiazine; 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-, radical ion(1+); 2-Chloro-10-(3-(dimethylamino)propyl)phenothiazine; 2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine; 2-Chloropromazine; 2-Cloro-10 (3-dimetilaminopropil)fenotiazina; 2-Cloro-10 (3-dimetilaminopropil)fenotiazina [Italian]; 2-chloro-10-(3-(dimethylamino)propyl)-phenothiazine; 2-chloro-N,N-dimethyl-10H-Phenothiazine-10-propanamine; 3-(2-Chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine; 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine; 3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine; 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine; Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine; Chloro-3 (dimethylamino-3 propyl)-10 phenothiazine [French]; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; N-(3-Dimethylaminopropyl)-3-chlorophenothiazine; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80; [3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine"	2726	C17H19ClN2S	Approved
M6APDG01346	Desipramine	"(3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5-(gamma-Methylaminopropyl)iminodibenzyl; DMI (pharmaceutical); DMI 50475; Demethylimipramine; Desimipramine; Desimpramine; Desipramin; Desipramina; Desipramina [INN-Spanish]; Desipramine (D4); Desipramine (INN); Desipramine Hcl; Desipramine [INN:BAN]; Desipraminum; Desipraminum [INN-Latin]; Desmethylimipramine; Dezipramine; Dimethylimipramine; Methylaminopropyliminodibenzyl; Monodemethylimipramine; N-(3-Methylaminopropyl)iminobibenzyl; Norimipramine; Norpramin (TN); Norpramine; Pentofran; Pertofrane (TN); Pertrofane; Sertofran; ZERO/006017"	2995	C18H22N2	Approved
M6APDG03011	Ergotamine	"(5'A)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman 2,3-dihydroxybutanedioate(2:1); 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione; Avetol; Cornutamin; Cornutamine; ERGOTAMINE (SEE ALSO: ERGOTAMINE TARTRATE (CAS 379-79-3)); ETIN; Ergam; Ergate; Ergomar; Ergomar (TN); Ergonsvine; Ergostat; Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-alpha)-(9CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); Ergotamin; Ergotamina [INN-Spanish]; Ergotamine (INN); Ergotamine [INN:BAN]; Ergotamine bitartrate; Ergotamine hemitartrate; Ergotamine tartrate; Ergotamine tartrate (VAN); Ergotamine tartrate, Avetol, Cornutamin, Ergam, Ergotartrate; Ergotamine, tartrate (2:1); Ergotamine, tartrate (2:1) (salt) (8CI); Ergotaminum [INN-Latin]; Ergotartrate; Ergoton-A; Exmigra; Femergin;Gynergen; Gotamine tartrate; Lingraine; Lingran; Medihaler ergotamine; Migretamine; Neo-ergotin; Rigetamin; Secagyn; Secupan; Temigran; Wigrettes"	8223	C33H35N5O5	Approved
M6APDG02534	Corticosterone	"(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE; (11beta)-11,21-Dihydroxypregn-4-ene-3,20-dione; 11,12-Dihydroxyprogesterone; 11,21-Dihydroxyprogesterone; 11-Hydroxycorticoaldosterone; 11-beta,21-Dihydroxypregn-3,20-dione; 11Beta,21-dihydroxypregn-4-ene-3,20-dione; 11beta,21-Dihydroxy-4-pregnene-3,20-dione; 11beta,21-Dihydroxyprogesterone; 17-Deoxycortisol; 4-Pregnene-11beta,21-diol-3,20-dione; 50-22-6; CCRIS 6753; CHEBI:16827; Compound B; Corticosteron; Corticosterone; Kendall's compound B; NSC9705; Reichstein's B; Reichstein's substance H; UNII-W980KJ009P"	5753	C21H30O4	Phase 3
M6APDG02158	Protriptyline	"3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; 5-(3-Methylaminopropyl)-5H-Dibenzo[a,d]cycloheptene; 5-(3-Methylaminopropyl)-5H-dibenzo(a,d)cycloheptene; 5H-Dibenzo[a, d]cycloheptene-5-propanamine, N-methyl-, hydrochloride; 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene; Amimetilina; Apo-Imipramine; Apo-Trimip; Impril; Maximed; N-3-(5H-Dibenzo(a,d)cyclohepten-5-yl)propyl-N-methylamine; N-Methyl-5H-dibenzo(a,d)cycloheptene-5-propylamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; Normethyl EX4442; Novo-Doxepin; Novo-Tripramine; Novopramine; Protriptilina; Protriptilina [INN-Spanish]; Protriptyline (INN); Protriptyline [INN:BAN]; Protriptylinum; Protriptylinum [INN-Latin]; Protryptyline; Rhotrimine; Triadapin 5; Triptil; Triptil hydrochloride; Triptyl; Vivactil; Vivactil (TN); Vivactyl"	4976	C19H21N	Approved
M6APDG00868	Pimozide	"1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one; ASTA Medica Brand of Pimozide; Antalon; Janssen Brand of Pimozide;Orap forte; McN-JR 6238; McN-JR-6238; Neoperidole; Opiran; Orap; Orap (TN); P 1793; Pharmascience Brand of Pimozide; Pimozida; Pimozida [INN-Spanish]; Pimozide (JAN/USP/INN); Pimozide [USAN:INN:BAN:JAN]; Pimozidum; Pimozidum [INN-Latin]; Primozida; Primozida [INN-Spanish]; R 6238; R-6238"	16362	C28H29F2N3O	Approved
M6APDG01325	Clomipramine	"10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-Chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 3-Chloroimipramine; 3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine; 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-(8CI); Anafranil (TN); Anafranil (free base); Anafranil base; Chlomipramine; Chlorimipramine; Clomicalm; Clomipramina; Clomipramina [INN-Spanish]; Clomipramine (INN); Clomipramine [INN:BAN]; Clomipraminum; Clomipraminum [INN-Latin]; G 34586; Hydiphen; Monochlorimipramine"	2801	C19H23ClN2	Approved
M6APDG01013	Amitriptyline	"10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene; Adepress; Adepril; Amitril; Amitriprolidine; Amitriptilina; Amitriptilina [INN-Spanish]; Amitriptilina [Italian]; Amitriptylin; Amitriptylin [German]; Amitriptyline (INN); Amitriptyline [INN:BAN]; Amitriptylinum; Amitriptylinum [INN-Latin]; Amitryptiline; Amitryptyline; Amytriptiline; Amytriptylin; Damilan; Damilen; Damitriptyline; Elanil; Elavil; Elavil (TN); Flavyl; Lantron; Laroxil; Laroxyl; Laroxyl (TN); MK 230; N 750; Proheptadiene; Redomex; Ro 4-1575; Sarotex; Seroten; Sylvemid; TP0; Triptanol; Triptilin; Triptisol; Tryptanol; [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine"	2160	C20H23N	Approved
M6APDG00864	Ivacaftor	Kalydeco (TN)	16220172	C24H28N2O3	Approved
M6APDG00639	Olanzapine	"2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine; ALKS-7921; Eli Lilly brand of olanzapine; KS-1090; LY 170053; LY-170052; LY-170053; Lanzac; Lilly brand of olanzapine; Midax; Olansek; Olanzapina; Olanzapine (JAN/USAN/INN); Olanzapine (OLA); Olanzapine [USAN:INN]; Olanzapinum; Olzapin (TN); Rexapin (TN); Symbyax; Zalasta; Zalasta (TN); Zolafren (TN); Zydis; Zydis (TN); Zyprexa; Zyprexa (TN); Zyprexa Intramuscular; Zyprexa Velotab; Zyprexa Zydis"	135398745	C17H20N4S	Approved
M6APDG01417	Fluoxetine	"(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine;(+/-)-Fluoxetine; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Animex-On; Dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Eufor; Floxetine; Fluoxetin; Fluoxetina; Fluoxetina [INN-Spanish]; Fluoxetina [Spanish]; Fluoxetine (Prozac); Fluoxetine (TN); Fluoxetine (USAN/INN); Fluoxetine Hcl; Fluoxetine [USAN:INN:BAN]; Fluoxetinum; Fluoxetinum [INN-Latin]; Fluval; Fontex; Lilly-110140; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; Portal; Prozac (TN); Prozac Weekly; Pulvules; Reconcile; Reneuron"	3386	C17H18F3NO	Approved
M6APDG02051	Pantoprazole	"5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole; Astropan; Astropan (TN); BY 1023; BY-1023; Controloc (TN); Inipomp (TN); Pantecta (TN); Pantoloc (TN); Pantopan (TN); Pantoprazol; Pantoprazol [INN-Spanish]; Pantoprazole (USAN/INN); Pantoprazole Na; Pantoprazole Sodium; Pantoprazole [USAN:BAN:INN]; Pantoprazolum; Pantoprazolum [INN-Latin]; Pantoprozole; Pantor; Pantor (TN); Pantotab (TN); Pantozol; Pantozol (TN); Protium; Protium (TN); Protonix; Protonix (TN); Protonix IV; SK&F 96022; SK&F-96022; SK-96022; SKF-96022; Somac; Somac (TN); Ulcepraz (TN)"	4679	C16H15F2N3O4S	Approved
M6APDG00942	Dicloxacillin	"(2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylpenicillin; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid; 6beta-{[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carboxamido}-2,2-dimethylpenam-3alpha-carboxylic acid; BRL 1702; Dichloroxacillin; Diclocil (TN); Diclossacillina; Diclossacillina [DCIT]; Dicloxaciclin; Dicloxacilin; Dicloxacilina; Dicloxacilina [INN-Spanish]; Dicloxacillin (USAN/INN); Dicloxacillin [USAN:INN:BAN]; Dicloxacillin sodium; Dicloxacillin, Monosodium Salt, Mono-Hydrate; Dicloxacilline; Dicloxacilline [INN-French]; Dicloxacillinum; Dicloxacillinum [INN-Latin]; Dicloxacycline; Dycill; Dynapen; Maclicine; Methyldichlorophenylisoxazolylpenicillin; Pathocil; R-13423"	18381	C19H17Cl2N3O5S	Approved
M6APDG01426	Oxcarbazepine	"10,11-Dihydro-10-oxo-5H-debenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide; Desitin brand of oxcarbazepine; Epilexter; Epliga; GP 47680; GP-47680; KIN-493; Novartis brand of oxcarbazepine; O0363; Oxacarbazepine; Oxaleptal (TN); Oxcarbamazepine; Oxcarbazepime; Oxcarbazepina; Oxcarbazepina [INN-Spanish]; Oxcarbazepine (USAN/INN); Oxcarbazepine [INN]; Oxcarbazepinum; Oxcarbazepinum [INN-Latin]; SPN-804; Timox; Trileptal; Trileptal (TN)"	34312	C15H12N2O2	Approved
M6APDG01451	Hydroxychloroquine	2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol; 2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol; 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol; 2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol; 7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline; 7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline; 7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258	3652	C18H26ClN3O	Approved
M6APDG02277	Cyclosporine	cyclosporin A; cyclosporine; Ciclosporin; Cyclosporine A; Ciclosporine; Neoral; Cyclosporin; Ciclosporinum; Ciclosporina; Sandimmune; Equoral; Neoplanta; Sandimmun; Sang-35; Gengraf; Sandimmun Neoral; UNII-83HN0GTJ6D; Antibiotic S 7481F1; Consupren; Restasis; Ramihyphin A; SangCyA; MFCD00274558; 83HN0GTJ6D; MLS001333756; CSA; S-Neoral; Cipol N; Sigmasporin Microoral; Sang 35; DSSTox_CID_365; Ciclosporinum [INN-Latin]; Ciclosporine [INN-French]; Ciclosporina [INN-Spanish]; DSSTox_RID_75541; Ciclosporin (Ciclosporin A)	5284373	C62H111N11O12	Approved
M6APDG01914	Nevirapine	"11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one; BI RG 587; BI-RG-587; BI-RG-587 & CD4-IgG; BIRG 0587; BIRG 587; BIRG-0587; BIRG-587; BIRG587; Cahill May Roberts Brand of Nevirapine; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; NEV; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; NVP; Nevirapine & CD4-IgG; Nevirapine & PRO 140; Nevirapine (JAN/USP/INN); Nevirapine [USAN:INN]; Promeco Brand of Nevirapine; Viramune; Viramune (TN); Viramune(TM); Viramune, BI-RG 587, Nevirapine"	4463	C15H14N4O	Approved
M6APDG02835	Sertraline	"(+)-Sertraline; (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; (1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine; (1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine; Apo-Sertraline; CP 51974; Lustral; Lustral (TN); SRE; Sertralina; Sertralina [Spanish]; Sertraline (INN); Sertraline (Zoloft); Sertraline [INN:BAN]; Sertraline [Zoloft]; Sertralinum; Sertralinum [Latin]; Zoloft (TN)"	68617	C17H17Cl2N	Approved
M6APDG02552	Prednisone	"(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione; Adasone; Ancortone; Apo-Prednisone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Dellacort A; Delta E; Delta E.; Delta cortelan; Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; Deltison; Deltisona; Deltisone; Deltra; Di-Adreson; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; In-Sone; Incocortyl; Juvason; Kortancyl; Liquid Pred; Lisacort; Lodotra; Me-Korti; Metacortandracin; Meticortelone (TN); Meticorten; Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Nisona; Nizon; Novoprednisone; Nurison; Orasone; Origen Prednisone; P1276; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicen-M; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisona [INN-Spanish]; Prednisone Intensol; Prednisone [INN:BAN]; Prednisonum; Prednisonum [INN-Latin]; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; SK-Prednisone; Servisone; Sone; Sterapred; Supercortil; U 6020; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Zenadrid (veterinary); Zenadrid [veterinary]"	5865	C21H26O5	Approved
M6APDG01404	Fentanyl	Abstral; Actiq; Duragesic-100; Duragesic-12; Duragesic-25; Duragesic-50; Duragesic-75; Fentanyl; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Fentanyl-100; Fentanyl-12; Fentanyl-25; Fentanyl-37; Fentanyl-50; Fentanyl-62; Fentanyl-75; Fentanyl-87; Fentora; Lazanda; Onsolis; Sublimaze Preservative Free; Subsys	3345	C22H28N2O	Approved
M6APDG01498	Losartan	"(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI); 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol; 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol; 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole; CL23623; Cozaar; Cozaar (TN); DUP 89; DuP-753; Hyzaar; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol"	3961	C22H23ClN6O	Approved
M6APDG02536	Prednisolone	"Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos"	5755	C21H28O5	Approved
M6APDG01441	Haloperidol	Aldo; Aloperidin; Aloperidin (TN); Aloperidol; Aloperidolo; Aloperidolo [DCIT]; Aloperidolo [Italian]; Aloperidon; Apo-Haloperidol; Bioperidolo; Bioperidolo (TN); Brotopon; Brotopon (TN); Dozic; Dozic (TN); Dozix; Duraperidol (TN); Einalon S; Einalon S (TN); Eukystol; Eukystol (TN); Fortunan; Galoperidol; H 1512; Haldol; Haldol (TN); Haldol La; Haldol Solutab; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidol (JP15/USP); Haloperidol (JP15/USP/INN); Haloperidol [USAN:INN:BAN:JAN]; Haloperidolum; Haloperidolum [INN-Latin]; Halopidol; Halopoidol; Halosten; Halosten (TN); Keselan; Keselan (TN); Lealgin compositum; Linton; Linton (TN);Novo-Peridol; McN-JR-1625; Mixidol; Pekuces; Peluces; Peluces (TN); Peridol; Pernox; Pms Haloperidol; R 1625; R-1625; Serenace; Serenace (TN); Serenase; Serenase (TN); Serenelfi; Sernas; Sernel; Sigaperidol; Sigaperidol (TN); Ulcolind; Uliolind; Vesalium	3559	C21H23ClFNO2	Approved
M6APDG02643	Nelfinavir	"ARV-SR0121; NFV; Nelfinavir (SARS infection); Nelfinavir (SARS infection), aRigen; SARS therapy, aRigen; Viracept (SARS infection), aRigen"	64143	C32H45N3O4S	Approved
M6APDG02620	Cytarabine	"(beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one; AR3; Alexan; Ara-C; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; Ara-Cytidine; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosyl Cytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; BTB15125; Beta-Ara C; Beta-Arabinosylcytosine; Beta-D-Arabinosylcytosine; Beta-cytosine arabinoside; CHX 3311; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Citarabina; Citarabina [INN-Spanish]; Cytarabin; Cytarabina; Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytarabine liposome injection; Cytarabinoside; Cytarabinum; Cytarabinum [INN-Latin]; Cytarbel; Cytonal; Cytosar; Cytosar-U; Cytosar-U (TN); Cytosine 1-beta-D-arabinofuranoside; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; Cytosine arabinoside (VAN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine, beta-D-arabinoside; Cytosine-1-beta-D-arabinofuranoside; Cytosine-beta-D-arabinofuranoside; Cytosine-beta-arabinoside; Cytosinearabinoside; DepoCyte; Depocyt; Depocyt (TN); Depocyt (liposomal); Erpalfa; Intrathecal (injected into the spinal fluid) DepoCyt; Intrathecal cytarabine (also known as ara-C); Iretin; Spongocytidine; Tarabine; U 19920A; U-19,920; U-19920; Udicil"	6253	C9H13N3O5	Approved
M6APDG02642	Efavirenz	"(-)-Efavirenz; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-(9; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one; DMP 266; DMP-266; EFV; EFZ; Efavirenz (JAN/INN); Efavirenz, (S)-isomer; Eravirenz; L 743726; L-741211; L-743,726; L-743725; L-743726; Met-SDF-1.beta. & Efavirenz; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; Stocrin; Stocrin (TN); Strocin (TM); Sustiva; Sustiva (TM); Sustiva (TN); Zoxazin-2-one"	64139	C14H9ClF3NO2	Approved
M6APDG01869	Tacrolimus	"(-)-FK 506; 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN; Advagraf; Advagraf (TN); FK 506; FK5; FK506; FR 900506; FR-900506; FR900506; Fk-506; Fujimycin; Graceptor; K506; L 679934; L-679934; LCP-Tacro; Modigraf; Prograf; Prograf (TN); Protopic; Protopic (TN); Protopy; Tacarolimus; Tacrolimus (INN); Tacrolimus (Prograf); Tacrolimus (anhydrous); Tacrolimus anhydrous; Tsukubaenolide"	445643	C44H69NO12	Approved
M6APDG00649	Valganciclovir	"5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one; Cymeval; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester; L-Valine, ester with ganciclovir; RO1079070/194; RS 79070; Valcyte (TN); Valganciclovir (INN); Valganciclovir (Oral); Valganciclovir [INN:BAN]; [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate"	135413535	C14H22N6O5	Approved
M6APDG02379	Paroxetine	"(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine; (-)-Paroxetine; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine; (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine; (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine; (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; (3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine; 3-(Benzo[1,3]Dioxol-5-Yl-Oxymethyl)-4-(4-Fluoro-Phenyl)-Piperidine Hydrochloride; Aropax; BRL 29060; BRL-29060; Casbol; FG 7051; FG-7051; Frosinor; Motivan; NNC-20-7051; Paroxetina; Paroxetina [INN-Spanish]; Paroxetine (TN); Paroxetine (USP/INN); Paroxetine Hcl; Paroxetine [USAN:INN:BAN]; Paroxetinum; Paroxetinum [INN-Latin]; PaxPar; Paxetil; Paxil; Paxil (TN); Paxil CR;Seroxat CR; Pexeva; Seroxat; Seroxat (TN); [3H]Paroxetine"	53316721	C19H20FNO3	Approved
M6APDG02837	Talinolol	"(+-)-N-Cyclohexyl-N'-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)urea; (+-)-Talinolol; 1-(3-(3-Cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol; 1-(4-(3-(TERT-BUTYLAMINO)-2-HYDROXYPROPOXY)PHENYL)-3-CYCLOHEXYLUREA; 1-(4-(cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol; 1-(4-Cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane; 38649-73-9; Cordanum; NCGC00164542-01; Racemic talinolol; Talinolol (INN); Talinolol [INN]; Talinololum [INN-Latin]"	68770	C20H33N3O3	Phase 1
M6APDG01524	Vindesine	"3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; DAVA; Desacetylvinblastine amide; Lilly 112531; Methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; Methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; Vindesin; Vindesina; Vindesina [INN-Spanish]; Vindesine (USAN/INN); Vindesine [USAN:BAN:INN]; Vindesine [USAN:INN:BAN]; Vindesinum; Vindesinum [INN-Latin]"	40839	C43H55N5O7	Approved
M6APDG01943	Nifedipine	"AWD Pharma Brand of Nifedipine; Adalat; Adalat (TN); Adalat 10; Adalat 20; Adalat 5; Adalat CC; Adalat CR; Adalat Crono; Adalat FT; Adalat GITS; Adalat GITS 30; Adalat LA; Adalat LP; Adalat Oros; Adalat PA; Adalat Retard; Adalat XL; Adalate; Adalate LP; Adapine; Adapress; Adcock Ingram Brand of Nifedipine; Adipine XL; Afeditab; Afeditab CR; Afeditab CR (TN); Alat; Aldipin; Alfadal; Alonix; Alonix S; Alpha-Nifedipine Retard;Apo-Nifed; Angipec; Anifed; Anpine; Aprical; Aprical long; Bay-1040; Bay-a-1040; Bay1040; Bayer Brand of Nifedipine; Bonacid; Calcibloc; Calcigard; Calcilat; Camont; Cardifen; Cardilat; Cardionorm; Chronadalate; Chronadalate LP; Citilat; Coracten; Coracten XL; Coral; Cordafen; Cordaflex; Cordalat; Cordicant; Cordilan; Cordipin; Cordipine; Corinfar; Corotrend; Corynphar; Depin; Dignokonstant; Dilafed; Dipinkor; Duranifin; Ecodipi; Ecodipin; Ecodipin E; Emaberin; Fedcor; Fedcor Retard; Fenamon; Fenamon SR; Fenigidin; Fenihidin; Fenihidine; Fortipine LA; Glopir; Hadipin; Hexadilat; Infedipin; Introcar; KB-1712P; KRKA Brand of Nifedipine; Kordafen; Korinfar; Macorel; Megalat; Monohydrochloride, Nifedipine; Myogard; N 7634; N1fedilat; Nedipin; Nicardia; Nifangin; Nifar; Nifdemin; Nifebene; Nifecard; Nifecor; Nifedepat; Nifediac; Nifedical; Nifedical (TN); Nifedical XL; Nifedicor; Nifedin; Nifedine; Nifedipine (JP15/USP/INN); Nifedipine Bayer Brand; Nifedipine GTIS; Nifedipine KRKA Brand; Nifedipine Monohydrochloride; Nifedipine Orion Brand; Nifedipine Pfizer Brand; Nifedipine Retard; Nifedipine [USAN:BAN:INN:JAN]; Nifedipine-GTIS; Nifedipino; Nifedipino [INN-Spanish]; Nifedipinum; Nifedipinum [INN-Latin]; Nifedipres; Nifedirex LP; Nifelan; Nifelat; Nifelat Q; Nifelate; Nifensar XL; Nificard; Nifidine; Nifipen; Niphedipine; Orion Brand of Nifedipine; Orix; Oxcord; Pfizer Brand of Nifedipine; Pidilat; Procardia; Procardia (TN); Procardia XL; Sepamit; Slofedipine XL; Tensipine MR; Tibricol; Vascard; Zenusin"	4485	C17H18N2O6	Approved
M6APDG02462	Atomoxetine	(-)-Tomoxetine; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine; Atomoxetine (INN); Attentin (TN); Strattera (TN); Tomoxetin (TN); Tomoxetina; Tomoxetina [Spanish]; Tomoxetine; Tomoxetine [INN]; Tomoxetinum; Tomoxetinum [Latin]	54841	C17H21NO	Approved
M6APDG01910	Cerivastatin	.	446156	C26H34FNO5	Approved
M6APDG02327	Fluvoxamine	(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; 2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine; Dumirox; Dumyrox; Faverin; Floxyfral; Fluvoxamina; Fluvoxamina [INN-Spanish]; Fluvoxamine (INN); Fluvoxamine [INN:BAN]; Fluvoxamine-CR; Fluvoxaminum; Fluvoxaminum [INN-Latin]; Luvox (TN); Maveral	5324346	C15H21F3N2O2	Approved
M6APDG01554	Idarubicin	"(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin; DM5; DMDR; I 1656; IMI 30; IMI-30; Idamycin; Idamycin (TN); Idarubicin (INN); Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin [INN:BAN]; Idarubicin hydrochloride; Idarubicina; Idarubicina [INN-Spanish]; Idarubicine; Idarubicine [INN-French]; Idarubicinum; Idarubicinum [INN-Latin]; Zavedos; Zavedos (TN)"	42890	C26H27NO9	Approved
M6APDG02189	Risperidone	"3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; 3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; Belivon; Consta, Risperdal; KS-1106; R 62 766; R 64 766, Risperdal, Risperidone; R 64,766; R 64766; R-118; R-64,766; R-64-766; R-64766; R64,766; R64766; Risperdal; Risperdal (TN); Risperdal Consta; Risperdal M-Tab; Risperdone; Risperidal; Risperidal M-Tab; Risperidona; Risperidona [Spanish]; Risperidone (JAN/USAN/INN); Risperidone (RIS); Risperidone [USAN:BAN:INN]; Risperidone, placebo; Risperidonum; Risperidonum [Latin]; Risperin; Rispolept; Rispolin; Sequinan"	5073	C23H27FN4O2	Approved
M6APDG02451	Dolutegravir	DTG; S/GSK1349572	54726191	C20H19F2N3O5	Approved
M6APDG02008	Melphalan	"(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine; AY3360000; Alanine Nitrogen Mustard; Alkeran; Alkeran (TN); At-290; CB 3025; CB-3025; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Levofalan; Levofolan; Levopholan; MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); Melfalan; Melfalano; Melfalano [INN-Spanish]; Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; Melphalanum; Melphalanum [INN-Latin]; P-Bis(beta-chloroethyl)aminophenylalanine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-L-Sarcolysin; P-L-sarcolysine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; SK-15673; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); TRANSGENIC MODEL EVALUATION (MELPHALAN)"	460612	C13H18Cl2N2O2	Approved
M6APDG01980	Sofosbuvir	"HSDB 8226; Hepcinat; Hepcvir; Resof; SOFOSBUVIR; Sofosbuvir (PSI-7977, GS-7977); Sofosbuvir [USAN:INN]; Sovaldi (TN); SoviHep"	45375808	C22H29FN3O9P	Approved
M6APDG01923	Azithromycin	Azasite (TN); Azibiot; Azifine; Azithramycine; Azithromycin (INN); Azithromycin (TN); Zitrocin	447043	C38H72N2O12	Approved
M6APDG00699	Talazoparib	"(8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one; (8s,9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1h-1,2,4-Triazol-5-Yl)-2,7,8,9-Tetrahydro-3h-Pyrido[4,3,2-De]phthalazin-3-One; LT-673; Talazoparib; Talazoparib (BMN 673); Talazoparib [USAN:INN]"	135565082	C19H14F2N6O	Approved
M6APDG00557	Baloxavir marboxil	"(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate; Baloxavir marboxil; Baloxavir marboxil (JAN/INN); Baloxavir marboxil [INN]; Xofluza (TN)"	124081896	C27H23F2N3O7S	Approved
M6APDG02447	Omadacycline	"Amadacycline; Amadacycline (intravenous), Merck & Co; Amadacycline (intravenous), Paratek/Novartis; Amadacycline (oral), Merck & Co; Amadacycline (oral), Paratek/ Novartis; Antibacterial aminomethycyclines, Paratek/Bayer; MK-2764; Omadacycline; Omadacycline (intravenous), Merck & Co; Omadacycline (intravenous), Paratek; Omadacycline (intravenous), Paratek/ Novartis; Omadacycline (oral), Merck & Co; Omadacycline (oral), Paratek; Omadacycline (oral), Paratek/ Novartis; Omadacycline tosylate; P-000538; P-000642; P-001075; P-001207; P-001221; P-00136; P-002352; PTK-0796; PTK-796; Sancycline derivatives, Paratek; Tetracycline analogs, GlaxoSmithKline/Paratek; Tetracycline analogs, Paratek/Merck & Co;Tetracycline analogs (multi-drug-resistant infections), Paratek/Bayer"	54697325	C29H40N4O7	Approved
M6APDG01838	Vibegron	Beova; Beova (TN); VIBEGRON; Vibegron (JAN/USAN); Vibegron [USAN:INN]; compound 7 [PMID: 26709102]; vibegronum	44472635	C26H28N4O3	Phase 3
M6APDG01695	Metildigoxin	"4'''-Methyldigoxin; 4'''-O-Methyldigoxin; Betamethyl digoxin; Digoxin, 4'''-O-methyl-; Lanirapid; Lanitop; MEDIGOXIN; Medigossina; Medigossina [DCIT]; Medigoxina; Medigoxina [Spanish]; Methyldigoxin; Metildigoxin; Metildigoxin [INN:BAN:JAN]; Metildigoxina; Metildigoxina [INN-Spanish]; Metildigoxine; Metildigoxine [INN-French]; Metildigoxinum; Metildigoxinum [INN-Latin]; beta-Methyl Digoxin; beta-Methyldigoxin; beta-Metildigoxina; beta-Metildigoxina [Spanish]"	443946	C42H66O14	Preclinical
M6APDG00596	Olmesartan medoxomil	"Benevas; Benicar; Benicar (TN); Benicar, Olmetec,Olmesartan; Berlin-Chemie Brand of Olmesartan Medoxomil; Forest Brand of Olmesartan Medoxomil; Olmesartan medoximil; Olmesartan medoxomil (JAN/USAN); Olmetec; Olmetec (TN); Olvance; Sankyo Brand of Olmesartan Medoxomil"	130881	C29H30N6O6	Approved
M6APDG00240	Hematoporphyrin	"1,3,5,8-Tetramethyl-2,4-bis(alpha-hydroxyethyl)prophine-6,7-dipropionic acid; 2,18-Porphinedipropionic acid, 7,12-bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-; 21H,23H-Porphine-2,18-dipropanoic acid, 7,12-bis(1-hydroxyethyl); 7,12-Bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoic acid; HEMATOPORPHYRIN; HP; HP (VAN); Haematoporphyrin; Hematoporphyrin I; Hematoporphyrin IX; ISOHEMATOPORPHYRIN IX; NSC 267084; NSC 59265; NSC59265; Photodyn"	11103	C34H38N4O6	Investigative
M6APDG01347	Valinomycin	Antibiotic N-329 B; Cyclic(D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl); Potassium ionophore I; UNII-N561YS75MN; Valinomicin; cyclo[-D-O-Val-D-Val-L-O-Ala-L-Val]3; valino; valinomycin	3000706	C54H90N6O18	Investigative
M6APDG01492	Ritonavir	"1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 538, ABT; A-84538; ABBOTT-84538; ABT 538; ABT 84538; ABT-538; ABT538; Abbott 84538; DRG-0244; N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; Norvir; Norvir (TM); Norvir (TN); Norvir Sec; RIT; RTV; Ritonavir (JAN/USAN/INN); Ritonavir [USAN]"	392622	C37H48N6O5S2	Approved
M6APDG02392	Sumatriptan	(3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide; GR 43175; GR 43175X; GR-43175; Imigran; Imigran (TN); Imitrex; Imitrex (TN); KS-1116; NP101; Sumatran; Sumatriptan (JAN/USP/INN); Sumatriptanum; Sumatriptanum [INN-Latin]; Sumax	5358	C14H21N3O2S	Approved
M6APDG00628	Acyclovir	"2-Amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one; 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; 2-Amino-9-(2-hydroxy-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one; 2-amino-9-{[(2-hydroxyethyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; 6H-Purin-6-one,2-amino-1,9-dihydro-9-((2-hydroxyethoxy)mehtyl); 9-((2-Hydroxyethoxy)methyl)guanine; 9-(2-Hydroxyethoxy)methylguanine; 9-HYROXYETHOXYMETHYLGUANINE; 9-[(2-Hydroxyethoxy)-methyl]guanine; 9-[(2-Hydroxyethoxy)methyl]guanine; A 4669; ACV; ACV & Pluronic F-68; Aciclovier; Aciclovir (JAN/INN); Aciclovir, Acycloguanosine, Zovirax, Acyclovir; Aciclovirum; Aciclovirum [INN-Latin]; Aciclovirum [Latin]; Acivir (TN); Acivirax (TN); Activir; AcycloFoam; Acycloguanosine; Acyclovir; Acyclovir & Pluronic F-68; Acyclovir (USP); Acyclovir Lauriad; Acyclovir [USAN]; Acyclovir-side chain-2-3H; Alti-Acyclovir; Avirax; B-LF& ACV; BW-248-U; BW-248U; BW-248U74; Bovine lactoferrin & 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; Cyclovir (TN); DRG-0008; Genvir; Hascovir; Herpex (TN); Maynar; Vipral; Virolex; Viropump; Virorax; W-248-U; Wellcome-248U; Zovir; Zovir (TN); Zovirax; Zovirax (TN); Zovirax Oral Acyclovir (ACV) Suspension"	135398513	C8H11N5O3	Approved
M6APDG01315	Citalopram	"1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile; 1,3-dihydro[3,4]benzofuran-5-carbonitrile; 1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; AE-641/00603021; Akarin; Akarin (TN); Celapram; Celapram (TN); Celexa; Celexa (TN); Celius; Celius (TN); Ciazil; Ciazil (TN); Cilift; Cilift (TN); Cipram; Cipram (TN); Cipramil (TN); Ciprapine; Ciprapine (TN); Citabax; Citabax (TN); Citadur; Citadur (TN); Citalec; Citalec (TN); Citalopram (USP/INN); Citalopram [Celexa]; Citalopram [INN:BAN]; Citalopramum; Citalopramum [INN-Latin]; Citaxin (TN); Citol (TN); Citopam; Citopam (TN); Citox (TN); Citrol (TN); Cytalopram; Dalsan; Dalsan (TN); Humorup; Lu 10-171; Lu-10-171; Nitalapram; Oropram; Pramcit; Recital; Recital (TN); Seropram; Seropram (TN); Talam; Talam (TN); Talohexal; Temperax; Vodelax; Zentius; Zentius (TN); Zetalo; Zetalo (TN); [3H]Citalopram"	2771	C20H21FN2O	Approved
M6APDG00647	Pemetrexed	"(2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID; Alimta; Alimta (TN); LY 231,514; LY 231514; LY-231,514; LY-2315; LY-231514; LY231514; LYA; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; Pemetrexed (INN); Pemetrexed [INN:BAN]"	135410875	C20H21N5O6	Approved
M6APDG01573	Oxaliplatin	"ACT 078; Oxaloplatine; Oxaloplatino; Oxalitin; NSC 271670; Oxalato(1,2-diaminocyclohexane)platinum(II); Platinum (II), (cyclohexane-1,2-diammine)oxalato-; CCRIS 9143; Platinum, (1,2-cyclohexanediamine-N,N')(ethanedioato(2-)-O,O')-, (SP-4-2-(trans))-; Platinum, (1,2-cyclohexanediamine-kappaN,kappaN')(ethanedioato(2-)-kappaO1,kappaO2)-, (SP-4-2-(trans))-; Oxaliplatin [USAN:USP:INN:BAN]; CS-0992; HY-17371; NCI60_002138"	43805	C8H12N2O4Pt	Approved
M6APDG01131	Arsenite	13768-07-5; AC1L2NJ5; Arsenenous acid; Arsenite (ion)	24577	AsHO2	Investigative
M6APDG02866	Ambrisentan	"(+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid; Ambrisentan [INN]; BSF 208075; BSF-208075; BSF208075; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe; Gilead brand of ambrisentan; LU 208075; LU-208075; LU208075; Letairis"	6918493	C22H22N2O4	Approved
M6APDG01589	Saquinavir	"(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide; (2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide; CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE; Fortovase; Fortovase (TN); Fortovase(TM); Invirase; Invirase (TN); Invirase(TM)(monomesylate); QNC-ASN-HPH-DIQ-NTB; ROC; Ro 31-8959; Ro 318959; Ro-31-8959; SQV; Saguinavir; Saquinavir (JAN/USP/INN)"	441243	C38H50N6O5	Approved
M6APDG00612	Vinblastine	"(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid; NDC 0002-1452-01; Nincaluicolflastine; Rozevin; VLB; VR-8; Vinblastin; Vinblastina; Vinblastina (TN); Vinblastina [DCIT]; Vinblastine (INN); Vinblastine [INN:BAN]; Vinblastinum; Vinblastinum [INN-Latin]; Vincaleucoblastin; Vincaleucoblastine; Vincaleukoblastine; Vincoblastine"	13342	C46H58N4O9	Approved
M6APDG02403	Indinavir	"(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; (2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide; Crixivan; Crixivan (TM); Crixivan (TN); IDV; Indinavir (*1:1 Sulfate salt*); Indinavir [USAN]; Indinavir, Sulfate (1:1); L 735524; L-735 524; L-735,524; L-735524; MK-639; N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide; Propolis+Indinavir; RS-253"	5362440	C36H47N5O4	Approved
M6APDG01587	Cisplatin	(SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Abiplatin; Biocisplatinum; Briplatin; Cis-DDP; Cis-Diamminedichloroplatinum; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Cismaplat; Cisplatin (Chemotherapy); Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Peyrone's chloride; Peyrone's salt; Plastin; Platamine; Platidiam; Platinoxan; Randa; Trans-diamminedichloridoplatinum(II)	441203	Cl2H6N2Pt+2	Approved
M6APDG03081	Lopinavir	"A 157378; A 157378.0; A-157378-0; A-157378.0; ABT 157378; ABT 378; ABT-378; ABT-378, LOPINAVIR; AIDS032937; Aluvia (TN); Aluviran; Kaletra (TN); Koletra; LPV; Lopinavir (JAN/USAN/INN); Lopinavir [USAN:INN:BAN]; RS-346"	92727	C37H48N4O5	Approved
M6APDG02317	Silodosin	"(R)-1-(3-hydroxypropyl)-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carboxamide; 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide; 160970-64-9; CHEMBL24778; CUZ39LUY82; KAD 3213; KAD-3213; KMD 3213; KMD-3213; Q-102517; Rapaflo; Rapflo; Silodosin-d6; Silodyx; UNII-CUZ39LUY82; Urief; Urorec"	5312125	C25H32F3N3O4	Approved
M6APDG01927	Nicardipine	"2-(Benzylmethylamino)ethylmethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Cardene (TN); Cardene IV; Methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Nicardipine (INN); Nicardipine LA; Nicardipine [INN:BAN]; Nicardipino; Nicardipino [INN-Spanish]; Nicardipinum; Nicardipinum [INN-Latin]; Y-93"	4474	C26H29N3O6	Approved
M6APDG01162	Canagliflozin	"(1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; 6S49DGR869; 842133-18-0; 928672-86-0; CHEBI:73274; Canagliflozin anhydrous; Canagliflozin hydrate; Invokana; JNJ 24831754ZAE; JNJ-28431754; TA 7284; TA-7284; UNII-6S49DGR869; canagliflozin hemihydrate"	24812758	C24H25FO5S	Approved
M6APDG00513	Empagliflozin	"(1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; 864070-44-0; AK160980; BI 10773; BI-10773; BI10773; CHEBI:82720; Empagliflozin (BI 10773); HDC1R2M35U; JARDIANCE; UNII-HDC1R2M35U"	11949646	C23H27ClO7	Approved
M6APDG01542	Mitoxantrone	"1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI); AN-584/42007670; DHAD; DHAQ; DHAQ (*Diacetate salt*); DHAQ HCl; Dihydroxyanthraquinone; Liposome Encapsulated Mitoxantrone (LEM); MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MIX; Misostol; Misostol (TN); Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantrone 2HCl; Mitoxantrone [INN]; Mitoxantronum; Mitoxantronum [INN-Latin]; Mitozantrone; Mitozantrone hydrochloride; Novantrone (TN); Novantrone(R) (mitoxantrone for injection concentrate)"	4212	C22H28N4O6	Approved
M6APDG03146	Lenvatinib	"4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide; E-7080, E7080; E7080"	9823820	C21H19ClN4O4	Approved
M6APDG01252	Verapamil	"(+-)-Verapamil; (+/-)-VERAPAMIL; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; Alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Arpamyl; Bosoptin (TN); CP-16533-1; Calan; Calan (TN); Calcan; Cordilox; Covera-HS (TN); D-365; Dexverapamil; Dilacoran; Drosteakard; Iproveratril; Isoptimo; Isoptin; Isoptin (TN); Isotopin; Vasolan; Veracim; Verapamil (Na-Ca chanel blocker); Verapamil (USAN/INN); Verapamil [USAN:BAN:INN]; Verapamil [USAN:INN:BAN]; Verapamilo; Verapamilo [INN-Spanish]; Verapamilum; Verapamilum [INN-Latin]; Veraptin; Verelan (TN); Verexamil"	2520	C27H38N2O4	Approved
M6APDG01362	Nizatidine	"(E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; Acinon; Acinon (TN); Antizid; Axid; Axid (TN); Axid Ar; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; LY 139037; LY-139037; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; Naxidine; Niatidine; Nizatidina; Nizatidina [Spanish]; Nizatidine (JAN/USP/INN); Nizatidine [USAN:BAN:INN:JAN]; Nizatidinum; Nizatidinum [Latin]; Nizax; Nizaxid; Panaxid; Splendil ER; Tazac; Tazac (TN); Ulcosol; Ulxid; ZE-101; ZL-101; Zanizal; Zinga"	3033637	C12H21N5O2S2	Approved
M6APDG01583	Dehydroascorbic acid	dehydroascorbate	440667	C6H6O6	Investigative
M6APDG00906	Biotin	Biodermatin; Bioepiderm; Bios II; Biotin Forte; Factor S; Lutavit H2; Meribin; Rovimix H2	171548	C10H16N2O3S	Phase 4
M6APDG00226	L-carnitine	"(-)-(R)-3-Hydroxy-4-(trimethylammonio)butyrate; (-)-Carnitine; (-)-L-Carnitin; (-)-L-Carnitine; (3-Carboxy-2-hydroxypropyl)trimethyl-ammonium hydroxide, inner salt; (3R)-3-hydroxy-4-(trimethylammonio)butanoate; (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate; (L-3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; (R)-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide; (R)-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; (R)-3-Hydroxy-4-(trimethylammonio)butyrate; (R)-3-Hydroxy-4-trimethylammoniobutyrate; (R)-Carnitine; 1-CARNITINE; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (2R)-(9CI); 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt; 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, innersalt; 3-carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium; Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, L-(8CI); Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide,inner salt; Bicarnesine; C-1985; Carnicor; Carniking; Carniking 50; Carnilean; Carnitene; Carnitine; Carnitine (L-form); Carnitolo; Carnitor; Carnitor (TN); Carnovis; Carrier; DRG-0211; Gamma-Trimethyl-ammonium-beta-hydroxybutirate; Gamma-Trimethyl-beta-hydroxybutyrobetaine; Karnitin; L-(-)-Carnitine; L-Carnitine inner salt; L-carnitine Base; L-gamma-trimethyl-beta-hydroxybutyrobetaine; Lefcar; Levocarnitina; Levocarnitina [Spanish]; Levocarnitine; Levocarnitine (JAN/USP/INN); Levocarnitine [USAN:INN]; Levocarnitinum; Levocarnitinum [Latin]; Metina; R-(-)-3-hydroxy-4-trimethylaminobutyrate; ST 198; Vitamin B T; Vitamin BT"	10917	C7H15NO3	Approved
M6APDG02352	Bosutinib	"4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propo; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (BCR-ABL inhibitor 3rd gen); Bosutinib (USAN); PF-5208763; SKI 606; SKI-606; SKI606; Xy]-3-quinolinecarbonitrile"	5328940	C26H29Cl2N5O3	Approved
M6APDG00761	Docetaxel	"(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; ANX-514; Docetaxel (INN); Docetaxel 114977-28-5; Docetaxel anhydrous; Docetaxel, Trihydrate; EmDOC; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; N-debenzoyl-N-Boc-10-deacetyl taxol; RP-56976; SDP-014; TXL; Taxotere; Taxotere (TN); Taxotere(R); XRP-6976L"	148124	C43H53NO14	Approved
M6APDG02701	Oseltamivir	"(-)-oseltamivir; (3R,4R,5S)-4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid; (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acid; 4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid; Agucort; Agucort (TN); Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate; Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate; Ethyl (5S,3R,4R)-4-(acetylamino)-5-amino-3-(ethylpropoxy)cyclohex-1-enecarboxylate; GS 4104; GS-4104; GS4104; OTV; Oseltamivir (INN); Oseltamivir [INN:BAN]; Oseltamivirum; Ro-64-0796; Ro-640796; Tamiflu (*Phosphate salt 1:1*); Tamiflu (TN); Tamiflu-Free; Tamvir"	65028	C16H28N2O4	Approved
M6APDG02659	Cannabidiol	"(-)-CBD; (-)-Cannabidiol; (-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol; (-)-trans-Cannabidiol; 19GBJ60SN5; CBD; Epidiolex; GWP42003-P; QHMBSVQNZZTUGM-ZWKOTPCHSA-N; UNII-19GBJ60SN5; delta1(2)-trans-Cannabidiol"	644019	C21H30O2	Approved
M6APDG02508	Ranolazine	"(-)-Ranolazine; CVT-303; KEG-1295; Latixa; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; RAN D; RS-43285; RS-43285-003; Ran4; Ranexa; Ranexa (TN); Ranexa, Ranolazine; Ranolazine (USAN/INN); Ranolazine 2HCl; Ranolazine dihydrochloride"	56959	C24H33N3O4	Approved
M6APDG02588	Clopidogrel	"Clopidogrel (captisol-enabled); Clopidogrel (captisol-enabled), The Medicines Co; Clopidogrel (captisol-enabled, cardiovascular disease), Cydex; Clopidogrel (captisol-enabled, cardiovascular disease), Prism Pharmaceuticals; PM-103"	60606	C16H16ClNO2S	Approved
M6APDG02625	L-threonine	Threonine	6288	C4H9NO3	Preclinical
M6APDG02974	Glycine	"(1-13c)glycinato; (15N)Glycine; 2,2-dialkylglycines; 2-Aminoacetic acid; AB-131/40217813; AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER; Acide aminoacetique; Acide aminoacetique [INN-French]; Acido aminoacetico; Acido aminoacetico [INN-Spanish]; Acidum aminoaceticum; Acidum aminoaceticum [INN-Latin]; Aciport; Aminoacetic acid; Aminoazijnzuur; Aminoessigsaeure; Aminoethanoic acid; Amitone; An alpha amino acid ester; Corilin; GLY (IUPAC abbrev); GLYCINE 1.5% IN PLASTIC CONTAINER; GLYCINE, ACS; Glicina; Glicina [INN-Spanish]; Glicoamin; Gly; Glycin; Glycine (JP15/USP); Glycine [INN]; Glycine iron sulphate (1:1); Glycine, homopolymer (VAN); Glycine, labeled with carbon-14; Glycine, non-medical; Glycine-UL-14C hydrochloride; Glycinum; Glycinum [INN-Latin]; Glycocoll; Glycolixir; Glycosthene; Glykokoll; Glyzin; Gyn-hydralin; H-Gly-OH; H2N-CH2-COOH; Hampshire glycine; Hgly; L-Glycine; L-alpha-amino acids; Leimzucker; Padil; Polyglycine; Polyglycine II; S04-0135; Sucre de gelatine"	750	C2H5NO2	Approved
M6APDG01015	Dabigatran	Pradaxa (TN)	216210	C25H25N7O3	Approved
M6APDG01588	Digitoxin	"5.beta.-Card-20(22)-enolide, 3.beta.,14-dihydroxy-, 3-[tris-(digitoxoside)]; Acedoxin; Asthenthilo; Cardidigin; Cardigin; Cardiolanata; Carditalin; Carditoxin; Coramedan; Cristapurat; Crystalline digitalin; Crystodigin; Crystodigin (TN); De-Tone; Digicor; Digilanid; Digilong; Digimed; Digimerck; Digipural; Digisidin; Digitalin, crystalline; Digitaline (TN); Digitaline cristallisee; Digitaline nativelle; Digitalinum verum; Digitoksim; Digitoksin; Digitophyllin; Digitossina; Digitossina [DCIT]; Digitoxigenin tridigitoxoside; Digitoxigenin-tridigitoxosid; Digitoxigenin-tridigitoxosid [German]; Digitoxin (JP15/USP/INN); Digitoxin [INN:BAN:JAN]; Digitoxina; Digitoxina [INN-Spanish]; Digitoxine; Digitoxine [INN-French]; Digitoxinum; Digitoxinum [INN-Latin]; Digitoxoside; Digitoxosidum; Digitrin; Ditaven; Glucodigin; Inhibits Na+/K+ ATPase; LT00244784; Lanatoxin; Lanostabil; Mono-digitoxid; Mono-digitoxid [German]; Mono-glycocard; Monodigitoxoside; Myodigin; Natigal; Pandigal; Panlanat; Purodigin; Purodigin, crystalline; Purpurid; Tardigal; Tri-digitoxoside; Tri-digitoxoside [German]; Unidigin"	441207	C41H64O13	Approved
M6APDG02287	Flavopiridol	"(-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one; Alvocidib [INN]; FLAVO; Flavopiridol; Flavopiridol hydrochloride; HMR-1275; HMR-1275, Alvocidib, L868275, Flavopiridol; L 868275; L-868275; L86-8275"	5287969	C21H20ClNO5	Phase 2
M6APDG02391	Romidepsin	"(1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; Antibiotic FR 901228; Chromadax; Chromadax (TN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; FK 228; FK-228; FK-901228; FK228; FR 901228; FR-901228; FR901228; HDInhib_000006; Istodax; Istodax (TN); L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; Romidepsin (USAN)"	5352062	C24H36N4O6S2	Approved
M6APDG02535	Hydrocortisone	"11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; 11beta,17,21-Trihydroxyprogesterone; 11beta-Hydrocortisone; 11beta-Hydroxycortisone; 17-Hydroxycorticosterone; 17alpha-Hydroxycorticosterone; ACETASOL HC; ACETIC ACID W/ HYDROCORTISONE; Acticort; Acticort (TN); Aeroseb HC; Aeroseb-HC; Ala-Cort; Ala-Scalp; Alacort; Algicirtis; Alphaderm; Amberin; Anflam; Anti-inflammatory hormone; Anucort; Anucort-HC; Anusol HC (TN); AnusolHC; Aquacort; Aquanil HC; Balneol-hc; Barseb HC; Basan-Corti; Beta-hc; COR-OTICIN; CaldeCORT Spray; Cetacort; Chronocort; Clear aid; Cleiton; Cobadex; Colocort; Colocort (TN); Component of Lubricort; Component of Neo-Cort-Dome; Component of Otalgine; Corhydron; Cort-Dome; Cortanal; Cortef; Cortef (TN); Cortenema; Cortesal; Corticreme; Cortifair; Cortifan; Cortiment; Cortisol; Cortisol alcohol; Cortisol, Hydrocortisone; Cortisolonum; Cortisporin; Cortisporin Otico; Cortispray; Cortolotion; Cortonema; Cortoxide; Cortril; Cremesone; Cremicort-H; Cutisol; Cyclodextrin-encapsulated hydrocortisone; Delacort; Derm-Aid; Dermacort; Dermaspray; Dermil; Dermocortal; Dermolate; Dihydrocostisone; Dioderm; Dome-cort; Domolene-HC; Drotic; DuoCort; Ef corlin; Efcorbin; Efcortelan; Efcortelin; Eldecort; Eldercort; Epicort; Epicortisol; Epiderm H; Esiderm H; Evacort; Ficortril; Fiocortril; Flexicort; Foille Insetti; Genacort; Genacort (lotion); Glycort; Gyno-Cortisone; H 4001; H-Cort; HC #1; HC #4; HC (HYDROCORTISONE); HYDROCORTISONE AND ACETIC ACID; HYDROCORTISONE IN ABSORBASE; Heb Cort; Heb-Cort; Hi-cor; Hidalone; Hidro-Colisona; Hidrocortisona [INN-Spanish]; Hycort; Hycortol; Hycortole; Hydracort; Hydrasson; Hydro-Adreson; Hydro-Colisona; Hydro-RX; Hydrocortal; Hydrocorticosterone; Hydrocortisone (JP15/USP/INN); Hydrocortisone [INN:BAN:JAN]; Hydrocortisone alcohol; Hydrocortisone base; Hydrocortisone free alcohol; Hydrocortisone solution; Hydrocortisone-Water Soluble; Hydrocortisonum [INN-Latin]; Hydrocortisyl; Hydrocortone; Hydroskin; Hydroxycortisone; Hytisone; Hytone; Hytone (TN); Hytone lotion; Idrocortisone; Idrocortisone [DCIT]; Incortin-H; Incortin-hydrogen; Kendall's compound F; Komed HC; Kyypakkaus; Lacticare HC; Lacticare-HC; Lactisona; Lubricort; Maintasone; Medicort; Meusicort; Mildison; Milliderm; Neo-Cortef; Neosporin-H Ear; Nogenic HC; Nutracort; Nystaform-HC; ORLEX HC; Optef; Otocort; Otosone-F; Pediotic Suspension; Penecort; Permicort; Polcort H; Preparation H Hydrocortisone Cream; Prepcort; Prevex HC; Proctocort; Proctozone HC; Protocort; Rectasol-HC; Rectoid; Reichstein's substance M; Remederm HC; Sanatison; Scalp-Cort; Scalpicin Capilar; Schericur; Scheroson F; Sigmacort; Signef; Stie-cort; Stiefcorcil; Synacort; Systral Hydrocort; Tarcortin; Texacort; Texacort lotion 25; Timocort; Transderma H; Traumaide; Uniderm; VoSol HC; Vytone; Zenoxone; [3H]cortisol"	5754	C21H30O5	Approved
M6APDG02527	Ceritinib	"1032900-25-6; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; AK174337; C28H36ClN5O3S; CHEBI:78432; CHEMBL2403108; Eritinib (LDK378); K418KG2GET; LDK 378; LDK-378; LDK378; LDK378(Ceritinib); NVP-LDK378-NX; UNII-K418KG2GET; ZYKADIA; ceritinib"	57379345	C28H36ClN5O3S	Approved
M6APDG03216	Rivaroxaban	XARELTO (TN)	9875401	C19H18ClN3O5S	Approved
M6APDG00268	Saxagliptin	"(1S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-amino(3-hydroxytricyclo[3.3; BMS 477118-11; BMS-477118; BMS-477118-11; Kombiglyze XR (TN); OPC-262; Onglyza; Onglyza (TN)"	11243969	C18H25N3O2	Approved
M6APDG02227	Quercetin	"2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 3',4',5,7-Tetrahydroxyflavan-3-ol; 3',4',5,7-tetrahydroxyflavon-3-ol; 3,3',4',5,7-Pentahydroxyflavone; 3,3',4',5,7-Pentahydroxyflavone dihydrate; 3,3',4,5,7-Pentahydroxyflavone; 3,5,7,3',4'-Pentahydroxyflavone; 3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-on; 3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one; C.I . natural yellow 10; C.I. 75670; C.I. Natural Yellow 10; C.I. Natural red 1; C.I. Natural yellow 10 & 13; CI Natural Yellow 10; CU-01000012502-3; Cyanidelonon 1522; Flavin meletin; KSC-10-126; KSC-23-76; KUC104418N; KUC107684N; Kvercetin; Kvercetin [Czech]; LIM-5662; LNS-5662; Meletin; MixCom3_000183; Natural Yellow 10; P0042; Q 0125; QUE; Quercetin content; Quercetin dihydrate; Quercetine; Quercetol; Quercitin; Quertin; Quertine; Sophoretin; T-Gelb bzw. grun 1; TNP00070; TNP00089; Xanthaurine"	5280343	C15H10O7	Approved
M6APDG02303	Eliglustat tartrate	Fabrazyme (TN)	52918379	C50H78N4O14	Approved
M6APDG00413	Idelalisib	"(S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 1146702-54-6; 5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; AK145603; CAL 101; CAL-101; CAL-101 (Idelalisib, GS-1101); CAL101; CHEBI:82701; CHEMBL2216870; GS-1101; Idelalisib; UNII-YG57I8T5M0; YG57I8T5M0; Zydelig"	11625818	C22H18FN7O	Approved
M6APDG00094	Betrixaban	74RWP7W0J9; Betrixaban (USAN); Betrixaban [USAN:INN]; Bevyxxa; D0J0BU; EX-A358; GTPL9602; MolPort-009-682-948; PRT 054021; PRT054021; QCR-99; SCHEMBL158591; UNII-74RWP7W0J9; ZINC3; betrixaban maleate; betrixaban/	10275777	C23H22ClN5O3	Approved
M6APDG02608	Clomiphene citrate	Clomid; Clomiphene Citrate; Milophene; Serophene	60974	C32H36ClNO8	Approved
M6APDG02401	Verteporfin	Visudyne (TN)	5362420	C41H42N4O8	Approved
M6APDG02265	Estradiol-17beta-glucuronide	[3H]-estradiol-17beta-glucuronide	5281887	C24H32O8	Investigative
M6APDG02188	Riluzole	"2-Amino-6-(trifluoromethoxy)-benzothiazole; 2-Amino-6-(trifluoromethoxy)benzothiazole; 2-Amino-6-trifluoro-methoxybenzothiazole; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; 2-amino-6-(trifluoromethoxyl)benzothiazole; 2-amino-6-trifluoromethoxybenzothiazole; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 6-trifluoromethoxybenzothiazole-2-yl-amine; ALBB-006046; Amino-2 trifluoromethoxy-6 benzothiazole; Amino-2 trifluoromethoxy-6 benzothiazole [French]; BF-37; PK-26124; PK-26124, RP-54274, Rilutek, Riluzole; R-116; RP 54274; RP-54274; Rilutek; Rilutek (TN); Riluzol; Riluzol [INN-Spanish]; Riluzole (JAN/USAN/INN); Riluzole HCl; Riluzole [USAN:INN]; Riluzolum; Riluzolum [INN-Latin]; ZERO/001785"	5070	C8H5F3N2OS	Approved
M6APDG01172	Ponatinib	Iclusig (TN)	24826799	C29H27F3N6O	Approved
M6APDG01054	Aspirin	2-Acetoxybenzoic acid; 50-78-2; ACETYLSALICYLIC ACID; Acenterine; Aceticyl; Acetonyl; Acetophen; Acetosal; Acetosalin; Acetylin; Acetylsalicylate; Acidum acetylsalicylicum; Acylpyrin; Aspergum; Aspirdrops; Benaspir; Colfarit; Easprin; Ecolen; Ecotrin; Empirin; Endydol; Enterosarein; Globentyl; Micristin; O-Acetylsalicylic acid; Pharmacin; Polopiryna; Pravigard; Premaspin; Rheumintabletten; Rhodine; Salcetogen; Saletin; Salicylic acid acetate; Solprin acid; Temperal; o-Acetoxybenzoic acid; o-Carboxyphenyl acetate	2244	C9H8O4	Approved
M6APDG00635	Rifampicin	"1-b]furan-21-yl acetate; 3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; 8CI); AZT + Rifampin; Abrifam; Archidyn; Arficin; Arzide; BA-41166E; Ba 41166; Ba 41166/E; Benemicin; Benemycin; DRG-0109; Dione 21-acetate; Dipicin; Doloresum; Eremfat; Famcin; Fenampicin; L-5103; L-5103 Lepetit; Piperine & Rifampicin; R-Cin; R/AMP; RFP; RMP; Ramp; Reserpine & Rifampicin; Rifa; Rifadin; Rifadin (TN); Rifadin I.V; Rifadin I.V.; Rifadin, Rimactane, Rifampicin, Rifampin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifam; Rifamicin AMP; Rifamor; Rifampicin; Rifampicin & EEP; Rifampicin & Propolis; Rifampicin (JP15/INN); Rifampicin SV; Rifampicin[INN:BAN:JAN]; Rifampicina; Rifampicina [INN-Spanish]; Rifampicine; Rifampicine [French]; Rifampicinum; Rifampicinum [INN-Latin]; Rifampin (USP); Rifampin [USAN]; Rifamsolin; Rifamycin AMP; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactan (TN); Rimactane; Rimactane (TN); Rimactazid; Rimactizid; Rimazid; Rimycin; Rimycin (TN); Sinerdol; Sinerdol (TN); Tubocin; Tubocin (TN)"	135398735	C43H58N4O12	Approved
M6APDG01984	Rhodamine 123	"RH 123; Rh-123, Huntington; Rhodamine 123; Rhodamine-123 (intravenous infusion); Rhodamine-123 (intravenous infusion), Huntington Medical Research Institutes"	4541001	C21H17N2O3+	Discontinued in Phase 1
M6APDG01409	Amoxicillin	"(-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D-(8CI); 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid; AMK (TN); AMOXICILLIN CRYSTALLINE; AMOXICILLIN PEDIATRIC; AMPC; Actimoxi; Actimoxi (TN); Alpha-Amino-p-hydroxybenzylpenicillin; Alphamox (TN); Amoclen; Amoksibos (TN); Amoksiklav (TN); Amolin; Amopen; Amopenixin; Amoxi; Amoxi-Mast; Amoxibiotic; Amoxibiotic (TN); Amoxicaps; Amoxicilina; Amoxicilina (TN); Amoxicilina [INN-Spanish]; Amoxicillanyl; Amoxicillin (INN); Amoxicillin (TN); Amoxicillin (anhydrous); Amoxicillin anhydrous; Amoxicilline; Amoxicilline [INN-French]; Amoxicilline [INN]; Amoxicillinum; Amoxicillinum [INN-Latin]; Amoxiclav (TN); Amoxidal (TN); Amoxiden; Amoxil; Amoxil (TN); Amoxin (TN); Amoxivet; Amoxycillin; Amoxycillin Trihydrate; Anemolin; Apo-Amoxi; Apo-Amoxi (TN); Aspenil; Augmentin (TN); BL-P 1410; BLP 1410; BRL-2333; Bactox (TN); Betalaktam (TN); Biomox; Bristamox; Cemoxin; Cilamox (TN); Clamoxyl; Clamoxyl (TN); Curam (TN); D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; D-Amoxicillin; Dedoxil (TN); Delacillin; DisperMox; Dispermox (TN); Duomox (TN); Efpenix; Enhancin (TN); Flemoxin; Geramox (TN); Gimalxina (TN); Hiconcil; Hiconcil (TN); Histocillin; Hydroxyampicillin; Ibiamox; Imacillin; Isimoxin (TN); Klavox (TN); Lamoxy; Lamoxy (TN); Larotid; Metafarma capsules; Metifarma capsules; Moxacin; Moxal; Moxatag; Moxatag (TN); Moxilen (TN); Moxypen (TN); Moxyvit (TN); Nobactam (TN); Novamoxin (TN); Ospamox; Ospamox (TN); P-Hydroxyampicillin; Pamoxicillin; Pamoxicillin (TN); Panamox (TN); Panklav (TN); Piramox; Polymox; Polymox (TN); Ro 10-8756; Robamox; Samthongcillin (TN); Sandoz (TN); Sawamox PM; Senox (TN); Sinacilin (TN); Sumox; Tolodina; Tolodina (TN); Trimox; Trimox (TN); Unicillin; Utimox; Vetramox; Wymox; Wymox (TN); Yucla (TN); Zerrsox (TN); Zimox (TN)"	33613	C16H19N3O5S	Approved
M6APDG01369	Prucalopride	"0A09IUW5TP; 179474-81-8; 4-Amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidyl)-7-benzofurancarboxamide; 4-Amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide; 4-Amino-5-chloro-N-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide; 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide; C18H26ClN3O3; CHEMBL117287; Motegrity; Prucalopride [USAN:INN:BAN]; R 093877; R-093877; R0-93877; R093877; UNII-0A09IUW5TP"	3052762	C18H26ClN3O3	Approved
M6APDG00114	Relugolix	Relumina; TAK-385	10348973	C29H27F2N7O5S	Phase 3
M6APDG00361	Pazopanib hydrochloride	"5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; 790713-33-6; 7RN5DR86CK; DSSTox_CID_28659; DSSTox_GSID_48733; DSSTox_RID_82929; GW 78603; GW 786034; GW-786034; GW786034; MFCD11616589; NCGC00188865-01; Pazopanib; Pazopanib (GW-786034); UNII-7RN5DR86CK; Votrient (TN)"	11525740	C21H24ClN7O2S	Approved
M6APDG00969	Tacrine	"1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine; BBL001044; CS 12602; Cognex; Cognex (TN); Romotal; Tacrina; Tacrina [INN-Spanish]; Tacrinal; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrine hydrochloride; Tacrinum; Tacrinum [INN-Latin]; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha"	1935	C13H14N2	Approved
M6APDG02876	Panobinostat	"(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide; Faridak; LBH 589; LBH-589; LBH-589B; LBH589; NVP-LBH-589; NVP-LBH589; Panobinostat, NVP-LBH589, LBH589"	6918837	C21H23N3O2	Approved
M6APDG02281	Levetiracetam	"(-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; Etiracetam levo-isomer; Etiracetam, S-isomer; Keppra; Keppra (TN); Keppra XR; Keppra, Keppra XR),Levetiracetam; L-059; Levetiracetam [INN]; Levetiracetamum [INN-Latin]; Levetiractam; Leviteracetam; SIB-S1; Torleva; UCB-22059; UCB-L 059; UCB-L059; Ucb L060"	5284583	C8H14N2O2	Approved
M6APDG01295	Cetirizine	(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(4-Chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-ethoxy)-acetic acid; (2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid; Cetiderm; Cetiderm (TN); Cetirizin; Cetirizina; Cetirizina [Spanish]; Cetirizine (INN); Cetirizine [INN:BAN]; Cetirizinum; Cetirizinum [Latin]; Cetrizine Hcl; Cetryn; Hitrizin Film Tablet; P-071; Reactine (TN); Setir; Virlix; Ziptek; Zirtek; Zyrlex; Zyrtec (TN); [(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid	2678	C21H25ClN2O3	Approved
M6APDG02047	Tenofovir	"(R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-(2-Phosphonylmethoxypropyl)adenine; (R)-PMPA; Apropovir; D,L-Tenofovir; GNA & Tenofovir; GS 1275; GS 1278; GS1278; HHA & Tenofovir; KS-5021; PMPA; PMPA-(R); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Galanthus nivalis agglutinin (GNA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Hippeastrum hybrid agglutinin(HHA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-(9CI); Phosphonic acid, [[2-(6-amino-9H-purin-9; TDF; TFV; Tenefovir; Viread (TN); Viread, Tenofovir; [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid"	464205	C9H14N5O4P	Approved
M6APDG00466	Uric acid	urate	1175	C5H4N4O3	Phase 2/3
M6APDG01496	Loperamide	"2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide; 4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide; 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide; Apo-Loperamide; Diamide (TN); Diarr-Eze; Dimor (TN); Imodium (TN); Imodium A-D Caplets; Ioperamide; Kaopectate II; Loperacap; Loperamida; Loperamida [INN-Spanish]; Loperamide (INN); Loperamide Monohydrochloride; Loperamide [INN:BAN]; Loperamidum; Loperamidum [INN-Latin]; Lopex (TN); Maalox Anti-Diarrheal; Nu-Loperamide; PMS-Loperamide; Pepto (TN); Pepto Diarrhea Control; R-18553; Rho-Loperamide"	3955	C29H33ClN2O2	Approved
M6APDG01537	Epirubicin	"(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-Epi-DXR; 4'-Epiadriamycin; 4'-epi-DX; 4'-epi-Doxorubicin; 4'-epidoxorubicin; 4-Epidoxorubicin; Ebewe (TN); Ellence; Ellence (TN); Epi-DX; Epiadriamycin; Epidoxorubicin; Epirubicin (INN); Epirubicin (TN); Epirubicin [INN:BAN]; Epirubicina; Epirubicina [INN-Spanish]; Epirubicina [Spanish]; Epirubicine; Epirubicine [French]; Epirubicine [INN-French]; Epirubicinum; Epirubicinum [INN-Latin]; Epirubicinum [Latin]; Farmorubicin (TN); IMI 28; Pharmorubicin (TN); Pharmorubicin Pfs; Pidorubicin; Pidorubicina; Pidorubicina [INN-Spanish]; Pidorubicine; Pidorubicine [INN-French]; Pidorubicinum; Pidorubicinum [INN-Latin]; Ridorubicin; WP 697"	41867	C27H29NO11	Approved
M6APDG00096	Edoxaban	Edoxaban	10280735	C24H30ClN7O4S	Approved
M6APDG02543	D-glucose	"(3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; 2280-44-6; CPC hydrate; Cartose Cerelose; Clearsweet 95; Clintose L; D-Glc; D-Glcp; D-Glucopyranose; D-Glucopyranose, anhydrous; D-Glucopyranoside; D-glucose-ring; DSSTox_CID_2910; EINECS 218-914-5; Glc; Glc-OH; Glucodin; Glucopyranose; Glucopyranose, D-; Glucopyranoside; Glucose 40; Glucose solution; Meritose; Meritose 200; Roferose ST; Staleydex 130; Staleydex 95M; glc-ring"	5793	C6H12O6	Approved
M6APDG01835	Dabrafenib	"1195765-45-7; CHEBI:75045; Dabrafenib (GSK2118436); Dabrafenib [USAN:INN]; GSK 2118436; GSK-2118436A; GSK2118436; GSK2118436A; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; QGP4HA4G1B; Tafinlar; UNII-QGP4HA4G1B"	44462760	C23H20F3N5O2S2	Approved
M6APDG01349	Ranitidine	"(E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; Noctone; Nu-Ranit; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Rani-Q; Rani-nerton; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidine (USAN/INN); Ranitidine HCL; Ranitidine [USAN:BAN:INN]; Ranitidinum; Ranitidinum [INN-Latin]; Ranitiget; Ranitin; Rantacid; Rantidine; Rantidine HCL; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ul-Pep; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantac (TN); Zantadin; Zantic"	3001055	C13H22N4O3S	Approved
M6APDG00165	SN-38	"(+)-7-ETHYL-10-HYDROXYCAMPTOTHECIN; (S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 0H43101T0J; 10-Hydroxy-7-ethylcamptothecin; 113015-38-6; 7-Ethyl-10-hydroxy camptothecin; 7-Ethyl-10-hydroxy-20(S)-camptothecin; 7-Ethyl-10-hydroxy-camptothecin; 7-Ethyl-10-hydroxycamptothecin; 7-Ethyl-10-hydroxycamptothecine; 86639-52-3; Captothecin, 7-ethyl-10-hydroxy-; LE-SN38; NSC673596; SN 38; SN 38 lactone; SN38; UNII-0H43101T0J"	104842	C22H20N2O5	Phase 2
M6APDG00359	Paliperidone	"Invega Sustenna; JNS-010; Paliperidone (depot injection, NanoCrystal); Paliperidone (depot injection, NanoCrystal), Johnson & Johnson; Paliperidone (injectable, NanoCrystal), Elan; Paliperidone palmitate; Xeplion"	115237	C23H27FN4O3	Approved
M6APDG00621	Pomalidomide	Actimid (TN); Pomalidomide (Immunomodulator)	134780	C13H11N3O4	Approved
M6APDG01303	Digoxin	"(3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 12beta-Hydroxydigitoxin; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}; Digitek (TN); Digoxin (JP15/USP); Lanoxicaps (TN); Lanoxin (TN)"	2724385	C41H64O14	Approved
M6APDG02631	Ivermectin	"IVERMECTIN; Ivermectin B1a; Dihydroavermectin B1a; 22,23-Dihydroavermectin B1a; 71827-03-7; avermectin H2B1a; UNII-91Y2202OUW"	6321424	C48H74O14	Approved
M6APDG01293	Deflazacort	Deflan (TN)	26709	C25H31NO6	Approved
M6APDG02796	Mercaptopurine	"1,7-Dihydro-6H-purine-6-thione; 1,9-dihydro-6H-purine-6-thione; 3,7-dihydropurine-6-thione; 3H-Purine-6-thiol; 6 MP; 6 Mercaptopurine; 6 Mercaptopurine Monohydrate; 6 Thiohypoxanthine; 6 Thiopurine; 6-MERCAPTOPURINE MONOHYDRATE; 6-MP; 6-Mercaptopurin; 6-Mercaptopurine; 6-Merkaptopurin; 6-Merkaptopurin [Czech]; 6-Purinethiol; 6-Thiohypoxanthine; 6-Thiopurine; 6-Thioxopurine; 7-Mercapto-1,3,4,6-tetrazaindene; 7H-purine-6-thiol; 9H-Purin-6-yl hydrosulfide; 9H-Purine-6(1H)-thione; AG-670/31547064; BW 57 323H; Glaxo Wellcome Brand of 6 Mercaptopurine; Glaxo Wellcome Brand of 6-Mercaptopurine; GlaxoSmithKline Brand of 6 Mercaptopurine; GlaxoSmithKline Brand of 6-Mercaptopurine; Ismipur; Leukerin; Leukerin, 99%-Carc; Leupu rin; Leupurin; M0063; Mercaleukim; Mercaleukin; Mercaptopurin; Mercaptopurin [German]; Mercaptopurina; Mercaptopurina Wellcome; Mercaptopurina [INN-Spanish]; Mercaptopurine (INN); Mercaptopurine (Purine analog); Mercaptopurine (VAN); Mercaptopurine (anhydrous); Mercaptopurine anhydrous; Mercaptopurinum; Mercaptopurinum [INN-Latin]; Mercapurin; Merkaptopuryna; Merkaptopuryna [Polish]; Mern; NCIMech_000025; PM6; Puri Nethol; Puri-Nethol; Purimethol; Purine-6(1H)-thione; Purine-6-thiol; Purineantimetabolite: inhibits nucleic acid replication; Purinethiol; Purinethol; Purinethol (TN); Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; Thiopurine; U-4748; Wellcome Brand of 6 Mercaptopurine; Wellcome Brand of 6-Mercaptopurine"	667490	C5H4N4S	Approved
M6APDG01239	Daclatasvir	1009119-64-5; 1214735-16-6; C40H50N8O6; CHEBI:82977; CHEMBL2023898; Daclatasvir (BMS-790052); Daclatasvir (USAN); Daclatasvir BMS 790052; EX-A410; KS-00000XPC; MLS006011140; SCHEMBL17897804; SCHEMBL2756027; cc-39; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate	25154714	C40H50N8O6	Approved
M6APDG02567	Vincristine	"22-Oxovincaleukoblastine; Indole alkaloid; LCR; Leurocristine; Lilly37231 (1:1 sulfate salt); Liposomal Vincristine; Marqibo; Onco TCS; Oncovin (1:1 sulfate salt); Oncovin (TN); Oncovine; Tecnocris; Tecnocris (TN); VCR; VIN; Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Vincasar; Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincristina; Vincristina [DCIT]; Vincristine (INN); Vincristine [INN:BAN]; Vincristinum; Vincristinum [INN-Latin]; Vincrstine; Vincrystine; Vinkristin; Z-D-Val-Lys(Z)-OH"	5978	C46H56N4O10	Approved
M6APDG00774	Ezetimibe	"(-)-Sch 58235; (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone); (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone; Essex brand of ezetimibe; Ezedoc; Ezetimib; Ezetimibe (JAN/USAN/INN); Ezetimibe [USAN:INN]; Ezetrol; Inegy (TN); MK-0653; MSD brand of ezetimibe; Merck brand of ezetimibe; SCH-58235; SCH58235; Sch 58235; Schering-Plough brand of ezetimibe; Vytorin (TN); Zetia; Zetia (TN); Zetia , Ezetrol, Ezetimibe; Zient"	150311	C24H21F2NO3	Approved
M6APDG00659	Nintedanib	"(Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; 1160294-26-7; 656247-17-5; 928326-83-4; BIBF 1120; BIBF-1120; BIBF1120; CHEBI:85164; G6HRD2P839; Intedanib; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; Vargatef"	135423438	C31H33N5O4	Approved
M6APDG00249	Regorafenib	24T2A1DOYB; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; BAY73-4506; BAY73-4506 hydrochloride; CHEBI:68647; CHEMBL1946170; Regorafenib (BAY 73-4506); Regorafenib [USAN:INN]; Regorafenibum; Stivarga; Stivarga (TN); UNII-24T2A1DOYB	11167602	C21H15ClF4N4O3	Approved
M6APDG01114	Colchicine	"(S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; 7-alpha-H-Colchicine; 7.alpha.H-Colchicine; 7alphaH-Colchicine; Benzo(a)heptalen-9(5H)-one; Binds to tubulin; C 9754; Colchicin; Colchicin [German]; Colchicina; Colchicina [Italian]; Colchicine (JP15/USP); Colchicine (TN); Colchicine [JAN]; Colchicine, (+-)-Isomer; Colchicine, (R)-Isomer; Colchicine, Colchicum autumnale; Colchicinum; Colchineos; Colchisol; Colchysat; Colcin; Colcrys; Colsaloid; Colstat; Condylon; Goutnil; Inhibits microtubular assembly; Kolkicin; LOC; MPC-004; N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-acetamide; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide; N-Acetyl trimethylcolchicinic acid methylether; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide; N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; Spindle poison"	23890	C21H23NO6	Approved
M6APDG02568	Sucrose	"57-50-1; Amerfand; Amerfond; Beet sugar; CCRIS 2120; CHEBI:17992; Cane sugar; Confectioner's sugar; D(+)-Saccharose; D(+)-Sucrose; D-(+)-Saccharose; D-Saccharose; D-Sucrose; Granulated sugar; HSDB 500; Microse; Rock candy; Rohrzucker; Saccharose; Saccharum; Sacharose; Sucraloxum [INN-Latin]; Sucrose [USAN:JAN]; Sucrose, dust; Sucrose, pure; Table sugar; White sugar; alpha-D-Glucopyranosyl beta-D-fructofuranoside; beta-D-Fructofuranosyl alpha-D-glucopyranoside; beta-D-Fructofuranosyl-alpha-D-glucopyranoside; sacarosa; sugar"	5988	C12H22O11	Phase 4
M6APDG01485	Leflunomide	"4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide; AP-501/42475599; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; Arava; Arava (TN); Arava, Leflunomide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; HWA 486; HWA-486; Hoechst Brand of Leflunomide; L 5025; Leflunomid; Leflunomida; Leflunomida [INN-Spanish]; Leflunomide (JAN/USAN/INN); Leflunomide [USAN:INN]; Leflunomidum; Leflunomidum [INN-Latin]; Lefunamide; Lefunomide [Inn-Spanish]; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; RS-34821; SU 101; SU 101 (pharmaceutical); SU-101; SU101"	3899	C12H9F3N2O2	Approved
M6APDG02813	Methylprednisolone	Depo-medrol; M-predrol; Medrol; Medrol Acetate; Methylprednisolone Acetate	6741	C22H30O5	Approved
M6APDG02430	Tetracycline	"(-)-Tetracycline; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide; Abramycin; Abricycline; Achromycin; Achromycin (naphthacene derivative); Achromycin V; Achromycin, naphthacene derivative; Agromicina; Ambramicina; Ambramycin; Amycin; Biocycline; Bristaciclin; Bristaciclin alpha; Bristaciclina; Bristacycline; Cefracycline; Cefracycline suspension; Centet (base); Ciclibion; Component of Tetrastatin; Copharlan; Criseociclina; Cyclomycin; Cyclopar; Cytome; Democracin; Deschlorobiomycin; Dumocyclin; Enterocycline; Hostacyclin; Lemtrex (base); Lexacycline; Limecycline; Liquamycin (Veterinary); Liquamycin, veterinary; Medocycline; Mericycline; Methyl-1,11-dioxo-2-naphthacenecarboxamide; Micycline; Neocycline; Omegamycin; Orlycycline; Panmycin; Panmycin (TN); Piracaps (base); Polycycline; Polycycline (VAN); Polycycline (antibiotic); Polycycline, antibiotic; Polyotic; Purocyclina; Resteclin; Robitet; Roviciclina; SK-Tetracycline; Sanclomycine; Solvocin; Sumycin; Sumycin (TN); Sumycin syrup; T-125; Tetra-Co; Tetrabon; Tetrachel; Tetraciclina; Tetraciclina [INN-Spanish]; Tetracycl; Tetracyclin; Tetracycline & VRC3375; Tetracycline (JAN/USP/INN); Tetracycline (internal use); Tetracycline Free Base; Tetracycline I; Tetracycline II; Tetracycline Monohydrochloride; Tetracycline [USAN:INN:BAN:JAN]; Tetracyclinum; Tetracyclinum [INN-Latin]; Tetracyn; Tetracyn (TN); Tetradecin; Tetrafil; Tetraverine; Tetrazyklin; Topicycline; Tsiklomistsin; Tsiklomitsin; Veracin; Vetacyclinum; Vetquamycin-324 (free base)"	54675776	C22H24N2O8	Approved
M6APDG02585	Levodopa	"Levodopa (optimized formulation, Parkinson's disease); Levodopa (optimized formulation, Parkinson's disease), Orion; More effective levodopa (Parkinson's disease), Orion"	6047	C9H11NO4	Approved
M6APDG01909	Fluvastatin	"(+)-(3R,5S)-fluvastatin; (-)-(3S,5R)-fluvastatin; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (Z,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; 7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Canef; Canef(TN); Cranoc; Fluindostatin; Fluvas; Fluvas (TN); Fluvastatin & Primycin; Fluvastatin (INN); Fluvastatin [INN:BAN]; Fluvastatina; Fluvastatina [INN-Spanish]; Fluvastatine; Fluvastatine [INN-French]; Fluvastatinum; Fluvastatinum [INN-Latin]; Lescol; Lescol (TN); Lescol XL; Vastin (TN); XU 62320; XU-62320"	446155	C24H26FNO4	Approved
M6APDG02601	Lamivudine	"(+/-)-(Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (+/-)-3TC; (+/-)-BCH-189; (+/-)-SddC; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-2'-Deoxy-3'-thiacytidine; (-)-BCH 189; (-)-BCH-189; (-)-NGPB-21; (-)-SddC; (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3' Dideoxy 3' thiacytidine; 2',3'-Dideoxy-3'-thiacytidine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-)-(Cis); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Hippeastrum hybrid agglutinin(HHA); 3'-Thia-2',3'-dideoxycytidine; 3TC; 3TC & GNA; 3TC & SST; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); 3TC and NV-01; 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; BCH 189; BCH-189; BCH-790; BCH189; Beta-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; Beta-L-2',3'-Dideoxy-3'-thiacytidine; Beta-L-3'-Thia-2',3'-dideoxycytidine; DRG-0126; DTHC; Epivir; Epivir (TN); Epivir(TM); Epivir-HBV; Epivir-HBV (TN); GG-714; GR-109714X; GR109714X; HHA & 3TC; HHA & Lamivudine; Hepitec; Heptivir; Heptodin; Heptovir; Heptovir (TN); LMV; Lamivir; Lamivudine & GNA; Lamivudine (JAN/USP/INN); Lamivudine [USAN:BAN:INN]; Lamivudine [USAN:INN:BAN]; Lamivudine, (2S-cis)-Isomer; Zeffix; Zeffix (TN); Zefix"	60825	C8H11N3O3S	Approved
M6APDG01061	Azathioprine	"6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; 6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; 6-[(1-Methyl-4-nitroimidazol-5-yl)-thio] purine; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine; A 4638; AI-981/34845012; Azamun; Azamun (TN); Azamun [Czech]; Azanin; Azasan; Azasan (TN); Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine; Azathioprin; Azathioprine (JP15/USP/INN); Azathioprine [USAN:INN:BAN:JAN]; Azathioprine sodium; Azathioprinum; Azathioprinum [INN-Latin]; Azathiopurine; Azatiopr in; Azatioprin; Azatioprina; Azatioprina [INN-Spanish]; Azothioprine; B. W. 57-322; BW 57-322; BW 57322; BW-57-322; Ccucol; Cytostatics; Immuran; Imuran; Imuran (TN); Imurek; Imurel; Imurel (TN); Methylnitroimidazolylmercaptopurine; Muran; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); [Methyl(nitroimidazolyl)mercaptopurine]"	2265	C9H7N7O2S	Approved
M6APDG02602	Irinotecan	"(+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Biotecan; Biotecan (TN); CP0; Campto (TN); Camptosar; Camptosar (TN); Camptosar, Campto, CPT-11, Irinotecan; IRINOTECAN HYDROCHLORIDE Trihydrate; IRINOTECAN, CPT-11; Irinotecan (INN); Irinotecan (TOPO1 inhibitor); Irinotecan Hcl; Irinotecan [INN:BAN]; Irinotecan hydrochloride; Irinotecanum; Irinotecanum [INN-Latin]"	60838	C33H38N4O6	Approved
M6APDG02060	Posaconazole	"Posaconazole; Noxafil; Sch 56592; Posaconazole SP; SCH56592; SCH-56592; UNII-6TK1G07BHZ; Schering 56592; CHEMBL1397; 6TK1G07BHZ; 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)PHENYL)-1-((2S,3S)-2-HYDROXYPENTAN-3-YL)-1H-1,2,4-TRIAZOL-5(4H)-ONE"	468595	C37H42F2N8O4	Approved
M6APDG01433	Glibenclamide	1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide; Abbenclamide; Adiab; Apo-Glibenclamide; Azuglucon; Bastiverit; Benclamin; Betanase; Betanese 5; Calabren; Cytagon; Daonil; Daonil (TN); Debtan; Dia-basan; Diabeta; Diabeta (TN); Diabiphage; Dibelet; Duraglucon; Euclamin; Euglucan; Euglucon; Euglucon (TN); Euglucon 5; Euglucon N; Euglykon; G 0639; GBN 5; Gen-Glybe; Gewaglucon; Gilemal; Glamide; Glibadone; Gliban; Gliben; Gliben-Puren N; Glibenbeta; Glibenclamid AL; Glibenclamid Basics; Glibenclamid Fabra; Glibenclamid Genericon; Glibenclamid Heumann; Glibenclamid Riker M; Glibenclamid Riker M.; Glibenclamid-Cophar; Glibenclamid-Ratiopharm; Glibenclamida; Glibenclamida [INN-Spanish]; Glibenclamide (JP15/INN); Glibenclamidum; Glibenclamidum [INN-Latin]; Glibenil; Glibens; Glibesyn; Glibet; Glibetic; Glibil; Gliboral; Glicem; Glidiabet; Glimel; Glimide; Glimidstata; Glisulin; Glitisol; Glubate; Gluben; Gluco-Tablimen; Glucobene; Glucohexal; Glucolon; Glucomid; Glucoremed; Glucoven; Glyben; Glybenclamide; Glybenzcyclamide; Glyburide; Glyburide (USP); Glyburide (micronized); Glyburide [USAN]; Glycolande; Glycomin; Glynase; Glynase (TN); HB 419; HB 420; HB-419; HB-420; HB419; HB420; Hemi-Daonil; Hexaglucon; Humedia; Lederglib; Libanil; Lisaglucon; Maninil; Med-Glionil; Melix; Micronase; Micronase (TN); Micronized glyburide; Miglucan; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; N-p-[2-(5-Chloro-2-methoxybenzamido)-ethyl]benzene-sulfonyl-N-cyclohexylurea; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; Nadib; Neogluconin; Norglicem 5; Normoglucon; Novo-Glyburide; Orabetic; Pira; Praeciglucon; PresTab; Prodiabet; Renabetic; Semi-Daonil (TN); Semi-Euglucon; Semi-Gliben-Puren N; Semi-daonil; Sugril; Suraben; Tiabet; U 26452; U-26452; UR 606; Yuglucon	3488	C23H28ClN3O5S	Approved
M6APDG02441	Teriflunomide	(2Z)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxobutanenitrile; (Z)-2-Cyano-alpha'alpha'alpha-trifluoro-3-hydroxy-p-crotonotoluidide; 2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide; 2-hydroxyethylidene-cyanoacetic acid-4-trifluoromethyl anilide; A 771726; A-771726; Active metabolite of leflunomide; Flucyamide; HMR 1726; HMR-1726; N-(4-Trifluoromethylphenyl)-2-cyano-2-hydroxycrotonamide; RS 61980; RS-61980; SU 20; SU-0020; Teriflunomide [INN]	54684141	C12H9F3N2O2	Approved
M6APDG02475	Tramadol	Conzip; Rybix Odt; Ryzolt; Tramadol Hydrochloride; Ultram; Ultram Er	5523	C16H25NO2	Approved
M6APDG00982	Cladribine	"(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine; Adenosine, 2-chloro-2'-deoxy; CL9; Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribine (JAN/USAN/INN); Cladribine [USAN:INN:BAN]; Cladribinum; CldAdo; Leustat; Leustatin; Leustatin (TN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Litak; Movectro;Mylinax; RWJ 26251; RWJ-26251; RWJ-26251-000"	20279	C10H12ClN5O3	Approved
M6APDG02630	L-tryptophan	"(-)-Tryptophan; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; (L)-TRYPTOPHAN; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; (S)-(-)-Tryptopha n; (S)-(-)-Tryptophan; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; (S)-2-Amino-3-(3-indolyl)propionic acid; (S)-Tryptophan; (S)-a-Amino-1H-indole-3-propanoic acid; (S)-a-Amino-b-indolepropionic acid; (S)-a-Aminoindole-3-propionic acid; (S)-alpha-Amino-1H-indole-3-propanoic acid; (S)-alpha-Amino-beta-indolepropionic acid; (S)-alpha-Aminoindole-3-propionic acid; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; 1-beta-3-Indolylalanine; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; 1H-Indole-3-alanine; 1H-Indole-3-alanine (VAN); 1beta-3-Indolylalanine; 2-Amino-3-(lH-indol-3-yl)-propanoic acid; 2-Amino-3-indolylpropanoic acid; 2-amino-3-indol-3-ylpropionic acid; 3-Indol-3-ylalanine; Alanine, 3-indol-3-yl; Alpha'-Amino-3-indolepropionic acid; Alpha-Amino-beta-(3-indolyl)-propionic acid; Alpha-amino-beta-(3-indolyl)-pr opionic acid; Alti-Tryptophan; Ardeytropin; EH 121; H-Trp-oh; Indole-3-alanine; Kalma; L-(-)-Tryptophan; L-(-)-Tryptophane; L-TRYPTOPHAN SIGMA GRADE; L-Trp; L-Tryptofan; L-Tryptophan (9CI); L-Tryptophan (JP15); L-Tryptophane; L-Ttp; L-a-Aminoindole-3-propionic acid; L-alpha-Aminoindole-3-propionic acid; L-alpha-amino-3-indolepropionic acid; L-b-3-Indolylalanine; L-beta-3-Indolylalanine; LTR; Lyphan; MT1; Optimax; Pacitron; Propionic acid, 2-amino-3-indol-3-yl; S(-)-1-alpha-Aminoindole-3-propionic acid; Sedanoct; T 0254; TRP NH3+ COOH; TRP-01; Triptofano; Triptofano [Spanish]; Trofan; Trp; Tryptacin; Tryptan; Tryptophan; Tryptophan (H-3); Tryptophan (USP/INN); Tryptophan (VAN); Tryptophan [USAN:INN]; Tryptophan, L-(8CI); Tryptophane; Tryptophane [French]; Tryptophanum; Tryptophanum [Latin]"	6305	C11H12N2O2	Approved
M6APDG02155	Riboflavin	"(-)-riboflavin; 6,7-Dimethyl-9-D-ribitylisoalloxazine; 7,8-Dimethyl-10-ribitylisoalloxazine; 83-88-5; Aqua-Flave; Beflavin; Beflavine; Dermadram; Fiboflavin; Flavaxin; Flavin BB; Flaxain; HYRE; Hyflavin; Lactobene; Lactoflavin; Lactoflavine; Ribipca; Ribocrisina; Riboderm; Riboflavina; Riboflavina [INN-Spanish]; Riboflavine; Riboflavine [INN-French]; Riboflavinequinone; Riboflavinum; Riboflavinum [INN-Latin]; Ribosyn; Ribotone; Ribovel; Russupteridine Yellow III; Vitaflavine; Vitamin Bi; Vitamin G; Vitasan B2"	493570	C17H20N4O6	Approved
M6APDG00638	Valacyclovir	"2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl L-valinate; 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate; 2-{[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]oxy}ethyl L-valinate; Acyclovir-valine; BW-256U; BW256U87; L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester; L-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9 H-purin-9-yl)methoxy]ethyl ester, monohydrochloride; TBB067866; Talavir; VACV; ValACV; Valaciclovir (INN); Valaciclovir Hcl; Valaciclovir [INN:BAN]; Valaciclovir, Valtrex; Valacyclover Hydrochloric; Valacyclover Hydrochloride; Valacyclovir; Valacyclovir, (L)-isomer; Valtrex; Valtrex (TN); Virval; Zelitrex; Zelitrex (TN)"	135398742	C13H20N6O4	Approved
M6APDG03213	Brilinta	AR-C126532; AZD-6140; Brilique; Ticagrelor; Ticagrelor (USAN/INN)	9871419	C23H28F2N6O4S	Approved
M6APDG00833	Asunaprevir	BMS 650032; BMS-650032; Sunvepra	16076883	C35H46ClN5O9S	Phase 3
M6APDG02651	Rifaximin	"Rifaximin; Rifaxidin; Rifacol; Xifaxan; Rifaximine; Rifamycin L 105; Rifamycin L 105SV; Rifaximina; Fatroximin; Normix; Rifaximinum; Rifamixin; Ritacol; Rifaximine [French]; Rifaximinum [Latin]; Rifaximina [Spanish]; Rifaximin [USAN:INN]; UNII-L36O5T016N; L 105SV; L 105 (Ansamacrolide antibiotic); L 105; C43H51N3O11; BRN 3584528; L36O5T016N; Rifaximin, 98%; Rifaximin (Xifaxan); MFCD00864973"	6436173	C43H51N3O11	Approved
M6APDG02455	Cabergoline	(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea; CG-101; Cabaser; Cabaser (TN); Cabaseril; Cabergolina; Cabergolina [Spanish]; Cabergoline (JAN/USAN/INN); Cabergoline [USAN:BAN:INN]; Cabergolinum; Cabergolinum [Latin]; Dostinex; Dostinex (TN); FCE-21336; Galastop; Sogilen	54746	C26H37N5O2	Approved
M6APDG02870	Indacaterol	"5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol (USAN/INN); QAB-149"	6918554	C24H28N2O3	Approved
M6APDG02466	Aliskiren fumarate	"(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]octanamide; Aliskiren (USAN/INN); Octanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]; Rasilez; Rasilez (TN); SPP 100; Tekturna (TN)"	5493444	C30H53N3O6	Approved
M6APDG01016	Tolvaptan	"(-)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide; 7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine; Benzazepine derivative, 32; N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide; OPC 41061; OPC-41061; Samsca; Samsca (TN)"	216237	C26H25ClN2O3	Approved
M6APDG01480	Lamotrigine	"3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine; BW 430C; BW-430C; Crisomet; Desitin Brand of Lamotrigine; EUR-1048; Faes Brand of Lamotrigine; GI 267119X; GW 273293; Glaxo Wellcome Brand of Lamotrigine; GlaxoSmithKline Brand of Lamotrigine; Juste Brand of Lamotrigine; L 3791; Labileno; Lamictal; Lamictal (TN); Lamictal Cd; Lamictal ODT; Lamictal XR; Lamictin; Lamictin (TN); Lamiktal; Lamitor; Lamotrigina; Lamotrigina [Spanish]; Lamotrigine (JAN/USAN/INN); Lamotrigine [USAN:INN:BAN]; Lamotriginum; Lamotriginum [Latin]"	3878	C9H7Cl2N5	Approved
M6APDG01365	Quinine	"(+)-Quinidine; (-)-Quinine; (1R)-(6-Methoxyquinolin-4-yl)((1S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (3A,8A,9r)-6'-methoxycinchonan-9-ol; (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (8-alpha,9R)-6'-Methoxycinchonan-9-ol; (8.alpha.,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-Quinine; (9R)-6'-methoxy-8alpha-cinchonan-9-ol; (R)-(-)-Quinine, 6-methoxycinchonidine; (R)-(-)-quinine; (R)-(6-Methoxy-quinolin-4-yl)-((2S,5S)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol; (R)-[(2S,4R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (S)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (S)-[(2R,4R,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; 6'-Methoxycinchonan-9-ol; 6'-Methoxycinchonidine; 6'-Methoxycinchonine; 6-Methoxycinchonine; Aflukin; Alpha-(6-Methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol; Beta-Quinine; Biquinate (*Bisulfate heptathydrate*); Chinin; Chinin [German]; Chinine; Chininum; Cin-Quin; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate; Coco-Quinine; Conchinin; Conquinine; Dentojel (*Bisulfate heptathydrate*); IBS-L0034250; Kinder Quinina; Kinder Quinina (TN); LT00645788;Q0028; Legatrin (TN); QUININE MONO HCL; Quinamm (*2:1 Sulfate salt*), dihydrate; Quindan; Quine (*2:1 Sulfate salt*, dihydrate); Quinidex; Quinidine; Quinimax; Quinina; Quinine (BAN); Quinine Dab; Quinine [BAN]; Quinine anhydrous; Quinine bisulfate; Quinine sulfate; Quinine sulphate; Quinine, Anhydrous; Quinine, polymers; Quinine, tannate; Quinineanhydrous; Quinoline alkaloid; Quinora; Quinsan (*2:1 Sulfate salt*), dihydrate; Quniacridine; SB01652"	3034034	C20H24N2O2	Approved
M6APDG00568	Erythromycin	"A/T/S; Abboticin; Abomacetin; Acneryne; Acnesol; Adecane-2,10-dione (non-preferred name); Ak-Mycin; Akne Cordes Losung; Akne-Mycin; Akne-mycin (TN); Aknederm Ery Gel; Aknemycin; Aknin; AustriaS; Benzamycin; Benzamycin Pak; C-Solve-2; Del-Mycin; Derimer; Deripil; Dotycin; Dumotrycin; E-Base; E-Base (base); E-Glades; E-Mycin; E-Mycin (base); E-Solve 2; E-mycin, Erycin, Robimysin; E0751; ERY; ERYC; ERYC (base); ERYTHROMYCIN STEARATE; Emgel; Emu-V; Emu-Ve; Emuvin; Emycin; Endoeritrin; Erecin; Erimycin-T; Erisone; Eritomicina; Eritrocina; Eritromicina; Eritromicina [INN-Spanish]; Ermycin; Eros; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-Tab (base); Ery-maxin; Eryacne; Eryacnen; Eryc (TN); Eryc 125; Eryc Sprinkles; Eryc-125; Eryc-250; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Erygel (TN); Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythra-Derm; Erythro; Erythro-Statin; Erythro-Teva; Erythroderm; Erythrogran; Erythroguent; Erythromast 36; Erythromid; Erythromycin & VRC3375; Erythromycin (JP15/USP/INN); Erythromycin A; Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Erythromycin Lactate; Erythromycin Ointment; Erythromycin [INN:BAN:JAN]; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Erythromycin, compd. with monododecyl sulfate, sodium salt; Erythromycine; Erythromycine [INN-French]; Erythromycinum; Erythromycinum [INN-Latin]; Erytop; Erytrociclin; Ilocaps; Ilosone (TN); Ilosone (estolate); Iloticina; Ilotycin; Ilotycin T.S; Ilotycin T.S.; Inderm; Inderm Gel; IndermRetcin; Kesso-Mycin; Latotryd; Lederpax; Mephamycin; Mercina; N-Methylerythromycin A; Oftalmolosa Cusi Eritromicina; Oftamolets; PCE Dispertab (base); Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pce (TN); Pharyngocin; Primacine; Propiocine; Proterytrin; R-P Mycin; Retcin; Robimycin; Romycin; Sans-acne; Sansac; Skid Gel E; Staticin; Staticin (TN); Stiemicyn; Stiemycin; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; T-Stat; T-stat (TN); Taimoxin-F; Theramycin Z; Tiloryth; Tiprocin; Torlamicina; Udima Ery Gel; Wemid"	12560	C37H67NO13	Approved
M6APDG00772	Levofloxacin	"(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (-)-Ofloxacin; (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (R)-isomer; (S)-(-)-Ofloxacin; (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (S)-Ofloxacin; Aeroquin; Cravit; Cravit (TN); Cravit Ophthalmic; D-Levofloxacin; DR 3354; DR-3355; DR-3355: L-isomer of ofloxacin; DR3355; Elequine; Floxacin; Floxel; HR 355; HR-355; Iquix; Iquix (TN); L-Ofloxacin; LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER; LFX; LVX; Leroxacin; Lesacin; Levaquin; Levaquin (TN); Levofloxacin (INN); Levofloxacin [USAN:INN:JAN]; Levofloxacin tablet, suspension or intravenous; Levofloxacine; Levofloxacine [INN-French];Levofloxacino [INN-Spanish]; Levofloxacino; Levofloxacinum; Levofloxacinum [INN-Latin]; Levokacin; Levox; Levoxacin; MP-376; Mosardal; Nofaxin; Ofloxacin; Ofloxacin S-(-)-form; Oftaquix; Oftaquix (TN); Quixin; Quixin (TN); R-Ofloxacin; RWJ 25213-097; RWJ-25213; Reskuin; S-(-)-Ofloxacin; Tavanic; Tavanic (TN); Volequin"	149096	C18H20FN3O4	Approved
M6APDG02442	Pravastatin	"(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid; Eptastatin; KS-5015; Oliprevin; Pravachol (TN); Pravastatin (INN); Pravastatin Sodium Salt; Pravastatin [INN:BAN]; Pravastatin tert-Octylamine Salt; Pravastatina; Pravastatina [Spanish]; Pravastatine; Pravastatine [French]; Pravastatinum; Pravastatinum [Latin]; Pravator; Pravator (TN); RMS-431; SQ-31,000; Selektine (TN); Vasten"	54687	C23H36O7	Approved
M6APDG02592	Topotecan	"(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin; Hycamptamine; Hycamptin; Hycamtamine; Hycamtin; Hycamtin (TN); SK&F-104864-A; SKF 104864; SKF-104864-A; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan Monohydrochloride, (S)-Isomer; Topotecan [INN:BAN]; Topotecan lactone; Topotecane; Topotecane [INN-French]; Topotecanum; Topotecanum [INN-Latin]"	60700	C23H23N3O5	Approved
M6APDG00565	Glutathione	5-L-Glutamyl-L-cysteinylglycine; 70-18-8; Agifutol S; Copren; Deltathione; GSH; Glutathion; Glutathione; Glutathione (reduced); Glutathione SH; Glutathione [JAN]; Glutathione-SH; Glutatiol; Glutatione; Glutide; Glutinal; Isethion; L-Glutathione reduced; L-Glutatione; L-gamma-glutamyl-L-cysteinylglycine; Ledac; Neuthion; Panaron; Tathion; Tathione; Triptide; gamma-L-Glutamyl-L-cysteinylglycine; gamma-L-Glutamylcysteinylglycine; gamma-L-glutamyl-L-cysteinyl-glycine; glutathione red; red. glutathione; reduced glutathione	124886	C10H17N3O6S	Approved
M6APDG01309	Cimetidine	"1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine; 1-Cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)methyl]thio]ethyl]guanidine; 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine; 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; Acibilin; Acinil; Altramet; Biomet400; Brumetidina; C 4522; CIMETIDINE A/AB; Ci metum; Cimal; Cimetadine; Cimetag; Cimetidina; Cimetidina [INN-Spanish]; Cimetidine (JP15/USP/INN); Cimetidine Hcl; Cimetidine [USAN:INN:BAN:JAN]; Cimetidinum; Cimetidinum [INN-Latin]; Cimetum; DRG-0150; Dyspamet; Edalene; Eureceptor; Evicer; FPF 1002; Gastrobitan; Gastromet; Histodil; Magicul; Metracin; N''-Cyano-N-methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine; N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)-ethyl)guanidine; N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-Cyano-N'-Methyl-N''-(2-(((5-Methyl-1H-Imidazol-4-YL)Methyl)Thio)Ethyl) Guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1 H-imidazol-4-yl) methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-[2-[[[5-methyl-1H-imidazol-4-yl]methyl]thio]ethyl]guanidine; N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine; N-cyano-N'-methyl-N''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; Peptol; SK&F-92334; SKF 92334; SKF-92334; Sigmetadine; Tagamet; Tagamet (TN); Tagamet HB (TN); Tagamet HB200 (TN); Tagamet Hb; Tagamet Hb 200; Tagamet, SKF-92334, Tratul, Tametin, Dyspamet, Acinil, Cimetidine; Tametin; Tratul; Ulcedin; Ulcedine; Ulcestop; Ulcimet; Ulcofalk; Ulcomedina; Ulcomet; Ulhys; Valmagen; Venopex"	2756	C10H16N6S	Approved
M6APDG02572	Cholesterol	(-)-Cholesterol; (3beta)-cholest-5-en-3-ol; 3-beta-Hydroxycholest-5-ene; 3beta-Hydroxycholest-5-ene; 5-Cholesten-3beta-ol; 5:6-Cholesten-3beta-ol; CCRIS 2834; Cholest-5-en-3-beta-ol; Cholest-5-en-3-ol (3beta)-; Cholest-5-en-3beta-ol; Cholesterin; Cholesterine; Cholesterol base H; Cholesteryl alcohol; Cholestrin; Cholestrol; Cordulan; Dastar; Dusoline; Dusoran; Dythol; HSDB 7; Hydrocerin; Kathro; Lanol; Lidinit; Lidinite; Nimco cholesterol base H; Provitamin D; Super hartolan; Tegolan; Tegolan (VAN); Wool alcohols B. P.	5997	C27H46O	Phase 2
M6APDG02680	Axitinib	"AG 013736; AG-013736; AG-013736, Axitinib; AG-13736; AG013736; Axitinib (VEGFR inhibitor); N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide"	6450551	C22H18N4OS	Approved
M6APDG01057	Atenolol	"(+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; (+-)-Atenolol; (+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; (1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; (inverted question mark)-Atenolol; 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol; 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid; 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide; 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; 2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide; 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; 2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; 4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide; 4-[2-Hydroxy-3-(isopropylamino)-propoxy]phenylacetamide; A 7655; Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl); Aircrit; Alinor; Altol; Anselol; Antipressan; Apo-Atenolol; Atcardil; Atecard; Atehexal; Atenblock; Atendol; Atenet; Ateni; Atenil; Atenol; Atenol 1A pharma; Atenol AL; Atenol Atid; Atenol Cophar; Atenol Fecofar; Atenol GNR; Atenol Gador; Atenol Genericon; Atenol Heumann; Atenol MSD; Atenol NM Pharma; Atenol Nordic; Atenol PB; Atenol Quesada; Atenol Stada; Atenol Tika; Atenol Trom; Atenol acis; Atenol ct; Atenol von ct; Atenol-Mepha; Atenol-Wolff; Atenol-ratiopharm; Atenolin; Atenolol (JP15/USP/INN); Atenolol [USAN:INN:BAN:JAN]; Atenololum; Atenololum [INN-Latin]; Atenomel; Atereal; Aterol; Betablok; Betacard; Betasyn; Betatop Ge; Blocotenol; Blokium; Cardaxen; Cardiopress; Corotenol; Cuxanorm; Duraatenolol; Duratenol; Evitocor; Farnormin; Felo-Bits; Hipres; Hypoten; Ibinolo; Internolol; Jenatenol; Juvental; Lo-ten; Loten; Lotenal; Myocord; Neatenol; Normalol; Normiten; Noten; Oraday; Ormidol; Panapres; Plenacor; Premorine; Prenolol; Prenormine; Prinorm; Scheinpharm Atenol; Seles beta; Selobloc; Serten; Servitenol; Stermin; Tenidon; Teno-basan; Tenobloc; Tenoblock; Tenolol; Tenoprin; Tenormin; Tenormin (TN); Tenormine; Tenormine [French]; Tensimin; Tensotin; Tredol; Unibloc; Uniloc; Vascoten; Vericordin; Wesipin; Xaten"	2249	C14H22N2O3	Approved
M6APDG02300	Imatinib	"112GI019; 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide; Alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide; Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI); CGP 57148B; Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib Methansulfonate; Imatinib [INN:BAN]; Imatinib free base; N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; STI; STI 571; STI571; Sti-571"	5291	C29H31N7O	Approved
M6APDG03164	Moxidectin	C37H53NO8; Cydectin; Moxidectin [USAN:INN:BAN]; Moxidectina; Moxidectina [INN-Spanish]; Moxidectine; Moxidectine [INN-French]; Moxidectinum; Moxidectinum [INN-Latin]; NGU5H31YO9; ProHeart 6; UNII-NGU5H31YO9	9832912	C37H53NO8	Approved
M6APDG00637	Ganciclovir	"2'-NDG; 2'-Nor-2'-deoxyguanosine; 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol; 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one; 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one; 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; 9-((1,3-Dihydroxy-2-propoxy)methyl)guanine; 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; BIOLF-62; BW 759; BW 759U; BW-759U; BW-795; BW-B 759U; Biolf 62; Citovirax; Cymevan; Cymeven; Cymevene; Cymevene (TN); Cytovene; Cytovene (TN); Cytovene-IV; DRG-0018; G 2536; GA2; GANCICLOVIR SODIUM; GCV; GCV & 1110U81; GCV & MSL; Ganciclovir & C34-dgA immunotoxin; Ganciclovir & D5-dgA immunotoxin; Ganciclovir (JAN/USP/INN); Ganciclovir [USAN:INN:BAN:JAN]; Ganciclovirum; Ganciclovirum [Latin]; Gancyclovir; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-and MSL, neutralizing monoclonal antibody; HHEMG; Hydroxyacyclovir; IN1478; MB3795; RS-21592; ST-605; Virgan; Vitrasert; Vitrasert (TN); Zirgan"	135398740	C9H13N5O4	Approved
M6APDG01405	Fexofenadine	"2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid; 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid; 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid; Allegra (TN); Carboxyterfenadine; F 9427; Fastofen (TN); Fexofenadine (INN); Fexofenadine [INN:BAN]; Fexofendine; MDL 16455; Telfast (TN); Terfenadine acid metabolite; Terfenadine carboxylate; Terfenadine-COOH; Terfenidine carboxylate, MDL 16455; Tilfur (TN)"	3348	C32H39NO4	Approved
M6APDG02564	L-glutamine	"AES-14; Aesgen-14; E-6014; Glutamine (INN); L-glutamine (oral, short bowel syndrome), Emmaus; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus/University of California Los Angeles; L-glutamine (topical, chemotherapy-induced mucositis), Aesgen; NutreStore; Saforis"	5961	C5H10N2O3	Approved
M6APDG01348	Estrone sulfate	Estrone 3-sulfate; Estrone hydrogen sulfate; Estrone sulphate; [3H]-estrone hydrogen sulfate; [3H]-estrone-3-sulphate; [3H]estrone-3-sulfate; [3H]estrone-3-sulphate	3001028	C18H22O5S	Approved
M6APDG01518	Meperidine	"1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]; 1-Methyl-4-phenylisonipecotic acid, ethyl ester;1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester; 4-Carbethoxy-1-methyl-4-phenylpiperidine; 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester; Demarol; Demerol; Demerol (TN); Dolcontral; Dolosal; Dolsin; Ethyl 1-methyl-4-phenylisonipecotate; Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate; Isonipecain; Isonipecaine; Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester; Lidol; Lydol; Meperidine solution; Meperidol; Methyl phenylpiperidine carbonic acid ethyl ester; N-Methyl-4-phenyl-4-carbethoxypiperidine; Nemerol; Operidine EPJ I; Operidine EPJ-I; Pethanol; Pethidin; Pethidine; Pethidine (INN); Pethidine DBL; Pethidine DBL (TN); Pethidineter; Pethidinum; Pethidinum [INN-Latin]; Petidina; Petidina [INN-Spanish]; Petydyna; Petydyna [Polish]; Phetidine; Piperosal; Pipersal; YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI)"	4058	C15H21NO2	Approved
M6APDG02578	Adefovir	"((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid; 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid; 9-(2-(Phosphonomethoxy)ethyl)adenine; 9-(2-Phosphonylmethoxyethyl)adenine; ADEFOVIR; GS 0393; GS 393; GS-0393; N-(2-Phophonomethoxyethyl-2,6-diaminopurine); N-(2-Phosphonylmethoxyethyl)adenine; PMEA; {[2-(6-Amino-9h-Purin-9-Yl)ethoxy]methyl}phosphonic Acid"	60172	C12H14Cl2N2	Approved
M6APDG01186	Simeprevir	TMC436	24873435	C38H47N5O7S2	Approved
M6APDG02667	Nilotinib	Nilotinib; Tasigna; AMN107; AMN 107; AMN-107; Nilotinib(AMN-107); Nilotinib (AMN-107); UNII-F41401512X; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide; CHEMBL255863; C28H22F3N7O; HHZIURLSWUIHRB-UHFFFAOYSA-N; NSC747599; MFCD09833716	644241	C28H22F3N7O	Approved
M6APDG00217	2-Deoxyglucose	"2-DG; 2-DG (epilepsy), NeurogenomeX; 2-DG (epilepsy), NeurogenomeX); 2-deoxy-D-glucose; D-arabinohexose; Dextrose; Glucose; University of Wisconsin-Madison/NeuroGenomeX"	108223	C6H12O5	Phase 1/2
M6APDG01395	L-glutamic acid	"(2S)-2-Aminopentanedioic acid; (S)-(+)-Glutamic acid; (S)-2-Aminopentanedioic acid; (S)-Glutamic acid; 1-Aminopropane-1,3-dicarboxylic acid; 2-Aminoglutaric acid; 2-aminopentanedioic acid; A-Aminoglutaric acid; A-Glutamic acid; Acide glutamique; Acide glutamique [INN-French]; Acido glutamico; Acido glutamico [INN-Spanish]; Acidum glutamicum; Acidum glutamicum [INN-Latin]; Acidum glutaminicum; Aciglut; Alpha-Aminoglutaric acid (VAN); Alpha-Glutamic acid; Alpha-L-Glutamic acid polymer; Alpha-aminoglutaric acid; D-Glutamiensuur; E 620; GLUTAMIC ACID; Glu; Glusate; Glut; Glutacid; Glutamate; Glutamic Acid (L-glutamic acid); Glutamic Acid [USAN:INN]; Glutamic acid (H-3); Glutamic acid (VAN); Glutamic acid polymer; Glutamic acid, L-(7CI,8CI); Glutamic acid, L-, peptides; Glutamicol; Glutamidex; Glutaminic acid; Glutaminic acid (VAN); Glutaminol; Glutaton; Gulutamine; Gulutamine (USP); H-Glu-OH; L-(+)-glutamic acid; L-2-Aminoglutaric acid; L-Glutamic acid (9CI); L-Glutamic acid (JAN); L-Glutamic acid hydrochloride; L-Glutamic acid, homopolymer; L-Glutamic acid, homopolymer (9CI); L-Glutaminic acid; L-Glutaminsaeure; L-a-Aminoglutaric acid; L-alpha-Aminoglutaric acid; L-glu; L-glutamate; POLYGLUTAMIC ACID; Poly(alpha-L-glutamic acid); Poly-L-glutamate; Sodium Glutamate (L-glutamic Acid)"	33032	C5H9NO4	Approved
M6APDG00817	Paraquat	"1,1'-dimethyl-4,4' bipyridinium dichloride"	15938	C12H14Cl2N2	Investigative
M6APDG02871	Fesoterodine fumarate	Toviaz (TN)	6918558	C26H37NO3	Approved